  | Kirk, B., Cawthon, P. M., Arai, H., Ávila-Funes, J. A., Barazzoni, R., Bhasin, S., Binder, E. F., Bruyère, O., Cederholm, T., Chen, L.-K., Cooper, C., Duque, G., Fielding, R., Guralnik, J., Kiel, D. P., Landi, F., Reginster, J.-Y., Sayer, A. A., Visser, M., ... Global Leadership Initiative in Sarcopenia (GLIS) group. (01 March 2024). The Conceptual Definition of Sarcopenia: Delphi Consensus from the Global Leadership Initiative in Sarcopenia (GLIS). Age and Ageing, 53 (3). doi:10.1093/ageing/afae052  Peer Reviewed verified by ORBi |
 | Beaudart, C., Sharma, M., Clark, P., Fujiwara, S., Adachi, J. D., Messina, O. D., Morin, S. N., Kohlmeier, L. A., Sangan, C. B., Nogues, X., Cruz-Priego, G. A., Cavallo, A., Cooper, F., Grier, J., Leckie, C., Montiel-Ojeda, D., Papaioannou, A., Raskin, N., Yurquina, L., ... Hiligsmann, M. (March 2024). Patients' preferences for fracture risk communication: the Risk Communication in Osteoporosis (RICO) study. Osteoporosis International, 35 (3), 451-468. doi:10.1007/s00198-023-06955-9 Peer Reviewed verified by ORBi |
 | Kim, A., Hong, J. H., Shin, W., Yoo, H., Jung, J.-G., Reginster, J.-Y., Kim, S., Bae, Y., Suh, J., Kim, S., Lee, E., & Silverman, S. (2024). A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males. Expert Opinion on Biological Therapy, 1 - 9. doi:10.1080/14712598.2024.2316846 Peer Reviewed verified by ORBi |
 | Herrero-Beaumont, G., Castro-Dominguez, F., Migliore, A., Naredo, E., Largo, R., & Reginster, J.-Y. (20 February 2024). Systemic osteoarthritis: the difficulty of categorically naming a continuous condition. Aging Clinical and Experimental Research, 36 (1), 45. doi:10.1007/s40520-024-02714-w Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Silverman, S. L., Singer, A. J., Pearman, L., Wang, Y., Caminis, J., & Reginster, J.-Y. (30 January 2024). Comparison of the cost-effectiveness of sequential treatment with abaloparatide in US men and women at very high risk of fractures. Aging Clinical and Experimental Research, 36 (1), 14. doi:10.1007/s40520-023-02682-7 Peer Reviewed verified by ORBi |
 | Vendrami, C., Shevroja, E., Gonzalez Rodriguez, E., Gatineau, G., Elmers, J., Reginster, J.-Y., Harvey, N. C., Lamy, O., & Hans, D. (2024). Muscle parameters in fragility fracture risk prediction in older adults: A scoping review. Journal of Cachexia, Sarcopenia and Muscle. doi:10.1002/jcsm.13418 Peer Reviewed verified by ORBi |
 | Beaudart, C., Tilquin, N., Abramowicz, P., Baptista, F., Peng, D. J., de Souza Orlandi, F., Drey, M., Dzhus, M., Fábrega-Cuadros, R., Fernandez-Garrido, J., Laurindo, L. F., Gasparik, A.-I., Geerinck, A., Emin, G., Iacob, S., Kilaitė, J., Kumar, P., Lee, S.-C., Lou, V. W. Q., ... Bruyère, O. (15 December 2023). Quality of life in sarcopenia measured with the SarQoL questionnaire: A meta-analysis of individual patient data. Maturitas, 180, 107902. doi:10.1016/j.maturitas.2023.107902 Peer Reviewed verified by ORBi |
  | Buckinx, F., Rezoulat, M., Lefranc, C., Reginster, J.-Y., & Bruyère, O. (15 November 2023). Comparing remote and face-to-face assessments of physical performance in older adults: A reliability study. Geriatric Nursing, 55, 71 - 78. doi:10.1016/j.gerinurse.2023.11.004 Peer Reviewed verified by ORBi |
 | Buckinx, F., Adam, S., Aubertin-Leheudre, M., De Saint Hubert, M., Mouton, A., Potier, F., Reginster, J.-Y., & Bruyère, O. (06 November 2023). Quality of Life and Health Determinants of Informal Caregivers Aged 65 Years and Over. Epidemiologia (Basel, Switzerland), 4 (4), 464 - 482. doi:10.3390/epidemiologia4040039 Peer reviewed |
 | Demonceau, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (2023). Assessment of risk factors associated with long-term mortality in nursing homes: result from the SENIOR cohort. Aging Clinical and Experimental Research. doi:10.1007/s40520-023-02579-5 Peer Reviewed verified by ORBi |
 | Honvo, G., Sabico, S., Veronese, N., Bruyère, O., Rizzoli, R., Amuthavalli Thiyagarajan, J., Mikton, C., Diaz, T., Cooper, C., & Reginster, J.-Y. (28 October 2023). Measures of attributes of locomotor capacity in older people: a systematic literature review following the COSMIN methodology. Age and Ageing, 52 (Supplement_4), 44 - iv66. doi:10.1093/ageing/afad139 Peer Reviewed verified by ORBi |
 | Ladang, A., KOVACS, S., Lengele, L., Locquet, M., Beaudart, C., Reginster, J.-Y., Bruyère, O., & Cavalier, E. (October 2023). Neurofilament-light chains (NF-L), a biomarker of neuronal damage, is increased in patients with severe sarcopenia: results of the SarcoPhAge study. Aging Clinical and Experimental Research, 35 (10), 2029 - 2037. doi:10.1007/s40520-023-02521-9 Peer Reviewed verified by ORBi |
 | Sanchez-Rodriguez, D., Demonceau, C., Bruyère, O., Cavalier, E., Reginster, J.-Y., & Beaudart, C. (October 2023). Intrinsic capacity and risk of death: Focus on the impact of using different diagnostic criteria for the nutritional domain. Maturitas, 176, 107817. doi:10.1016/j.maturitas.2023.107817 Peer Reviewed verified by ORBi |
 | Veronese, N., Soysal, P., Demurtas, J., Solmi, M., Bruyère, O., Christodoulou, N., Ramalho, R., Fusar-Poli, P., Lappas, A. S., Pinto, D., Frederiksen, K. S., Corbi, G. M., Karpenko, O., Georges, J., Durães, J., Schlögl, M., Yilmaz, O., Sieber, C., Shenkin, S. D., ... endorsed by the European Academy of Neurology. (October 2023). Physical activity and exercise for the prevention and management of mild cognitive impairment and dementia: a collaborative international guideline. European Geriatric Medicine, 14 (5), 925 - 952. doi:10.1007/s41999-023-00858-y Peer reviewed |
 | Beaudart, C., Demonceau, C., Sabico, S., Veronese, N., Cooper, C., Harvey, N., Fuggle, N., Bruyère, O., Rizzoli, R., & Reginster, J.-Y. (September 2023). Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis. Aging Clinical and Experimental Research, 35 (9), 1789 - 1806. doi:10.1007/s40520-023-02478-9 Peer Reviewed verified by ORBi |
 | Ladang, A., Beaudart, C., Reginster, J.-Y., Al-Daghri, N., Bruyère, O., Burlet, N., Cesari, M., Cherubini, A., da Silva, M. C., Cooper, C., Cruz-Jentoft, A. J., Landi, F., Laslop, A., Maggi, S., Mobasheri, A., Ormarsdottir, S., Radermecker, R., Visser, M., Yerro, M. C. P., ... Cavalier, E. (September 2023). Correction: Biochemical Markers of Musculoskeletal Health and Aging to be Assessed in Clinical Trials of Drugs Aiming at the Treatment of Sarcopenia: Consensus Paper from an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the Centre Académique de Recherche et d'Expérimentation en Santé (CARES SPRL), Under the Auspices of the World Health Organization Collaborating Center for the Epidemiology of Musculoskeletal Conditions and Aging. Calcified Tissue International, 113 (3), 357 - 358. doi:10.1007/s00223-023-01114-y Peer Reviewed verified by ORBi |
 | Moon, R. J., Reginster, J.-Y., Al-Daghri, N., Thiyagarajan, J. A., Beaudart, C., Bruyère, O., Burlet, N., Chandran, M., da Silva, M. C., Conaghan, P. G., Dere, W. H., Diez-Perez, A., Hadji, P., Halbout, P., Hiligsmann, M., Kanis, J. A., McCloskey, E. V., Ormarsdottir, S., Prieto-Alhambra, D., ... Harvey, N. C. (August 2023). Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Osteoporosis International, 34 (8), 1283 - 1299. doi:10.1007/s00198-023-06827-2 Peer Reviewed verified by ORBi |
 | Buckinx, F., Reginster, J.-Y., & Bruyère, O. (2023). Frailty Change Based on Minimally Important Difference in Nursing Home Residents: The SENIOR Cohort Findings. Journal of the American Medical Directors Association. doi:10.1016/j.jamda.2023.06.005 Peer Reviewed verified by ORBi |
 | Cooper, C., Dawson-Hughes, B., Halbout, P., Harvey, N., Kanis, J. A., Reginster, J.-Y., Rizzoli, R., & International Osteoporosis Foundation. (July 2023). In Memoriam : Lorie Fitzpatrick MD - 1954-2023. Osteoporosis International, 34 (7), 1281 - 1282. doi:10.1007/s00198-023-06767-x Peer Reviewed verified by ORBi |
 | Demonceau, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (July 2023). Investigation of the relationships between frailty, nutritional status and muscle strength and the incidence and severity of Covid-19 among the residents of nursing homes. Results from the SENIOR cohort. Maturitas, 177, 107800. doi:10.1016/j.maturitas.2023.107800 Peer Reviewed verified by ORBi |
 | Pegreffi, F., Reginster, J.-Y., Bruyère, O., & Veronese, N. (June 2023). Comment on: The Effect of Intra-articular Hyaluronic Acid Injections and Payer Coverage on Total Knee Arthroplasty Procedures: Evidence From Large US Claims Database. Arthroplasty Today, 21, 101128. doi:10.1016/j.artd.2023.101128 Peer Reviewed verified by ORBi |
 | Messina, O. D., Vidal, M., Adami, G., Vidal, L. F., Clark, P., Torres, J. A. M., Lems, W., Zerbini, C., Arguissain, C., Reginster, J.-Y., & Lane, N. E. (2023). Chronic arthritides and bone structure: focus on rheumatoid arthritis-an update. Aging Clinical and Experimental Research. doi:10.1007/s40520-023-02432-9 Peer Reviewed verified by ORBi |
 | Beaudart, C., Reginster, J.-Y., Amuthavalli Thiyagarajan, J., Bautmans, I., Bauer, J., Burlet, N., Cesari, M., Cherubini, A., Cooper, C., Cruz-Jentoft, A. J., Dawson-Hughes, B., Fielding, R. A., Harvey, N. C., Landi, F., Laslop, A., Maggi, S., Montero-Errasquin, B., Concepción, P. Y. M., Rolland, Y., ... Bruyère, O. (23 May 2023). Measuring health-related quality of life in sarcopenia: summary of the SarQoL psychometric properties. Aging Clinical and Experimental Research, 35, 1581-1593. doi:10.1007/s40520-023-02438-3 Peer Reviewed verified by ORBi |
 | Demonceau, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (06 May 2023). Predictors of 8-year survival in nursing homes : Results from the SENIOR cohort [Paper presentation]. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, Barcelone, Spain. |
 | Beaudart, C., Demonceau, C., Reginster, J.-Y., Locquet, M., Cesari, M., Cruz Jentoft, A. J., & Bruyère, O. (2023). Sarcopenia and health-related quality of life: A systematic review and meta-analysis. Journal of Cachexia, Sarcopenia and Muscle. doi:10.1002/jcsm.13243 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Silverman, S. S., Singer, A. J., Pearman, L., Mathew, J., Wang, Y., Caminis, J., & Reginster, J.-Y. (2023). Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States. PharmacoEconomics. doi:10.1007/s40273-023-01270-x Peer Reviewed verified by ORBi |
 | Prokopidis, K., Giannos, P., Reginster, J.-Y., Bruyère, O., Petrovic, M., Cherubini, A., Triantafyllidis, K. K., Kechagias, K. S., Dionyssiotis, Y., Cesari, M., Ibrahim, K., Scott, D., Barbagallo, M., Veronese, N., & Special interest group in Systematic Reviews and Meta-analyses and the Task Force on Pharmaceutical Strategy of the European Geriatric Medicine Society (EuGMS). (April 2023). Sarcopenia is associated with a greater risk of polypharmacy and number of medications: a systematic review and meta-analysis. Journal of Cachexia, Sarcopenia and Muscle, 14 (2), 671 - 683. doi:10.1002/jcsm.13190 Peer Reviewed verified by ORBi |
 | Li, N., Beaudart, C., Cauley, J. A., Ing, S. W., Lane, N. E., Reginster, J.-Y., Silverman, S., Singer, A. J., & Hiligsmann, M. (April 2023). Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review. PharmacoEconomics, 41 (4), 363 - 391. doi:10.1007/s40273-022-01239-2 Peer Reviewed verified by ORBi |
 | Li, N., Beaudart, C., Cauley, J. A., Ing, S. W., Lane, N. E., Reginster, J.-Y., Silverman, S., Singer, A. J., & Hiligsmann, M. (April 2023). Correction to: Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review. PharmacoEconomics, 41 (4), 393. doi:10.1007/s40273-023-01255-w Peer Reviewed verified by ORBi |
 | Bruyère, O., Detilleux, J., & Reginster, J.-Y. (08 March 2023). Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand. Medicines (Basel, Switzerland), 10 (3), 23. doi:10.3390/medicines10030023 |
 | Ladang, A., Beaudart, C., Reginster, J.-Y., Al-Daghri, N., Bruyère, O., Burlet, N., Cesari, M., Cherubini, A., da Silva, M. C., Cooper, C., Cruz-Jentoft, A. J., Landi, F., Laslop, A., Maggi, S., Mobasheri, A., Ormarsdottir, S., Radermecker, R., Visser, M., Yerro, M. C. P., ... Cavalier, E. (12 January 2023). Biochemical Markers of Musculoskeletal Health and Aging to be Assessed in Clinical Trials of Drugs Aiming at the Treatment of Sarcopenia: Consensus Paper from an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the Centre Académique de Recherche et d'Expérimentation en Santé (CARES SPRL), Under the Auspices of the World Health Organization Collaborating Center for the Epidemiology of Musculoskeletal Conditions and Aging. Calcified Tissue International, online. doi:10.1007/s00223-022-01054-z Peer Reviewed verified by ORBi |
 | Westbury, L. D., Beaudart, C., Bruyère, O., Cauley, J. A., Cawthon, P., Cruz-Jentoft, A. J., Curtis, E. M., Ensrud, K., Fielding, R., Johansson, H., Kanis, J. A., Karlsson, M. K., Lane, N. E., Lengele, L., Lorentzon, M., McCloskey, E., Mellström, D., Newman, A. B., Ohlsson, C., ... International Musculoskeletal Ageing Network. (05 January 2023). Recent sarcopenia definitions-prevalence, agreement and mortality associations among men: Findings from population-based cohorts. Journal of Cachexia, Sarcopenia and Muscle, online. doi:10.1002/jcsm.13160 Peer Reviewed verified by ORBi |
 | Fuggle, N., Al-Daghri, N., Bock, O., Branco, J., Bruyère, O., Casado, E., Cavalier, E., Cortet, B., de Wit, M., Giusti, A., Halbout, P., Harvey, N. C., Hiligsmann, M., Kaufman, J.-M., Kurth, A., Maggi, S., Matijevic, R., Minisola, S., Palacios, S., ... Cooper, C. (03 January 2023). Correction: Novel formulations of oral bisphosphonates in the treatment of osteoporosis. Aging Clinical and Experimental Research, online. doi:10.1007/s40520-022-02319-1 Peer Reviewed verified by ORBi |
 | Demonceau, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (2023). Investigation of the factors associated with the incidence and severity of COVID-19 in nursing home. Results from the SENIOR cohort. Aging Clinical and Experimental Research, 35 (suppl 1), 306. Peer Reviewed verified by ORBi |
 | Beaudart, C., Demonceau, C., Reginster, J.-Y., Locquet, M., Cesari, M., Cruz Jentoft, A. J., & Bruyère, O. (2023). Health-related quality of life in sarcopenia: a systematic review and meta-analysis. Aging Clinical and Experimental Research, 35 (suppl 1), 58-59. Peer Reviewed verified by ORBi |
 | Zhao, X.-X., Xie, W.-Q., Xiao, W.-F., Li, H.-Z., Naranmandakh, S., Bruyere, O., Reginster, J.-Y., & Li, Y.-S. (2023). Perlecan: Roles in osteoarthritis and potential treating target. Life Sciences, 312. doi:10.1016/j.lfs.2022.121190 Peer Reviewed verified by ORBi |
 | Demonceau, C., Beaudart, C., Reginster, J.-Y., Veronese, N., & Bruyère, O. (2023). The interconnection between Covid-19, sarcopenia and lifestyle. Maturitas, 169, 56-57. doi:10.1016/j.maturitas.2022.09.009 Peer Reviewed verified by ORBi |
 | Demonceau, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (2023). Predictors of 8-year survival in nursing homes: results from the SENIOR cohort. Aging Clinical and Experimental Research, 35 (suppl 1), 60. Peer Reviewed verified by ORBi |
 | Beaudart, C., Sanchez Rodriguez, M. D. C., Demonceau, C., Cavalier, E., Reginster, J.-Y., & Bruyère, O. (2023). Screening for malnutrition by the MNA-SF, diagnosis by the Global Leadership Initiative on Malnutrition (GLIM) criteria, or both? Predictive capacity for mortality in a 9-year follow-up in the SarcoPhAge cohort. Aging Clinical and Experimental Research, 35 (suppl 1), 335. Peer Reviewed verified by ORBi |
 | Buckinx, F., Adam, S., Aubertin-Leheudre, M., De Saint Hubert, M., Mouton, A., Potier, F., Reginster, J.-Y., & Bruyère, O. (2023). Health determinants of informal caregivers aged 65 years and over. Aging Clinical and Experimental Research, 35 (suppl 1), 288. Peer Reviewed verified by ORBi |
 | Beaudart, C., Demonceau, C., Sabico, S., Veronese, N., Cooper, C., Harvey, N., Bruyère, O., Rizzoli, R., & Reginster, J.-Y. (2023). Efficacy of osteoporosis treatments in men: a systematic review and meta-analysis. Aging Clinical and Experimental Research, 35 (suppl 1), 249. Peer Reviewed verified by ORBi |
 | Beaudart, C., Demonceau, C., Reginster, J.-Y., & Bruyère, O. (2023). Measure of health-related quality of life in interventional studies aiming at the management of sarcopenia: results from a systematic literature review. Aging Clinical and Experimental Research, 35 (suppl 1), 190. Peer Reviewed verified by ORBi |
 | Demonceau, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (2023). Investigation of the factors associated with the incidence and severity of Covid-19 in nursing home. Results from the SENIOR cohort [Paper presentation]. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, Barcelone, Spain. |
 | Tenti, S., Bruyère, O., Cheleschi, S., Reginster, J.-Y., Veronese, N., & Fioravanti, A. (2023). An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis. Therapeutic Advances in Musculoskeletal Disease, 15, 1759720X231158618. doi:10.1177/1759720X231158618 Peer Reviewed verified by ORBi |
 | Buckinx, F., Charles, A., Demonceau, C., Reginster, J.-Y., & Bruyère, O. (2023). L’activité physique en maison de repos : contributions de la cohorte SENIOR. Revue Médicale de Liège. |
 | Veronese, N., Honvo, G., Bruyère, O., Rizzoli, R., Barbagallo, M., Maggi, S., Sabico, S., Al-Daghri, N., Cooper, C., Pegreffi, F., & Reginster, J.-Y. (2023). Knee osteoarthritis and adverse health outcomes: an umbrella review of meta-analyses of observational studies. Aging Clinical and Experimental Research, 35 (suppl 1), 271. Peer Reviewed verified by ORBi |
 | Beaudart, C., Sanchez Rodriguez, M. D. C., Demonceau, C., Cavalier, E., Reginster, J.-Y., & Bruyère, O. (2023). Intrinsic capacity using the MNA-SF and the Global Leadership Initiative of Malnutrition (GLIM) criteria in the nutritional domain and mortality-risk: A 9-year follow-up in the SarcoPhAge cohortr. Aging Clinical and Experimental Research, 35 (suppl 1), 334-S335. Peer Reviewed verified by ORBi |
 | Buckinx, F., Maton, L., Dalimier, V., Mouton, A., Lengele, L., Reginster, J.-Y., & Bruyère, O. (2023). Development and validation of new exercises to promote physical activity in nursing home settings, through qualitative method. Aging Clinical and Experimental Research, 35 (suppl 1), 51. Peer Reviewed verified by ORBi |
 | Buckinx, F., Charles, A., Demonceau, C., Reginster, J.-Y., & Bruyère, O. (2023). Etude de la survenue des événements de santé indésirables en maison de repos : apports de la cohorte Liégeoise SENIOR. Revue Médicale de Liège, 78, 715-718. Editorial Reviewed verified by ORBi |
 | Kanis, J. A., McCloskey, E. V., Harvey, N. C., Cooper, C., Rizzoli, R., Dawson-Hughes, B., Maggi, S., & Reginster, J.-Y. (07 November 2022). Intervention thresholds and diagnostic thresholds in the management of osteoporosis. Aging Clinical and Experimental Research, 34, 3155-3157. doi:10.1007/s40520-022-02216-7 Peer Reviewed verified by ORBi |
 | Veronese, N., Honvo, G., Bruyère, O., Rizzoli, R., Barbagallo, M., Maggi, S., Smith, L., Sabico, S., Al-Daghri, N., Cooper, C., Pegreffi, F., & Reginster, J.-Y. (2022). Knee osteoarthritis and adverse health outcomes: an umbrella review of meta-analyses of observational studies. Aging Clinical and Experimental Research. doi:10.1007/s40520-022-02289-4 Peer Reviewed verified by ORBi |
 | Fuggle, N., Al-Daghri, N., Bock, O., Branco, J., Bruyère, O., Casado, E., Cavalier, E., Cortet, B., de Wit, M., Giusti, A., Halbout, P., Harvey, N. C., Hiligsmann, M., Kaufman, J.-M., Kurth, A., Maggi, S., Matijevic, R., Minisola, S., Palacios, S., ... Cooper, C. (November 2022). Novel formulations of oral bisphosphonates in the treatment of osteoporosis. Aging Clinical and Experimental Research, 34 (11), 2625 - 2634. doi:10.1007/s40520-022-02272-z Peer Reviewed verified by ORBi |
 | Chevalley, T., Brandi, M. L., Cashman, K. D., Cavalier, E., Harvey, N. C., Maggi, S., Cooper, C., Al-Daghri, N., Bock, O., Bruyère, O., Rosa, M. M., Cortet, B., Cruz-Jentoft, A. J., Cherubini, A., Dawson-Hughes, B., Fielding, R., Fuggle, N., Halbout, P., Kanis, J. A., ... Rizzoli, R. (November 2022). Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group. Aging Clinical and Experimental Research, 34 (11), 2603 - 2623. doi:10.1007/s40520-022-02279-6 Peer Reviewed verified by ORBi |
 | Kanis, J. A., McCloskey, E. V., Harvey, N. C., Cooper, C., Rizzoli, R., Dawson-Hughes, B., Maggi, S., & Reginster, J.-Y. (2022). The need to distinguish intervention thresholds and diagnostic thresholds in the management of osteoporosis. Osteoporosis International. doi:10.1007/s00198-022-06567-9 Peer Reviewed verified by ORBi |
 | Veronese, N., & Reginster, J.-Y. (18 October 2022). Authors' Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations. Drugs, 82 (14), 1513-1514. doi:10.1007/s40265-022-01789-x Peer Reviewed verified by ORBi |
 | Veronese, N., Cooper, C., Bruyère, O., Al-Daghri, N., Branco, J., Cavalier, E., Cheleschi, S., da Silva Rosa, M. C., Conaghan, P. G., Dennison, E. M., de Wit, M., Fioravanti, A., Fuggle, N. R., Haugen, I. K., Herrero-Beaumont, G., Honvo, G., Laslop, A., Matijevic, R., Migliore, A., ... Reginster, J.-Y. (16 September 2022). Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations. Drugs, 82 (13), 1347-1355. doi:10.1007/s40265-022-01773-5 Peer Reviewed verified by ORBi |
 | Buckinx, F., Maton, L., Dalimier, V., Mouton, A., Lengele, L., Reginster, J.-Y., & Bruyère, O. (16 September 2022). Development and Validation of New Exercises to Promote Physical Activity in Nursing Home Settings. Geriatrics, 7 (5), 100. doi:10.3390/geriatrics7050100 Peer reviewed |
 | Veronese, N., Bolzetta, F., Cacco, C., Cester, A., Smith, L., Demurtas, J., Cooper, C., Rizzoli, R., Caruso, M. G., Notarnicola, M., Reginster, J.-Y., Maggi, S., Barbagallo, M., Trott, M., & Dominguez, L. J. (13 August 2022). Dietary acrylamide and incident osteoporotic fractures: an 8-year prospective cohort study. Aging Clinical and Experimental Research, 34 (10), 2441-2448. doi:10.1007/s40520-022-02214-9 Peer Reviewed verified by ORBi |
 | BRUYERE, O., Reginster, J.-Y., & Honvo, G. (August 2022). Health Economic Evaluation of a High and Low Molecular Weight Hyaluronic Acid Formulation for the Treatment of Knee Osteoarthritis. Post Hoc Analyses from a Randomized Clinical Trial. Rheumatology and Therapy, 9 (4), 1119-1128. doi:10.1007/s40744-022-00466-5 Peer Reviewed verified by ORBi |
 | BRUYERE, O., Reginster, J.-Y., & Beaudart, C. (July 2022). Lifestyle approaches to prevent and retard sarcopenia: A narrative review. Maturitas, 161, 44-48. doi:10.1016/j.maturitas.2022.02.004 Peer Reviewed verified by ORBi |
 | Demonceau, C., Reginster, J.-Y., & Bruyère, O. (2022). Ostéosarcopénie : quand les deux ne font qu'un. Medi-Sphere, (705), 14-16. Editorial reviewed |
 | Hiligsmann, M., Li, N., Cooper, C., Reginster, J.-Y., Silverman, S., Carswell, C., & Husereau, D. (12 April 2022). Improving the reporting of economic evaluation in osteoporosis: the value of CHEERS 2022 statement. Osteoporosis International, 33 (8), 1641-1642. doi:10.1007/s00198-022-06400-3 Peer Reviewed verified by ORBi |
 | Locquet, M., Sanchez Rodriguez, M. D. C., Bruyère, O., Geerinck, A., Lengele, L., Reginster, J.-Y., & Beaudart, C. (2022). Intrinsic Capacity Defined Using Four Domains and Mortality Risk: A 5-Year Follow-Up of the SarcoPhAge Cohort. The journal of nutrition, health & aging, 26 (1), 23-29. doi:10.1007/s12603-021-1702-7 Peer reviewed |
 | Geerinck, A., Locquet, M., Hiligsmann, M., Reginster, J.-Y., Bruyère, O., & Beaudart, C. (2022). Patients' preferences for quality-of-life aspects in sarcopenia: a best-worst scaling study. European Geriatric Medicine, 13 (2), 483-91. doi:10.1007/s41999-021-00563-8 Peer reviewed |
 | Veronese, N., Honvo, G., Amuthavalli Thiyagarajan, J., Rizzoli, R., Cooper, C., BRUYERE, O., Mikton, C., Sumi, Y., Diaz, T., Reginster, J.-Y., Banerjee, A., & members of the WHO Collaborating Center Working Group on Locomotor Capacity. (2022). Attributes and definitions of locomotor capacity in older people: a World Health Organisation (WHO) locomotor capacity working group meeting report. Aging Clinical and Experimental Research, 34 (3), 481-483. doi:10.1007/s40520-022-02080-5 Peer Reviewed verified by ORBi |
 | Veronese, N., Smith, L., Zigoura, E., Barbagallo, M., Dominguez, L. J., Barone, A., Cella, A., Cooper, C., Rizzoli, R., Reginster, J.-Y., Maggi, S., & Pilotto, A. (2022). Multidimensional prognostic index and the risk of fractures: an 8-year longitudinal cohort study in the Osteoarthritis Initiative. Archives of Osteoporosis, 17 (1), 5. doi:10.1007/s11657-021-01015-3 Peer Reviewed verified by ORBi |
 | Tenti, S., Veronese, N., Cheleschi, S., Seccafico, I., BRUYERE, O., Reginster, J.-Y., & Fioravanti, A. (2022). Prescription-grade crystalline glucosamine sulfate as an add-on therapy to conventional treatments in erosive osteoarthritis of the hand: results from a 6-month observational retrospective study. Aging Clinical and Experimental Research, 34 (7), 1613-1625. doi:10.1007/s40520-022-02151-7 Peer Reviewed verified by ORBi |
 | Cheleschi, S., Tenti, S., Seccafico, I., Mondanelli, N., Reginster, J.-Y., & Fioravanti, A. (2022). MicroRNA as possible mediators of celecoxib and glucosamine sulfate-induced effects on apoptosis and oxidative stress: an in vitro study on human osteoarthritic chondrocytes. Aging Clinical and Experimental Research, 34 (S1), 239-240. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2022). Multimodal pharmacological approach: from evidence-based to daily practice. Aging Clinical and Experimental Research, 34 (S1), 103. Peer Reviewed verified by ORBi |
 | Honvo, G., Veronese, N., Bruyère, O., Rizzoli, R., Amuthavalli Thiyagarajan, J., Cooper, C., & Reginster, J.-Y. (2022). Measurement tools for attributes of locomotor capacity in older people: protocol for a systematic review of available tools and evidence-based recommendations. Aging Clinical and Experimental Research, 34 (S1), 450. Peer Reviewed verified by ORBi |
 | Veronese, N., Stefanac, S., Koyanagi, A., Al-Daghri, N., Sabico, S., Cooper, C., Rizzoli, R., Reginster, J.-Y., Barbagallo, M., Di Bella, G., Mandalà, C., Dominguez, L., Smith, L., & Maggi, S. (2022). Lower limb muscle strength and muscle mass are associated with incident symptomatic knee osteoarthritis: a longitudinal cohort study. Aging Clinical and Experimental Research, 34 (S1), 50. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2022). Шановні читачі! Bolʹ, Sustavy, Pozvonočnik, 12 (1), 1. doi:10.22141/pjs.12.1.2022.321 Peer Reviewed verified by ORBi |
 | Arden, N., Perry, T. A., Bannuru, R. R., Bruyère, O., Cooper, C., Haugen, I. K., Hochberg, M. C., McAlindon, T. E., Mobasheri, A., & Reginster, J.-Y. (2022). How can we explain the differences between the OARSI and ESCEO Guidelines for the management of knee osteoarthritis? Osteoporosis International, 32 (Suppl 1), 57-58. Peer Reviewed verified by ORBi |
 | Honvo, G., Reginster, J.-Y., Mobasheri, A., Lengele, L., Avouac, B., Rizzoli, R., & Bruyère, O. (2022). Post-marketing safety surveillance of anti-osteoarthritis drugs: a protocol for a systematic review of published literature. Osteoporosis International, 32 (Suppl 1), 242-243. Peer Reviewed verified by ORBi |
 | LADANG, A., KOVACS, S., Lengele, L., Reginster, J.-Y., Bruyère, O., & Cavalier, E. (2022). Neurofilament-light chains (NF-L), a biomarker of neuronal damage, is increased in sarcopenic patients: results of the sarcophage study. Osteoporosis International, 32 (Suppl 1), 53. Peer Reviewed verified by ORBi |
 | Willers, C., Norton, N., Harvey, N. C., Jacobson, T., Johansson, H., Lorentzon, M., McCloskey, E. V., Borgström, F., Kanis, J. A., Kaux, J.-F. (Other coll.), Reginster, J.-Y. (Other coll.), Bruyère, O. (Other coll.), Cavalier, E. (Other coll.), & LECART, M.-P. (Other coll.). (January 2022). Osteoporosis in Europe: a compendium of country-specific reports. Archives of Osteoporosis, 17 (1), 23. doi:10.1007/s11657-021-00969-8 Peer Reviewed verified by ORBi |
 | Lengele, L., Locquet, M., Moutschen, M., Beaudart, C., Kaux, J.-F., Gillain, S., Shadouh, C., Reginster, J.-Y., & Bruyère, O. (2022). Relationships between malnutrition, sarcopenia, and frailty and the incidence of Covid-19 in older adults: data from the sarcophage cohort. Osteoporosis International, 32 (Suppl 1), 50. Peer Reviewed verified by ORBi |
 | Veronese, N., Demurtas, J., Smith, L., Reginster, J.-Y., Bruyère, O., Honvo, G., & Maggi, S. (2022). Glucosamine sulphate: an umbrella review of health outcomes. Osteoporosis International, 32 (Suppl 1), 43. Peer Reviewed verified by ORBi |
 | Kanis, J. A., Harvey, N. C., McCloskey, E., Veronese, N., Lorentzon, M., Cooper, C., Rizzoli, R., Adib, G., Al-Daghri, N., Campusano, C., Chandran, M., Dawson-Hughes, B., Javaid, K., Jiwa, F., Johansson, H., Lee, J. K., Liu, E., Messina, D., Minski, O., ... Reginster, J.-Y. (2022). Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporosis International, 33 (Suppl 1), 24. Peer Reviewed verified by ORBi |
 | Bruyère, O., Detilleux, J., & Reginster, J.-Y. (2022). Health technology assessment of different glucosamine formultaions and preparations currently marketed in Thailand: impact of their clinical effect and selling price. Aging Clinical and Experimental Research, 34 (S1), 285. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Silverman, S., Singer, A., Pearman, L., Mathew, J., Wang, Y., Caminis, J., & Reginster, J.-Y. (2022). Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate in US men at imminent risk of fracture. Journal of Managed Care and Specialty Pharmacy, 28, 105. Peer Reviewed verified by ORBi |
 | Tenti, S., Veronese, N., Cheleschi, S., Seccafico, I., Reginster, J.-Y., & Fioravanti, A. (2022). Erosive osteoarthritis of the hand: efficacy of prescription-grade crystalline glucosamine sulfate as an add-on therapy to conventional treatments. Aging Clinical and Experimental Research, 34 (S1), 49-50. Peer Reviewed verified by ORBi |
 | Bruyère, O., Reginster, J.-Y., & Honvo, G. (2022). Health economics evaluation of a high and low molecular weight hyaluronic acid formulation in patients with knee osteoarthritis. Analysis from a randomized clinical trial. Aging Clinical and Experimental Research, 34 (S1), 50. Peer Reviewed verified by ORBi |
 | Ladang, A., Kovacs, S., Lengele, L., Locquet, M., Reginster, J.-Y., Bruyère, O., & Cavalier, E. (2022). Neurofilament light chain concentration in an aging population. Aging Clinical and Experimental Research, 34 (2), 331-339. doi:10.1007/s40520-021-02054-z Peer Reviewed verified by ORBi |
 | Beaudart, C., Boonen, A., Li, N., Bours, S., Goemaere, S., Reginster, J.-Y., Roux, C., McGowan, B., Diez-Perez, A., Rizzoli, R., Cooper, C., & Hiligsmann, M. (2022). Patient preferences for lifestyle behaviours in osteoporotic fracture prevention: a cross-European discrete choice experiment. Osteoporosis International, 33, 1335-1346. doi:10.1007/s00198-022-06310-4 Peer Reviewed verified by ORBi |
 | Lengele, L., Locquet, M., Moutschen, M., Beaudart, C., KAUX, J.-F., Gillain, S., Reginster, J.-Y., & Bruyère, O. (January 2022). Frailty but not sarcopenia nor malnutrition increases the risk of developing COVID-19 in older community-dwelling adults. Aging Clinical and Experimental Research, 34 (1), 223-234. doi:10.1007/s40520-021-01991-z Peer Reviewed verified by ORBi |
 | Curtis, E. M., Reginster, J.-Y., Al-Daghri, N., Biver, E., Brandi, M. L., CAVALIER, E., Hadji, P., Halbout, P., Harvey, N. C., Hiligsmann, M., Javaid, M. K., Kanis, J. A., Kaufman, J.-M., Lamy, O., Matijevic, R., Perez, A. D., RADERMECKER, R., Rosa, M. M., Thomas, T., ... Cooper, C. (2022). Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clinical and Experimental Research, 34, 695-714. doi:10.1007/s40520-022-02100-4 Peer Reviewed verified by ORBi |
 | Locquet, M., Bonnard, F., Beaudart, C., COENDO, C., Gillain, S., Reginster, J.-Y., & Bruyère, O. (2022). An assessment of the Toulouse Saint Louis University mini falls assessment tool to predict incident falls among older adults residing in nursing homes: a 6-month prospective study. Osteoporosis International, 32 (Suppl 1), 230. Peer Reviewed verified by ORBi |
 | Geerinck, A., Beaudart, C., Reginster, J.-Y., Wojszel, Z. B., De Souza Orlandi, F., Bahat, G., Erdogan, T., Montero-Errasquin, B., Alekna, V., & Bruyère, O. (2022). Measurement properties of the Short Form Sarcopenia Quality of Life (SF-SARQOL) Questionnaire in an international dataset. Osteoporosis International, 32 (Suppl 1), 249. Peer Reviewed verified by ORBi |
 | Beaudart, C., Boonen, A., Li, N., Bours, S., Goemaere, S., Reginster, J.-Y., Roux, C., McGowan, B., Diez-Perez, A., Rizzoli, R., Cooper, C., & Hiligsmann, M. (2022). Patient’s preferences for lifestyle changes in osteoporotic fracture prevention: a cross-european discrete-choice experiment. Osteoporosis International, 32 (supp1), 89 and 46-47. Peer Reviewed verified by ORBi |
 | Messina O.D., Clarck, P. E. C., Mendez-Sanchez L.M.S., Peralta, M. L. P., Cerdas, S., Campusano, C., Visal Neira, L. F., Lasaretti Castro, M. L., Morales Torres, J., Harvey, N. C., Reginster, J.-Y., & Zerbini, C. F. (2022). Latin American consensus on the management of glucocorticoid induces osteoporosis : a preliminary communication. Osteoporosis International, 32 (supp 1), 288-289. Peer Reviewed verified by ORBi |
 | Veronese, N., Smith, L., ZIGOURA, E., BARBAGALLO, M., DOMINGUEZ, M., COOPER, C., RIZZOLI, R., Reginster, J.-Y., MAGGI, S., & PILOTTO, A. (2022). Multidimensional prognostic index and the risk of fractures: an 8-year longitudinal cohort study in the osteoarthritis initiative. Osteoporosis International, 32 (supp1), 46. Peer Reviewed verified by ORBi |
 | Bahat, G., Muge Catikkas, N., Yavuz, D. G., Borman, P., Guzel, R., Esra Bozkurt, M., & Reginster, J.-Y. (2022). The current situation in the approach to osteoporosis in older adults in Turkey: aeas in need of improvement with a model for other populations. Aging Clinical and Experimental Research, 34 (S1), 96. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2022). Management of hand osteoarthritis: how can the ACR guidelines be applied to an European population in a patient-centric approach. Aging Clinical and Experimental Research, 34 (S1), 55. Peer Reviewed verified by ORBi |
 | Chevalley, T., Brandi, M., Cavalier, E., Harvey, N., Iolascon, G., Cooper, C., Hannouche, D., Kaux, J.-F., Kurth, A., Maggi, S., Maier, G., Papavasiliou, K., Al-Daghri, N., Sosa-Henriquez, M., Suhm, N., Tarantino, U., Reginster, J.-Y., & Rizzoli, R. (October 2021). How can the orthopedic surgeon ensure optimal vitamin D status in patients operated for an osteoporotic fracture? Osteoporosis International, 32 (10), 1921-1935. doi:10.1007/s00198-021-05957-9 Peer Reviewed verified by ORBi |
 | Fuggle, N. R., Singer, A., Gill, C., Patel, A., Medeiros, A., Mlotek, A. S., Pierroz, D. D., Halbout, P., Harvey, N. C., Reginster, J.-Y., Cooper, C., & Greenspan, S. L. (April 2021). Correction to: How has COVID-19 affected the treatment of osteoporosis? An IOF-NOF-ESCEO global survey. Osteoporosis International, 32 (4), 801. doi:10.1007/s00198-021-05905-7 Peer Reviewed verified by ORBi |
 | Geerinck, A., Locquet, M., Reginster, J.-Y., Bruyère, O., & Beaudart, C. (2021). Letter to the Editor: Discriminative Power of the Sarcopenia Quality of Life (SarQoL®) Questionnaire with the EWGSOP2 Criteria [letter to the editor]. The Journal of frailty & aging, 10 (2), 193-194. doi:10.14283/jfa.2020.47 Peer reviewed |
 | Slomian, J., Reginster, J.-Y., Emonts, P., & Bruyère, O. (2021). Identifying maternal needs following childbirth: comparison between pregnant women and recent mothers. BMC Pregnancy and Childbirth, 21 (1), 405. doi:10.1186/s12884-021-03858-7 Peer Reviewed verified by ORBi |
 | Chandran, M., Ganesan, G., Tan, K. B., Reginster, J.-Y., & Hiligsmann, M. (January 2021). Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women. Osteoporosis International, 32 (1), 133-144. doi:10.1007/s00198-020-05536-4 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Maggi, S., Veronese, N., Sartori, L., & Reginster, J.-Y. (2021). Cost-effectiveness of buffered soluble alendronate 70mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy. Osteoporosis International, 32, 595-606. doi:10.1007/s00198-020-05802-5 Peer Reviewed verified by ORBi |
 | Geerinck, A., Locquet, M., Bruyère, O., Reginster, J.-Y., & Beaudart, C. (2021). Evaluating quality of life in frailty: applicability and clinimetric properties of the SarQoL(®) questionnaire. Journal of Cachexia, Sarcopenia and Muscle, 12 (2), 319-330. doi:10.1002/jcsm.12687 Peer Reviewed verified by ORBi |
 | Migliore, A., Blicharski, T., Plebanski, R., Zegota, Z., Gyula, G., Rannou, F., & Reginster, J.-Y. (2021). Knee Osteoarthritis Pain Management with an Innovative High and Low Molecular Weight Hyaluronic Acid Formulation (HA-HL): A Randomized Clinical Trial. Rheumatology and Therapy, 8 (4), 1617-1636. doi:10.1007/s40744-021-00363-3 Peer Reviewed verified by ORBi |
 | Cheleschi, S., Tenti, S., Giannotti, S., Veronese, N., Reginster, J.-Y., & Fioravanti, A. (2021). A combination of celecoxib and glucosamine sulfate has anti-inflammatory and chondroprotective effects: results from an in vitro study on human osteoarthritic chondrocytes. International Journal of Molecular Sciences, 22, 8980. doi:10.3390/ijms22168980 Peer Reviewed verified by ORBi |
 | Cooper, C., Halbout, P., Dawson-hughes, B., Harvey, N. C., Kanis, J. A., Reginster, J.-Y., & Rizzoli, R. (2021). In memory of Harry K. Genant. Osteoporosis International, 32, 607-608. doi:10.1007/s00198-021-05857-y Peer Reviewed verified by ORBi |
 | Parsons, C. M., Judge, A., Meyer, R., Bruyère, O., Petit-Dop, F., Chapurlat, R., Reginster, J.-Y., Cooper, C., & Inskip, H. (January 2021). Determining individual trajectories of joint space loss: improved statistical methods for monitoring knee osteoarthritis disease progression. Osteoarthritis and Cartilage, 29 (1), 59-67. doi:10.1016/j.joca.2020.09.009 Peer Reviewed verified by ORBi |
 | Arden, N. K., Perry, T. A., Bannuru, R. R., Bruyère, O., Cooper, C., Haugen, I. K., Hochberg, M. C., McAlindon, T. E., Mobasheri, A., & Reginster, J.-Y. (2021). Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nature Reviews Rheumatology, 17, 59-66. doi:10.1038/s41584-020-00523-9 Peer Reviewed verified by ORBi |
 | Fuggle, N. R., Singer, A., Gill, C., Patel, A., Medeiros, A., Mlotek, A. S., Pierroz, D. D., Halbout, P., Harvey, C. N., Reginster, J.-Y., Cooper, C., & Greenspan, S. L. (2021). How has COVID-19 affected the treatment of osteoporosis? An IOF-NOF-ESCEO global survey. Osteoporosis International, 32, 611-617. doi:10.1007/s00198-020-05793-3 Peer Reviewed verified by ORBi |
 | Locquet, M., Bonnard, F., Beaudart, C., COENDO, C., Gillain, S., Reginster, J.-Y., & Bruyère, O. (2021). An Assessment of the Toulouse Saint Louis University Mini Falls Assessment Tool to Predict Incident Falls among Older Adults Residing in Nursing Homes: A 6-Month Prospective Study. Journal of Nutrition, Health and Aging, 25 (7), 933-937. doi:10.1007/s12603-021-1651-1 Peer Reviewed verified by ORBi |
 | Lengele, L., Bruyère, O., Beaudart, C., Reginster, J.-Y., & Locquet, M. (2021). Malnutrition, assessed by the Global Leadership Initiative on Malnutrition (GLIM) criteria but not by the mini nutritional assessment (MNA), predicts the incidence of sarcopenia over a 5-year period in the SarcoPhAge cohort. Aging Clinical and Experimental Research, 33 (6), 1507-1517. doi:10.1007/s40520-021-01880-5 Peer Reviewed verified by ORBi |
 | Li, N., Cornelissen, D., Silverman, S., Pinto, D., Si, L., Kremer, I., Bours, S., de Bot, R., Evers, S., van den Bergh, J., Reginster, J.-Y., & Hiligsmann, M. (2021). An Updated Systematic Review of Cost‑Effectiveness Analyses of Drugs for Osteoporosis. PharmacoEconomics, 39, 181-209. doi:10.1007/s40273-020-00965-9 Peer Reviewed verified by ORBi |
 | Lengele, L., Bruyère, O., Beaudart, C., Reginster, J.-Y., & Locquet, M. (2021). Impact of malnutrition status on muscle parameter changes over a 5-year follow-up of community-dwelling older adults from the SarcoPhage Cohort. Nutrients, 13 (2), 407. doi:10.3390/nu13020407 Peer Reviewed verified by ORBi |
 | Geerinck, A., Locquet, M., Reginster, J.-Y., Bruyère, O., & Beaudart, C. (2021). Discriminative power of the Sarcopenia Quality of Life (SarQoL) questionnaire with the EWGSOP2 criteria [letter to the editor]. Journal of Frailty and Aging, 10 (2), 193-194. Peer Reviewed verified by ORBi |
 | Chandran, M., Ganesan, G., Tan, K. B., Reginster, J.-Y., & Hiligsmann, M. (2021). Using health-economic evidence to support policy-level decision-making in Singapore-sensitivity analysis that provides further confidence in fracture probability-based cost-effective intervention thresholds. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 32, 787-789. doi:10.1007/s00198-021-05876-9 Peer reviewed |
 | Beaudart, C., Bauer, J. M., Landi, F., Bruyère, O., Reginster, J.-Y., & Hiligsmann, M. (2021). Experts' preferences for sarcopenia outcomes: a discrete-choice experiment from a working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) in collaboration with the European Union of Geriatric Medicine Society (EUGMS). Aging Clinical and Experimental Research, 33, 1079-1083. doi:10.1007/s40520-021-01794-2 Peer Reviewed verified by ORBi |
 | Grygorieva, N., Povoroznyuk, R., Matijevic, R., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2021). In memoriam: Vladyslav Povoroznyuk. Osteoporosis International, 32 (9), 1905-1906. doi:10.1007/s00198-021-06048-5 Peer Reviewed verified by ORBi |
 | McClung, M. R., Bolognese, M. A., Brown, J. P., Reginster, J.-Y., Langdahl, B. L., Shi, Y., Timoshanko, J., Libanati, C., Chines, A., & Oates, M. K. (2021). Skeletal responses to romosozumab after 12 months of denosumab. Journal of Bone and Mineral Research Plus, 5 (7), 10512. doi:10.1002/jbm4.10512 Peer reviewed |
 | Lengele, L., Bruyère, O., Beaudart, C., Reginster, J.-Y., & Loquet, M. (2021). Correction to: Malnutrition, assessed by the Global Leadership Initiative on Malnutrition (GLIM) criteria but not by the mini nutritional assessment (MNA), predicts the incidence of sarcopenia over a 5‑year period in the SarcoPhAge cohort. Aging Clinical and Experimental Research. doi:10.1007/s40520-021-01901-3 Peer Reviewed verified by ORBi |
 | Bahat, G., Catikkas, N. M., KARAN, M. A., & Reginster, J.-Y. (2021). Orthogeriatrics: a vital requirement for improving fragility fracture patient care internationally with particular reference to Turkey. Archives of Osteoporosis, 16. doi:10.1007/s11657-021-00967-w Peer Reviewed verified by ORBi |
 | Zhang, Z., Huang, C., Cao, Y., Mu, R., Zhang, M. C., Xing, D., Fan, D., Ding, Y., Guo, J., Hou, Y., Jianhao, L., Veronese, N., Reginster, J.-Y., Bruyère, O., Cavalier, E., & Zhang, H. (2021). 2021 revised algorithm for the management of knee osteoarthritis-the Chinese viewpoint. Aging Clinical and Experimental Research, 33 (8), 2141-2147. doi:10.1007/s40520-021-01906-y Peer Reviewed verified by ORBi |
 | Bruyère, O., Detilleux, J., & Reginster, J.-Y. (2021). Cost-Effectiveness Assessment of Different Glucosamines in Patients with Knee Osteoarthritis: A Simulation Model Adapted to Germany. Current Aging Science, 14 (3), 242-248. doi:10.2174/1874609814666210415092845 Peer reviewed |
 | Bahat, G., Catikkas, N. M., Yavuz, D. G., Borman, P., Guzel, R., & Reginster, J.-Y. (2021). The current situation in the approach to osteoporosis in older adults in Turkey: areas in need of improvement with a model for other populations. Archives of Osteoporosis, 16 (1). doi:10.1007/s11657-021-01038-w Peer Reviewed verified by ORBi |
 | Veronese, N., Stefanac, S., Koyanagi, A., Al-Daghri, N. M., Sabico, S., Cooper, C., Rizzoli, R., Reginster, J.-Y., Barbagallo, M., Dominguez, L. J., Smith, L., & Maggi, S. (2021). Lower Limb Muscle Strength and Muscle Mass Are Associated With Incident Symptomatic Knee Osteoarthritis: A Longitudinal Cohort Study. Frontiers in Endocrinology, 12. doi:10.3389/fendo.2021.804560 Peer Reviewed verified by ORBi |
 | Beaudart, C., Bonnefoy, M., Gilbert, T., Paillaud, E., Raynaud-Simon, A., Guérin, O., Jeandel, C., Le Sourd, B., Haine, M., Ferry, M., Rolland, Y., Berrut, G., Reginster, J.-Y., & Bruyère, O. (2021). Quelle qualité de vie pour le patient sarcopénique ? Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 19 (3), 245-252. doi:10.1684/pnv.2021.0948 Peer reviewed |
 | Yeap, S. S., Tanavalee, A., Perez, E. C., Tan, M. P., Reyes, B. H. M., Lee, J. K., Norhamdan, M. Y., Vista, E. S., Chan, W. S., Cong, S. B., Tam, P. T. T., Kaufman, J.-M., Reginster, J.-Y., Veronese, N., & Penserga, E. (2021). 2019 revised algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint. Aging Clinical and Experimental Research, 33, 1149-1156. doi:10.1007/s40520-021-01834-x Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Beaudart, C., Al-Daghri, N., Avouac, B., Bauer, J., Bere, N., Bruyère, O., Cerreta, F., Cesari, M., Rosa, M. M., Cooper, C., Cruz Jentoft, A. J., Dennison, E., Geerinck, A., Gielen, E., Landi, F., Laslop, A., Maggi, S., Prieto Yerro, M. C., ... Fielding, R. A. (2021). Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults. Aging Clinical and Experimental Research, 33, 3-17. doi:10.1007/s40520-020-01663-4 Peer Reviewed verified by ORBi |
 | Geerinck, A., Beaudart, C., Reginster, J.-Y., Locquet, M., Monseur, C., GILLAIN, S., & Bruyère, O. (2021). Development and validation of a short version of the Sarcopenia Quality of Life questionnaire: the SF‑SarQoL. Quality of Life Research, 30 (8), 2349-2362. doi:10.1007/s11136-021-02823-3 Peer Reviewed verified by ORBi |
 | Locquet, M., Bruyère, O., Lengele, L., Reginster, J.-Y., & Beaudart, C. (2021). Relationship between smoking and the incidence of sarcopenia: The SarcoPhAge cohort. Public Health, 193, 101-108. doi:10.1016/j.puhe.2021.01.017 Peer Reviewed verified by ORBi |
 | Rolland, Y., Cesari, M., Fielding, R. A., Reginster, J.-Y., Vellas, B., & Cruz-Jentoft, A. J. (2021). Osteoporosis in Frail Older Adults: Recommendations for Research from the ICFSR Task Force 2020. The Journal of frailty & aging, 10 (2), 168-175. doi:10.14283/jfa.2021.4 Peer reviewed |
 | Reginster, J.-Y., & Veronese, N. (2021). Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment. Aging Clinical and Experimental Research, 33, 37-47. doi:10.1007/s40520-020-01643-8 Peer Reviewed verified by ORBi |
 | Neuprez, A., Kaux, J.-F., Locquet, M., Beaudart, C., & Reginster, J.-Y. (January 2021). The presence of erosive joints is a strong predictor of radiological progression in hand osteoarthritis: results of a 2-year prospective follow-up of the Liège Hand Osteoarthritis Cohort (LIHOC). Arthritis Research and Therapy, 23 (1), 12 (9. doi:10.1186/s13075-020-02390-x Peer Reviewed verified by ORBi |
 | Sanchez Rodriguez, M. D. C., Locquet, M., Bruyère, O., Lengele, L., CAVALIER, E., Reginster, J.-Y., & Beaudart, C. (2021). Prediction of 5-year mortality risk by malnutrition according to the GLIM format using seven pragmatic approaches to define the criterion of loss of muscle mass. Clinical Nutrition, 40 (4), 2188-2199. doi:10.1016/j.clnu.2020.09.047 Peer Reviewed verified by ORBi |
 | Geerinck, A., Dawson-Hughes, B., Beaudart, C., Locquet, M., Reginster, J.-Y., & Bruyère, O. (2021). Assessment of the performance of the SarQoL questionnaire in screening for sarcopenia in older people. Aging Clinical and Experimental Research, 33, 2149-2155. doi:10.1007/s40520-021-01913-z Peer Reviewed verified by ORBi |
 | DEROISY, R., NEUPREZ, A., LEONARD, Y., LECART, M.-P., MASSENET, V., GILLET, P., Reginster, J.-Y., & KAUX, J.-F. (December 2020). Identification, through a Fracture Liaison Service, of undiagnosed vertebral fractures in patients hospitalized for a prevalent hip fragility fracture. Osteoporosis International, 31 (S1), 200. Peer Reviewed verified by ORBi |
 | Beaudart, C., Lengele, L., Leclercq, V., Geerinck, A., Sanchez Rodriguez, M. D. C., Bruyère, O., & Reginster, J.-Y. (December 2020). Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta‑Analysis with a 6‑Month Time Horizon. Drugs, 80 (18), 1947-1959. doi:10.1007/s40265-020-01423-8 Peer Reviewed verified by ORBi |
| Geerinck, A., Reginster, J.-Y., Locquet, M., Monseur, C., Gillain, S., Bruyère, O., & Beaudart, C. (December 2020). Clinimetric properties of the newly developed short form sarcopenia quality of life (SF-SarQoL) questionnaire [Poster presentation]. Society on Sarcopenia, Cachexia and Wasting Disorders conference. |
 | NEUPREZ, A., DEROISY, R., LEONARD, Y., LECART, M.-P., MASSENET, V., GILLET, P., KAUX, J.-F., & Reginster, J.-Y. (December 2020). Secondary fracture prevention in hip fracture patients: 6-year impact of a Fracture Liaison Service. Osteoporosis International, 31 (S1), 199-200. Peer Reviewed verified by ORBi |
 | Honvo, G., Lengele, L., Charles, A., Reginster, J.-Y., & Bruyère, O. (December 2020). Role of Collagen Derivatives in Osteoarthritis and Cartilage Repair: A Systematic Scoping Review With Evidence Mapping. Rheumatology and Therapy, 7 (4), 703-740. doi:10.1007/s40744-020-00240-5 Peer Reviewed verified by ORBi |
 | Buckinx, F., Lecocq, G., Bornheim, S., Van Beveren, J., VALCU, C.-A., DANIEL, C., Bruyère, O., Reginster, J.-Y., D'Hooghe, P., & Kaux, J.-F. (August 2020). French translation and validation of the Achilles Tendon Total Rupture Score "ATRS". Foot and Ankle Surgery, 26 (6), 662-668. doi:10.1016/j.fas.2019.08.010 Peer Reviewed verified by ORBi |
 | Locquet, M., Willems, T., Specque, C., Beaudart, C., Bruyère, O., Van Beveren, J., Dardenne, N., Reginster, J.-Y., & Kaux, J.-F. (July 2020). Cross-cultural adaptation, translation, and validation of the functional assessment scale for acute hamstring injuries (FASH) questionnaire for French-speaking patients. Disability and Rehabilitation, 42 (14), 2076-2082. doi:10.1080/09638288.2018.1544669 Peer Reviewed verified by ORBi |
 | Geiker, N. R. W., Mølgaard, C., Iuliano, S., Rizzoli, R., Manios, Y., van Loon, L. J. C., Lecerf, J.-M., Moschonis, G., Reginster, J.-Y., Givens, I., & Astrup, A. (April 2020). Correction to: Impact of whole dairy matrix on musculoskeletal health and aging–current knowledge and research gaps (Osteoporosis International, (2019), 10.1007/s00198-019-05229-7). Osteoporosis International, 31 (4), 795. doi:10.1007/s00198-019-05262-6 Peer Reviewed verified by ORBi |
 | Fuggle, N. R., Cooper, C., Oreffo, R. O. C., Price, A. J., Kaux, J.-F., Maheu, E., Cutolo, M., Honvo, G., Conaghan, P. G., Berenbaum, F., Branco, J., Brandi, M. L., Cortet, B., Veronese, N., Kurth, A. A., Matijevic, R., Roth, R., Pelletier, J. P., Martel-Pelletier, J., ... Reginster, J.-Y. (April 2020). Alternative and complementary therapies in osteoarthritis and cartilage repair. Aging Clinical and Experimental Research, 32 (4), 547-560. doi:10.1007/s40520-020-01515-1 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Reginster, J.-Y., & Silverman, S. (March 2020). The Value of a Patient-Level Modeling Approach and Need for Better Reporting in Economic Evaluations of Osteoporosis [letter to the editor]. Journal of Managed Care and Specialty Pharmacy, 26 (3), 334-335. doi:10.18553/jmcp.2020.26.3.334 Peer Reviewed verified by ORBi |
 | Neuprez, A., Neuprez, A., KAUX, J.-F., KURTH, W., DANIEL, C., THIRION, T., Hustin, J.-P., Gillet, P., Bruyère, O., & Reginster, J.-Y. (March 2020). Total joint replacement improves pain, functional quality of life, and health utilities in patients with late-stage knee and hip osteoarthritis for up to 5 years. Clinical Rheumatology, 39 (3), 861-871. doi:10.1007/s10067-019-04811-y Peer Reviewed verified by ORBi |
 | Geerinck, A., Beaudart, C., Locquet, M., Reginster, J.-Y., & Bruyère, O. (March 2020). Association between frailty and quality of life measured with the SarQoL®, SF-36 and EQ-5D questionnaires in older people from the SarcoPhAge cohort [Poster presentation]. International Conference on Frailty and Sarcopenia Research, Toulouse, France. |
 | Locquet, M., Bornheim, S., Colas, L., Van Beveren, J., Bruyère, O., Reginster, J.-Y., & Kaux, J.-F. (March 2020). Erratum à « Traduction en langue française, adaptation transculturelle et validation du questionnaire “Victorian Institute of Sport Assessment Scale for Proximal Hamstring Tendinopathy” (VISA-H) [J. Traumatol. Sport 36 (2019) 217–221](S0762915X19300385)(10.1016/j.jts.2019.04.001). Journal de Traumatologie du Sport, 37 (1), 62. doi:10.1016/j.jts.2020.01.001 Peer reviewed |
 | Chiu, W.-Y., Lin, C.-J., Yang, W.-S., Tsai, K.-S., & Reginster, J.-Y. (2020). Racial difference in bioavailability of oral ibandronate between Caucasian and Taiwanese postmenopausal women. Osteoporosis International. doi:10.1007/s00198-019-05127-y Peer Reviewed verified by ORBi |
 | Fuggle, N. R., Kassim Javaid, M., Fujita, M., Halbout, P., Dawson-Hughes, B., Rizzoli, R., Reginster, J.-Y., Kanis, J., & Cooper, C. (2020). Fracture risk assessment and how to implement a Fracture Liaison Service. In Orthogeriatrics: The management of older patients with fragility fractures (Second Edition, pp. 241-256). Paolo Falaschi, David Marsh Eds. doi:10.1007/978-3-030-48126-1 |
 | Charles, A., Buckinx, F., Locquet, M., Reginster, J.-Y., Petermans, J., Gruslin, B., & Bruyère, O. (2020). Prediction of adverse outcomes in nursing home residents according to intrinsic capacity proposed by the World Health Organization. Journal of Gerontology: Series A, Biological Sciences and Medical Sciences, 75 (8), 1594-1599. doi:10.1093/gerona/glz218 Peer reviewed |
 | Hiligsmann, M., Williams, S. A., Fitzpatrick, L. A., Silverman, S. S., Weiss, R., & Reginster, J.-Y. (2020). Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs alendronate monotherapy in women at increased risk of fracture: a US payer perspective. Seminars in Arthritis and Rheumatism, 50, 394-400. doi:10.1016/j.semarthrit.2020.02.004 Peer Reviewed verified by ORBi |
 | Charles, A., Buckinx, F., Mouton, A., Reginster, J.-Y., & Bruyère, O. (2020). Motivational climate of group exercise sessions in nursing homes. Archives of Public Health, 78 (1), 43. doi:10.1186/s13690-020-00425-y Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Beaudart, C., Bruyère, O., Biver, E., Bauer, J., Cruz-Jentoft, A. J., Gesmundo, A., Goissier, S., Landi, F., Locquet, M., Maggi, S., Rizzoli, R., Rolland, Y., Vaquero, N., Cooper, C., & Reginster, J.-Y. (2020). Outcome priorities for older persons with sarcopenia. Journal of the American Directors Associations, 21 (2), 267-271.e2. doi:10.1016/j.jamda.2019.08.026 Peer reviewed |
 | Ruiz, J. G., Dent, E., Morley, J. E., Merchant, R. A., Beilby, J., Beard, J., Tripathy, C., Sorin, M., Andrieu, S., Aprahamian, I., Arai, H., Aubertin-Leheudre, M., Bauer, J. M., Cesari, M., Chen, L.-K., Cruz-Jentoft, A. J., Barreto, P. D. S., Dong, B., Ferrucci, L., ... Vellas, B. (2020). Erratum to: Screening for and Managing the Person with Frailty in Primary Care: ICFSR Consensus Guidelines (The journal of nutrition, health & aging, (2020), 10.1007/s12603-020-1492-3). Journal of Nutrition, Health and Aging. doi:10.1007/s12603-020-1547-5 |
 | Parsons, C. M., Judge, A., Meyer, R., Bruyère, O., Petir-Dop, F., Chapurlat, R., Reginster, J.-Y., Inskip, H., & Cooper, C. (2020). Improved statistical methods for monitoring knee osteoarthritis disease progression. Osteoporosis International, 31 (S1), 524. Peer Reviewed verified by ORBi |
 | Veronese, N., Demurtas, J., Smith, L., Reginster, J.-Y., Bruyère, O., Beaudart, C., Honvo, G., & Maggi, S. (2020). Glucosamine sulphate: an umbrella review of health outcomes. Therapeutic Advances in Musculoskeletal Disease, 12, 1-12. doi:10.1177/1759720X20975927 Peer Reviewed verified by ORBi |
 | Kanis, J. A., Harvey, N. C., McCloskey, E. V., Bruyère, O., Veronese, N., Lorentzon, M., Cooper, C., Rizzoli, R., Adib, G., Al-Daghri, N., Campusano, C., Chandran, M., Dawson-Hughes, B., Javaid, M. K., Jiwa, F., Johansson, H., Lee, J. K., Liu, E., Messina, O., ... Reginster, J.-Y. (2020). ESCEO-IOF algorithm for the management of low/high/very high risk of fracture. Osteoporosis International, 31 (S1), 33. Peer Reviewed verified by ORBi |
 | Sanchez Rodriguez, M. D. C., Locquet, M., Reginster, J.-Y., Cavalier, E., Bruyère, O., & Beaudart, C. (2020). Mortality in malnourished older adults diagnosed by ESPEN and GLIM criteria in the SarcoPhAge study. Journal of Cachexia, Sarcopenia and Muscle, 11 (5), 1200-1211. doi:10.1002/jcsm.12574 Peer Reviewed verified by ORBi |
 | Sanchez Rodriguez, M. D. C., Locquet, M., Reginster, J.-Y., CAVALIER, E., Bruyère, O., & Beaudart, C. (2020). Diagnosis of malnutrition using GLIM criteria : validity of 7 pragmatic approaches which do not require the measurement of muscle mass. Osteoporosis International, 31 (S1), 618. Peer Reviewed verified by ORBi |
 | Geerinck, A., Bruyère, O., Locquet, M., Gillain, S., Monseur, C., Reginster, J.-Y., & Beaudart, C. (2020). Development of a short version of the sarcopenia quality of life (SARQOL®) questionnaire. Osteoporosis International, 31 (S1), 450-451. Peer Reviewed verified by ORBi |
 | Lengele, L., Beaudart, C., Locquet, M., Reginster, J.-Y., & Bruyère, O. (2020). 5-year adverse outcomes of sarcopenia diagnosed according to six different definitions. Osteoporosis International, 31 (S1), 47-48. Peer Reviewed verified by ORBi |
 | Charles, A., Girard, A., Buckinx, F., Mouton, A., Reginster, J.-Y., & Bruyère, O. (2020). Senior physical activity contests in nursing homes: a feasibility study. Aging Clinical and Experimental Research, 32 (5), 869-876. doi:10.1007/s40520-020-01529-9 Peer Reviewed verified by ORBi |
 | Guralnik, J., Bandeen-Roche, K., Bhasin, S. A. R., Eremenco, S., Landi, F., Muscedere, J., Perera, S., Reginster, J.-Y., Woodhouse, L., & Vellas, B. (2020). Clinically Meaningful Change for Physical Performance: Perspectives of the ICFSR Task Force. Journal of Frailty and Aging, 9 (1), 9-13. doi:10.14283/jfa.2019.33 Peer Reviewed verified by ORBi |
 | ALLEPAERTS, S., Buckinx, F., Bruyère, O., Reginster, J.-Y., PAQUOT, N., & GILLAIN, S. (2020). Clinical impact of nutritional status and energy balance in elderly hospitalized patients. Journal of Nutrition, Health and Aging, 24 (10), 1073-79. doi:10.1007/s12603-020-1527-9 Peer Reviewed verified by ORBi |
 | Bruyère, O., Dardenne, N., Donneau, A.-F., & Reginster, J.-Y. (2020). Responder Profile to Pharmaceutical-Grade Chondroitin Sulfate: An Analysis of the CONCEPT Trial. Advances in Therapy, 37 (11), 4641-4648. doi:10.1007/s12325-020-01484-x Peer Reviewed verified by ORBi |
 | Cornelissen, D., de Kunder, S., Si, L., Reginster, J.-Y., Evers, S., Boonen, A., & Hiligsmann, M. (2020). Interventions to improve adherence to anti-osteoporosis medications: an updted systematic review. Osteoporosis International, 31 (9), 1645-1669. doi:10.1007/s00198-020-05378-0 Peer Reviewed verified by ORBi |
 | Buckinx, F., Bruyère, O., Lengele, L., Reginster, J.-Y., Marchal, Q., Hurtrez, P., & Mouton, A. (2020). The effects of GAMotion (a giant exercising board game) on physical capacity, motivation and quality of life among nursing home residents: A pilot interventional study. Experimental Gerontology, 138, 110983. doi:10.1016/j.exger.2020.110983 Peer Reviewed verified by ORBi |
 | Charles, A., Detilleux, J., Buckinx, F., Reginster, J.-Y., Gruslin, B., & Bruyère, O. (2020). Physical performance trajectories and mortality among nursing home residents: results of the SENIOR cohort. Age and Ageing, 49 (5), 800-806. doi:10.1093/ageing/afaa034 Peer Reviewed verified by ORBi |
 | Beaudart, C., Bruyère, O., Geerinck, A., Hajaoui, M., Scafoglieri, A., Perkisas, S., Bautmans, I., Gielen, E., Reginster, J.-Y., & Buckinx, F. (2020). Equation models developed with bioelectric impedance analysis tools to assess muscle mass: A systematic review. Clinical Nutrition ESPEN, 35, 47-62. doi:10.1016/j.clnesp.2019.09.012 Peer reviewed |
 | Geiker, N. R. W., Molgaard, C., Iuliano, S., Rizzoli, R., Manios, Y., van LOON, L. J. C., Lecerf, J. M., Moschonis, G., Reginster, J.-Y., Givens, I., & Astrup, A. (2020). Impact of whole dairy matrix on musculoskeletal health and aging-current knowledge and research gaps. Osteoporosis International, 31, 601–615. doi:10.1007/s00198-019-05229-7 Peer Reviewed verified by ORBi |
 | Mavungu Landu, D. J., Marini Djang'Eing'A, R., Hubert, P., Frederich, M., Michel, B., Gretry, L., Messina Ndzomo, J. P., Bruyère, O., Reginster, J.-Y., & Manzambi Kuwekita, J. (2020). Les déterminants de l’accès à des médicaments antipaludiques de qualité en territoires périurbains africains : résultats d’une enquête menée à Kinshasa (Congo). Journal d’Épidémiologie et de Santé Publique, 21, 85-100. Peer reviewed |
 | Hiligsmann, M., Maggi, S., Onder, G., Galluzzo, L., & Reginster, J.-Y. (2020). Cost-effectiveness of BINISTO (buffered soluble alendronate 70 mg) effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy. Osteoporosis International, 31 (S1), 58. Peer Reviewed verified by ORBi |
 | Veronese, N., Cacco, C., Smith, L., Dermutas, J., Cooper, C., Reginster, J.-Y., Barbagallo, M., & Maggi, S. (2020). Dietary acrylamide and incident osteoporotic fractures: an 8-year longitudinal cohort study. Osteoporosis International, 31 (S1), 383. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2020). What’s makes a difference between SYSADOAs. Osteoporosis International, 31 (S1), 624. Peer Reviewed verified by ORBi |
 | Kanis, J. A., Harvey, N. C., McCloskey, E., Bruyère, O., Veronese, N., Lorentzon, M., Cooper, C., Rizzoli, R., Adib, G., Al-Daghri, N., Campusano, C., Chandran, M., Dawson-Hughes, B., Javaid, K., Jiwa, F., Johansson, H., Lee, J. K., Liu, E., Messina, D., ... Reginster, J.-Y. (2020). Algorithm for the management of patients at low, high and vey high risk of osteoporotic fractures. Osteoporosis International, 31 (1), 1-12. doi:10.1007/s00198-019-05176-3 Peer Reviewed verified by ORBi |
 | Ruiz, J. G., Dent, E., Morley, J. E., Merchant, R. A., Beilby, J., Beard, J., Tripathy, C., Sorin, M., Andrieu, S., Aprahamian, I., Arai, H., Aubertin-Leheudre, M., Bauer, J. M., Cesari, M., Chen, L.-K., Cruz-Jentoft, A. J., De Souto Barreto, P., Dong, B., Ferrucci, L., ... Vellas, B. (2020). Screening for and Managing the Person with Frailty in Primary Care: ICFSR Consensus Guidelines. Journal of Nutrition, Health and Aging, 24 (9), 920-927. doi:10.1007/s12603-020-1492-3 Peer reviewed |
 | Beaudart, C., Lengele, L., Geerinck, A., Leclercq, V., Sanchez Rodriguez, M. D. C., Bruyère, O., & Reginster, J.-Y. (2020). Efficacy of symptomatic treatments for knee OA: a systematic review and network meta-analysis with a 6-month time-horizon. Osteoporosis International, 31 (S1), 56. Peer Reviewed verified by ORBi |
 | Charles, A., Girard, A., Buckinx, F., Mouton, A., Reginster, J.-Y., & Bruyère, O. (2020). Senior physical activity contests in nursing homes: a feasibility study. Osteoporosis International, 31 (S1), 217. Peer Reviewed verified by ORBi |
 | LADANG, A., Beaudart, C., Locquet, M., Reginster, J.-Y., & Bruyère, O. (2020). Evaluation of a panel of microRNAs that predicts fragility fracture risk: a pilot study. Calcified Tissue International, 106 (3), 239-247. doi:10.1007/s00223-019-00628-8 Peer Reviewed verified by ORBi |
 | McClung, M. R., Bolognese, M. A., Brown, J. P., Reginster, J.-Y., Langdahl, B. L., Ruiz-Santiago, N., Shi, Y., Rojeski, M., Timoshanko, J., Libanati, C., Kassahun, H., & Oates, M. (2020). Romosozumab after Denosumab improves lumbar spine and maintains total hip bone mineral density in postmenopausal women with low bone mass. Osteoporosis International, 31 (S1), 41-42. Peer Reviewed verified by ORBi |
 | Chandran, M., Ganesan, G., Tan, K. B., Reginster, J.-Y., Yong, E. L., & Hiligsmann, M. (2020). Cost-effectiveness of FRAX® based intervention tresholds for management of osteoporosis in Singaporean women. Osteoporosis International, 31 (S1), 459. Peer Reviewed verified by ORBi |
 | Rozenberg, S., Al-Daghri, N., Aubertin-Leheudre, M., Brandi, M.-L., Cano, A., Collins, P., Cooper, C., Genazzani, A. R., Hillard, T., Kanis, J. A., Kaufman, J.-M., Lambrinoudaki, I., Laslop, A., McCloskey, E., Palacios, S., Prieto-Alhambra, D., Reginster, J.-Y., Rizzoli, R., Rosano, G., ... Harvey, N. C. (2020). Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis? Osteoporosis International, 31, 2271-2286. doi:10.1007/s00198-020-05497-8 Peer Reviewed verified by ORBi |
 | Geerinck, A., Beaudart, C., Locquet, M., Reginster, J.-Y., & Bruyère, O. (2020). Association between SARC-F and quality of life measured by SARQOL® questionnaire in older, community-dwelling subjects friom the SarcoPhAge cohort. Osteoporosis International, 31 (S1), 451. Peer Reviewed verified by ORBi |
 | Geerinck, A., Locquet, M., Bruyère, O., Reginster, J.-Y., & Beaudart, C. (2020). Evaluating quality of life in frailty: applicability and psychometric properties of the SARQOL® questionnaire. Osteoporosis International, 31 (S1), 450. Peer Reviewed verified by ORBi |
 | Charles, A., Buckinx, F., Reginster, J.-Y., Mouton, A., & Bruyère, O. (2020). Motivational climate of group exercise sessions in nursing homes. Osteoporosis International, 31 (S1), 217-218. Peer Reviewed verified by ORBi |
 | Beaudart, C., Bauer, J., Landi, F., Bruyère, O., Reginster, J.-Y., & Hiligsmann, M. (2020). A discrete-choice experiment to assess experts’ preferences for sarcopenia outcomes. Osteoporosis International, 31 (S1), 320. Peer Reviewed verified by ORBi |
 | Beaudart, C., Bruyère, O., Cruz-Jentoft, A. J., Vaquero-Pinto, M. N., Locquet, M., Bauer, J., Cooper, C., Rolland, Y., Dupuy, C., Landi, F., Reginster, J.-Y., Maggi, S., Rizzoli, R., & Hiligsmann, M. (2020). Patient’s engagement in the identification of critical outcomes in sarcopenia. Journal of the American Directors Associations, 21 (2), 284-286. doi:10.1016/j.jamda.2019.09.004 Peer reviewed |
 | Lengele, L., Moehlinger, P., Bruyère, O., Locquet, M., Reginster, J.-Y., & Beaudart, C. (2020). Association between Changes in Nutrient Intake and Changes in Muscle Strength and Physical Performance in the SarcoPhAge Cohort. Nutrients, 12 (11), 3485, 1-16. doi:10.3390/nu12113485 Peer Reviewed verified by ORBi |
 | Borgström, F., Karlsson, L., Ortsäter, G., Norton, N., Halbout, P., Cooper, C., Lorentzon, M., McCloskey, E. V., Harvey, N. C., Javaid, M. K., Kanis, J. A., Reginster, J.-Y., Ferrari, S., & for the International Osteoporosis Foundation. (2020). Fragility fractures in Europe: burden, management and opportunities. Archives of Osteoporosis, 15 (1). doi:10.1007/s11657-020-0706-y Peer Reviewed verified by ORBi |
 | McClung, M. R., Bolognese, M. A., Brown, J. P., Reginster, J.-Y., Langdahl, B. L., Maddox, J., Shi, Y., Rojeski, M., Meisner, P. D., & Grauer, A. (2020). A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. Osteoporosis International, 31 (11), 2231-2241. doi:10.1007/s00198-020-05502-0 Peer Reviewed verified by ORBi |
 | Kanis, J. A., Cooper, C., Dawson-Hughes, B., Harvey, N. C., Johansson, H., Lorentzon, M., McCloskey, E. V., Reginster, J.-Y., & Rizzoli, R. (2020). FRAX and ethnicity. Osteoporosis International, 31, 2063-2067. doi:10.1007/s00198-020-05631-6 Peer Reviewed verified by ORBi |
 | Ansari, M. G. A., Hussain, S. D., Wani, K. A., Yakout, S. M., Al-Disi, D., Alokail, M. S., Reginster, J.-Y., & Al-Daghri, N. M. (January 2020). Influence of bone mineral density in circulating adipokines among postmenopausal Arab women. Saudi Journal of Biological Sciences, 27 (1), 374-379. doi:10.1016/j.sjbs.2019.10.007 Peer Reviewed verified by ORBi |
 | Li, N., Cornelissen, D., Silverman, S., Pinto, D., Si, L., Kremer, I., Bours, S., Boonen, A., Evers, S., van den Bergh, J., Reginster, J.-Y., & Hiligsmann, M. (2020). An updated systematic review of cost-effectiveness analysis of drugs for osteoporosis. Osteoporosis International, 31 (S1), 491. Peer Reviewed verified by ORBi |
 | Lorentzon, M., Branco, J., Brandi, M. L., Bruyère, O., Chapurlat, R., Cooper, C., Cortet, B., Diez-Perez, A., Ferrari, S., Gasparik, A., Herrman, M., Jorgensen, N. R., Kanis, J. A., Kaufman, J. M., Laslop, A., Locquet, M., Matijevic, R., McCloskey, E. V., Minisola, S., ... CAVALIER, E. (2020). Clinical application of bone turnover markers in postmenopausal osteoporosis. Osteoporosis International, 31 (S1), 65-66. Peer Reviewed verified by ORBi |
 | Buckinx, F., Marchal, Q., Hurtrez, P., Bruyère, O., Reginster, J.-Y., & Mouton, A. (2020). The effects of GAMotion (a giant exercising board game) on physical capacity, motivation and quality of life among nursing home residents: a randomized controlled trial. Osteoporosis International, 31 (S1), 261. Peer Reviewed verified by ORBi |
 | Charles, A., Detilleux, J., Buckinx, F., Reginster, J.-Y., Gruslin, B., & Bruyère, O. (2020). Physical performance trajectories and mortality among nursing-home residents: the results of the SENIOR Cohort. Osteoporosis International, 31 (S1), 57. Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Reginster, J.-Y., Bruyère, O., & Croisier, J.-L. (2020). Muscle strengthevaluated using the hand-held dynamometer MicroFET2 in older adults: a reliability study. Osteoporosis International, 31 (S1), 301-302. Peer Reviewed verified by ORBi |
 | Beaudart, C., Locquet, M., Lengele, L., Reginster, J.-Y., & Bruyère, O. (2020). Performance of the “Yubi-wakka (finger-ring) test as self-screening method for sarcopenia using the SarcoPhAge, Belgian cohort study. Osteoporosis International, 31 (S1), 85 and 302. Peer Reviewed verified by ORBi |
 | Beaudart, C., Locquet, M., Lengele, L., Reginster, J.-Y., & Bruyère, O. (2020). The different diagnosis criteria of the EWGSOP2 definition and long-term clinical outcomes. Osteoporosis International, 31 (S1), 58. Peer Reviewed verified by ORBi |
 | Veronese, N., Demurtas, J., Soysal, P., Smith, O., Bruyère, O., Reginster, J.-Y., Beaudart, C., Cooper, C., Mirko, M., & Maggi, S. (2020). Sarcopenia and health-related outcomes: an umbrella review of observational studies. Osteoporosis International, 31 (S1), 198-199. Peer Reviewed verified by ORBi |
 | Fuggle, N. R., Cooper, C., Harvey, N. C., Al-Daghri, N., Brandi, M.-L., Bruyère, O., Cano, A., Dennison, E. M., Diez-Perez, A., Kaufman, J.-M., Palacios, S., Prieto-Alhambra, D., Rozenberg, S., Thomas, T., Tremollieres, F., Rizzoli, R., Kanis, J. A., & Reginster, J.-Y. (2020). Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs. Drugs, 80 (15), 1537-52. doi:10.1007/s40265-020-01364-2 Peer Reviewed verified by ORBi |
 | Dzhus, M., Dzhus, M., Masnyi, M., Kulyk, M., Mostbauer, H., Ivashkivsky, O., Boyko, Y., Cherchenko, K., Geerinck, A., Reginster, J.-Y., Bruyère, O., & Beaudart, C. (2020). Cross-sectional evaluation of the sarcopenia quality of life (Sarqol) questionnaire: Translation and validation of its psychometric properties. Annals of Geriatric Medicine and Research, 24 (2), 139-147. doi:10.4235/AGMR.20.0020 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Dennison, E., Beaudart, C., Herrero-Beaumont, G., Branco, J., Bruyère, O., Conaghan, P. G., Cooper, C., Al-Daghri, N., Jiwa, F., Lems, W., Pinto, D., Rizzoli, R., Thomas, T., Uebelhart, D., Veronese, N., & Reginster, J.-Y. (2020). A discrete-choice experiment to assess patients’preferences for osteoarthritis treatment: an ESCEO working group. Seminars in Arthritis and Rheumatism, 50 (5), 859-866. doi:10.1016/j.semarthrit.2020.08.005 Peer Reviewed verified by ORBi |
 | Kanis, J. A., Harvey, N. C., McCloskey, E., Bruyère, O., Veronese, N., Lorentzon, M., Cooper, C., Rizzoli, R., Adib, G., Al-Daghri, N., Campusano, C., Chandran, M., Dawson-Hughes, B., Javaid, K., Jiwa, F., Johansson, H., Lee, J. K., Liu, E., Messina, D., ... Reginster, J.-Y. (2020). Correction to: Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 31 (4), 797-798. doi:10.1007/s00198-020-05297-0 Peer reviewed |
 | Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2020). Correction to: European guidance for the diagnosis and management of osteoporosis in postmenopausal women (Osteoporosis International, (2019), 30, 1, (3-44), 10.1007/s00198-018-4704-5). Osteoporosis International, 31, 801. doi:10.1007/s00198-020-05303-5 Peer Reviewed verified by ORBi |
 | Al-Saleh, Y., Al-Daghri, N. M., Sabico, S., Alessa, T., Al Emadi, S., Alawadi, F., Al Qasaabi, S., Alfutaisi, A., Al Izzi, M., Mukhaimer, J., Suhaili, A. R., Reginster, J.-Y., & Sulimani, R. (2020). Diagnosis and management of osteoporosis in postmenopausal women in Gulf Cooperation Council (GCC) countries: consensus statement of the GCC countries’ osteoporosis societies under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Archives of Osteoporosis, 15 (1), 109. doi:10.1007/s11657-020-00778-5 Peer Reviewed verified by ORBi |
 | Al-Daghri, N. M., Yakout, S., Aljohani, N., Al-Saleh, Y., Al-Attas, O. S., Reginster, J.-Y., Al-Disi, D., & Alokail, M. S. (2020). Vitamin D Status and its correlation with Parathyroid Hormone level among population in Riyadh, Saudi Arabia. Journal of King Saud University - Science, 32 (3), 2016-2019. doi:10.1016/j.jksus.2020.02.002 |
 | Locquet, M., Bornheim, S., Colas, L., Van Beveren, J., Bruyère, O., Reginster, J.-Y., & Kaux, J.-F. (December 2019). Traduction en langue française, adaptation transculturelle et validation du questionnaire « Victorian Institute of Sport Assessment Scale for Proximal Hamstring Tendinopathy » (VISA-H). Journal de Traumatologie du Sport, 36 (4), 217-221. doi:10.1016/j.jts.2019.04.001 Peer reviewed |
| Geerinck, A., Beaudart, C., Dardenne, N., Reginster, J.-Y., & Bruyère, O. (December 2019). An exploration of the structural validity of the Sarcopenia Quality of Life (SarQoL) questionnaire with exploratory and confirmatory factor analysis [Paper presentation]. Journée des doctorants en Santé Publique. |
 | McClung, M. R., O'Donoghue, M. L., Papapoulos, S. E., Bone, H., Langdahl, B., Saag, K. G., Reid, I. R., Cavallari, I., Bonaca, M. P., Wiviott, S. D., de Villers, T., Ling, X., Lippuner, K., Nakamura, T., Reginster, J.-Y., Rodrigez-Portales, J. A., Roux, C., Zanchetta, J., Zerbini, C. A. F., ... LOFT Ivestigators. (19 October 2019). Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicenter, randomized, double-blind, placebo-controlled trial and LOFT Extension Study. The Lancet Diabetes and Endocrinology, published online. doi:10.1016/S2213-8587(19)30346-8 Peer Reviewed verified by ORBi |
 | Gillain, S., Boutaayamou, M., Schwartz, C., BRUYERE, O., Bruls, O., CROISIER, J.-L., SALMON, E., Reginster, J.-Y., GARRAUX, G., & PETERMANS, J. (October 2019). Using supervised learning machine algorithm to identify future fallers based on gait patterns: a two-year longitudinal study [Poster presentation]. XXIIèmes Journées d'Automne de la SBGG, LIEGE, Belgium. |
 | Gillain, S., Boutaayamou, M., Schwartz, C., Dardenne, N., BRUYERE, O., Bruls, O., Croisier, J.-L., SALMON, E., Reginster, J.-Y., GARRAUX, G., & Petermans, J. (October 2019). Identify future fallers based on gait symmetry dual task changes: a two-year longitudinal study [Poster presentation]. 22èmes Journées d'Automne de la SBGG, LIEGE, Belgium. |
 | Bauer, J. M., Cruz-Jentoft, A. J., Fielding, R. A., Kanis, J. A., Reginster, J.-Y., Bruyère, O., Cesari, M., Chapurlat, R., Al-Daghri, N., Dennison, E., Kaufman, J.-M., Landi, F., Laslop, A., Locquet, M., Maggi, S., McCloskey, E., Perna, S., Rizzoli, R., Rolland, Y., ... FMedSci, C. C. (August 2019). Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review. Calcified Tissue International, 105 (2), 109-24. doi:10.1007/s00223-019-00561-w Peer Reviewed verified by ORBi |
 | Veronese, N., Cooper, C., Reginster, J.-Y., Hochberg, M., Branco, J., Bruyère, O., Chapurlat, R., Al-Daghri, N., Dennison, E., Herrero-Beaumont, G., Kaux, J.-F., Maheu, E., Rizzoli, R., Roth, R., Rovati, L. C., Uebelhart, D., Vlaskovska, M., & Scheen, A. (August 2019). Type 2 diabetes mellitus and osteoarthritis. Seminars in Arthritis and Rheumatism, 49 (1), 9-19. doi:10.1016/j.semarthrit.2019.01.005 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Beaudart, C., Bruyère, O., Biver, E., Bauer, J., Cruz-Jentoft, A. J., Gesmundo, A., Goisser, S., Lansi, F., Locquet, M., Maggi, S., Rizzoli, R., Rolland, Y., Vaquero, N., & Reginster, J.-Y. (July 2019). A cross-european discrete choice experiment to assess patients’ preferences for sarcopenia outcomes. Osteoporosis International, 30 (S2), 190. Peer Reviewed verified by ORBi |
 | Bruyère, O., Detilleux, J., & Reginster, J.-Y. (July 2019). Cost-effectiveness assessment of different glucosamines in patients with knee osteoarthritis: A simulation model adapted to Germany. Osteoporosis International, 30 (S2), 181-S182. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., & Reginster, J.-Y. (July 2019). Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France. Osteoporosis International, 30 (S2), 182. Peer Reviewed verified by ORBi |
 | Veronese, N., Cooper, C., Guglielmi, G., Rizzoli, R., Punzi, L., Al-Daghri, N., Smith, L., Reginster, J.-Y., & Maggi, S. (July 2019). Mediterranean diet and knee osteoarthritis outcomes: a longitudinal cohort study. Osteoporosis International, 30 (S2), 457. Peer Reviewed verified by ORBi |
 | Hajaoui, M., Locquet, M., Beaudart, C., Reginster, J.-Y., PETERMANS, J., & Bruyère, O. (July 2019). Sarcopenia : performance of the SARC-F questionnaire according to the european consensus criteria, EWGSOP1 vs. EWGSOP2. Osteoporosis International, 30 (S2), 539-S540. Peer Reviewed verified by ORBi |
 | Beaudart, C., Bruyère, O., Reginster, J.-Y., Bauer, J., Cooper, C., Cruz-Jentoft, A. J., Dupuy, C., Landi, F., Locquet, M., Maggi, S., Rizzoli, R., Rolland, Y., Vaquero, N., & Hiligsmann, M. (July 2019). Identification and prioritization of important oucomes for patients in sarcopenia. Osteoporosis International, 30 (S2), 189-S190. Peer Reviewed verified by ORBi |
 | LADANG, A., Beaudart, C., Locquet, M., Reginster, J.-Y., Bruyère, O., & Cavalier, E. (July 2019). Fragility fracture risk prediction in elderly people based on a micro RNA panel. Osteoporosis International, 30 (S2), 299-S300. Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Durieux, N., Reginster, J.-Y., & Bruyère, O. (July 2019). Relationship between the changes over time of bone and muscle health in children and adults : a systematic review and meta-analysis. Osteoporosis International, 30 (S2), 176-S177. Peer Reviewed verified by ORBi |
 | Al-Daghri, N., Abdi, S., Mohammed, A., Ansari, M. G., Amer, O., Hussain, S. D., Aljohani, N., Al-Disi, D., & Reginster, J.-Y. (July 2019). Associations of Rankl and OPG gene polymorphisms in arab women with and without osteoporosis. Osteoporosis International, 30 (S2), 307. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (July 2019). ESCEO recommendations for clinical trials for hand osteoarthritis. Osteoporosis International, 30 (S2), 776. Peer Reviewed verified by ORBi |
 | Honvo, G., Bannuru, R. R., Bruyère, O., Rannou, F., Herrero-Beaumont, G., Uebelhaert, D., Cooper, C., Arden, N., Conaghan, P. G., Reginster, J.-Y., Thomas, T., & McAlindon, T. (July 2019). Recommendations for the reporting of harms in manuscripts on studies assessing osteoarthritis drugs: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Osteoporosis International, 30 (S2), 569-S570. Peer Reviewed verified by ORBi |
 | Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (July 2019). SL2. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, 30 (S2), 153-S154. Peer Reviewed verified by ORBi |
 | Honvo, G., Bruyère, O., Geerinck, A., Veronese, N., & Reginster, J.-Y. (July 2019). Effect of oral chondroitin on pain in patients with knee osteoarthritis: outcomes of a comprehensive meta-analysis exploring inconsistencies in randomised, placebo-controlled trials. Osteoporosis International, 30 (S2), 175. Peer Reviewed verified by ORBi |
 | Honvo, G., Reginster, J.-Y., Rannou, F., Rygaert, X., Geerinck, A., Rabenda, V., McAlindon, T., Charles, A., Fuggle, N. R., Cooper, C., Curtis, E. M., Arden, N., Avouac, B., & Bruyère, O. (July 2019). Safety of an intra-articular hyaluronic acid injections in osteoarthritis: outcomes of a systematic review and meta-analysis. Osteoporosis International, 30 (S2), 290. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Honvo, G., Geerinck, A., & Bruyère, O. (July 2019). Efficacy and tolerance of pharmaceutical-grade chondroitin sulfate: what does evidence-based medicine say? Osteoporosis International, 30 (S2), 779. Peer Reviewed verified by ORBi |
 | Honvo, G., Bruyère, O., Geerinck, A., Veronese, N., & Reginster, J.-Y. (July 2019). Effect of oral chondroitin sulfate on functional status in patients with knee osteoarthritis: outcomes of a comprehensive meta-analysis exploring inconsistencies in randomized, placebo-controlled trials. Osteoporosis International, 30 (S2), 452-S453. Peer Reviewed verified by ORBi |
 | Abdi, S., Mohammed, A., Amer, O., Ansari, M. G., Aljohani, N., Alokail, M., Reginster, J.-Y., & Al-Daghri, N. (July 2019). Association of genetic polymorphisms with osteopenia in Saudi postmenopausal women. Osteoporosis International, 30 (S2), 308. Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Croisier, J.-L., Reginster, J.-Y., & Bruyère, O. (July 2019). Determinants and health consequences of a rapid muscle health decline in older adults from the SacoPhAge study. Osteoporosis International, 30 (S2), 211 and S275. Peer Reviewed verified by ORBi |
 | Kaux, J.-F., Bornheim, S., Remy, G., Van Beveren, J., Reginster, J.-Y., Bruyère, O., Dardenne, N., & Buckinx, F. (2019). Cross-cultural adaptation, translation in French and validation of the Anterior Knee Pain Scale (AKPS). In V. Bunc & E. Tsolakidis, Book of abstracts - 24th Annual Congress of the European College of Sport Science (pp. 400). Peer reviewed |
 | Charles, A., Buckinx, F., Mouton, A., Reginster, J.-Y., Gruslin, B., & Bruyère, O. (July 2019). Energy expenditure of nursing home residents and participation in exercise classes: an analysis of the SENIOR cohort. Osteoporosis International, 30 (S2), 430. Peer Reviewed verified by ORBi |
 | Buckinx, F., Beaudart, C., Reginster, J.-Y., Rolland, Y., Cesari, M., Rizzoli, R., PETERMANS, J., & Bruyère, O. (July 2019). Development of a frailty specific patient reported outcome (PRO): the FRAILQOL. Osteoporosis International, 30 (S2), 465-S466. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Williams, S. A., Fitzpatrick, L. A., Silverman, S., Weiss, R., & Reginster, J.-Y. (July 2019). Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy for USA women at increased risk of fracture. Osteoporosis International, 30 (S2), 503-S504. Peer Reviewed verified by ORBi |
 | Parsons, C. M., Meyer, R., Judge, A., Bruyère, O., Petit-Dop, F., Chapurlat, R., Reginster, J.-Y., Inskip, H., & Cooper, C. (July 2019). Determining individual trajectories of joint space loss: a Bayesian approach for assessing osteoarthritis progression. Osteoporosis International, 30 (S2), 537-S538. Peer Reviewed verified by ORBi |
 | Sabico, S., Bassam, R., Alnaami, A., Khattak, M., Lei, K., Al-Daghri, N., Reginster, J.-Y., & Alokail, M. (July 2019). Associations of bone metabolism markers with neck circumference in adult arab women. Osteoporosis International, 30 (S2), 307-S308. Peer Reviewed verified by ORBi |
 | Fuggle, N. R., Curtis, E. M., Shaw, S., Spooner, L., Bruyère, O., Ntanil, G., Parsons, C., Conaghan, P. G., Corp, N., Honvo, G., Maggi, S., Uebelhart, D., Baird, J., Dennison, E. M., Reginster, J.-Y., & Cooper, C. (July 2019). Safety of analgesics, non-steroidal anti-inflammatory drugs and opioids. Osteoporosis International, 30 (S2), 186-S187. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (July 2019). Management of knee osteoarthritis in 2019: an updated algorithm from the European society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Osteoporosis International, 30 (S2), 158-S159. Peer Reviewed verified by ORBi |
 | Beaudart, C., Rolland, Y., Cruz-Jentoft, A. J., Bauer, J. M., Sieber, C., Cooper, C., Al-Daghri, N., Araujo de Carvalho, I., Bautmans, I., Bernabei, R., Bruyère, O., Cesari, M., Cherubini, A., Dawson-Hughes, B., Kanis, J. A., Kaufman, J. M., Landi, F., Maggi, S., McCloskey, J., ... Fielding, R. A. (July 2019). Assessment of muscle function and physical performance in daily clinical practice: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Calcified Tissue International, 105 (1), 1-14. doi:10.1007/s00223-019-00545-w Peer Reviewed verified by ORBi |
 | Honvo, G., Bruyère, O., & Reginster, J.-Y. (June 2019). Update on the role of pharmaceutical‑grade chondroitin sulfate in the symptomatic management of knee osteoarthritis. Aging Clinical and Experimental Research, 31 (8), 1163-1167. doi:10.1007/s40520-019-01253-z Peer Reviewed verified by ORBi |
 | Buckinx, F., Bornheim, S., Remy, G., Van Beveren, J., Reginster, J.-Y., Bruyère, O., Dardenne, N., & Kaux, J.-F. (May 2019). French translation and validation of the “Anterior Knee Pain Scale” (AKPS). Disability and Rehabilitation, 41 (9), 1089-1094. doi:10.1080/09638288.2017.1419288 Peer Reviewed verified by ORBi |
 | Geerinck, A., Alekna, V., Beaudart, C., Bautmans, I., Cooper, C., De Souza Orlandi, F., Konstantynowicz, J., Monterro-Errasquin, B., Topinkova, E., Tsekoura, M., Reginster, J.-Y., & Bruyère, O. (29 April 2019). Standard error of measurement and smallest detectable change of the Sarcopenia Quality of Life (SarQoL) questionnaire: An analysis of subjects from 9 validation studies. PLoS ONE, 14 (4). doi:10.1371/journal.pone.0216065 Peer Reviewed verified by ORBi |
 | Honvo, G., Bruyère, O., Geerinck, A., & Reginster, J.-Y. (April 2019). Symptomatic efficacy of oral chondroitin sulfate in knee osteoarthritis: A systematic review and meta-analysis of randomized, placebo-controlled trials. Osteoarthritis and Cartilage, 27 (Suppl 1), 498–S499. doi:10.1016/j.joca.2019.02.558 Peer Reviewed verified by ORBi |
 | LADANG, A., Beaudart, C., Locquet, M., Reginster, J.-Y., Bruyère, O., & CAVALIER, E. (April 2019). Risk-fracture prediction in elderly people based on a microRNA panel [Poster presentation]. IOF-WHO osteoporosis congress. |
 | Honvo, G., Reginster, J.-Y., Geerinck, A., & Bruyère, O. (April 2019). Safety of oral chondroitin sulfate in the management of knee osteoarthritis: results of a new meta-analysis of randomized. Placebo-controlled trials. Osteoarthritis and Cartilage, 27 (Suppl 1), 499. doi:10.1016/j.joca.2019.02.559 Peer Reviewed verified by ORBi |
 | Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (22 February 2019). Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcified Tissue International, online. doi:10.1007/s00223-018-00512-x Peer Reviewed verified by ORBi |
 | Yakout, S. M., Alkahtani, S. A., Al-Disi, D., Aljaloud, K. S., Khattak, M. N. K., Alokail, M. S., Reginster, J.-Y., Sabico, S., & Al-Daghri, N. M. (2019). Coexistence of pre-sarcopenia and metabolic syndrome in Arab men. Calcified Tissue International, 104, 130-136. doi:10.1007/s00223-018-0477-2 Peer Reviewed verified by ORBi |
 | Kucharz, E. J., Szántó, S., Ivanova Goycheva, M., Petronijević, M., Šimnovec, K., Domżalski, M., Gallelli, L., Kamenov, Z., Konstantynowicz, J., Radunović, G., Šteňo, B., Stoilov, R., Stok, R., Vrana, R., Bruyère, O., Cooper, C., & Reginster, J.-Y. (2019). Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis. Rheumatology International, 39, 1117-1123. doi:10.1007/s00296-019-04332-6 Peer Reviewed verified by ORBi |
 | Kucharz, E. J., Szántó, S., Ivanova Goycheva, M., Petronijević, M., Šimnovec, K., Domżalski, M., Gallelli, L., Kamenov, Z., Konstantynowicz, J., Radunović, G., Šteňo, B., Stoilov, R., Stok, R., Vrana, R., Bruyère, O., Cooper, C., & Reginster, J.-Y. (2019). Correction to: Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis (Rheumatology International, (2019), 39, 7, (1117-1123), 10.1007/s00296-019-04332-6). Rheumatology International, 39 (9), 1661-1662. doi:10.1007/s00296-019-04347-z Peer Reviewed verified by ORBi |
 | Charles, A., Buckinx, F., Mouton, A., Reginster, J.-Y., Petermans, J., Gruslin, B., & Bruyère, O. (2019). Energy expenditure of nursing home residents and participation in exercise classes: an analysis of the SENIOR cohort [letter to the editor]. Journal of the American Medical Directors Association, 20 (9), 1183-1184. doi:10.1016/j.jamda.2019.04.007 Peer Reviewed verified by ORBi |
 | Buckinx, F., Croisier, J.-L., Charles, A., Petermans, J., Reginster, J.-Y., Rygaert, X., & Bruyère, O. (2019). Normative data for isometric strength of 8 different muscle groups and their usefulness as a predictor of loss of autonomy among physically active nursing home residents: The senior cohort. Journal of Musculoskeletal Neuronal Interactions, 19 (3), 258-265. Peer reviewed |
 | Biver, E., Berenbaum, F., Valdes, A. M., Araujo de Carvalho, I., Bindels, L. B., Brandi, M. L., Calder, P. C., Castronovo, V., Cavalier, E., Cherubini, A., Cooper, C., Dennison, E., Franceschi, C., Fuggle, N., Laslop, A., Miossec, P., Thomas, T., Tuzun, S., Veronese, N., ... Rizzoli, R. (2019). Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). Ageing Research Reviews, 55. doi:10.1016/j.arr.2019.100946 Peer Reviewed verified by ORBi |
 | Thiyagarajan, J. A., Araujo de Carvalho, I., Peña-Rosas, J. P., Chadha, S., Mariotti, S. P., Dua, T., Albanese, E., Bruyère, O., Cesari, M., Dangour, A., Dias, A., Guerra, M., Keeffe, J., Kerse, N., Khan, Q. U. A., Liu, C.-J., Murthy, G. V. S., Ndegwa, S. N., Reginster, J.-Y., ... Beard, J. R. (2019). Redesigning care for older people to preserve physical and mental capacity: WHO guidelines on community-level interventions in integrated care. PLoS Medicine, 16 (10). doi:10.1371/journal.pmed.1002948 Peer Reviewed verified by ORBi |
 | Honvo, G., Bruyère, O., Geerinck, A., Veronese, N., & Reginster, J.-Y. (2019). Efficacy of chondroitin sulfate in patients with knee osteoarthritis: a comprehensive meta-analysis exploring inconsistencies in randomized, placebo-controlled trials. Advances in Therapy, 36 (5), 1085-99. doi:10.1007/s12325-019-00921-w Peer Reviewed verified by ORBi |
 | Slomian, J., Honvo, G., EMONTS, P., Reginster, J.-Y., & Bruyère, O. (2019). Consequences of maternal postpartum depression: a systematic review of maternal and infant outcomes. Women's Health, 15, 1-55. doi:10.1177/1745506519844044 Peer Reviewed verified by ORBi |
 | Buckinx, F., Charles, A., Reginster, J.-Y., PETERMANS, J., & Bruyère, O. (2019). Apports de la cohorte liégeoise SENIOR dans l’étude de la fragilité en maison de repos. Revue Médicale de Liège, 74 (4), 212-217. Peer reviewed |
 | Martel-Pelletier, J., Maheu, E., Pelletier, J. P., Alekseeva, L., Mkinsi, O., Branco, J., Monod, P., Planta, F., Reginster, J.-Y., & Rannou, F. (January 2019). A new decision tree for diagnosis and management of osteoarthritis in primary care: international consensus of experts. Aging Clinical and Experimental Research, 31 (1), 19-30. doi:10.1007/s40520-018-1077-8 Peer Reviewed verified by ORBi |
 | Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2019). Executive summary of European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Aging Clinical and Experimental Research, 31, 15-17. doi:10.1007/s40520-018-1109-4 Peer Reviewed verified by ORBi |
 | CRUZ-JENTOFT, J., BAHAT, G., BAUER, J., BOIRIE, Y., Bruyère, O., CEDERHOLM, T., Cooper, C., LANDI, F., ROLLAND, Y., SAYER, A. A., SCHNEIDER, M., SIEBER, C. C., TOPINKOVA, E., VANDEWOUDE, M., VISSER, M., ZAMBONI, M., BAUTMANS, I., BAEYENS, J. P., CESARI, M., ... SCHOLS, J. (2019). Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing, 48, 16-31. doi:10.1093/ageing/afy169 Peer Reviewed verified by ORBi |
 | Beaudart, C., Sanchez Rodriguez, M. D. C., Locquet, M., Reginster, J.-Y., Lengele, L., & Bruyère, O. (2019). Malnutrition as a strong predictor of the onset of sarcopenia. Nutrients, 11 (12), 2883. doi:10.3390/nu11122883 Peer Reviewed verified by ORBi |
 | Charles, A., Buckinx, F., Cataldo, D., Rygaert, X., Gruslin, B., Reginster, J.-Y., & Bruyère, O. (2019). Relationship between peak expiratory flow and incidence of frailty, deaths and falls among nursing home residents: Results of the SENIOR cohort. Archives of Gerontology and Geriatrics, 85. doi:10.1016/j.archger.2019.103913 Peer Reviewed verified by ORBi |
 | Veronese, N., Demurtas, J., Soysal, P., Smith, L., Torbahn, G., Schoene, D., Schwingshackl, L., Sieber, C., Bauer, J., Cesari, M., Bruyère, O., Reginster, J.-Y., Beaudart, C., Cruz-Jentoft, A. J., Cooper, C., Petrovic, M., Maggi, S., & the Special Interest Groups in Systematic Reviews and Meta-analyses for healthy ageing Sarcopenia and Frailty and resilience in older persons of the European Geriatric Medicine Society (EuGMS). (2019). Sarcopenia and health-related outcomes: an umbrella review of observational studies. European Geriatric Medicine, 10 (6), 853-862. doi:10.1007/s41999-019-00233-w Peer reviewed |
 | Curtis, E., Fuggle, N., Shaw, S., Spooner, S., Ntani, G., Parsons, C., Corp, N., Honvo, G., Baird, J., Maggi, S., Dennison, E., Bruyère, O., Reginster, J.-Y., & Cooper, C. (2019). Safety of cyclooxygenase-2 inhibitors in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs and Aging, 36 (suppl 1), 25-44. doi:10.1007/s40266-019-00664-x Peer Reviewed verified by ORBi |
 | FUGGLE, N., Curtis, E., Shaw, S., Spooner, L., Bruyère, O., Ntani, G., Parsons, C., Conaghan, P. G., Corp, N., Honvo, G., Uebelhart, D., Baird, J., Dennison, E., Reginster, J.-Y., & Cooper, C. (2019). Safety of opioids in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs and Aging, 36 (suppl 1), 129-143. doi:10.1007/s40266-019-00666-9 Peer Reviewed verified by ORBi |
 | Albassam, R. S., Sabico, S., Alnaami, A. M., Khattak, M. N. K., Lei, K. Y., Al-daghri, N. M., Reginster, J.-Y., & Alokail, M. S. (2019). Bone metabolism markers are associated with neck circumference in adult Arab women. Osteoporosis International. doi:10.1007/s00198-018-04830-6 Peer Reviewed verified by ORBi |
 | Honvo, G., Bannuru, R. R., Bruyère, O., Rannou, F., Herrero-Beaumont, G., Uebelhart, D., Cooper, C., Arden, N., Conaghan, P. G., Reginster, J.-Y., Thomas, T., & McAlindon, T. (2019). Recommendations for the reporting harms in manuscripts on clinical trials assessing osteoarthritis drugs: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Drugs and Aging, 36 (suppl 1), 145-159. doi:10.1007/s40266-019-00667-8 Peer Reviewed verified by ORBi |
 | Xia, W., Cooper, C., Li, M., Xu, L., Rizzoli, R., Zhu, M., Lin, H., Beard, J., Ding, Y., Yu, W., CAVALIER, E., Zhang, Z., Kanis, J. A., Cheng, Q., Wang, Q., & Reginster, J.-Y. (2019). East meets West: current practices and policies in the management of musculoskeletal aging. Aging Clinical and Experimental Research, 31 (10), 1351-1373. doi:10.1007/s40520-019-01282-8 Peer Reviewed verified by ORBi |
 | Veronese, N., Shivappa, N., Stubbs, B., Smith, T., Hebert, J. R., Cooper, C., Guglielmi, G., Reginster, J.-Y., Rizzoli, R., & Maggi, S. (2019). The relationship between the dietary inflammatory index and prevalence of radiographic symptomatic osteoarthritis: data from the Osteoarthritis Initiative. European Journal of Nutrition. doi:10.1007/s00394-017-1589-6 Peer Reviewed verified by ORBi |
 | Bruyère, O., Honvo, G., Veronese, N., Arden, N. K., Branco, J., Curtis, E. M., Al-Daghri, N. M., Herrero-Beaumont, G., Martel-Pelletier, J., Pelletier, J.-P., Rannou, F., Rizzoli, R., Roth, R., Uebelhart, D., Cooper, C., & Reginster, J.-Y. (2019). An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Seminars in Arthritis and Rheumatism, 49 (3), 337-350. doi:10.1016/j.semarthrit.2019.04.008 Peer Reviewed verified by ORBi |
 | GILLAIN, S., Boutaayamou, M., Schwartz, C., Dardenne, N., Bruyère, O., Bruls, O., Croisier, J.-L., SALMON, E., Reginster, J.-Y., GARRAUX, G., & PETERMANS, J. (2019). Gait symmetry in the dual task condition as a predictor of future falls among independent older adults: a 2-year longitudinal study. Aging Clinical and Experimental Research, 31 (8), 1057-1067. doi:10.1007/s40520-019-01210-w Peer Reviewed verified by ORBi |
 | Bruyère, O., Beaudart, C., Ethgen, O., Reginster, J.-Y., & Locquet, M. (2019). The health economics burden of sarcopenia: a systematic review. Maturitas, 119, 61-9. doi:10.1016/j.maturitas.2018.11.003 Peer Reviewed verified by ORBi |
 | Veronese, N., Koyanagi, A., Stubbs, B., Cooper, C., Guglielmi, G., Rizzoli, R., Schofield, P., Punzi, P., Al-Daghri, N., Smith, L., Maggi, S., & Reginster, J.-Y. (2019). Statin use and knee osteoarthritis outcomes: a longitudinal cohort study. Arthritis Care and Research, 71, 1052-1058. doi:10.1002/acr.23735 Peer Reviewed verified by ORBi |
 | Kendler, D. L., Chines, A., Brandi, M. L., Papapoulos, Lewiecki, E. M., Reginster, J.-Y., Munoz Torres, M., Wang, A., & Bone, H. G. (January 2019). The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies. Osteoporosis International, 30 (1), 71-78. doi:10.1007/s00198-018-4687-2 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Reginster, J.-Y., Tosteson, A. N. A., Bukata, S. V., Saag, K. G., Gold, D. T., Halbout, P., Jiwa, F., Lewiecki, E. M., Pinto, D., Adachi, J. D., Al-Daghri, N., Bruyère, O., Chandran, M., Cooper, C., Harvey, N. C., Einhorn, T. A., Kanis, J. A., Kendler, D. L., ... Silverman, S. (January 2019). Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporosis International, 30 (1), 45-57. doi:10.1007/s00198-018-4744-x Peer Reviewed verified by ORBi |
 | Buckinx, F., Paquot, N., FADEUR, M., BACUS, L., Reginster, J.-Y., Allepaerts, S., Petermans, J., Biquet, S., & Bruyère, O. (2019). Assessment of the energy expenditure of Belgian nursing home residents using indirect calorimetry. Nutrition, 57, 12-16. doi:10.1016/j.nut.2018.05.010 Peer Reviewed verified by ORBi |
 | Beaudart, C., Locquet, M., Touvier, M., Reginster, J.-Y., & Bruyère, O. (2019). Association between dietary nutrient intake and sarcopenia in the SarcoPhAge study. Aging Clinical and Experimental Research, 31, 815-824. doi:10.1007/s40520-019-01186-7 Peer Reviewed verified by ORBi |
 | Diez-Perez, A., Brandi, M. L., AL-Daghri, N., Branco J.C., Bruyère, O., Cavalli, L., Cooper, C., Cortet, B., Dawson-Hughes, B., Dimai, H. P., Gonnelli, S., Hadji, P., Halbout, P., Kaufman, J. M., Kurth, A., Locquet, M., Maggi, S., Matijevic, R., Reginster, J.-Y., ... Thierry, T. (2019). Radiofrequency echographic multi-spectrometry for the in-vivo assessment of bone strength: state of the art—outcomes of an expert consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clinical and Experimental Research, 31 (10), 1375-1389. doi:10.1007/s40520-019-01294-4 Peer Reviewed verified by ORBi |
 | Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (January 2019). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, 30 (1), 3-44. doi:10.1007/s00198-018-4704-5 Peer Reviewed verified by ORBi |
 | Bauer, J. M., Cruz-Jentoft, A. J., Fielding, R. A., Kanis, J. A., Reginster, J.-Y., Bruyère, O., Cesari, M., Chapurlat, R., Al-Daghri, N., Dennison, E., Kaufman, J.-M., Landi, F., Laslop, A., Locquet, M., Maggi, S., McCloskey, E., Perna, S., Rizzoli, R., Rolland, Y., ... Cooper, C. (2019). Correction to: Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review (Calcified Tissue International, (2019), 105, 2, (109-124), 10.1007/s00223-019-00561-w). Calcified Tissue International, 105 (2), 125-126. doi:10.1007/s00223-019-00587-0 Peer Reviewed verified by ORBi |
 | Dent, E., Morley, J. E., Cruz-Jentoft, A. J., Woodhouse, L., Rodriguez-Manas, L., Fried, L. P., Woo, J., Aprahamian, I., Sandford, A., Lundy, J., Landi, F., Beilby, J., Martin, F. C., Bauer, J. M., Ferrucci, L., Merchant, R. A., Dong, B., Arai, H., Hoogendijk, E. O., ... Vellas, D. (2019). Physical frailty: ICFSR International Clinical Practice Guidelines for Identification and Management. Journal of Nutrition, Health and Aging, 23 (9), 771-787. doi:10.1007/s12603-019-1273-z Peer Reviewed verified by ORBi |
 | Wani, K. A., Yakout, S. M., Ansari, M. G. A., Sabico, S., Hussain, S. D., Alokail, M. S., Sheshah, E., Aljohani, N. J., Al-Saleh, Y., Reginster, J.-Y., & Al-Daghri, N. M. (2019). Metabolic syndrome in Arab adults with low bone mineral density. Nutrients. doi:10.3390/nu11061405 Peer Reviewed verified by ORBi |
 | Hajaoui, M., Locquet, M., Beaudart, C., Reginster, J.-Y., Petermans, J., & Bruyère, O. (2019). Sarcopenia: Performance of the SARC-F Questionnaire According to the European Consensus Criteria, EWGSOP1 and EWGSOP2 [letter to the editor]. Journal of the American Medical Directors Association, 20 (9), 1182-1183. doi:10.1016/j.jamda.2019.05.021 Peer Reviewed verified by ORBi |
 | Saengnipanthkul, S., Waikakul, S., Rojanasthien, S., Totemchokchyakarn, K., Srinkapaibulaya, A., Cheh Chin, T., Mai Hong, N., Bruyère, O., Cooper, C., Reginster, J.-Y., & Lwin, M. (2019). Differentiation of patented crystalline glucosamine sulfate from other glucosamine preparations will optimize osteoarthritis treatment. International Journal of Rheumatic Diseases, 22 (3), 376-385. doi:10.1111/1756-185X.13068 Peer Reviewed verified by ORBi |
 | Alekna, V., Kilaite, J., Tamulaitiene, M., Geerinck, A., Mastaviciute, A., Bruyère, O., Reginster, J.-Y., & Beaudart, C. (2019). Validation of the Lithuanian version of sarcopenia‑specific quality of life questionnaire (SarQoL®). European Geriatric Medicine, 10, 761-767. doi:10.1007/s41999-019-00208-x Peer reviewed |
 | Reginster, J.-Y., Bruyère, O., Conaghan, P. G., McAlindon, T., & Cooper, C. (2019). Importance of safety in the management of osteoarthritis and the need for updated meta-analyses and recommendations for reporting harms. Drugs and Aging, 36 (Suppl 1), 3-6. doi:10.1007/s40266-019-00659-8 Peer Reviewed verified by ORBi |
 | Honvo, G., Reginster, J.-Y., Rannou, F., Rygaert, X., Geerinck, A., Rabenda, V., McAlindon, T., Charles, A., Fuggle, N., Cooper, C., Curtis, E., Arden, N., Avouac, B., & Bruyère, O. (2019). Safety of intra-articular hyaluronic acid injections in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs and Aging, 36 (suppl 1), 101-127. doi:10.1007/s40266-019-00657-w Peer Reviewed verified by ORBi |
 | Ferrari, S., Libanati, C., Lin, C., Brown, J. P., Cosman, F., Czerwinski, E., de Gregorio, L. H., Malouf-Sierra, J., Reginster, J.-Y., Wang, A., Wagman, R. B., & Lewiecki, E. M. (2019). Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of denosumab treatment. Journal of Bone and Mineral Research, 34, 1033-1040. doi:10.1002/jbmr.3722 Peer Reviewed verified by ORBi |
 | de Wit, M., Cooper, C., Reginster, J.-Y., Tugwell, P., Bere, N., Conaghan, P., Roberts, C., Aujoulat, I., Al-Daghri, N., Araujo de Carvalho, I., Barker, M., Bedlington, N., Brandi, M. L., Bruyère, O., Burlet, N., Halbout, P., Hiligsmann, M., Jiwa, F., Kanis, J. A., ... Vlaskovska, M. (2019). Practical guidance for patient-centred health research. The Lancet, 393, 1095-1096. doi:10.1016/S0140-6736(19)30034-0 Peer Reviewed verified by ORBi |
 | Hilisgmann, M., Williams, S. A., Fitzpatrick, L. A., Silverman, S. S., Weiss, R., & Reginster, J.-Y. (2019). Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture. Seminars in Arthritis and Rheumatism, 49, 184-196. doi:10.1016/j.semarthrit.2019.01.006 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., & Reginster, J.-Y. (2019). Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France. Osteoporosis International, 30, 649-658. doi:10.1007/s00198-018-04821-7 Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2019). EWGSOP2 versus EWGSOP1: impact of the prevalence of sarcopenia and its major health consequences. Journal of the American Medical Directors Association, 20 (3), 384-385. doi:10.1016/j.jamda.2018.11.027 Peer Reviewed verified by ORBi |
 | Eymard, F., Parsons, C., Edwards, M. H., Petit-Dop, F., Reginster, J.-Y., Bruyère, O., Chevalier, X., Cooper, C., & Richette, P. (2019). Impact du traitement par statines dans la progression radiologique de la gonarthrose: résultats issus de l'analyse post-hoc de l'essai SEKOIA. Revue du Rhumatisme, 86, 81-86. doi:10.1016/j.rhum.2018.09.002 Peer Reviewed verified by ORBi |
 | Gillain, S., Boutaayamou, M., Schwartz, C., Bruls, O., Bruyère, O., Croisier, J.-L., Salmon, E., Reginster, J.-Y., Garraux, G., & Petermans, J. (2019). Using supervised learning machine algorithm to identify future fallers based on gait patterns: A two-year longitudinal study. Experimental Gerontology, 127 (first online). doi:10.1016/j.exger.2019.110730 Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Hajaoui, M., PETERMANS, J., Reginster, J.-Y., & Bruyère, O. (2019). Three-Year Adverse Health Consequences of Sarcopenia in Community-Dwelling Older Adults According to 5 Diagnosis Definitions. Journal of the American Medical Directors Association, 20, 43-46. doi:10.1016/j.jamda.2018.06.004 Peer Reviewed verified by ORBi |
 | Buckinx, F., Charles, A., Quabron, A., Van Hees, T., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2019). Impact of frailty status on the cost of drugs and dietary supplements prescribed to nursing home residents: the SENIOR cohort. Aging Clinical and Experimental Research, 31, 875-880. doi:10.1007/s40520-019-01162-1 Peer Reviewed verified by ORBi |
 | Geerinck, A., Beaudart, C., Dardenne, N., Reginster, J.-Y., & Bruyère, O. (2019). An exploration of the structural validity of the sarcopenia quality of life (SARQOL®) questionnaire with exploratory and confirmatory factor analysis. Osteoporosis International, 30 (S2), 537. Peer Reviewed verified by ORBi |
 | Bruyère, O., Reginster, J.-Y., Honvo, G., & Detilleux, J. (2019). Cost-effectiveness evaluation of glucosamine for osteoarthritis based on simulation of individual patient data obtained from aggregated data in published studies. Aging Clinical and Experimental Research, 31 (6), 881-887. doi:10.1007/s40520-019-01138-1 Peer Reviewed verified by ORBi |
 | Cooper, C., Chapurlat, R., Al-Daghri, N., Herrero-Beaumont, G., Bruyère, O., Rannou, F., Roth, R., Uebelhart, D., & Reginster, J.-Y. (2019). Safety of oral non-selective non-steroidal anti-inflammatory drugs in osteoarthritis: what does the literature say ? Drugs and Aging, 36 (suppl 1), 15-24. doi:10.1007/s40266-019-00660-1 Peer Reviewed verified by ORBi |
 | Parsons, C., Judge, A., Leyland, K., Bruyère, O., Petit Dop, F., Chapurlat, R., Reginster, J.-Y., Edwards, M., Dennison, E., Cooper, C., Inskip, H., & SEKOIA Study Group. (2019). Novel approach to estimate osteoarthritis progression: use of the reliable change index in the evaluation of joint space loss. Arthritis Care and Research, 71 (2), 300-7. doi:10.1002/acr.23596 Peer Reviewed verified by ORBi |
 | Veronese, N., & Reginster, J.-Y. (2019). The effects of calorie restriction, intermittent fasting and vegetarian diets on bone health. Aging Clinical and Experimental Research, 31, 753-758. doi:10.1007/s40520-019-01174-x Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Bianic, F., Campbell, R., Martin, M., Williams, S. A., & Fitzpatrick, L. A. (2019). Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporosis International. doi:10.1007/s00198-019-04947-2 Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Reginster, J.-Y., & Bruyère, O. (2019). Association between the decline in muscle health and the decline in bone health in older individuals from the SarcoPhAge Cohort. Calcified Tissue International, 104, 273-284. doi:10.1007/s00223-018-0503-4 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Pinto, D., Dennison, E., Al-Daghri, N., Beaudart, C., Branco, J., Bruyère, O., Conaghan, P. G., Cooper, C., Herrero-Beaumont, G., Jiwa, F., Lems, W., Rizzoli, R., Thomas, T., Veronese, N., & Reginster, J.-Y. (January 2019). Patients’ preferences for osteoarthritis treatment: the value of stated-preference studies. Aging Clinical and Experimental Research, 31 (1), 1-3. doi:10.1007/s40520-018-1098-3 Peer Reviewed verified by ORBi |
 | Honvo, G., Leclercq, V., Geerinck, A., Thomas, T., Veronese, N., Charles, A., Rabenda, V., Beaudart, C., Cooper, C., Reginster, J.-Y., & Bruyère, O. (2019). Safety of topical non-steroidal anti-inflammatory drugs in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs and Aging, 36 (suppl 1), 45-64. doi:10.1007/s40266-019-00661-0 Peer Reviewed verified by ORBi |
 | Alkahtani, S. A., Yakout, S. M., Reginster, J.-Y., & Al-Daghri, N. M. (2019). Effect of acute downhill running on bone markers in responders and non-responders. Osteoporosis International. doi:10.1007/s00198-018-4673-8 Peer Reviewed verified by ORBi |
 | de Wit, M., Cooper, C., Tugwell, P., Bere, N., Kirwan, J., Conaghan, P. G., Roberts, C., Aujoulat, I., Al-Daghri, N., Araujo de Carvalho, I., Barker, M., Bedlington, N., Brandi, M. L., Bruyère, O., Burlet, N., Halbout, P., Hiligsmann, M., Jiwa, F., Kanis, J. A., ... Reginster, J.-Y. (2019). Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clinical and Experimental Research, 31 (7), 905-915. doi:10.1007/s40520-019-01193-8 Peer Reviewed verified by ORBi |
 | Veronese, N., Koyanagi, A., Stubbs, B., Cooper, C., Guglielmi, G., Rizzoli, R., Punzi, L., Rogoli, D., Caruso, M. G., Rotolo, O., Notarnicola, M., Al-Daghri, N. M., Smith, L., Reginster, J.-Y., & Maggi, S. (2019). Mediterranean diet and knee osteoarthritis outcomes: a longitudinal cohort study. Clinical Nutrition. doi:10.1016/j.clnu.2018.11.032 Peer Reviewed verified by ORBi |
 | Honvo, G., Reginster, J.-Y., Rabenda, V., Geerinck, A., Mkinsi, O., Charles, A., Rizzoli, R., Cooper, C., Avouac, B., & Bruyère, O. (2019). Safety of symptomatic slow-acting drugs for osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs and Aging, 36 (suppl 1), 65-99. doi:10.1007/s40266-019-00662-z Peer Reviewed verified by ORBi |
 | Lorentzon, M., Branco, J. C., Brandi, M. L., Bruyère, O., Chapurlat, R. D., Cooper, C., Cortet, B., Diez-Perez, A. D., Ferrari, S. L., Gasparik, A. I., Herrmann, M., Jorgensen, N. R., Kanis, J. A., Kaufman, J.-M., Laslop, A., Locquet, M., Matijevic, R., McCloskey, E. V., Minisola, S., ... Cavalier, E. (2019). Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. Advances in Therapy, 36 (10), 2811-2824. doi:10.1007/s12325-019-01063-9 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Cornelissen, D., Vrijens, B., Abrahamsen, B., Al-Daghri, N., Biver, E., Brandi, M. L., Bruyère, O., Burlet, N., Cooper, C., Cortet, B., Dennison, E., Diez-Perez, A., Gasparik, A., Grosso, A., Hadji, P., Halbout, P., Kanis, J. A., Kaufman, J. M., ... Reginster, J.-Y. (2019). Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). Osteoporosis International, 30 (11), 2155-2165. doi:10.1007/s00198-019-05104-5 Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Durieux, N., Reginster, J.-Y., & Bruyère, O. (2019). Relationship between the changes over time of bone mass and muscle health in children and adults: A systematic review and meta-analysis. BMC Musculoskeletal Disorders, 20, 429. doi:10.1186/s12891-019-2752-4 Peer Reviewed verified by ORBi |
 | Charles, A., Buckinx, F., Locquet, M., Reginster, J.-Y., PETERMANS, J., Gruslin, B., & Bruyère, O. (2019). Intrinsic capacity and its association with mortality over 3 years in nursing homes: Results of the SENIOR cohort. Osteoporosis International, 30 (S2), 177-178. Peer Reviewed verified by ORBi |
 | Geerinck, A., Beaudart, C., Reginster, J.-Y., & Bruyère, O. (2019). Comparison of the psychometric properties of the SarQoL® questionnaire with the EWGSOP and EWGSOP2 criteria for sarcopenia. Osteoporosis International, 30 (S2), 179. Peer Reviewed verified by ORBi |
| Geerinck, A., Beaudart, C., Bautmans, I., Cooper, C., De Souza Orlandi, F., Konstantynowicz, J., Monterro-Errasquin, B., Topinkova, E., Tsekoura, M., Reginster, J.-Y., & Bruyère, O. (13 November 2018). Standard error of measurement and smallest detectable change of the SarQoL questionnaire: an analysis of subjects from 8 validation studies [Poster presentation]. European congress of the International society for Pharmaeconomics and Outcomes Research (ISPOR), Barcelona, Spain. |
 | Geerinck, A., Bruyère, O., Locquet, M., Reginster, J.-Y., & Beaudart, C. (November 2018). Evaluation of the responsiveness of the SarQoL® questionnaire, a patient-reported outcome measure specific to sarcopenia. Advances in Therapy, 35, 1842-1858. doi:10.1007/s12325-018-0820-z Peer Reviewed verified by ORBi |
| Geerinck, A., Beaudart, C., Bautmans, I., Cooper, C., De Souza Orlandi, F., Konstantynowicz, J., Monterro-Errasquin, B., Topinkova, E., Tsekoura, M., Reginster, J.-Y., & Bruyère, O. (11 October 2018). Standard error of measurement and smallest detectable change of the SarQoL questionnaire: an analysis of subjects from 8 validation studies [Paper presentation]. 14th International Congress of the European Geriatric Medicine Society, Berlin, Germany. |
 | Reginster, J.-Y., Bianic, F., Campbell, R., Martin, M., Williams, S. A., & Fitzpatrick, L. A. (September 2018). Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Arthritis and Rheumatology, 70 (S9), 2308. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Bruyère, O., & Cooper, C. (July 2018). Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms. Annals of the Rheumatic Diseases, 77 (7), 1-2. doi:10.1136/annrheumdis-2017-212251 Peer Reviewed verified by ORBi |
 | Vellucci, R., Terenzi, R., Kanis, J. A., Kress, H. G., Mediati, R. D., Reginster, J.-Y., Rizzoli, R., & Brandi, M. L. (July 2018). Understanding osteoporotic pain and its pharmacological treatment. Osteoporosis International, 29 (7), 1477-1491. doi:10.1007/s00198-018-4476-y Peer Reviewed verified by ORBi |
 | GILLAIN, S., Boutaayamou, M., Schwartz, C., WOJTASIK, V., CHRISTELBACH, S., Dardenne, N., Bruls, O., Bruyère, O., Reginster, J.-Y., CROISIER, J.-L., GARRAUX, G., & PETERMANS, J. (June 2018). Dépister les sujets à risque de chute parmi nos aînés robutes: intérêt de la marche rapide [Poster presentation]. Congrès de la CIFGG, Montreux, Switzerland. |
 | Buckinx, F., Bornheim, S., Remy, G., Van Beveren, J., Reginster, J.-Y., Bruyère, O., Dardenne, N., & Kaux, J.-F. (2018). French cross-cultural adaptation and measurement properties of the “ANTERIOR KNEE PAIN SCALE”. In Abstract Book - 21st European Congress of Physical and Rehabilitation Medicine (pp. 399). Peer reviewed |
 | Charles, A., Buckinx, F., Cataldo, D., Rygaert, X., Reginster, J.-Y., & Bruyère, O. (22 April 2018). Relationship between peak expiratory flow, physical capacity and incidence of frailty among nursing home residents [Poster presentation]. WCO IOF - ESCEO, Cracovie, Poland. |
 | GEERINCK, A., Bruyère, O., Locquet, M., Reginster, J.-Y., & Beaudart, C. (21 April 2018). Evaluation of the responsiveness of a patient-reported outcome measure specific to sarcopenia: the SarQoL questionnaire [Poster presentation]. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, Krakow, Poland. |
 | Buckinx, F., Charles, A., Quabron, A., Van Hees, T., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2018). Impact du statut de fragilité des résidents de maisons de repos sur le coût lié à la consommation de produits pharmaceutiques : résultats de la cohorte SENIOR. Cahiers de l'Année Gérontologique, 15. Peer Reviewed verified by ORBi |
 | Buckinx, F., Croisier, J.-L., Charles, A., Petermans, J., Reginster, J.-Y., Rygaert, X., & Bruyère, O. (2018). Valeurs normatives de la force isométrique pour 8 groupes musculaires différents et leur valeur predictive de la perte d’autonomie chez les personnes âgées résidant en maison de repos: l’étude SENIOR. Cahiers de l'Année Gérontologique, 28. Peer Reviewed verified by ORBi |
 | Buckinx, F., Charles, A., Quabron, A., VAN HEES, T., Petermans, J., Reginster, J.-Y., & Bruyère, O. (05 April 2018). Impact of the frailty status on the cost of drugs consumed in nursing homes: results froim the Senior cohort. Osteoporosis International, 29 S1, 356. Peer Reviewed verified by ORBi |
 | Buckinx, F., Adam, S., Charles, A., Rygaert, X., Reginster, J.-Y., & Bruyère, O. (2018). Agisme en maison de repos : résultats de la cohorte SENIOR. Cahiers de l'Année Gérontologique, 28. Peer Reviewed verified by ORBi |
 | Charles, A., Buckinx, F., Cataldo, D., Reginster, J.-Y., Rygaert, X., & Bruyère, O. (05 April 2018). Relation entre le débit expiratoire de pointe, les capacités physiques et l’incidence de la fragilité chez les personnes âgées résidant en maison de repos : résultats de la cohorte SENIOR [Paper presentation]. 6ème Congrès Fragilité du Sujet Âgé Le Vieillissement en Santé Prévention de la Perte d'Autonomie, Paris, France. |
 | Rabenda, V., Leclercq, V., Reginster, J.-Y., & Bruyère, O. (April 2018). Critical appraisal of psychometric methods used in validation of patient-reported outcomes measures. Osteoporosis International, 29 S1, 480-481. Peer Reviewed verified by ORBi |
 | Rannou, F., Martel-Pelletier, J., Pelletier, J., Mkinsi, O., Branco, J., Alekseeva, L., Monod, P., Planta, F., Maheu, E., & Reginster, J.-Y. (April 2018). A new decision tree for diagnosis and management of osteoarthritis in primary care: international consensus of experts. Osteoporosis International, 29 S1, 509-510. Peer Reviewed verified by ORBi |
 | Charles, A., Buckinx, F., Cataldo, D., Reginster, J.-Y., Rygaert, X., & Bruyère, O. (April 2018). Relationship between peak expiratory flow, physical capacity and incidence of frailty among nursing home residents. Osteoporosis International, 29 S1, 548. Peer Reviewed verified by ORBi |
 | Buckinx, F., Charles, A., Rygaert, X., Reginster, J.-Y., Petermans, J., & Bruyère, O. (April 2018). Dynamic approach of the frailty status in nursing homes: 2-year prospective follow-up of the Senior cohort. Osteoporosis International, 29 S1, 59. Peer Reviewed verified by ORBi |
 | Veronese, N., Shivappa, N., Hebert, J., Cooper, C., Guglielmi, G., Reginster, J.-Y., Rizzoli, R., & Maggi, S. (April 2018). Pro-inflammatory dietary pattern is associated with fractures in women: an eight year longitudinal cohort study. Osteoporosis International, 29 S1, 64-65. Peer Reviewed verified by ORBi |
 | Bruyère, O., Curtis, E., Honvo, G., Fuggle, N., Reginster, J.-Y., & Cooper, C. (April 2018). Reassessment of the safety of anti-osteoarthritis medications. Osteoporosis International, 29 S1, 324-325. Peer Reviewed verified by ORBi |
 | Ferrari, S., McCloskey, E., Bouxsein, M., De Schepper, J., & Reginster, J.-Y. (April 2018). AGN1 local osteo-enhancement procedure (LOEP): an emerging, minimally-invasive surgical treatment to address osteoporosis-related bone loss in proximal femurs. Osteoporosis International, 29 S1, 555-556. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (April 2018). Safety of anti-osteoarthtritis medications: results of ESCEO 2017 working groups. Osteoporosis International, 29 S1, 555. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Williams, S. A., Fitzpatrick, L. A., & Reginster, J.-Y. (April 2018). Cost-effectiveness of abaloparatide for the treatment of postmenopausal women with osteoporosis. Osteoporosis International, 29 S1, 43-44. Peer Reviewed verified by ORBi |
 | Cooper, C., Reginster, J.-Y., & Belissa-Mathiot, P. (April 2018). EE joint replacement in patients with knee osteoarthritis: a long tem follow-up study in patients of the CL3-12911-018 study. Osteoporosis International, 29 S1, 251. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (April 2018). Dairy products in the prevention and treatment of sarcopenia: outcomes of the ESCEO working groups. Osteoporosis International, 29 S1, 78. Peer Reviewed verified by ORBi |
 | Honvo, G., Leclercq, V., GEERINCK, A., Rabenda, V., Beaudart, C., Cooper, C., Reginster, J.-Y., & Bruyère, O. (April 2018). Adverse events associated with topical non-steroidal anti-inflammatory drugs (NSAIDS) in osteoarthritis: a systematic review and meta-analysis of randomized, placebo-controlled trials. Osteoporosis International, 29 S1, 550. Peer Reviewed verified by ORBi |
 | Neuprez, A., Neuprez, A., KAUX, J.-F., KURTH, W., DANIEL, C., THIRION, T., HUSKIN, J.-P., Gillet, P., Bruyère, O., & Reginster, J.-Y. (April 2018). Early Clinically Relevant Improvement in Quality of Life and Clinical Outcomes 1 Year Postsurgery in Patients with Knee and Hip Joint Arthroplasties. Cartilage, 9 (2), 127-139. doi:10.1177/1947603517743000 Peer Reviewed verified by ORBi |
 | Konstantynowicz, J., Abramowicz, P., Glinkowski, W., Taranta, E., Marcinowicz, L., Reginster, J.-Y., Bruyère, O., & Beaudart, C. (April 2018). The polish validation of the Sarquol®, a quality of life questionnaire specific for sarcopenia: the evidence of a good utility. Osteoporosis International, 29 S1, 541-542. Peer Reviewed verified by ORBi |
 | Rabenda, V., Leclercq, V., Reginster, J.-Y., & Bruyère, O. (April 2018). Review of terminology of measurement properties for patient-reported outcomes measures. Osteoporosis International, 29 S1, 482. Peer Reviewed verified by ORBi |
 | Neuprez, A., Neuprez, A., Maheu, E., Bruyère, O., Kaux, J.-F., & Reginster, J.-Y. (April 2018). Determinants of clinical and radiological progression of hand osteoarthritis over 2 years. Osteoporosis International, 29 S1, 438. Peer Reviewed verified by ORBi |
 | Buckinx, F., Charles, A., Rygaert, X., Reginster, J.-Y., Adam, S., & Bruyère, O. (April 2018). Own attitude regarding aging among nursing home residents: results of the Senior cohort. Osteoporosis International, 29 S1, 357. Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Reginster, J.-Y., Petermans, J., & Bruyère, O. (April 2018). Three-year adverse health consequences of sarcopenia in community-dwelling older adults: Results from the SarcoPhAge cohort study. Osteoporosis International, 29 S1, 60-61. Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Reginster, J.-Y., Hajaoui, M., & Bruyère, O. (April 2018). Association between decline in muscle health and bone health in older individuals fom the SarcoPhAge cohort. Osteoporosis International, 29 S1, 212. Peer Reviewed verified by ORBi |
 | Beaudart, C., Locquet, M., Touvier, M., Reginster, J.-Y., & Bruyère, O. (April 2018). Association between dietary nutrient intake and sarcopenia: the SarcoPhAge cohort study. Osteoporosis International, 29 S1, 57. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Williams, S. A., Fitzpatrick, L. A., Silverman, S., Weiss, R., & Reginster, J.-Y. (April 2018). Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for the prevention of osteoporotic fractures in postmenopausal women at increased risk of fracture. Osteoporosis International, 29 S1, 302. Peer Reviewed verified by ORBi |
 | GEERINCK, A., Bruyère, O., Locquet, M., Reginster, J.-Y., & Beaudart, C. (April 2018). Evaluation of the responsiveness of the SARQOL® questionnaire: results from the SarcoPhAge study. Osteoporosis International, 29 S1, 300. Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Reginster, J.-Y., & Bruyère, O. (April 2018). Consequences of relevant muscle function decline over 1 year in older individuals living in the community: results from the SarcoPhAge study. Osteoporosis International, 29 S1, 339. Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Reginster, J.-Y., & Bruyère, O. (April 2018). Determinants of rapid muscle function declines over 1 year in community-dwelling older adults: the SarcoPhAge study. Osteoporosis International, 29 S1, 339-340. Peer Reviewed verified by ORBi |
 | Veronese, N., Maggi, S., Cooper, C., & Reginster, J.-Y. (April 2018). Statins and incident knee osteoarthritis: results from the osteoarthritis initiative. Osteoporosis International, 29 S1, 328. Peer Reviewed verified by ORBi |
 | Honvo, G., Rabenda, V., GEERINCK, A., Cooper, C., Reginster, J.-Y., & Bruyère, O. (April 2018). Adverse events associated with symptomatic slow-acting drugs in osteoarthritis (SYSADOAS): a systematic review and stratified meta-analysis of randomized, placebo-controlled trials. Osteoporosis International, 29 S1, 549-550. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Bianic, F., Campbell, R., Martin, M., Williams, S. A., & Fitzpatrick, L. A. (April 2018). Abaloparatide for risk reduction of non-vertebral fractures in postmenopausal women with osteoporosis: an updated network meta-analysis. Osteoporosis International, 29 S1, 42. doi:10.1007/s00198-018-4470-4 Peer Reviewed verified by ORBi |
 | Beaudart, C., Bruyère, O., Reginster, J.-Y., Bauer, J., Cooper, C., Cruz-Jentoft, A., Landi, F., Locquet, M., Maggi, S., Rizzoli, R., Rolland, Y., Vaquero, N., & Hiligsmann, M. (April 2018). Patient’s engagement in the identification of critical outcomes in sarcopenia. Osteoporosis International, 29 S1, 299. Peer Reviewed verified by ORBi |
 | Felsenberg, D., Chapurlat, R., Rizzoli, R., Reginster, J.-Y., & Belissa-Mathiot, P. (April 2018). A 24 months prospective, randomized, double-blind study to assess the effect of daily oral administration of 2g of strontium ranelate vs placebp on BMD in postmenpausal. Osteoporosis International, 29 S1, 250-251. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Arden, N. K., Haugen, I., Rannou, F., Cavalier, E., Bruyère, O., Branco, J., Chapurlat, R., Basset, S., Al-Daghri, N., Dennison, E., Herrero-Beaumont, G., Laslop, A., Leeb, B., Maggi, S., Mkinsi, O., Povzun, A., Prieto-Alhambra, D., Thomas, T., ... Cooper, C. (April 2018). Guidelines for the conduct of pharmacological clinical trials in hand osteoarthritis: consensus of a working group of the ESCEO. Osteoporosis International, 29 (Suppl1), 71-2. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Arden, N. K., Haugen, I. K., Rannou, F., Cavalier, E., Bruyère, O., Branco, J., Chapurlat, R., Collaud Basset, S., Al-Daghri, N. M., Dennison, E. M., Herrero-Beaumont, G., Laslop, A., Leeb, B. F., Maggi, S., Mkinsi, O., Povzun, A. S., Prieto-Alhambra, D., Thomas, T., ... Cooper, C. (2018). Guidelines for the conduct of pharmacological clinical trials in hand osteoarthritis: Consensus of a Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Seminars in Arthritis and Rheumatism, 48, 1-8. doi:10.1016/j.semarthrit.2017.12.003 Peer Reviewed verified by ORBi |
 | Beaudart, C., Locquet, M., Reginster, J.-Y., Delandsheere, L., Petermans, J., & Bruyère, O. (2018). Quality of life in sarcopenia measured with the SarQoL®: impact of the use of different diagnosis definitions. Aging Clinical and Experimental Research, 30, 307-313. doi:10.1007/s40520-017-0866-9 Peer Reviewed verified by ORBi |
 | Vellas, B., Fielding, R. A., Bens, C., Bernabei, R., Cawthon, P. M., Cederholm, T., Cruz-Jentoft, A. J., Del Signore, S., Donahue, S., Morley, J., Pahor, M., Reginster, J.-Y., Rodriguez Manas, L., Rolland, Y., Roubenoff, R., Sinclair, A., & Cesari, M. (2018). Implications of ICD-10 for Sarcopenia Clinical Practice and Clinical Trials: Report by the International Conference on Frailty and Sarcopenia Research Task Force. Journal of Frailty and Aging, 7 (1), 2-9. doi:10.14283/jfa.2017.30 Peer Reviewed verified by ORBi |
 | Slomian, J., Vigneron, L., EMONTS, P., Reginster, J.-Y., & Bruyère, O. (2018). Evaluation du site internet Happy-Mums.be conçu en vue de tenter d’aider les mères à combler leurs besoins en période postnatale [Poster presentation]. 46ème Assises Nationales des Sages-Femmes, Marseille, France. |
 | Robinson, S. M., Reginster, J.-Y., Rizzoli, R., Shaw, S. C., Kanis, J. A., Bautmans, I., Bischoff-Ferrari, H., Bruyère, O., Cesari, M., Dawson-Hughes, B., Fielding, R. A., Kaufman, J. M., Landi, F., Malafarina, V., Rolland, Y., Van Loon, L. J., Vellas, B., Visser, M., & Cooper, C. (2018). Does nutrition play a role in the prevention and management of sarcopenia? Clinical Nutrition, 37, 1121-1132. doi:10.1016/j.clnu.2017.08.016 Peer Reviewed verified by ORBi |
 | Buckinx, F., Landi, F., Cesari, F., Fielding, R. A., Visser, M., Engelke, K., Maggi, S., Dennison, E., Al-daghri, N. M., ALLEPAERTS, S., Bauer, J., Bautmans, I., Brandi, M. L., Bruyère, O., Cederholm, T., Cerrata, F., Cherubini, A., Cooper, C., Cruz-Jentoft, A., ... Kanis, J. A. (2018). Pitfalls in the measurement of muscle mass; a need for a reference standard. Journal of Cachexia, Sarcopenia and Muscle, 9, 269-278. doi:10.1002/jcsm.12268 Peer Reviewed verified by ORBi |
 | Marcucci, G., Masi, L., Ferrari, S., Haffner, D., Javaid, M. K., Kamenicky, P., Reginster, J.-Y., Rizzoli, R., & Brandi, M. L. (2018). Phosphate wasting disorders in adults. Osteoporosis International, 29, 2369-2387. doi:10.1007/s00198-018-4618-2 Peer Reviewed verified by ORBi |
 | Buckinx, F., Bruyère, O., Reginster, J.-Y., Charles, A., DELANAYE, P., & CAVALIER, E. (2018). Plasma Klotho and Mortality Risk Among Nursing Home Residents: Results From the SENIOR Cohort [letter to the editor]. Journal of the American Medical Directors Association, 19 (12), 1139-1140. doi:10.1016/j.jamda.2018.08.010 Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Bruyère, O., Kanis, J. A., Delandsheere, L., & Reginster, J.-Y. (2018). Bone health assessment in older people with or without muscle health impairment. Osteoporosis International, 29, 1057-1067. doi:10.1007/s00198-018-4384-1 Peer Reviewed verified by ORBi |
 | Beaudart, C., Rabenda, V., Simmons, M., Geerinck, A., Araujo De Carvalho, I., Reginster, J.-Y., Amuthavalli Thiyagarajan, J., & Bruyère, O. (2018). Effects of protein, essential amino acids, B-Hydroxy B-Methylbutyrate, creatine, Dehydroepiandrosterone and fatty acid supplementation on muscle mass, muscle strength and physical performance in older people aged 60 years and over. A systematic review of the litterature. Journal of Nutrition, Health and Aging, 22 (1), 117-130. doi:10.1007/s12603-017-0934-z Peer Reviewed verified by ORBi |
 | Beaudart, C., Biver, E., Bruyère, O., Cooper, C., Al-Daghri, N., Reginster, J.-Y., & Rizzoli, R. (2018). Quality of life assessment in musculo-skeletal health. Aging Clinical and Experimental Research, 30 (5), 413-418. doi:10.1007/s40520-017-0794-8 Peer Reviewed verified by ORBi |
 | Buckinx, F., Landi, F., Cesari, M., Fielding, R., Visser, M., Engelke, K., Maggi, S., Dennison, E., Al-Daghri, N., ALLEPAERTS, S., Bauer, J., Bautmans, I., Brandi, M.-L., Bruyère, O., Cederholm, T., Cerreta, F., Cherubini, A., Cooper, C., Cruz-Jentoft, A., ... Kanis, J. (2018). The authors reply: Letter on: "Pitfalls in the measurement of muscle mass: a need for a reference standard" by Clark et al. Journal of Cachexia, Sarcopenia and Muscle, 9 (7), 1272-1274. doi:10.1002/jcsm.12387 Peer Reviewed verified by ORBi |
 | Buckinx, F., Landi, F., Cesari, M., Fielding, R. A., Visser, M., Engelke, K., Maggi, S., Dennison, E., Al-Daghri, N. M., ALLEPAERTS, S., Bauer, J., Bautmans, I., Brandi, M. L., Bruyère, O., Cederholm, T., Cerreta, F., Cherubini, A., Cooper, C., Cruz-Jentoft, A., ... Kanis, J. A. (2018). The authors reply: Dual energy X-ray absorptiometry: gold standard for muscle mass ? by Scafoglieri et al. Journal of Cachexia, Sarcopenia and Muscle, 9, 788-790. doi:10.1002/jcsm.12329 Peer Reviewed verified by ORBi |
 | Gasparik, A. I., Mihai, G., Beaudart, C., Bruyère, O., Pop, R.-M., Reginster, J.-Y., & Pascanu, I. M. (2018). Correction to: Psychometric performance of the Romanian version of the SarQoL®, a health-related quality of life questionnaire for sarcopenia (Archives of Osteoporosis, (2017), 12, 1, (103), 10.1007/s11657-017-0397-1). Archives of Osteoporosis, 13 (1), 98. doi:10.1007/s11657-018-0516-7 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Fardellone, P., & Reginster, J.-Y. (2018). Promouvoir la consommation de produits laitiers pour prévenir les fractures: un investissement rentable. Revue du Rhumatisme (Edition Francaise), 85 (3), 220-221. doi:10.1016/j.rhum.2018.01.001 Peer reviewed |
 | Buckinx, F., Croisier, J.-L., Reginster, J.-Y., Lenaerts, C., Brunois, T., Rygaert, X., PETERMANS, J., & Bruyère, O. (2018). Prediction of the Incidence of Falls and Deaths Among Elderly Nursing Home Residents: The SENIOR Study. Journal of the American Medical Directors Association, 19 (1), 18-24. doi:10.1016/j.jamda.2017.06.014 Peer Reviewed verified by ORBi |
 | Neuprez, A., Neuprez, A., KURTH, W., Gillet, P., Bruyère, O., & Reginster, J.-Y. (2018). Profile of osteoarthritic patients undergoing hip or knee arthroplasty, a step toward a definition of the “need for surgery”. Aging Clinical and Experimental Research, 30, 315-321. doi:10.1007/s40520-017-0780-1 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2018). CONCEPT provides robust evidence that chondroitin sulfate is superior to placebo and similar to celecoxib in the symptomatic management of osteoarthritis. Annals of the Rheumatic Diseases, 77 (2), 1-2. doi:10.1136/annrheumdis-2017-212115 Peer Reviewed verified by ORBi |
 | Veronese, N., Stubbs, B., Solmi, M., Smith, T. O., Reginster, J.-Y., & Maggi, S. (2018). Osteoarthritis increases the risk of cardiovascular disease: Data from the osteoarthritis initiative. Journal of Nutrition, Health and Aging, 22 (3), 371-376. doi:10.1007/s12603-017-0941-0 Peer Reviewed verified by ORBi |
 | GILLAIN, S., Boutaayamou, M., Beaudart, C., DEMONCEAU, M., Bruyère, O., Reginster, J.-Y., Garraux, G., & PETERMANS, J. (2018). Assessing gait parameters with accelerometer-based methods to identify older adults at risk of falls: a systematic review. European Geriatric Medicine, 9, 435-448. doi:10.1007/s41999-018-0061-3 Peer reviewed |
 | Locquet, M., Beaudart, C., Delandsheere, L., Reginster, J.-Y., & Bruyère, O. (2018). Subjective sleep quality among sarcopenic and non-sarcopenic older adults - results from the SarcoPhAge Cohort. Journal of Frailty and Aging, 7, 176-181. doi:10.14283/jfa.2018.13 Peer Reviewed verified by ORBi |
 | Rizzoli, R., Biver, E., Bonjour, J. P., Coxam, V., Goltzam, D., Kanis, J. A., Lappe, J., Rejnmark, L., Sahni, S., Weaver, C., Weiler, H., & Reginster, J.-Y. (2018). Benefits and safety of dietary protein for bone health- an expert consensus paper endorsed by the European Society for Clinical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases and by the International Osteoporosis Foundation. Osteoporosis International, 29, 1933-1948. doi:10.1007/s00198-018-4534-5 Peer Reviewed verified by ORBi |
 | Vellucci, R., Terenzi, R., Kanis, J. A., Kress, H. G., Mediati, R. D., Reginster, J.-Y., Rizzoli, R., & Brandi, M. L. (2018). Understanding osteoporotic pain and its pharmacological treatment: supplementary presentation. Osteoporosis International, 29, 2153-2154. doi:10.1007/s00198-018-4536-3 Peer Reviewed verified by ORBi |
 | Beaudart, C., Locquet, M., Bornheim, S., Reginster, J.-Y., & Bruyère, O. (2018). French translation and validation of the sarcopenia screening tool SARC-F. European Geriatric Medicine, 9, 29-37. doi:10.1007/s41999-017-0007-1 Peer reviewed |
 | Hiligsmann, M., & Reginster, J.-Y. (2018). The projected public health and economic impact of vitamin D fortified dairy products for fracture prevention in France. Expert Review of Pharmacoeconomics and Outcomes Research, 18, 191-195. doi:10.1080/14737167.2017.1375406 Peer Reviewed verified by ORBi |
 | Veronese, N., Stubbs, B., Koyanagi, A., Hebert, J., Cooper, C., Caruso, M., Guglielmi, G., Reginster, J.-Y., Rizzoli, R., Maggi, S., & Shivappa, N. (2018). Pro-inflammatory dietary pattern is associated with fractures in women: an eight-year longitudinal cohort study. Osteoporosis International, 29 (1), 143-151. doi:10.1007/s00198-017-4251-5 Peer Reviewed verified by ORBi |
 | Bruyère, O., Cooper, C., Al-Daghri, N., Dennison, E. M., Rizzoli, R., & Reginster, J.-Y. (2018). Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clinical and Experimental Research, 30, 111-117. doi:10.1007/s40520-017-0861-1 Peer Reviewed verified by ORBi |
 | Malafarina, V., Reginster, J.-Y., Cabrerizo, S., Bruyère, O., Kanis, J. A., Martinez, J. A., & Zulet, M. A. (2018). Nutritional status and nutritional treatment are related to outcomes and mortality in older adults with hip fracture. Nutrients, 10, 555. doi:10.3390/nu10050555 Peer Reviewed verified by ORBi |
 | Dierks, R. M. L., Bruyère, O., & Reginster, J.-Y. (2018). Critical analysis of valuation and strategical orientation of merger and acquisition deals in the pharmaceutical industry. Expert Review of Pharmacoeconomics and Outcomes Research, 18 (2), 147-60. doi:10.1080/14737167.2018.1417040 Peer Reviewed verified by ORBi |
 | Cesari, M., Araujo de Carvalho, I., Amuthavalli Thiyagarajan, J., Cooper, C., Martin, F. C., Reginster, J.-Y., Vellas, B., & Beard, J. R. (2018). Evidence for the domains supporting the construct of intrinsic capacity. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 73 (12), 1653-1660. doi:10.1093/Gerona/gly011 Peer Reviewed verified by ORBi |
 | Buckinx, F., Charles, A., Rygaert, X., Reginster, J.-Y., Adam, S.* , & Bruyère, O.*. (2018). Own attitude toward aging among nursing home residents: results of the SENIOR cohort. Aging Clinical and Experimental Research, 10, 1151-1159. doi:10.1007/s40520-018-1013-y Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Reginster, J.-Y., Hattersley, G., Williams, G., Hu, M. Y., Fitzpatrick, L. A., & Lewiecki, E. M. (2018). Abaloparatide is an effective treatment option for postmenopausal osteoporosis: review of the number needed to treat compared with teriparatide. Calcified Tissue International, 103, 540-545. doi:10.1007/s00223-018-0450-0 Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Reginster, J.-Y., PETERMANS, J., & Bruyère, O. (2018). Comparison of the performance of five screening methods for sarcopenia. Clinical Epidemiology, 10, 71-82. doi:10.2147/CLEP.S148638 Peer Reviewed verified by ORBi |
 | Veronese, N., Punzi, L., Sieber, C., Bauer, J., Reginster, J.-Y., Maggi, S., & On behalf of theTask Finish Group on Arthritis of the European Geriatric Medicine Society. (2018). Sarcopenic osteoarthritis: a new entity in geriatric medicine? European Geriatric Medicine, 9 (2), 141-148. doi:10.1007/s41999-018-0034-6 Peer reviewed |
 | Konstantynowicz, J., Abramowicz, P., Glinkowski, W., Taranta, E., Marcinowicz, L., Dymitrowicz, M., Reginster, J.-Y., Bruyère, O., & Beaudart, C. (2018). Polish Validation of the SarQoL®, a Quality of Life Questionnaire Specific to Sarcopenia. Journal of Clinical Medicine, 7, 323-332. doi:10.3390/jcm7100323 Peer Reviewed verified by ORBi |
 | Slomian, J., Vigneron, L., EMONTS, P., Reginster, J.-Y., & Bruyère, O. (2018). The "Happy Mums" website dedicated to the perinatal period: evaluation of its acceptability by parents and professionals. Midwifery, 66, 17-24. doi:10.1016/j.midw.2018.07.009 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Fardellone, P., & Reginster, J.-Y. (2018). Promoting the consumption of dairy products for fracture prevention: A good value for money? Joint Bone Spine, 85, 403-404. doi:10.1016/j.jbspin.2017.11.009 Peer Reviewed verified by ORBi |
 | Bahat, G., Yilmaz, O., Merve Oren, M., Akif Karan, M., Reginster, J.-Y., Bruyère, O., & Beaudart, C. (2018). Cross-cultural adaptation and validation of the SARC-F to assess sarcopenia: methodological report from European Union Geriatric Medicine Society Sarcopenia Special Interest Group. European Geriatric Medicine, 9, 23-28. doi:10.1007/s41999-017-0003-5 Peer reviewed |
 | Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2018). Review of the guideline of the American College of Physicians on the treatment of osteoporosis. Osteoporosis International, 29, 1505-1510. doi:10.1007/s00198-018-4504-y Peer Reviewed verified by ORBi |
 | Eymard, F., Parsons, C., Edwards, M. H., Petit-Dop, F., Reginster, J.-Y., Bruyère, O., Chevalier, X., Cooper, C., & Richette, P. (2018). Statin use and knee osteoarthritis progression: Results from a post-hoc analysis of the SEKOIA trial. Joint Bone Spine, 85 (5), 609-614. doi:10.1016/j.jbspin.2017.09.014 Peer Reviewed verified by ORBi |
 | Mavungu Landu, D. J., Frederich, M., Hubert, P., Manzambi Kuwekita, J., Reginster, J.-Y., Michel, B., Gretry, L., Mbongo Pasi, C., Mavungu Nsiona, J., Mbinze, J., & Marini Djang'Eing'A, R. (23 November 2017). Consommation des médicaments antipaludiques : Analyse des échantillons et caractéristiques des pharmacies en territoires périurbains de Kinshasa [Paper presentation]. Premier Congrès sur la Gestion Intégrée du Risque Sanitaire (COGIRS I), Kinshasa, Congo - Kinshasa. |
 | Mavungu Landu, D. J., Mbuyi Kaluka Tshibanda, J., Dasnoy, C., Gretry, L., Mikobi Mikobi, C., Kayembe, J. M., Longo Mbenza, B., Marini Djang'Eing'A, R., Hubert, P., Reginster, J.-Y., Michel, B., Manzambi Kuwekita, J., Jansen, O., & Frederich, M. (10 November 2017). Processus d’intégration de la Médecine traditionnelle dans le système national de soins de la République Démocratique du Congo : Cas de trois zones de santé de Kinshasa [Paper presentation]. Médecines en Afrique, entre tradition et modernité, Liège, Belgium. |
 | Mavungu Landu, D. J., Mikobi Mikobi, C., Beya, R., Pipo Tshiasuma, M., Kayembe, J. M., Gretry, L., Marini Djang'Eing'A, R., Hubert, P., Reginster, J.-Y., Michel, B., Manzambi Kuwekita, J., & Frederich, M. (10 November 2017). Expérience de l’intégration des cours de Médecine traditionnelle dans la Faculté de Médecine de l’Université Notre-Dame du Kasayi à Kananga [Paper presentation]. Médecines en Afrique, entre tradition et modernité, Liège, Belgium. |
 | Mavungu Landu, D. J., Liégeois, S., Manzambi Kuwekita, J., Mbinze Kindenge, J., Mavungu Nsiona, J., Hubert, P., Michel, B., Reginster, J.-Y., Frederich, M., Marini Djang'Eing'A, R., & Gretry, L. (13 October 2017). The quality of artemether-lumefantrine combination and characteristics of pharmacies in the periurban areas of kinshasa (Kwete Minga, M., Trans.). Tropical Medicine and International Health, 22 (1), 76. Peer Reviewed verified by ORBi |
 | Tordrup, D., Chouaid, C., Cuijpers, P., Dab, W., van Dongen, J. M., Espin, J., Jönsson, B., Léonard, C., McDaid, D., McKee, M., Pereira Miguel, J., Patel, A., Reginster, J.-Y., Ricciardi, W., Rutten-Van Molken, Prevolnik Rupel, V., Sach, T., Sassi, F., Vaugh, N., & Bertollini, R. (2017). Priorities for health economic methodological research: results of an expert consultation. International Journal of Technology Assessment in Health Care, 1-11. doi:10.1017/S0266462317000666 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (September 2017). Chondroitin sulfate reduces pain and improves function in knee osteoarthritis significantly better than placebo, independently of the definition of responders. Arthritis and Rheumatism, 69S10, 1675. Peer Reviewed verified by ORBi |
 | Buckinx, F., Reginster, J.-Y., Morelle, A., Paquot, N., Labeye, N., Locquet, M., Adam, S.* , & Bruyère, O.*. (04 July 2017). Influence of environmental factors on food intake among nursing home residents: a survey combined with a video approach. Clinical Interventions in Aging, 12, 1055-1064. doi:10.2147/CIA.S135937 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Kanis, J. A., Cooper, C., Rizzoli, R., Abrahamsen, B., Al-Daghri, N. M., BRANDI, M. L., CANNATA-ANDIA, J., Cortet, B., Dimai, H. P., Ferrari, S., Hadji, P., Harvey, N. C., Kraezlin, M., Kurth, A., McCloskey, E., Minisola, S., Thomas, T., & Reginster, J.-Y. (July 2017). Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporosis International, 28 (7), 2023-2034. doi:10.1007/s00198-017-4009-0 Peer Reviewed verified by ORBi |
 | Bone, H. G., Wagman, R. B., Brandi, M. L., Brown, J. P., Chapurlat, R., Cummings, S. R., Czerwiski, E., Fahrleitner-Pammer, A., Kendler, D. L., Lippuner, K., Reginster, J.-Y., Roux, C., Malouf, J., Bradley, N. M., Daizadeh, N. S., Wang, A., Dakin, P., Pannacciulli, N., Dempster, D. W., & Papapopoulos, S. (July 2017). 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. The Lancet Diabetes and Endocrinology, 5, 513-523. doi:10.1016/S2213-8587(17)30138-9 Peer Reviewed verified by ORBi |
 | Slomian, J., Bruyère, O., Reginster, J.-Y., & Emonts, P. (May 2017). The internet as a source of information used by women after childbirth to meet their need for information: A web-based survey. Midwifery, 48, 46-52. doi:10.1016/j.midw.2017.03.005 Peer Reviewed verified by ORBi |
 | Cianferotti, L., Bertoldo, F., Bischoff-Ferrari, H., Bruyère, O., Cooper, C., Cutolo, M., Kanis, J. A., Kaufman, J.-M., Reginster, J.-Y., Rizzoli, R., & Brandi, M. L. (April 2017). Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). Endocrine, 56 (2), 245-61. doi:10.1007/s12020-017-1290-9 Peer Reviewed verified by ORBi |
 | Beaudart, C., Edwards, M., Moss, C., Reginster, J.-Y., Moon, R., Parsons, C., DEMOULIN, C., Rizzoli, R., Biver, E., Dennison, E., Bruyère, O., & Cooper, C. (March 2017). English translation and validation of the SarQoL®, a quality of life questionnaire specific for sarcopenia. Age and Ageing, 46 (2), 271-7. doi:10.1093/ageing/afw192 Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Delandsheere, L., Reginster, J.-Y., Kanis, J. A., & Bruyère, O. (March 2017). Bone quality assessment among sarcopenic and non sarcopenic elderly subjects from the SarcoPhAge Study. Osteoporosis International, 28 Suppl 1, 206-207. Peer Reviewed verified by ORBi |
 | Beaudart, C., Locquet, M., Reginster, J.-Y., PETERMANS, J., & Bruyère, O. (March 2017). The SarcoPhAge study: evolution of sarcopenic subjects after 2 years of follow-up. Osteoporosis International, 28 Suppl 1, 208. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Dudler, J., Blicharski, T., Pavelka, K., & Lanzarotti, A. (March 2017). Pharmaceutical-grade chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the chondroitin vs celecoxib vs placebo trial (CONCEPT). Osteoporosis International, 28 Suppl 1, 56. Peer Reviewed verified by ORBi |
 | Beaudart, C., Dawson, A., Shaw, S. C., Harvey, N. C., Kanis, J. A., Binkley, N., Reginster, J.-Y., Chapurlat, R., Chan, D. C., Bruyère, O., Rizzoli, R., Cooper, C., & Dennison, E. M. (March 2017). Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporosis International, 28 (6), 1817-33. doi:10.1007/s00198-017-3980-9 Peer Reviewed verified by ORBi |
 | Buckinx, F., Lenaerts, C., Brunois, T., Rygaert, X., Reginster, J.-Y., PETERMANS, J., & Bruyère, O. (March 2017). Interest of 10 current definitions of frailty to predict the incidence of falls and deaths among elderly nursing home residents. Osteoporosis International, 28 Suppl 1, 69. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Burlet, N., Fardellone, P., Al-Daghri, N., & Reginster, J.-Y. (March 2017). Public health and economic impact of vitamin D-fortified dairy products for fracture prevention in France. Osteoporosis International, 28 Suppl 1, 71-72. Peer Reviewed verified by ORBi |
 | Buckinx, F., Reginster, J.-Y., Beaudart, C., Brunois, T., Lenaerts, C., Croisier, J.-L., PETERMANS, J., & Bruyère, O. (March 2017). Sarcopenia in nursing home residents: the senior cohort. Osteoporosis International, 28 Suppl 1, 123-124. Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Delandsheere, L., Reginster, J.-Y., & Bruyère, O. (March 2017). Sensitivity and specificity of the sarc-F questionnaire according to different definitions of sarcopenia: results from the SarchoPhAge study. Osteoporosis International, 28 Suppl 1, 201. Peer Reviewed verified by ORBi |
 | CAVALIER, E., Reginster, J.-Y., & DELANAYE, P. (March 2017). Impact of the renal function on sclerostin determination: illustration with four different ELISA methods in patients undergoing GFR determination with Iohexol. Osteoporosis International, 28 Suppl 1, 629. Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Delandsheere, L., Reginster, J.-Y., & Bruyère, O. (March 2017). Subjective sleep quality in sarcopenic vs non-sarcopenic older adults from the sarcophage cohort. Osteoporosis International, 28 Suppl 1, 173-174. Peer Reviewed verified by ORBi |
 | Neuprez, A., KURTH, W., GILLET, P., Bruyère, O., & Reginster, J.-Y. (March 2017). Profile of osteoarthritic patients undergoing total hip and knee arthroplasty. Osteoporosis International, 28 Suppl 1, 252. Peer Reviewed verified by ORBi |
 | CAVALIER, E., & Reginster, J.-Y. (March 2017). Biomarkers of osteoarthritis : practical considerations. Osteoporosis International, 28 Suppl 1, 625-626. Peer Reviewed verified by ORBi |
 | Buckinx, F., Reginster, J.-Y., Beaudart, C., Brunois, T., Lenaerts, C., Croisier, J.-L., PETERMANS, J., & Bruyère, O. (March 2017). Prevalence of sarcopenia according to 10 different operational definitions of frailty. Osteoporosis International, 28 (Supp 1), 317-318. Peer Reviewed verified by ORBi |
 | Ethgen, O., Beaudart, C., Buckinx, F., Bruyère, O., & Reginster, J.-Y. (March 2017). The Future Prevalence of Sarcopenia in Europe: A Claim for Public Health Action. Calcified Tissue International, 100 (3), 229-234. doi:10.1007/s00223-016-0220-9 Peer Reviewed verified by ORBi |
 | DIEZ-PEREZ, A., NAYLOR, K. E., ABRAHAMSEN, B., AGNUSDEI, D., Brandi, M. L., COOPER, C., DENNISON, E., ERIKSEN, E. F., GOLD, D. T., GUANABENS, N., HADJI, P., HILIGSMANN, M., HORNE, R., JOSSE, R., KANIS, J. A., OBERMAYER-PIETSCH, B., PRIETO-ALHAMBRA, D., Reginster, J.-Y., Rizzoli, R., ... EASTELL, R. (March 2017). International Osteoporosis Foundation and European Calcified Tissue Society working group. Recommendations for the screening of the adherence to oral bisphosphonates. Osteoporosis International, 28 (3), 767-774. doi:10.1007/s00198-017-3906-6 Peer Reviewed verified by ORBi |
 | HILIGSMANN, M., BURLET, N., FARDELLONE, P., AL-DAGHRI, N., & Reginster, J.-Y. (March 2017). Public Health impact and economic evaluation of vitamin D-fortified dairy products for fracture prevention in France. Osteoporosis International, 28 (3), 833-840. doi:10.1007/s00198-016-3786-1 Peer Reviewed verified by ORBi |
 | Kendler, D. L., Chines, A., Brandi, M. L., Papapoulos, S., Lewiecki, E. M., Reginster, J.-Y., Roux, C., Munos-Torres, M., Wang, A., & Bone, H. G. (March 2017). The risk of subsequent osteoporotic fractures is decreased in patients experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies. Osteoporosis International, 28 Suppl 1, 174-175. Peer Reviewed verified by ORBi |
 | HADJI, P., Aapro, M. S., BODY, J. J., GNANT, M., BRANDI, M. L., Reginster, J.-Y., ZILLIKENS, M. C., GLÜER, C. C., de VILLIERS, T., BABER, R., ROODMAN, G. D., COOPER, C., LANGDAHL, B., PALACIOS, S., KANIS, J., AL-DAGHRI, N., NOGUES, X., FINK ERIKSEN, E., KURTH, A., ... COLEMAN, R. E. (March 2017). Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS and SIOG. Journal of Bone Oncology, 23 (7), 1-12. doi:10.1016/j.jbo.2017.03.001 Peer Reviewed verified by ORBi |
 | Veronese, N., Smith, T., Reginster, J.-Y., & Maggi, S. (March 2017). Osteoarthritis increases the risk of cardiovascular disease: data from the osteoarthritis initiative. Osteoporosis International, 28 Suppl 1, 58-59. Peer Reviewed verified by ORBi |
 | Libon, F., Courtois, J., LE GOFF, C., LUKAS, P., Fabregat Cabello, N., SEIDEL, L., CAVALIER, E., Reginster, J.-Y., & NIKKELS, A. (March 2017). Effect of body surface, body site and sunscreen application on production of Vitamin D and 25-hydroxyvitamin D after a single narrowband UVB exposure. Osteoporosis International, 28 Suppl 1, 143-144. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Black, D. M., Hattersley, G., Williams, G., Hu, M., Fitzpatrick, L. A., & Lewiecki, E. M. (March 2017). Abaloparatide-SC for postmenopausal osteoporosis: analysis of the number needed to treat compared with teriparatide. Osteoporosis International, 28 Suppl 1, 62-63. Peer Reviewed verified by ORBi |
 | Veronese, N., Stubbs, B., Crepaldi, G., Solmi, M., Cooper, C., Reginster, J.-Y., Rizzoli, R., & Maggi, S. (March 2017). Low bone mineral density and fractures are associated with incident cardiovascular disease: a systematic review and meta-analysis. Osteoporosis International, 28 Suppl 1, 180-181. Peer Reviewed verified by ORBi |
 | Veronese, N., Stubbs, B., Smith, T., Reginster, J.-Y., & Maggi, S. (March 2017). The relationship between knee osteoarthritis and incident hypertension: a representative longitudinal study. Osteoporosis International, 28 Suppl 1, 181-182. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (March 2017). Daily management of knee osteoarthritis: from the ESCEO algorithm to the CONCEPT study. Osteoporosis International, 28 Suppl 1, 638. Peer Reviewed verified by ORBi |
 | Buckinx, F., Mouton, A., Reginster, J.-Y., Croisier, J.-L., Dardenne, N., Beaudart, C., Nelis, J., Lambert, E., Appelboom, G., & Bruyère, O. (February 2017). Relationship between ambulatory physical activity assessed by activity trackers and physical frailty among nursing home residents. Gait and Posture, 54, 56-61. doi:10.1016/j.gaitpost.2017.02.010 Peer Reviewed verified by ORBi |
 | Herrero-Beaumont, G., Roman-Blas, J. A., Bruyère, O., Cooper, C., Kanis, J., Maggi, S., Rizzoli, R., & Reginster, J.-Y. (February 2017). Clinical settings in knee osteoarthritis: Pathophysiology guides treatment. Maturitas, 96, 54-57. doi:10.1016/j.maturitas.2016.11.013 Peer Reviewed verified by ORBi |
 | Bruyère, O., Cavalier, E., Buckinx, F., & Reginster, J.-Y. (January 2017). Relevance of vitamin D in the pathogenesis and therapy of frailty. Current Opinion in Clinical Nutrition and Metabolic Care, 20 (1), 26-29. doi:10.1097/MCO.0000000000000334 Peer Reviewed verified by ORBi |
 | Buckinx, F., ALLEPAERTS, S., PAQUOT, N., Reginster, J.-Y., De Cock, C., PETERMANS, J., & Bruyère, O. (2017). Energy and nutrient content of food served and consumed by nursing home residents. Journal of Nutrition, Health and Aging, 21 (6), 727-32. doi:10.1007/s12603-016-0782-2 Peer Reviewed verified by ORBi |
 | Beaudart, C., Zaaria, M., Pasleau, F., Reginster, J.-Y., & Bruyère, O. (2017). Health outcomes of sarcopenia: a systematic review and metaanalysis. Osteoporosis International, 28 Suppl 1, 67. Peer Reviewed verified by ORBi |
 | Gasparik, A. I., Mihai, G., Beaudart, C., Bruyère, O., Pop, R. M., Reginster, J.-Y., & Pascanu, I. M. (2017). Psychometric performance of the Romanian version of the SarQoL®, a health-related quality of life questionnaire for sarcopenia. Archives of Osteoporosis, 12, 103. doi:10.1007/s11657-017-0397-1 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Rizzoli, R., Kanis, J. A., & Cooper, C. (2017). Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women [letter to the editor]. Annals of Internal Medicine, 167 (12), 902-903. doi:10.7326/L17-0488 Peer Reviewed verified by ORBi |
 | Kanis, J. A., Cooper, C., Rizzoli, R., Abrahamsen, B., Al-Daghri, N. M., Brandi, M. L., Cannata-Andia, J., Cortet, B., Dimai, H. P., Ferrari, S., Hadji, P., Harvey, N. C., Kraenzlin, M., Kurth, A., McCloskey, E., Minisola, S., Thomas, T., Reginster, J.-Y., & for the European Society for Clinical and Economic Aspects of Osteoporosis, O. A. M. D. E. (2017). Erratum to: Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting (Osteoporosis International, (2017), 28, 7, (2023-2034), 10.1007/s00198-017-4009-0). Osteoporosis International, 28 (11), 3285-3286. doi:10.1007/s00198-017-4161-6 Peer Reviewed verified by ORBi |
 | ROUSSEAU, A.-F., Bawin, M., CAVALIER, E., Reginster, J.-Y., DAMAS, P., & Bruyère, O. (2017). Occurrence of bone fracture in the 2 years following a prolonged ICU stay: a retrospective study including a control group. Osteoporosis International, 28 (Suppl 1), 504. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Al-Daghri, N., & Bruyère, O. (2017). Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis. Expert Opinion on Pharmacotherapy, 18 (17), 1811-1813. doi:10.1080/14656566.2017.1395021 Peer Reviewed verified by ORBi |
 | CIANFEROTTI, L., BERTOLDO, F., CARINI, M., KANIS, J. A., LAPINI, A., LONGO, N., MARTORANA, G., MIRONE, V., Reginster, J.-Y., RIZZOLI, R., & BRANDI, M. L. (2017). The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation. Oncotarget, 8, 75646-75663. doi:10.18632/oncotarget.17980 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2017). Differentiation between various Chondroitin sulfate formulations in symptomatic knee osteoarthritis. Annals of the Rheumatic Diseases. doi:10.1136/annrheumdis-2017-212460 Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Delandsheere, L., Reginster, J.-Y., & Bruyère, O. (2017). Sensibilité et spécificité du questionnaire SARC-F selon les différentes définitions de la sarcopénie: résultats de l'étude SarcoPhAge. L'Année Gérontologique, 31 (1), 44. Peer reviewed |
 | Harvey, N. C.* , Biver, E.* , Kaufman, J.-M., Bauer, J., Branco, J., Brandi, M. L., Bruyère, O., Coxam, V., Cruz-Jentoft, A., Czerwinski, E., Dimai, H., Fardellone, P., Landi, F., Reginster, J.-Y., Dawson-Hughes, B., Kanis, J. A., Rizzoli, R.* , & Cooper, C.*. (2017). The role of calcium supplementation in healthy musculoskeletal ageing - An expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis ans Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF). Osteoporosis International, 28 (2), 447-62. doi:10.1007/s00198-016-3773-6 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Beaudart, C., Locquet, M., Reginster, J.-Y., PETERMANS, J., & Bruyère, O. (2017). Results of the SarcoPhAge study after 2 years of follow-up. Journal of Frailty and Aging, 6 Suppl 1, 111-112. Peer Reviewed verified by ORBi |
 | Beaudart, C., Biver, E., Reginster, J.-Y., Rizzoli, R., Bolland, Y., PETERMANS, J., GILLAIN, S., Buckinx, F., Dardenne, N., & Bruyère, O. (2017). Validation of the SarQoL, a specific health-related quality of life questionnaire for Sarcopenia. Journal of Cachexia, Sarcopenia and Muscle, 8 (2), 238-44. doi:10.1002/jcsm.12149 Peer Reviewed verified by ORBi |
 | Slomian, J., EMONTS, P., Vigneron, L., Acconcia, A., Glowacz, F., Reginster, J.-Y., Oumourgh, M., & Bruyère, O. (2017). Identifying maternal needs following childbirth: A qualitative study among mothers, fathers and professionals. BMC Pregnancy and Childbirth, 17 (1), 213. doi:10.1186/s12884-017-1398-1 Peer Reviewed verified by ORBi |
 | Veronese, N., Stubbs, B., Noale, M., Solmi, M., Luchini, C., Smith, T. O., Cooper, C., Guglielmi, G., Reginster, J.-Y., Rizzoli, R., & Maggi, S. (2017). Adherence to a Mediterranean diet is associated with lower prevalence of osteoarthritis: Data from the osteoarthritis initiative. Clinical Nutrition, 36, 1609-1614. doi:10.1016/j.clnu.2016.09.035 Peer Reviewed verified by ORBi |
 | Gielen, E., Bergmann, P., Bruyère, O., Cavalier, E., DELANAYE, P., Goemaere, S., Kaufman, J.-M., Locquet, M., Reginster, J.-Y., Rozenberg, S., Vandenbroucke, A.-M., & Body, J.-J. (2017). Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club. Calcified Tissue International, 101 (2), 111-31. doi:10.1007/s00223-017-0266-3 Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Delandsheere, L., Reginster, J.-Y., & Bruyère, O. (2017). Sensibility and sensitivity of the SARC-F questionnaire according to different definitions of sarcopenia: results from the SarcoPhAge study. Journal of Frailty and Aging, 6 Suppl 1, 119-120. Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Delandsheere, L., Reginster, J.-Y., & Bruyère, O. (2017). Subjective sleep quality in sarcopenic versus non-sarcopenic older adults from the SarcoPhAge study. Journal of Frailty and Aging, 6 Suppl 1, 56. Peer Reviewed verified by ORBi |
 | Buckinx, F., Lenaerts, C., Brunois, T., Reginster, J.-Y., PETERMANS, J., & Bruyère, O. (2017). Intérêt de 10 définitions actuelles de la fragilité pour prédire l'incidence des décès chez des sujets âgés résidant en maison de repos. L'Année Gérontologique, 31 (1), 11-12. Peer reviewed |
 | Beaudart, C., Zaaria, M., Pasleau, F., Reginster, J.-Y., & Bruyère, O. (January 2017). Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis. PLoS ONE, 12 (1), 0169548. doi:10.1371/journal.pone.0169548 Peer Reviewed verified by ORBi |
 | Slomian, J., EMONTS, P., Erpicum, M., Vigneron, L., Reginster, J.-Y., & Bruyère, O. (2017). What should a website dedicated to the postnatal period contain? A Delphi survey among parents and professionals. Midwifery, 53, 9-14. doi:10.1016/j.midw.2017.07.004 Peer Reviewed verified by ORBi |
 | Cooper, C., Rannou, F., Richette, P., Bruyère, O., Al-Daghri, N., Altman, R. D., Brandi, M. L., Collaud Basser, S., Herrero-Beaumont, G., Migliore, A., Pavelka, K., Uebelhart, D., & Reginster, J.-Y. (2017). Use of Intra-Articular Hyaluronic Acid in the Management of Knee Osteoarthritis in Clinical Practice. Arthritis Care and Research, 69 (9), 1287-96. doi:10.1002/acr.23204 Peer Reviewed verified by ORBi |
 | Slomian, J., Emonts, P., Vigneron, L., Acconcia, A., Reginster, J.-Y., Oumourgh, M., & Bruyère, O. (2017). Meeting the Needs of Mothers During the Postpartum Period: Using Co-Creation Workshops to Find Technological Solutions. JMIR Research Protocols, 6 (5), 76. doi:10.2196/resprot.6831 Peer Reviewed verified by ORBi |
 | Beaudart, C., Reginster, J.-Y., Geerinck, A., Locquet, M., & Bruyère, O. (2017). Current review of the SarQoL®: a health-related quality of life questionnaire specific to sarcopenia. Expert Review of Pharmacoeconomics and Outcomes Research, 17 (4), 335-341. doi:10.1080/14737167.2017.1360768 Peer Reviewed verified by ORBi |
 | Locquet, M., Honvo, G., Rabenda, V., Van Hees, T., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2017). Adverse Health Events Related to Self-Medication Practices Among Elderly: A Systematic Review. Drugs and Aging, 34 (5), 359-365. doi:10.1007/s40266-017-0445-y Peer Reviewed verified by ORBi |
 | ROUSSEAU, A.-F., CAVALIER, E., Reginster, J.-Y., DAMAS, P., & Bruyère, O. (2017). Occurrence of Clinical Bone Fracture Following a Prolonged Stay in Intensive Care Unit: A Retrospective Controlled Study. Calcified Tissue International, 101 (5), 465-472. doi:10.1007/s00223-017-0300-5 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Dudler, J., Blicharski, T., & Pavelka, K. (2017). Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the Chondroitin versus Celecoxib versus placebo trial (CONCEPT). Annals of the Rheumatic Diseases, 0n line, 1-7. doi:10.1136/annrheumdis-2016-210860 Peer Reviewed verified by ORBi |
 | Buckinx, F., Lenaerts, C., Brunois, T., Reginster, J.-Y., PETERMANS, J., & Bruyère, O. (2017). Interest in 10 current definitions of frailty to predict the incidence of death among elderly nursing home residents. Journal of Frailty and Aging, 6 Suppl 1, 72-73. Peer Reviewed verified by ORBi |
 | Ferrari, S., Reginster, J.-Y., Brandi, M. L., Kanis, J. A., Devogelaer, J.-P., Kaufman, J.-M., Féron, J.-M., Kurth, A., & Rizzoli, R. (2017). Erratum to: Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture (Archives of Osteoporosis, (2016), 11, 1, (37), 10.1007/s11657-016-0292-1). Archives of Osteoporosis, 12, 25. doi:10.1007/s11657-017-0319-2 Peer Reviewed verified by ORBi |
 | Pavelka, K., Bruyère, O., Cooper, C., Kanis, J. A., Leeb, B. F., Maheu, E., Martel-Pelletier, J., Monfort, J., Pelletier, J.-P., Rizzoli, R., & Reginster, J.-Y. (2017). Erratum to: Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO (Drugs & Aging, (2016), 33, 2, (75-85), 10.1007/s40266-016-0347-4). Drugs and Aging, 34, 413. doi:10.1007/s40266-017-0457-7 Peer Reviewed verified by ORBi |
 | Beaudart, C., Zaaria, M., Pasleau, F., Reginster, J.-Y., & Bruyère, O. (2017). Analyse des conséquences cliniques de la sarcopénie: une revue systématique et méta-analyse. L'Année Gérontologique, 31 (1), 18. Peer reviewed |
 | Al-Daghri, N., Al-Saleh, Y., Aljohani, N., Sulimani, R., Al-Othman, A., Alfawaz, H., Fouda, M., Al-Amri, F., Shahrani, A., Alharbi, M., ALSHAHRANI, F., Tamini, W., Sabico, S., Rizzoli, R., & Reginster, J.-Y. (2017). Vitamin D status correction in Saudi Arabia: an experts' consensus under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO). Archives of Osteoporosis, 12, 1. doi:10.1007/s11657-016-0295-y Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Reginster, J.-Y., PETERMANS, J., GILLAIN, S., Quabron, A., Slomian, J., Buckinx, F., & Bruyère, O. (2017). Prevalence of concomitant bone and muscle wasting in elderly women from the SarcoPhAge cohort: preliminary results. Journal of Frailty and Aging, 6 (1), 18-23. doi:10.14283/jfa.2016.111 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Dellaert, B. G., Dirksen, C. D., Watson, V., Bours, S., Goemaere, S., Reginster, J.-Y., Roux, C., McGowan, B., Silke, C., Whelan, B., Diez-Perez, A., Torres, E., Papadakis, G., Rizzoli, R., Cooper, C., Pearson, G., & Boonen, A. (2017). Patients' preferences for anti-osteoporosis drug treatment: A cross-European discrete choice experiment. Rheumatology, 56 (7), 1167-1176. doi:10.1093/rheumatology/kex071 Peer Reviewed verified by ORBi |
 | Bruyère, O., Buckinx, F., Beaudart, C., Reginster, J.-Y., Bauer, J., Cederholm, T., Cherubini, A., Cooper, C., Cruz-Jentoft, A. J., Landi, F., Maggi, S., Rizzoli, R., Sayer, A. A., Sieber, C., Vellas, B., & Cesari, M. (2017). How clinical practitioners assess frailty in their daily practice: an international survey. Aging Clinical and Experimental Research, 29, 905-12. doi:10.1007/s40520-017-0806-8 Peer Reviewed verified by ORBi |
 | Bruyère, O., CAVALIER, E., & Reginster, J.-Y. (2017). Vitamin D and osteosarcopenia: an update from epidemiological studies. Current Opinion in Clinical Nutrition and Metabolic Care, 20 (6). doi:10.1097/MCO.0000000000000411 Peer Reviewed verified by ORBi |
 | Zaaria, M., Pasleau, F., Reginster, J.-Y., & Bruyère, O. (2017). Health outcomes of sarcopenia: a systematic review and meta-analysis. Journal of Frailty and Aging, 6 Suppl 1, 25. Peer Reviewed verified by ORBi |
 | Beaudart, C., Locquet, M., Reginster, J.-Y., PETERMANS, J., & Bruyère, O. (2017). L'étude SarcoPhAge: devenir des sujets sarcopéniques après 2 ans de suivi. L'Année Gérontologique, 31 (1), 42. Peer reviewed |
 | Hiligsmann, M., Neuprez, A., Buckinx, F., Locquet, M., & Reginster, J.-Y. (2017). A scoping review of the public health impact of vitamin D - fortified dairy products for fracture prevention. Archives of Osteoporosis, 12, 57. doi:10.1007/s11657-017-0352-1 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2017). Ostéoporose et sarcopénie: convergences et divergences. Revue Médicale Suisse, 13 (547), 184-185. Peer Reviewed verified by ORBi |
 | Dierks, R. M. L., Bruyère, O., & Reginster, J.-Y. (2017). Micro Factors Bringing the Pharmaceutical Industry to a Seismic Shaking A Qualitative Research. Expert Review of Pharmacoeconomics and Outcomes Research, 17 (3), 267-74. doi:10.1080/14737167.2017.1351877 Peer Reviewed verified by ORBi |
 | Buckinx, F., Reginster, J.-Y., BRUNOIS, T., Lenaerts, C., Beaudart, C., Croisier, J.-L., PETERMANS, J., & Bruyère, O. (2017). Prevalence of sarcopenia in a population of nursing home residents according to their frailty status: results of the SENIOR cohort. Journal of Musculoskeletal and Neuronal Interactions, 17 (3), 209-17. Peer Reviewed verified by ORBi |
 | Bruyère, O., Cooper, C., Arden, N., Branco, J., Brandi, M. L., Herrero-Beaumont, G., Berenbaum, F., Dennison, E., Devogelaer, J.-P., Hochberg, M., Kanis, J., Laslop, A., McAlindon, T., Reiter, S., Richette, P., Rizzoli, R., & Reginster, J.-Y. (2017). Erratum to: Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Epidemiology and Phenotype of Osteoarthritis (Drugs & Aging, (2015), 32, 3, (179-187), 10.1007/s40266-015-0243-3). Drugs and Aging, 34, 411. doi:10.1007/s40266-017-0456-8 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Al-Daghri, N., Kaufman, J.-M., & Bruyère, O. (2017). Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis. Expert Opinion on Pharmacotherapy, 1-3. doi:10.1080/14656566.2017.1418857 Peer Reviewed verified by ORBi |
 | Bruyère, O., Cooper, C., Cutolo, M., & Reginster, J.-Y. (2017). International endorsement of the ESCEO algorithm for management of knee osteoarthritis in clinical practice [letter to the editor]. Seminars in Arthritis and Rheumatism, 47 (2), 10. doi:10.1016/j.semarthrit.2017.07.002 Peer Reviewed verified by ORBi |
 | Buckinx, F., Reginster, J.-Y., GILLAIN, S., PETERMANS, J., Brunois, T., & Bruyère, O. (2017). Prevalence of Frailty in Nursing Home Residents According to Various Diagnostic Tools. Journal of Frailty and Aging, 6 (3), 122-8. doi:10.14283/jfa.2017.20 Peer Reviewed verified by ORBi |
 | Buckinx, F., Croisier, J.-L., Reginster, J.-Y., Dardenne, N., Beaudart, C., Slomian, J., Leonard, S., & Bruyere, O. (2017). Reliability of muscle strength measures obtained with a hand-held dynamometer in an elderly population. Clinical Physiology and Functional Imaging, 37 (3), 332-40. doi:10.1111/cpf.12300 Peer Reviewed verified by ORBi |
 | Harvey, N. C. W., McCloskey, E. V., Mitchell, P. J., Dawson-Hughes, B., Pierroz, D. D., Reginster, J.-Y., Rizzoli, R., Cooper, C., & Kanis, A. (2017). Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporosis International, 28, 1507-1529. doi:10.1007/s00198-016-3894-y Peer Reviewed verified by ORBi |
 | VERONESE, B., STUBBS, B., CREPALDI, G., SOLMI, M., COOPER, C., HARVEY, N. C., Reginster, J.-Y., RIZZOLI, R., CIVITELLI, R., SCHOFIELD, P., MAGGI, S., & LAMB, S. E. (2017). Relationship between low bone mineral density and fractures with incident cardiovascular disease: a systematic review and meta-analysis. Journal of Bone and Mineral Research, 32, 1126-1135. doi:10.1002/jbmr.3089 Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Larbuisson, R., Leclercq, V., Buckinx, F., Kaux, J.-F., Reginster, J.-Y., & Bruyère, O. (January 2017). Self-Administration of Medicines and Dietary Supplements Among Female Amateur Runners: A Cross-Sectional Analysis. Advances in Therapy, 33 (12), 2257-2268. doi:10.1007/s12325-016-0426-2 Peer Reviewed verified by ORBi |
 | Neuprez, A., Delcour, J.-P., Fatemi, F., Gillet, P., Crielaard, J.-M., Bruyère, O., & Reginster, J.-Y. (15 December 2016). Patients' expectations impact their satisfaction following total hip or knee arthroplasty. PLoS ONE, 11 (12), 1-14. doi:10.1371/journal.pone.0167911 Peer Reviewed verified by ORBi |
 | Mavungu Landu, D. J., Liégeois, S., Manzambi Kuwekita, J., Mbinze Kindenge, J., Hubert, P., Michel, B., Reginster, J.-Y., Frederich, M., & Marini Djang'Eing'A, R. (14 December 2016). Qualité des médicaments antipaludéens et caractéristiques des pharmacies des territoires périurbains de Kinshasa [Poster presentation]. CONGRES INTERNATIONAL DE LA PATHOLOGIE INFECTIEUSE ET PARASITAIRE, Kinshasa, Congo - Kinshasa. |
| Buckinx, F., PAQUOT, N., FADEUR, M., Bacus, L., Reginster, J.-Y., ALLEPAERTS, S., PETERMANS, J., Biquet, S., & Bruyère, O. (10 November 2016). Assessment of energy expenditure of nursing home residents with indirect calorimetry [Paper presentation]. International Nursing Home Research Conference - International Working Group, Barcelone, Spain. |
 | Beaudart, C., McCloskey, E., Bruyère, O., Cesari, M., Rolland, Y., Rizzoli, R., Araujo de Carvalho, I., Amuthavalli Thiyagarajan, J., Bautmans, I., Bertière, M.-C., Brandi, M. L., Al-Daghri, N. M., Burlet, N., CAVALIER, E., Cerreta, F., Cherubini, A., Fielding, R., Gielen, E., Landi, F., ... Cooper, C. (October 2016). Sarcopenia in daily practice: assessment and management. BMC Geriatrics, 16 (170). doi:10.1186/s12877-016-0349-4 Peer Reviewed verified by ORBi |
 | Dierks, R. M. L., Bruyère, O., Reginster, J.-Y., & Richy, F. (October 2016). Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry. Expert Review of Pharmacoeconomics and Outcomes Research, 16 (5), 571-8. doi:10.1080/14737167.2016.1239534 Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Reginster, J.-Y., PETERMANS, J., GILLAIN, S., Quabron, A., Slomian, J., Buckinx, F., & Bruyère, O. (29 September 2016). Prevalence of concomitant bone and muscle wasting in patients from the SarcoPhAge Study [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Bruxelles, Belgium. |
 | Buckinx, F., Morelle, A., Adam, S., Reginster, J.-Y., Labeye, N., Locquet, M., & Bruyère, O. (29 September 2016). Influence of environmental factors on food intakes of nursing home residents: a survey combined to a video approach [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Bruxelles, Belgium. |
 | Slomian, J., EMONTS, P., Reginster, J.-Y., Vigneron, L., Acconcia, A., & Bruyère, O. (29 September 2016). Identification de solutions technologiques potentielles en réponse aux besoins des mères dans l'année suivant leur accouchement [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Bruxelles, Belgium. |
 | Reginster, J.-Y., & CONCEPT author's group. (September 2016). Pharmaceutical grade chondroitin sulfate improves knee osteoarthritis symptoms more than placebo and as much as celecoxib: results of the chondroitin vs celecoxib vs placebo trial (CONCEPT). Arthritis and Rheumatism, 68S10, 3067-3068. Peer Reviewed verified by ORBi |
 | Kendler, D. L., Chines, A., Brandi, M. L., Papapoulos, S., Lewiecki, E. M., Reginster, J.-Y., Roux, C., Munos Torres, M., Wang, A., & Bone, H. G. (September 2016). The risk of subsequent osteoporotic fractures is decreased in patients experiencing fracture while on denosumab. Arthritis and Rheumatism, 68S10, 427-429. Peer Reviewed verified by ORBi |
 | Cavalier, E., Bergmann, P., Bruyère, O., DELANAYE, P., Durnez, A., Devogelaer, J.-P., Ferrari, S. L., Gielen, E., Goemaere, S., Kaufman, J.-M., Nzeusseu Toukap, A., Reginster, J.-Y., ROUSSEAU, A.-F., Rozenberg, S., Scheen, A., & Body, J.-J. (July 2016). The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club. Osteoporosis International, 27, 2181-2195. doi:10.1007/s00198-016-3561-3 Peer Reviewed verified by ORBi |
 | Kucharz, E. J., Kovalenko, V., Szanto, S., Bruyère, O., Cooper, C., & Reginster, J.-Y. (June 2016). A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. Current Medical Research and Opinion, 32 (6), 997-1004. doi:10.1185/03007995.2016.1154521 Peer Reviewed verified by ORBi |
 | Bruyère, O., Beaudart, C., Reginster, J.-Y., Buckinx, F., Schoene, D., Hirani, V., Cooper, C., Kanis, J. A., Rizzoli, R., McCloskey, E., Cederholm, T., Cruz-Jentoft, A., & Freiberger, E. (June 2016). Assessment of muscle mass, muscle strength and physical performance in clinical practice: An international survey. European Geriatric Medicine, 7 (3), 243-6. doi:10.1016/j.eurger.2015.12.009 Peer reviewed |
 | Slomian, J., EMONTS, P., Vigneron, L., Acconcia, A., Glowacz, F., Reginster, J.-Y., Oumourgh, M., & Bruyère, O. (May 2016). Identification des besoins des mères dans l’année suivant leur accouchement : une étude qualitative [Poster presentation]. 44èmes Assises Nationales des Sages-Femmes, Saint-Malo, France. |
Slomian, J., Bruyère, O., Reginster, J.-Y., & EMONTS, P. (May 2016). Quelle est la place d’internet pour combler le besoin d’information des nouvelles mères ? [Poster presentation]. 44èmes Assises Nationales des Sages-Femmes. |
 | Locquet, M., Beaudart, C., LARBUISSON, R., Buckinx, F., KAUX, J.-F., Reginster, J.-Y., & Bruyère, O. (May 2016). Self-Medication Practice among Amateur Runners: Prevalence and Associated Factors. Journal of Sports Science and Medicine, 15 (2), 387-8. Peer Reviewed verified by ORBi |
CAVALIER, E., WATAR, F., KOVACS, S., Beaudart, C., Buckinx, F., Bruyère, O., LE GOFF, C., & Reginster, J.-Y. (16 April 2016). Evaluation of the intra-individual variability of Myostatin and Activin A (and PIIINP): impact on the least significant change and follow-up of the patients [Paper presentation]. World Congresse on Osteoporosis Osteoarthritis and musculoskeletal diseases, Malaga, Spain. |
 | Delvaux, F., Rochcongar, P., Bruyère, O., Bourlet, G., DANIEL, C., Diverse, P., Reginster, J.-Y., & Croisier, J.-L. (09 April 2016). Return-to-play criteria after anterior cruciate ligament reconstruction: actual medicine practice in professional soccer teams [Poster presentation]. FIFA - Football Medicine Strategies, London, United Kingdom. Peer reviewed |
 | CAVALIER, E., CARLISI, I., KOVACS, S., WATAR, F., Beaudart, C., Buckinx, F., Bruyère, O., & Reginster, J.-Y. (April 2016). Brain-derived neurotrophic factor (BDNF) in normal healthy and hemodialyzed populations. Osteoporosis International, 27 (Supplement 1), 512. Peer Reviewed verified by ORBi |
 | Bone, H. G., Brandi, M. L., Brown, J. P., Chapurlat, R., Cummings, S. R., Czerwinski, E., Fahrleitner-Pammer, A., Kendler, D. L., Lippuner, K., Reginster, J.-Y., Wittinghoff, E., Daizadeh, S., Wang, A., Dakin, P., Wagman, R. B., & Papapoulos, S. E. (April 2016). Ten years of Denosumab (DMAB) treatment in postmenopausal women with osteoporosis. Results from the FREEDOM Extension trial. Osteoporosis International, 27 (Supplement 1), 135-136. Peer Reviewed verified by ORBi |
 | Buckinx, F., Reginster, J.-Y., Beaudart, C., Croisier, J.-L., PETERMANS, J., & Bruyère, O. (April 2016). Prevalence of sarcopenia in a population of nursing home residents according to their frailty status: results of the Senior cohort. Osteoporosis International, 27 (supplement 1), 55-56. Peer Reviewed verified by ORBi |
 | Beaudart, C., Edwards, M., Dennison, E. M., Moss, C., Bruyère, O., Reginster, J.-Y., Moon, R. J., Cooper, C., & Demoulin, C. (April 2016). English translation and cross-cultural adaptation of the SarQuoL® questionnaire. Osteoporosis International, 27 (Supplement 1), 221-222. Peer Reviewed verified by ORBi |
 | Buckinx, F., Reginster, J.-Y., Croisier, J.-L., PETERMANS, J., & Bruyère, O. (April 2016). Physical and muscle performances among elderly nursing home residents. Osteoporosis International, 27 (Supplement 1), 217. Peer Reviewed verified by ORBi |
 | Neuprez, A., KURTH, W., THIRION, T., DANIEL, C., HUSKIN, J.-P., GILLET, P., Bruyère, O., & Reginster, J.-Y. (April 2016). Age-standardized quality of life after hip or knee arthoplasty. Osteoporosis International, 27 (Supplement 1), 541-542. Peer Reviewed verified by ORBi |
 | Buckinx, F., Reginster, J.-Y., GILLAIN, S., PETERMANS, J., Brunois, T., & Bruyère, O. (April 2016). Prevalence of frailty among nursing home, according to different operational definitions. Osteoporosis International, 27 (Supplement 1), 216-217. Peer Reviewed verified by ORBi |
 | Rannou, F., Maheu, & Reginster, J.-Y. (April 2016). Efficacy and safety of hyaluronic acid in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Osteoporosis International, 27 (supplement 1), 66. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (April 2016). Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Osteoporosis International, 27 (supplement 1), 65. Peer Reviewed verified by ORBi |
 | CAVALIER, E., Piron, C., WATAR, F., KOVACS, S., Beaudart, C., Buckinx, F., Bruyère, O., LE GOFF, C., & Reginster, J.-Y. (April 2016). Evaluation of the intra-individual variability of myostatin and activin A, two biomarkers of sarcopenia: impact on the least significant change and followup of the patients. Osteoporosis International, 27 (supplement 1), 56. Peer Reviewed verified by ORBi |
 | Miller, P., Pannacciulli, N., Brown, J. P., Czerwinski, E., Nedergaard, S., Bolognese, M. A., Malouf, J., Bone, H. G., Reginster, J.-Y., Singer, A., Wang, A., Wagman, R. B., & Cummings, S. R. (April 2016). A randomized double-blind study of Denosumab (DMAB) compared with Zoledronic acid (ZOL) in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. Osteoporosis International, 27 (SUPPLEMENT1), 42. Peer Reviewed verified by ORBi |
 | Ferrari, S., ADAMI, S., Brown, J. P., Cosman, F., Czerwinski, E., de Gregorio, L. H., Malouf, J., Reginster, J.-Y., Daizadeh, N. S., Wang, A., Wagman, R. B., & Lewiecki, E. M. (April 2016). relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 10 years of Denosumab (DMAB) treatment. Osteoporosis International, 27 (Supplement 1), 49-50. Peer Reviewed verified by ORBi |
 | Ethgen, O., Tchoconte, C., Beaudart, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (April 2016). The future prevalence of sarcopenia in Europe. Osteoporosis International, 27 (Supplement 1), 53-54. Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Reginster, J.-Y., PETERMANS, J., GILLAIN, S., Quabron, A., Slomian, J., Buckinx, F., & Bruyère, O. (April 2016). Prevalence of concomitant bone and muscle wasting in patients from the SarcoPhAge study. Osteoporosis International, 27 (supplement 1), 129. Peer Reviewed verified by ORBi |
 | Pavelka, K., Bruyère, O., Cooper, C., Kanis, J. A., Leeb, B. F., Maheu, E., Martel-Pelletier, J., Monfort, J., Pelletier, J.-P., Rizzoli, R., & Reginster, J.-Y. (February 2016). Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs and Aging, 33 (2), 75-85. doi:10.1007/s40266-016-0347-4 Peer Reviewed verified by ORBi |
 | Cooper, C., Bardin, T., Brandi, M. L., Cacoub, P., Caminis, J., Civitelli, R., Cutolo, M., Dere, W., Devogelaer, J. P., Diez-Perez, A., Einhorn, T. A., Emonts, P., Ethgen, O., Kanis, J. A., Kaufman, J. M., Kvien, T. K., Lems, W. F., McCloskey, E., Miossec, P., ... Reginster, J.-Y. (February 2016). Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Aging Clinical and Experimental Research, 28 (1), 1-16. doi:10.1007/s40520-015-0522-1 Peer Reviewed verified by ORBi |
 | Edwards, M. H., Parsons, C., Bruyère, O., Petit Dop, F., Chapurlat, R., Roemer, F. W., Guermazi, A., Zaim, S., Genant, H., Reginster, J.-Y., Dennison, E. M., Cooper, C., & The SEKOIA Study Group. (2016). High Kellgren-Lawrence Grade and Bone Marrow Lesions Predict Worsening Rates of Radiographic Joint Space Narrowing; The SEKOIA Study. Journal of Rheumatology, 43 (3), 657-65. doi:10.3899/jrheum.150053 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Cooper, C., Rizzoli, R., Kanis, J. A., Appelboom, G., Bautmans, I., Bischoff-Ferrari, H. A., Boers, M., Brandi, M. L., Bruyère, O., Cherubini, A., Flamion, B., Fielding, R. A., Gasparik, A. I., Van Loon, L., McCloskey, E., Mitlak, B. H., Pilotto, A., Reiter-Niesert, S., ... Cruz-Jentoft, A. J. (2016). Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. Aging Clinical and Experimental Research, 28 (1), 47-58. doi:10.1007/s40520-015-0517-y Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Beaudart, C., Buckinx, F., & Bruyère, O. (January 2016). Osteoporosis and sarcopenia: two diseases or one? Current Opinion in Clinical Nutrition and Metabolic Care, 19 (1), 31-6. doi:10.1097/MCO.0000000000000230 Peer Reviewed verified by ORBi |
 | Bruyère, O., Cooper, C., Pelletier, J. P., Maheu, E., Rannou, F., Branco, J., Brandi, M. L., Kanis, J. A., Altman, R. D., Hochberg, M. C., Martel-Pelletier, J., & Reginster, J.-Y. (2016). A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis - From evidence-based medicine to the real-life setting. Seminars in Arthritis and Rheumatism, 45 (4 Suppl), 3-S11. doi:10.1016/j.semarthrit.2015.11.010 Peer Reviewed verified by ORBi |
 | Ferrari, S., Reginster, J.-Y., Brandi, M. L., Kanis, J. A., Devogelaer, J. P., Kaufmann, J. P., Feron, J. M., Kurth, A., & Rizzoli, R. (2016). Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture. Archives of Osteoporosis, 11, 37. doi:10.1007/s11657-016-0292-1 Peer Reviewed verified by ORBi |
 | Blain, H., Masud, T., Dargent-Molina, P., Martin, F. C., Rosendahl, E., van der Velde, N., Bousquet, J., Benetos, A., Cooper, C., KANIS, J. A., Reginster, J.-Y., Rizzoli, R., Cortet, B., Barbagallo, M., Dreinhöfer, K. E., Vellas, B., Maggi, S., & Strandberg, T. (2016). A comprehensive fracture prevention strategy in older adults : the European Union Geriatric Medicine Society (EUGMS) statement. Aging Clinical and Experimental Research, 28, 797-803. doi:10.1007/s40520-016-0588-4 Peer Reviewed verified by ORBi |
 | Locquet, M., Bruyère, O., Beaudart, C., & Reginster, J.-Y. (2016). Ostéoporose et sarcopénie: un même combat ? Ortho-Rhumato, 14 (4), 34-36. |
 | Runhaar, J., DEROISY, R., van Middelkoop, M., Barbetta, F., Barbetta, B., Oei, E. H., Vroeginddeweij, D., Giacovelli, G., Bruyère, O., Rovati, L. C., Reginster, J.-Y., & Bierma-Zeinstra, S. M. A. (2016). The role of diet and exercise and of glucosamine sulfate in the prevention of knee osteoarthritis: Further results from the PRevention of knee Osteoarthritis in Overweight Females (PROOF) study. Seminars in Arthritis and Rheumatism, 45 (4 Suppl), 42-S48. doi:10.1016/j.semarthrit.2015.11.001 Peer Reviewed verified by ORBi |
 | Schaap, L. A., Fox, B., Henwood, T., Bruyère, O., Reginster, J.-Y., Beaudart, C., Buckinx, F., Roberts, H., Cooper, C., Cherubini, A., Dell'Aquilla, G., Maggio, M., & Volpato, S. (2016). Grip strength measurement: Towards a standardized approach in sarcopenia research and practice. European Geriatric Medicine, 7 (3), 247-255. doi:10.1016/j.eurger.2015.11.012 Peer reviewed |
 | de Carvalho, I. A., Aboderin, I., Arikawa-Hirasawa, E., Cesari, M., Furukawa, Y., Robledo, L. M. G., Morley, J. E., Pot, A. M., Reginster, J.-Y., Shaw, G., Tomita, N., & Beard, J. R. (2016). Innovation for healthy ageing: A call for papers. Bulletin of the World Health Organization, 94 (6), 407-407. doi:10.2471/BLT.16.176743 Peer Reviewed verified by ORBi |
 | Cavalier, E., Beaudart, C., Buckinx, F., Bruyère, O., & Reginster, J.-Y. (2016). Critical analytical evaluation of promising markers for sarcopenia. European Geriatric Medicine, 7 (3), 239-242. doi:10.1016/j.eurger.2015.11.002 Peer reviewed |
 | Reginster, J.-Y., Cooper, C., & Bruyère, O. (2016). Re: Kucharz EJ, Kovalenko V, Szántó S, et al. A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. Curr Med Res Opin 2016;32:997-1004 [letter to the editor]. Current Medical Research and Opinion, 32 (11), 1771-1772. doi:10.1080/03007995.2016.1239575 Peer Reviewed verified by ORBi |
 | MILLER, P. D., PANNACCIULLI, N., BROWN, J. P., CZERWINSKI, E., NEDERGAARD, B. S., BOLOGNESE, M. A., MALOUF, J., BONE, H. G., Reginster, J.-Y., SINGER, A., WANG, C., WAGMAN, R. B., & CUMMINGS, S. R. (2016). A randomized double-blind study of denosumab compared with zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonate. Arthritis and Rheumatology, 67 (S10), 1181-1182. Peer Reviewed verified by ORBi |
 | Buckinx, F., Reginster, J.-Y., Cavalier, E., PETERMANS, J., RICOUR, C., Dardenne, C., & Bruyère, O. (January 2016). Determinants of vitamin D supplementation prescription in nursing homes: a survey among general practitioners. Osteoporosis International, 27, 881-6. doi:10.1007/s00198-015-3469-3 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Cooper, C. (2016). Optimizing the management of osteoarthritis-Transitioning evidence-based guidelines into practical guidance for real-world clinical practice. Seminars in Arthritis and Rheumatism, 45 (4 Suppl), 1-S2. doi:10.1016/j.semarthrit.2015.10.014 Peer Reviewed verified by ORBi |
 | CAVALIER, E., Piron, C., WATAR, F., KOVACS, S., Beaudart, C., Buckinx, F., Bruyère, O., LE GOFF, C., & Reginster, J.-Y. (2016). Evaluation of the intra-individual variability of myostatin and activin A, two biomarkers of sarcopenia. Impact of the least significant change and follow-up of the patients. Journal of Frailty and Aging, 5 (Supplement 1), 82. Peer Reviewed verified by ORBi |
 | Beaudart, C., Edwards, M., Dennisson, E., Moss, C., Bruyère, O., Reginster, J.-Y., Moon, R., Demoulin, C., & Cooper, C. (2016). English translation and cross-cultural adaptation of the SARQOL Questionnaire. Journal of Frailty and Aging, 5 (Supplement 1), 58. Peer Reviewed verified by ORBi |
 | Buckinx, F., Reginster, J.-Y., CROISIER, J.-L., PETERMANS, J., & Bruyère, O. (2016). Physical and muscle performances among elderly nursing home residents. Results fo the senior cohort. Journal of Frailty and Aging, 5 (Supplement 1), 69. Peer Reviewed verified by ORBi |
 | Maheu, E., Rannou, F., & Reginster, J.-Y. (2016). Efficacy and safety of hyaluronic acid in the management of osteoarthritis : Evidence from real-life setting trials and surveys. Seminars in Arthritis and Rheumatism, 45 (4 Suppl), 28-S33. doi:10.1016/j.semarthrit.2015.11.008 Peer Reviewed verified by ORBi |
 | Penton, H., Hiligsmann, M., Harrison, M., Reginster, J.-Y., Boonen, A., & Bansback, N. (2016). Potential cost-effectiveness for using patient decision aids to guide osteoporosis treatment. Osteoporosis International, 27, 2697-2707. doi:10.1007/s00198-016-3596-5 Peer Reviewed verified by ORBi |
 | Bruyère, O., Beaudart, C., Locquet, M., Buckinx, F., PETERMANS, J., & Reginster, J.-Y. (2016). Sarcopenia as a public health problem. European Geriatric Medicine, 7 (3), 272-5. doi:10.1016/j.eurger.2015.12.002 Peer reviewed |
 | CAVALIER, E., Carlisi, A. S., WATAR, F., KOVACS, S., Beaudart, C., Buckinx, F., Bruyère, O., & Reginster, J.-Y. (2016). Brain-derived neurotrophic factor (BDNF) in normal healthy and hemodialyzed populations. Journal of Frailty and Aging, 5 (Supplement 1), 116. Peer Reviewed verified by ORBi |
 | Buckinx, F., Reginster, J.-Y., GILLAIN, S., PETERMANS, J., BRUNOIS, T., & Bruyère, O. (2016). Prevalence of frailty among nursing home, according to different operational definitions. Journal of Frailty and Aging, 5 (Supplement 1), 69. Peer Reviewed verified by ORBi |
 | Buckinx, F., Reginster, J.-Y., Beaudart, C., CROISIER, J.-L., PETERMANS, J., & Bruyère, O. (2016). Prevalence of sarcopenia in a population of nursing home residents according to their frailty status: Results of the senior cohort. Journal of Frailty and Aging, 5 (Supplement 1), 34. Peer Reviewed verified by ORBi |
 | Ethgen, O., Hiligsmann, M., Burlet, N., & Reginster, J.-Y. (January 2016). Cost-effectiveness of personalized supplementation with vitamin D-rich dairy products in the prevention of osteoporotic fractures. Osteoporosis International, 27, 301-308. doi:10.1007/s00198-015-3319-3 Peer Reviewed verified by ORBi |
 | Rozenberg, S., Body, J.-J., Bruyère, O., Bergmann, P., Brandi, M. L., Cooper, C., Devogelaer, J.-P., Gielen, E., Goemaere, S., Kaufman, J.-M., Rizzoli, R., & Reginster, J.-Y. (2016). Effects of Dairy Products Consumption on Health: Benefits and Beliefs-A Commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. Calcified Tissue International, 98 (1), 1-17. doi:10.1007/s00223-015-0062-x Peer Reviewed verified by ORBi |
 | Bruyère, O., Altman, R. D., & Reginster, J.-Y. (2016). Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Seminars in Arthritis and Rheumatism, 45 (4 Suppl), 12-S17. doi:10.1016/j.semarthrit.2015.11.011 Peer Reviewed verified by ORBi |
 | Detilleux, J., REGINSTER, J.-Y., Chines, A., & Bruyère, O. (2016). A Bayesian path analysis to estimate causal effects of bazedoxifene acetate on incidence of vertebral fractures, either directly or through non-linear changes in bone mass density. Statistical Methods in Medical Research, 25 (1), 400-412. doi:10.1177/0962280212456655 Peer Reviewed verified by ORBi |
 | ROUSSEAU, A.-F., Michel, L., Bawin, M., CAVALIER, E., Reginster, J.-Y., DAMAS, P., & Bruyère, O. (2016). Incidence of bone fractures after critical illness. Intensive Care Medicine Experimental, 4 (Suppl 1), 1131. Peer Reviewed verified by ORBi |
 | Buckinx, F., Reginster, J.-Y., Petermans, J., Croisier, J.-L., Beaudart, C., BRUNOIS, T., & Bruyère, O. (2016). Relationship between frailty, physical performance and quality of life among nursing home residents: the SENIOR cohort. Aging Clinical and Experimental Research, 28 (6), 1149-57. doi:10.1007/s40520-016-0616-4 Peer Reviewed verified by ORBi |
Slomian, J., EMONTS, P., Glowacz, F., Reginster, J.-Y., Bruyère, O., Vigneron, L., & Acconcia, A. (2016). Identification des besoins des mères dans l’année suivant leur accouchement : une étude qualitative. In De l'expertise scientifique à l'expertise profane : postures, enjeux et méthodes dans le champ de la psychologie de la santé. Peer reviewed |
 | Blain, H., Masud, T., Dargent-Molina, P., Martin, F., Rosendahl, E., van der Velde, N., Bousquet, J., Benetos, A., Cooper, C., Kanis, J. A., Reginster, J.-Y., Rizzoli, R., Cortet, B., Barbagallo, M., Dreinhöfer, K., Vellas, B., Maggi, S., Strandberg, T., Alvarez, M. N., ... Adachi, R. (2016). A comprehensive fracture prevention strategy in older adults: The European union geriatric medicine society (EUGMS) statement. European Geriatric Medicine, 7 (6), 519-525. doi:10.1016/j.eurger.2016.04.012 Peer reviewed |
 | Blain, H., Masud, T., Dargent-Molina, P., Martin, F., Rosendahl, E., van der Velde, N., Bousquet, J., Benetos, A., Cooper, C., Kanis, J. A., Reginster, J.-Y., Rizzoli, R., Cortet, B., Barbagallo, M., Dreinhöfer, K. E., Vellas, B., Maggi, S., & Strandberg, T. (2016). A comprehensive fracture prevention strategy in older adults: The European Union Geriatric Medicine Society (EUGMS) statement. Journal of Nutrition, Health and Aging, 20 (6), 647-652. doi:10.1007/s12603-016-0741-y Peer Reviewed verified by ORBi |
 | Miller, P. D., Pannacciulli, N., Brown, J. P., Czerwinski, E., Nedergaard, B. S., Bolognese, M. A., Malouf, J., Bone, H. G., Reginster, J.-Y., Singer, A., Wang, C., Wagman, R. B., & Cummings, S. R. (2016). Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. Journal of Clinical Endocrinology and Metabolism, 101 (8), 3163-3170. doi:10.1210/jc.2016-1801 Peer Reviewed verified by ORBi |
 | SMOLEN, J. S., COLLAUD BASSET, S., BOERS, M., BREEDVELD, F., EDWARDS, C. J., KVIEN, T. K., MIOSSEC, P., SOKKA-ISLER, T., van VOLLENHOVEN, R. F., Abadie, E. C., Bruyère, O., COOPER, C., MÄKINEN, H., THOMAS, T., TUGWELL, P., & Reginster, J.-Y. (2016). Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. Annals of the Rheumatic Diseases, 75, 1268-1271. doi:10.1136/annrheumdis-2016-209429 Peer Reviewed verified by ORBi |
 | Locquet, M., Beaudart, C., Reginster, J.-Y., PETERMANS, J., GILLAIN, S., Quabron, A., Slomian, J., Buckinx, F., & Bruyère, O. (2016). Prevalence of concomitant bone and muscle wasting in patients from the SarcoPhAge Study. Journal of Frailty and Aging, 5 (Supplement 1), 84. Peer Reviewed verified by ORBi |
 | Manzambi Kuwekita, J., Gosset, C., Guillaume, M., Balula Semutsari, M.-P., Tshiama Kabongo, E., Bruyère, O., & Reginster, J.-Y. (30 December 2015). Le couplage « Micro-crédit, Micro-assurance santé et Offre des soins » peut améliorer l’accessibilité aux soins de santé de qualité en milieu urbain africain : Résultats d’une expérience menée dans la zone de santé de Bandalungwa à Kinshasa, Congo. Médecine et Santé Tropicales, 25, 381-385. doi:10.1684/mst.2015.0520 Peer Reviewed verified by ORBi |
 | Ethgen, O., Hiligsmann, M., Burlet, N., & Reginster, J.-Y. (2015). Public health impact and cost-effectiveness of dairy products supplemented with vitamin D in prevention of osteoporotic fractures. Archives of Public Health. doi:10.1186/s13690-015-0099-3 Peer Reviewed verified by ORBi |
 | PAPAPOULOS, S., LIPPUNER, K., ROUX, C., LIN, C. J., KENDLER, D. L., LEWIECKI, E. M., BRANDI, M. L., CZEWINSKI, E., FRANEK, E., LAKATOS, P., MAUTALEN, C., MINISOLA, S., Reginster, J.-Y., JENSEN, J., DAIZADEH, N. S., WANG, A., GAVIN, M., LIBANATI, C., WAGMAN, R. B., & BONE, H. G. (December 2015). The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporosis International, 26 (12), 2773-2783. doi:10.1007/s00198-015-3234-7 Peer Reviewed verified by ORBi |
 | Manzambi Kuwekita, J., Mbadu Kivuidi, V., Bruyère, O., & Reginster, J.-Y. (2015). Le tradipraticien est un acteur incontournable dans l’offre des soins de santé en territoire péri-urbain : équilibre entre légitimité et illégalité ? In J.-M. Halleux & J. Bogaert (Ed.), Territoires Périurbains (Cette oeuvre est sous licence Creative Commons. Vous êtes libre de reproduire, de modifier, de distribuer et de communiquer cette création au public selon les conditions suivantes : • paternité (BY) : vous devez citer le nom de l’auteur original de la manière indiquée par l’auteur de l’oeuvre ou le titulaire des droits qui vous confère cette autorisation (mais pas d’une manière qui suggérerait qu’ils vous soutiennent ou approuvent votre utilisation de l’oeuvre) ; • pas d’utilisation commerciale (NC) : vous n’avez pas le droit d’utiliser cette création à des fins commerciales ; • partage des conditions initiales à l’identique (SA) : si vous modifiez, transformez ou adaptez cette création, vous n’avez le droit de distribuer la création qui en résulte que sous un contrat identique à celui-ci. À chaque réutilisation ou distribution de cette création, vous devez faire apparaître clairement au public les conditions contractuelles de sa mise à disposition. Chacune de ces conditions peut être levée si vous obtenez l’autorisation du titulaire des droits sur cette oeuvre. Rien dans ce contrat ne diminue ou ne restreint le droit moral de l’auteur, pp. 184-193). Gembloux, Belgium: Presses Agronomiques de Gembloux. Peer reviewed |
 | Beaudart, C., Reginster, J.-Y., PETERMANS, J., & Bruyère, O. (December 2015). Qualité de vie du patient sarcopénique : apport de l’étude liégeoise SarcoPhAge. Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 13 (4), 391-5. doi:10.1684/pnv.2015.0571 Peer reviewed |
 | Bruyère, O., DEROISY, R., Dardenne, N., Cavalier, E., COFFINER, M., da silva, S., De Niet, S., & Reginster, J.-Y. (December 2015). A phase IV, two-armed, randomized, cross-over study comparing compliance with once-a-month administration of vitamin D3 to compliance with daily administration of a fixed-dose combination of vitamin D3 and calcium during two 6-month periods. Osteoporosis International, 26 (12), 2863-8. doi:10.1007/s00198-015-3205-z Peer Reviewed verified by ORBi |
 | Beaudart, C., Biver, E., Reginster, J.-Y., Rizzoli, R., Rolland, Y., Bautmans, I., PETERMANS, J., GILLAIN, S., Buckinx, F., & Bruyère, O. (17 November 2015). Development and validation of a self-administrated quality of life questionnaire specific to sarcopenia: the SarQoL [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Liège, Belgium. |
 | Bruyère, O., Reginster, J.-Y., Dardenne, N., Nelis, J., Lambert, E., Appelboom, G., & Buckinx, F. (17 November 2015). Relationship between ambulatory physical activity assessed by activity trackers and physical frailty among nursing home residents [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Liège, Belgium. |
 | Slomian, J., EMONTS, P., Reginster, J.-Y., Vigneron, L., Acconcia, A., & Bruyère, O. (17 November 2015). Identification des besoins d'une mère dans l'année suivant son accouchement : comparaison entre les femmes ayant vécu au moins un épisode de détresse psychologique et celles n'en ayant pas vécu [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Liège, Belgium. |
 | Locquet, M., Beaudart, C., LARBUISSON, R., Buckinx, F., KAUX, J.-F., Reginster, J.-Y., & Bruyère, O. (17 November 2015). Prevalence and factors associated with self-medication practice among amateur runners [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Liège, Belgium. |
 | Ferrari, S., Libanati, C., Lin, J., Adami, S., Brown, J., Cosman, F., Czerwinski, E., De Gregorio, L., Malouf, J., Reginster, J.-Y., Daizadeh, N., Wang, A., Wagman, R., & Lewiecki, E. (November 2015). Pourcentage de femmes atteignant des T-scores de DMO non ostéoporotiques au rachis lombaire (RL) et à la hanche totale (HT) après 8 ans de traitement par denosumab (DMAb). Revue du Rhumatisme, 82 (S1), 35-A36. Peer Reviewed verified by ORBi |
 | Chapurlat, R., Langdahl, B., Teglbjaerg, C., HO, P. R., Czerwinski, E., Kendler, D., Reginster, J.-Y., Kivitz, A., LEWIECKI, E., Miller, P., Bolognese, M., McClung, M., Bone, H., Ljunggren, O., Abrahamsen, B., Gruntmanis, U., Wagman, R., Siddhanti, S., & Orwoll, E. (November 2015). Traitement par denosumab chez des hommes à masse osseuse basse: résultats à 24 mois de l'étude ADAMO. Revue du Rhumatisme, 82 (S1), 123-A124. Peer Reviewed verified by ORBi |
 | Buckinx, F., Paquot, N., Allepaerts, S., Reginster, J.-Y., Petermans, J., & Bruyère, O. (September 2015). Energy and nutrient contents of food served and consumed by nursing home residents. European Geriatric Medicine, 6S1, 124. Peer reviewed |
 | Buckinx, F., Croisier, J.-L., Reginster, J.-Y., Petermans, J., & Bruyère, O. (September 2015). Impact of the frailty status on muscle mass and muscle strength of nursing home residents. European Geriatric Medicine, 6S1, 85. Peer reviewed |
 | Buckinx, F., Reginster, J.-Y., Cavalier, E., Petermans, J., Dardenne, C., & Bruyère, O. (September 2015). Derteminants of prescription of vitamin D supplementations in nursing homes: an online survey among general practitioners. European Geriatric Medicine, 6S1, 139. Peer reviewed |
 | Buckinx, F., Croisier, J.-L., Reginster, J.-Y., Petermans, J., & Bruyère, O. (September 2015). Correlation between muscle mass and muscle strength among nursing home residents. European Geriatric Medicine, 6S1, 84-s85. Peer reviewed |
 | Beaudart, C., Reginster, J.-Y., Rizzoli, R., Biver, E., Rolland, Y., Bautmans, I., Petermans, J., GILLAIN, S., Buckinx, F., Van Beveren, J., Jacquemain, M., Italiano, P., Dardenne, N., & Bruyère, O. (September 2015). Development and validation of a self-administrated quality of life questionnaire specific to sarcopenia: the SarQol. European Geriatric Medicine, 6S1, 84. Peer reviewed |
 | Beaudart, C., Reginster, J.-Y., Petermans, J., GILLAIN, S., Quabron, A., Locquet, M., Slomian, J., Buckinx, F., & Bruyère, O. (September 2015). Quality of life and physical components linked to sarcopenia: baseline data of the SarcoPhAge study. European Geriatric Medicine, 6S1, 7-s8. Peer reviewed |
| GILLAIN, S., Petermans, J., Dardenne, N., Beaudart, C., Buckinx, F., GARRAUX, G., REGINSTER, J.-Y., Bruyère, O., DEMONCEAU, M., WOJTASIK, V., & Schwartz, C. (April 2015). Comparison of body composition, muscle force and physical performances between faller and non-faller people included in a cohort of 100 community dwelling volunteers : the Gaby Study. Journal of Frailty and Aging, 4 (S1), 106. Peer Reviewed verified by ORBi |
 | Manzambi Kuwekita, J., Eloko Eya Matangelo, G., Bruyère, O., Gosset, C., Guillaume, M., & Reginster, J.-Y. (31 March 2015). Financement de la santé et recouvrement des coûts : le lourd fardeau des ménages congolais. Résultats des comptes nationaux de la santé. Journal d’Épidémiologie et de Santé Publique, 15 (Mars 2015), 15-27. Peer reviewed |
 | Manzambi Kuwekita, J., Bruyère, O., Guillaume, M., Gosset, C., & Reginster, J.-Y. (23 March 2015). Comment optimiser l’efficience de l’aide internationale, dans le domaine de la santé, en République Démocratique du Congo. Santé Publique: Revue Multidisciplinaire pour la Recherche et l'Action, 27 (Janvier-Févier), 129-134. doi:10.3917/spub.151.0129 Peer Reviewed verified by ORBi |
 | Buckinx, F., Reginster, J.-Y., Dardenne, N., Croisier, J.-L., Kaux, J.-F., Beaudart, C., Slomian, J., & Bruyère, O. (March 2015). Concordance between muscle mass assessed by bioelectrical impedance analysis and by dual energy X-ray absorptionmetry among elderly people: a cross-sectional study. Osteoporosis International, 26 (S1), 53. Peer Reviewed verified by ORBi |
 | Buckinx, F., Reginster, J.-Y., Dardenne, N., Croisier, J.-L., Kaux, J.-F., Beaudart, C., Slomian, J., & Bruyère, O. (March 2015). Concordance between muscle mass assessed by bioelectrical impedance analysis and by dual energy X-ray absorptionmetry among elderly people: a cross-sectional study. BMC Musculoskeletal Disorders, 16 (1), 60-67. doi:10.1186/s12891-015-0510-9 Peer Reviewed verified by ORBi |
 | Neuprez, A., Bruyère, O., Dardenne, N., Distèche, S., Maheu, E., Burlet, N., & Reginster, J.-Y. (March 2015). Assessment and determinants of aesthetic discomfort in hand osteoarthritis: The Liège Hand Osteoarthritis Cohort (LICOH). Osteoporosis International, 26 (S1), 43-S44. Peer Reviewed verified by ORBi |
 | Buckinx, F., Reginster, J.-Y., CROISIER, J.-L., PETERMANS, J., Goffart, E., & Bruyère, O. (2015). Physical abilities of elderly nursing home residents: The SENIOR cohort. The Journal of Nursing Home Research Sciences, 1, 43-44. Peer reviewed |
 | Buckinx, F., Reginster, J.-Y., CROISIER, J.-L., PETERMANS, J., Goffart, E., & Bruyère, O. (2015). Relationship between isometric strength of 6 muscle groups of the lower limbs and motor skills among nursing home residents. The Journal of Nursing Home Research Sciences, 1, 44. Peer reviewed |
 | Neuprez, A., Bruyère, O., Dardenne, N., DISTECHE, S., MAHEU, E., BURLET, N., D'HOOGHE, P., & Reginster, J.-Y. (2015). Assessment and determinants of aesthetic discomfort in hand osteoarthritis. Annals of the Rheumatic Diseases, 74, 1942. doi:10.1136/annrheumdis-2015-207718 Peer Reviewed verified by ORBi |
 | Cutolo, M., Berenbaum, F., Hochberg, M., Punzi, L., & Reginster, J.-Y. (2015). Commentary on recent therapeutic guidelines for osteoarthritis. Seminars in Arthritis and Rheumatism, 44, 611-617. doi:10.1016/j.semarthrit.2014.12.003 Peer Reviewed verified by ORBi |
 | McClung, M., Langdahl, B., Papapoulos, S., Saag, K., Adami, S., Bone, H., De Villiers, T., Kiel, D., Kung, A., Kumar KM, P., Lim, S., Ling, X., Lippuner, K., Mautalen, C., Nakamura, T., Reginster, J.-Y., Reid, I., Rodriguez-Portales, A., Roux, C., ... Lombardi, A. (2015). Ocanacatib antifracture efficacy and saftey in postmenopausal women with osteoporosis: results from the phase III long-term adonacatib fracture trial (LOFT). Osteoporosis International, 26 (S1), 35-S36. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Brandi, M., Cannata-Andia, J., Cooper, C., Cortet, B., Feron, J., Genant, H., Palacios, S., Ringe, J., & Rizzoli, R. (2015). The position of Strontium ranelate in today's management of osteoporosis. Osteoporosis International, 26 (S1), 39. Peer Reviewed verified by ORBi |
 | Eymard, F., Parsons, C., Edwards, M., Petit-Dop, F., Reginster, J.-Y., Bruyère, O., Richette, P., Cooper, C., & Chevalier, X. (2015). Diabetes is a risk factor for knee osteoarthritis progression. Osteoarthritis and Cartilage, 23, 851-859. doi:10.1016/j.joca.2015.01.013 Peer Reviewed verified by ORBi |
 | Slomian, J., Reginster, J.-Y., Gaspard, U., Streel, S., Beaudart, C., Appelboom, G., Buckinx, F., & Bruyère, O. (2015). Exploring the Interest in and the Usage of the Internet Among Patients Eligible for Osteoporosis Screening. Calcified Tissue International, 96, 518-526. doi:10.1007/s00223-015-9987-3 Peer Reviewed verified by ORBi |
 | FOX, B., HENWOOD, T., SCHAAP, L., Bruyère, O., Reginster, J.-Y., Beaudart, C., Buckinx, F., ROBERTS, H., COOPER, C., CHERUBINI, A., dell'AQUILLA, G., MAGGIO, M., & VOLPATO, S. (2015). Adherence to a standardized protocol for measuring grip strength and appropriate cut-off values in adults over 65 years with sarcopenia: a systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports, 13 (10), 50-59. doi:10.11124/jbisrir-2015-2256 Peer Reviewed verified by ORBi |
 | Bruyère, O., & Reginster, J.-Y. (2015). Quels types d'étude pour quels objectifs ? OncoHemato : Revue Multidisciplinaire d'Oncologie et Hématologie, 9 (1), 34-36. |
 | Harvey, N. C., Gluer, C. C., Binkley, N., McCloskey, E. V., Brandi, M.-L., Cooper, C., Kendler, D., Lamy, O., Laslop, A., Camargos, B. M., Reginster, J.-Y., Rizzoli, R., & Kanis, J. A. (2015). Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. BONE, 78, 216-224. doi:10.1016/j.bone.2015.05.016 Peer Reviewed verified by ORBi |
 | Buckinx, F., Reginster, J.-Y., CAVALIER, E., PETERMANS, J., RICOUR, C., Dardenne, C., & Bruyère, O. (2015). Determinants of prescription of vitamin D supplementation in nursing homes: a survey among general practitioners. The Journal of Nursing Home Research Sciences, 1, 43. Peer reviewed |
 | NEUPREZ, A., Delcour, J.-P., Fatemi, F., GILLET, P., Mawet, M., François, G., Bruyère, O., CRIELAARD, J.-M., Gosset, C., & Reginster, J.-Y. (2015). Development and validation of the French version of a tool assessing patient's expectations in lower limb osteoarthritis. Journal of Orthopaedics, 12, 46-57. doi:10.1016/j.jor.2014.06.002 Peer Reviewed verified by ORBi |
 | Rabenda, V., Bruyère, O., Cooper, C., Rizzoli, R., Buckinx, F., Quabron, A., & Reginster, J.-Y. (2015). Publication outcomes of the abstracts presented at the 2011 European Congress on Osteoporosis, Osteoarthritis and Musculo-Skeletal Diseases (ECCEO-IOF11) : A position paper of the European Society for Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculo-Skeletal Diseases (ESCEO) and the International Osteoporosis and Other Skeletal Diseases Foundation (IOF). Archives of Osteoporosis, 10 (1). doi:10.1007/s11657-015-0216-5 Peer Reviewed verified by ORBi |
 | Beaudart, C., Reginster, J.-Y., Slomian, J., Buckinx, F., Locquet, M., Quabron, A., & Bruyère, O. (2015). Health related quality of life in sarcopenia. Osteoporosis International, 26 (S1), 148-149. Peer Reviewed verified by ORBi |
 | Beaudart, C., Reginster, J.-Y., Petermans, J., GILLAIN, S., Quabron, A., Locquet, M., Slomian, J., Buckinx, F., & Bruyère, O. (2015). Clinical components linked to sarcopenia: the sarcophage study. Osteoporosis International, 26 (S1), 144. Peer Reviewed verified by ORBi |
 | Beaudart, C., Reginster, J.-Y., Petermans, J., GILLAIN, S., Quabron, A., Locquet, M., Slomian, J., Buckinx, F., & Bruyère, O. (2015). Clinical components linked to sarcopenia: the sarcophage study. Journal of Frailty and Aging, 4 (S1), 89. Peer Reviewed verified by ORBi |
 | Beaudart, C., Biver, E., Reginster, J.-Y., Rizzoli, R., Rolland, Y., Bautmans, I., PETERMANS, J., GILLAIN, S., Buckinx, F., van beveren, J., Jacqemain, M., Italiano, P., Dardenne, N., & Bruyère, O. (2015). Development of a self-administrated quality of life questionnaire for sarcopenia in elderly subjects: the SarQol. Age and Ageing, 44, 960-966. doi:10.1093/ageing/afv133 Peer Reviewed verified by ORBi |
 | FERRARI, S., ADACHI, J. D., LUPPUNER, K., ZAPALOWSKI, C., MILLER, P. D., Reginster, J.-Y., TORRING, O., KENDLER, D. L., DAIZADEH, N. S., WANG, A., O'MALLEY, C. D., WAGMAN, R. B., LIBANATI, C., & LEWICKI, E. M. (2015). Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporosis International, 26, 2763-2771. doi:10.1007/s00198-015-3179-x Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., REITER-NIESERT, S., Bruyère, O., BERENBAUM, F., BRANDI, M. L., BRANCO, J., DEVOGELAER, J. P., HERRERO-BAUMONT, G., KANIS, J., MAGGI, S., MAHEU, E., RICHETTE, P., RIZZOLI, R., & COOPER, C. (2015). Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medical products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement. Osteoarthritis and Cartilage, 23, 2086-2093. doi:10.1016/j.joca.2015.07.001 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2015). How can we help implementing ESCEO algorithm in real life? Osteoporosis International, 26 (S1), 382. Peer Reviewed verified by ORBi |
 | Bruyère, O., Reginster, J.-Y., & Cooper, C. (2015). Should your Algorithm Include Plasma Rich in Growth Factors in the Light of Its Clinical Efficacy and Safety?: By Vaquerizo V. et al. Seminars in Arthritis and Rheumatism, 44 (4), 12-e13. doi:10.1016/j.semarthrit.2014.09.008 Peer Reviewed verified by ORBi |
 | Beaudart, C., Reginster, J.-Y., Rizzoli, R., Rolland, Y., Bautmans, I., Biver, E., Petermans, J., GILLAIN, S., Van Beveren, J., Jacquemain, M., Italiano, P., Dardenne, N., & Bruyère, O. (2015). Development of a self-administrated quality of life questionnaire specific to sarcopenia in elderly aged 65 and older : the SarQol. Journal of Frailty and Aging, 4 (S1), 31-32. Peer Reviewed verified by ORBi |
 | Buckinx, F., Reginster, J.-Y., Dardenne, N., Beaudart, C., Slomian, J., GILLAIN, S., Petermans, J., RICOUR, C., Goffart, E., & Bruyère, O. (2015). Prevalence of frailty in nursing home residents according to various diagnostic tools. Journal of Frailty and Aging, 4 (S1), 61. Peer Reviewed verified by ORBi |
 | Bruyère, O., & Reginster, J.-Y. (2015). Letter to the Editor. Seminars in Arthritis and Rheumatism, 44 (5), 15. doi:10.1016/j.semarthrit.2014.09.001 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Bruyère, O. (2015). Recommendation for the management of knee osteoarthritis. Bone, Muscle and Joint Diseases, (S35), 40. Peer reviewed |
 | Buckinx, F., Reginster, J.-Y., Dardenne, N., Beaudart, C., Slomian, J., GILLAIN, S., Petermans, J., RICOUR, C., Goffart, E., & Bruyère, O. (2015). Prevalence of frailty in nursing home residents according to various diagnostic tools. Osteoporosis International, 26 (S1), 160-S161. Peer Reviewed verified by ORBi |
 | Papapoulos, S., Roux, C., Bone, H., Dakin, P., Czerwinski, E., Frey, D., Kendler, D., Lewiecki, E., Malouf, J., Mellström, D., Reginster, J.-Y., Resch, H., Daizadeh, N., Wang, A., Gavin, M., Wagman, R., & Brandi, M. (2015). Denosumab treatment in postmenopausal women with osteoporosis for up to 9 years: results through year 6 of the freedom extension. Osteoporosis International, 26 (S1), 37-S39. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Reiter-Niesert, S., Bruyère, O., Berenbaum, F., Brandi, M., Branco, J., Devogelaer, J., Herrero-Beaumont, G., Kanis, J., Maggi, S., Maheu, E., Richette, P., Rizzoli, R., & Cooper, C. (2015). Recommendations for an update of the current (2010) European Regulatory Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes. Osteoporosis International, 26 (S1), 59. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Cooper, C., Rizzoli, R., Kanis, J., Appelboom, G., Bautmans, I., Bischoff-Ferrari, H., Boers, M., Brandi, M., Bruyère, O., Cherubini, A., Flamion, B., Fielding, R., Van Loon, L., McCloskey, E., Mitlak, B., Pilotto, A., Reiter-Niesert, S., Rolland, Y., ... Cruz-Jentoft, A. (2015). Recommendations for the registration of drugs to treat sarcopenia. Osteoporosis International, 26 (S1), 62. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2015). Current regulatory requirements for registration of drugs to be used in osteoarthritis in Europe and need for clarification. Osteoporosis International, 26 (S1), 60. Peer Reviewed verified by ORBi |
 | Neuprez, A., Bruyère, O., MAHEU, E., Dardenne, N., Burlet, N., D'HOOGHE, P., DISTECHE, S., & Reginster, J.-Y. (2015). Aesthetic discomfort in hand osteoarthritis: results from the LIège Hand Osteoarthritis Cohort (LIHOC). Arthritis Research and Therapy, 17, 346. doi:10.1186/s13075-015-0807-y Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Cooper, C., Hochberg, M., Pelletier, J.-P., Rizzoli, R., Kanis, J., Abadie, E., Maheu, E., Brandi, M. L., Devogelaer, J.-P., Branco, J., Herrero-Beaumont, G., D'Hooghe, P., & Bruyère, O. (2015). Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis. Current Medical Research and Opinion, 31 (5), 1041-1045. doi:10.1185/03007995.2015.1027183 Peer Reviewed verified by ORBi |
 | Langdahl, B. L., Teglbjaerg, C. S., Ho, P.-R., Chapurlat, R., Czerwinski, E., Kendler, D. L., Reginster, J.-Y., Kivitz, A., Lewiecki, E. M., Miller, P. D., Bolognese, M. A., McClung, M. R., Bone, H. G., Ljunggren, O., Abrahamsen, B., Gruntmanis, U., Yang, Y.-C., Wagman, R. B., Mirza, F., ... Orwoll, E. (2015). A 24-month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial. Journal of Clinical Endocrinology and Metabolism, 100 (4), 1335-1342. doi:10.1210/jc.2014-4079 Peer Reviewed verified by ORBi |
 | Slomian, J., LECLERC, A.-F., Maquet, D., JERUSALEM, G., LIFRANGE, E., COUCKE, P., Bury, T., TOMASELLA, M., Reginster, J.-Y., Bruyère, O., & Crielaard, J.-M. (2015). Prevalence of endocrine therapies that could affect bone health in women following a rehabilitation program after surgery for breast cancer. Osteoporosis International, 26 (S1), 375. Peer Reviewed verified by ORBi |
 | Ferrari, S., Libanati, C., Lin, C., Adami, S., Brown, J., Cosman, F., Czerwinski, E., De Gregorio, L., Malouf, J., Reginster, J.-Y., Daizadeh, N., Wang, A., Wagman, R., Lewiecki, E., & Cummings, S. (2015). Percentage of women achieving non-osteoporotic BMD T-scores at the lumbar spine (LS) and total hip (TH) during up to 8 years of Denosumab (Dmab) treatment. Osteoporosis International, 26 (S1), 149-S150. Peer Reviewed verified by ORBi |
 | Ethgen, O., Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2015). Cost-effectiveness of dairy products supplemented with vitamin D in the prevention of osteoporotic fractures. Osteoporosis International, 26 (S1), 372-S373. Peer Reviewed verified by ORBi |
 | Rabenda, V., Bruyère, O., Cavalier, E., DEROISY, R., LECART, M.-P., COLLETTE, J., & Reginster, J.-Y. (2015). Serum concentrations of osteoprotegerin (OPG) and dickkope-1 (DKK1) poorly predict bone mineral density changes and fracture incidence in postmenopausal osteoporotic women. Osteoporosis International, 26 (S1), 240. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2015). Glucosamine and chondroitin salts in the management of osteoarthritis in Europe. Osteoporosis International, 26 (S1), 60-S61. Peer Reviewed verified by ORBi |
 | Harvey, N., Binkley, N., Brandi, M., Camargos, B., Cooper, C., Glüer, C., Kanis, J., Kendler, D., Lamy, O., Laslop, A., Reginster, J.-Y., & Rizzoli, R. (2015). Trabecular bone score (TBS) as a new complementary appproach for osteoporosis evaluation in clinical practice. Osteoporosis International, 26 (S1), 60. Peer Reviewed verified by ORBi |
 | Bruyère, O., Reginster, J.-Y., & Ethgen, O. (2015). La médecine personnalisée : aspects pharmacoéconomiques. Revue Médicale de Liège, 70 (5-6), 339-342. Peer reviewed |
 | NEUPREZ, A., Bruyère, O., Dardenne, N., DISTECHE, S., Maheu, E., Burlet, N., & Reginster, J.-Y. (2015). Baseline characteristics of the Liège Hand Osteoarthritis Cohort (LIHOC). Annals of the Rheumatic Diseases, 74 (Supp2), 1346. doi:10.1136/annrheumdis-2015-eular.3393 Peer Reviewed verified by ORBi |
 | FERRARI, S., LIBANATI, C., LIN, C., ADAMI, S., BROWN, J. P., COSMAN, F., CZERWINSKI, E., de GREGORIO, L. H., MALOUF, J., Reginster, J.-Y., DAIZADEH, N. S., WANG, A., WAGMAN, R. B., & LEWIECKI, E. M. (2015). Relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 8 years of denosumab treatment. Arthritis and Rheumatology, 67 (s10), 487-489. Peer Reviewed verified by ORBi |
 | BROWN, J. P., DAKIN, P., HADJI, P., McCLUNG, M. R., MILLER, P. D., Reginster, J.-Y., WAGMAN, R. B., WANG, A., & McCLOSKEY, E. (2015). Can we use bone turnover markers as targets for antiresorptive treatment in postmenopausal osteoporosis ? an analysis from two phase 3 clinical trials. Arthritis and Rheumatology, 67 (S10), 515-517. Peer Reviewed verified by ORBi |
 | Buckinx, F., Croisier, J.-L., Reginster, J.-Y., Dardenne, N., Beaudart, C., Slomian, J., & Bruyère, O. (2015). Reliability of muscle strength measures obtained with a hand-held dynamometer in an elderly population. Osteoporosis International, 26 (S1), 161. Peer Reviewed verified by ORBi |
 | Buckinx, F., Rolland, Y., Reginster, J.-Y., RICOUR, C., Petermans, J., & Bruyère, O. (2015). Burden of frailty in the elderly population: perspectives for a public health challenge. Archives of Public Health, 73 (1), 19-25. doi:10.1186/s13690-015-0068-x Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Evers, S. M., Ben Sedrine, W., Kanis, J. A., Ramaekers, B., Reginster, J.-Y., Silverman, S., Wyers, C. E., & Boonen, A. (2015). A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis. PharmacoEconomics, 33 (3), 205-224. doi:10.1007/s40273-014-0231-1 Peer Reviewed verified by ORBi |
 | Buckinx, F., Beaudart, C., Slomian, J., Maquet, D., Demonceau, M., Gillain, S., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2015). Added value of a triaxial accelerometer assessing gait parameters to predict falls and mortality among nursing home residents: A two-year prospective study. Technology and Health Care, 23, 195-203. doi:10.3233/THC-140883 Peer Reviewed verified by ORBi |
 | Beaudart, C., Reginster, J.-Y., Petermans, J., GILLAIN, S., Quabron, A., Locquet, M., Slomian, J., Buckinx, F., & Bruyère, O. (2015). Quality of life and physical components linked to sarcopenia: The SarcoPhAge study. Experimental Gerontology, 69, 103-110. doi:10.1016/j.exger.2015.05.003 Peer Reviewed verified by ORBi |
 | Bruyère, O., Reginster, J.-Y., Dardenne, N., Nelis, J., Lambert, E., Appelboom, G., & Buckinx, F. (2015). Relationship between ambulatory physical activity assessed by activity trackers and physical frailty among nursing home residents. The Journal of Nursing Home Research Sciences, 1, 28. Peer reviewed |
 | Rizzoli, R., Stevenson, J. C., Bauer, J. M., Van Loon, L. J. C., Walrand, S., Kanis, J. A., Cooper, C., Brandi, M.-L., Diez-Perez, A., & Reginster, J.-Y. (2015). Erratum: The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (Maturitas (2014) 79 (122-132)). Maturitas, 80 (3), 337. doi:10.1016/j.maturitas.2014.11.005 Peer Reviewed verified by ORBi |
 | Ayora, A. F., HERION, F., ROMPEN, E., Reginster, J.-Y., Magremanne, M., & LAMBERT, F. (2015). Dramatic osteonecrosis of the jaw associated with oral bisphosphonates, periodontitis and dental implant removal. Journal of Clinical Periodontology, 42, 190-195. doi:10.1111/jcpe.12322 Peer Reviewed verified by ORBi |
 | Beaudart, C., Reginster, J.-Y., Slomian, J., Dardenne, N., Quabron, A., SLANGEN, C., GILLAIN, S., Petermans, J., & Bruyère, O. (2015). Estimation of sarcopenia prevalence using various assessment tools. Experimental Gerontology, 61, 31-37. doi:10.1016/j.exger.2014.11.014 Peer Reviewed verified by ORBi |
 | Beaudart, C., Reginster, J.-Y., Croisier, J.-L., Slomian, J., Buckinx, F., Locquet, M., Quabron, A., & Bruyère, O. (2015). Is there a specific pattern of lean/fat mass ratio in sarcopenic subjects? Osteoporosis International, 26 (S1), 145-S146. Peer Reviewed verified by ORBi |
 | Beaudart, C., Reginster, J.-Y., Bautmans, I., Croisier, J.-L., Slomian, J., Buckinx, F., Locquet, M., Quabron, A., & Bruyère, O. (2015). Muscle fatigue resistance and self-perceived fatigue in relation with sarcopenia and quality of life. Journal of Frailty and Aging, 4 (S1), 61-62. Peer Reviewed verified by ORBi |
 | Beaudart, C., Reginster, J.-Y., Slomian, J., Buckinx, F., Locquet, M., Quabron, A., & Bruyère, O. (2015). Health related quality of life in sarcopenia. Journal of Frailty and Aging, 4 (S1), 61. Peer Reviewed verified by ORBi |
 | Beaudart, C., Reginster, J.-Y., Croisier, J.-L., Slomian, J., Buckinx, F., Locquet, M., Quabron, A., & Bruyère, O. (2015). Correlation between muscle mass and muscle strength and their association with physical performance and gait speed. Osteoporosis International, 26 (S1), 49. Peer Reviewed verified by ORBi |
 | Rabenda, V., Bruyère, O., Kanis, J., Cooper, C., Rizzoli, R., Buckinx, F., Quabron, A., & Reginster, J.-Y. (2015). Publication outcomes of the abstracts presented at the 2011 European Congress on Osteoporosis, Osteoarthritis and Musculo-skeletal Diseases (ECCEO-IOF11). Osteoporosis International, 26 (S1), 211. Peer Reviewed verified by ORBi |
 | Delvaux, F., Rochcongar, P., Bruyère, O., DANIEL, C., Reginster, J.-Y., & Croisier, J.-L. (2015). Retour au sport après plastie du ligament croisé antérieur : critères utilisés dans les cubs professionnels de football. Science & Sports, 30, 33-40. Peer Reviewed verified by ORBi |
 | Bruyère, O., & Reginster, J.-Y. (2015). Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome. Endocrine, 48 (1), 65-68. doi:10.1007/s12020-014-0357-0 Peer Reviewed verified by ORBi |
 | Cianferotti, L., Cricelli, C., Kanis, J. A., Nuti, R., Reginster, J.-Y., Ringe, J. D., Rizzoli, R., & Brandi, M. L. (2015). The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Endocrine. doi:10.1007/s12020-015-0606-x Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Brandi, M. L., Cannata-Andia, J., Cooper, C., Bortet, B., Genant, H., Palacios, S., Ringe, J. D., Rizzoli, R., & Feron, J. M. (2015). The position of Strontium ranelate in today's management of osteoporosis. Osteoporosis International, 26, 1667-1671. doi:10.1007/s00198-015-3109-y Peer Reviewed verified by ORBi |
 | CAVALIER, E., GADISSEUR, R., GEBOES, S., BEKAERT, A.-C., CARLISI, I., Bruyère, O., & Reginster, J.-Y. (2015). Critical evaluation of promising markers for sarcopenia. Osteoporosis International, 26 (S1), 49-S50. Peer Reviewed verified by ORBi |
 | Bruyère, O., Cooper, C., Arden, N., Branco, J., Brandi, M., Herrero-Beaumont, G., Berenbaum, F., Dennison, E., Devogelaer, J., Hochberg, M., Kanis, J., Laslop, A., McAlindon, T., Reiter, S., Richette, P., Rizzoli, R., & Reginster, J.-Y. (2015). Can we identify patients with high risk of osteoarthritis progression who will respond to treatment ? A focus on epidemiology and phenotype of osteoarthritis. Drugs and Aging, 32 (3), 179-187. doi:10.1007/s40266-015-0243-3 Peer Reviewed verified by ORBi |
 | Beaudart, C., Biver, E., Reginster, J.-Y., Rizzoli, R., Rolland, Y., Bautmans, I., Petermans, J., GILLAIN, S., Buckinx, F., Van Beveren, J., Jacquemain, M., Italiano, P., & Bruyère, O. (2015). Development of a self-administrated quality of life questionnaire specific to sarcopenia in elderly aged 65 years and older: the SARQOL. Osteoporosis International, 26 (S1), 145. Peer Reviewed verified by ORBi |
 | Neuprez, A., Bruyère, O., Dardenne, N., DISTECHE, S., Maheu, E., Burlet, N., & Reginster, J.-Y. (2015). Baseline characteristics of the Liège hand osteoarthritis cohort (LIHOC). Osteoporosis International, 26 (S1), 167. Peer Reviewed verified by ORBi |
 | Buckinx, F., Croisier, J.-L., Reginster, J.-Y., Dardenne, N., Beaudart, C., Slomian, J., & Bruyère, O. (2015). Reliability of eight muscle strength measures obtained with a hand-held dynamometer in an elderly population. Journal of Frailty and Aging, 4 (S1), 60-1. Peer Reviewed verified by ORBi |
 | APPELBOOM, G., TAYLOR, B. E., BRUCE, E., BASSILE, C. C., MALAKIDIS, C., YANG, A., YOUNGERMAN, B., D'AMICO, R., BRUCE, S., Bruyère, O., Reginster, J.-Y., DUMONT, E., & CONNOLLY, E. S. (2015). Mobile phone-connected wearable motion sensors to assess postoperative mobilization. Journal of Medical Internet Research Mobile and Ubiquitous Health, 3 (3), 78. Peer reviewed |
 | Reginster, J.-Y., NEUPREZ, A., LECART, M.-P., Beaudart, C., Buckinx, F., Slomian, J., & Bruyère, O. (2015). Ostéoporose et Médecine Personnalisée. Revue Médicale de Liège, 70 (5-6), 321-324. Peer reviewed |
 | Neuprez, A., Bruyère, O., Dardenne, N., DISTECHE, S., Maheu, E., Burlet, N., & Reginster, J.-Y. (2015). Assessment and determinants of aesthetic discomfort in hand osteoarthritis: the LIège Hand Osteoarthritis Cohort (LIHOC). Annals of the Rheumatic Diseases, 74 (Supp2), 110. doi:10.1136/annrheumdis-2015-eular.2778 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Ben Sedrine, W., Bruyère, O., Evers, S. M., Rabenda, V., & Reginster, J.-Y. (2015). Cost-effectiveness of vitamin D and calcium supplementation in the treatment of elderly women and men with osteoporosis. European Journal of Public Health, 25 (1), 20-25. doi:10.1093/eurpub/cku119 Peer Reviewed verified by ORBi |
 | Arden, N., Richette, P., Cooper, C., Bruyère, O., Abadie, E., Branco, J., Brandi, M.-L., Berenbaum, F., Clerc, C., Dennison, E., Devogelaer, J.-P., Hochberg, M., D'Hooghe, P., Herrero-Baumont, G., Kanis, J. A., Laslop, A., Leblanc, V., Maggi, S., Mautone, G., ... Reginster, J.-Y. (2015). Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on biomarkers ans frailty. Drugs and Aging, 32, 529-535. doi:10.1007/s40266-015-0276-7 Peer Reviewed verified by ORBi |
 | Buckinx, F., PAQUOT, N., ALLEPAERTS, S., Reginster, J.-Y., PETERMANS, J., Backes, C., & Bruyère, O. (2015). Energy and nutrient contents of food served and consumed by nursing home residents. The Journal of Nursing Home Research Sciences, 1, 43. Peer reviewed |
 | Buckinx, F., Croisier, J.-L., Reginster, J.-Y., PETERMANS, J., Goffart, E., & Bruyère, O. (2015). Relationship between isometric strength of six lower limb muscle groups and motor skills among nursing home residents. Journal of Frailty and Aging, 4 (4), 184-7. doi:10.14283/jfa.2015.70 Peer Reviewed verified by ORBi |
 | Delvaux, F., Rochcongar, P., Bruyère, O., DANIEL, C., Reginster, J.-Y., & Croisier, J.-L. (2015). Retour au sport après plastie du ligament croisé antérieur: Critères utilisés dans les clubs professionnels de football. Science & Sports, 30 (1), 33-40. doi:10.1016/j.scispo.2014.11.001 Peer Reviewed verified by ORBi |
 | Lo Presti, M.* , Abraham, M.* , Appelboom, G., Bruyère, O., Slomian, J., Reginster, J.-Y., & Connolly Jr, E. S. (2015). Clinical Trials Using Mobile Health Applications. Pharmaceutical Medicine, 29 (1), 17-25. doi:10.1007/s40290-015-0085-7 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Arden, N. K., Richette, P., Cooper, C., Bruyère, O., Abadie, E. C., Branco, J., Brandi, M., Berenbaum, F., Clerc, C., Dennison, E., Devogelaer, J., Hochberg, M., Herrero-Beaumont, G., Kanis, J., Laslop, A., Leblanc, V., Maggi, S., Mautone, G., Pelletier, J., ... Reginster, J.-Y. (2015). Can we identify patients to be treated in osteoarthritis? Osteoporosis International, 26 (S1), 61-62. Peer Reviewed verified by ORBi |
 | Beaudart, C., Reginster, J.-Y., Bautmans, I., Croisier, J.-L., Slomian, J., Buckinx, F., Locquet, M., Quabron, A., & Bruyère, O. (2015). Grip fatigue resistance and self-perceived fatigue in relation with sarcopenia and quality of life. Osteoporosis International, 26 (S1), 147-S148. Peer Reviewed verified by ORBi |
 | Beaudart, C., Reginster, J.-Y., Croisier, J.-L., Slomian, J., Buckinx, F., Locquet, M., Quabron, A., & Bruyère, O. (2015). Correlation between muscle mass and muscle strength and their association with physical performance and gait speed. Journal of Frailty and Aging, 4 (S1), 61. Peer Reviewed verified by ORBi |
 | Beaudart, C., Reginster, J.-Y., Croisier, J.-L., Slomian, J., Buckinx, F., Locquet, M., Quabron, A., & Bruyère, O. (2015). Is there a specific pattern of lean/fat mass ratio in sarcopenic subjects? Journal of Frailty and Aging, 4 (S1), 61. Peer Reviewed verified by ORBi |
 | Buckinx, F., Reginster, J.-Y., Dardenne, N., Croisier, J.-L., Kaux, J.-F., Slomian, J., Beaudart, C., & Bruyère, O. (November 2014). Concordance entre la masse musculaire mesurée par impédance bioélectrique et par absorptiométrie radiologique à double énergie. Cahiers de l'Année Gérontologique, 6 (Suppl. 1), 182. Peer Reviewed verified by ORBi |
 | GILLAIN, S., Schwartz, C., Boutaayamou, M., Demonceau, M., CROISIER, J.-L., Bruls, O., GARRAUX, G., REGINSTER, J.-Y., & PETERMANS, J. (October 2014). Validation des paramètres de marche par un système accélérométrique (Locométrix*) à l'aide d'un système opto-électronique 3D (Coda Motion ). Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 12 (supplément 3). Peer reviewed |
 | Bruyère, O., & Reginster, J.-Y. (May 2014). Quels types d'étude pour quels objectifs? Medi-Sphere, 445, 38-9. |
 | Manzambi Kuwekita, J., Bruyère, O., & REGINSTER, J.-Y. (31 March 2014). Le rôle du tradipraticien dans l’offre des soins de sante de proximité en zones de sante semi-rurales : résultats d’une étude menée dans la commune périphérique de Kisenso à Kinshasa, Congo. Journal d’Épidémiologie et de Santé Publique, XIII, 59-66. Peer reviewed |
 | Bruyère, O., Reginster, J.-Y., Bellamy, N., Chapurlat, R., Richette, P., & Cooper, C. (March 2014). Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis. Rheumatology, 53, 1457-64. doi:10.1093/rheumatology/keu018 Peer Reviewed verified by ORBi |
 | Papapoulos, S., Lippuner, K., Roux, C., Lin, C., Kendler, D., Lewiecki, E., Brandi, M., Czerwinski, E., Franek, E., Lakatos, P., Mautalen, C., Minisola, S., Reginster, J.-Y., Jensen, S., Daizadeh, N., Wang, A., Gavin, M., Wagman, R., & Bone, H. (2014). Eight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the freedom extension. Osteoporosis International, 25 (2), 46-47. Peer Reviewed verified by ORBi |
 | Buckinx, F., Beaudart, C., Slomian, J., Maquet, D., Demonceau, M., GILLAIN, S., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). Facteurs de risque de chute chez des sujets résidant en maison de repos : étude prospective d'une durée de 2 ans. Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 12 (1), 164-165. Peer reviewed |
 | REGINSTER, J.-Y. (2014). Response to Dr Bolland's eLetter: Strontium and cardiovascular events. Annals of the Rheumatic Diseases, 73 (2), 9. doi:10.1136/annrheumdis-2013-204535 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Dellaert, B., Dirksen, C., Van der Weijden, T., Watson, V., Goemaere, S., Reginster, J.-Y., Roux, C., Mcgowan, B., Silke, C., Whelan, B., Diez-Perez, A., Torres, E., Papadakis, G., Rizzoli, R., Cooper, C., Pearson, G., & Boonen, A. (2014). Preferences of patients for osteoporosis drug treatment: a cross-european discrete choice experiment. Osteoporosis International, 25 (2), 227-228. Peer Reviewed verified by ORBi |
 | Ferrari, S., Adachi, J., Lippuner, K., Zapalowski, C., Miller, P., Reginster, J.-Y., Törring, O., Kendler, D., Daizadeh, N., Wang, A., Omalley, C., Libanati, C., Wagman, R., & Lewiecki, E. (2014). Further reduction in nonvertebral fracture rate is observed following 3 years of denosumab treatment: results with up to 7 years in the freedom extension. Osteoporosis International, 25 (2), 56. Peer Reviewed verified by ORBi |
 | Parsons, C., Edwards, M., Bruyère, O., Petit-Dop, F., Beliaa, P., Genant, H., Guermazi, A., Roemer, F., Zaim, S., Chapurlat, R., Reginster, J.-Y., Dennison, E., & Cooper, C. (2014). Impact of bone marrow lesion on the progression of knee osteoarthritis in the Sekoia study. Osteoporosis International, 25 (2), 142. Peer Reviewed verified by ORBi |
 | Parsons, C., Edwards, M., Eymard, F., Reginster, J.-Y., Bruyère, O., Petit-Dop, F., Richette, P., Chevalier, X., Dennison, E., & Cooper, C. (2014). Impact of components of the metabolic syndrome on progression of knee osteoarthritis in the Sekoia study. Osteoporosis International, 25 (2), 230. Peer Reviewed verified by ORBi |
 | NEUPREZ, A., François, G., KURTH, W., THIRION, T., DANIEL, C., HUSKIN, J.-P., & Reginster, J.-Y. (2014). Quality of life benefits of knee arthroplasty for osteoarthritis. Osteoporosis International, 25 (2), 40. Peer Reviewed verified by ORBi |
 | Kanis, J., Johansson, H., Odén, A., McCloskey, E., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2014). A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis: the impact of severe osteoporosis and contraindications. Osteoporosis International, 25 (2), 48-49. Peer Reviewed verified by ORBi |
 | Chevalier, X., Richette, P., Bruyère, O., Chapurlat, R., Cooper, C., & Reginster, J.-Y. (2014). Strontium ranelate decreases the number of rapid radiological progressors from the first year in SEKOIA study. Osteoarthritis and Cartilage, 22 (1), 461. Peer Reviewed verified by ORBi |
 | Eymard, F., Edwards, M., Parsons, C., Cooper, C., Petit-Dop, F., Reginster, J.-Y., Bruyère, O., Richette, P., & Chevalier, X. (2014). Impact of components of the metabolic syndrome on knee osteoarthritis progression in the SEKOIA study. Osteoarthritis and Cartilage, 22 (1), 376. Peer Reviewed verified by ORBi |
 | Bruyère, O., & Reginster, J.-Y. (2014). Monitoring of osteoporosis therapy. Best Practice and Research. Clinical Endocrinology and Metabolism, 28, 835-41. doi:10.1016/j.beem.2014.07.001 Peer Reviewed verified by ORBi |
 | Rizzoli, R., Branco, J., Brandi, M., Boonen, S., Bruyère, O., Cacoub, P., Cooper, C., Diez-Perez, A., Duder, J., Fielding, R., Harvey, N., Hiligsmann, M., Kanis, J., Petermans, J., Ringe, J., Tsouderos, Y., Weinman, J., & Reginster, J.-Y. (2014). Erratum to: Management of osteoporosis of the oldest old. Osteoporosis International, 25, 2531. doi:10.1007/s00198-014-2830-2 Peer Reviewed verified by ORBi |
 | Beaudart, C., Rizzoli, R., Bruyère, O., Reginster, J.-Y., & Biver, E. (2014). Sarcopenia: burden and challenges for public health. Archives of Public Health, 72, 45-60. doi:10.1186/2049-3258-72-45 Peer Reviewed verified by ORBi |
 | Papapoulos, S., McClung, M., Langdahl, B., Saag, K., Adami, S., Bone, H., de Villiers, T., Kiel, D., Kung, A., Kumar, P., Lim, S., Ling, X., Lippuner, K., Mautalen, C., Nakamura, T., Reginster, J.-Y., Reid, I., Rodriguez-Portales, J., Roux, C., ... Gurner, D. (2014). Safety and tolerability of odanacatib therapy in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial. Osteoporosis International, 25 (5), 604-605. Peer Reviewed verified by ORBi |
 | McClung, M., Langdahl, B., Papapoulos, S., Saag, K., Adami, S., Bone, H., de Villiers, T., Kiel, D., Kung, A., Kumar, P., Lim, S., Ling, X., Lippuner, K., Mautalen, C., Nakamura, T., Reginster, J.-Y., Reid, I., Rodriguez-Portales, J., Roux, C., ... Lombardi, A. (2014). Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial. Arthritis and Rheumatism, 66 (11), 987. Peer Reviewed verified by ORBi |
 | Beaudart, C., Buckinx, F., Rabenda, V., GILLAIN, S., Cavalier, E., Slomian, J., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). The effects of vitamin D on skeletal muscle strength, muscle mass and muscle power: a systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Endocrinology and Metabolism, 99 (11), 4336-4345. doi:10.1210/jc.2014-1742 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2014). Don't drop the guard: osteoporosis is still a fatal disease ! Medicographia, 36 (2), 139-140. Peer reviewed |
 | Hiligsmann, M., Ben Sedrine, W., Bruyère, O., Jeholet, P., Misson, V., Pire, G., & Reginster, J.-Y. (2014). Economic evaluation of an osteoporosis screening campaign: using FRAX as a prescreening tool. Osteoporosis International, 25 (2), 38-39. Peer Reviewed verified by ORBi |
 | Eymard, F., Parsons, C., Edwards, M., Petit-Dop, F., Reginster, J.-Y., Bruyère, O., Richette, P., Cooper, C., & Chevalier, X. (2014). Implication des troubles métaboliques dans la progression radiologique de la gonarthrose : analyse post-hoc issue de l'essai randomisé SEKOIA. Revue du Rhumatisme, 81 (Suppl. 1), 92. Peer Reviewed verified by ORBi |
 | Buckinx, F., Beaudart, C., Slomian, J., Maquet, D., Demonceau, M., GILLAIN, S., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). Evolution over two years of functional and motor abilities among nursing home residents. Journal of Frailty and Aging, 3 (1), 45. Peer Reviewed verified by ORBi |
 | NEUPREZ, A., Rompen, E., Crielaard, J.-M., & Reginster, J.-Y. (2014). Teriparatide Therapy for Denosumab-Induced Osteonecrosis of the Jaw in a Male Osteoporotic Patient. Calcified Tissue International, 95, 94-96. doi:10.1007/s00223-014-9858-3 Peer Reviewed verified by ORBi |
 | Appelboom, G., Yang, A. H., Christophe, B. R., Bruce, E. M., Slomian, J., Bruyère, O., Bruce, S. S., Zacharia, B. E., Reginster, J.-Y., & Sander Connolly, E. J. (2014). The promise of wearable activity sensors to define patient recovery. Journal of Clinical Neuroscience, 21, 1089-1093. doi:10.1016/j.jocn.2013.12.003 Peer Reviewed verified by ORBi |
 | GILLAIN, S., Schwartz, C., Dramé, M., Demonceau, M., Bruyère, O., Croisier, J.-L., Bruls, O., Garraux, G., Reginster, J.-Y., & Petermans, J. (2014). Validation des paramètres de marche par un système accélérométrique (Locométrix ®) à l’aide d’un système opto-électronique 3D (Coda Motion ®). Cahiers de l'Année Gérontologique, 6 (Suppl. 1), 186. Peer Reviewed verified by ORBi |
 | Beaudart, C., GILLAIN, S., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). Sarcopénie. Quoi de neuf en 2014 ? Revue Médicale de Liège, 69 (5-6), 251-257. Peer reviewed |
 | Beaudart, C., Reginster, J.-Y., Slomian, J., Buckinx, F., Locquet, M., & Bruyère, O. (2014). Prevalence of sarcopenia: the impact of different diagnostic cut-off limits. Journal of Musculoskeletal and Neuronal Interactions, 14 (4), 425-31. Peer Reviewed verified by ORBi |
 | Beaudart, C., SLANGEN, C., Buckinx, F., Slomian, J., Quabron, A., Petermans, J., GILLAIN, S., Reginster, J.-Y., & Bruyère, O. (2014). Evaluation de la prévalence de la sarcopénie selon différents outils de diagnostic. Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 12 (1), 42. Peer reviewed |
 | Beaudart, C., Buckinx, F., Slomian, J., Quabron, A., Petermans, J., GILLAIN, S., Reginster, J.-Y., & Bruyère, O. (2014). Prevalence of sarcopenia according to different diagnostic tools. Journal of Frailty and Aging, 3 (1), 43. Peer Reviewed verified by ORBi |
 | Beaudart, C., Reginster, J.-Y., Slomian, J., Buckinx, F., Quabron, A., Dardenne, N., & Bruyère, O. (2014). Prévalence de la sarcopénie : impact de l'utilisation de différentes valeurs seuils de diagnostic. Cahiers de l'Année Gérontologique, 6 (Suppl. 1), 126. Peer Reviewed verified by ORBi |
 | Buckinx, F., Reginster, J.-Y., Petermans, J., Beaudart, C., & Bruyère, O. (2014). Effets de la vibrotonie corporelle totale sur le risque de chute de la personne âgée: Mise au point. Ortho-Rhumato, 12 (6), 6-9. |
 | Bruyère, O., Cavalier, E., & Reginster, J.-Y. (2014). La prévalence du déficit en vitamine D en Belgique et en Europe chez les femmes âgées. Ortho-Rhumato, 12 (4), 3. |
 | Appelboom, G., LoPresti, M., Reginster, J.-Y., Sander Connolly, E., & Dumont, E. P. L. (2014). The quantified patient: a patient participatory culture. Current Medical Research and Opinion, 1-3. doi:10.1185/03007995.2014.954032 Peer Reviewed verified by ORBi |
 | Parsons, C., Edwards, M., Bruyère, O., Belissa, P., Genant, H., Guermazi, A., Roemer, F., Zaim, S., Reginster, J.-Y., Dennison, E., & Cooper, C. (2014). Impact of bone marrow lesion on the progression of knee osteoarthritis in the SEKOIA study. Rheumatology, 53 (1), 130. Peer Reviewed verified by ORBi |
 | Slomian, J., Reginster, J.-Y., Ethgen, O., Appelboom, G., & Bruyère, O. (2014). Opportunity and challenges of eHealth and mHealth for patients and caregivers. Austin Journal of Public Health and Epidemiology, 1 (2), 3-5. Peer reviewed |
 | Reginster, J.-Y., NEUPREZ, A., Dardenne, N., Beaudart, C., & Bruyère, O. (2014). Efficacy and safety of currently marketed anti-osteoporosis medications. Best Practice and Research. Clinical Endocrinology and Metabolism, 28, 809-34. doi:10.1016/j.beem.2014.09.003 Peer Reviewed verified by ORBi |
 | Buckinx, F., Beaudart, C., Maquet, D., Demonceau, M., Crielaard, J.-M., Reginster, J.-Y., & Bruyère, O. (2014). Evaluation of the impact of 6-month training by whole body vibration on the risk of falls among nursing home residents, observed over a 12-month period: a single blind, randomized controlled trial. Aging Clinical and Experimental Research, 26 (4), 369-376. doi:10.1007/s40520-014-0197-z Peer Reviewed verified by ORBi |
 | DELANAYE, P., KRZESINSKI, J.-M., Warling, X., Moonen, M., Smelten, N., Médart, M., Bruyère, O., REGINSTER, J.-Y., Pottel, H., & CAVALIER, E. (2014). Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron. Clinical Practice, 128, 127-134. doi:10.1159/000366449 Peer Reviewed verified by ORBi |
 | Rizzoli, R., Dawson-Hughes, B., Kaufman, J.-M., Fardellone, P., Brandi, M. L., Vellas, B., COLLETTE, J., & Reginster, J.-Y. (2014). Correction of vitamin D insufficiency with combined strontium ranelate and vitamin D3 in osteoporotic patients. European Journal of Endocrinology, 170 (3), 441-50. doi:10.1530/EJE-13-0775 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Dellaert, B. G., Dirksen, C. D., van der Weijden, T., Goemaere, S., Reginster, J.-Y., Watson, V., & Boonen, A. (2014). Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment. Arthritis Research and Therapy, 16 (1), 36. doi:10.1186/ar4465 Peer Reviewed verified by ORBi |
 | McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., Katz, L., Maddox, J., Yang, Y.-C., Libanati, C., & Bone, H. G. (2014). Romosozumab in Postmenopausal Women with Low Bone Mineral Density. New England Journal of Medicine, 370, 412-420. doi:10.1056/NEJMoa1305224 Peer Reviewed verified by ORBi |
 | Buckinx, F., Beaudart, C., Slomian, J., Maquet, D., Demonceau, M., GILLAIN, S., PETERMANS, J., Reginster, J.-Y., & Bruyère, O. (2014). Risk factors for falls among elderly nursing home residents: a 2-year prospective study. Osteoporosis International, 25 (2), 36-37. Peer Reviewed verified by ORBi |
 | Slomian, J., Streel, S., Appleboom, G., Beaudart, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (2014). Could internet use be promising in health prevention and promotion in menopausal women ? A preliminary report. Osteoporosis International, 25 (2), 309. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2014). An algorithm guideline for the management of knee osteoarthritis in Europe: A report from a taskforce of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Osteoporosis International, 25 (2), 66. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Cooper, C., Guillemin, F., Hochberg, M. C., Tugwell, P., Arden, N., Berenbaum, F., Boers, M., Boonen, A., Branco, J. C., Maria-Luisa, B., Bruyère, O., Gasparik, A., Kanis, J. A., Kvien, T. K., Martel-Pelletier, J., Pelletier, J.-P., Pinedo-Villanueva, R., Pinto, D., ... Reginster, J.-Y. (2014). A reference case for economic evaluations in osteoarthritis: An expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 44, 271-282. doi:10.1016/j.semarthrit.2014.06.005 Peer Reviewed verified by ORBi |
 | Buckinx, F., Beaudart, C., Slomian, J., Maquet, D., Demonceau, M., GILLAIN, S., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). Evolution sur deux ans des capacités fonctionnelles et motrices de sujets âgés résidant en maison de repos. Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 12 (1), 57-58. Peer reviewed |
 | Reginster, J.-Y. (2014). Algorithm for the symptomatic and structural treatment of osteoarthritis. Osteoporosis International, 25 (5), 564. Peer Reviewed verified by ORBi |
 | Langdahl, B., Teglbjaerg, C., Ho, P., Chapurlat, R., Czerwinski, E., Kendler, D., Reginster, J.-Y., Kivitz, A., Lewiecki, M., Miller, P., Bolognese, M., McClung, M., Bone, H., Ljunggren, O., Abrahamsen, B., Gruntmanis, U., Yang, Y., Wagman, R., Siddhanti, S., & Orwoll, E. (2014). Denosumab for the treatment of men with low bone mineral density: 24-month results from the Adamo Trial. Endocrine Reviews, 35 (3), 22-1. Peer Reviewed verified by ORBi |
 | Delvaux, F., Rochcongar, P., Bruyère, O., Bourlet, G., DANIEL, C., Diverse, P., Reginster, J.-Y., & Croisier, J.-L. (2014). Return-to-play criteria after hamstring injury: Actual medicine practice in professional soccer teams. Journal of Sports Science and Medicine, 13, 721-723. Peer Reviewed verified by ORBi |
 | Bruyère, O., Slomian, J., Beaudart, C., Buckinx, F., CAVALIER, E., GILLAIN, S., PETERMANS, J., & Reginster, J.-Y. (2014). Prevalence of vitamin D inadequacy in European women aged over 80 years. Osteoporosis International, 25 (2), 196. Peer Reviewed verified by ORBi |
 | Donneau, A.-F., & Reginster, J.-Y. (2014). Cardiovascular safety of strontium ranelate: real-life assessment in clinical practice. Osteoporosis International, 25, 397-398. doi:10.1007/s00198-013-2583-3 Peer Reviewed verified by ORBi |
 | Douxfils, J., Buckinx, F., Mullier, F., Minet, V., Rabenda, V., Reginster, J.-Y., Hainaut, P., Bruyère, O., & Dogne, J.-M. (2014). Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of the American Heart Association, 3 (3), 000515. doi:10.1161/JAHA.113.000515 Peer Reviewed verified by ORBi |
 | Ellis, A. G., Reginster, J.-Y., Luo, X., Bushmakin, A. G., Williams, R., Sutradhar, S., Mirkin, S., & Jansen, J. P. (2014). Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women. Current Medical Research and Opinion, 30 (8), 1617-1626. doi:10.1185/03007995.2014.908279 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Kaufman, J., & Gangjii, V. (2014). Preference for and acceptability of two formulations of a dietary supplement containing calcium plus vitamin D3: a randomized, open-label, crossover trial in adult patients with calcium and vitamin D deficiencies. Current Therapeutic Research, 66 (1), 23-34. Peer Reviewed verified by ORBi |
 | Beaudart, C., Buckinx, F., Rabenda, V., GILLAIN, S., CAVALIER, E., Slomian, J., PETERMANS, J., Reginster, J.-Y., & Bruyère, O. (2014). The effects of vitamin D on skeletal muscle strength, muscle mass and muscle power: a meta-analysis of randomized controlled trials. Osteoporosis International, 25 (2), 46. Peer Reviewed verified by ORBi |
 | Buckinx, F., Beaudart, C., Slomian, J., Maquet, D., Demonceau, M., GILLAIN, S., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). Evolution over two years of functional and motor abilities among nursing home residents. Osteoporosis International, 25 (2), 121. Peer Reviewed verified by ORBi |
 | Kanis, J., Rizzoli, R., Cooper, C., & Reginster, J.-Y. (2014). Challenges for the development of bone forming agents in Europe: introduction. Osteoporosis International, 25 (2), 66-67. Peer Reviewed verified by ORBi |
 | Miller, P., Recker, R., Harris, S., Silverman, S., Felsenberg, D., Reginster, J.-Y., Day, B., Barr, C., & Masanauskaite, D. (2014). Long-term fracture rates seen with continued ibandronate treatment : pooled analysis of DIVA and MOBILE long-term extension studies. Osteoporosis International, 25 (1), 349-357. doi:10.1007/s00198-013-2518-z Peer Reviewed verified by ORBi |
 | Buckinx, F., Slomian, J., Maquet, D., Demonceau, M., GILLAIN, S., PETERMANS, J., Reginster, J.-Y., & Bruyère, O. (2014). Prognostic factors of death among nursing homes residents followed prospectively for a period of 2 years. Osteoporosis International, 25 (2), 121-122. Peer Reviewed verified by ORBi |
 | Buckinx, F., Beaudart, C., Slomian, J., Maquet, D., Demonceau, M., GILLAIN, S., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). Prognostic factors of death among nursing homes residents followed prospectively for a period of 2 years. Journal of Frailty and Aging, 3 (1), 40. Peer Reviewed verified by ORBi |
 | Edwards, M., Parsons, C., Eymard, F., Reginster, J.-Y., Bruyère, O., Petit-Dop, F., Richette, P., Chavalier, X., Dennison, E., & Cooper, C. (2014). Impact of components of the metabolic syndrome on progression of knee osteoarthritis in the SEKOIA study. Rheumatology, 53 (1), 31. Peer Reviewed verified by ORBi |
 | Bruyère, O., & Reginster, J.-Y. (2014). Vitamine D et sujet âgé. Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 12 (1), 5-6. Peer reviewed |
 | Beaudart, C., Buckinx, F., Rabenda, V., CAVALIER, E., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). The effects of vitamin D on skeletal muscle strength, muscle mass and muscle power: a meta-analysis of randomized controlled trials. Journal of Frailty and Aging, 3 (1), 27. Peer Reviewed verified by ORBi |
 | Beaudart, C., Reginster, J.-Y., Slomian, J., Buckinx, F., & Bruyère, O. (2014). Association between lean mass and hip bone mineral density. Arthritis and Rheumatism, 66 (11), 95. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2014). Préface. Best Practice and Research. Clinical Endocrinology and Metabolism, 28, 765. doi:10.1016/j.beem.2014.09.005 Peer Reviewed verified by ORBi |
 | Bruyère, O., Demoulin, M., Beaudart, C., Hill, J. C., Maquet, D., Genevay, S., Mahieu, G., REGINSTER, J.-Y., Crielaard, J.-M., & Demoulin, C. (2014). Validity and Reliability of the French Version of the STarT Back Screening Tool for Patients With Low Back Pain. Spine, 39 (2), 123-E128. doi:10.1097/BRS.0000000000000062 Peer Reviewed verified by ORBi |
 | Buckinx, F., Reginster, J.-Y., Cavalier, E., Slomian, J., Beaudart, C., & Bruyère, O. (2014). Evaluation du nombre de résidents en maison de retraite médicalisée bénéficiant d'une supplémentation en vitamine D. Cahiers de l'Année Gérontologique, 6 (Suppl. 1), 68. Peer Reviewed verified by ORBi |
 | Appelboom, G., Camacho, E., Abraham, M., Bruce, S., Dumont, E., Zacharia, B., D'Amico, R., Slomian, J., Reginster, J.-Y., Bruyère, O., & Connolly, E. (2014). Smart wearable body sensors for patient self-assessment and monitoring. Archives of Public Health, 72, 28-44. doi:10.1186/2049-3258-72-28 Peer Reviewed verified by ORBi |
 | Bruyère, O., Slomian, J., Beaudart, C., Buckinx, F., Cavalier, E., GILLAIN, S., Petermans, J., & Reginster, J.-Y. (2014). Prevalence of vitamin D inadequacy in European women aged over 80 years. Archives of Gerontology and Geriatrics, 59, 78-82. doi:10.1016/j.archger.2014.03.010 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2014). L'ostéoporose demeure une maladie fatale : la vigilance reste de mise. Medicographia, 36 (2), 141-142. Peer reviewed |
 | Cortet, B., Rizzoli, R., & Reginster, J.-Y. (2014). Ranélate de strontium : diminution du risque cardiaque observé dans le traitement de l'ostéoporose sévère par l'ajout de nouvelles contre-indications cardiovasculaires [Poster presentation]. 27ème Congrès Français de Rhumatologie, Paris, France. |
 | Reginster, J.-Y., NEUPREZ, A., LECART, M.-P., Sarlet, N., Distèche, S., & Bruyère, O. (2014). Traitement de l'osteoporose post-menopausique: quoi de neuf en 2014? Revue Médicale de Liège, 69 (7-8), 441-53. Peer reviewed |
 | Kanis, J. A., McCloskey, E., Branco, J., Brandi, M.-L., Dennison, E., Devogelaer, J.-P., Ferrari, S., Kaufman, J.-M., Papapoulos, S., Reginster, J.-Y., & Rizzoli, R. (2014). Goal-directed treatment of osteoporosis in Europe. Osteoporosis International, 25 (11), 2533-2543. doi:10.1007/s00198-014-2787-1 Peer Reviewed verified by ORBi |
 | Lotz, M., Martel-Pelletier, J., Christiansen, C., Brandi, M.-L., Bruyère, O., Chapurlat, R., Collette, J., Cooper, C., Giacovelli, G., Kanis, J. A., Karsdal, M. A., Kraus, V., Lems, W. F., Meulenbelt, I., Pelletier, J.-P., Raynauld, J.-P., Reiter-Niesert, S., Rizzoli, R., Sandell, L. J., ... Reginster, J.-Y. (2014). Republished: Value of biomarkers in osteoarthritis: current status and perspectives. Postgraduate Medical Journal, 90 (1061), 171-8. Peer Reviewed verified by ORBi |
Arden, N., Blanco, F., Cooper, C., Guermazi, A., Hayashi, D., Hunter, D., Javaid, M., Rannou, F., Roemer, F., & Reginster, J.-Y. (2014). Atlas of osteoarthritis. Springer Verlag. |
 | Beaudart, C., Reginster, J.-Y., Slomian, J., Buckinx, F., & Bruyère, O. (2014). Association entre la masse musculaire totale et la densité minérale osseuse de la hanche. Cahiers de l'Année Gérontologique, 6 (Suppl. 1), 125-6. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., NEUPREZ, A., Beaudart, C., Buckinx, F., Slomian, J., Distèche, S., & Bruyère, O. (2014). Bone forming agents for the management of osteoporosis. Panminerva Medica, 56 (2), 97-114. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., NEUPREZ, A., Beaudart, C., LECART, M.-P., Sarlet, N., Bernard, D., Distèche, S., & Bruyère, O. (2014). Antiresorptive Drugs Beyond Bisphosphonates and Selective Oestrogen Receptor Modulators for the Management of Postmenopausal Osteoporosis. Drugs and Aging, 31, 413-424. doi:10.1007/s40266-014-0179-z Peer Reviewed verified by ORBi |
 | Beaudart, C., Buckinx, F., Slomian, J., Quabron, A., PETERMANS, J., Reginster, J.-Y., Bruyère, O., & GILLAIN, S. (2014). Prevalence of sarcopenia according to different diagnostic tools. Osteoporosis International, 25 (2), 115. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Ferrari, S., & Hadji, P. (2014). Current challenges in the treatment of osteoporosis: an opportunity for bazedoxifene. Current Medical Research and Opinion, 30 (6), 1165-1176. doi:10.1185/03007995.2014.890927 Peer Reviewed verified by ORBi |
 | Appelboom, G., Sussman, E. S., Raphael, P., Julliere, Y., Reginster, J.-Y., & Connolly, E. S. (2014). A Critical Assessment of Approaches to Outpatient Monitoring. Current Medical Research and Opinion, 1-2. doi:10.1185/03007995.2014.904774 Peer Reviewed verified by ORBi |
 | Kanis, J. A., Rizzoli, R., Cooper, C., & Reginster, J.-Y. (2014). Challenges for the Development of Bone-Forming Agents in Europe. Calcified Tissue International, 94, 469-473. doi:10.1007/s00223-014-9844-9 Peer Reviewed verified by ORBi |
 | NEUPREZ, A., François, G., KURTH, W., THIRION, T., DANIEL, C., HUSKIN, J.-P., Gillet, P., & Reginster, J.-Y. (2014). Radiological and clinical profile of osteoarthritis patients undergoing total knee replacement surgery. Osteoporosis International, 25 (2), 358. Peer Reviewed verified by ORBi |
 | Ellis, A., Reginster, J.-Y., Luo, X., Cappelleri, J., Chines, A., Sutradhar, S., & Jansen, J. (2014). Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis. Value in Health, 17, 424-432. doi:10.1016/j.jval.2014.01.008 Peer Reviewed verified by ORBi |
 | Slomian, J., Appelboom, G., Ethgen, O., Reginster, J.-Y., & Bruyère, O. (2014). Can new information and communication technologies help in the management of osteoporosis ? Women's Health, 10 (3), 229-232. doi:10.2217/whe.14.15 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2014). Cardiac concerns associated with strontium ranelate. Expert Opinion on Drug Safety, 13 (9), 1-5. doi:10.1517/14740338.2014.939169 Peer Reviewed verified by ORBi |
 | Roux, C., Binkley, N., Boonen, S., Kiel, D. P., Ralston, S. H., Reginster, J.-Y., Pong, A., Rosenberg, E., & Santora, A. (2014). Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis. Calcified Tissue International, 94 (2), 153-7. doi:10.1007/s00223-013-9763-1 Peer Reviewed verified by ORBi |
 | Buckinx, F., Beaudart, C., Slomian, J., Maquet, D., Demonceau, M., GILLAIN, S., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). Facteurs pronostiques de décès chez des sujets résidant en maison de repos suivis d'une manière prospective pendant une période de 2 ans. Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 12 (1), 73-74. Peer reviewed |
 | Beaudart, C., Buckinx, F., Rabenda, V., GILLAIN, S., CAVALIER, E., Slomian, J., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2014). Les effets d'une supplémentation en vitamine D sur la force, la masse et la puissance musculaire : une méta-analyse d'essais randomisés contrôlés. Gériatrie et Psychologie Neuropsychiatrie du Vieillissement, 12 (1), 73. Peer reviewed |
 | Rizzoli, R., Stevenson, J., Bauer, J., Van Loon, L., Walrand, S., Kanis, J., Cooper, C., Brandi, M., Diez-Perez, A., & Reginster, J.-Y. (2014). The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women : A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Maturitas, 79, 122-132. doi:10.1016/j.maturitas.2014.07.005 Peer Reviewed verified by ORBi |
 | Lewieck, E., Papapoulos, S., Lippuner, K., Roux, C., Lin, C., Kendler, D., Brandi, M., Czerwinski, E., Franek, E., Lakatos, P., Minisola, S., Reginster, J.-Y., Jensen, S., Kaizadeh, N., Wang, A., Gavin, M., Wagman, R., & Bone, H. (2014). Effect of denosumab treatment in postmenopausal women with osteoporosis: eight-year results from the freedom extension, phase 3 clinical trial. Endocrine Reviews, 35 (3), 22-1. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2014). Introduction: historical and current perspectives on osteoarthritis. In N. Arden, F. Blanco, C. Cooperr, A. Guermazi, D. Hayashi, D. Hunter, M. Jawaid, F. Rannou, F. Roemer, ... J.-Y. Reginster (Eds.), Atlas of Osteoarthritis (pp. 11-19). Springer Verlag. Peer reviewed |
 | Bruyère, O., Cooper, C., Pelletier, J., Branco, J., Brandi, L., Guillemin, F., Hochberg, M., Kanis, J., Kvien, T., Martel-Pelletier, J., Rizzoli, R., Silverman, S., & Reginster, J.-Y. (2014). An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 44, 253-263. doi:10.1016/j.semarthrit.2014.05.014 Peer Reviewed verified by ORBi |
 | McClung, M., Langdahl, B., Papapoulos, S., Saag, K., Adami, S., Bone, H., de Villiers, T., Kiel, D., Kung, A., Kumar, P., Lim, S., Ling, X., Lippuner, K., Mautalen, C., Nakamura, T., Reginster, J.-Y., Reid, I., Rodriguez-Portales, J., Roux, C., ... Lombardi, A. (2014). Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial. Osteoporosis International, 25 (5), 573-575. Peer Reviewed verified by ORBi |
 | Ferrari, S., Libanati, C., Lin, C., Adami, S., Brown, J., Cosman, F., Czerwinski, E., de Gregorio, L., Malouf, J., Reginster, J.-Y., Daizadeh, N., Wang, A., Wagman, R., Lewiecki, E., & Cummings, S. (2014). Percentage of women achieving non-osteoporotic BMD T-scores at the spine and hip over 8 years of denosumab treatment. Arthritis and Rheumatism, 66 (11), 986-S987. Peer Reviewed verified by ORBi |
 | Marcucci, G., Zimran, A., Bembi, B., Kanis, J., Reginster, J.-Y., Rizzoli, R., Cooper, C., & Brandi, M. L. (2014). Gaucher Disease and Bone Manifestations. Calcified Tissue International, 95 (6), 477-494. doi:10.1007/s00223-014-9923-y Peer Reviewed verified by ORBi |
 | LoPresti, M., Appelboom, G., Bruyère, O., Reginster, J.-Y., Klug, E., & Connolly Jr, E. S. (2014). Patient engagement in clinical research through mobile technology. Clinical Practice, 11 (6), 549-51. doi:10.2217/CPR.14.68 Peer Reviewed verified by ORBi |
 | Slomian, J., GASPARD, U., Reginster, J.-Y., Streel, S., Beaudart, C., Appelboom, G., Buckinx, F., & Bruyère, O. (2014). Des interventions de prévention ou de promotion de la santé utilisant Internet pourraient-elles être prometteuses chez des femmes aux alentours de la ménopause ? Cahiers de l'Année Gérontologique, 6 (Suppl. 1), 205. Peer Reviewed verified by ORBi |
 | Slomian, J., Streel, S., Appleboom, G., Beaudart, C., Buckinx, F., Reginster, J.-Y., & Bruyère, O. (2014). Internet as a tool for health: survey on the interest and the use of the internet among subjects from an osteoporosis centre - A preliminary report. Osteoporosis International, 25 (2), 64. Peer Reviewed verified by ORBi |
 | Beaudart, C., Reginster, J.-Y., Cavalier, E., & Bruyère, O. (2014). Les effets d'une supplémentation en vitamine D sur la fonction musculaire. Ortho-Rhumato, 12 (5), 33-37. |
 | GILLAIN, S., ELBOUZ, L., Beaudart, C., Bruyère, O., Reginster, J.-Y., & PETERMANS, J. (2014). Les chutes de la personne âgée. Revue Médicale de Liège, 69 (5-6), 258-264. Peer reviewed |
 | NEUPREZ, A., Coste, S., Rompen, E., Crielaard, J.-M., & REGINSTER, J.-Y. (2014). Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab. Osteoporosis International, 25, 393-395. doi:10.1007/s00198-013-2437-z Peer Reviewed verified by ORBi |
 | Rizzoli, R., Branco, J., Brandi, M.-L., Boonen, S., Bruyère, O., Cacoub, P., Cooper, C., Diez-Perez, A., Duder, J., Fielding, R. A., Harvey, N. C., Hiligsmann, M., Kanis, J. A., Petermans, J., Ringe, J. D., Tsouderos, Y., Weinman, J., & Reginster, J.-Y. (2014). Management of osteoporosis of the oldest old. Osteoporosis International, 25, 2507-2529. doi:10.1007/s00198-014-2755-9 Peer Reviewed verified by ORBi |
 | Bruyère, O., CAVALIER, E., Souberbielle, J.-C., Bischoff-Ferrari, H., Beaudart, C., Buckinx, F., Reginster, J.-Y., & Rizzoli, R. (2014). Effects of vitamin D in the elderly population : current status and perspectives. Archives of Public Health, 72, 32-42. doi:10.1186/2049-3258-72-32 Peer Reviewed verified by ORBi |
 | Manzambi Kuwekita, J., Bruyère, O., REGINSTER, J.-Y., Buhendwa, E., Bokanga, R., & Mwanyimi, P. (19 December 2013). Les acteurs non étatiques jouent un rôle déterminant dans le fonctionnement des services publics en territoires périurbains [Poster presentation]. Territoires périurbains: développement, enjeux et perspectives dans les pays du Sud, Gembloux, Belgium. |
 | Manzambi Kuwekita, J., Mbadu Kivuidi, V., Bruyère, O., & Reginster, J.-Y. (19 December 2013). Le tradipraticien est un acteur crédible dans l'offre des soins en territoire périurbain: Résultats d'une étude menée dans la commune de Kisenso à Kinshasa, Congo [Paper presentation]. Colloque Territoires périurbains: Développement, Enjeux et Perspectives dans les Pays du Sud, Gembloux, Belgium. |
 | Manzambi Kuwekita, J., Guillaume, M., Balula Semutsari, M.-P., Tshiama Kabongo, E., Mayamba Kilela, J., Bruyère, O., & Reginster, J.-Y. (December 2013). Étude des conditions de vie et d’accessibilité aux soins de santé de qualité des populations en situation de précarité, dans la zone de sante de Bandalungwa à Kinshasa (Congo) grâce à la micro-assurance santé en 2008. Journal d’Épidémiologie et de Santé Publique, 12, 47-61. Peer reviewed |
 | Beaudart, C., Buckinx, F., Rabenda, V., GILLAIN, S., CAVALIER, E., Slomian, J., PETERMANS, J., Reginster, J.-Y., & Bruyère, O. (28 November 2013). Les effets d’une supplémentation en vitamine D sur la force musculaire : une méta-analyse d’essais randomisés contrôlés [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Bruxelles, Belgium. |
 | Buckinx, F., Beaudart, C., Maquet, D., Demonceau, M., CRIELAARD, J.-M., Reginster, J.-Y., & Bruyère, O. (28 November 2013). Etude de l'impact d'un entraînement de 6 mois par vibrothérapie sur le risque de chute, observé pendant une durée d'un an, chez les patients résidant en maison de repos. Etude randomisée contrôlée menée en simple aveugle [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Bruxelles, Belgium. |
 | Manzambi Kuwekita, J., Gosset, C., Guillaume, M., Nsita Zaya Nsita, B., Tshefu Pongo, G., Eloko Eya Matangelo, G., Balula Semutsari, M.-P., Tshiama Kabongo, E., Bruyère, O., & REGINSTER, J.-Y. (30 September 2013). Micro-crédit, Augmentation du pouvoir d’achat et Amélioration des conditions de vie des populations précaires en milieu urbain africain : Résultats d’une expérience menée dans la zone de santé de Bandalungwa à Kinshasa, Congo. Psychologie et Société Nouvelle, XII (3), 3-14. Peer reviewed |
 | Bruyère, O., Slomian, J., Beaudart, C., Buckinx, F., Cavalier, E., GILLAIN, S., Petermans, J., & Reginster, J.-Y. (September 2013). Importance du déficit en vitamine D chez les femmes françaises ostéoporotiques et ostéopéniques âgées de plus de 80 ans. Cahiers de l'Année Gérontologique, 5 (1-2), 75. Peer Reviewed verified by ORBi |
 | Buckinx, F., Beaudart, C., Demonceau, M., Maquet, D., Crielaard, J.-M., Reginster, J.-Y., & Bruyère, O. (September 2013). Evaluation de l'impact d'un entraînement de six mois par vibrotonie corporelle sur le risque de chute des patients résidant en maison de repos, observé pendant une période de 12 mois. Cahiers de l'Année Gérontologique, 5 (1-2), 119-120. Peer Reviewed verified by ORBi |
 | Beaudart, C., Buckinx, F., Maquet, D., Crielaard, J.-M., Reginster, J.-Y., & Bruyère, O. (September 2013). Caractéristiques cliniques des sujets répondeurs à la vibrotonie corporelle totale. Cahiers de l'Année Gérontologique, 5 (1-2), 118-119. Peer Reviewed verified by ORBi |
 | Croisier, J.-L., Rochcongar, P., Bruyère, O., Reginster, J.-Y., Bourlet, G., Diverse, P., DANIEL, C., & Delvaux, F. (September 2013). Critères de retour sur le terrain après plastie LCA chez le footballeur professionnel. European Journal of Sports Medicine, 1 (1). Peer Reviewed verified by ORBi |
 | Beaudart, C., Buckinx, F., Rabenda, V., GILLAIN, S., CAVALIER, E., Petermans, J., Reginster, J.-Y., & Bruyère, O. (September 2013). Les effets d'une supplémentation en vitamine D sur la force musculaire : une méta-analyse d'essais randomisés contrôlés. Cahiers de l'Année Gérontologique, 5 (1-2), 38. Peer Reviewed verified by ORBi |
 | Bruyère, O., Hiligsmann, M., Zegels, B., NEUPREZ, A., & Reginster, J.-Y. (September 2013). Risk of hip fracture in community-dwelling and institutionalized osteoporotic patients: A 3-year study. International Journal of Gerontology, 7 (3), 167-70. doi:10.1016/j.ijge.2012.11.015 Peer Reviewed verified by ORBi |
 | Rizzoli, R., Reginster, J.-Y., Arnal, J.-F., Bautmans, I., Beaudart, C., Bischoff-Ferrari, H., Biver, E., Boonen, S., Brandi, M.-L., Chines, A., Cooper, C., Epstein, S., Fielding, R. A., Goodpaster, B., Kanis, J. A., Kaufman, J.-M., Laslop, A., Malafarina, V., Rodriguez Mañas, L., ... Bruyère, O. (July 2013). Quality of life in sarcopenia and frailty. Calcified Tissue International, 93, 101-120. doi:10.1007/s00223-013-9758-y Peer Reviewed verified by ORBi |
 | Bruyère, O., Beaudart, C., Buckinx, F., Reginster, J.-Y., Maquet, D., & Mourey, F. (June 2013). Effets de la Whole body vibration sur le risque de chute de la personne âgée : une mise au point. Kinésithérapie Scientifique, 544, 55-58. Peer reviewed |
 | Cooper, C., Adachi, J. D., Bardin, T., Berenbaum, F., Flamion, B., Jonsson, H., Kanis, J. A., Pelousse, F., Lems, W. F., Pelletier, J.-P., Martel-Pelletier, J., Reiter, S., Reginster, J.-Y., Rizzoli, R., & Bruyère, O. (June 2013). How to define responders in osteoarthritis. Current Medical Research and Opinion, 29 (6), 719-29. doi:10.1185/03007995.2013.792793 Peer Reviewed verified by ORBi |
 | Delvaux, F., Rochcongar, P., Bruyère, O., Bourlet, G., DANIEL, C., Diverse, P., Reginster, J.-Y., & Croisier, J.-L. (25 April 2013). Return-To-Play criteria after hamstring injury: actual medicine practice in professional soccer [Poster presentation]. 3rd congress of the European College of Sport and Exercise Physicians, Frankfurt am Main, Germany. Peer reviewed |
 | Reginster, J.-Y., Pelousse, F., & Bruyère, O. (April 2013). Safety concerns with the long-term management of osteoporosis. Expert Opinion on Drug Safety, 12 (4), 507-22. doi:10.1517/14740338.2013.793669 Peer Reviewed verified by ORBi |
 | Bruyère, O., Detalle, A.-S., Demonceau, M., Beaudart, C., Croisier, J.-L., Crielaard, J.-M., Reginster, J.-Y., & Maquet, D. (April 2013). Quantitative gait assessment using an accelerometer technology as a predictive tool of falls among nursing home residents: a 6-month prospective study. Osteoporosis International, 24 (Suppl.1), 210. Peer Reviewed verified by ORBi |
 | Beaudart, C., Buckinx, F., Maquet, D., Crielaard, J.-M., Reginster, J.-Y., & Bruyère, O. (April 2013). Clinical characteristics of patients responsive to whole body vibration. Osteoporosis International, 24 (Suppl.1), 243. Peer Reviewed verified by ORBi |
 | Lotz, M., Martel-Pelletier, J., Christiansen, C., Berenbaum, F., Brandi, M. L., Bruyère, O., Chapurlat, R., COLLETTE, J., Cooper, C., Heinegard, D., Kanis, J. A., Kraus, V., Laslop, A., Lems, W., Lohmander, S., Meulenbelt, I., Pelletier, J.-P., Raynauld, J.-P., Reiter, S., ... Reginster, J.-Y. (April 2013). What is the value of biomarkers for drug development in osteoarthritis? Osteoporosis International, 24 (Suppl.1), 77-78. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Cooper, C., Arden, N., Boers, M., Branco, J., Brandi, M. L., Bruyère, O., Guillemin, F., Hochberg, M., Hunter, D., Kanis, J. A., Kvien, T., Laslop, A., Petit-Dop, F., Pelletier, J.-P., Pinto, D., Reiter, S., Rizzoli, R., Rovati, L. C., ... Reginster, J.-Y. (April 2013). Health economics in osteoarthritis. Osteoporosis International, 24 (Suppl.1), 79-80. Peer Reviewed verified by ORBi |
 | Pelletier, J.-P., Peterfy, C., Brandi, M. L., Bruyère, O., Chapurlat, R., Cicuttini, F., Conaghan, P., Doherty, M., Genant, H. K., Guermazi, A., Hochberg, M., Hunter, D., Kanis, J. A., Kloppenburg, M., Laredo, J., Martel-Pelletier, J., McAlindon, T., Nevitt, M., Raynauld, J.-P., ... Cooper, C. (April 2013). What is the predictive value of MRI for the occurrence of hard clinical endpoints in knee osteoarthritis? Osteoporosis International, 24 (Suppl.1), 84-85. Peer Reviewed verified by ORBi |
 | Bruyère, O., Fossi, M., Zegels, B., LEONORI, L., Hiligsmann, M., Neuprez, A., & Reginster, J.-Y. (April 2013). Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria. Rheumatology International, 33 (4), 973-8. doi:10.1007/s00296-012-2460-y Peer Reviewed verified by ORBi |
 | Rizzoli, R., Reginster, J.-Y., Arnal, J.-F., Bautmans, I., Bischoff-Ferrari, H., Biver, E., Boonen, S., Brandi, M. L., Chines, A., Cooper, C., Dahlin-Ivanoff, S., Epstein, S., Kanis, J. A., Fielding, R. A., Goodpaster, B., Laslop, A., Malafarina, V., Rodriguez Mañas, L., Mitlak, B., ... Bruyère, O. (April 2013). Quality of life in sarcopenia and frailty. Osteoporosis International, 24 (Suppl.1), 76-77. Peer Reviewed verified by ORBi |
 | NEUPREZ, A., François, G., Delcour, J., Fatemi, F., Bruyère, O., Gosset, C., Mancuso, C., Gillet, P., & Reginster, J.-Y. (April 2013). Validity of the French hip and knee replacement expectations surveys. Osteoporosis International, 24 (Suppl.1), 374. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Ben Sedrine, W., Rabenda, V., Bruyère, O., & Reginster, J.-Y. (April 2013). Cost-effectiveness of vitamin D and calcium supplementation in the treatment of postmenopausal women. Osteoporosis International, 24 (Suppl.1), 198. Peer Reviewed verified by ORBi |
 | DEROISY, R., Reginster, J.-Y., & Bruyère, O. (April 2013). Reproducibility of joint space width assessment when external calibration on the radiograph is missing. Osteoporosis International, 24 (Suppl.1), 379. Peer Reviewed verified by ORBi |
 | Bruyère, O., Richette, P., Bellamy, N., Brown, J., Chapurlat, R., Chevalier, X., Czerwinski, E., Devogelaer, J., March, L., Pavelka, K., Punzi, L., Cooper, C., & Reginster, J.-Y. (April 2013). Strontium ranelate improves osteoarthritis symptoms compared to placebo in patients with knee OA: The SEKOIA study. Osteoporosis International, 24 (Suppl.1), 49-51. Peer Reviewed verified by ORBi |
 | Beaudart, C., Buckinx, F., Demonceau, M., Maquet, D., Crielaard, J.-M., Reginster, J.-Y., & Bruyère, O. (April 2013). Evaluation of the impact of a 6-month training by whole body vibration on the risk of falls among nursing home residents. Osteoporosis International, 24 (Suppl.1), 246-247. Peer Reviewed verified by ORBi |
 | Zegels, B., LEONORI, L., Crozes, P., Uebelhart, D., Bruyère, O., & Reginster, J.-Y. (April 2013). Equivalence of a single dose (1200mg) compared to a 3-time a day dose (400mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis: Results of a randomized double blind placebo controlled study. Osteoporosis International, 24 (Suppl.1), 383. Peer Reviewed verified by ORBi |
 | Bruyère, O., Nicolet, D., Compère, S., Rabenda, V., Jeholet, P., Zegels, B., Maassen, P., Pire, G., & Reginster, J.-Y. (April 2013). Perception, knowledge, and use by general practitioners of Belgium of a new WHO tool (FRAX ) to assess the 10-year probability of fracture. Rheumatology International, 33 (4), 979-83. doi:10.1007/s00296-012-2461-x Peer Reviewed verified by ORBi |
 | Bruyère, O., Cooper, C., Pavelka, K., Rabenda, V., Buckinx, F., Beaudart, C., & Reginster, J.-Y. (April 2013). Changes in the structure and the symptoms of the osteoarthritis knee and prediction of future knee replacement over an 8-year follow-up period. Osteoporosis International, 24 (Suppl.1), 209. Peer Reviewed verified by ORBi |
 | Devogelaer, J.-P., Sambrook, P., Reid, D. M., Goemaere, S., Ish-Shalom, S., COLLETTE, J., Su, G., Bucci-Rechtweg, C., Papanastasiou, P., & Reginster, J.-Y. (06 March 2013). Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids. Rheumatology, 52 (6), 1058-69. doi:10.1093/rheumatology/kes410 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Kanis, J. A., Compston, J., Cooper, C., Flamion, B., Bergmann, P., Body, J.-J., Boonen, S., Bruyère, O., Devogelaer, J.-P., Goemaere, S., Kaufman, J.-M., Rozenberg, S., & Reginster, J.-Y. (March 2013). Health Technology Assessment in Osteoporosis. Calcified Tissue International, 93 (1), 1-14. doi:10.1007/s00223-013-9724-8 Peer Reviewed verified by ORBi |
 | Manzambi Kuwekita, J., & Reginster, J.-Y. (2013). Financement de la Santé et Extension de la Protection Sociale dans les Pays en Développement - L'expérience du PNPS à Bandalungwa, Kinshasa, Congo. Liège, Belgium: Les Editions du Céfal. |
 | Bruyère, O., Detalle, A.-S., Demonceau, M., Beaudart, C., Croisier, J.-L., Crielaard, J.-M., Reginster, J.-Y., & Maquet, D. (2013). Quantitative gait assessment using an accelerometer technology as a predictive tool of falls among nursing home residents: a 6-month prospective study. In Proceedings of the meeting. Peer reviewed |
 | Beaudart, C., Maquet, D., Mannarino, M., Crielaard, J.-M., Reginster, J.-Y., & Bruyère, O. (2013). Effects of 3 months of controlled whole body vibrations with low exposure period on the risk of falls among nursing home residents. In Proceeding of the meeting. Peer reviewed |
 | Brandi, M., Reginster, J.-Y., Rizzoli, R., & Cannata-Andia, J. (14 February 2013). Comment on Freemantle et al. : Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatements. Osteoporosis International, 24 (6), 1929-30. doi:10.1007/s00198-013-2297-6 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Ben Sedrine, W., Bruyère, O., & Reginster, J.-Y. (February 2013). Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis. Osteoporosis International, 24 (8), 2291-300. doi:10.1007/s00198-013-2272-2 Peer Reviewed verified by ORBi |
 | Manzambi Kuwekita, J., & Reginster, J.-Y. (2013). Perception et comportement de recours aux soins de santé dans les pays en voie de développement. Le cas de la République Démocratique du Congo. (Tous droits de reproduction, d'adaptation et de traduction réservés pour tous pays). Liège, Belgium: Les Editions du Céfal. |
 | Reginster, J.-Y. (Ed.), Bruyère, O. (Ed.), Cianferotti, L. (Other coll.), Brandi, M. L. (Other coll.), Griffith, J. F. (Other coll.), Genant, H. K. (Other coll.), Gielen, E. (Other coll.), Laurent,, M. (Other coll.), Milisen, K. (Other coll.), Boonen, S. (Other coll.), Holroyd, C. R. (Other coll.), Jagannath, D. (Other coll.), Cooper, C. (Other coll.), & McClung, M. R. (Other coll.). (2013). Osteoporosis. London, United Kingdom: Future Medicine Ltd. doi:10.2217/9781780841687 |
 | Hiligsmann, M., VAN DURME, C., Geusens, P., Dellaert, B. G., Dirksen, C. D., van der Weijden, T., Reginster, J.-Y., & Boonen, A. (2013). Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis. Patient Preference and Adherence, 7, 133-9. doi:10.2147/PPA.S38408 Peer Reviewed verified by ORBi |
 | Rabenda, V., Nicolet, D., Beaudart, C., Bruyère, O., & Reginster, J.-Y. (2013). Relationship between use of antidepressants and risk of fractures: a meta-analysis. Osteoporosis International, 24, 121-137. doi:10.1007/s00198-012-2015-9 Peer Reviewed verified by ORBi |
 | Zegels, B., Crozes, P., Uebelhart, D., Bruyère, O., & REGINSTER, J.-Y. (2013). Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis and Cartilage, 21 (1), 22-27. doi:10.1016/j.joca.2012.09.017 Peer Reviewed verified by ORBi |
 | McClung, M., Grauer, A., Boonen, S., Brown, J., Diez-Perez, A., Langdahl, B., Reginster, J.-Y., Zanchetta, J., Katz, L., Maddox, J., Yang, Y., Libanati, C., & Bone, H. (2013). Inhibition of sclerostin with romosozumab in postmenopausal women with low BMD : phase 2 trial results. Osteoporosis International, 24 (1), 38-S39. Peer Reviewed verified by ORBi |
 | Brandi, M., & Reginster, J.-Y. (2013). Nutrition and bone health : turning beliefs into knowledge for healthy behaviour. Osteoporosis International, 24 (1), 388-S389. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., & Reginster, J.-Y. (2013). Health Economics Analyses in Osteoporosis. In R. Arinoviche Schenker & M. Arriagada Maldini (Eds.), Temas de osteoporosis y otras enfermedades oseas (pp. 337-358). Santiago, Chile: Fundacion Chilena de osteoporosis. Peer reviewed |
 | Dere, W., Avouac, B., Boers, M., Buxton, M., Christiansen, C., Dawson, A., Gennari, C., Guillemin, F., Lawaetz, H., Ornskov, F., Roumagnac, I., & Reginster, J.-Y. (2013). Erratum to : Recommendations for the health economics analysis to be performed with a drug to be registered in prevention or treatment of osteoporosis. Calcified Tissue International, 93, 193. doi:10.1007/s00223-013-9760-4 Peer Reviewed verified by ORBi |
 | Roux, C., Binkley, N., Boonen, S., Kiel, D. P., Ralston, S. H., REGINSTER, J.-Y., Pong, A., Rosenberg, E., & Santora, A. (2013). Erratum to: Vitamin D Status and Bone Mineral Density Changes During Alendronate Treatment in Postmenopausal Osteoporosis. Calcified Tissue International. doi:10.1007/s00223-013-9791-x Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Dellaert, B., Dirksen, C., Van der Weijden, T., Goemaere, S., Reginster, J.-Y., Watson, V., & Boonen, A. (2013). Patients' preferences for osteoporosis drug therapy : a discrete choice experiment. Osteoporosis International, 24 (1), 53. Peer Reviewed verified by ORBi |
 | Cooper, C., Berembaum, F., Nash, P., Zamani, O., Cohen-Solal, M., Bianchi, G., Branco, J., Navarro Sarabia, F., & Reginster, J.-Y. (2013). Strontium ranelate prevents radiological progression in patients with primary knee osteoarthritis. Osteoporosis International, 24 (1), 306-307. Peer Reviewed verified by ORBi |
 | Cooper, C., Fielding, R., Visser, M., van Loon, L. J., Rolland, Y., Orwoll, E., Reid, K., Boonen, S., Dere, W., Epstein, S., Mitlak, B., Tsouderos, Y., Sayer, A. A., Rizzoli, R., REGINSTER, J.-Y., & Kanis, J. A. (2013). Tools in the assessment of sarcopenia. Calcified Tissue International, 93 (3), 201-10. doi:10.1007/s00223-013-9757-z Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Pelousse, F., & Bruyère, O. (2013). Is there potential for strontium ranelate in the management of osteoarthritis ? Clinical Practice, 10 (2), 201-207. doi:10.2217/cpr.12.83 Peer Reviewed verified by ORBi |
 | Rizzoli, R., Boonen, S., Brandi, M.-L., Bruyère, O., Cooper, C., Kanis, J. A., Kaufman, J.-M., Ringe, J. D., Weryha, G., & Reginster, J.-Y. (2013). Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Current Medical Research and Opinion, 29 (4), 305-13. doi:10.1185/03007995.2013.766162 Peer Reviewed verified by ORBi |
 | Bruyère, O., Cooper, C., Pavelka, K., Rabenda, V., Buckinx, F., Beaudart, C., & REGINSTER, J.-Y. (2013). Changes in Structure and Symptoms in Knee Osteoarthritis and Prediction of Future Knee Replacement Over 8 Years. Calcified Tissue International, 93, 502-507. doi:10.1007/s00223-013-9781-z Peer Reviewed verified by ORBi |
 | Beaudart, C., Buckinx, F., Maquet, D., Crielaard, J.-M., Reginster, J.-Y., & Bruyère, O. (2013). What are the clinical characteristics of patients improving their gait and body balance with whole body vibration ? Results of a 3-month randomized controlled trial. European Geriatric Medicine, 4 (S1), 53. Peer reviewed |
 | Beaudart, C., Buckinx, F., Rabenda, V., GILLAIN, S., Cavalier, E., Slomian, J., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2013). Les effets d'une supplémentation en vitamine D sur la force, la masse et la puissance musculaire : une méta-analyse d'essais randomisés contrôlés. Revue du Rhumatisme, 80 (S1), 180-A181. Peer Reviewed verified by ORBi |
 | Bruyère, O., Zegels, B., Crozes, P., Uebelhart, D., & Reginster, J.-Y. (2013). Evaluation de l'amélioration cliniquement pertinente ressentie par les patients sous différents modes d'administration de sulfate de chondroïtine : résultats d'une étude randomisée, contrôlée et en double insu. Revue du Rhumatisme, 80 (S1), 123-A124. Peer Reviewed verified by ORBi |
| Hiligsmann, M., Boonen, A., Dirksen, C. D., Ben Sedrine, W., & REGINSTER, J.-Y. (2013). Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women. Expert Review of Pharmacoeconomics and Outcomes Research, 13 (1), 19-28. doi:10.1586/erp.12.76 Peer Reviewed verified by ORBi |
 | Lotz, M., Martel-Pelletier, J., Christiansen, C., Brandi, M.-L., Bruyère, O., Chapurlat, R., Collette, J., Cooper, C., Giacovelli, G., Kanis, J. A., Karsdal, M. A., Kraus, V., Lems, W. F., Meulenbelt, I., Pelletier, J.-P., Raynauld, J.-P., Reiter-Niesert, S., Rizzoli, R., Sandell, L. J., ... REGINSTER, J.-Y. (2013). Value of biomarkers in osteoarthritis: current status and perspectives. Annals of the Rheumatic Diseases, 72, 1756-1763. doi:10.1136/annrheumdis-2013-203726 Peer Reviewed verified by ORBi |
 | Kaufman, J., Reginster, J.-Y., Boonen, S., Brandi, M., Cooper, C., Dere, W., Devogelaer, J., Diez-Perez, A., Kanis, J., McCloskey, E., Mitlak, B., Orwoll, E., Ringe, J., Weryha, G., & Rizzoli, R. (2013). Treatment of osteoporosis in men. BONE, 53 (1), 134-44. doi:10.1016/j.bone.2012.11.018 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Ellis, A., Luo, X., Bushmakin, A., Mirkin, S., & Jansen, J. (2013). Indirect comparison of bazedoxifene vs. oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women. Osteoporosis International, 24 (1), 37. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2013). Pharmacological management : osteoporosis and osteoarthritis, similarities and differences. Osteoporosis International, 24 (1), 75-S76. Peer Reviewed verified by ORBi |
 | Bone, H. G., Chapurlat, R., Brandi, M.-L., Brown, J. P., Czerwinski, E., Krieg, M.-A., Man, Z., Mellstrom, D., Radominski, S. C., REGINSTER, J.-Y., Resch, H., Roman Ivorra, J. A., Roux, C., Vittinghoff, E., Daizadeh, N. S., Wang, A., Bradley, M. N., Franchimont, N., Geller, M. L., ... Papapoulos, S. (2013). The Effect of 3 or 6 Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension. Journal of Clinical Endocrinology and Metabolism. doi:10.1210/jc.2013-1597 Peer Reviewed verified by ORBi |
 | REGINSTER, J.-Y., & Pelousse, F. (2013). ACP Journal Club: supplementation with vitamin D did not reduce cartilage volume loss or pain in knee osteoarthritis. Annals of Internal Medicine, 158 (8), 9. Peer Reviewed verified by ORBi |
 | Ethgen, O., De Lemos Esteves, F., Bruyère, O., & REGINSTER, J.-Y. (2013). What do we know about the safety of corticosteroids in rheumatoid arthritis? Current Medical Research and Opinion, 29 (9), 1147-60. doi:10.1185/03007995.2013.818531 Peer Reviewed verified by ORBi |
 | Beaudart, C., Buckinx, F., Rabenda, V., GILLAIN, S., Cavalier, E., Petermans, J., Reginster, J.-Y., & Bruyère, O. (2013). The effects of vitamin D on skeletal muscle strenght : a meta-analysis of randomized controlled trials. European Geriatric Medicine, 4 (S1), 72. Peer reviewed |
 | Buckinx, F., Beaudart, C., Demonceau, M., Maquet, D., Crielaard, J.-M., Reginster, J.-Y., & Bruyère, O. (2013). Impact of a 6-month training by whole body vibration on functional and motor abilities among nursing home residents observed over a 12-months period. European Geriatric Medicine, 4 (S1), 54-S55. Peer reviewed |
 | Bruyère, O., Slomian, J., Beaudart, C., Buckinx, F., CAVALIER, E., GILLAIN, S., Petermans, J., & REGINSTER, J.-Y. (2013). Prevalence of vitamin D inadequacy in European postmenopausal women aged over 80 years. European Geriatric Medicine, 4 (S1), 13-S14. Peer reviewed |
 | NEUPREZ, A., Delcour, J., Fatemi, F., GILLET, P., Mawet, M., François, G., Bruyère, O., Crielaard, J.-M., Gosset, C., & Reginster, J.-Y. (2013). Développement et validation de la version française d'un questionnaire traitant des attentes des patients dans l'arthrose des membres inférieurs. Revue du Rhumatisme, 80 (S1), 181. Peer Reviewed verified by ORBi |
 | Brown, J., McClung, M., Grauer, A., Boonen, S., Diez-Perez, A., Langdahl, B., Reginster, J.-Y., Zanchetta, J., Katz, L., Maddox, J., Yang, Y., Libanati, C., & Bone, H. (2013). Inhibition de la sclérostine par le romosozumab chez des femmes ménopausées ayant une DMO basse : résultats de l'étude de phase 2. Revue du Rhumatisme, 80 (S1), 73. Peer Reviewed verified by ORBi |
 | Chevalier, X., Richette, P., Bruyère, O., Chapurlat, R., Cooper, C., & Reginster, J.-Y. (2013). Le ranélate de strontium diminue la proportion de patients progressant rapidement dès la première année : une analyse post hoc de l'étude SEKOIA. Revue du Rhumatisme, 80 (S1), 59-A60. Peer Reviewed verified by ORBi |
 | Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2013). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, 24 (1), 23-57. doi:10.1007/s00198-012-2074-y Peer Reviewed verified by ORBi |
 | REGINSTER, J.-Y., Beaudart, C., NEUPREZ, A., & Bruyère, O. (2013). Strontium ranelate in the treatment of knee osteoarthritis: new insights and emerging clinical evidence. Therapeutic Advances in Musculoskeletal Disease, 5 (5), 268-276. doi:10.1177/1759720X13500862 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Ben Sedrine, W., & REGINSTER, J.-Y. (2013). Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women. Journal of Bone and Mineral Research, 28 (4), 807-15. doi:10.1002/jbmr.1819 Peer Reviewed verified by ORBi |
 | Pelletier, J.-P., Cooper, C., Peterfy, C., REGINSTER, J.-Y., Brandi, M.-L., Bruyère, O., Chapurlat, R., Cicuttini, F., Conaghan, P. G., Doherty, M., Genant, H., Giacovelli, G., Hochberg, M. C., Hunter, D. J., Kanis, J. A., Kloppenburg, M., Laredo, J.-D., McAlindon, T., Nevitt, M., ... Guermazi, A. (2013). What is the predictive value of MRI for the occurrence of knee replacement surgery in knee osteoarthritis? Annals of the Rheumatic Diseases, 72 (10), 1594-1604. doi:10.1136/annrheumdis-2013-203631 Peer Reviewed verified by ORBi |
 | Beaudart, C., Maquet, D., Mannarino, M., Buckinx, F., Demonceau, M., Crielaard, J.-M., Reginster, J.-Y., & Bruyère, O. (2013). Effects of 3 months of short sessions of controlled whole body vibrations on the risk of falls among nursing home residents. BMC Geriatrics, 13 (42). doi:10.1186/1471-2318-13-42 Peer Reviewed verified by ORBi |
 | Genant, H., Zaim, S., Guermazi, A., Roemer, F., Beaulieu, A., Hall, S., Alekseeva, L., Roorda, L., Verbruggen, G., Wittoek, R., Peterfy, C., Cooper, C., & Reginster, J.-Y. (2013). Strontium ranelate effect on knee osteoarthritis progression : a MRI analysis. Osteoporosis International, 24 (1), 312-313. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2013). The general approach to the patient with osteoarthritis : is a treatment algorithm feasible ? Osteoporosis International, 24 (1), 385. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Badurski, J., Bellamy, N., Bensen, W., Chapurlat, R., Chevalier, X., Christiansen, C., Genant, H., Navarro, F., Sambrook, P., Spector, T., & Cooper, C. (2013). Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Annals of the Rheumatic Diseases, 72 (2), 179-86. doi:10.1136/annrheumdis-2012-202231 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Cooper, C., Arden, N., Boers, M., Branco, J. C., Luisa Brandi, M., Bruyère, O., Guillemin, F., Hochberg, M. C., Hunter, D. J., Kanis, J. A., Kvien, T. K., Laslop, A., Pelletier, J.-P., Pinto, D., Reiter-Niesert, S., Rizzoli, R., Rovati, L. C., Severens, J. L. H., ... REGINSTER, J.-Y. (2013). Health economics in the field of osteoarthritis: An Expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 43 (3), 303-313. doi:10.1016/j.semarthrit.2013.07.003 Peer Reviewed verified by ORBi |
 | Svedbom, A., Hernlund, E., Ivergard, M., Compston, J., Cooper, C., Stenmark, J., McCloskey, E., Jonsson, B., Kanis, J., Hiligsmann, M., & Reginster, J.-Y. (2013). Osteoporosis in the European Union : a compendium of country-specific reports. Archives of Osteoporosis, 8 (137), 1-218. doi:10.1007/s11657-013-0137-0 Peer Reviewed verified by ORBi |
 | REGINSTER, J.-Y., DEBERG, M., Henrotin, Y., & Christgau, S. (11 December 2012). Detection of specific nitrated markers. |
 | COLSON, L., Vander Rest, C., Reginster, J.-Y., DELANAYE, P., CAVALIER, E., LE GOFF, C., Crielaard, J.-M., & Kaux, J.-F. (December 2012). Ostéomalacie hypophosphatémique hyperphosphaturique avec hypersécrétion de FGF-23. Lettre du Rhumatologue, 387, 26-29. Peer reviewed |
 | Beaudart, C., Maquet, D., Mannarino, M., Buckinx, F., Demonceau, M., CRIELAARD, J.-M., Reginster, J.-Y., & Bruyère, O. (20 November 2012). Evaluation de l'impact d'un entraînement de trois mois par vibrotonie sur le risque de chute chez des patients résidant en maison de repos [Paper presentation]. Journée des Doctorants de l'Ecole Doctorale "SPSS", Liège, Belgium. |
 | Bruyère, O., Bergmann, P., Body, J.-J., Boonen, S., Devogelaer, J.-P., Goemaere, S., Kaufman, J.-M., Rozenberg, S., & Reginster, J.-Y. (October 2012). Nécessité de nouveaux critères de remboursement pour traiter l'ostéoporose en Belgique. Ortho-Rhumato, 10 (5), 3. |
 | REGINSTER, J.-Y., Neuprez, A., LECART, M.-P., SARLET, N., & Bruyère, O. (October 2012). Role of glucosamine in the treatment for osteoarthritis. Rheumatology International, 32 (10), 2959-67. doi:10.1007/s00296-012-2416-2 Peer Reviewed verified by ORBi |
 | Bruyère, O., Detilleux, J., Chines, A., & Reginster, J.-Y. (September 2012). Relationships Between Changes in Bone Mineral Density or Bone Turnover Markers and Vertebral Fracture Incidence in Patients Treated with Bazedoxifene. Calcified Tissue International, 91 (4), 244-9. doi:10.1007/s00223-012-9629-y Peer Reviewed verified by ORBi |
 | Bruyère, O., Ethgen, O., Neuprez, A., Zegels, B., Gillet, P., HUSKIN, J.-P., & Reginster, J.-Y. (2012). Health-related quality of life after total knee or hip replacement for osteoarthritis: a 7-year prospective study. Archives of Orthopaedic and Trauma Surgery. doi:10.1007/s00402-012-1583-7 Peer Reviewed verified by ORBi |
 | Neuprez, A., François, G., Bruyère, O., Kovats, V., KURTH, W., HUSKIN, J.-P., GILLET, P., & Reginster, J.-Y. (June 2012). Radiological and clinical profil of osteoarthritic patients undergoing of total joint replacement. Annals of the Rheumatic Diseases, 71 (Suppl.3), 693. Peer Reviewed verified by ORBi |
 | Bruyère, O., Demoulin, M., Brereton, C., Humblet, F., Flynn, D., Hill, J. C., Maquet, D., Van Beveren, J., Reginster, J.-Y., CRIELAARD, J.-M., & Demoulin, C. (June 2012). Translation validation of a new back pain screening questionnaire (the STarT Back Screening Tool) in French. Archives of Public Health, 70. doi:10.1186/0778-7367-70-12 Peer Reviewed verified by ORBi |
 | Neuprez, A., François, G., Bruyère, O., Kovats, V., THIRION, T., VAN CAUWENBERGE, H., DANIEL, C., GILLET, P., & Reginster, J.-Y. (June 2012). Assessment of quality of life in patients undergoing total joint replacement for OA of the lower limb. Annals of the Rheumatic Diseases, 71 (Suppl.3), 693. Peer Reviewed verified by ORBi |
 | Bruyère, O., Buckinx, F., & Reginster, J.-Y. (June 2012). A very high prevalence of vitamin D inadequacy combined with low dietary calcium intake is found in European postmenopausal women. Annals of the Rheumatic Diseases, 71 (Suppl.3), 716. Peer Reviewed verified by ORBi |
 | Bruyère, O., Roux, C., Nicolet, D., Fechtenbaum, J., DEROISY, R., & Reginster, J.-Y. (June 2012). Severity of incident vertebral fracture and future fracture risk: a 3-year prospective study. Annals of the Rheumatic Diseases, 71 (Suppl.3), 716. Peer Reviewed verified by ORBi |
 | Bruyère, O., Nicolet, D., Compère, S., Rabenda, V., Jeholet, P., ZEGELS, B., Maassen, P., Pire, G., & Reginster, J.-Y. (June 2012). Perception, knowledge and use by general practitioners of Belgium of the FRAX tool. Annals of the Rheumatic Diseases, 71 (Suppl.3), 716. Peer Reviewed verified by ORBi |
 | Bruyère, O., Roux, C., Nicolet, D., Fechtenbaum, J., DEROISY, R., & Reginster, J.-Y. (June 2012). Severe prevalent vertebral fractures predict subsequent vertebral and nonvertebral fractures: a 3-year prospective study. Annals of the Rheumatic Diseases, 71 (Suppl.3), 588. Peer Reviewed verified by ORBi |
 | Bruyère, O., & Reginster, J.-Y. (June 2012). Relationships between changes in bone mineral density and vertebral fractures incidence: an analysis of the last 2 years of a 10-year treatment with strontium ranelate. Annals of the Rheumatic Diseases, 71 (Suppl.3), 590. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Roberfroid, D., Dubois, C., Parmentier, Y., Carton, J., Detilleux, J., GILLET, P., & Reginster, J.-Y. (May 2012). Trends in hip fracture incidence and in the prescription of anti-osteoporosis medications during same time period in Belgium (2000-2007). Arthritis Care and Research, 64 (5), 744-750. Peer Reviewed verified by ORBi |
 | Rizzoli, R., Dawson-Hughes, B., Kaufman, J., Fardellone, P., Brandi, M., Vellas, B., COLLETTE, J., & Reginster, J.-Y. (May 2012). Efficacy of a strontium ranelate 2 G/vitamin D3 1000 UI combination on the correction of vitamin D insufficiency. Osteoporosis International, 23 (S2), 225. Peer Reviewed verified by ORBi |
 | Bruyère, O., Avouac, B., Richette, P., Maheu, E., Bruel, P., Coxam, V., Guillou, G. B., Lugrin, A.-E., Merceron, C., Pauquai, T., Rannou, F., Ythier-Moury, P., Tsouderos, Y., Urban, N., Rovati, L., Guicheux, J., & Reginster, J.-Y. (April 2012). Health claims assessment in the field of joint and cartilage: a consensus viewpoint of the Group for the Respect of Ethics and Excellence in Science. Current Medical Research and Opinion, 28 (4), 611-6. doi:10.1185/03007995.2012.674934 Peer Reviewed verified by ORBi |
 | Bruyère, O., Roux, C., Nicolet, D., Fechtenbaum, J., DEROISY, R., & Reginster, J.-Y. (March 2012). Severe prevalent vertebral fractures predict subsequent vertebral and nonvertebral fractures: a 3-year prospective study. Osteoporosis International, 23 (Suppl. 2), 361-362. Peer Reviewed verified by ORBi |
 | Bruyère, O., Zegels, B., LEONORI, L., Rabenda, V., Janssen, A., Bourges, C., & Reginster, J.-Y. (March 2012). Effect of collagen hydrolysate in articular pain: A 6-month randomized, double-blind, placebo controlled study. Osteoporosis International, 23 (Suppl. 2), 362-363. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Ben Sedrine, W., Bruyère, O., & Reginster, J.-Y. (March 2012). Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women. Osteoporosis International, 23 (Suppl. 2), 312-313. Peer Reviewed verified by ORBi |
 | Bruyère, O., Rabenda, V., & Reginster, J.-Y. (March 2012). Prediction of future knee surgery in patient with osteoarhtritis by the use of a new definition of x-ray progression. Osteoporosis International, 23 (Suppl. 2), 363. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Van Durme, C., Geusens, P., Dellaert, B., Dirksen, C., Van der Weijden, T., Reginster, J.-Y., & Boonen, A. (March 2012). What are the most important medication attributes for patients with osteoporosis ? Results from a qualitative study. Osteoporosis International, 23 (S2), 81-82. Peer Reviewed verified by ORBi |
 | COLLETTE, J., & Reginster, J.-Y. (March 2012). Strontium ranelate uncouples bone formation from bone resorption in male osteoporotic patients. Osteoporosis International, 23 (S2), 365-366. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Chapurlat, R., Christiansen, C., Genant, H., Bellamy, N., Bensen, W., Navarro, F., Badurski, J., Nasonov, E., Chevalier, X., Sambrook, P., Spector, T., & Cooper, C. (March 2012). Strontium ranelate reduces the number of radiological or radioclinical progressors in patients with primary knee osteoarthritis. Osteoporosis International, 23 (S2), 366-367. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Chapurlat, R., Christiaensen, C., Genant, H., Bellamy, N., Bensen, W., Navarro, F., Badurski, J., Nasonov, E., Chevalier, X., Sambrook, P., Spector, T., & Cooper, C. (March 2012). Structure modifying effects of strontium ranelate in knee osteoarthritis. Osteoporosis International, 23 (S2), 58-59. Peer Reviewed verified by ORBi |
 | Boonen, S., Reginster, J.-Y., Kaufman, J., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., Dimai, H., Eriksen, E., Brixen, K., Antunez, O., Su, G., Hruska, J., Vanderschueren, D., & Orwoll, E. (March 2012). Efficacy of once-yearly zoledronic acid 5 mg in men with osteoporosis with different levels of serum total testosterone. Osteoporosis International, 23 (S2), 79-80. Peer Reviewed verified by ORBi |
 | Bruyère, O., Roux, C., Nicolet, D., Fechtenbaum, J., DEROISY, R., & Reginster, J.-Y. (March 2012). Severity of incident vertebral fracture and future fracture risk: a 3-year prospective study. Osteoporosis International, 23 (Suppl. 2), 60-61. Peer Reviewed verified by ORBi |
 | Gensburger, D., DEROISY, R., Arlot, M., Bruyère, O., Chapurlat, R., & Reginster, J.-Y. (March 2012). Assessment of joint space narrowing in knee osteoarthritis has good long-term intercentre reproducibility when read in pairs with a semi-automated device. Osteoporosis International, 23 (Suppl. 2), 247-248. Peer Reviewed verified by ORBi |
 | Bruyère, O., Nicolet, D., Compère, S., Rabenda, V., Jeholet, P., Zegels, B., Maassen, P., Pire, G., & Reginster, J.-Y. (March 2012). Perception, knowledge and use by general practitioners of Belgium of the FRAX tool. Osteoporosis International, 23 (Suppl. 2), 363-364. Peer Reviewed verified by ORBi |
 | DEROISY, R., Bruyère, O., Gensburger, D., Chapurlat, R., & Reginster, J.-Y. (March 2012). Long-term (3 years) reproducibility for the radiological assessment of knee osteoarthritis. Osteoporosis International, 23 (Suppl. 2), 219-220. Peer Reviewed verified by ORBi |
 | Ellis, A., Jansen, J., Luo, X., Cappelleri, J., Chines, A., Sutradhar, S., & Reginster, J.-Y. (March 2012). Indirect comparison of bazedoxifene vs. oral bisphosphonates for the prevention of nonvertebral fractures in high-risk postmenopausal osteoporosis population. Osteoporosis International, 23 (S2), 64-65. Peer Reviewed verified by ORBi |
 | Papapoulos, S., Brown, J., Chapurlat, R., Franchimont, N., Brandi, M., Czerwinski, E., Krieg, M., Man, Z., Mellström, D., Radominski, S., Reginster, J.-Y., Resch, H., Roman, J., Roux, C., Daizadeh, N., Geller, M., Smith, S., Wagman, R., Cummings, S., & Bone, H. (March 2012). Denosumab treatment of postmenopausal women with osteoporosis for 6 years : results from the first 3 years of the freedom extension. Osteoporosis International, 23 (S2), 76. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Binkley, N., Boonen, S., Kiel, D., Ralston, S., Roux, C., Pong, A., Rosenberg, E., & Santora, A. (March 2012). Correlations between 25(OH)D and BMD change in postmenopausal osteoporotic women : secondary analyses of a 1-year trial of weekly alendronate (ALN) plus vitamin D3 5600 IU vs. standard care. Osteoporosis International, 23 (S2), 238-239. Peer Reviewed verified by ORBi |
 | Papapoulos, S., Chapurlat, R., Libanati, C., Brandi, M., Brown, J., Czerwinski, E., Krieg, M. A., Man, Z., Mellstrom, D., Radominski, S., Reginster, J.-Y., Resch, H., Roman, J., Roux, C., Vittinghoff, E., Austin, M., Daizadeh, N., Bradley, M., Grauer, A., ... Bone, H. (March 2012). Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension. Journal of Bone and Mineral Research, 27 (3), 694-701. doi:10.1002/jbmr.1479 Peer Reviewed verified by ORBi |
 | Neuprez, A., François, G., Bruyère, O., Kovats, V., KURTH, W., HUSKIN, J.-P., Gillet, P., & Reginster, J.-Y. (March 2012). Radiological and clinical profil of osteoarthritic patients undergoing of total joint replacement. Osteoporosis International, 23 (Suppl. 2), 129-130. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Ben Sedrine, W., Bruyère, O., & Reginster, J.-Y. (March 2012). An economic evaluation of strontium ranelate for the treatment of male osteoporosis. Osteoporosis International, 23 (Suppl. 2), 305-306. Peer Reviewed verified by ORBi |
 | Bruyère, O., & Reginster, J.-Y. (March 2012). Relationships between changes in bone mineral density and vertebral fractures incidence: an analysis of the last 2 years of a 10-year treatment with strontium ranelate. Osteoporosis International, 23 (Suppl. 2), 362. Peer Reviewed verified by ORBi |
 | Cooper, C., Deltour, N., Speirs, C., Meyer, O., & Reginster, J.-Y. (March 2012). Strontium ranelate and risk of venous thromboembolism (VTE) : an update of a retrospective cohort study in the UK general practice research database (GPRD). Osteoporosis International, 23 (S2), 364-365. Peer Reviewed verified by ORBi |
 | Bruyère, O., Buckinx, F., & Reginster, J.-Y. (March 2012). A very high prevalence of vitamin D inadequacy combined with low dietary calcium intake is found in European postmenopausal women. Osteoporosis International, 23 (Suppl. 2), 361. Peer Reviewed verified by ORBi |
 | Bruyère, O., Rizzoli, R., Coxam, V., Avouac, B., Chevalier, T., Fabien-Soulé, V., Kanis, J. A., Kaufman, J.-M., Tsouderos, Y., & Reginster, J.-Y. (February 2012). Assessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). Osteoporosis International, 23, 193-199. doi:10.1007/s00198-011-1561-x Peer Reviewed verified by ORBi |
 | Goldhahn, J., Feron, J. M., Kanis, J. A., Papapoulos, S., Reginster, J.-Y., Rizzoli, R., Dere, W., Mitlak, B., Tsouderos, Y., & Boonen, S. (2012). Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcified Tissue International, 90, 343-353. doi:10.1007/s00223-012-9587-4 Peer Reviewed verified by ORBi |
 | Rabenda, V., Bruyère, O., & REGINSTER, J.-Y. (2012). Risk of nonvertebral fractures among elderly postmenopausal women using antidepressants. BONE, 51 (4), 674-679. doi:10.1016/j.bone.2012.07.030 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., & Reginster, J.-Y. (2012). Incidence des fractures de hanche en fonction des médicaments prescrits contre l'ostéoporose. Ortho-Rhumato, 10 (4), 3. Peer reviewed |
 | Body, J.-J., Bergmann, P., Boonen, S., Devogelaer, J.-P., Gielen, E., Goemaere, S., Kaufman, J.-M., Rozenberg, S., & REGINSTER, J.-Y. (2012). Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. Osteoporosis International, 23 Suppl 1, 1-23. doi:10.1007/s00198-011-1891-8 Peer Reviewed verified by ORBi |
 | Sambrook, P. N., Roux, C., Devogelaer, J. P., Saag, K., Lau, C. S., Reginster, J.-Y., Bucci-Rechtweg, C., Su, G., & Reid, D. M. (2012). Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. BONE, 50, 289-295. doi:10.1016/j.bone.2011.10.024 Peer Reviewed verified by ORBi |
| Chapurlat, R., Papapoulos, S., Brown, J., Franchimont, N., Brandi, M., Czerwinski, E., Krieg, M., Man, Z., Mellstrom, D., Radominski, S., Reginster, J.-Y., Resch, H., Roman, J., Roux, C., Daizadeh, N., Geller, M., Smith, S., Wagman, R., Cummings, S., & Bone, H. (2012). Treatment of postmenopausal women with osteoporosis for six years with denosumab : three-year results from the freedom extension. Annals of the Rheumatic Diseases, 71 (3), 588. Peer Reviewed verified by ORBi |
| Hiligsmann, M., Van Durme, C., Geusens, P., Dellaert, B., Dirksen, C., Van der Weijden, T., Reginster, J.-Y., & Boonen, A. (2012). Nominal group technique to prioritize preferences for medication attributes from the patients’ perspective : the case of osteoporosis. Annals of the Rheumatic Diseases, 71 (3), 597. Peer Reviewed verified by ORBi |
 | Rizzoli, R., Cooper, C., Reginster, J.-Y., Abrahamsen, B., Adachi, J., Brandi, M., Bruyère, O., Compston, J., Ducy, P., Ferrari, S., Harvey, N., Kanis, J., Karsenty, G., Laslop, A., Rabenda, V., & Vestergaard, P. (2012). Antidepressant medications and osteoporosis. BONE, 51, 606-613. doi:10.1016/j.bone.2012.05.018 Peer Reviewed verified by ORBi |
 | Cooper, C., REGINSTER, J.-Y., Chapurlat, R., Christiansen, C., Genant, H., Bellamy, N., Bensen, W., Navarro, F., Badurski, J., Nasonov, E., Chevalier, X., & Sambrook, P. N. (2012). Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial. Current Medical Research and Opinion, 28 (2), 231-9. doi:10.1185/03007995.2011.648758 Peer Reviewed verified by ORBi |
 | Henrotin, Y., & Reginster, J.-Y. (2012). New drugs and nutraceuticals in the treatment of osteoarthritis. In S. Cox Gad (Ed.), Development of Therapeutic Agents Handbook (pp. 847-880). Hoboken, United States - New Jersey: Wiley. Peer reviewed |
 | Reginster, J.-Y. (2012). Ranelato de estroncio : Um tratamentao de primeira linha para a osteoporose pos-menopausica. Expert Approaches in Osteoporosis, 13-23. Peer reviewed |
 | Hiligsmann, M., Boonen, A., Rabenda, V., & REGINSTER, J.-Y. (2012). The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert Review of Pharmacoeconomics and Outcomes Research, 12 (2), 159-66. doi:10.1586/erp.12.8 Peer Reviewed verified by ORBi |
 | Rizzoli, R., Body, J., De Censi, A., Reginster, J.-Y., Piscitelli, P., & Brandi, M. (2012). Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer : an ESCEO position paper. Osteoporosis International, 23, 2567-2576. doi:10.1007/s00198-011-1870-0 Peer Reviewed verified by ORBi |
 | Bolognese, M., Miller, P., Reginster, J.-Y., Franchimont, N., Bianchi, G., Chapurlat, R., Hawkins, F., Kendler, D., Oliveri, B., Zanchetta, J., Daizadeh, N., Wang, A., Wagman, R., & Papapoulos, S. (2012). Relationship between changes in bone mineral density and incidence of fracture with 6 years of Denosumab treatment. Arthritis and Rheumatism, 64 (S10), 847. Peer Reviewed verified by ORBi |
 | Collette, J., Bruyère, O., & Reginster, J.-Y. (2012). Strontium ranelate decreases the level of urinary CTX-II in patients with knee osteoarthritis. Arthritis and Rheumatism, 64 (S10), 111. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2012). Toujours pas facile de faire des vieux os. Tempo Médical, 348, 204-206. Peer reviewed |
 | Chevalier, X., Chapurlat, R., Cooper, C., & Reginster, J.-Y. (2012). Le ranélate de strontium diminue le nombre de progresseurs radiologiques ou radiocliniques chez les patients ayant une arthrose primaire du genou. Revue du Rhumatisme, 79 (S1), 270. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Chapurlat, R., Christiansen, C., Genant, H., Bellamy, N., Bensen, W., Navarro, F., Badurski, J., Nasonov, E., Chevalier, X., Sambrook, P., Spector, T., & Cooper, C. (2012). Strontium ranelate in knee osteoarthritis trial (SEKOIA) : a structural and symptomatic efficacy. Arthritis and Rheumatism, 64 (S10), 681. Peer Reviewed verified by ORBi |
 | Bruyère, O., Bellamy, N., Brown, J., Richette, P., Punzi, L., Chevalier, X., Cooper, C., & Reginster, J.-Y. (2012). Clinically meaningful effect of strontium ranelate on knee osteoarthritis symptoms. Arthritis and Rheumatism, 64 (S10), 110. Peer Reviewed verified by ORBi |
| Cooper, C., Chapurlat, R., Christiansen, C., Genant, H., Bellamy, N., Bensen, W., Navarro, F., Badurski, J., Nasonov, E., Chevalier, X., Sambrook, P., Spector, T., & Reginster, J.-Y. (2012). Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis : a randomized, double-blind, placebo-controlled international trial. Annals of the Rheumatic Diseases, 71 (3), 693. Peer Reviewed verified by ORBi |
 | REGINSTER, J.-Y. (2012). Randomised control trial in people with hand osteoarthritis, chondroitin sulphate therapy for 6 months improves pain and function compared with placebo. Evidence-Based Medicine, 17 (5), 152-153. doi:10.1136/ebmed-2011-100515 Peer Reviewed verified by ORBi |
 | Boonen, S., REGINSTER, J.-Y., Kaufman, J.-M., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., Lipschitz, S., Dimai, H. P., Witvrouw, R., Eriksen, E., Brixen, K., Russo, L., Claessens, F., Papanastasiou, P., Antunez, O., Su, G., Bucci-Rechtweg, C., Hruska, J., ... Orwoll, E. (2012). Fracture risk and zoledronic acid therapy in men with osteoporosis. New England Journal of Medicine, 367 (18), 1714-1723. doi:10.1056/NEJMoa1204061 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Ben Sedrine, W., & Reginster, J.-Y. (2012). Cost-effectiveness of Bazedoxifene compared with Raloxifene in the treatment of postmenopausal osteoporotic women. Arthritis and Rheumatism, 64 (S10), 834. Peer Reviewed verified by ORBi |
 | Orwoll, E., Teglbjærg, C. S., Langdahl, B. L., Chapurlat, R., Czerwinski, E., Kendler, D. L., REGINSTER, J.-Y., Kivitz, A., Lewiecki, E. M., Miller, P. D., Bolognese, M. A., McClung, M. R., Bone, H. G., Ljunggren, Ö., Abrahamsen, B., Gruntmanis, U., Yang, Y.-C., Wagman, R. B., Siddhanti, S., ... Boonen, S. (2012). A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. Journal of Clinical Endocrinology and Metabolism, 97 (9), 3161-3169. doi:10.1210/jc.2012-1569 Peer Reviewed verified by ORBi |
 | NEUPREZ, A., François, G., Bruyère, O., Kovats, V., KURTH, W., HUSKIN, J.-P., GILLET, P., & Reginster, J.-Y. (2012). Evolution temporelle du profil clinique des patients arthrosiques allant bénéficier d’une arthroplastie de hanche ou de genou. Revue du Rhumatisme, 79 (S1), 272. Peer Reviewed verified by ORBi |
 | Bruyère, O., Rabenda, V., & Reginster, J.-Y. (2012). Utilisation d'une nouvelle définition de la progression radiologique pour prédire la future chirurgie du genou chez des patients arthrosiques. Revue du Rhumatisme, 79 (S1), 266. Peer Reviewed verified by ORBi |
 | Rizzoli, R., Adachi, J. D., Cooper, C., Dere, W., Devogelaer, J. P., Diez-Perez, A., Kanis, J. A., Laslop, A., Mitlak, B., Papapoulos, S., Ralston, S., Reiter, S., Werhya, G., & REGINSTER, J.-Y. (2012). Management of glucocorticoid-induced osteoporosis. Calcified Tissue International, 91 (4), 225-243. doi:10.1007/s00223-012-9630-5 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., McGowan, B., Bennett, K., Barry, M., & REGINSTER, J.-Y. (2012). The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value in Health, 15 (5), 604-12. doi:10.1016/j.jval.2012.02.001 Peer Reviewed verified by ORBi |
 | Bruyère, O., Zegels, B., Leonori, L., Rabenda, V., Janssen, A., Bourges, C., & Reginster, J.-Y. (2012). Effect of collagen hydrolysate in articular pain: A 6-month randomized, double-blind, placebo controlled study. Complementary Therapies in Medicine, 20, 124-130. doi:10.1016/j.ctim.2011.12.007 Peer Reviewed verified by ORBi |
 | Kanis, J. A., Reginster, J.-Y., Kaufman, J. M., Ringe, J. D., Adachi, J. D., Hiligsmann, M., Rizzoli, R., & Cooper, C. (2012). A reappraisal of generic bisphosphonates in osteoporosis. Osteoporosis International, 23, 213-221. doi:10.1007/s00198-011-1796-6 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Kaufman, J. M., Goemaere, S., Devogelaer, J. P., Benhamou, C. L., Felsenberg, D., Diaz-Curiel, M., Brandi, M. L., Badurski, J., Wark, J., Balogh, A., Bruyère, O., & Roux, C. (2012). Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporosis International, 23, 1115-1122. doi:10.1007/s00198-011-1847-z Peer Reviewed verified by ORBi |
 | Cooper, C., Reginster, J.-Y., Cortet, B., Diaz-Curiel, M., Lorenc, R. S., Kanis, J. A., & Rizzoli, R. (2012). Long-term treatment of osteoporosis in postmenopausal women : a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Current Medical Research and Opinion, 28, 475-491. doi:10.1185/03007995.2012.663750 Peer Reviewed verified by ORBi |
 | Roux, C., Reid, D. M., Devogelaer, J. P., Saag, K., Lau, C. S., Reginster, J.-Y., Papanastasiou, P., Bucci-Rechtweg, C., Su, G., & Sambrook, P. N. (2012). Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Osteoporosis International, 23, 1083-90. doi:10.1007/s00198-011-1800-1 Peer Reviewed verified by ORBi |
 | Wampers, M., Hanssens, L., van Winkel, R., Heald, A., Collette, J., Peuskens, J., Reginster, J.-Y., SCHEEN, A., & De Hert, M. (2012). Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: Results from a 3-month prospective open-label study. European Neuropsychopharmacology, 22, 17-26. doi:10.1016/j.euroneuro.2011.03.010 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Chapurlat, R., Bellamy, N., Czerwinski, E., Devogelaer, J., March, L., Pavelka, K., & Cooper, C. (2012). Effects of Strontium ranelate on knee osteoarthritis pain : a responder analysis. Arthritis and Rheumatism, 64 (S10), 110. Peer Reviewed verified by ORBi |
 | NEUPREZ, A., François, G., Bruyère, O., Kovats, V., THIRION, T., Van Cauwenberghe, H., DANIEL, C., GILLET, P., & Reginster, J.-Y. (2012). Profils clinique et radiologique des patients arthrosiques allant bénéficier d'une arthroplastie de hanche ou de genou. Revue du Rhumatisme, 79 (S1), 272. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Van Durme, C., Geusens, P., Dellaert, B., Dirksen, C., Van Der Weijden, T., Reginster, J.-Y., & Boonen, A. (2012). Quelles sont les caractéristiques des médicaments les plus importantes pour les patients ostéoporotiques ? Résultats d'une étude qualitative. Revue du Rhumatisme, 79 (S1), 238. Peer Reviewed verified by ORBi |
 | Chevalier, X., Chapurlat, R., Cooper, C., & Reginster, J.-Y. (2012). Effet structuro-modulateur du ranélate de strontium dans la gonarthrose : l'étude SEKOIA. Revue du Rhumatisme, 79 (S1), 271. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., & Reginster, J.-Y. (2012). Un monde médical et économique en pleine évolution : maladies complexes et intérêt de l’évaluation économique des technologies de santé. Revue Médicale de Liège, 67 (5-6), 258-262. Peer reviewed |
 | Reginster, J.-Y., & Hiligsmann, M. (2012). Economics in osteoporosis : how can we reconciliate the prescribers and the payer ? Osteoporosis International, 23 (6), 655-S661. Peer Reviewed verified by ORBi |
 | Cooper, C., Dere, W., Evans, W., Kanis, J., Rizzoli, R., Sayer, A., Sieber, C., Kaufman, J., Abellan van Kan, G., Boonen, S., Adachi, J., Mitlak, B., Tsouderos, Y., Rolland, Y., & Reginster, J.-Y. (2012). Frailty and sarcopenia : definitions and outcome parameters. Osteoporosis International, 23, 1839-1848. doi:10.1007/s00198-012-1913-1 Peer Reviewed verified by ORBi |
 | Rizzoli, R., Dawson-Hughes, B., Kaufman, J., Fardellone, P., Brandi, M., Vellas, B., Collette, J., & Reginster, J.-Y. (2012). Correction of vitamin D insufficiency with the fixed daily combination strontium ranelate 2 g/vitamin D3 1000 IU over 12 months. Arthritis and Rheumatism, 64 (S10), 835. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Bruyère, O., & COLLETTE, J. (2012). Strontium ranelate treatment increases osteoprotegerin serum levels in postmenopausal osteoporotic women [letter to the editor]. BONE, 50, 1201-2. doi:10.1016/j.bone.2011.12.024 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Roberfroid, D., Dubois, C., Parmentier, Y., Carton, J., Detilleux, J., Gillet, P., & Reginster, J.-Y. (December 2011). Evolution récente de l'incidence des fractures de hanche et de la consommation de médicaments anti-ostéoporotiques en Belgique. Revue du Rhumatisme, 78 (Suppl. 5), 43-44. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., McGowan, B., Bennett, K., Barry, M., & Reginster, J.-Y. (November 2011). The clinical and economic implications of non-adherence with osteoporosis medications in Ireland [Paper presentation]. ESPACOMP Meeting, Utrecht, Netherlands. |
Hiligsmann, M., & Reginster, J.-Y. (04 October 2011). Actualités dans le diagnostic et le traitement de l'ostéoporose: aspects cliniques et pharmaco-économiques [Paper presentation]. Enseignement Post Universitaire, Liège, Belgium. |
 | VAN DER REST, C., CAVALIER, E., KAUX, J.-F., KRZESINSKI, J.-M., HUSTINX, R., REGINSTER, J.-Y., & DELANAYE, P. (October 2011). Tumor-induced osteomalacia: The tumor may stay hidden! Clinical Biochemistry, 44 (14-15), 1264-6. doi:10.1016/j.clinbiochem.2011.07.013 Peer Reviewed verified by ORBi |
 | VAN DER REST, C., CAVALIER, E., COLSON, L., KAUX, J.-F., KRZESINSKI, J.-M., REGINSTER, J.-Y., HUSTINX, R., & DELANAYE, P. (August 2011). Hypophosphatémie et ostéomalacie oncogénique. Revue Médicale Suisse, 7, 1630-3. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Pire, G., & Reginster, J.-Y. (June 2011). Economic evaluation of osteoporosis screening strategy conducted in the Province of Liège with the cooperation of Liège Province Santé [Paper presentation]. WHO European Healthy Cities Networks Phase V (2009-2013). Third Annual Business & Technical Conference, Liège, Belgium. |
 | Reginster, J.-Y., DEBERG, M., Henrotin, Y., & Christgau, S. (29 March 2011). Detection of specific nitrated markers. |
 | Bruyère, O., Hiligsmann, M., Zegels, B., Neuprez, A., & Reginster, J.-Y. (March 2011). Risk of hip fracture in community-dwelling and institutionalized osteoporotic patients: a 3-year study. Osteoporosis International, 22 (Suppl.1), 332-333. Peer Reviewed verified by ORBi |
 | Rabenda, V., Hiligsmann, M., & Reginster, J.-Y. (March 2011). Compliance to daily placebo treatment in a postmenopausal osteoporotic women population: characteristics and impact on mortality. Osteoporosis International, 22 (Suppl.1), 287-288. Peer Reviewed verified by ORBi |
 | Bruyère, O., Detilleux, J., Chines, A., & Reginster, J.-Y. (March 2011). Relationship between changes in bone mineral density or bone turnover markers and vertebral fracture incidence in patients treated with Bazedoxifene. Osteoporosis International, 22 (Suppl.1), 324. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Kaufman, J.-M., Devogelaer, J.-P., Benhamou, C. L., & Roux, C. (March 2011). Long-term efficacy and safety of strontium ranelate in postmenopausal osteoporotic women: results over 10 years. Osteoporosis International, 22 (Suppl.1), 110-111. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Gathon, H.-J., Bruyère, O., Daubie, M., Parmentier, Y., Dercq, J.-P., & Reginster, J.-Y. (March 2011). Hospitalisation costs of hip fractures in Belgium. Osteoporosis International, 22 (Suppl.1), 332. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., & Reginster, J.-Y. (March 2011). Cost-effectiveness of Denosumab compared with generic alendronate in the treatment of postmenopausal osteoporotic women. Osteoporosis International, 22 (Suppl.1), 112-113. Peer Reviewed verified by ORBi |
 | Boonen, S., Su, G., Incera, E., Orwoll, E., Kaufman, J.-M., Reginster, J.-Y., Rizzoli, R., Lippuner, K., Vanderschueren, D., Bucci-Rechtweg, C., Antunez, O., & Papanastasiou, P. (March 2011). Antifracture efficacy and safety of once-yearly Zoledronic acid 5mg in men with osteoporosis: a prospective, randomized, controlled trial. Osteoporosis International, 22 (Suppl.1), 112. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (March 2011). Protecting men and women from fracture. Osteoporosis International, 22 (Suppl.1), 413-414. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (March 2011). The true clinical relevance of crystalline glucosamine sulphate in the treatment of knee osteoarthritis. Osteoporosis International, 22 (Suppl.1), 410. Peer Reviewed verified by ORBi |
Merville, M.-P., Deroyer, C., Bruyère, O., & Reginster, J.-Y. (March 2011). Strontium ranelate increases cell viability in IL-1 beta stimulated human chondrocytes [Paper presentation]. 1st IOF-ESCEO Pre-clinical Symposium (2011), European Congress on Osteoporosis and Osteoarthritis ECCEO11-IOF, Valencia, Spain. |
 | Papapoulos, S., Man, Z., Mellstrom, D., Radominski, S., Reginster, J.-Y., Resch, H., Roman, J., Roux, C., Cummings, S., Bone, H., Chapurlat, R., Brandi, M., Brown, J., Czerwinski, E., Daizadeh, N., Grauer, A., Krieg, M. A., & Libanati, C. (March 2011). Five-year Denosumab treatment of postmenopausal women with osteoporosis: results from the first two years of the freedom trial extension. Osteoporosis International, 22 (Suppl.1), 107-108. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Binkley, N., Boonen, S., Kiel, D., Ralston, S., Roux, C., Chen, L., Rosenberg, E., & Santora, A. (March 2011). Weekly alendronate plus vitamin D3 5,600 IU vs. standard care: effect on serum 25(OH) vitamin D, bone turnover markers, and BMD in osteoporotic postmenopausal women with vitamin D inadequacy - 1 year results of a randomized trial. Osteoporosis International, 22 (Suppl.1), 291-292. Peer Reviewed verified by ORBi |
 | Bruyère, O., Neuprez, A., Fossi, M., Zegels, B., LEONORI, L., Hiligsmann, M., & Reginster, J.-Y. (March 2011). Reimbursement of drugs against osteoporosis based on FRAX® instead of the current criteria would reduce by 30% the cost (in a societal perspective) of anti-osteoporosis treatment in Belgium. Osteoporosis International, 22 (Suppl.1), 333-334. Peer Reviewed verified by ORBi |
DEROISY, R., Bruyère, O., & Reginster, J.-Y. (March 2011). Stable precision over time when assessing the cartilage loss on knee osteoarthritis radiograph [Paper presentation]. 1st IOF-ESCEO Pre-clinical Symposium (2011), European Congress on Osteoporosis and Osteoarthritis ECCEO11-IOF, Valencia, Spain. |
 | Bruyère, O., Rabenda, V., & Reginster, J.-Y. (March 2011). A new definition of progressor in osteoarthritis clinical trial that takes into account intermediate visits: a proof of concept study. Osteoporosis International, 22 (Suppl.1), 367-368. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Gathon, H.-J., Bruyère, O., Beaudart, C., Kolh, P., JACQUES, J., Gillet, P., & Reginster, J.-Y. (March 2011). Patient out-of-pocket contributions related to hip fracture hospital costs in Belgium. Osteoporosis International, 22 (Suppl.1), 333. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Detilleux, J., Gillet, P., Parmentier, Y., Dercq, J.-P., Carton, J., & Reginster, J.-Y. (March 2011). Incidence of hip fracture in Belgium between 2000 and 2007 and future projections. Osteoporosis International, 22 (Suppl.1), 145. Peer Reviewed verified by ORBi |
 | Cummings, S. R., McClung, M., Reginster, J.-Y., Cox, D., Mitlak, B., Stock, J., Amewou-Atisso, M., Powles, T., Miller, P., Zanchetta, J., & Christiansen, C. (February 2011). Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. Journal of Bone and Mineral Research, 26 (2), 397-404. doi:10.1002/jbmr.191 Peer Reviewed verified by ORBi |
 | Bruyère, O., & Reginster, J.-Y. (2011). Les allégations de santé dans le domaine de la santé osseuse. Ortho-Rhumato, 9 (6), 215. Peer reviewed |
 | Rabenda, V., Bruyère, O., & Reginster, J.-Y. (2011). Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression. Osteoporosis International, 22, 893-901. doi:10.1007/s00198-010-1469-x Peer Reviewed verified by ORBi |
 | Brown, J. P., Bone, H. G., Chapurlat, R., Libanati, C., Brandi, M. L., Czerwinski, E., Krieg, M. A., Man, Z., Mellstrom, D., Radominski, S. C., Reginster, J.-Y., Resch, H., Roman Ivorra, J. A., Roux, C., Daizadeh, N. S., Grauer, A., Cummings, S. R., & Papapoulos, S. (2011). Extended safety observations from denosumab administration in postmenopausal women from FREEDOM and FREEDOM extension trials. Arthritis and Rheumatism, 63 (S10), 431-432. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2011). What's new on the horizon in therapy. Osteoporosis International, 22 (S5), 682. Peer Reviewed verified by ORBi |
 | Body, J. J., Bergmann, P., Boonen, S., Boutsen, Y., Bruyère, O., Devogelaer, J.-P., Goemaere, S., Hollevoet, N., Kaufman, J.-M., Milisen, K., Rozenberg, S., & Reginster, J.-Y. (2011). Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club. Osteoporosis International, 22 (11), 2769-88. doi:10.1007/s00198-011-1545-x Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2011). Ostéroporose, le mal sournois. Athena, 276, 22-25. |
 | Chapurlat, R., Bone, H. G., Brandi M L, Brown, J. P., Czerwinski, E., Daizadeh, N. S., Grauer, A., Krieg, M. A., Libanati, C., Man, Z., Mellstrom, D., Radominski, S., Reginster, J.-Y., & Resch, H. (2011). Treatment of postmenopausal women with osteoporosis for 5 years with denosumab : two-year results from the FREEDOM trial extension. Annals of the Rheumatic Diseases, 70 (S3), 166-167. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., McGowan, B., Bennett, K., Barry, M., & Reginster, J.-Y. (2011). The clinical and economic burden of poor adherence with osteoporosis medications in Ireland. Value in Health, 14, 312. Peer Reviewed verified by ORBi |
 | Chapurlat, R., Roux, C., Papapoulos, S., Man, Z., Mellstrom, D., Radominski, S., Reginster, J.-Y., Resch, H., Roman, J., Cummings, S., Bone, H., Brandi, M., Brown, J., Czerwinski, E., Daizadeh, N., Grauer, A., Krieg, M. A., & Libanati, C. (2011). Traitement durant cinq ans par denosumab (DMAb) chez des femmes ménopausées ostéoporotiques : résultats d'efficacité des deux premières années de l'extension de l'essai FREEDOM. Revue du Rhumatisme, 78 (S5), 214. Peer Reviewed verified by ORBi |
 | LECART, M.-P., & Reginster, J.-Y. (2011). Current options for the management of postmenopausal osteoporosis. Expert Opinion on Pharmacotherapy, 12 (16), 2533-52. doi:10.1517/14656566.2011.618123 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2011). Strontium ranelate : an effective solution whatever the patient profiles. Osteoporosis International, 22 (S5), 756-S757. Peer Reviewed verified by ORBi |
 | Bone, H. G., Chapurlat, R., Brandi, M. L., Brown, J. P., Czerwinski, E., Daizadeh, N., Grauer, A., Krieg, M.-A., Man, Z., Mellstrom, D., Radominski, S., Reginster, J.-Y., Resch, H., Roman, J. A., Roux, C., Cummings, S. R., Libanati, C., & Papapoulos, S. (2011). Denosumab therapy in postmenopausal women with osteoporosis : results from the first two years of the freedom trial extension. Endocrine Reviews, 32, 29-1. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2011). Glucosamine sulfate for structure modification in osteoarthritis : fact of fantasy ? Ortopedia, Traumatologia, Rehabilitacja, 13 (S1), 44. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Chapurlat, R., Christiansen, C., Genant, H., Bellamy, N., Bensen, W., Navarro, F., Badurski, J., Nasonov, E., Chevalier, X., Sambrook, P. N., & Cooper, C. (2011). Efficacy and safety of strontium ranelate in the treatment of knee ostoarthritis : a randomized, double-blind, placebo-controlled international trial. Osteoporosis International, 22 (S5), 742-S743. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2011). Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs, 71 (1), 65-78. doi:10.2165/11587570-000000000-00000 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Kaufman, J. M., Devogelaer, J. P., Benhamou, C. L., & Roux, C. (2011). Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Arthritis and Rheumatism, 63 (S10), 436. Peer Reviewed verified by ORBi |
 | Rizzoli, R., Akesson, K., Bouxsein, M., Kanis, J. A., Napoli, N., Papapoulos, S., Reginster, J.-Y., & Cooper, C. (2011). Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporosis International, 22, 373-390. doi:10.1007/s00198-010-1453-5 Peer Reviewed verified by ORBi |
 | Johansson, H., Kanis, J. A., McCloskey, E. V., Oden, A., Devogelaer, J. P., Kaufman, J. M., Neuprez, A., Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2011). A FRAX(R) model for the assessment of fracture probability in Belgium. Osteoporosis International, 22 (2), 453-61. doi:10.1007/s00198-010-1218-1 Peer Reviewed verified by ORBi |
 | Miossec, P., Verweij, C. L., Klareskog, L., Pitzalis, C., Barton, A., Lekkerkerker, F., Reiter, S., Laslop, A., Breedveld, F., Abadie, E., Flamion, B., Dere, W., Mpofu, S., Goel, N., Ethgen, O., Mitlak, B., Ormarsdottir, S., RAO, R. F., Tsouderos, Y., & Reginster, J.-Y. (2011). Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Annals of the Rheumatic Diseases, 70 (10), 1713-8. doi:10.1136/ard.2011.154252 Peer Reviewed verified by ORBi |
 | Smolen, J. S., Boers, M., Abadie, E., Breedveld, F. C., Emery, P., Bardin, T., Goel, N., Ethgen, D. J., Avouac, B. P., Dere, W. H., Durez, P., Matucci-Cerinic, M., Flamion, B., Laslop, A., Lekkerkerker, F. J., Miossec, P., Mitlak, B. H., Ormarsdottir, S., Paolozzi, L., ... Reginster, J.-Y. (2011). Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. Current Medical Research and Opinion, 27 (2), 315-25. doi:10.1185/03007995.2010.542135 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., & Reginster, J.-Y. (2011). Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. PharmacoEconomics, 29 (10), 895-911. doi:10.2165/11539980-000000000-00000 Peer Reviewed verified by ORBi |
 | Bone, H., Chapurlat, R., Brandi, M., Brown, J., Czerwinski, E., Daizadeh, N., Grauer, A., Krieg, M., Man, Z., Mellstrom, D., Radominski, S., Reginster, J.-Y., Resch, H., Roman, J., Roux, C., Cummings, S., Libanati, C., Papopoulos, S., & Thiebaud, D. (2011). Long-term denosuamab treatment in postmenopausal women with osteoporosis : results from the first two years of the FREEDOM trial extension. Osteoporosis International, 22 (S4), 527-S528. Peer Reviewed verified by ORBi |
 | Bruyère, O., Nicolet, D., Compère, S., Rabenda, V., Jeholet, P., Maassen, P., Pire, G., & Reginster, J.-Y. (2011). Perception, connaissance et utilisation de l'outil FRAX auprès des médecins généralistes de la Province de Liège (Belgique). Revue du Rhumatisme, 78 (S5), 142. Peer Reviewed verified by ORBi |
 | Bruyère, O., & Reginster, J.-Y. (2011). Relation entre les variations de densité minérale osseuse et l'incidence des fractures vertébrales : analyse des 2 dernières années de 10 ans de traitement par ranélate de strontium. Revue du Rhumatisme, 78 (S5), 217. Peer Reviewed verified by ORBi |
 | Orwoll, E., Stubbe Teglbjaerg, C., Langdahl, B., Chapurlat, R., Czerwinski, E., Kenkler, D. L., Reginster, J.-Y., Kivitz, A., Lewieck, E. M., Miller, P., Bolognese, M. A., Bone, H. G., Ljunggren, O., Abrahamsen, B., Yan, Y.-C., Grauer, A., Libanati, C., Hall, J. W., & Boonen, S. (2011). A phase 3 study of the efficacy and safety of Denosumab in men with low bone mineral density : design of the ADAMO. Journal of Bone and Mineral Research, 26 (S1), 511. Peer Reviewed verified by ORBi |
 | Boonen, S., Kaufman, J. M., Reginster, J.-Y., Rizzoli, R., Lippuner, K., Vanderschueren, D., Hruska, J., Antunez, O., Papanastasiou, P., Su, G., & Orwoll, E. (2011). Reduction in incidence of vertebral fractures with once yearly zoledronic acid in men with osteoporosis. Journal of Bone and Mineral Research, 26 (S1), 23. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Kaufman, J. M., Devogelaer, J. D., Benhamou, C. L., & Roux, C. (2011). Long-term treatment of postmenopausal osteoporotic women with strontium ranelate : results at 10 years. Annals of the Rheumatic Diseases, 70 (S3), 167. Peer Reviewed verified by ORBi |
 | Rizzoli, R., & Reginster, J.-Y. (2011). Adverse drug reactions to osteoporosis treatments. Expert Review of Clinical Pharmacology, 4 (5), 593-604. doi:10.1586/ecp.11.42 Peer Reviewed verified by ORBi |
 | Musette, P., Kaufman, J.-M., Rizzoli, R., Cacoub, P., Brandi, M. L., & REGINSTER, J.-Y. (2011). Cutaneous side effects of antiosteoporosis treatments. Therapeutic Advances in Musculoskeletal Disease, 3 (1), 31-41. doi:10.1177/1759720X10387202 Peer Reviewed verified by ORBi |
 | Bone, H. G., Chapurlat, R., Libanati, C., Brandi ML, Brown, J. P., Czerwinski, E., Krieg, M. A., Man, Z., Mellstrom, D., Radominski, S. C., Reginster, J.-Y., Resch, H., Roman Ivorra, J. A., Roux, C., Daizadeh, N. S., Grauer, A., Cummings, S. R., & Papapoulos, S. (2011). Safety observations from denosumab long-term extension and cross-over studies in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research, 26 (S1), 22-23. Peer Reviewed verified by ORBi |
 | Rizzoli, R., Reginster, J.-Y., Boonen, S., Breart, G., Diez-Perez, A., Felsenberg, D., Kaufman, J.-M., Kanis, J. A., & Cooper, C. (2011). Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcified Tissue International, 89 (2), 91-104. doi:10.1007/s00223-011-9499-8 Peer Reviewed verified by ORBi |
 | Ralston, S. H., Binkley, N., Boonen, S., Kiel, D. P., Reginster, J.-Y., Roux, C., Chen, L., Rosenberg, E., & Santora, A. (2011). Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency. Calcified Tissue International, 88 (6), 485-94. doi:10.1007/s00223-011-9482-4 Peer Reviewed verified by ORBi |
 | Miller, P. D., Recker, R. R., Reginster, J.-Y., Riis, B. J., Czerwinski, E., Masanauskaite, D., Kenwright, A., Lorenc, R., Stakkestad, J. A., & Lakatos, P. (2011). Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study. Osteoporosis International. doi:10.1007/s00198-011-1773-0 Peer Reviewed verified by ORBi |
 | Kanis, J. A., Cooper, C., Hiligsmann, M., Rabenda, V., Reginster, J.-Y., & Rizzoli, R. (2011). Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporosis International, 22 (10), 2565-73. doi:10.1007/s00198-011-1668-0 Peer Reviewed verified by ORBi |
 | Roux, C., Chartier, C., Boonen, S., Douglas, K., Ralston, S., Reginster, J.-Y., Chen, L., Rosenberg, E., & Santora, A. (2011). Taux sérique de vitamine D et réponse au traitement par alendronate. Revue du Rhumatisme, 78 (S5), 102. Peer Reviewed verified by ORBi |
 | Smolen, J. S., Boers, M., Abadie, E., Breedveld, F. C., Emery, P., Bardin, T., Goel, N., Ethgen, D. J., Avouac, B. P., Durez, P., Flamion, B., Laslop, A., Miossec, P., Reiter, S., & Reginster, J.-Y. (2011). Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis. Rheumatology, 50 (10), 1732-6. doi:10.1093/rheumatology/keq413 Peer Reviewed verified by ORBi |
 | Bruyère, O., Neuprez, A., Fossi, M., Beaudart, C., Zegels, B., Leonori, L., Hiligsmann, M., & Reginster, J.-Y. (November 2010). Le remboursement des traitements contre l'ostéoporose basé sur l'utilisation de l'outil FRAX plutôt que sur les critères actuels permettrait de réduire de 30% le coût, dans une perspective sociétale, du traitement de l'ostéoporose en Belgique. Revue du Rhumatisme, 77 (Suppl.3), 66-67. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Neuprez, A. (November 2010). Strontium ranelate: a look back at its use for osteoporosis. Expert Opinion on Pharmacotherapy, 11 (17), 2915-2927. doi:10.1517/14656566.2010.533170 Peer Reviewed verified by ORBi |
 | Merville, M.-P., Deroyer, C., Bruyère, O., & Reginster, J.-Y. (November 2010). Le ranélate de strontium augmente la viabilité de chondrocytes humains stimulés par IL-1 bêta. Revue du Rhumatisme, 77 (Suppl.3), 222. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Kaufman, J.-M., Goemaere, S., Benhamou, C. L., Balogh, A., Albanese, C., Badurski, J., & Roux, C. (November 2010). Ranélate de strontium : efficacité à long terme sur 10 ans chez les femmes ménopausées ostéoporotiques. Revue du Rhumatisme, 77 (Suppl.3), 99-100. Peer Reviewed verified by ORBi |
Hiligsmann, M., & Reginster, J.-Y. (November 2010). Intérêts des analyses économiques dans la prise en charge de l’ostéoporose postménopausée. |
 | Hiligsmann, M., & Reginster, J.-Y. (November 2010). Cost-effectiveness of denosumab compared with generic alendronate in the treatment of postmenopausal osteoporotic women. Value in Health, 13 (7), 309. doi:10.1016/S1098-3015(11)72193-3 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Detilleux, J., Gillet, P., Parmentier, Y., Dercq, J.-P., Carton, J., & Reginster, J.-Y. (November 2010). Trend of hip fracture incidence in Belgium between 2000 and 2007 and future projections. Value in Health, 13 (7), 303. doi:10.1016/S1098-3015(11)72162-3 Peer Reviewed verified by ORBi |
 | Bruyère, O., Hiligsmann, M., Zegels, B., Neuprez, A., & Reginster, J.-Y. (November 2010). Résider en institution : un facteur de risque indépendant de fractures de hanche ? Une étude prospective d’une durée de 3 ans. Revue du Rhumatisme, 77 (Suppl.3), 67-68. Peer Reviewed verified by ORBi |
 | Bruyère, O., Collette, J., & Reginster, J.-Y. (November 2010). Effet à long terme du ranélate de strontium sur le taux sérique de propeptide C-terminal du collagène de type I (PICP) et sur le taux urinaire de télopeptide N-terminal du collagène de type I (U-NTX) chez des femmes ménopausées atteintes d’ostéoporose. Revue du Rhumatisme, 77 (Suppl.3), 183. Peer Reviewed verified by ORBi |
 | Collette, J., Bruyère, O., & Reginster, J.-Y. (November 2010). Effet du ranélate de strontium sur le taux d’ostéoprotégérine sérique chez des femmes ménopausées ostéoporotiques traitées pendant 3 ans. Revue du Rhumatisme, 77 (Suppl.3), 184. Peer Reviewed verified by ORBi |
 | Bruyère, O., Ethgen, O., Neuprez, A., Zegels, B., Gillet, P., Huskin, J.-P., & Reginster, J.-Y. (November 2010). Etude de la qualité de vie après la mise en place d’une prothèse de hanche ou de genou pour cause d’arthrose : une étude de cohorte avec un suivi de 7 ans. Revue du Rhumatisme, 77 (Suppl.3), 141. Peer Reviewed verified by ORBi |
 | Chapurlat, R., Papapoulos, S., Bone, H. G., Brandi, M. L., Brown, J., Czerwinski, E., Daizadeh, N. S., Grauer, A., Haller, C., Krieg, M.-A., Libanati, C., Man, Z., Mellstrom, D., Radominski, S., Reginster, J.-Y., Resch, H., Roman Ivora, J. A., & Cummings, S. R. (October 2010). Long-term denosumab treatment of postmenopausal women with osteoporosis: results from the first year extension study of the FREEDOM trial. Arthritis and Rheumatism, 62 (10), 903. Peer Reviewed verified by ORBi |
 | Saag, K., Roux, C., Devogelaer, J. P., Lau, C. S., Reginster, J.-Y., Bucci-Rechtweg, C., Su, G., Sambrook, P. N., & Reid, D. M. (October 2010). Effectiveness of zoledronic acid in the prevention and treatment of glucocorticoid-induced osteoporosis in men and premenopausal women. Arthritis and Rheumatism, 62 (10), 902-S903. Peer Reviewed verified by ORBi |
 | Bruyère, O., Detilleux, J., Akadi, C., & Reginster, J.-Y. (October 2010). Relationship between changes in bone mineral density or bone turnover markers and vertebral fracture incidence in patients treated with bazedoxifene. Arthritis and Rheumatism, 62 (10), 406-S407. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., DEBERG, M., Henrotin, Y., & Christgau, S. (01 June 2010). Method for monitoring collagen type II degradation in cartilage. |
 | Reginster, J.-Y., Hiligsmann, M., & Bruyère, O. (June 2010). Strontium ranelate: long-term efficacy against vertebral, nonvertebral and hip fractures in patients with postmenopausal osteoporosis. Therapeutic Advances in Musculoskeletal Disease, 2 (3), 133-143. doi:10.1177/1759720X10362824 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (June 2010). Preparing new regulatory guidelines: the role of the Group for the Respect of Ethics and Excellence in Science (GREES). Annals of the Rheumatic Diseases, 69 (Suppl.3), 42. Peer Reviewed verified by ORBi |
 | Bruyère, O., Vanoverberghe, M., Neuprez, A., Ethgen, O., Zegels, B., Gillet, P., Huskin, J.-P., & Reginster, J.-Y. (June 2010). Health-related quality of life after total knee or hip replacement: a 7-year prospective study. Annals of the Rheumatic Diseases, 69 (Suppl.3), 469. Peer Reviewed verified by ORBi |
 | Bruyère, O., Collette, J., & Reginster, J.-Y. (June 2010). Long-term effect of strontium ranelate on serum C-terminal propeptide of type I Procollagen (PICP) and urine cross-linked N-telopeptide (U-NTX) in women with postmenopausal osteoporosis. Annals of the Rheumatic Diseases, 69 (Suppl.3), 602. Peer Reviewed verified by ORBi |
 | Collette, J., Bruyère, O., Vanoverberghe, M., & Reginster, J.-Y. (June 2010). Effect of strontium ranelate on serum osteoprotegerin in women with postmenopausal osteoporosis treated over three years. Annals of the Rheumatic Diseases, 69 (Suppl.3), 602. Peer Reviewed verified by ORBi |
 | Zegels, B., Theiler, M., Crozes, P., Uebelhart, D., & Reginster, J.-Y. (May 2010). Single oral dose of (1200 mg) sachet of chondroitin 4&6 sulfate (CS) relieves pain and improves function. Results of a double-blind study, versus placebo and an active treatment in knee OA patients. Osteoporosis International, 21 (Suppl.1), 356. Peer Reviewed verified by ORBi |
 | Bruyère, O., Vanoverberghe, M., Neuprez, A., Ethgen, O., Zegels, B., Gillet, P., Huskin, J.-P., & Reginster, J.-Y. (May 2010). Health-related quality of life after total knee or hip replacement : a 7-year prospective study. Osteoporosis International, 21 (Suppl.1), 26. Peer Reviewed verified by ORBi |
 | SCHOLTISSEN, S., Bruyère, O., Neuprez, A., Severens, H., Herrero-Beaumont, G., Rovati, L., Hiligsmann, M., & Reginster, J.-Y. (May 2010). Cost-effectiveness of glucosamine sulfate compared to acetaminophen in the treatment of knee osteoarthrits: a French health care perspective. Osteoporosis International, 21 (Suppl.1), 167. Peer Reviewed verified by ORBi |
 | Sambrook, P. N., Roux, C., Devogelaer, J. P., Saag, K., Lau, C. S., Reginster, J.-Y., Bucci-Rechtweg, C., Su, G., & Reid, D. M. (May 2010). Bisphosphonates and glucocorticoid osteoporosis in men : results of a randomized controlled trial comparing zoledronic acid with risedronate. Osteoporosis International, 21 (Suppl.1), 19. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., & Reginster, J.-Y. (May 2010). Cost-effectiveness of denosumab compared with oral bisphosphonates in the treatment of postmenopausal osteoporotic women. Osteoporosis International, 21 (S1), 30. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., McClung, M., Cox, D., Mitlak, B., Stock, J., Amewou-Atisso, M., Miller, P., Christiansen, C., & Cummings, S. (May 2010). Effects of arzoxifene on fracture incidence in postmenopausal women with osteoporosis or with low bone mass. Osteoporosis International, 21 (Suppl.1), 23-24. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., Bruyère, O., & Reginster, J.-Y. (May 2010). The burden of non-adherence with oral bisphosphonates and the potential cost-effectiveness of adherence-enhancing interventions. Osteoporosis International, 21 (S1), 381. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (May 2010). Interpreting the current evidence on glucosamine sulfate effects as a symptom-modifying drug in knee osteoarthtritis. Osteoporosis International, 21 (Suppl.1), 395. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & De Vriese, S. (May 2010). The impact of nutrition on bone health. Osteoporosis International, 21 (Suppl.1), 389. doi:10.1007/s00198-010-1245-y Peer Reviewed verified by ORBi |
 | Deroisy, R., Roux, J. P., Bruyère, O., Gensburger, D., Chapurlat, R., & Reginster, J.-Y. (May 2010). Long term agreement between two different centres regarding joint space narrowing measurement in knee osteoarthritis. Osteoporosis International, 21 (Suppl.1), 233-234. Peer Reviewed verified by ORBi |
 | Neuprez, A., Johansson, H., Kanis, J., McCloskey, E. V., Oden, A., Bruyère, O., Hiligsmann, M., Devogelaer, J., Kaufman, J., & Reginster, J.-Y. (May 2010). A FRAX® model for the assessment of fracture probability in Belgium. Osteoporosis International, 21 (Suppl.1), 255. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Neuprez, A., Hiligsmann, M., & Bruyère, O. (February 2010). Oral calcitonin in the management of osteoarthritis: hope or fantasy ? International Journal of Clinical Rheumatology, 5 (1), 53-58. doi:10.2217/ijr.09.68 Peer Reviewed verified by ORBi |
 | Bruyère, O., Cavalier, E., Collette, J., & Reginster, J.-Y. (2010). La vitamine D en association avec le calcium dans le traitement de l’ostéoporose. Ortho-Rhumato, 8, 53-55. |
 | Hiligsmann, M., Gathon, H.-J., Bruyère, O., Ethgen, O., Rabenda, V., & Reginster, J.-Y. (2010). Cost-Effectiveness of Osteoporosis Screening Followed by Treatment: The Impact of Medication Adherence. Value in Health, 13 (4), 394-401. doi:10.1111/j.1524-4733.2009.00687.x Peer Reviewed verified by ORBi |
 | Collette, J., Bruyère, O., Vanoverberghe, M., & Reginster, J.-Y. (2010). Effect of strontium ranelate on serum osteoprotegerin in women with postmenopausal osteoporosis treated over three years. Osteoporosis International, 21 (Suppl.1), 311-312. Peer Reviewed verified by ORBi |
 | Rabenda, V., Bruyère, O., & Reginster, J.-Y. (2010). Relationship between bone mineral density changes and risk of nonvertebral fractures among women receiving calcium with or without vitamin D supplementation: a meta-analysis. Osteoporosis International, 21 (Suppl.1), 268. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2010). Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. BONE, 46 (2), 440-6. doi:10.1016/j.bone.2009.08.052 Peer Reviewed verified by ORBi |
 | Rabenda, V., & Reginster, J.-Y. (2010). Prévention et traitement de l’ostéoporose: éviter l’inertie clinique et motiver l’adhésion au traitement. Revue Médicale de Liège, 65, 358-365. Peer reviewed |
 | Collette, J., Bruyère, O., Kaufman, J. M., Lorenc, R., Felsenberg, D., Spector, T. D., Diaz-Curiel, M., Boonen, S., & Reginster, J.-Y. (2010). Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover. Osteoporosis International, 21 (2), 233-41. doi:10.1007/s00198-009-0940-z Peer Reviewed verified by ORBi |
 | Bruyère, O., Reginster, J.-Y., Croisier, J.-L., Crielaard, J.-M., & Maquet, D. (2010). Rehabilitation in osteoporotic subjects - Myth or reality? European Musculoskeletal Review, 5 (1), 36-39. Peer reviewed |
 | Bruyère, O., Collette, J., & Reginster, J.-Y. (2010). The effects of strontium ranelate on biochemical markers of bone turnover and their relationship with bone mineral density: reply to Stepan et al. Osteoporosis International, 21, 1039-1040. doi:10.1007/s00198-009-1156-y Peer Reviewed verified by ORBi |
 | Seeman, E., Boonen, S., Borgstrom, F., Vellas, B., Aquino, J.-P., Semler, J., Benhamou, C.-L., Kaufman, J.-M., & Reginster, J.-Y. (2010). Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. BONE, 46 (4), 1038-42. doi:10.1016/j.bone.2009.12.006 Peer Reviewed verified by ORBi |
 | Body, J. J., Bergmann, P., Boonen, S., Boutsen, Y., Devogelaer, J. P., Goemaere, S., Kaufman, J. M., Rozenberg, S., & Reginster, J.-Y. (2010). Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporosis International, 21 (10), 1657-80. doi:10.1007/s00198-010-1223-4 Peer Reviewed verified by ORBi |
 | Bruyère, O., Kanis, J. A., Ibar-Abadie, M.-E., Alsayed, N., Brandi, M. L., Burlet, N., Cahall, D. L., Chines, A., Devogelaer, J.-P., Dere, W., Goel, N., Hughes, N., Kaufman, J.-M., Korte, S., Mitlak, B. H., Niese, D., Rizzoli, R., Rovati, L. C., & Reginster, J.-Y. (2010). The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). Osteoporosis International, 21 (5), 713-22. doi:10.1007/s00198-010-1190-9 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., Gathon, H.-J., Ethgen, O., & Reginster, J.-Y. (2010). Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications. Calcified Tissue International, 86, 202-210. doi:10.1007/s00223-009-9329-4 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2010). National implementation of the ESCEO guidance and its consequences. Medicographia, 32, 67-70. Peer reviewed |
 | Reginster, J.-Y., & Brandi, M. L. (2010). Fracture prevention in osteoporosis: assessing risks, providing solutions. Osteoporosis International, 21 Suppl 2, 401-2. doi:10.1007/s00198-010-1243-0 Peer Reviewed verified by ORBi |
 | Scheen, A., Hanssens, L., Wampers, M., Van Winkel, R., Collette, J., Reginster, J.-Y., & de Hert, M. A. (2010). Effets contrastés de l’olanzapine et de la rispéridone sur les taux plasmatiques d’adiponectine chez les patients schizophrènes nouvellement traités. In Diabetes and Metabolism (pp. 21, O78). Elsevier. Peer reviewed |
 | Devogelaer, J. P., Reginster, J.-Y., Rompen, E., Boutsen, Y., Body, J. J., Bergmann, P., Rozenberg, S., GASPARD, U., & Reychler, H. (2010). L'ostéonécrose maxillaire associée aux traitements aux bisphosphonates dans le traitement de l'ostéoporose. Consensus interdisciplinaire. Louvain Medical, 129 (8), 305-309. Peer reviewed |
 | Reginster, J.-Y. (2010). Interest of lasofoxifene in the treatment of osteoporosis. Evaluation of "Lasofoxifene in postmenopausal women with osteoporosis". N Engl J Med 2010;362:686-96. Expert Opinion on Pharmacotherapy, 11 (10), 1773-5. doi:10.1517/14656561003785755 Peer Reviewed verified by ORBi |
 | Bruyère, O., Collette, J., & Reginster, J.-Y. (2010). Long-term effect of strontium ranealte on serum C-terminal propeptide of type I procollagen (PICP) and urine cross-linked N-telopeptide (U-NTX) in women with postmenopausal osteoporosis. Osteoporosis International, 21 (Suppl.1), 312. Peer Reviewed verified by ORBi |
 | Bruyère, O., Reginster, J.-Y., Croisier, J.-L., Crielaard, J.-M., & Maquet, D. (2010). Rehabilitation in osteoarthritis. Therapy, 7 (6), 669-674. doi:10.2217/thy.10.76 Peer Reviewed verified by ORBi |
 | Rabenda, V., & Reginster, J.-Y. (2010). Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures. Osteoporosis International, 21 (12), 1993-2002. doi:10.1007/s00198-009-1155-z Peer Reviewed verified by ORBi |
 | Pelletier, J.-P., Martel-Pelletier, J., & Reginster, J.-Y. (2010). Osteoarthritis in 2010. Therapy, 7 (6), 575-577. doi:10.2217/thy.10.71 Peer Reviewed verified by ORBi |
 | SCHOLTISSEN, S., Bruyère, O., NEUPREZ, A., Severens, J. L., Herrero-Beaumont, G., Rovati, L., Hiligsmann, M., & Reginster, J.-Y. (2010). Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. International Journal of Clinical Practice, 64 (6), 756-62. doi:10.1111/j.1742-1241.2010.02362.x Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2010). Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporosis International, 21, 157-165. doi:10.1007/s00198-009-0924-z Peer Reviewed verified by ORBi |
 | Hiligsmann, M., & Reginster, J.-Y. (2010). Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. BONE, 47, 34-40. doi:10.1016/j.bone.2010.03.009 Peer Reviewed verified by ORBi |
 | Bruyère, O., Collette, J., Rizzoli, R., Decock, C., Ortolani, S., Cormier, C., Detilleux, J., & Reginster, J.-Y. (2010). Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. Osteoporosis International, 21, 1031-1036. doi:10.1007/s00198-009-1078-8 Peer Reviewed verified by ORBi |
Reginster, J.-Y. (2010). Strontium ranelate: a new era in the management of osteoporosis. In Chinese Journal of Osteoporosis (pp. 1). Peer reviewed |
 | Musette, P., Brandi, M. L., Cacoub, P., Kaufman, J. M., Rizzoli, R., & Reginster, J.-Y. (2010). Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporosis International, 21, 723-732. doi:10.1007/s00198-009-1097-5 Peer Reviewed verified by ORBi |
Neuprez, A., & Reginster, J.-Y. (2010). Prevention and treatment of postmenopausal osteoporosis. In R. Rizzoli (Ed.), Atlas of postmenopausal osteoporosis (Third edition, pp. 83-114). London, United Kingdom: Current Medicine Group Publ. |
 | Breart, G., Cooper, C., Meyer, O., Speirs, C., Deltour, N., & Reginster, J.-Y. (2010). Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database. Osteoporosis International, 21, 1181-1195. doi:10.1007/s00198-009-1050-7 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., Bruyère, O., & Reginster, J.-Y. (2010). The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy, 96, 170-176. doi:10.1016/j.healthpol.2010.01.014 Peer reviewed |
 | Reginster, J.-Y., Altman, R. D., & Hochberg, M. C. (2010). Prescribed regimen is effective [letter to the editor]. BMJ: British Medical Journal, 341, 6335. doi:10.1136/bmj.c6335 Peer Reviewed verified by ORBi |
 | Rabenda, V., & Reginster, J.-Y. (2010). Overcoming problems with adherence to osteoporosis medication. Expert Review of Pharmacoeconomics and Outcomes Research, 10 (6), 677-89. doi:10.1586/erp.10.76 Peer Reviewed verified by ORBi |
 | Bergmann, P., Body, J. J., BOONEN, S., Boutsen, Y., Devogelaer, J. P., Goemaere, S., Kaufman, J., Reginster, J.-Y., & Rozenberg, S. (2010). Loading and skeletal development and maintenance. Journal of Osteoporosis, 2011, 786752. doi:10.4061/2011/786752 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Vanoverberghe, M., Neuprez, A., Bruyère, O., & Reginster, J.-Y. (2010). Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis. Expert Review of Pharmacoeconomics and Outcomes Research, 10 (4), 359-366. doi:10.1586/erp.10.53 Peer Reviewed verified by ORBi |
 | Neuprez, A., Johansson, H., Kanis, J., McCloskey, E. V., Oden, A., Bruyère, O., Hiligsmann, M., Devogelaer, J.-P., Kaufmann, J.-M., & Reginster, J.-Y. (December 2009). Rationalisation du remboursement des médicaments de l'ostéoporose : de la mesure isolée de la densité osseuse à l’intégration des facteurs cliniques de risque fracturaire. Validation de l’algorithme FRAX®. Revue Médicale de Liège, 64 (12), 612-619. Peer reviewed |
 | Hiligsmann, M., Rabenda, V., Bruyère, O., & Reginster, J.-Y. (October 2009). The clinical and economic burden of nonadherence with osteoporosis medications. Value in Health, 12 (7), 444. doi:10.1016/S1098-3015(10)75197-4 Peer Reviewed verified by ORBi |
 | Bruyère, O., COLLETTE, J., DEROISY, R., Rabenda, V., Neuprez, A., Hiligsmann, M., & Reginster, J.-Y. (October 2009). Biochemical markers of bone and cartilage remodelling: interest in the prediction of lumbar disc degeneration progression and effects of strontium ranelate over a 3-year period. Arthritis and Rheumatism, 60 (number 10 (suppl.)), 313. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., Bruyère, O., & Reginster, J.-Y. (October 2009). The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Arthritis and Rheumatism, 60 (number 10 (suppl.)), 328. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., & Reginster, J.-Y. (June 2009). The clinical and economic burden of nonadherence with oral bisphosphonates in osteoporotic patients. Annals of the Rheumatic Diseases, 68 (S3), 667. Peer Reviewed verified by ORBi |
 | Haris, S. T., Reginster, J.-Y., Harley, C., Blumentals, W. A., Poston, S. A., & Silverman, S. L. (May 2009). Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. BONE, 44, 758-765. Peer Reviewed verified by ORBi |
 | Sambrook, P., Reid, D., Devogelaer, J.-P., Reginster, J.-Y., Saag, K., Roux, C., Papanastasiou, P., Maylandt, K., Fashola, T., & Mesenbrink, P. (April 2009). Effect of single annual infusion of zoledronic acid on bone turnover markers versus daily oral risedronate in patients with glucocorticoid-induced osteoporosis. Osteoporosis International, 20 (Suppl.1), 128-129. Peer Reviewed verified by ORBi |
 | Bruyère, O., Collette, J., Deroisy, R., Rabenda, V., Hiligsmann, M., & Reginster, J.-Y. (March 2009). Prediction of spinal osteoarthritis progression by assessment of biochemical markers of bone and cartilage remodelling: a 3-year study. Osteoporosis International, 20 (Suppl.1), 8. Peer Reviewed verified by ORBi |
 | Felsenberg, D., Czerwinski, E., Stakkestad, J., Neate, C., Masanauskaite, D., & Reginster, J.-Y. (March 2009). Efficacy of monthly oral ibandronate is maintained over 5 years: The MOBILE LTE study. Osteoporosis International, 20 (Suppl.1), 15. Peer Reviewed verified by ORBi |
 | Richy, F., Dukas, L., & Reginster, J.-Y. (March 2009). Prevention of falls, bone loss and fractures : D-hormone analogs or native vitamin D? a meta-perspective. Osteoporosis International, 20 (Suppl.1), 90. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., & Reginster, J.-Y. (March 2009). Cost-utility of denosumab for the treatment of postmenopausal osteoporotic women. Osteoporosis International, 20 (S1), 5. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Neuprez, A., Scholtissen, S., & Reginster, J.-Y. (March 2009). Cost-effectiveness of strontium ranelate versus intravenous ibandronate in the treatment of postmenopausal women. Osteoporosis International, 20 (S1), 130. Peer Reviewed verified by ORBi |
 | Bruyère, O., & Reginster, J.-Y. (March 2009). Treatment of osteoarthritis with glucosamine sulftate: from clinical to economic data. Osteoporosis International, 20 (Suppl.1), 182. Peer Reviewed verified by ORBi |
 | Bruyère, O., Decock, C., Collette, J., Ortolani, S., Cormier, C., Detilleux, J., Frankinet, P., & Reginster, J.-Y. (March 2009). Relationship between 3-month changes in biochemical markers of bone remodelling and 3-year changes in bone mineral density in patients treated with strontium ranelate. Osteoporosis International, 20 (Suppl.1), 86-87. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., Gathon, H.-J., Ethgen, O., & Reginster, J.-Y. (March 2009). Clinical en economic implications of non-adherence with osteoporosis medications. Osteoporosis International, 20 (S1), 16. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (March 2009). Cost-utility of strontium ranelate for the prevention and treatment of postmenopausal osteoporotic women. Osteoporosis International, 20 (S1), 129. Peer Reviewed verified by ORBi |
 | Bruyère, O., Detilleux, J., Decock, C., & Reginster, J.-Y. (March 2009). Relationship between changes in bone mineral density and vertebral fracture incidence: an analysis of the last 3 years of an 8-year treatment with strontium ranelate. Osteoporosis International, 20 (Suppl.1), 11. Peer Reviewed verified by ORBi |
 | Rabenda, V., & Reginster, J.-Y. (March 2009). Positive impact of compliance to strontium ranelate on the risk of non-vertebral osteoporotic fractures. Osteoporosis International, 20 (Suppl.1), 89. Peer Reviewed verified by ORBi |
 | Siverman, S., Poston, S., Blumenthals, W., & Reginster, J.-Y. (March 2009). Fracture risk in women ≥ 65 years with once-monthly oral bisphosphonate compared with weekly bisphosphonates: subanalysis from the evaluation of ibandronate efficacy (VIBE) database study. Osteoporosis International, 20 (Suppl.1), 153. Peer Reviewed verified by ORBi |
 | Bruyère, O., Hiligsmann, M., Frankinet, P., Detilleux, J., & Reginster, J.-Y. (March 2009). Association between changes in bone mineral density and fracture incidence in postmenopausal women receiving calcium and vitamin D : A 3-year study. Osteoporosis International, 20 (Suppl.1), 87-88. Peer Reviewed verified by ORBi |
 | Scholtissen, S., Bruyère, O., Hiligsmann, M., Neuprez, A., Pavelka, K., Rovati, L., & Reginster, J.-Y. (March 2009). Effect of glucosamine sulfate on health utility data in patients with knee osteoarthritis : reanalysis of two 3-year prospective studies. Osteoporosis International, 20 (Suppl.1), 18. Peer Reviewed verified by ORBi |
 | Rabenda, V., Bruyère, O., & Reginster, J.-Y. (March 2009). Relationship between changes in bone mineral density and compliance to strontium ranelate. Osteoporosis International, 20 (Suppl.1), 152-153. Peer Reviewed verified by ORBi |
 | Goemaere, S., Pornel, B., Mathy, L., van Steenberghe, Thomas, M., & Reginster, J.-Y. (March 2009). BEATRIS - Better adherence to treatment with ibandronate in osteoporosis: bone markers feedback study. Osteoporosis International, 20 (Suppl.1), 23. Peer Reviewed verified by ORBi |
 | Roux, C., Fashola, T., Reid, D., Devogelaer, J.-P., Saag, K., Lau, C., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., & Hartl, F. (March 2009). Effect on single annual infusion of zoledronic acid (5mg) on lumbar spine bone mineral density versus daily oral risedronate (5mg) in subgroups of patients receiving glucocorticoid therapy. Osteoporosis International, 20 (Suppl.1), 7-8. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Devogelaer, J.-P., Hiligsmann, M., Kaufman, J.-M., Neuprez, A., Johansson, H., & Kanis, J. A. (March 2009). FRAX(r) and the assessment of fracture probability in men and women from Belgium. Osteoporosis International, 20 (Suppl.1), 38-39. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (March 2009). How does the efficacy of Protelos translate into patient benefits ? Osteoporosis International, 20 (Suppl.1), 178. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (March 2009). The antifracture efficacy of ibandronate: a compendium of evidence. Osteoporosis International, 20 (Suppl.1), 182-183. Peer Reviewed verified by ORBi |
 | Scholtissen, S., Bruyère, O., Hiligsmann, M., Neuprez, A., Herrero-Beaumont, G., Rovati, L., & Reginster, J.-Y. (March 2009). Glucosamine sulfate in the treatment of knee osteoarthritis: impact on health utility. Osteoporosis International, 20 (Suppl.1), 149. Peer Reviewed verified by ORBi |
 | NEUPREZ, A., Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2009). Efficacite anti-fracturaire de l'ibandronate administre par voie intraveineuse: de la complexite des etudes epidemiologiques interventionnelles a la pratique quotidienne. Revue Médicale de Liège, 64 (10), 525-9. Peer reviewed |
 | Kaux, J.-F., Le Goff, C., Debray, F.-G., Crielaard, J.-M., & Reginster, J.-Y. (2009). Le cas clinique du mois. Osteogenesis imperfecta. Revue Médicale de Liège. Peer reviewed |
 | Rizzoli, R., Bruyère, O., Cannata-Andia, J. B., Devogelaer, J.-P., Lyritis, G., Ringe, J. D., Vellas, B., & Reginster, J.-Y. (2009). Management of osteoporosis in the elderly. Current Medical Research and Opinion, 25 (10), 2373-2387. doi:10.1185/03007990903169262 Peer Reviewed verified by ORBi |
 | Bruyère, O., Scholtissen, S., Neuprez, A., Severens, H., Herrero-Beaumont, G., Rovati, L., Hiligsmann, M., & Reginster, J.-Y. (2009). Analyses coût-efficacité du sulfate de glucosamine chez des patients gonarthrosiques : comparaison avec le paracétamol. Revue du Rhumatisme, 76, 1097. Peer Reviewed verified by ORBi |
 | Bruyère, O., Scholtissen, S., Neuprez, A., Hiligsmann, M., & Reginster, J.-Y. (2009). Effets du sulfate de chondroitine sur les indices d'utilité de santé chez des sujets gonarthrosiques et analyses économiques préliminaires. Revue du Rhumatisme, 76, 1051. Peer Reviewed verified by ORBi |
 | Bergmann, P., Body, J.-J., Boonen, S., Boutsen, Y., Devogelaer, J.-P., Goemaere, S., Kaufman, J.-M., Reginster, J.-Y., & Gangji, V. (2009). Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. International Journal of Clinical Practice, 63 (1), 19-26. doi:10.1111/j.1742-1241.2008.01911.x Peer Reviewed verified by ORBi |
Reginster, J.-Y. (2009). Strontium ranelate in the therapeutic strategies for osteoporosis, including glucocorticoid-induced osteoporosis (GIO). In Bone (pp. 45, S3, 131). Peer reviewed |
 | Reid, D. M., Devogelaer, J.-P., Saag, K., Roux, C., Lau, C.-S., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., Hartl, F., Fashola, T., Mesenbrink, P., & Sambrook, P. N. (2009). Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. The Lancet, 373 (9671), 1253-63. doi:10.1016/S0140-6736(09)60250-6 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Ethgen, O., Bruyère, O., Richy, F., Gathon, H.-J., & Reginster, J.-Y. (2009). Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in Osteoporosis. Value in Health, 12 (5), 687-696. doi:10.1111/j.1524-4733.2008.00497.x Peer Reviewed verified by ORBi |
 | Kahan, A., Uebelhart, D., De Vathaire, F., Delmas, P. D., & Reginster, J.-Y. (2009). Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism, 60 (2), 524-33. doi:10.1002/art.24255 Peer Reviewed verified by ORBi |
 | Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2009). The International Osteoporosis Foundation: history, objectives and achievements. Osteoporosis International, 20 Suppl 3, 241-2. doi:10.1007/s00198-008-0700-5 Peer Reviewed verified by ORBi |
 | Bruyère, O., Varela, A. R., Adami, S., Detilleux, J., Rabenda, V., Hiligsmann, M., & Reginster, J.-Y. (2009). Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women. European Journal of Epidemiology, 24, 707-712. doi:10.1007/s10654-009-9381-4 Peer Reviewed verified by ORBi |
 | Meunier, P., Roux, C., Ortolani, S., Diaz-Curiel, M., Compston, J., Marquis, P., Cormier, C., Isaia, G., Badurski, J., Wark, J. D., Collette, J., & Reginster, J.-Y. (2009). Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporosis International, 20, 1663-73. doi:10.1007/s00198-008-0825-6 Peer Reviewed verified by ORBi |
Ethgen, O., Hiligsmann, M., & Reginster, J.-Y. (2009). Modelling the uptake and diffusion of innovative technology: a critical and strategic feature of budget impact analysis and risk-sharing agreements. In Value in Health (pp. 12, A395). Peer reviewed |
Chapurlat, R., Felsenberg, F., & Reginster, J.-Y. (2009). L'efficacité de l'ibandronate oral mensuel est maintenue sur 5 ans : l'étude MOBILE extension long terme (ELT). In Revue du Rhumatisme (pp. 76, 1069). Peer reviewed |
 | Bruyère, O., Decock, C., Delhez, M., Collette, J., & Reginster, J.-Y. (2009). Highest prevalence of vitamin D inadequacy in institutionalized women compared with noninstitutionalized women: a case-control study. Women's Health, 5 (1), 49-54. doi:10.2217/17455057.5.1.49 Peer Reviewed verified by ORBi |
 | Cranney, A., Wells, G. A., Yetisir, E., Adami, S., Cooper, C., Delmas, P. D., Miller, P. D., Papapoulos, S., Reginster, J.-Y., Sambrook, P. N., Silverman, S., Siris, E., & Adachi, J. D. (2009). Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporosis International, 20 (2), 291-7. doi:10.1007/s00198-008-0653-8 Peer Reviewed verified by ORBi |
 | Bruyère, O., Brandi, M. L., Burlet, N., Harvey, N., Lyritis, G., Minne, H., Boonen, S., REGINSTER, J.-Y., Rizzoli, R., & Akesson, K. (2009). La gestione post-frattura del paziente con frattura di femore: Una visione prospettica. Clinical Cases in Mineral and Bone Metabolism, 6 (3), 270-279. Peer Reviewed verified by ORBi |
Sambrook, P., Devogelaer, J. P., Reginster, J.-Y., Saag, K., Roux, C., Lau, C., Papanastasiou, P., Schoenborn-Kellenberger, O., Maylandt, K., Fashola, T., Mesenbrink, P., & Reid, D. (2009). Effect of a single i.v. infusion of zoledronic acid on bone turnover markers versus oral risedronate in patients with glucocorticoid-induced osteoporosis. In Bone (pp. 44, 96). New York, United States - New York: Elsevier Science. Peer reviewed |
 | Bruyère, O., DeCock, C., Mottet, C., Neuprez, A., MALAISE, O., & Reginster, J.-Y. (2009). Low dietary calcium in European postmenopausal osteoporotic women. Public Health Nutrition, 12 (1), 111-114. doi:10.1017/S1368980008002024 Peer Reviewed verified by ORBi |
 | Scholtissen, S., Guillemin, F., Bruyère, O., Collette, J., Dousset, B., Kemmer, C., Culot, S., Cremer, D., Dejardin, H., Hubermont, G., Lefebvre, D., Pascal-Vigneron, V., Weryha, G., & Reginster, J.-Y. (2009). Assessment of determinants for osteoporosis in elderly men. Osteoporosis International, 20 (7), 1157-66. doi:10.1007/s00198-008-0789-6 Peer Reviewed verified by ORBi |
 | Bruyère, O., & Reginster, J.-Y. (2009). The need for economic evaluation in osteoarthritis. Aging Health, 5 (5), 591-594. doi:10.2217/ahe.09.57 Peer Reviewed verified by ORBi |
 | Bruyère, O., De Cock, C., Deroisy, R., & Reginster, J.-Y. (2009). Bone mineral density and health related quality of life: a 3-year follow-up study of osteoportic postmenopaul women. The Open Geritric Medicine Journal, 2, 44-52. Peer reviewed |
 | Neuprez, A., Johansson, H., Kanis, J., Mc Closkey, E., Oden, A., Bruyère, O., Hiligsmann, M., Devogelaer, J.-P., Kaufman, J.-M., & Reginster, J.-Y. (2009). Rationalisation du remboursement des médicaments de l'ostéoporose : de la mesure isolée de la densité osseuse à l'intégration des facteurs cliniques de risque fracturaire. Validation de l'algorithme FRAX(r). Revue du Rhumatisme, 76, 1070-1. Peer Reviewed verified by ORBi |
 | Rabenda, V., Hiligsmann, M., & Reginster, J.-Y. (2009). Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opinion on Pharmacotherapy, 10 (14), 2303-15. doi:10.1517/14656560903140533 Peer Reviewed verified by ORBi |
 | Bruyère, O., SCHOLTISSEN, S., NEUPREZ, A., Hiligsmann, M., Toukouki, A., & Reginster, J.-Y. (2009). Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis. Journal of Medical Economics, 12 (4), 356-360. doi:10.3111/13696990903438617 Peer Reviewed verified by ORBi |
 | Compston, J., Reid, D. M., Boisdron, J., Brandi, M.-L., Burlet, N., Cahall, D., Delmas, P. D., Dere, W., Devogelaer, J.-P., Fitzpatrick, L. A., Flamion, B., Goel, N., Korte, S., Laslop, A., Mitlak, B., Ormarsdottir, S., Ringe, J., Rizzoli, R., Tsouderos, Y., ... REGINSTER, J.-Y. (2009). Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: An update from the Group for the Respect of Ethics and Excellence in Science (Osteoporosis International DOI: 10.1007/s00198-008-0670-7). Osteoporosis International, 20 (3), 497-498. doi:10.1007/s00198-008-0735-7 Peer Reviewed verified by ORBi |
 | Richy, F., Scarpignato, C., Lanas, A., & Reginster, J.-Y. (2009). Efficacy and safety of piroxicam revisited. A global meta-analysis of randomised clinical trials. Pharmacological Research, 60, 254-263. doi:10.1016/j.phrs.2009.03.021 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Hiligsmann, M., Rabenda, V., Zegels, B., Neuprez, A., & Bruyère, O. (2009). Ibandronate in the management of postmenopausal osteoporosis. Clinical Medicine. Therapeutics, 1, 1409-1421. Peer reviewed |
 | Reginster, J.-Y., Bruyère, O., Sawicki, A., Roces-Varela, A., Fardellone, P., Roberts, A., & Devogelaer, J.-P. (2009). Long-term treatment of postmenopausal osteoporosis with strontium ranelate: Results at 8 years. BONE, 45, 1059-64. doi:10.1016/j.bone.2009.08.004 Peer Reviewed verified by ORBi |
 | ZEGELS, B., Theiler, R., Crozes, P., Uebelhart, D., & Reginster, J.-Y. (2009). Une prise orale unique (1200 mg) de sulfate de chondroïtine 4 & 6 (CS) réduit la douleur et améliore la fonction. Résultats d'une étude en double insu, contre placebo et un comparateur actif, chez des patients souffrants de gonarthrose (OA). Revue du Rhumatisme, 76, 1071. Peer Reviewed verified by ORBi |
 | Bruyère, O., Detilleux, J., Decock, C., & Reginster, J.-Y. (2009). Relations entre les variations de densité minérale osseuse et l'incidence des fractures vertébrales: analyse des 3 dernières années d'un traitement de 8 ans sous ranélate de strontium. Revue du Rhumatisme, 76, 1070. Peer Reviewed verified by ORBi |
 | Bruyère, O., & Reginster, J.-Y. (2009). Place de la densitométrie osseuse dans le diagnostic et le suivi des patients ostéoporotiques. Ortho-Rhumato, 7, 3-5. |
 | Reginster, J.-Y., Deroisy, R., NEUPREZ, A., Hiligsmann, M., Zegels, B., & Bruyère, O. (2009). Strontium ranelate: new data on fracture prevention and mechanisms of action. Current Osteoporosis Reports, 7 (3), 96-102. doi:10.1007/s11914-009-0016-1 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., Gathon, H.-J., Ethgen, O., Bruyère, O., & Reginster, J.-Y. (December 2008). Impact of medication non-compliance and non-persistence on pharmacoeconomic evaluations in osteoporosis. Osteoporosis International, 19 (S2), 282. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (December 2008). Cost-utility of calcium and vitamin D supplementation in the treatment of postmenopausal osteoporotic women. Osteoporosis International, 19 (S2), 363. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (December 2008). Cost-utility of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women. Osteoporosis International, 19 (S2), 450. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Rabenda, V., Gathon, H.-J., Ethgen, O., & Reginster, J.-Y. (November 2008). Impact of medication non-compliance and non-persistence on pharmacoeconomic evaluations in osteoporosis. Value in Health, 11 (6), 542. doi:10.1016/S1098-3015(10)66788-5 Peer Reviewed verified by ORBi |
 | Rabenda, V., & Reginster, J.-Y. (November 2008). Effet positif de l'observance au ranélate de strontium sur le risque de fractures ostéoporotiques non vertébrales. Revue du Rhumatisme, 75 (10-11), 1127. Peer Reviewed verified by ORBi |
 | Bruyère, O., Hiligsmann, M., FRANKINET, P., Detilleux, J., & Reginster, J.-Y. (October 2008). Association between changes in bone mineral density and fracture incidence in postmenopausal osteoporotic women receiving calcium and vitamin D: a 3-year follow-up study. Arthritis and Rheumatism, 58 (Suppl.1), 743. Peer Reviewed verified by ORBi |
 | Rabenda, V., & Reginster, J.-Y. (October 2008). Positive impact of compliance of strontium ranelate on the risk of nonvertebral osteoporotic fractures. Arthritis and Rheumatism, 58, 99. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Sawicki, A., Roces-Varela, A., Fardellone, P., & Roberts, A. (October 2008). Strontium ranelate : long-term efficacy over 8 years in postmenopausal osteoporotic women. Arthritis and Rheumatism, 58, 941. Peer Reviewed verified by ORBi |
 | Bruyère, O., Decock, C., COLLETTE, J., Ortolani, S., Cormier, C., Detilleux, J., FRANKINET, P., & Reginster, J.-Y. (October 2008). Relationship between 3-month changes in biochemical markers of bone remodelling and 3-year changes in bone mineral density in patients treated with strontium ranelate. Arthritis and Rheumatism, 58 (Suppl.1), 743. Peer Reviewed verified by ORBi |
 | REGINSTER, J.-Y., DEBERG, M., Henrotin, Y., & Christgau, S. (12 August 2008). Method for monitoring collagen type II degradation in cartilage. |
 | Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (July 2008). Efficiency of calcium and vitamin D in the management of osteoporosis [Paper presentation]. 7th European Conference on Health Economics, Rome, Italy. |
 | REGINSTER, J.-Y., DEBERG, M., Henrotin, Y., & Christgau, S. (01 July 2008). Detection of specific nitrated markers. |
 | DeCock, C., Bruyère, O., Collette, J., & Reginster, J.-Y. (July 2008). Déficit en vitamine D chez les femmes françaises ostéoporotiques et ostéopéniques. Revue du Rhumatisme, 75, 839-844. doi:10.1016/j.rhum.2007.10.623 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Ethgen, O., Pire, G., Gathon, H.-J., & Reginster, J.-Y. (July 2008). Efficiency and recommendations for osteoporosis screening strategy [Paper presentation]. 7th European Conference on Health Economics, Rome, Italy. |
 | Bruyère, O., Delhez, M., Collette, J., & Reginster, J.-Y. (June 2008). Prevalence of vitamin D inadequacy in institutionalized osteoporotic postmenopausal women. Annals of the Rheumatic Diseases, 67 (Suppl.II), 403. Peer Reviewed verified by ORBi |
 | Bruyère, O., Collette, J., Christiansen, F., Fardellone, F., Detroz, A., Deroisy, R., & Reginster, J.-Y. (June 2008). Association between lumbar disc degeneration and biochemical markers of bone and cartilage remodelling. Annals of the Rheumatic Diseases, 67 (Suppl.II), 231. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Felsenberg, D., Boonen, S., Diez-Perez, A., Rizzoli, R., Brandi, M. L., Spector, T. D., Brixen, K., Goemaere, S., Cormier, C., Balogh, A., Delmas, P. D., & Meunier, P. J. (June 2008). Strontium ranelate decreases the risk of hip fracture over 3 and 5 years in post menopausal women at high risk. Annals of the Rheumatic Diseases, 67 (Suppl.II), 540. Peer Reviewed verified by ORBi |
 | Reid, D. M., Devogelaer, J.-P., Saag, K., Roux, C., Lau, C., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., Hartl, F., Fashola, T., Mesenbrink, P., & Sambrook, P. (June 2008). A single infusion of zoledronic acid 5 mg is significantly more effective than daily oral risedronate 5 mg in increasing bone mineral density of the lumbar spine, hip, femoral neck and trochanter in patients with glucocorticoid-induced osteoporosis. Annals of the Rheumatic Diseases, 67 (Suppl.II), 56. Peer Reviewed verified by ORBi |
 | Bruyère, O., Roces-Varela, A., Adami, S., & Reginster, J.-Y. (June 2008). Association between changes in bone mineral density and vertebral fracture incidence in untreated postmenopausal women : a 3-year prospective study. Annals of the Rheumatic Diseases, 67 (Suppl.II), 89. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Boisdron, J., & Barr, C. E. (June 2008). Vertebral fracture efficacy of monthly ibandronate versus weekly bisphosphonates: analysis of a retrospective cohort study. Annals of the Rheumatic Diseases, 67 (Suppl.II), 539. Peer Reviewed verified by ORBi |
 | Saag, K. G., Devogelaer, J.-P., Reid, D. M., Sambrook, P., Goemaere, S., Ish-Shalom, S., Collette, J., Papanastasiou, P., Ferreira, A., Eriksen, E. F., Fashola, T., Schoenborn-Kellenberger, O., Chappard, D., & Reginster, J.-Y. (June 2008). Effects of a single 5 mg infusion of zoledronic acid and oral risedronate (5 mg/day) on bone remodeling over one year in patients with glucocorticoid-induced osteoporosis. Annals of the Rheumatic Diseases, 67 (Suppl.II), 542. Peer Reviewed verified by ORBi |
 | Bruyère, O., Pieck, C., Hiligsmann, M., Zegels, B., Delhez, M., Mottet, C., & Reginster, J.-Y. (June 2008). Place of residence as a risk factor for hip fracture? A case-control 3-year study. Annals of the Rheumatic Diseases, 67 (Suppl.II), 428. Peer Reviewed verified by ORBi |
 | Bruyère, O., Brandi, M., Vellas, B., Hiligsmann, M., & Reginster, J.-Y. (June 2008). Relationship between long-term changes in femoral neck bone mineral density and hip fracture incidence in untreated postmenopausal osteoporotic women. Annals of the Rheumatic Diseases, 67 (Suppl.II), 403. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Barr, C. E., Blumentals, W. A., & Harris, S. T. (June 2008). Similar non-vertebral antifracture efficacy demonstrated with monthly ibandronate versus weekly bisphosphonate therapy: A retrospective cohort study. Annals of the Rheumatic Diseases, 67 (Suppl.II), 539. Peer Reviewed verified by ORBi |
 | Goemaere, S., Bergman, P., Body, J. J., Boonen, S., Devogelaer, J.-P., Kaufman, J.-M., Rozenberg, S., & Reginster, J.-Y. (April 2008). Utility audit of Belgian DXA centers. Osteoporosis International, 19 (Suppl.1), 205. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Ethgen, O., Pire, G., & Reginster, J.-Y. (April 2008). Efficiency and recommendations for osteoporosis screening strategy. Osteoporosis International, 19 (S1), 116. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (April 2008). Cost-utility of strontium ranelate in the treatment of postmenopausal women. Osteoporosis International, 19 (S1), 6. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Felsenberg, D., Boonen, S., Diez-Perez, A., Rizzoli, R., Brandi, M. L., Spector, T., Brixen, K., Goemaere, S., & Cormier, C. (April 2008). Strontium ranelate demonstrates efficacy against hip fracture over 3 and 5 years in postmenopausal women at high risk of hip fracture. Osteoporosis International, 19 (Suppl.1), 26-27. Peer Reviewed verified by ORBi |
 | Bruyère, O., Pieck, C., Hiligsmann, M., Zegels, B., Delhez, M., Mottet, C., & Reginster, J.-Y. (April 2008). Place of residence as a risk factor for hip fracture? A case-control 3-year study. Osteoporosis International, 19 (Suppl.1), 200. Peer Reviewed verified by ORBi |
 | Bruyère, O., Brandi, M. L., Vellas, B., Hiligsmann, M., & Reginster, J.-Y. (April 2008). Changes in femoral neck bone mineral density are associated with hip fracture incidence in untreated postmenopausal women. Osteoporosis International, 19 (Suppl.1), 18-19. Peer Reviewed verified by ORBi |
 | Scholtissen, S., Guillemin, F., Kemmer, C., Culot, S., Bruyère, O., & Reginster, J.-Y. (April 2008). Assessement of risk factors for osteoporotic fractures in elderly men. Osteoporosis International, 19 (Suppl.1), 200-201. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Blumentals, W., Barr, C., Silverman, S., & Poston, S. (April 2008). Fracture efficacy of monthly ibandronate and weekly bisphosphonate therapy: a retrospective cohort study. Osteoporosis International, 19 (Suppl.1), 9. Peer Reviewed verified by ORBi |
 | Bruyère, O., Collette, J., Christiansen, C., Padrino, J. M., Fardellone, J. P., Detroz, A., Deroisy, R., & Reginster, J.-Y. (April 2008). Association between spinal osteoarthritis and biochemical markers of bone and cartilage remodelling. Osteoporosis International, 19 (Suppl.1), 200. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (April 2008). Reducing non-vertebral fracture risk: ibandronate doses used in clinical practice. Osteoporosis International, 19 (Suppl.1), 221. Peer Reviewed verified by ORBi |
| Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (April 2008). Efficiency of calcium and vitamin D supplementation in the management of osteoporosis. Osteoporosis International, 19 (S1), 113. Peer Reviewed verified by ORBi |
 | DeCock, C., Bruyère, O., & Reginster, J.-Y. (April 2008). Bone Mineral Density and health-related quality of life: a 3-year follow-up in osteoporotic postmenopausal women. Osteoporosis International, 19 (Suppl.1), 54. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Sawicki, A., Roces-Varela, A., Fardellone, P., & Roberts, A. (April 2008). Strontium ranelate: 8 years efficacy on vertebral and nonvertebral fractures in postmenopausal osteoporotic women. Osteoporosis International, 19 (Suppl.1), 131-132. Peer Reviewed verified by ORBi |
 | Reid, D. M., Devogelaer, J.-P., Saag, K., Roux, C., Lau, C. S., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., Fashola, T., & Sambrook, P. (April 2008). A single infusion of zoledronic acid 5 mg (ZOL) is significantly more effective than daily oral risedronate 5 mg (RIS) in increasing bone mineral density (BMD) of the lumbar spine (LS), hip, femoral neck and trochanter in patients with glucocorticoid-induced osteoporosis (GIO). Osteoporosis International, 19 (Suppl.1), 23-24. Peer Reviewed verified by ORBi |
 | Collette, J., Reginster, J.-Y., Zerbini, C., Neate, C., Sederati, F., & Delmas, P. D. (April 2008). Reduction in bone remodelling markers with monthly oral ibandronate (150 mg) and weekly alendronate (70 mg): results from the motion study. Osteoporosis International, 19 (Suppl.1), 207. Peer Reviewed verified by ORBi |
 | Bruyère, O., Roces-Varela, A., Adami, S., & Reginster, J.-Y. (April 2008). Association between changes in bone mineral density and vertebral fracture incidence in untreated postmenopausal women. Osteoporosis International, 19 (Suppl.1), 199. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (April 2008). Cost-effectiveness of mass screening and targeted biphosphonates treatment in osteoporosis. Osteoporosis International, 19 (S1), 117. Peer Reviewed verified by ORBi |
 | Bruyère, O., Delferriere, D., Roux, C., Wark, J. D., Spector, T., Devogelaer, J.-P., Brixen, K., Adami, S., Fechtenbaum, J., Kolta, S., & Reginster, J.-Y. (March 2008). Effects of Strontium Ranelate on Spinal Osteoarthritis Progression. Annals of the Rheumatic Diseases, 67 (3), 335-9. doi:10.1136/ard.2007.075572 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Collette, J., NEUPREZ, A., Zegels, B., Deroisy, R., & Bruyère, O. (10 February 2008). Role of Biochemical Markers of Bone Turnover as Prognostic Indicator of Successful Osteoporosis Therapy. BONE, 42, 832-836. doi:10.1016/j.bone.2008.01.021 Peer Reviewed verified by ORBi |
 | Bruyère, O., Pavelka, K., Rovati, L. C., Gatterova, J., Giacovelli, G., Olejarova, M., Deroisy, R., & Reginster, J.-Y. (February 2008). Total Joint Replacement after Glucosamine Sulphate Treatment in Knee Osteoarthritis: Results of a Mean 8-Year Observation of Patients from Two Previous 3-Year, Randomised, Placebo-Controlled Trials. Osteoarthritis and Cartilage, 16 (2), 254-60. doi:10.1016/j.joca.2007.06.011 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Collette, J., Neuprez, A., & Bruyère, O. (2008). Strontium ranelate in the management of spinal and peripheral osteoporosis. Review of Endocrinology, 26-33. Peer reviewed |
 | Bruyère, O., Hiligsmann, M., FRANKINET, P., Detilleux, J., & Reginster, J.-Y. (2008). Association between changes in bone mineral density and fracture incidence in postmenopausal osteoporotic women receiving calcium and vitamin D : a 3-year follow-up study. Osteoporosis International, 19 (S2), 274. Peer Reviewed verified by ORBi |
 | Bruyère, O., Decock, C., Collette, J., Ortolani, S., Cormier, C., Detilleux, J., Franquinet, P., & Reginster, J.-Y. (2008). Relationship between 3-month changes in biochemical markers of bone remodelling and 3-year changes in bone mineral density in patients treated with strontium ranelate. Osteoporosis International, 19 (S2), 244. Peer Reviewed verified by ORBi |
 | NEUPREZ, A., & Reginster, J.-Y. (2008). Bone-forming agents in the management of osteoporosis. Best Practice and Research. Clinical Endocrinology and Metabolism, 22 (5), 869-83. doi:10.1016/j.beem.2008.06.003 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., NEUPREZ, A., & Bruyère, O. (2008). Ibandronate in profile: drug characteristics and clinical efficacy. Expert Opinion on Drug Metabolism and Toxicology, 4 (7), 941-51. doi:10.1517/17425255.4.7.941 Peer Reviewed verified by ORBi |
 | MacDonald, T. M., Reginster, J.-Y., Littlejohn, T. W., Richard, D., Lheritier, K., Krammer, G., & Rebuli, R. (2008). Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. Journal of Hypertension, 26 (8), 1695-702. doi:10.1097/HJH.0b013e328302c9fe Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2008). Protelos – unrivalled efficacy in the short-and long-term. OsteOpinion, 4, 4-5. Peer reviewed |
 | Hiligsmann, M., Bruyère, O., & Reginster, J.-Y. (2008). Risque à long terme de survenue d'une fracture ostéoporotique en Belgique. Revue Médicale de Liège, 63 (7-8), 480-487. Peer reviewed |
 | Reginster, J.-Y., & Poston, S. (2008). Risque de fracture chez les femmes atteintes d'ostéoporose post-ménopausique primaire sous ibandronate oral mensuel ou bisphosphonates hebdomadaires : analyse additionnelle de l'étude des fractures sur base de données VIBE (eValuation of IBandronate Efficacy). Revue du Rhumatisme, 75, 1030. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Sawicki, A., Races-Varela, A., Fardellone, P., & Roberts, A. (2008). Le ranélate de strontium maintient son efficacité sur 8 ans chez les femmes ménopausées ostéoporotiques. Revue du Rhumatisme, 75, 998. Peer Reviewed verified by ORBi |
 | Kanis, J. A., Burlet, N., Cooper, C., Delmas, P. D., Reginster, J.-Y., Borgstrom, F., & Rizzoli, R. (2008). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, 19 (4), 399-428. doi:10.1007/s00198-008-0560-z Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Pire, G., & Reginster, J.-Y. (2008). Evaluation économique de la campagne de dépistage de l'ostéoporose menée en Province de Liège avec le concours de Liège Province Santé. Revue Médicale de Liège, 63 (10), 588-94. Peer reviewed |
 | Hiligsmann, M., Ethgen, O., Bruyère, O., & Reginster, J.-Y. (2008). An Economic Evaluation of Quantitative Ultrasonometry as Pre-Screening Test for the Identification of Patients with Osteoporosis. Disease Management and Health Outcomes, 16 (6), 429-438. doi:10.2165/0115677-200816060-00008 Peer Reviewed verified by ORBi |
 | Goldhahn, J., Scheele, W. H., Mitlak, B. H., Abadie, E., Aspenberg, P., Augat, P., Brandi, M.-L., Burlet, N., Chines, A., Delmas, P. D., Dupin-Roger, I., Ethgen, D., Hanson, B., Hartl, F., Kanis, J. A., Kewalramani, R., Laslop, A., Marsh, D., Ormarsdottir, S., ... Reginster, J.-Y. (2008). Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis. BONE, 43 (2), 343-7. doi:10.1016/j.bone.2008.04.017 Peer Reviewed verified by ORBi |
 | REGINSTER, J.-Y., Adami, S., Lakatos, P., Greenwald, M., Stepan, J. J., & Silverman, S. L. (2008). Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 Year results from the MOBILE study (Annals of the Rheumatic Diseases (2006) 65, (654-661)). Annals of the Rheumatic Diseases, 67 (2), 280. doi:10.1136/ard.2005.044958.corr1 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2008). Treating bone as a living tissue : a step forward in fracture prevention. Osteoporosis International, 19 (2), 506. Peer Reviewed verified by ORBi |
 | Kanis, J. A., & Reginster, J.-Y. (2008). European guidance for the diagnosis and management of osteoporosis in postmenopausal women--what is the current message for clinical practice? Polskie Archiwum Medycyny Wewnetrznej, 118 (10), 538-40. Peer reviewed |
 | Rizzoli, R., Burlet, N., Cahall, D., Delmas, P. D., Eriksen, E. F., Felsenberg, D., Grbic, J., Jontell, M., Landesberg, R., Laslop, A., Wollenhaupt, M., Papapoulos, S., Sezer, O., Sprafka, M., & Reginster, J.-Y. (2008). Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. BONE, 42 (5), 841-7. doi:10.1016/j.bone.2008.01.003 Peer Reviewed verified by ORBi |
 | Seeman, E., Devogelaer, J.-P., Lorenc, R., Spector, T., Brixen, K., Balogh, A., Stucki, G., & Reginster, J.-Y. (2008). Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. Journal of Bone and Mineral Research, 23 (3), 433-8. doi:10.1359/jbmr.071105 Peer Reviewed verified by ORBi |
 | Compston, J., Reid, D. M., Boisdron, J., Brandi, M.-L., Burlet, N., Cahall, D., Delmas, P. D., Dere, W., Devogelaer, J.-P., Fitzpatrick, L. A., Flamion, B., Goel, N., Korte, S., Laslop, A., Mitlak, B., Ormarsdottir, S., Ringe, J., Rizzoli, R., Tsouderos, Y., ... Reginster, J.-Y. (2008). Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporosis International, 19 (9), 1247-50. doi:10.1007/s00198-008-0670-7 Peer Reviewed verified by ORBi |
 | Roux, C., Reid, D., Devogelaer, J. P., Saag, K., Lau, C., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., Hartl, F., Fashola, T., Mesenbrink, P., & Sambrook, P. (2008). Effect of zoledronic acid (single 5 mg infusion) on lumbar spine bone mineral density versus oral risedronate (5 mg/day) over one year in subgroups of patients receiving glucocorticoid therapy. Osteoporosis International, 19 (S2), 248-249. Peer Reviewed verified by ORBi |
 | Bruyère, O., Burlet, N., Delmas, P. D., Rizzoli, R., Cooper, C., & Reginster, J.-Y. (2008). Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskeletal Disorders, 9, 165. doi:10.1186/1471-2474-9-165 Peer Reviewed verified by ORBi |
 | Ormarsdottir, S., Reginster, J.-Y., & Abadie, E. (2008). European regulatory perspectives for innovative therapies. Osteoporosis International, 19 (6), 725-31. doi:10.1007/s00198-008-0576-4 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2008). New developments in the management of osteoporosis. Climacteric: the Journal of the International Menopause Society, 11 (S2), 30. Peer Reviewed verified by ORBi |
 | Malaise, O., Neuprez, A., & Reginster, J.-Y. (2008). Traitements non hormonaux de l’ostéoporose postménopausique. Gynécologie Obstétrique et Fertilité, 36, 815-822. doi:10.1016/j.gyobfe.2007.05.026 Peer Reviewed verified by ORBi |
 | Hanssens, L., Scheen, A., van Winkel, R., Van Eyck, D., Reginster, J.-Y., & De Hert, M. (2008). Le cerveau au centre des regulations metaboliques: anomalies chez les patients schizophrenes traites par antipsychotiques atypiques. Revue Médicale de Liège, 63 (5-6), 417-23. Peer reviewed |
 | Miller, P. D., Epstein, S., Sedarati, F., & Reginster, J.-Y. (2008). Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Current Medical Research and Opinion, 24 (1), 207-13. doi:10.1185/030079908X253889 Peer Reviewed verified by ORBi |
 | Stakkestad, J. A., Lakatos, P., Lorenc, R., Sedarati, F., Neate, C., & Reginster, J.-Y. (2008). Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clinical Rheumatology, 27 (8), 955-60. doi:10.1007/s10067-007-0824-6 Peer Reviewed verified by ORBi |
 | Rizzoli, R., Boonen, S., Brandi, M. L., Burlet, N., Delmas, P., & Reginster, J.-Y. (2008). The role of calcium and vitamin D in the management of osteoporosis. BONE, 42 (2), 246-9. doi:10.1016/j.bone.2007.10.005 Peer Reviewed verified by ORBi |
 | De Cock, C., Bruyère, O., Collette, J., & Reginster, J.-Y. (2008). Vitamin D inadequacy in French osteoporotic and osteopenic women. Joint Bone Spine, 75 (5), 567-72. doi:10.1016/j.jbspin.2007.10.012 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Ethgen, O., Gathon, H.-J., & Reginster, J.-Y. (2008). Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women. BONE, 43 (6), 991-4. doi:10.1016/j.bone.2008.08.119 Peer Reviewed verified by ORBi |
 | Devogelaer, J.-P., Bergmann, P., Body, J.-J., Boutsen, Y., Goemaere, S., Kaufman, J.-M., Reginster, J.-Y., Rozenberg, S., & Boonen, S. (2008). Management of patients with Paget's disease: a consensus document of the Belgian Bone Club. Osteoporosis International, 19 (8), 1109-17. doi:10.1007/s00198-008-0629-8 Peer Reviewed verified by ORBi |
 | Bruyère, O., & Reginster, J.-Y. (2008). Correlation between increased bone mineral density and decreased fracture risk - Bone mineral density as a tool to monitor postmenopausal osteoporosis treatment. Medicographia, 30 (4), 355-359. Peer reviewed |
 | Hanssens, L., van Winkel, R., Wampers, M., Van Eyck, D., Scheen, A., Reginster, J.-Y., Collette, J., Peuskens, J., & De Hert, M. (2008). A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. Schizophrenia Research, 106 (2-3), 308-14. doi:10.1016/j.schres.2008.09.008 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Felsenberg, D., Boonen, S., Diez-Perez, A., Rizzoli, R., Brandi, M.-L., Spector, T. D., Brixen, K., Goemaere, S., Cormier, C., Balogh, A., Delmas, P. D., & Meunier, P. J. (2008). Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis and Rheumatism, 58 (6), 1687-95. doi:10.1002/art.23461 Peer Reviewed verified by ORBi |
 | Chappard, D., Saag, K., Devogelaer, J., Reid, D., Sambrook, P., Goemaere, S., COLLETTE, J., Ish-Shalom, S., Papanastasiou, P., Ferreira, A., Eriksen, E., Schoenborn-Kellenberger, O., & Reginster, J.-Y. (2008). Effets d'une perfusion unique d'acide zolédronique 5 mg versus risédronate (5 mg/jour) sur le remodelage osseux sur 1 an chez des patients avec ostéroporose cortisonique. Revue du Rhumatisme, 75, 1036. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Blumentals, W., & Harris, S. (2008). Efficacité comparable de l'ibandronate mensuel ou d'un bisphosphonate hebdomadaire sur les fractures non vertébrales : une étude de cohorte rétrospective (VIBE, eValuation of IBandronate Efficacy). Revue du Rhumatisme, 75, 1020. Peer Reviewed verified by ORBi |
 | Goldhahn, J., Mitlak, B., Aspenberg, P., Kanis, J. A., Rizzoli, R., & Reginster, J.-Y. (2008). Critical issues in translational and clinical research for the study of new technologies to enhance bone repair. Journal of Bone and Joint Surgery. American Volume, 90 Suppl 1, 43-7. doi:10.2106/JBJS.G.01090 Peer Reviewed verified by ORBi |
 | Bruyère, O., & Reginster, J.-Y. (2008). Vitamin D status and response to antiosteoporotic therapy. Women's Health, 4 (5), 445-7. doi:10.2217/17455057.4.5.445 Peer Reviewed verified by ORBi |
 | Rabenda, V., & Reginster, J.-Y. (2008). Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures. Osteoporosis International, 19 (S2), 366-367. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2008). L’osteoporosi nel nuovo millennio : la crescente domanda di risorse sanitarie. Clinical Cases in Mineral and Bone Metabolism, 5 (3), 269. Peer Reviewed verified by ORBi |
 | NEUPREZ, A., Hiligsmann, M., Scholtissen, S., Bruyère, O., & Reginster, J.-Y. (2008). Strontium ranelate: The first agent of a new therapeutic class in osteoporosis. Advances in Therapy, 25 (12), 1235-56. doi:10.1007/s12325-008-0125-8 Peer Reviewed verified by ORBi |
 | Rabenda, V., Mertens, R., Fabri, V., Vanoverloop, J., Sumkay, F., Vannecke, C., Deswaef, A., Verpooten, G. A., & Reginster, J.-Y. (2008). Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporosis International, 19 (6), 811-8. doi:10.1007/s00198-007-0506-x Peer Reviewed verified by ORBi |
 | Bruyère, O., Brandi, M.-L., Burlet, N., Harvey, N., Lyritis, G., Minne, H., Boonen, S., Reginster, J.-Y., Rizzoli, R., & Akesson, K. (2008). Post-fracture management of patients with hip fracture: a perspective. Current Medical Research and Opinion, 24 (10), 2841-51. doi:10.1185/03007990802381430 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Ethgen, O., Richy, F., & Reginster, J.-Y. (2008). Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcified Tissue International, 82 (4), 288-92. doi:10.1007/s00223-008-9117-6 Peer Reviewed verified by ORBi |
 | Sambrook, P., Devogelaer, J., Reginster, J.-Y., Saag, K., Roux, C., Lau, C., Papanastasiou, P., Schoenborn-Kellenberger, O., Maylandt, K., Fashola, T., Mesenbrink, P., & Reid, D. (2008). Effect of a single 5 mg infusion of zoledronic acid on bone turnover markars vs. oral risedronate (5 mg/day) over 1 year in patients with glucocorticoid-induced osteoporosis. Osteoporosis International, 19 (S2), 376. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2008). Structure modification in osteoarthritis : fact or fantasy ? Osteoporosis International, 19 (S2), 230-231. Peer Reviewed verified by ORBi |
 | Roux, C., Reid, D., Devogelaer, J. P., Saag, K., Lau, C., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., Harti, F., Fashola, T., Mesenbrink, P., & Sambrook, P. (2008). Une perfusion d'acide zolédronique 5 mg est plus efficace que le risédronate 5 mg/j per os sur l'augmentation de la densité lombaire et fémorale au cours de l'ostéoporose cortisonique. Revue du Rhumatisme, 75, 1020. Peer Reviewed verified by ORBi |
 | Fleischmann, R., Tannenbaum, H., Patel, N. P., Notter, M., Sallstig, P., & Reginster, J.-Y. (2008). Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis. BMC Musculoskeletal Disorders, 9, 32. doi:10.1186/1471-2474-9-32 Peer Reviewed verified by ORBi |
 | Bruyère, O., Detilleux, J., Decock, C., & Reginster, J.-Y. (2008). Relationships between changes in bone mineral density and vertebral fracture incidence : an analysis of the last 3 years of an 8-year treatment with strontium ranelate. Osteoporosis International, 19 (S2), 459. Peer Reviewed verified by ORBi |
 | Rabenda, V., Vanoverloop, J., Fabri, V., Mertens, R., Sumkay, F., Vannecke, C., Deswaef, A., Verpooten, G. A., & Reginster, J.-Y. (2008). Low incidence of anti-osteoporosis treatment after hip fracture. Journal of Bone and Joint Surgery. American Volume, 90 (10), 2142-8. doi:10.2106/JBJS.G.00864 Peer Reviewed verified by ORBi |
| Eisman, J. A., Civitelli, R., Adami, S., Czerwinski, E., Recknor, C., Prince, R., Reginster, J.-Y., Zaidi, M., Felsenberg, D., Hughes, C., Mairon, N., Masanauskaite, D., Reid, D. M., Delmas, P. D., & Recker, R. R. (2008). Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. Journal of Rheumatology, 35 (3), 488-97. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (December 2007). Efficience d'un dépistage de masse de l'ostéoporose par ultrasons: approche économique par microsimulation. Revue du Rhumatisme, 74 (10-11), 1072-3. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (December 2007). Analyse coût-efficacité d'un dépistage de masse de l'ostéoporose par DEXA combiné à un traitement par alendronate chez la femme ostéoporotique. Revue du Rhumatisme, 74 (10-11), 1072-3. Peer Reviewed verified by ORBi |
 | Bruyère, O., Roux, C., Badurski, J., Isaia, G., de Vernejoul, M. C., Cannata, J., Ortolani, S., Slosman, D., Detilleux, J., & Reginster, J.-Y. (December 2007). Relationship between Change in Femoral Neck Bone Mineral Density and Hip Fracture Incidence During Treatment with Strontium Ranelate. Current Medical Research and Opinion, 23 (12), 3041-5. doi:10.1185/030079907X242818 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (November 2007). Le ranelate de strontium (Protelos). Revue Médicale de Liège, 62 (11), 685-7. Peer reviewed |
 | Reginster, J.-Y., Heraud, F., Zegels, B., & Bruyère, O. (October 2007). Symptom and structure modifying properties of chondroitin sulfate in osteoarthritis. Mini Reviews in Medicinal Chemistry, 7 (10), 1051-1061. doi:10.2174/138955707782110088 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (October 2007). Cost-effectiveness of bone densitometry screening combined with alendronate therapy for those who have osteoporosis. Value in Health, 10 (6), 236. doi:10.1016/S1098-3015(10)64899-1 Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (October 2007). Cost-effectiveness of osteoporosis screening campaign for Belgian women. Value in Health, 10 (6), 395. doi:10.1016/S1098-3015(10)65384-3 Peer Reviewed verified by ORBi |
 | Lekkerkerker, F., Kanis, J. A., Alsayed, N., Bouvenot, G., Burlet, N., Cahall, D., Chines, A., Delmas, P., Dreiser, R. L., Ethgen, D., Hughes, N., Kaufman, J. M., Korte, S., Kreutz, G., Laslop, A., Mitlak, B., Rabenda, V., Rizzoli, R., Santora, A., ... Reginster, J.-Y. (October 2007). Adherence to treatment of osteoporosis: a need for study. Osteoporosis International, 18 (10), 1311-1317. doi:10.1007/s00198-007-0410-4 Peer Reviewed verified by ORBi |
 | Rabenda, V., Fabri, V., Mertens, R., Vanoverloop, J., Deswaef, A., Verpooten, G., Vannecke, C., Thorre, K., & Reginster, J.-Y. (September 2007). Impact of poor adherence to bisphosphonates therapy on hip fracture risk in osteoporotic women. Arthritis and Rheumatism, 56 (number 9 (suppl.)), 271. Peer Reviewed verified by ORBi |
 | Tancredi, A., Legros, J.-J., Pire, G., Maassen, P., Luyckx, F., & Reginster, J.-Y. (September 2007). Analysis of the discriminant ability of shorter versions of the French ADAM questionnaire. Aging Male, 10 (3), 159-164. doi:10.1080/13685530701433121 Peer Reviewed verified by ORBi |
 | Bruyère, O., Delferriere, D., Roux, C., Wark, J. D., Spector, T., Devogelaer, J.-P., Brixen, K., Adami, S., Fechtenbaum, J., Kolta, S., & Reginster, J.-Y. (September 2007). Effects of strontium ranelate on radiographic spinal osteoarthritis progression. Arthritis and Rheumatism, 56 (number 9 (suppl.)), 315. Peer Reviewed verified by ORBi |
 | Richy, F., Scarpignato, C., Lanas, A., Singh, G., & Reginster, J.-Y. (September 2007). NSAIDs in the management of musculoskeletal conditions: a comparative meta-analysis of the efficacy/safety profile of piroxicam. Arthritis and Rheumatism, 56 (number 9 (suppl.)), 599-600. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Borges, J. L., Recknor, C., Sedarati, F., Neate, C., & Cosman, F. (September 2007). Oral ibandronate (150mg) administered monthly provides similar improvements in hip bone mineral density as oral alendronate (70mg) administered weekly in postmenopausal osteoporosis. Arthritis and Rheumatism, 56 (number 9 (suppl.)), 611. Peer Reviewed verified by ORBi |
 | MacDonald, T. M., Reginster, J.-Y., Littlejohn, T. W., Richard, D., Lheritier, K., & Krammer, G. (September 2007). Improved blood pressure control with lumiracoxib compared with ibuprofen: a randomized trial in osteoarthritis patients with controlled hypertension. Arthritis and Rheumatism, 56 (number 9 (suppl.)), 659. Peer Reviewed verified by ORBi |
 | Rabenda, V., Fabri, V., Mertens, R., Vanoverloop, J., Deswaef, A., Verpooten, G., Vannecke, C., Thorre, K., & Reginster, J.-Y. (September 2007). Undertreatment with anti-osteoporotic drugs after hip fracture. Arthritis and Rheumatism, 56 (number 9 (suppl.)), 614. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (25 August 2007). Calcium and vitamin D for osteoporotic fracture risk. The Lancet, 370 (9588), 632-634. doi:10.1016/S0140-6736(07)61315-4 Peer Reviewed verified by ORBi |
 | Malaise, O., Bruyère, O., & Reginster, J.-Y. (August 2007). Strontium ranelate normalizes bone mineral density in osteopenic patients. Aging Clinical and Experimental Research, 19 (4), 330-333. doi:10.1007/BF03324710 Peer Reviewed verified by ORBi |
 | Bruyère, O., Roux, C., Detilleux, J., Slosman, D. O., Spector, T. D., Fardellone, P., Brixen, K., Devogelaer, J. P., Diaz-Curiel, M., Albanese, C., Kaufman, J. M., Pors-Nielsen, S., & Reginster, J.-Y. (August 2007). Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. Journal of Clinical Endocrinology and Metabolism, 92 (8), 3076-3081. doi:10.1210/jc.2006-2758 Peer Reviewed verified by ORBi |
 | Richy, F., Rabenda, V., Mawet, A., & Reginster, J.-Y. (August 2007). Flurbiprofen in the symptomatic management of rheumatoid arthritis: a valuable alternative. International Journal of Clinical Practice, 61 (8), 1396-1406. doi:10.1111/j.1742-1241.2007.01452.x Peer Reviewed verified by ORBi |
 | Bruyère, O., Malaise, O., NEUPREZ, A., Collette, J., & Reginster, J.-Y. (August 2007). Prevalence of vitamin D inadequacy in European postmenopausal women. Current Medical Research and Opinion, 23 (8), 1939-1944. doi:10.1185/030079907X219562 Peer Reviewed verified by ORBi |
 | Bruyère, O., & Reginster, J.-Y. (August 2007). Highlights from the Seventh European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. Expert Opinion on Pharmacotherapy, 8 (11), 1779-1784. doi:10.1517/14656566.8.11.1779 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (July 2007). The efficacy of glucosamine sulfate in osteoarthritis: Financial and nonfinancial conflict of interest. Arthritis and Rheumatism, 56 (7), 2105-2110. doi:10.1002/art.22852 Peer Reviewed verified by ORBi |
 | Bruyère, O., Delferriere, D., Roux, C., Fechtenbaum, J., Kolta, S., & Reginster, J.-Y. (July 2007). Positive effects of strontium ranelate on spine osteoarthritis progression. Annals of the Rheumatic Diseases, 66 (Suppl.II), 58. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Malmstrom, K., Mehta, A., Bergman, G., Ko, A. T., Curtis, S. P., & Reicin, A. S. (July 2007). Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Annals of the Rheumatic Diseases, 66 (7), 945-951. doi:10.1136/ard.2006.059162 Peer Reviewed verified by ORBi |
 | MacDonald, T., Littlejohn, T., Richard, D., Lheritier, K., Krammer, G., & Reginster, J.-Y. (June 2007). Improved blood pressure control but similar efficacy with lumiracoxib 100 mg OD compared to ibuprofen 600 mg TID in hypertensive patients with osteoarthritis: randomised controlled trial. Annals of the Rheumatic Diseases, 66 (Suppl.II), 502. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Brixen, K., Cormier, C., & Cannata Andia, J. B. (June 2007). Long term efficacy of strontium ranelate in reducing the risk of vertebral and non-vertebral including hip fractures in post menopausal osteoporotic women over 5 years. Annals of the Rheumatic Diseases, 66 (Suppl.II), 102. Peer Reviewed verified by ORBi |
 | Bruyère, O., Roux, C., Detilleux, J., & Reginster, J.-Y. (June 2007). Increase in femoral neck bone mineral density is associated with decrease in vertebral and hip fracture incidence during a 3-year treatment with strontium ranelate. Annals of the Rheumatic Diseases, 66 (Suppl.II), 521. Peer Reviewed verified by ORBi |
 | COLLETTE, J., Reginster, J.-Y., Bruyère, O., Roux, C., Lorenc, R., Felsenberg, D., & Spector, T. D. (May 2007). Strontium ranelate decreases vertebral fracture risk whatever the level of pretreatment bone turnover markers. Calcified Tissue International, 80 (Suppl.1), 29-30. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Brixen, K., Cormier, C., & Cannata, J. (May 2007). Strontium ranelate demonstrates vertebral and non-vertebral antifracture efficacy including hip fractures over 5 years in postmenopausal osteoporotic women. Calcified Tissue International, 80 (Suppl.1), 47. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Cooper, C., Sedarati, F., Neate, C., & Stakkestad, J. A. (May 2007). The MOBILE study long-term extension: progressive improvements in efficacy with oral ibandronate (1500mg) when administered monthly. Calcified Tissue International, 80 (Suppl.1), 144. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (May 2007). Managing the osteoporotic patient today. BONE, 40 (5, Suppl. 1), 12-S18. doi:10.1016/j.bone.2007.02.004 Peer Reviewed verified by ORBi |
 | COLLETTE, J., Reginster, J.-Y., Bruyère, O., DEROISY, R., Jupsin, I., Devogelaer, J.-P., Adami, S., & Marcelli, C. (May 2007). Dissociation between bone formation and bone resorption evidenced by changes in biochemical markers of bone turnover in patients treated with strontium ranelate. Calcified Tissue International, 80 (Suppl.1), 120. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Bruyère, O., & NEUPREZ, A. (May 2007). Current role of glucosamine in the treatment of osteoarthritis. Rheumatology, 46 (5), 731-735. doi:10.1093/rheumatology/kem026 Peer Reviewed verified by ORBi |
 | Neuprez, A., Bruyère, O., Collette, J., & Reginster, J.-Y. (26 April 2007). Vitamin D inadequacy in Belgian postmenopausal osteoporotic women. BMC Public Health, 7 (147), 64. doi:10.1186/1471-2458-7-64 Peer Reviewed verified by ORBi |
 | Bruyère, O., De Cock, C., Neuprez, A., MALAISE, O., & Reginster, J.-Y. (March 2007). Calcium daily food intake is very low in European postmenopausal women. Osteoporosis International, 18 (Suppl.1), 125. Peer Reviewed verified by ORBi |
 | Stakkestad, J. A., Lorenc, R., Czerwinski, E., Sedarati, F., Neate, C., & Reginster, J.-Y. (March 2007). Oral ibandronate (150 mg) continues to be effective and well tolerated when administered monthly: the mobile study long-term extension. Osteoporosis International, 18 (Suppl.1), 135-136. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Vignon, E., Uebelhart, D., & Kahan, A. (March 2007). STOPP (STudy on Osteoarthritis Progression Prevention): chondroitin sulfate reduces the progression of joint space narrowing in knee OA. Osteoporosis International, 18 (Suppl.1), 187-188. Peer Reviewed verified by ORBi |
 | Kahan, A., Vignon, E., Uebelhart, D., & Reginster, J.-Y. (March 2007). A randomized controlled trial with chondroitin sulfate involving over 600 patients: STOPP (STudy on Osteoarthritis Progression Prevention). Osteoporosis International, 18 (Suppl.1), 14-15. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Imschoot, J. (March 2007). Low dietary calcium intake in patients treated for osteoporosis. Osteoporosis International, 18 (Suppl.1), 132. Peer Reviewed verified by ORBi |
 | Bruyère, O., MALAISE, O., Neuprez, A., Collette, J., & Reginster, J.-Y. (March 2007). Prevalence of vitamin D inadequacy is high in European postmenopausal women. Osteoporosis International, 18 (Suppl.1), 124. Peer Reviewed verified by ORBi |
 | Collette, J., Reginster, J.-Y., Bruyère, O., Roux, C., Lorenc, R., Felsenberg, D., & Spector, T. D. (March 2007). Strontium ranelate decreases vertebral fracture risk whatever the level of pretreatment bone turnover markers. Osteoporosis International, 18 (Suppl.1), 127-128. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (March 2007). First-choice treatment for post menopausal osteoporotic patients. Osteoporosis International, 18 (Suppl.1), 178. Peer Reviewed verified by ORBi |
 | Neuprez, A., Bruyère, O., & Reginster, J.-Y. (March 2007). Vitamin D inadequacy in Belgian postmenopausal women. Osteoporosis International, 18 (Suppl.1), 123. Peer Reviewed verified by ORBi |
 | Rabenda, V., & Reginster, J.-Y. (March 2007). Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporosis International, 18 (Suppl.1), 19-20. Peer Reviewed verified by ORBi |
 | Gadois, C., Zegels, B., Dohuu, J. P., Lespessailles, E., Neveu, J. P., Fardellone, P., Roux, C., Kolta, S., & Reginster, J.-Y. (March 2007). Effect of age on a fractal bone texture parameter assessed by high resolution digital X Ray: a multicenter pilot study. Osteoporosis International, 18 (Suppl.1), 102. Peer Reviewed verified by ORBi |
 | Czerwinski, E., Reginster, J.-Y., Jonkanski, I., Neate, C., & Eisman, J. A. (March 2007). Intermittent intravenous (i.v.) ibandronate injections are more effective than an established daily oral regimen: DIVA 2-year results. Osteoporosis International, 18 (Suppl.1), 127. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (March 2007). Introduction and welcome. Osteoporosis International, 18 (Suppl.1), 182-183. Peer Reviewed verified by ORBi |
 | Collette, J., Reginster, J.-Y., Bruyère, O., Deroisy, R., Jupsin, I., Devogelaer, J.-P., Adami, S., & Marcelli, C. (March 2007). Dissociation between bone formation and bone resorption evidenced by changes in biochemical markers of bone turnover in patients treated with strontium ranelate. Osteoporosis International, 18 (Suppl.1), 125. Peer Reviewed verified by ORBi |
 | Bruyère, O., Pavelka, K., Rovati, L. C., Gatterova, J., Giacovelli, G., Olejarova, M., Deroisy, R., & Reginster, J.-Y. (March 2007). Total joint replacement after glucosamine sulfate treatment of knee osteoarthritis: results from a 8-year prospective cohort. Osteoporosis International, 18 (Suppl.1), 81. Peer Reviewed verified by ORBi |
 | Rabenda, V., Mertens, R., Fabri, V., Vanoverloop, J., Sumkay, F., Thorre, K., Voisey, J., Vannecke, C., Deswaef, A., Verpooten, G., Devillers, J., & Reginster, J.-Y. (March 2007). Low incidence of osteoporosis treatment after hip fracture. Osteoporosis International, 18 (Suppl.1), 72-73. Peer Reviewed verified by ORBi |
 | Bruyère, O., Delferriere, D., Roux, C., Fechtenbaum, J., Kolta, S., & Reginster, J.-Y. (March 2007). Strontium ranelate prevents spine osteoarthritis progression in patients with prevalent spinal osteoarthritis. Osteoporosis International, 18 (Suppl1), 16-S17. Peer Reviewed verified by ORBi |
 | Hiligsmann, M., Richy, F., Ethgen, O., Bruyère, O., & Reginster, J.-Y. (March 2007). Rationale and development of an individual patient-based model to accurately assess the efficacy of osteoporosis management. Osteoporosis International, 18 (S1), 169. Peer Reviewed verified by ORBi |
 | Rabenda, V., Manette, C., Lemmens, R., Mariani, A. M., Struvay, N., & Reginster, J.-Y. (February 2007). Prevalence and impact of osteoarthritis and osteoporosis on health-related quality of life among active subjects. Aging Clinical and Experimental Research, 19 (1), 55-60. doi:10.1007/BF03325211 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Malaise, O., NEUPREZ, A., & Bruyère, O. (February 2007). Strontium ranelate in the prevention of osteoporotic fractures. International Journal of Clinical Practice, 61 (2), 324-328. doi:10.1111/j.1742-1241.2006.01249.x Peer Reviewed verified by ORBi |
Zegels, B., Theiler, R., Crozes, P., Uebelhart, D., & Reginster, J.-Y. (2007). Une prise orale unique (1200mg) de sulfate de chondroitine 4&6 (CS) réduit la douleur et améliore la fonction. Résultats d'une étude en double insu, contre placebo et un comparateur actif, chez des patients souffrant de gonarthrose (OA). In Revue du Rhumatisme. Peer reviewed |
 | Reginster, J.-Y. (2007). Bone Forming Angents. European Musculoskeletal Review, 90-92. |
 | Pastoret, V., Carstanjen, B., Lejeune, J.-L., Farnir, F., Remy, B., Reginster, J.-Y., Serteyn, D., & Gabriel, A. (2007). Evaluation of serum osteocalcin and CTX-I in Ardenner horses with special reference to juvenile interphalangeal joint disease. Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine, 54 (9), 458-63. doi:10.1111/j.1439-0442.2007.00951.x Peer Reviewed verified by ORBi |
 | MacDonald, T. M., Reginster, J.-Y., Richard, D., Lheritier, K., Krammer, G., & Littlejohn, T. (2007). Reduced destabilization of blood pressure with lumiracoxib compared to ibuprofen in osteoarthritis patients with controlled hypertension treated with ACE-inhibitor monotherapy. Osteoarthritis and Cartilage, 15 (C), 149. Peer Reviewed verified by ORBi |
 | Bruyère, O., & Reginster, J.-Y. (2007). Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip Osteoarthritis. Drugs and Aging, 24 (7), 573-580. doi:10.2165/00002512-200724070-00005 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2007). Leczenie osteoporozy--jakie mamy mozliwosci. Polskie Archiwum Medycyny Wewnetrznej, 117 (7), 283-4. doi:10.20452/pamw.156 Peer reviewed |
 | Bruyère, O., Genant, H., Kothari, M., Zaim, S., White, D., Peterfy, C., Burlet, N., Richy, F., Ethgen, D., Montague, T., Dabrowski, C., & Reginster, J.-Y. (January 2007). Longitudinal study of magnetic resonance imaging and standard X-rays to assess disease progression in osteoarthritis. Osteoarthritis and Cartilage, 15 (1), 98-103. doi:10.1016/j.joca.2006.06.018 Peer Reviewed verified by ORBi |
 | Alexandersen, P., Karsdal, M. A., Qvist, P., Reginster, J.-Y., & Christiansen, C. (January 2007). Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women. BONE, 40 (1), 218-222. doi:10.1016/j.bone.2006.07.028 Peer Reviewed verified by ORBi |
 | Rizzoli, R., Boonen, S., Brandi, M. L., Burlet, N., Delmas, P., & REGINSTER, J.-Y. (2007). Vápník a vitamin D v léčbě osteoporózy. Ceska Revmatologie, 15 (3), 153-156. Peer Reviewed verified by ORBi |
| Reginster, J.-Y., Burlet, N., Close, P., & Bruyère, O. (2007). Injectable bisphosphonates for the treatment of osteoporosis. Women's Health, 3 (6), 719-23. doi:10.2217/17455057.3.6.719 Peer Reviewed verified by ORBi |
 | Miller, P. D., Zerbini, C. A. F., Recker, R. R., Sedarati, F., Neate, C., & Reginster, J.-Y. (2007). Clinical comparison in BMD gains with monthly oral ibandronate (150 mg) and weekly oral alendronate (70 mg) : results from the MOTION study. Journal of Bone and Mineral Research, 22 (S1), 451. Peer Reviewed verified by ORBi |
 | Body, J.-J., Bergmann, P., Boonen, S., Boutsen, Y., Devogelaer, J.-P., Goemaere, S., Reginster, J.-Y., Rozenberg, S., & Kaufman, J. M. (2007). Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club. Osteoporosis International, 18 (11), 1439-50. doi:10.1007/s00198-007-0439-4 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2007). Actualites therapeutiques dans le traitement de l'osteoporose postmenopausique. Revue Médicale de Liège, 62 (5-6, May-Jun), 352-9. Peer reviewed |
 | Malaise, O., Bruyère, O., & Reginster, J.-Y. (2007). Intraveinous paracetamol: a review of efficacy and safety in therapeutic use. Future Neurology, 2 (6), 673-688. doi:10.2217/14796708.2.6.673 Peer Reviewed verified by ORBi |
 | Rizzoli, R., Burlet, N., Cahall, D., Delmas, P. D., Eriksen, E. F., Felsenberg, D., Grbic, J., Jontell, M., Landesberg, R., Laslop, A., Matton, P., Papapoulos, S., Sezer, O., Sprafka, M., & Reginster, J.-Y. (2007). of osteonecrosis of the jaw on osteoporosis management: executive summary of an ESCEO and Foundation for Research on Osteoporosis and other Bone Diseases Working Group Meeting. Aging Health, 3, 731-734. doi:10.2217/1745509X.3.6.731 Peer Reviewed verified by ORBi |
 | Neuprez, A., Hiligsmann, M., Bruyère, O., Ethgen, O., & Reginster, J.-Y. (2007). Prevention of hip fractures in osteoporosis. Minerva Ortopedica e Traumatologica, 58 (5), 423-437. Peer reviewed |
 | Bruyère, O., & Reginster, J.-Y. (2007). Structure modification in osteoarthritis. European Musculoskeletal Review, 27-30. Peer reviewed |
 | Goemaere, S., Vanderschueren, D., Kaufman, J. M., Reginster, J.-Y., Boutsen, Y., Poriau, S., Callens, J., Raeman, F., Depresseux, G., Borghs, H., Devogelaer, J. P., & Boonen, S. (2007). Dual energy X-ray absorptiometry-based assessment of male patients using standardized bone density values and a national reference database. Journal of Clinical Densitometry, 10 (1, JAN-MAR), 25-33. doi:10.1016/j.jocd.2006.10.002 Peer Reviewed verified by ORBi |
 | Rizzoli, R., Boonen, S., Brandi, M. L., Burlet, N., Delmas, P., & Reginster, J.-Y. (2007). Le calcium et la vitamine D dans la prise en charge de l'ostéoporose. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction, 36 (6), 615-617. doi:10.1016/j.jgyn.2007.05.007 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2007). Considerations in building the evidence in osteoporosis management. BONE, 41 (S1), 30-S31. doi:10.1016/j.bone.2007.08.009 Peer Reviewed verified by ORBi |
| Reginster, J.-Y., Malaise, O., NEUPREZ, A., Jouret, V. E., & Close, P. (2007). Intermittent bisphosphonate therapy in postmenopausal osteoporosis - Progress to date. Drugs and Aging, 24 (5), 351-359. doi:10.2165/00002512-200724050-00001 Peer Reviewed verified by ORBi |
 | Bruyère, O., MALAISE, O., Neuprez, A., Collette, J., & Reginster, J.-Y. (December 2006). Prévalence élevée de la carence en vitamine D chez la femme ménopausée en Europe et principalement en France : analyse d'une cohorte de 8532 sujets. Revue du Rhumatisme, 73, 1052. Peer Reviewed verified by ORBi |
 | Richy, F., Bruyère, O., & Reginster, J.-Y. (December 2006). Tendance dans l'utilisation de biphosphonates, de vitamine D et de calcium dans l'ostéoporose postménopausique : une analyse à 10 ans. Revue du Rhumatisme, 73, 1174. Peer Reviewed verified by ORBi |
 | Bruyère, O., Cormier, C., Fardellone, P., Kahan, A., Kolta, S., Kuntz, J. L., Javier, R. M., Meunier, P., & Reginster, J.-Y. (December 2006). Corrélation entre l'augmentation de la densité minérale osseuse et la réduction du risque fracturaire lors d'un traitement par ranélate de strontium. Revue du Rhumatisme, 73, 1060. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Kahan, A., & Vignon, E. (November 2006). A two-year prospective, randomized, double-blind, controlled study assessing the effect of chondroitin 4&6 sulfate (CS) on the structural progression of knee osteoarthritis: STOPP (Study on Osteoarthritis Progression Prevention). Arthritis and Rheumatism, 54 (Suppl). Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Meunier, P., Roux, C., Compston, J., & Ortolani, S. (November 2006). Strontium ranelate: an anti-osteoporotic treatment demonstrated vertebral and nonvertebral anti-fracture efficacy over five years in post menopausal osteoporotic women. Arthritis and Rheumatism, 54 (Suppl). Peer Reviewed verified by ORBi |
 | Bruyère, O., Delmas, P. D., Devogelaer, J.-P., Slosman, D. O., Albanese, C., & Reginster, J.-Y. (November 2006). Increase in femoral neck bone mineral density is associated with decrease in hip fracture incidence during treatment with strontium ranelate. Arthritis and Rheumatism, 54 (Suppl), 586. Peer Reviewed verified by ORBi |
 | Bruyère, O., MALAISE, O., Neuprez, A., COLLETTE, J., & Reginster, J.-Y. (November 2006). European postmenopausal osteoporotic women have high prevalence of vitamin D inadequacy. Arthritis and Rheumatism, 54 (Suppl), 585. Peer Reviewed verified by ORBi |
 | Lewiecki, E., Reginster, J.-Y., Elizondo-Alanis, L., Neate, C., & Adami, S. (November 2006). Progressive bone density gains with once-monthly oral ibandronate: the MOBILE study long-term extension. Arthritis and Rheumatism, 54, 584. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (November 2006). L'ibandronate (Bonviva), dans le traitement de l'osteoporose postmenopausique. Revue Médicale de Liège, 61 (11), 783-6. Peer reviewed |
 | Reginster, J.-Y., COLLETTE, J., Bruyère, O., DEROISY, R., & Jupsin, I. (November 2006). Biochemical markers of bone turnover confirm the dual mode of action of strontium ranelate: increase in bone formation and decrease in bone resorption. Arthritis and Rheumatism, 54 (Suppl), 590. Peer Reviewed verified by ORBi |
 | Bruyère, O., Detilleux, J., & Reginster, J.-Y. (November 2006). Bone mineral density assessment is an appropriate monitoring tool for the management of strontium ranelate-treated osteoporotic patients. Arthritis and Rheumatism, 54 (Suppl), 586. Peer Reviewed verified by ORBi |
 | Richy, F. Y., Hiligsmann, M., & Reginster, J.-Y. (November 2006). Prescription and coprescription patterns of bone-active substances among postmenopausal women: an epidemiological study in Belgium, Europe. Arthritis and Rheumatism, 54, 84. Peer Reviewed verified by ORBi |
 | Altman, R. D., Abramson, S., Bruyère, O., Clegg, D., Herrero-Beaumont, G., Maheu, E., Moskowitz, R., Pavelka, K., & Reginster, J.-Y. (October 2006). Commentary: osteoarthritis of the knee and glucosamine. Osteoarthritis and Cartilage, 14 (10), 963-966. doi:10.1016/j.joca.2006.06.010 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Gieschke, R. (October 2006). Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis. Current Drug Metabolism, 7 (7), 827-836. doi:10.2174/138920006778520624 Peer Reviewed verified by ORBi |
 | Bouee, S., Lafuma, A., Fagnani, F., Meunier, P. J., & Reginster, J.-Y. (October 2006). Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries. Rheumatology International, 26 (12), 1063-1072. doi:10.1007/s00296-006-0180-x Peer Reviewed verified by ORBi |
 | Rabenda, V., Manette, C., Lemmens, R., Mariani, A. M., Struvay, N., & Reginster, J.-Y. (September 2006). The direct and indirect costs of the chronic management of osteoporosis: a prospective follow-up of 3440 active subjects. Osteoporosis International, 17 (9), 1346-1352. doi:10.1007/s00198-005-0066-x Peer Reviewed verified by ORBi |
 | Close, P., NEUPREZ, A., & Reginster, J.-Y. (August 2006). Developments in the pharmacotherapeutic management of osteoporosis. Expert Opinion on Pharmacotherapy, 7 (12), 1603-1615. doi:10.1517/14656566.7.12.1603 Peer Reviewed verified by ORBi |
 | Delmas, P. D., Licata, A. A., Reginster, J.-Y., Crans, G. G., Chen, P., Misurski, D. A., Wagman, R. B., & Mitlak, B. H. (August 2006). Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. BONE, 39 (2), 237-243. doi:10.1016/j.bone.2006.02.003 Peer Reviewed verified by ORBi |
 | Bruyère, O., Collette, J., Kothari, M., Zaim, S., White, D., Genant, H., Peterfy, C., Burlet, N., Ethgen, D., Montague, T., Dabrowski, C., & Reginster, J.-Y. (August 2006). Osteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study. Annals of the Rheumatic Diseases, 65 (8), 1050-1054. doi:10.1136/ard.2005.045914 Peer Reviewed verified by ORBi |
 | Rabenda, V., Burlet, N., Belaiche, J., Raeman, F., Richy, F., & Reginster, J.-Y. (July 2006). Determinants of gastro-protective drugs co-prescription during treatment with nonselective NSAIDs: a prospective survey of 2197 patients recruited in primary care. Osteoarthritis and Cartilage, 14 (7), 625-630. doi:10.1016/j.joca.2006.01.002 Peer Reviewed verified by ORBi |
 | Seeman, E., Vellas, B., Benhamou, C. L., Aquino, J. P., Semler, J., Kaufman, J. M., Hoszowski, K., Varela, A. R., Fiore, C., Brixen, K., Reginster, J.-Y., & Boonen, S. (July 2006). Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. Journal of Bone and Mineral Research, 21 (7), 1113-1120. doi:10.1359/jbmr.060404 Peer Reviewed verified by ORBi |
 | Bruyère, O., Reginster, J.-Y., Giacovelli, G., Barbetta, B., Rovati, L. C., & Pavelka, K. (July 2006). Clinical significance of the long-term symptom-modifying effects of glucosamine sulfate: comment on the article by Brandt and Mazzuca. Arthritis and Rheumatism, 54 (7), 2339-2341. doi:10.1002/art.21867 Peer Reviewed verified by ORBi |
 | Czerwinski, E., Nuti, R., Greenwald, M., Burdeska, A., Leigh, C., & Reginster, J.-Y. (June 2006). Upper gastrointestinal safety and tolerability profile of once-monthly and daily oral ibandronate: mobile 2-year analysis. Annals of the Rheumatic Diseases, 65 (Suppl.II), 415. Peer Reviewed verified by ORBi |
 | Bruyère, O., MALAISE, O., Neuprez, A., & Reginster, J.-Y. (June 2006). Young postmenopausal women have high prevalence of inadequate serum vitamin D levels: results of a European study. Osteoporosis International, 17 (Suppl.2), 56. Peer Reviewed verified by ORBi |
 | Richy, F., Bruyère, O., Maassen, P., Pire, G., & Reginster, J.-Y. (June 2006). Self-reported versus measured prevalence of osteoporosis. An age-stratified analysis of its diagnostic coverage. Osteoporosis International, 17 (Suppl.2), 45-46. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Meunier, P. J., Roux, C., Compson, J., & Ortolani, S. (June 2006). Strontium ranelate: an anti-osteoporotic treatment demonstrated vertebral and nonvertebral anti fracture efficacy over 5 years in post menopausal osteoporotic women. Osteoporosis International, 17 (Suppl.2), 14. Peer Reviewed verified by ORBi |
 | Seeman, E., Sawicki, A., Reginster, J.-Y., Roux, C., Rubinacci, A., Diaz-Curiel, M., Kaufman, J.-M., De Vernejoul, M. C., Aquino, J. P., & Meunier, P. J. (June 2006). Strontium ranelate reduces the risk of vertebral fracture in patients with osteopenia. Osteoporosis International, 17 (Suppl.2), 85. Peer Reviewed verified by ORBi |
 | Richy, F., Bruyère, O., Mawet, A., & Reginster, J.-Y. (June 2006). Prescription and coprescription patterns of bone-active substances among postmenopausal women. Osteoporosis International, 17 (Suppl.2), 60. Peer Reviewed verified by ORBi |
 | MALAISE, O., Bruyère, O., Deroisy, R., Jupsin, I., & Reginster, J.-Y. (June 2006). Strontium Ranelate normalizes bone mineral density in osteopenic patients. Osteoporosis International, 17 (Suppl.2), 103. Peer Reviewed verified by ORBi |
 | Bruyère, O., MALAISE, O., Neuprez, A., & Reginster, J.-Y. (June 2006). High prevalence of inadequate serum vitamind D levels in osteoporotic European postmenopausal women. Osteoporosis International, 17 (Suppl.2), 33-34. Peer Reviewed verified by ORBi |
 | Seeman, E., Vellas, B., Benhamou, C. L., Aquino, J. P., Semler, J., Kaufman, J.-M., Hoszowski, K., Roces-Varela, A., Fiore, C. E., Brixen, K., Reginster, J.-Y., & Boonen, S. (June 2006). Strontium ranelate reduces the risk of fracture in elderly women with osteoporosis in the first year of treatment. Osteoporosis International, 17 (Suppl.2), 85-86. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Hawker, G., Bolognese, M., Coutant, K., Hughes, C., Sedarati, F., & Stone, M. (June 2006). Influence of baseline patient characteristics on response to one-monthly and daily oral ibandronate therapy: 2-year findings from MOBILE. Annals of the Rheumatic Diseases, 65 (Suppl.II), 426. Peer Reviewed verified by ORBi |
 | Delmas, P. D., Adami, S., Strugala, C., Stakkestad, J. A., Reginster, J.-Y., Felsenberg, D., Christiansen, C., Civitelli, R., Drezner, M. K., Recker, R. R., Bolognese, M., Hughes, C., Masanauskaite, D., Ward, P., Sambrook, P., & Reid, D. M. (June 2006). Intravenous ibandronate injections in postmenopausal women with osteoporosis - One-year results from the dosing intravenous administration study. Arthritis and Rheumatism, 54 (6), 1838-1846. doi:10.1002/art.21918 Peer Reviewed verified by ORBi |
 | Rabenda, V., Manette, C., Lemmens, R., Mariani, A. M., Struvay, N., & Reginster, J.-Y. (June 2006). Direct and indirect costs attributable to osteoarthritis in active subjects. Journal of Rheumatology, 33 (6), 1152-1158. Peer Reviewed verified by ORBi |
 | Roux, C., Reginster, J.-Y., Fechtenbaum, J., Kolta, S., Sawicki, A., Tulassay, Z., Luisetto, G., Padrino, J. M., Doyle, D., Prince, R., Fardellone, P., Sorensen, O., & Meunier, P. J. (June 2006). Vertebral fracture risk reduction with strontium ranelate in women with post-menopausal osteoporosis is independent of baseline risk factors. Osteoporosis International, 17 (Suppl.2), 92. Peer Reviewed verified by ORBi |
 | Boonen, S., Bischoff-Ferrari, H. A., Cooper, C., Lips, P., Ljunggren, O., Meunier, P. J., & Reginster, J.-Y. (May 2006). Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: A review of the evidence. Calcified Tissue International, 78 (5), 257-270. doi:10.1007/s00223-005-0009-8 Peer Reviewed verified by ORBi |
Seeman, E., Sawicki, A., Reginster, J.-Y., Roux, C., Rubinacci, A., Diaz-Curiel, M., Kaufman, J. M., De Vernejoul, M. C., Aquino, J. P., & Meunier, P. J. (May 2006). Strontium ranelate reduces the risk of vertebral fracture in patients with osteopenia. Osteoporosis International, 17 (Suppl. 2), 209. |
 | Reginster, J.-Y., Adami, S., Lakatos, P., Greenwald, M., Stepan, J. J., Silverman, S. L., Christiansen, C., Rowell, L., Mairon, N., Bonvoisin, B., Drezner, M. K., Emkey, R., Felsenberg, D., Cooper, C., Delmas, P. D., & Miller, P. D. (May 2006). Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Annals of the Rheumatic Diseases, 65 (5), 654-661. doi:10.1136/ard.2005.044958 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Rabenda, V., & NEUPREZ, A. (April 2006). Adherence, patient preference and dosing frequency: Understanding the relationship. BONE, 38 (4 Suppl 1), 2-6. doi:10.1016/j.bone.2006.01.150 Peer Reviewed verified by ORBi |
 | NEUPREZ, A., Gillet, P., Collette, C., & Reginster, J.-Y. (April 2006). L'osteodensitometrie dans le depistage de l'osteoporose: le paradoxe Belge. Revue Médicale de Liège, 61 (4), 249-55. Peer reviewed |
 | Roux, C., Reginster, J.-Y., Fechtenbaum, J., Kolta, S., Sawicki, A., Tulassay, Z., Luisetto, G., Padrino, J. M., Doyle, D., Prince, R., Fardellone, P., Sorensen, O. H., & Meunier, P. J. (April 2006). Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. Journal of Bone and Mineral Research, 21 (4), 536-542. doi:10.1359/jbmr.060101 Peer Reviewed verified by ORBi |
 | Bruyère, O., & Reginster, J.-Y. (April 2006). Assessment of structure-modifying drugs in osteoarthritis: surrogate or hard clinical end points? Future Rheumatology, 1 (2), 199-206. doi:10.2217/17460816.1.2.199 Peer Reviewed verified by ORBi |
 | Bruyère, O., MALAISE, O., Neuprez, A., & Reginster, J.-Y. (March 2006). High prevalence of inadequate serum vitamind D levels in osteoporotic European postmenopausal women. Osteoporosis International, 17 (Suppl.1), 86. Peer Reviewed verified by ORBi |
 | Roux, C., Reginster, J.-Y., Fechtenbaum, J., Kolta, S., Sawicki, A., Tulassay, Z., Luisetto, G., Padrino, J. M., Doyle, D., Prince, R., Fardellone, P., Sorensen, O. H., & Meunier, P. J. (March 2006). Vertebral fracture risk reduction with strontium ranelate in women with post-menopausal osteoporosis is independent of baseline risk factors. Osteoporosis International, 17 (Suppl.1), 50. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Meunier, P. J., Roux, C., Compston, J., & Ortolani, S. (March 2006). Strontium ranelate: an anti-osteoporotic treatment demonstrated vertebral and nonvertebral anti fracture efficacy over 5 years in post menopausal osteoporotic women. Osteoporosis International, 17 (Suppl.1), 11. Peer Reviewed verified by ORBi |
 | Richy, F., Bruyère, O., Maassen, P., Pire, G., & Reginster, J.-Y. (March 2006). Self-reported versus measured prevalence of osteoporosis. An age-stratified analysis of its diagnostic coverage. Osteoporosis International, 17 (Suppl.1), 93-94. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Brixen, K., Cormier, C., & Cannata, J. (March 2006). Strontium ranelate demonstrates vertebral and non-vertebral ANTI fracture efficacy including hip fractures over 5 years in post menopausal osteoporotic women. Osteoporosis International, 18 (Suppl.1), 21. Peer Reviewed verified by ORBi |
 | De Reilhac, P., Micheletti, M. C., Chevallier, T., & Reginster, J.-Y. (March 2006). MISSION study: prevalence of osteoporotic fractures in France, in 6841 menopausal women with or without hormone replacement therapy. Osteoporosis International, 17 (Suppl.1), 100. Peer Reviewed verified by ORBi |
 | Bruyère, O., Roux, C., Cannata, J. B., Rizzoli, R., Brixen, K., Brandi, M. L., & Reginster, J.-Y. (March 2006). Associations between increase in bone mineral density and decrease in clinical vertebral fracture incidence during a treatment with strontium ranelate. Osteoporosis International, 17 (Suppl.1), 8. Peer Reviewed verified by ORBi |
 | Bruyère, O., Fardellone, P., Kaufman, J.-M., Adami, S., Torrijos, A., & Reginster, J.-Y. (March 2006). One-year increase in hip (hip or femoral neck) bone mineral density pridicts long-term (3 years) decrease in vertebral fracture incidence in patients treated with strontium ranelate. Osteoporosis International, 17 (Suppl.1), 96. Peer Reviewed verified by ORBi |
 | Seeman, E., Vellas, B., Benhamou, C. L., Aquino, J. P., Semler, J., Kaufman, J.-M., Hoszowski, K., Roces Varela, A., Fiore, C. E., Brixen, K., & Reginster, J.-Y. (March 2006). Strontium ranelate reduces the risk of fracture in elderly women with osteoporosis in the first year of treatment. Osteoporosis International, 17 (Suppl.1), 7. Peer Reviewed verified by ORBi |
 | Seeman, E., Sawicki, A., Reginster, J.-Y., Roux, C., Rubinacci, A., Diaz-Curiel, M., Kaufman, J.-M., de Vernejoul, M. C., Aquino, J. P., & Meunier, P. J. (March 2006). Strontium ranelate reduces the risk of vertebral fracture in patients with osteopenia. Osteoporosis International, 17 (Suppl.1), 50. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Stakkestad, J. A., Lorenc, R., Hughes, C., Mairon, N., Coutant, K., & Adami, S. (March 2006). Once-monthly dosing of oral ibandronate is highly efficacious: 2-year results from mobile. Osteoporosis International, 17 (Suppl.1), 64-65. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (March 2006). Requirements for clinical trials in osteoporosis and osteoarthritis: what is new in 2006? Osteoporosis International, 17 (Suppl.1), 119. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (March 2006). Multirisk assessment in postmenopausal women. Osteoporosis International, 17 (Suppl.1), 112. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Richy, F., & Bruyère, O. (March 2006). Activite antalgique de la glucosamine dans l'arthrose: quoi de neuf en 2006? Revue Médicale de Liège, 61 (3), 169-72. Peer reviewed |
 | Bruyère, O., MALAISE, O., Neuprez, A., & Reginster, J.-Y. (March 2006). Early postmenopausal women have high prevalence of inadequate serum vitamin D levels. Results of a European study. Osteoporosis International, 17 (Suppl.1), 85-86. Peer Reviewed verified by ORBi |
 | MALAISE, O., Bruyère, O., Deroisy, R., Jupsin, I., & Reginster, J.-Y. (March 2006). Strontium Ranelate normalizes bone mineral density in osteopenic patients. Osteoporosis International, 17 (Suppl.1), 63. Peer Reviewed verified by ORBi |
 | Bruyère, O., Giacovelli, G., Pavelka, K., Rovati, L., & Reginster, J.-Y. (March 2006). Effect of glucosamine sulfate on newly proposed/recommended clinical trial end-points in patients with knee osteoarthritis. Osteoporosis International, 17 (Suppl.1), 13. Peer Reviewed verified by ORBi |
 | Goemaere, S., Vanderschueren, D., Kaufman, J.-M., Reginster, J.-Y., Boutsen, Y., Poriau, S., Callens, J., Raeman, F., Depresseux, G., Devogelaer, J.-P., Borghs, H., & Boonen, S. (March 2006). DXA-based assessment of male patients using standardized bone density values and a national reference database. Osteoporosis International, 17 (Suppl.1), 54. Peer Reviewed verified by ORBi |
 | Bruyère, O., Kothari, M., Peterfy, C., Zaim, S., White, D., Burlet, N., Richy, F., Ethgen, D., Montague, T., Dabrowski, C., Genant, H., & Reginster, J.-Y. (March 2006). Longitudinal study of magnetic resonance imaging and fixed-flexion radiography to assess progression of osteoarthritis of the knee. Osteoporosis International, 17 (Suppl.1), 85. Peer Reviewed verified by ORBi |
 | Goemaere, S., Bergmann, P., Body, J. J., Boonen, S., Boutsen, Y., Devogelaer, J.-P., Kaufman, J.-M., Rozenberg, S., & Reginster, J.-Y. (March 2006). Belgian bone specialists are eagerly looking to the availability of new medications in osteoporosis. Osteoporosis International, 17 (Suppl.1), 27. Peer Reviewed verified by ORBi |
 | Tancredi, A., Polet, A. S., Bosio-Le Goux, B., Augendre-Ferrante, B., & Reginster, J.-Y. (March 2006). Association between osteoporosis and cardiovascular risk factors in postmenopausal women. Osteoporosis International, 17 (Suppl.1), 84. Peer Reviewed verified by ORBi |
 | Richy, F., Bruyère, O., Mawet, A., & Reginster, J.-Y. (March 2006). Prescription and coprescription patterns of bone-active substances among postmenopausal women. Osteoporosis International, 17 (Suppl.1), 93. Peer Reviewed verified by ORBi |
 | Bruyère, O., Delmas, P. D., Devogelaer, J.-P., Slosman, D. O., Albanese, C., & Reginster, J.-Y. (March 2006). Relations between increase in femoral neck bone mineral density and decrease in hip fracture incidence during treatment with strontium ranelate. Osteoporosis International, 17 (Suppl.1), 96. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Altman, R. D. (March 2006). Osteoarthritis of the knee and glucosamine: a commentary. Osteoporosis International, 17 (Suppl.1), 111. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Nevitt, M. C., Chen, P., Dore, R. K., Kiel, D. P., Zanchetta, J. R., Glass, E. V., & Krege, J. H. (March 2006). Reduction in the risk of back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Osteoporosis International, 17 (Suppl.1), 5. Peer Reviewed verified by ORBi |
 | Bruyère, O., MALAISE, O., Neuprez, A., & Reginster, J.-Y. (March 2006). Calcium daily food intake in European post-menopausal women. Osteoporosis International, 17 (Suppl.1), 101. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (February 2006). Adherence and persistence: Impact on outcomes and health care resources. BONE, 38 (2 Suppl 2), 18-21. doi:10.1016/j.bone.2005.11.013 Peer Reviewed verified by ORBi |
 | Burlet, N., & Reginster, J.-Y. (2006). Strontium ranelate - The first dual acting treatment for postmenopausal osteoporosis. Clinical Orthopaedics and Related Research, (443), 55-60. doi:10.1097/01.blo.0000200247.27253.e9 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Devogelaer, J. P. (February 2006). Raloxifene reduces fractures in postmenopausal women with osteoporosis. Clinical Orthopaedics and Related Research, 443, 48-54. doi:10.1097/01.blo.0000200234.99436.24 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Burlet, N. (February 2006). Osteoporosis: A still increasing prevalence. BONE, 38 (2 Suppl 1), 4-9. doi:10.1016/j.bone.2005.11.024 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Felsenberg, D., Cooper, C., Stakkestad, J. A., Miller, P. D., Kendler, D. L., Adami, S., McClung, M. R., Bolognese, M. A., Civitelli, R., Dumont, E., Bonvoisin, B., Recker, R. R., & Delmas, P. D. (February 2006). A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Osteoporosis International, 17 (2), 159-166. doi:10.1007/s00198-005-1957-6 Peer Reviewed verified by ORBi |
 | Nevitt, M. C., Chen, P. Q., Dore, R. K., Reginster, J.-Y., Kiel, D. P., Zanchetta, J. R., Glass, E. V., & Krege, J. H. (February 2006). Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporosis International, 17 (2), 273-280. doi:10.1007/s00198-005-2013-2 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Bruyère, O. (2006). Effets symptomatiques de la glucosamine dans l’arthrose. Que dire des nouvelles études européenne (GUIDE) et américaine (GAIT) ? Ortho-Rhumato, 4, 56-58. |
| Reginster, J.-Y. (2006). Santé osseuse et ostéoporose: la supplémentation vitamino-calcique en fonction de l’âge. Hygiène - Journal de l'Association Française des femmes médecins, 32, 36. |
 | Reginster, J.-Y., Abadie, E., Delmas, P., Rizzoli, R., Dere, W., der Auwera, P., Avouac, B., Brandi, M. L., Daifotis, A., Diez-Perez, A., Calvo, G., Johnell, O., Kaufman, J. M., Kreutz, G., Laslop, A., Lekkerkerker, F., Mitlak, B., Nilsson, P., Orloff, J., ... Flamion, B. (January 2006). Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men. Osteoporosis International, 17 (1), 1-7. doi:10.1007/s00198-005-1984-3 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Sarlet, N. (2006). The Treatment of Severe Postmenopausal Osteoporosis : A Review of Current and Emerging Therapeutic Options. Treatments in Endocrinology, 5 (1), 15-23. doi:10.2165/00024677-200605010-00003 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2006). Intravenous ibandronate in the treatment of osteoporosis: A viewpoint by Jean-Yves Rginster. Drugs, 66 (12), 1602-1602. doi:10.2165/00003495-200666120-00006 Peer Reviewed verified by ORBi |
 | Richy, F., Lecart, M.-P., Mawet, A., Paquot, B., & Reginster, J.-Y. (2006). Interet de la densitometrie osseuse dans le depistage et le suivi therapeu- tique des patients osteoporotiques: integration avec les facteurs cliniques et biologiques. Revue Médicale de Liège, 61 (5-6, May-Jun), 291-300. Peer reviewed |
 | Devogelaer, J. P., Goemaere, S., Boonen, S., Body, J.-J., Kaufman, J. M., Reginster, J.-Y., Rozenberg, S., & Boutsen, Y. (January 2006). Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporosis International, 17 (1), 8-19. doi:10.1007/s00198-005-2032-z Peer Reviewed verified by ORBi |
 | Nevitt, M. C., Chen, P., Kiel, D. P., Reginster, J.-Y., Dore, R. K., Zanchetta, J. R., Glass, E. V., & Krege, J. H. (2006). Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Osteoporosis International, 17 (11), 1630-7. doi:10.1007/s00198-006-0177-z Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Rabenda, V. (2006). Patient Preference in the Management of Postmenopausal Osteoporosis with Bisphosphonates. Clinical Interventions in Aging, 1 (4), 415-23. doi:10.2147/ciia.2006.1.4.415 Peer Reviewed verified by ORBi |
 | Hanssens, L., De Hert, M., Wampers, M., Reginster, J.-Y., & Peuskens, J. (2006). Pharmacological Treatment of Ambulatory Schizophrenic Patients in Belgium. Clinical Practice and Epidemiology in Mental Health, 2, 11. doi:10.1186/1745-0179-2-11 Peer reviewed |
 | Manette, C., Collette, J., Sarlet, N., Tancredi, A., Zegels, B., & Reginster, J.-Y. (2006). Comprehensive therapy in osteoporosis using a single drug: From ADFR to strontium ranelate. Current Medicinal Chemistry, 13 (13), 1585-1590. doi:10.2174/092986706777442057 Peer Reviewed verified by ORBi |
 | Tancredi, A., & Reginster, J.-Y. (2006). Osteoporosis and cardiovascular disease: in nonskeletal risk important in patients requiring an antiosteoporotic treatment? Future Rheumatology, 1, 481-491. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Bruyère, O. (2006). Effets symptomatiques de la glucosamine dans l’arthrose. Pharma-Sphère, 110, 26-28. |
 | Rovati, L. C., Pavelka, K., Giacovelli, G., & Reginster, J.-Y. (2006). Assessment of joint space narrowing with conventional standing antero-posterior radiographs: relief in mild-to-moderate pain is not a confounder in recent osteoarthritis structure-modifying drug trials. Osteoarthritis and Cartilage, 14 (Suppl. A), 14-A18. doi:10.1016/j.joca.2006.02.022 Peer Reviewed verified by ORBi |
 | Richy, F., & Reginster, J.-Y. (2006). Diagnosis of osteoporosis without prevalent fractures: are we missing our main target? Osteoporosis Action, 1, 2-3. Peer reviewed |
 | O'Donnell, S., Cranney, A., Wells, G. A., Adachi, J., & Reginster, J.-Y. (2006). Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database of Systematic Reviews, 18 (CD00), 5326. doi:10.1002/14651858.CD005326.pub3 Peer Reviewed verified by ORBi |
 | Eastell, R., Krege, J. H., Chen, P. Q., Glass, E. V., & Reginster, J.-Y. (January 2006). Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Current Medical Research and Opinion, 22 (1), 61-66. doi:10.1185/030079905X75096 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Rabenda, V. (2006). Adherence to anti-osteoporotic treatment: does it really matter? Future Rheumatology, 1, 37-40. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Bruyère, O. (2006). Symptomatische effecten van de glucosamine bij artrose. Wat onthouden we uit de nieuwe Europese (GUIDE) en Noord-Amerikaanse (GAIT) studies ? Medi-Sfeer, 271, 15-17. |
 | Reginster, J.-Y., & Bruyère, O. (2006). Effets symptomatiques de la glucosamine dans l’arthrose. Que retenir des nouvelles études européenne (GUIDE) et nord-américaine (GAIT) ? Medi-Sphere, 271, 15-17. |
 | Richy, F., & Reginster, J.-Y. (2006). A simple method for detecting and adjusting meta-analyses for publication Bias. Internet Journal of Epidemiology, 3 (2). Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Bruyère, O. (2006). Symptomatische effecten van de glucosamine bij artrose. Wat onthouden we uit de nieuwe Europese (GUIDE) en Noord-Amerikaanse (GAIT) studies? Ortho-Rhumato, 4, 56-58. Peer reviewed |
 | Bruyère, O., Richy, F., & Reginster, J.-Y. (December 2005). Three year joint space narrowing predicts long term incidence of knee surgery in patients with osteoarthritis: an eight year prospective follow up study. Annals of the Rheumatic Diseases, 64 (12), 1727-1730. doi:10.1136/ard.2005.037309 Peer Reviewed verified by ORBi |
 | Sanchez, C., Deberg, M., Piccardi, N., Msika, P., Reginster, J.-Y., & Henrotin, Y. (November 2005). Osteoblasts from the sclerotic subchondral bone downregulate aggrecan but upregulate metalloproteinases expression by chondrocytes. This effect is mimicked by interleukin-6, -1 beta and oncostatin M pre-treated non-sclerotic osteoblasts. Osteoarthritis and Cartilage, 13 (11), 979-987. doi:10.1016/j.joca.2005.03.008 Peer Reviewed verified by ORBi |
 | Sanchez, C., Deberg, M., Piccardi, N., Msika, P., Reginster, J.-Y., & Henrotin, Y. (November 2005). Subchondral bone osteoblasts induce phenotypic changes in human osteoarthritic chondrocytes. Osteoarthritis and Cartilage, 13 (11), 988-997. doi:10.1016/j.joca.2005.07.012 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Rabenda, V. (05 October 2005). Observance et persistance: impact sur l'efficience des traitements de l'osteoporose. Revue Médicale Suisse, 1 (35), 2278-81. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (October 2005). Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis. Expert Opinion on Pharmacotherapy, 6 (13), 2301-2313. doi:10.1517/14656566.6.13.2301 Peer Reviewed verified by ORBi |
 | Silverman, S., Greenwald, M., Hawker, G., Hughes, C., Mairon, N., Bonvoisin, B., & Reginster, J.-Y. (September 2005). Once-monthly oral ibandronate (Boniva) dosing is highly efficacious in postmenopausal osteoporosis: 2-year results from MOBILE. Arthritis and Rheumatism, 52 (number 9 (suppl.)), 735-736. Peer Reviewed verified by ORBi |
 | Richy, F., Bruyère, O., Maassen, P., Pire, G., & Reginster, J.-Y. (September 2005). Self-reported versus measured prevalence of osteoporosis. An age-stratified analysis of its diagnostic coverage. Arthritis and Rheumatism, 52 (number 9 (suppl.)), 228-229. Peer Reviewed verified by ORBi |
 | Kothari, M., Bruyère, O., COLLETTE, J., Peterfy, C., Zaim, S., White, D., Burlet, N., Ethgen, D. J., Montague, T., Dabrowski, C., Reginster, J.-Y., & Genant, H. K. (September 2005). Magnetic Resonance Imaging and biochemical markers of osteoarthritis of the knee. Arthritis and Rheumatism, 52 (number 9 (suppl.)), 71. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Lecart, M. P., & Richy, F. (September 2005). Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss. Journal of Rheumatology, 32 (Suppl. 76), 21-25. Peer Reviewed verified by ORBi |
 | Kothari, M., Peterfy, C., Bruyère, O., Zaim, S., White, D., Burlet, N., Ethgen, D. J., Montague, T., Dabrowski, C., Reginster, J.-Y., & Genant, H. K. (September 2005). Longitudinal study of magnetic resonance imaging and fixed-flexion radiography to assess progression of osteoarthritis of the knee. Arthritis and Rheumatism, 52 (number 9 (suppl.)), 65. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Wilson, K. M., Dumont, E., Bonvoisin, B., & Barrett, J. (September 2005). Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: Results from the monthly oral pilot study. Journal of Clinical Endocrinology and Metabolism, 90 (9), 5018-5024. doi:10.1210/jc.2004-1750 Peer Reviewed verified by ORBi |
 | Tancredi, A., Reginster, J.-Y., Luyckx, F., & Legros, J.-J. (August 2005). No major month to month variation in free testosterone levels in aging mates. Minor impact on the biological diagnosis of 'andropause'. Psychoneuroendocrinology, 30 (7), 638-646. doi:10.1016/j.psyneuen.2005.02.002 Peer Reviewed verified by ORBi |
 | Gourlay, M. L., Miller, W. C., Richy, F., Garrett, J. M., Hanson, L. C., & Reginster, J.-Y. (August 2005). Performance of osteoporosis risk assessment tools in postmenopausal women aged 45-64 years. Osteoporosis International, 16 (8), 921-927. doi:10.1007/s00198-004-1775-2 Peer Reviewed verified by ORBi |
 | Miller, P. D., McClung, M. R., Macovei, L., Stakkestad, J. A., Luckey, M., Bonvoisin, B., Reginster, J.-Y., Recker, R. R., Hughes, C., Lewiecki, E. M., Felsenberg, D., Delmas, P. D., Kendler, D. L., Bolognese, M. A., Mairon, N., & Cooper, C. (August 2005). Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. Journal of Bone and Mineral Research, 20 (8), 1315-1322. doi:10.1359/JBMR.050313 Peer Reviewed verified by ORBi |
 | Kung, A. W. C., Ho, A. Y. Y., Ross, P. D., & Reginster, J.-Y. (July 2005). Development of a clinical assessment tool in identifying Asian men with low bone mineral density and comparison of its usefulness to quantitative bone ultrasound. Osteoporosis International, 16 (7), 849-855. doi:10.1007/s00198-004-1778-z Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (18 June 2005). Treatment of postmenopausal osteoporosis. BMJ: British Medical Journal, 330 (7505), 856-860. doi:10.1136/bmj.330.7496.859 Peer Reviewed verified by ORBi |
 | Adami, S., Tanko, L. B., Nuti, R., Leigh, C., Mairon, N., Sedarati, F., & Reginster, J.-Y. (June 2005). Upper gastrointestinal safety and tolerability profile of once-monthly and daily oral ibandronate is similar in postmenopausal osteoporosis: 1-year results from MOBILE. Annals of the Rheumatic Diseases, 64 (Suppl.III), 364. Peer Reviewed verified by ORBi |
 | Roux, C., Fardellone, P., Fechtenbaum, J., Kolta, S., Kruse, H., Sawicki, A., Hoszowski, K., Padrino, J. M., Sorensen, H., Reginster, J.-Y., & Meunier, P. (June 2005). Strontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women whatever the baseline vertebral fractures status. Annals of the Rheumatic Diseases, 64 (Suppl.III), 359. Peer Reviewed verified by ORBi |
 | Cooper, C., Delmas, P. D., Felsenberg, D., Hughes, C., Mairon, N., Bonvoisin, B., & Reginster, J.-Y. (June 2005). Two-year efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: the MOBILE study. Annals of the Rheumatic Diseases, 64 (Suppl.III), 68. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Lorenc, R., Stepan, J. J., Hughes, C., Mairon, N., Bonvoisin, B., & Cooper, C. (June 2005). Once-monthly and daily oral ibandronate are at least as effective in improving proximal femur BMD in postmenopausal osteoporosis: 12-month data from MOBILE. Annals of the Rheumatic Diseases, 64 (Suppl.III), 93. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Stepan, J. J., Halse, J., Hughes, C., Mahoney, P., Masanauskaite, D., & Stakkestad, J. A. (June 2005). Intravenous ibandronate injections are at least as effective as daily oral ibandronate: consistent effect across subgroups. Annals of the Rheumatic Diseases, 64 (Suppl.III), 365. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Nevitt, M. C., Chen, P., Dore, R. K., Kiel, D. P., Zanchetta, J. R., Glass, E. V., & Krege, J. H. (June 2005). Reduction in the risk of back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Annals of the Rheumatic Diseases, 64 (Suppl.III), 521. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Richy, F., Rabenda, V., & Tancredi, A. (June 2005). Global prevalence and skeletal implications of vitamin D inadequacy. Annals of the Rheumatic Diseases, 64 (Suppl.III), 362. Peer Reviewed verified by ORBi |
 | Rabenda, V., Burlet, N., Ethgen, O., Raeman, F., Belaiche, J., & Reginster, J.-Y. (May 2005). A naturalistic study of the determinants of health related quality of life improvement in osteoarthritic patients treated with non-specific non-steroidal antiinflammatory drugs. Annals of the Rheumatic Diseases, 64 (5), 688-693. doi:10.1136/ard.2004.026658 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Seeman, E., De Vernejoul, M. C., Adami, S., Compston, J., Phenekos, C., Devogelaer, J. P., Curiel, M. D., Sawicki, A., Goemaere, S., Sorensen, O. H., Felsenberg, D., & Meunier, P. J. (May 2005). Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. Journal of Clinical Endocrinology and Metabolism, 90 (5), 2816-2822. doi:10.1210/jc.2004-1774 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (April 2005). The high prevalence of inadequate serum vitamin D levels and implications for bone health. Current Medical Research and Opinion, 21 (4), 579-585. doi:10.1185/030079905X41435 Peer Reviewed verified by ORBi |
 | Richy, F., Deroisy, R., Lecart, M.-P., Hanssens, L., Mawet, A., & Reginster, J.-Y. (April 2005). D-Hormone analog alfacalcidol: an update on its role in post-menopausal osteoporosis and rheumatoid arthritis management. Aging Clinical and Experimental Research, 17 (2), 133-142. doi:10.1007/BF03324586 Peer Reviewed verified by ORBi |
 | Jupsin, I., Collette, J., Henrotin, Y., Bruyère, O., Sarlet, N., & Reginster, J.-Y. (April 2005). Strontium Ranelate (Fujisawa/Servier). Current Opinion in Investigational Drugs, 6 (4), 435-44. Peer Reviewed verified by ORBi |
 | Altman, R. D., Abadie, E., Avouac, B., Bouvenot, G., Branco, J., Bruyère, O., Calvo, G., Devogelaer, J.-P., Dreiser, R. L., Herrero-Beaumont, G., Kahan, A., Kreutz, G., Laslop, A., Lemmel, E. M., Menkes, C., Pavelka, K., Van De Putte, L., Vanhaelst, L., & Reginster, J.-Y. (March 2005). OC31.. Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. Osteoporosis International, 16 (Suppl.3), 10. Peer Reviewed verified by ORBi |
 | Bruyère, O., Kothari, M., Zaim, S., White, D., Peterfy, C., Genant, H. K., Ethgen, D., Montague, T., Burlet, N., LEONORI, L., & Reginster, J.-Y. (March 2005). One-year progression of knee osteoarthritis: correlations between X-Rays and magnetic resonance imaging changes. Osteoporosis International, 16 (Suppl.3), 46-47. Peer Reviewed verified by ORBi |
 | Richy, F., Schacht, E., Bruyère, O., Ethgen, O., Gourlay, M., & Reginster, J.-Y. (March 2005). An indirect comparison of the efficacies of vitamin D and its hydroxylated analogs in postmenopausal and corticosteroid-induced osteoporosis. Osteoporosis International, 16 (Suppl.3), 29. Peer Reviewed verified by ORBi |
 | Bruyère, O., Kothari, M., Zaim, S., White, D., Peterfy, C., Burlet, N., Ethgen, D., Montague, T., & Reginster, J.-Y. (March 2005). Knee whole-organ MRI score (WORMS) as a surrogate marker for X-ray joint space narrowing. Osteoporosis International, 16 (Suppl.3), 6. Peer Reviewed verified by ORBi |
 | Seeman, E., Vellas, B., Meunier, P. J., Roux, C., Adami, S., Aquino, J. P., Semler, J., Graham, J., Sorensen, O. H., Padrino, J. M., Rizzoli, R., Spector, T., Kaufman, J.-M., Boonen, S., & Reginster, J.-Y. (March 2005). Vertebral and non-vertebral anti-fracture efficacy of strontium ranelate in very elderly women with osteoporosis. Osteoporosis International, 16 (Suppl.3), 6. Peer Reviewed verified by ORBi |
 | Tancredi, A., Legros, J.-J., Pire, G., Maassen, P., LUYCKX, F., & Reginster, J.-Y. (March 2005). Analysis of the discriminant ability of shorter versions of the French ADAM questionnaire. Osteoporosis International, 16 (Suppl.3), 39. Peer Reviewed verified by ORBi |
 | Richy, F., Ethgen, O., Bruyère, O., & Reginster, J.-Y. (March 2005). Screening for osteoporosis: systematic DXA or pre-screening with questionnaires? An economic point of view. Osteoporosis International, 16 (Suppl.3), 101. Peer Reviewed verified by ORBi |
 | Bouée, S., Lafuma, A., Fagnani, F., Meunier, P. J., & Reginster, J.-Y. (March 2005). Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in six European countries. Osteoporosis International, 16 (Suppl.3), 13. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Cooper, C., Miller, P. D., Hughes, C., Mairon, N., Bonvoisin, B., & Delmas, P. D. (March 2005). Monthly oral ibandronate is at least as effective as daily oral ibandronate: 1-year results from MOBILE. Osteoporosis International, 16 (Suppl.3), 81-82. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Rizzoli, R., Balogh, A., Badurski, J., Spector, T., Tulassay, Z., Felsenberg, D., Cannata, J. B., Phenekos, C., Ortolani, S., & Meunier, P. J. (March 2005). strontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women without prevalent vertebral fracture. Osteoporosis International, 16 (Suppl.3), 53. Peer Reviewed verified by ORBi |
 | Alexandersen, P., Tanko, L. B., Bagger, Y. Z., Hansen, H., Reginster, J.-Y., & Christiansen, C. (March 2005). Strontium ranelate inhibits urinary excretion of CTX-II, a marker of cartilage degradation, in postmenopausal women. Osteoporosis International, 16 (suppl.3), 60. Peer Reviewed verified by ORBi |
 | Ljunggren, Ö., Andonopoulos, A. P., Lehtonen-Veromaa, M., Lems, W. F., & Reginster, J.-Y. (March 2005). Preference and acceptability of calcium plus vitamin D3 formulations. Osteoporosis International, 16 (Suppl.3), 52. Peer Reviewed verified by ORBi |
 | Tancredi, A., Reginster, J.-Y., LUYCKX, F., & LEGROS, J.-J. (March 2005). No major month to month variations in free testosterone levels in aging males. Minor impact on the biological diagnosis of "andropause". Osteoporosis International, 16 (Suppl.3), 107. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (March 2005). Osteoporosis: a still increasing prevalence. Osteoporosis International, 16 (Suppl.3), 119. Peer Reviewed verified by ORBi |
 | Richy, F., Schacht, E., Bruyère, O., Ethgen, O., Gourlay, M., & Reginster, J.-Y. (March 2005). Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: A comparative meta-analysis. Calcified Tissue International, 76 (3), 176-186. doi:10.1007/s00223-004-0005-4 Peer Reviewed verified by ORBi |
 | Deberg, M., Labasse, A., Christgau, S., Cloos, P., Bang Henriksen, D., Chapelle, J.-P., Zegels, B., Reginster, J.-Y., & Henrotin, Y. (March 2005). New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis and Cartilage, 13 (3), 258-265. doi:10.1016/j.joca.2004.12.002 Peer Reviewed verified by ORBi |
 | Ethgen, O., GILLAIN, D., Gillet, P., Gosset, C., Jousten, A., & Reginster, J.-Y. (March 2005). Age- and sex-stratified prevalence of physical disabilities and handicap in the general population. Osteoporosis International, 16 (Suppl.3), 25. Peer Reviewed verified by ORBi |
 | Delmas, P. D., Sambrook, P., Recker, R., Hughes, C., Ward, P., Masanauskaite, D., & Reginster, J.-Y. (March 2005). Intermittent intravenous ibandronate injections and daily oral ibandronate provide at least equivalent increases in bone mineral density: 1-year results from DIVA. Osteoporosis International, 16 (Suppl.3), 7. Peer Reviewed verified by ORBi |
 | Delmas, P. D., Khaltaev, N., Arriagada, M., Brandi, M. L., Cannata, J., Lau, E., Lederman, R., Lorenc, R., Minne, H., Morales-Torres, J., Morii, H., Sambrook, P., Torralba, T., Zanchetta, J., & Reginster, J.-Y. (March 2005). The management of postmenopausal osteoporosis: a position paper of the world health origination collaborating center on public health aspects of rheumatic diseases. Osteoporosis International, 16 (Suppl.3), 47. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Richy, F., Rabenda, V., & Tancredi, A. (March 2005). Vitamin D inadequacy: global prevalence and skeletal implications. Osteoporosis International, 16 (Suppl.3), 64. Peer Reviewed verified by ORBi |
 | Rabenda, V., Burlet, N., Ethgen, O., Raeman, F., BELAICHE, J., & Reginster, J.-Y. (March 2005). A naturalistic study of the determinants of healthrelated quality of life improvement in osteoarthritic patients treated with non-specific non-steroidal anti-inflammatory drugs. Osteoporosis International, 16 (Suppl.3), 100-101. Peer Reviewed verified by ORBi |
 | Tancredi, A., Bosio-Le goux, B., Augendre-Ferrante, B., & Reginster, J.-Y. (March 2005). Osteoporosis in daily clinical practice: prevalence of acute predictors in French postmenopausal women. Osteoporosis International, 16 (Suppl.3), 108-109. Peer Reviewed verified by ORBi |
 | Gourlay, M. L., Richy, F., Garrett, J. M., Amick, H. R., Busby, M. G., Renner, J. B., Posner, J., & Reginster, J.-Y. (March 2005). Body composition, bone mineral density and Baecke physical activity scores in women aged 25 to 49 years. Osteoporosis International, 16 (Suppl.3), 106. Peer Reviewed verified by ORBi |
 | Kaufman, J.-M., DEROISY, R., Gangji, V., & Reginster, J.-Y. (March 2005). Patients prefer calcium+vitamin D3 chewable tablets (Steovit D3) above calcium+vitamin D3 effervescent powder (Cacit D3). Osteoporosis International, 16 (Suppl.3). Peer Reviewed verified by ORBi |
 | Rabenda, V., Manette, C., Lemmens, R., Mariani, A.-M., Struvay, N., & Reginster, J.-Y. (March 2005). Prevalence and impact of osteoarthritis and osteoporosis on health-related quality of life among active subjects. Osteoporosis International, 16 (Suppl.3), 110. Peer Reviewed verified by ORBi |
 | Rabenda, V., Manette, C., Lemmens, R., Mariani, A.-M., Struvay, N., & Reginster, J.-Y. (March 2005). Impact of health professionals utilization induced by musculoskeletal disorders among active subjects. Osteoporosis International, 16 (Suppl.3), 110. Peer Reviewed verified by ORBi |
 | Eastell, R., Chen, P., Krege, J. H., & Reginster, J.-Y. (March 2005). Identification of responders to teriparatide therapy by procollagen Type I N-Propeptide (P1NP) using the least significant change approach. Osteoporosis International, 16 (Suppl.3), 5. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Richy, F., & Bruyère, O. (March 2005). A critical analysis of the efficacy of estrogens on spinal and non-spinal fracture reduction. Osteoporosis International, 16 (Suppl.3), 47. Peer Reviewed verified by ORBi |
 | Richy, F., DEROISY, R., LECART, M.-P., Hanssens, L., Schacht, E., & Reginster, J.-Y. (March 2005). D-hormone analog alfacalcidol: its role in postmenopausal osteoporosis and rheumatoid arthritis management. Osteoporosis International, 16 (Suppl.3), 105-106. Peer Reviewed verified by ORBi |
 | Tancredi, A., Bosio-Le Goux, B., Augendre-Ferrante, B., & Reginster, J.-Y. (March 2005). Postmenopausal women initiating an antiosteoporotic treatment reported high prevalence of risk factors for cardiovascular diseases. Osteoporosis International, 16 (Suppl.3), 107. Peer Reviewed verified by ORBi |
 | Tancredi, A., Bosio-Le Goux, B., Augendre-Ferrante, B., & Reginster, J.-Y. (March 2005). Cross-sectional assessment of risk factors associated with breast cancer among French postmenopausal women being prescribed an antiosteoporotic treatment. Osteoporosis International, 16 (Suppl.3), 108. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (March 2005). Compliance and persistence: impact on outcomes and healthcare resources. Osteoporosis International, 16 (Suppl.3), 115. Peer Reviewed verified by ORBi |
 | Bruyère, O., COLLETTE, J., Kothari, M., Zaim, S., White, D., Peterfy, C., Burlet, N., Ethgen, D., Montague, T., & Reginster, J.-Y. (March 2005). Baseline hyaluronic acid measurement predicts one-year changes in knee magnetic resonance imaging global score (WORMS) in patients with knee osteoarthritis. Osteoporosis International, 16 (Suppl.3), 47. Peer Reviewed verified by ORBi |
 | Bruyère, O., Kothari, M., Zaim, S., White, D., Peterfy, C., Genant, H. K., Ethgen, D., Montague, T., Burlet, N., Richy, F., & Reginster, J.-Y. (March 2005). Femoro-tibial joint space width, assessed by standard X-Ray, is associated with tibial cartilage volume and thickness, assessed by magnetic resonance imaging. Osteoporosis International, 16 (Suppl.3), 46. Peer Reviewed verified by ORBi |
 | Rabenda, V., MANETTE, C., Lemmens, R., Mariani, A. M., Struvay, N., & Reginster, J.-Y. (March 2005). Indirect costs induced by osteoarthritis and osteoporosis in the workplace. Osteoporosis International, 16 (Suppl.3), 13-14. Peer Reviewed verified by ORBi |
 | Bruyère, O., Richy, F., & Reginster, J.-Y. (March 2005). Three-year joint space narrowing predicts long-term incidence of knee surgery in patients with osteoarthritis: an 8-year prospective follow-up study. Osteoporosis International, 16 (Suppl.3), 77. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Imschoot, J., & Ghys, A. (March 2005). Short-term daily administration of 1500 mg glucosamine contributes to symptomatic improvement of osteoarthritis. Osteoporosis International, 16 (Suppl.3), 33. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Sarlet, N., LEJEUNE, E., & Leonori, L. (March 2005). Strontium Ranelate: A New Treatment for Postmenopausal Osteoporosis with a Dual Mode of Action. Current Osteoporosis Reports, 3 (1), 30-4. doi:10.1007/s11914-005-0025-7 Peer Reviewed verified by ORBi |
 | Ethgen, O., Richy, F., Cools, P., Devillers, J., & Reginster, J.-Y. (March 2005). Health-related quality of life as a predictor of direct costs in osteoarthritis. Osteoporosis International, 16 (Suppl.3), 59. Peer Reviewed verified by ORBi |
 | Abadie, E., Devogealer, J.-P., Ringe, J., Ethgen, D., Bouvenot, G., Kreutz, G., Laslop, A., Orloff, J., Vanderauwera, P., Delmas, P., Dere, W. H., Branco, J., Altman, R. D., Avouac, B., Menkes, C. J., Vanhaelst, L., Mitlak, B., Tsouderos, Y., & Reginster, J.-Y. (March 2005). Recommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from GREES. Osteoporosis International, 16 (Suppl.3), 47. Peer Reviewed verified by ORBi |
 | Boonen, S., Body, J.-J., Boutsen, Y., Devogelaer, J. P., Goemaere, S., Kaufman, J. M., Rozenberg, S., & Reginster, J.-Y. (March 2005). Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporosis International, 16 (3), 239-254. doi:10.1007/s00198-004-1812-1 Peer Reviewed verified by ORBi |
 | Ethgen, O., Gosset, C., De Maeseneer, J., & Reginster, J.-Y. (March 2005). Physical functionning is the most severely affected health-related quality of life dimension during the aging process. Osteoporosis International, 16 (Suppl.3), 25-26. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Chen, P., Dore, R. K., Kiel, D. P., Zanchetta, J. R., Glass, E. V., & Krege, J. H. (March 2005). The effects of teriparatide on the risk of back pain in men and women with osteoporosis: A meta-analysis. Osteoporosis International, 16 (Suppl.3), 10-11. Peer Reviewed verified by ORBi |
 | Bruyère, O., Pavelka, K., Richy, F., Giacovelli, G., Rovati, L. C., & Reginster, J.-Y. (March 2005). Responders to glucosamine sulfate in knee osteoarthritis. Osteoporosis International, 16 (Suppl.3), 77. Peer Reviewed verified by ORBi |
 | Tancredi, A., Reginster, J.-Y., LUYCKX, F., & LEGROS, J.-J. (March 2005). Interest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers. Osteoporosis International, 16 (Suppl.3), 107. Peer Reviewed verified by ORBi |
 | Tancredi, A., Bosio-Le Goux, B., Augendre-Ferrante, B., & Reginster, J.-Y. (March 2005). Management of osteoporosis after multi-risks assessment in French postmenopausal women. Osteoporosis International, 16 (Suppl.3), 108. Peer Reviewed verified by ORBi |
 | Rabenda, V., Burlet, N., BELAICHE, J., Raeman, F., Richy, F., & Reginster, J.-Y. (March 2005). Determinants of gastroprotective drugs co-prescription during treatment with non selective NSAIDS: A prospective survey of 2197 patients recruited in primary care. Osteoporosis International, 16 (Suppl.3), 101. Peer Reviewed verified by ORBi |
 | Bruyère, O., Wuidart, M. A., Di Palma, E., Gourlay, M., Ethgen, O., Richy, F., & Reginster, J.-Y. (February 2005). Controlled whole body vibration to decrease fall risk and improve health-related quality of life of nursing home residents. Archives of Physical Medicine and Rehabilitation, 86 (2), 303-307. doi:10.1016/j.apmr.2004.05.019 Peer Reviewed verified by ORBi |
 | Deberg, M., Labasse, A., Collette, J., Seidel, L., Reginster, J.-Y., & Henrotin, Y. (2005). One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression. Osteoarthritis and Cartilage, 13 (12), 1059-65. doi:10.1016/j.joca.2005.06.014 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Bruyère, O., Fraikin, G., & Henrotin, Y. (2005). Current Concepts in the Therapeutic Management of Osteoarthritis with Glucosamine. Bulletin. Hospital for Joint Diseases, 63 (1-2), 31-36. Peer Reviewed verified by ORBi |
 | Abadie, E., Devogelaer, J.-P., Ringe, J. D., Ethgen, D. J., Bouvenot, G. M., Kreutz, G., Laslop, A., Orloff, J. J., Vanderauwera, P. M., Delmas, P. D., Dere, W. H., Branco, J., Altman, R. D., Avouac, B. P., Menkes, C. J., Vanhaelst, L., Mitlak, B. H., Tsouderos, Y., & Reginster, J.-Y. (2005). Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science. Seminars in Arthritis and Rheumatism, 35 (1), 1-4. doi:10.1016/j.semarthrit.2005.03.006 Peer Reviewed verified by ORBi |
 | Giacovelli, G., Bruyère, O., Barbetta, B., Pavelka, K., Reginster, J.-Y., & Rovati, L. C. (2005). Clinical relevance of pain and function outcomes in glucosamine sulfate long-term trials. Osteoarthritis and Cartilage, 13 (A), 69. Peer Reviewed verified by ORBi |
 | Altman, R. D., Abadie, E., Avouac, B., Bouvenot, G., Branco, J., Bruyère, O., Calvo, G., Devogelaer, J. P., Dreiser, R. L., Herrero-Beaumont, G., Kahan, A., Kreutz, G., Laslop, A., Lemmel, E. M., Menkes, C. J., Pavelka, K., Van De Putte, L., Vanhaelst, L., & Reginster, J.-Y. (January 2005). Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. Osteoarthritis and Cartilage, 13 (1), 13-19. doi:10.1016/j.joca.2004.10.012 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2005). Following up on patients with osteoporosis. BONE, 36 (S2), 474-5. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Zikan, V., Lorenc, R., Hughes, C., Mairon, N., Bonvoisin, B., & Stakkestad, J. A. (2005). Once-monthly dosing of oral ibandronate is at least as effective as daily dosing in postmenopausal osteoporosis : 1-year results from mobile. BONE, 36 (S2), 416. Peer Reviewed verified by ORBi |
 | Chevalier, T., Daures, J. P., Micheletti, M. C., Reginster, J.-Y., & Groupe MISSION. (2005). Méthodologie de l'enquête MISSION (Ménopause, risque de cancer du sein, morbidité et prévalence). Journal de Gynécologie, Obstétrique et Biologie de la Reproduction, 34 (7-C1), 658-665. Peer Reviewed verified by ORBi |
 | Sanchez, C., Deberg, M., Piccardi, N., Msika, P., Reginster, J.-Y., & Henrotin, Y. (2005). P228. Subchondral Bone Osteoblasts Induce Phenotypic Changes in Human Osteoarthritic Chondrocytes. Osteoporosis International, 16 (Suppl.3), 55-56. Peer Reviewed verified by ORBi |
 | Sanchez, C., Deberg, M., Piccardi, N., Msika, P., Reginster, J.-Y., & Henrotin, Y. (2005). Avocado/soybean unsaponifiables prevent osteoarthritic subchondral osteoblasts-induced cartilage degradation. Osteoporosis International, 16 (Suppl.3), 56. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Burlet, N., & LECART, M.-P. (2005). Ibandronate: a new perspective in the treatment of osteoporosis. Therapy, 2, 179-189. doi:10.1586/14750708.2.2.179 Peer Reviewed verified by ORBi |
 | Roux, C., Fechtenbaum, J., Kolta, S., Reginster, J.-Y., & Meunier, P. J. (2005). Le ranélate de strontium est efficace quel que soit le nombre de fractures vertébrales prévalentes. Revue du Rhumatisme, 72, 1110. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2005). Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: A comprehensive review. Current Pharmaceutical Design, 11 (28), 3711-3728. doi:10.2174/138161205774580750 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Sarlet, N., & Lecart, M.-P. (January 2005). Fractures in osteoporosis: the challenge for the new millennium. Osteoporosis International, 16 (Suppl. 1), 1-S3. doi:10.1007/s00198-004-1752-9 Peer Reviewed verified by ORBi |
 | Schacht, E., Richy, F., & Reginster, J.-Y. (2005). The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. Journal of Musculoskeletal and Neuronal Interactions, 5 (3), 273-84. Peer Reviewed verified by ORBi |
 | Delmas, P. D., Khaltaev, N., Arriagada, M., Brandi, M. L., Cannata, J., Lau, E., Lederman, R., Lorenc, R., Minne, H., Morales-Torres, J., Morii, H., Sambrook, P., Torralba, T., Zanchetta, J., & Reginster, J.-Y. (2005). The Management of Postmenopausal Osteoporosis: A Position Paper of the World Health Origination Collaborating Center on Public Health Aspects of Rheumatic Diseases. Journal of Musculoskeletal and Neuronal Interactions, 5 (2), 105-9. Peer Reviewed verified by ORBi |
 | Delmas, P. D., Rizzoli, R., Cooper, C., & Reginster, J.-Y. (January 2005). Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation. Osteoporosis International, 16 (1), 1-5. doi:10.1007/s00198-004-1813-0 Peer Reviewed verified by ORBi |
 | Mathy, M., Burton, S., Deby, G., Devel, P., Reginster, J.-Y., & Henrotin, Y. (2005). Influence of oxygen tension on nitric oxide and prostaglandin E2 synthesis by bovine chondrocytes. Osteoarthritis and Cartilage, 13 (1), 74-9. doi:10.1016/j.joca.2004.09.009 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., LECART, M.-P., Bruyère, O., & Burlet, N. (2005). Glucosamine sulphate in osteoarthritis: from symptoms to structure modification. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 4, 217-220. doi:10.2174/1568014054065212 Peer Reviewed verified by ORBi |
 | Rabenda, V., Hanssens, L., De Ceulaer, F., & Reginster, J.-Y. (2005). Is there any interest in combining treatments in osteoporosis? Current Rheumatology Reviews, 1, 49-55. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2005). Adherence, patient preference and dosing frequency : understanding the relationship. BONE, 36 (S2), 475-6. Peer Reviewed verified by ORBi |
 | Cooper, C., Stepan, J. J., Lorenc, R., Hughes, C., Coutant, K., Sedarati, F., & Reginster, J.-Y. (2005). Monthly oral ibandronate is at least as effective as daily oral ibandronate in increasing hip BMD in postmenopausal osteoporosis : 1-year results from mobile. BONE, 36 (S2), 417. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Kaufman, J. M., & Gangjii, V. (2005). Preference for and acceptability of two formulations of a dietary supplement containing calcium plus vitamin D-3: A randomized, open-label, crossover trial in adult patients with calcium and vitamin D deficiencies. Current Therapeutic Research, 66 (1, JAN-FEB), 23-34. doi:10.1016/j.curtheres.2005.03.003 Peer Reviewed verified by ORBi |
 | Sanchez, C., Deberg, M., Piccardi, N., Msika, P., Reginster, J.-Y., & Henrotin, Y. (2005). Interleukin-1, Interleukin-6 and Oncostatin M Stimulate Normal Subchondral Osteoblasts to Induce Cartilage Degradation [Poster presentation]. 5th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO 5), Roma, Italy. |
 | Chevallier, T., Daures, J.-P., Micheletti, M.-C., & Reginster, J.-Y. (2005). Methodologie de l'enquete MISSION (Menopause, rISque de cancer du SeIn, mOrbidite et prevaleNce). Journal de Gynécologie, Obstétrique et Biologie de la Reproduction, 34 (7 Pt 1), 658-65. Peer Reviewed verified by ORBi |
 | Sanchez, C., Deberg, M., Piccardi, N., Msika, P., Reginster, J.-Y., & Henrotin, Y. (2005). Interleukin-1, Interleukin-6 and Oncostatin M Stimulate Normal Subchondral Osteoblasts to Induce Cartilage Degradation. Osteoporosis International, 16 (Suppl 3), 54-S55. Peer Reviewed verified by ORBi |
 | Bruyère, O., Edwards, J., & Reginster, J.-Y. (2005). Fracture prevention in postmenopausal women. Clinical Evidence, 13, 1419-1434. Peer Reviewed verified by ORBi |
 | Bruyère, O., Edwards, J., & Reginster, J.-Y. (2005). what are the effects of treatments to prevent fractures in postmenopausal osteoporosis. BMJ Clinical evidence, 13, 325-327. Peer reviewed |
 | Fardellone, P., Roux, C., Fechtenbaum, J., Kolta, S., Kruse, H. P., Sawicki, A., Hoszowski, K., Padrino, J., Sorensen, O., Reginster, J.-Y., & Meunier, P. (2005). Strontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women whatever the baseline vertebral fracture status. BONE, 36 (S2), 403. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Richy, F., Rabenda, V., & tancredi, A. (2005). Vitamin D inadequacy : global prevalence and skeletal implications. BONE, 36 (S2), 462. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Deberg, M., Henrotin, Y., & Christgau, S. (22 December 2004). DETECTION OF SPECIFIC NITRATED MARKERS. |
 | Reginster, J.-Y., Deberg, M., Henrotin, Y., & Christgau, S. (15 December 2004). METHOD FOR MONITORING COLLAGEN TYPE II DEGRADATION IN CARTILAGE. |
 | Richy, F., Ethgen, O., Bruyère, O., Mawet, A., & Reginster, J.-Y. (December 2004). Primary prevention of osteoporosis: Mass screening scenario or prescreening with questionnaires? An economic perspective. Journal of Bone and Mineral Research, 19 (12), 1955-1960. doi:10.1359/JBMR.040903 Peer Reviewed verified by ORBi |
 | Lecart, M.-P., Bruyère, O., & Reginster, J.-Y. (December 2004). Combination/Sequential Therapy in Osteoporosis. Current Osteoporosis Reports, 2 (4), 123-30. doi:10.1007/s11914-996-0011-8 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Devogelaer, J.-P. (November 2004). Traitement de l'osteoporose postmenopausique en 2004. Revue Médicale de Liège, 59 (11), 633-47. Peer reviewed |
 | Richy, F., Deceulaer, F., Ethgen, O., Bruyère, O., & Reginster, J.-Y. (November 2004). Development and validation of the ORACLE score to predict risk of osteoporosis. Mayo Clinic Proceedings, 79 (11), 1402-1408. doi:10.4065/79.11.1402 Peer Reviewed verified by ORBi |
 | Tannenbaum, H., Berenbaum, F., Reginster, J.-Y., Zacher, J., Robinson, J., Poor, P. G., Bliddal, H., Uebelhart, D., Adami, S., Navarro, F., Lee, A., Moore, A., & Gimona, A. (November 2004). Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Annals of the Rheumatic Diseases, 63 (11), 1419-1426. doi:10.1136/ard.2003.015974 Peer Reviewed verified by ORBi |
 | Sanchez, C., Deberg, M., Devel, P., Reginster, J.-Y., Henrotin, Y., & Burton, S. (October 2004). Differential Regulation of Chondrocyte Metabolism by Oncostatin M and Interleukin-6. Osteoarthritis and Cartilage, 12 (10), 801-10. doi:10.1016/j.joca.2004.06.011 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Brixen, K., Bianchi, G., Hensen, J., Balogh, A., Lorenc, R., Cannata, J. B., & Fardellone, P. (September 2004). A new treatment for the reduction of vertebral and non-vertebral fractures in post-menopausal women with osteoporosis. Arthritis and Rheumatism, 50 (number 9 (suppl.)), 291. Peer Reviewed verified by ORBi |
 | Tancredi, A., Reginster, J.-Y., Schleich, F., Pire, G., Maassen, P., Luyckx, F., & Legros, J.-J. (September 2004). Interest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers. European Journal of Endocrinology, 151 (3), 355-360. doi:10.1530/eje.0.1510355 Peer Reviewed verified by ORBi |
 | Recker, R. R., Silverman, S. L., Kendler, D. L., Dumont, E., Bonvoisin, B., Hughes, C., & Reginster, J.-Y. (September 2004). Tolerability of monthly oral ibandronate in postmenopausal osteoporosis: 1-year results from the MOBILE Study. Arthritis and Rheumatism, 50 (number 9 (suppl.)), 293. Peer Reviewed verified by ORBi |
 | Tanko, L. B., Bagger, Y. Z., Alexandersen, P., Devogelaer, J. P., Reginster, J.-Y., Chick, R., Olson, M., Benmammar, H., Mindeholm, L., Azria, M., & Christiansen, C. (September 2004). Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: Acute and 3-month effects on biomarkers of bone turnover. Journal of Bone and Mineral Research, 19 (9), 1531-1538. doi:10.1359/JBMR.040715 Peer Reviewed verified by ORBi |
 | Alexandersen, P., Tanko, L. B., Bagger, Y. Z., Hansen, H. B., & Reginster, J.-Y. (September 2004). Strontium treatment has a pronounced Effect on cartilage degradation in postmenopausal women. Arthritis and Rheumatism, 50 (number 9 (suppl.)), 346. Peer Reviewed verified by ORBi |
 | Boonen, S., Rizzoli, R., Meunier, P. J., Stone, M., Nuki, G., Syversen, U., Lehtonen-Veromaa, M., Lips, P., Johnell, O., & Reginster, J.-Y. (July 2004). The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report [letter to the editor]. Osteoporosis International, 15 (7), 511-519. doi:10.1007/s00198-004-1621-6 Peer Reviewed verified by ORBi |
 | Richy, F., Bruyère, O., Ethgen, O., Rabenda, V., Bouvenot, G., Audran, M., Herrero-Beaumont, G., Moore, A., Eliakim, R., Haim, M., & Reginster, J.-Y. (July 2004). Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach [letter to the editor]. Annals of the Rheumatic Diseases, 63 (7), 759-766. doi:10.1136/ard.2003.015925 Peer Reviewed verified by ORBi |
 | Cooper, C., Adami, S., Stepan, J. J., Wiese, C., Wilson, K., Coutant, K., Dumont, E., & Reginster, J.-Y. (2004). A novel bisphosphonate dosing regimen: once-monthly oral ibandronate. Annals of the Rheumatic Diseases. Peer Reviewed verified by ORBi |
 | Holgate, S. T., Bousquet, J., Chung, K. F., Bisgaard, H., Pauwels, R., Fabbri, L., Rabe, K., Doherty, M., Snell, N. J. C., Cuss, F., D'Amato, M., & Reginster, J.-Y. (June 2004). Summary of recommendations for the design of clinical trials and the registration of drugs used in the treatment of asthma. Respiratory Medicine, 98 (6), 479-487. doi:10.1016/j.rmed.2003.12.005 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Richy, F. (2004). The OST risk tool performs consistently for identifying women at risk of osteoporosis across populations. Annals of the Rheumatic Diseases. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (June 2004). Prevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities [letter to the editor]. Journal of Internal Medicine, 255 (6), 615-628. doi:10.1111/j.1365-2796.2004.01292.x Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Fischer, C. L., Beualieu, A., Malmstrom, K., Curtis, S. P., Miller, E. R., Bergman, G., Smolar, J., & Reicin, A. S. (2004). Etoricoxib demonstrates similar efficacy and improved gastrointestinal safety compared to naproxen in two 138-week randomized studies of osteoarthritis patients. Annals of the Rheumatic Diseases. Peer Reviewed verified by ORBi |
 | Gieschke, R., & Reginster, J.-Y. (2004). Clinical utility of a pharmacostatistical model for ibandronate in osteoporosis. Annals of the Rheumatic Diseases. Peer Reviewed verified by ORBi |
 | Hanssens, L. C., De Ceulaer, F., Tancredi, A., Bruyère, O., Richy, F., Halkin, V., Pire, G., Maassen, P., & Reginster, J.-Y. (May 2004). Evaluation of prevalence of osteoporosis and osteopenia in men presenting at multiple risk detection campaign. Osteoporosis International, 15 (Suppl.1), 54. Peer Reviewed verified by ORBi |
 | Richy, F., Gourlay, M., Ethgen, O., Bruyère, O., & Reginster, J.-Y. (May 2004). BMD in men: which normative data? Osteoporosis International, 15 (Suppl.1), 54. Peer Reviewed verified by ORBi |
 | Ethgen, O., Bruyère, O., Richy, F., Dardennes, C., & Reginster, J.-Y. (May 2004). Health-related quality of life in total hip and total knee arthroplasty - A qualitative and systematic review of the literature. Journal of Bone and Joint Surgery. American Volume, 86 (5), 963-974. doi:10.2106/00004623-200405000-00012 Peer Reviewed verified by ORBi |
 | Hanssens, L., Tancredi, A., DeCeulaer, F., Bruyère, O., Zegels, B., Halkin, V., Pire, G., Maassen, P., & Reginster, J.-Y. (May 2004). Evaluation of the relationship between IGF-1, IGF-BP3, BMD and age in men presenting at a multiple risk detection campaign. Osteoporosis International, 15 (Suppl.1), 48-49. Peer Reviewed verified by ORBi |
 | Adami, S., Meunier, P. J., Devogelaer, J.-P., Hoszowski, K., Fardellone, P., Benhamou, V., Brixen, K., Bonidan, O., Marcelli, C., Reginster, J.-Y., & Fechtenbaum, J. (May 2004). Strontium ranelate reduces the risk of vertebral and non-vertebral fractures in Caucasian women with postmenopausal osteoporosis. Osteoporosis International, 15 (Suppl.1), 93-94. Peer Reviewed verified by ORBi |
 | Rizzoli, R., Reginster, J.-Y., Diaz-Curiel, M., Ortolani, S., Benhamou, C., Compston, J., & Meunier, P. J. (May 2004). Patients at high risk of hip fracture benefit from treatment with strontium ranelate. Osteoporosis International, 15 (Suppl.1), 18. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Dumont, E., Wiese, C., Wilson, K., & Schimmer, R. C. (May 2004). Oral monthly ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study (MOPS). Osteoporosis International, 15 (Suppl.1), 105-106. Peer Reviewed verified by ORBi |
 | Ethgen, O., Tancredi, A., Jacques, J., Bruyère, O., Richy, F., & Reginster, J.-Y. (May 2004). Do patients with osteoporotic hip fracture recover their initial health-related quality of life? Osteoporosis International, 15 (Suppl.1), 50. Peer Reviewed verified by ORBi |
 | DeCeulaer, F., Hanssens, L., Tancredi, A., Bruyère, O., Richy, F., Pire, G., Maassen, P., & Reginster, J.-Y. (May 2004). Evaluation of the osteoporosis self-assessment tool (OST) as a screening test for osteoporosis and osteopenia in men. Osteoporosis International, 15 (Suppl.1), 54. Peer Reviewed verified by ORBi |
 | Sambrook, P., Reginster, J.-Y., Recker, R. R., Seeman, E., Nuti, R., Kelly, S., Gilbride, J., & Bonvoisin, B. (May 2004). Novel ibandronate regimens in postmenopausal osteoporosis: design of the dosing intravenous administration (DIVA) study. Osteoporosis International, 15 (Suppl.1), 118. Peer Reviewed verified by ORBi |
 | Richy, F., Gourlay, M., Ross, P., Sen, S. S., Radican, L., Deceulaer, F., Ben Sedrine, W., Ethgen, O., & Reginster, J.-Y. (May 2004). Risk assessment tools for osteoporosis: scope and limits. Osteoporosis International, 15 (Suppl.1), 11. Peer Reviewed verified by ORBi |
 | Gieschke, R., & Reginster, J.-Y. (May 2004). Successful prediction of biomarker response to oral monthly ibandronate. Osteoporosis International, 15 (Suppl.1), 97. Peer Reviewed verified by ORBi |
 | Richy, F., Ethgen, O., Bruyère, O., & Reginster, J.-Y. (April 2004). Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporosis International, 15 (4), 301-310. doi:10.1007/s00198-003-1570-5 Peer Reviewed verified by ORBi |
 | Abadie, E., Ethgen, D., Avouac, B., Bouvenot, G., Branco, J., Bruyère, O., Calvo, G., Devogelaer, J.-P., Dreiser, R. L., Herrero-Beaumont, G., Kahan, A., Kreutz, G., Laslop, A., Lemmel, E. M., Nuki, G., Van de Putte, L., Vanhaelst, L., & Reginster, J.-Y. (April 2004). Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthritis and Cartilage, 12 (4), 263-268. doi:10.1016/j.joca.2004.01.006 Peer Reviewed verified by ORBi |
 | Ethgen, O., Vanparijs, P., Delhalle, S., Rosant, S., Bruyère, O., & Reginster, J.-Y. (March 2004). Social support and health-related quality of life in hip and knee osteoarthritis. Quality of Life Research, 13 (2), 321-330. doi:10.1023/B:QURE.0000018492.40262.d1 Peer Reviewed verified by ORBi |
 | Sarkar, S., Reginster, J.-Y., Crans, G. G., Diez-Perez, A., Pinette, K. V., & Delmas, P. D. (March 2004). Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. Journal of Bone and Mineral Research, 19 (3), 394-401. doi:10.1359/JBMR.0301243 Peer Reviewed verified by ORBi |
| Reginster, J.-Y. (February 2004). Chondromodulation en 2003: reve ou realite? Revue Médicale de la Suisse Romande, 124 (2), 85-7. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Sarkar, S., Zegels, B., Henrotin, Y., Bruyère, O., Agnusdei, D., & Collette, J. (February 2004). Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. BONE, 34 (2), 344-351. doi:10.1016/j.bone.2003.10.004 Peer Reviewed verified by ORBi |
 | Meunier, P. J., Roux, C., Seeman, E., Ortolani, S., Badurski, J. E., Spector, T. D., Cannata, J., Balogh, A., Lemmel, E.-M., Pors-Nielsen, S., Rizzoli, R., Genant, H. K., & Reginster, J.-Y. (29 January 2004). The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New England Journal of Medicine, 350 (5), 459-468. doi:10.1056/NEJMoa022436 Peer Reviewed verified by ORBi |
Pasquasy, N., Gosset, C., Dejace, A., De Waele, A., Englebert, L., Hogge, Y., Reginster, J.-Y., & Rondal, P. (2004). Formations organisées dans le cadre de la « Fonction de référent hospitalier pour la continuité des soins ». Hôpitaux disposant de lits Sp. Exercice 2003. |
 | REGINSTER, J.-Y., Richy, F., & Bruyère, O. (2004). A critical analysis of the efficacy of estrogens on spinal and non-spinal fracture reduction. Reproduction Humaine et Hormones, XVII (5), 419-423. Peer reviewed |
 | Bruyère, O., Pavelka, K., Rovati, L. C., Deroisy, R., Olejarova, M., Gatterova, J., Giacovelli, G., & Reginster, J.-Y. (2004). Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause, 11 (2), 138-143. doi:10.1097/01.GME.0000087983.28957.5D Peer Reviewed verified by ORBi |
 | Bruyère, O., Pavelka, K., Richy, F., Giacovelli, G., Rovati, L. C., & Reginster, J.-Y. (2004). Responders to glucosamine sulfate in knee osteoarthritis. Arthritis and Rheumatism, 50 (suppl.1), 29. Peer Reviewed verified by ORBi |
 | Ethgen, O., & Reginster, J.-Y. (January 2004). Degenerative musculoskeletal disease. Annals of the Rheumatic Diseases, 63 (1), 1-3. doi:10.1136/ard.2003.009613 Peer Reviewed verified by ORBi |
 | Richy, F., Ethgen, O., Bruyère, O., deceulaer, F., & Reginster, J.-Y. (2004). From sample size to effect-size : small study effect investigation (SSEi). Internet Journal of Epidemiology, 1 (2). Peer Reviewed verified by ORBi |
 | Richy, F., Gourlay, M., Ross, P. D., Sen, S. S., Radican, L., De Ceulaer, F., Ben Sedrine, W., Ethgen, O., Bruyère, O., & Reginster, J.-Y. (January 2004). Validation and comparative evaluation of the osteoporosis self-assessment tool (OST) in a Caucasian population from Belgium. QJM: Monthly Journal of the Association of Physicians, 97 (1), 39-46. doi:10.1093/qjmed/hch002 Peer Reviewed verified by ORBi |
 | Sawicki, A., Reginster, J.-Y., Roux, C., Rubinacci, A., Diaz-Curiel, M., Kaufman, J., Seeman, E., De Vernejoul, M., Aquino, J., & Meunier, P. (2004). Strontium ranelate reduces the risk of vertebral fractures in postmenopausal women with osteopenia. Osteoporosis International, 15 (S1), 119-120. Peer Reviewed verified by ORBi |
 | REGINSTER, J.-Y., Ben Sedrine, W., Viethel, P., Micheletti, M. C., Chevallier, T., & Audran, M. (2004). Validation of OSIRIS, a prescreening tool for the identification of women with an increased risk of osteoporosis. Gynecological Endocrinology, 18 (1), 3-8. doi:10.1080/09513590310001651713 Peer Reviewed verified by ORBi |
 | Sanchez, C., Deberg, M., Piccardi, N., Msika, P., Reginster, J.-Y., & Henrotin, Y. (2004). Subchondral bone osteoblasts induce phenotypic changes in human osteoarthritic chondrocytes. Osteoarthritis and Cartilage, 12 (Suppl. B), 99-S100. Peer Reviewed verified by ORBi |
 | Sanchez, C., Deberg, M., Piccardi, N., Msika, P., Reginster, J.-Y., & Henrotin, Y. (2004). Subchondral Bone Osteoblasts Induce Phenotypic Changes in Human Osteoarthritic Chondrocytes [Poster presentation]. 9th World Congress of the OsteoArthritis Research Society International (OARSI), Chicago, United States - Illinois. |
 | Reginster, J.-Y., & LECART, M.-P. (2004). Treatment of osteoporosis with biphosphonates - Do compliance and persistence matter ? Business briefing : Long-term Healthcare, 5, 65-68. Peer reviewed |
 | Rizzoli, R., Reginster, J.-Y., Diaz-Curiel, M., Ortolani, S., Benhamou, C., Compston, J., & Meunier, P. J. (2004). Patients at high risk of hip fracture benefit from treatment with strontium ranelate. Calcified Tissue International, 74 (S1), 83-S84. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Rizzoli, R., Balogh, A., Badurski, J., Spector, T., Tulassay, Z., Felsenberg, D., Cannata, J. B., Phenekos, C., Ortolani, S., & Meunier, P. J. (2004). Strontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women without prevalent vertebral fracture. Calcified Tissue International, 74 (S1), 83. Peer Reviewed verified by ORBi |
 | Bruyère, O., Richy, F., & Reginster, J.-Y. (2004). Minimal joint space narrowing is a better predictor of the need for surgery than mean joint space narrowing : an 8-year prospective followup study in knee osteoarthritis. Osteoarthritis and Cartilage, 12 (SB), 54. Peer Reviewed verified by ORBi |
 | REGINSTER, J.-Y., LECART, M.-P., DEROISY, R., & Lousberg, C. (2004). Strontium ranelate: a new paradigm in the treatment of osteoporosis. Expert Opinion on Investigational Drugs, 13 (7), 857-64. doi:10.1517/13543784.13.7.857 Peer Reviewed verified by ORBi |
 | Sanchez, C., Deberg, M., Mathy, M., Devel, P., Reginster, J.-Y., & Henrotin, Y. (2004). Etude de l’influence des ostéoblastes sous-chondraux sur l’initiation de la différenciation hypertrophique des chondrocytes humains. Revue du Rhumatisme, 71 (10-11), 917-918. Peer Reviewed verified by ORBi |
 | Sanchez, C., Deberg, M., Devel, P., Reginster, J.-Y., & Henrotin, Y. (2004). Régulation du Métabolisme des Chondrocytes par l'Oncostatine M et l'Interleukine 6. Revue du Rhumatisme, 71 (10-11), 1008. Peer Reviewed verified by ORBi |
 | Christgau, S., Henrotin, Y., Tanko, L. B., Rovati, L. C., Collette, J., Bruyère, O., Deroisy, R., & Reginster, J.-Y. (2004). Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. Clinical and Experimental Rheumatology, 22 (1, JAN-FEB), 36-42. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Deberg, M., Dubuc, J. E., Quettier, E., Christgau, S., & Reginster, J.-Y. (2004). Type II collagen peptides for measuring cartilage degradation. Biorheology, 41 (3-4), 543-547. Peer Reviewed verified by ORBi |
 | Sanchez, C., Deberg, M., Piccardi, N., Msika, P., Reginster, J.-Y., & Henrotin, Y. (2004). Furanic avocado/soybean unsaponifiables prevent osteoarthritic subchondral osteoblasts-induced cartilage degradation. Osteoarthritis and Cartilage, 12 (Suppl. B), 108-S109. Peer Reviewed verified by ORBi |
 | Sanchez, C., Deberg, M., Piccardi, N., Msika, P., Reginster, J.-Y., & Henrotin, Y. (2004). Interleukin-1, interleukin-6 and oncostatin M stimulate normal subchondral osteoblasts to induce cartilage degradation. Osteoarthritis and Cartilage, 12 (Suppl. B), 98. Peer Reviewed verified by ORBi |
 | Sanchez, C., Deberg, M., Piccardi, N., Msika, P., Reginster, J.-Y., & Henrotin, Y. (2004). Furanic Avocado/Soybean Unsaponifiables Prevent Osteoarthritic Subchondral Osteoblasts- Induced Cartilage Degradation [Poster presentation]. 9th World Congress of the OsteoArthritis Research Society International (OARSI), Chicago, United States - Illinois. |
 | Reginster, J.-Y. (2004). A new paradigm in the treatment of postmenopausal osteoporosis: strontium ranelate (Protelos°). Medicographia, 26 (3), 238-243. Peer reviewed |
 | Ben Sedrine, W., Ethgen, O., Devogelaer, J.-P., Depresseux, G., Kaufman, J.-M., Goemaere, S., & Reginster, J.-Y. (2004). Evaluation of proposals of Belgian Social Security Institute for reimbursement of bone densitometry tests. Toward a cost-effective strategy for osteoporosis screening? Aging Clinical and Experimental Research, 16 (5), 413-419. doi:10.1007/bf03324573 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Devogelaer, J. (2004). Traitement de l’ostéoporose postménopausique en 2004. L'agenda Gynécologique, 36, 22-28. Peer reviewed |
Sanchez, C., Deberg, M., Devel, P., Reginster, J.-Y., & Henrotin, Y. (2004). Régulation du Métabolisme des Chondrocytes par l'Oncostatine M et l'Interleukine 6 [Poster presentation]. 17e Congrès Français de Rhumatologie, Paris, France. |
Pasquasy, N., Gosset, C., Dejace, A., De Waele, A., Englebert, L., Hogge, Y., Reginster, J.-Y., & Rondal, P. (2004). Formations organisées dans le cadre de la « Fonction de référent hospitalier pour la continuité des soins ». Hôpitaux psychiatriques. Exercice 2003. |
 | Sanchez, C., Deberg, M., Piccardi, N., Msika, P., Reginster, J.-Y., & Henrotin, Y. (2004). Les ostéoblastes arthrosiques inhibent la synthèse d’agrécane et stimulent la production de métalloprotéases par les chondrocytes humains. Revue du Rhumatisme, 71 (10-11), 917. Peer Reviewed verified by ORBi |
 | Lindsay, R., Scheele, W. H., Neer, R., Pohl, G., Adami, S., Mautalen, C., Reginster, J.-Y., Stepan, J. J., Myers, S. L., & Mitlak, B. H. (2004). Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Archives of Internal Medicine, 164 (18), 2024-30. doi:10.1001/archinte.164.18.2024 Peer Reviewed verified by ORBi |
 | Ethgen, O., Gillain, D., Gillet, P., Gosset, C., Jousten, A., & Reginster, J.-Y. (2004). Age- and sex-stratified prevalence of physical disabilities and handicap in the general population. Aging Clinical and Experimental Research, 16 (5), 389-97. doi:10.1007/BF03324569 Peer Reviewed verified by ORBi |
 | Richy, F., Gourlay, M. L., Garrett, J., Hanson, L., & Reginster, J.-Y. (2004). Osteoporosis prevalence in men varies by the normative reference. Journal of Clinical Densitometry, 7, 127-133. doi:10.1385/JCD:7:2:127 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2004). Fractures vertébrales ostéoporotiques et raloxifène (Evista°). Patient Care, 27, 27-28. Peer Reviewed verified by ORBi |
 | Sawicki, A., Reginster, J.-Y., Roux, C., Rubinacci, A., Diaz-Curiel, M., Kaufman, J., Seeman, E., De Vernejoul, M. C., Aquino, J. P., & Meunier, P. J. (2004). Strontium ranelate reduces the risk of vertebral fractures in postmenopausal women with osteopenia. Calcified Tissue International, 74 (S1), 84. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Miller, P., Delmas, P., Lorenc, R., Stakkestad, J., Christiansen, C., Wiese, C., Wilson, K., Coutant, K., Bonvoisin, B., & Dumont, E. (2004). Once-monthly oral ibandronate a new bisphosphonate dosing concept. Calcified Tissue International, 74 (S1), 85. Peer Reviewed verified by ORBi |
 | Bruyère, O., Pavelka, K., Richy, F., Giacovelli, G., Rovati, L. C., & Reginster, J.-Y. (2004). Responders to glucosamine sulfate in knee osteoarthritis. Osteoporosis International, 12 (SB), 76. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Henrotin, Y. (2004). Les nouveaux médicaments de l'arthrose. Pharma-Sphère, 85, 22-25. Peer reviewed |
 | Adami, S., Meunier, J., Devogelaer, J., Hoszowski, K., Fardellone, P., Benhamou, C., Brixen, K., Bonidan, O., Marcelli, C., Reginster, J.-Y., & Fechtenbaum, J. (2004). Strontium ranelate reduces the risk of vertebral and non-vertebral fractures in Caucasian women with post-menopausal osteoporosis. Calcified Tissue International, 74 (S1), 37-38. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., LECART, M.-P., & SARLET, N. (2004). Traitement structurel de l'arthrose : le point en 2004. Ortho-Rhumato, 2 (3), 52-54. Peer reviewed |
 | Devogelaer, J.-P., & Reginster, J.-Y. (2004). L'ostéodensitométrie. Ortho-Rhumato, 2, 102-107. Peer reviewed |
 | Reginster, J.-Y. (November 2003). Chairman's introduction. Osteoporosis International, 14 (Suppl. 7), 104. Peer Reviewed verified by ORBi |
 | Richy, F., Bruyère, O., Ethgen, O., Rabenda, V., Deceulaer, F., Bonvenot, G., Audran, M., Herrero-Beaumont Cuenca, G., Moore, A., Eliakim, R., Van De Putte, L., Haim, M., & Reginster, J.-Y. (November 2003). Time-dependent assessment of the gastrointestinal risk induced by low-dose aspirin intake: a meta-analysis. Osteoporosis International, 14 (Suppl. 7), 95. Peer Reviewed verified by ORBi |
 | De Ceulaer, F., Hanssens, L., Tancredi, A., Bruyère, O., Richy, F., Pire, G., Maassen, P., & Reginster, J.-Y. (November 2003). Evaluation of the osteoporosis self-assessment tool (OST) as a screening test for osteoporosis and osteopenia in men. Osteoporosis International, 14 (Suppl. 7), 93. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Lorenc, R. S., Spector, T. D., Benhamou, C., Isaia, G., Brixen, K., Stucki, G., Prins, J., Walravens, M., Cannata, J. B., De Chatel, R., & Meunier, P. J. (November 2003). Strontium ranelate reduces the risk of non vertebral fractures in women with postmenopausal osteoporosis. Osteoporosis International, 14 (Suppl. 7), 51-52. Peer Reviewed verified by ORBi |
 | Ethgen, O., Gosset, C., Richy, F., & Reginster, J.-Y. (November 2003). Physical function is the most severely impaired health-related quality of life dimension during the aging process. Osteoporosis International, 14 (Suppl. 7), 65. Peer Reviewed verified by ORBi |
 | Rabenda, V., Richy, F., Belaiche, J., Raeman, F., Haim, M., & Reginster, J.-Y. (November 2003). Incidence of gastrointestinal symptoms among patients taking conventional non-steroidal anti-inflammatory drugs: a pragmatic study in 1946 Belgian outpatients. Osteoporosis International, 14 (Suppl. 7), 90. Peer Reviewed verified by ORBi |
 | Richy, F., & Reginster, J.-Y. (November 2003). Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporosis International, 14 (Suppl. 7), 68. Peer Reviewed verified by ORBi |
 | Bruyère, O., Pavelka, K., Rovati, L. C., Deroisy, R., Olejarova, M., Gatterova, J., Giacovelli, G., & Reginster, J.-Y. (November 2003). Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two large, randomised, placebo-controlled, double-blind, 3-year studies. Osteoporosis International, 14 (Suppl. 7), 62. Peer Reviewed verified by ORBi |
 | Hanssens, L., Tancredi, A., De Ceulaer, F., Bruyère, O., Zegels, B., Halkin, V., Pire, G., Maassen, P., & Reginster, J.-Y. (November 2003). Evaluation of the relationship between IGF-I, IGF-BP3, BMD and age in men presenting at a multiple risk detection campaign. Osteoporosis International, 14 (Suppl. 7), 90-S91. Peer Reviewed verified by ORBi |
 | Bruyère, O., Wuidart, M. A., di Palma, E., Gourlay, M., Ethgen, O., Richy, F., & Reginster, J.-Y. (November 2003). Controlled whole body vibration to decrease fall risk and improve health related quality of life in elderly patients. Osteoporosis International, 14 (Suppl. 7), 63. Peer Reviewed verified by ORBi |
 | Ethgen, O., Tancredi, A., Brugneaux, C., Richy, F., Bruyère, O., & Reginster, J.-Y. (November 2003). Prospective evaluation of health-related quality of life in total hip and knee arthroplasties. Osteoporosis International, 14 (Suppl. 7), 66. Peer Reviewed verified by ORBi |
 | Christin-Maitre, S., Laveille, C., Collette, J., Brion, N., & Reginster, J.-Y. (01 November 2003). Pharmacodynamics of follicle stimulating hormone (FSH) in postmenopausal women during pulsed estrogen therapy: Evidence that FSH release and synthesis are controlled by distinct pathways. Journal of Clinical Endocrinology and Metabolism, 88 (11), 5405-5413. doi:10.1210/jc.2003-030094 Peer Reviewed verified by ORBi |
 | Bosio Le Goux, B., Augendre-Ferrante, B., Tancredi, A., & Reginster, J.-Y. (November 2003). High prevalence of risk factors for cardiovascular diseases in postmenopausal women being prescribed an antiosteoporotic treatment. Osteoporosis International, 14 (Suppl. 7), 87. Peer Reviewed verified by ORBi |
 | Richy, F., Gourlay, M., Ross, P. D., Sen, S. S., Radican, L., De Ceulaer, F., Ben Sedrine, W., Ethgen, O., & Reginster, J.-Y. (November 2003). Risk assessment tools for osteoporosis: scope and limits. Osteoporosis International, 14 (Suppl. 7), 68-69. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Balogh, A., Badurski, J., Spector, T. D., Pors-Nielsen, S., Felsenberg, D., Cannata, J. B., Phenekos, C., Rizzoli, R., Ortolani, S., Seeman, E., & Meunier, P. J. (November 2003). Strontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women without prevalent vertebral fracture. Osteoporosis International, 14 (Suppl. 7), 7-8. Peer Reviewed verified by ORBi |
 | Pavelka, K., Bruyère, O., Rovati, L. C., Olejarova, M., Giacovelli, G., & Reginster, J.-Y. (November 2003). Relief in mild-to-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure modifying drug trials. Osteoporosis International, 14 (Suppl. 7), 62-63. Peer Reviewed verified by ORBi |
 | Richy, F., Pire, G., Maassen, P., Gourlay, M., Ethgen, O., Bruyère, O., & Reginster, J.-Y. (November 2003). Evaluation of a campaign for osteoporosis screening in the general population: what is the follow-up given by general practitioners to a positive screening result? Osteoporosis International, 14 (Suppl. 7), 67. Peer Reviewed verified by ORBi |
 | Richy, F., Gourlay, M., Neuprez, A., Ethgen, O., Bruyère, O., & Reginster, J.-Y. (November 2003). Bone mineral density and vertebral fractures in women who have discontinued hormone replacement therapy: a retrospective population-based study. Osteoporosis International, 14 (Suppl. 7), 67. Peer Reviewed verified by ORBi |
 | Hanssens, L., De Ceulaer, F., Tancredi, A., Bruyère, O., Richy, F., Halkin, V., Pire, G., Maassen, P., & Reginster, J.-Y. (November 2003). Evaluation of prevalence of osteoporosis and osteopenia in men presenting at multiple risk detection campaign. Osteoporosis International, 14 (Suppl. 7), 90. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Wiese, C., Wilson, K., & Schimmer, R. C. (November 2003). Oral monthly ibandronate decrease bone turnover in postmenopausal women with low bone mass: results from the monthly oral pilot study (MOPS). Osteoporosis International, 14 (Suppl. 7), 5. Peer Reviewed verified by ORBi |
 | Rabenda, V., Belaiche, J., Raeman, F., Haim, M., & Reginster, J.-Y. (November 2003). Use of healthcare resources related to gastrointestinal toxicity of NSAIDS. Osteoporosis International, 14 (Suppl. 7), 14. Peer Reviewed verified by ORBi |
 | Deberg, M., Labasse, A., Christgau, S., Henriksen, D. B., Zegels, B., & Reginster, J.-Y. (November 2003). Cartilage degradation and oxidative damage in OA and RA patients. Osteoporosis International, 14 (Suppl. 7), 44-45. Peer Reviewed verified by ORBi |
 | Combescure, C., Daures, J. P., Chevallier, T., Ethgen, O., Richy, F., Viethel, P., & Reginster, J.-Y. (November 2003). Economic evaluation of OSIRIS® (osteoporosis index of risk), a prescreening tool for prediction of osteoporosis risk, using decision trees and Markov models. Osteoporosis International, 14 (Suppl. 7), 88. Peer Reviewed verified by ORBi |
 | Xu, L., Liu, J., Lin, J., Wang, S., Wu, Y., Huang, Q., Boudes, P., Korner, P., Tegtmeier, J., Xiaoxiang, C., Collette, J., & Reginster, J.-Y. (November 2003). Effects of bazedoxifene (TSE-424), a novel tissue selective estrogen receptor modulator (SERM), on biochemical markers of bone metabolism in a chinese population. Osteoporosis International, 14 (Suppl. 7), 97-98. Peer Reviewed verified by ORBi |
 | Tancredi, A., Bosio-Le Goux, B., & Reginster, J.-Y. (November 2003). Assessment of the risk of cardiovascular diseases in women with increased risk of osteoporosis. Osteoporosis International, 14 (Suppl. 7), 89. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (November 2003). Therapeutic adherence: why does it matter? Osteoporosis International, 14 (Suppl. 7), 102-103. Peer Reviewed verified by ORBi |
Ethgen, O., Tancredi, A., Lejeune, E., Kvasz, A., Zegels, B., & Reginster, J.-Y. (November 2003). Do utility values and willingness to pay suitably reflect health outcome in hip and knee osteoarthritis? A comparative analysis with the WOMAC index. Journal of Rheumatology, 30 (11), 2452-2459. Peer Reviewed verified by ORBi |
 | Bosio-Le Goux, B., Cortet, B., Lopes, P., & Reginster, J.-Y. (November 2003). The robustness of the relation between risk factors for osteoporosis and risk factors for cardiovascular diseases in postmenopausal women increases with age. Osteoporosis International, 14 (Suppl. 7), 98. Peer Reviewed verified by ORBi |
 | Rabenda, V., Ethgen, O., Belaiche, J., Raeman, F., Haim, M., & Reginster, J.-Y. (November 2003). Impact of osteoarthritis and chronic back pain on health-related quality of life among patients on NSAIDS. Osteoporosis International, 14 (Suppl. 7), 89-90. Peer Reviewed verified by ORBi |
 | Richy, F., Schacht, E., & Reginster, J.-Y. (November 2003). Vitamin D versus its two metabolites alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a cumulative meta-analysis of their effects on bone loss and fracture rate. Osteoporosis International, 14 (Suppl. 7), 88-89. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Viethel, P., Combescure, C., Richy, F., Micheletti, M. C., Chevallier, T., & Daures, J. P. (November 2003). Pragmatic evaluation of a recently validated screening tool for osteoporosis risk: OSIRIS® (osteoporosis index of risk). Osteoporosis International, 14 (Suppl. 7), 94-95. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Viethel, P., Micheletti, M. C., Chevallier, T., & Audran, M. (November 2003). Prospective validation in 798 postmenopausal women of a new screening tool for osteoporosis risk assessment: OSIRIS® (osteoporosis index of risk). Osteoporosis International, 14 (Suppl. 7), 94. Peer Reviewed verified by ORBi |
 | Bosio-Le Goux, B., Augendre-Ferrante, B., Tancredi, A., & Reginster, J.-Y. (November 2003). Assessment of osteoporosis in daily clinical practice. Osteoporosis International, 14 (Suppl. 7), 86. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Deberg, M., Labasse, A., Collette, J., Christgau, S., Henriksen, D. B., Seidel, L., Rovati, L. C., & Reginster, J.-Y. (November 2003). One-year increase of Coll 2-1 level in urine is predictive of OA progression. Osteoporosis International, 14 (Suppl. 7), 12. Peer Reviewed verified by ORBi |
 | Richy, F., Gourlay, M., Ethgen, O., Bruyère, O., & Reginster, J.-Y. (November 2003). BMD in men: which normative data? Osteoporosis International, 14 (Suppl. 7), 66-67. Peer Reviewed verified by ORBi |
 | Abadie, E., Avouac, B., Bouvenot, G., Branco, J., Bruyère, O., Calvo, G., Devogelaer, J.-P., Dieppe, P., Dreiser, R. L., Herrero-Beaumont, G., Kreutz, G., Laslop, A., Lemmel, E. M., Nuki, G., Van de Putte, L., & Reginster, J.-Y. (November 2003). Do new methods of investigation allow faster assessment of drugs efficacy in osteoarthritis? Osteoporosis International, 14 (Suppl. 7), 2. Peer Reviewed verified by ORBi |
 | Bruyère, O., Compère, S., Gathy, C., Rovati, L. C., Giacovelli, G., Deroisy, R., & Reginster, J.-Y. (November 2003). Five-year follow-up patients issued from a previous 3-year randomised, controlled trial of glucosamine sulfate in knee osteoarthritis. Osteoporosis International, 14 (Suppl 7), 9. Peer Reviewed verified by ORBi |
 | Richy, F., Pire, G., Maassen, P., Ethgen, O., Gourlay, M., Bruyère, O., & Reginster, J.-Y. (November 2003). Evaluation of an osteoporosis screening campaign in the general population: does misclassification by screening test impact on the perception of the campaign? Osteoporosis International, 14 (Suppl. 7), 68. Peer Reviewed verified by ORBi |
 | Ethgen, O., Tancredi, A., Jacques, J., Bruyère, O., Richy, F., & Reginster, J.-Y. (November 2003). Do patient with osteoporotic hip fracture recover their initial health-related quality of life? Osteoporosis International, 14 (Suppl. 7), 66. Peer Reviewed verified by ORBi |
 | Ethgen, O., Rabenda, V., Bruyère, O., & Reginster, J.-Y. (November 2003). Projecting the prevalence of osteoarthritis and osteoporosis over the five forthcoming decades: their increasing impact on public health. Osteoporosis International, 14 (Suppl. 7), 65-66. Peer Reviewed verified by ORBi |
 | Richy, F., Gourlay, M., Ethgen, O., Bruyère, O., & Reginster, J.-Y. (November 2003). Rational to use OSIRIS® (osteoporosis index of risk) to prescreen for osteoporosis in the general population. Osteoporosis International, 14 (Suppl. 7), 67-68. Peer Reviewed verified by ORBi |
 | Tanko, L. B., Bagger, Y. Z., Devogelaer, J.-P., Mindeholm, L., Chick, R., Benmammar, H., Azria, M., Reginster, J.-Y., & Christiansen, C. (November 2003). Uncoupling of bone formation and resorption with a novel oral formulation of salmon calcitonin in postmenopausal women. Osteoporosis International, 14 (Suppl. 7), 4. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Adachi, J. R., Qu, Y., Siddhanti, S., & Keech, C. (November 2003). Comparison of raloxifene and alendronate on markers of cardiovascular health in postmenopausal women with osteoporosis. Osteoporosis International, 14 (Suppl. 7), 42. Peer Reviewed verified by ORBi |
 | Richy, F., Bruyère, O., Ethgen, O., Rabenda, V., Bouvenot, G., Audran, M., Herrero Beaumont Cuenca, G., Moore, A., Eliakim, R., Van De Putte, L., Haim, M., & Reginster, J.-Y. (November 2003). Time-dependent risk of gastrointestinal complications induced by NSAIDS use: a consensus statement using meta-analytic approach. Osteoporosis International, 14 (Suppl. 7), 9. Peer Reviewed verified by ORBi |
 | Pavelka, K., Bruyère, O., Rovati, L. C., Olejarova, M., Giacovelli, G., & Reginster, J.-Y. (October 2003). Relief in mild-to-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials. Osteoarthritis and Cartilage, 11 (10), 730-737. doi:10.1016/S1063-4584(03)00166-3 Peer Reviewed verified by ORBi |
 | Bruyère, O., Compere, S., Rovati, L. C., Giacovelli, G., DEROISY, R., & Reginster, J.-Y. (October 2003). Five-year follow-up of patients from a previous 3-year randomised, controlled trial of glucosamine sulfate in knee osteoarthritis. Osteoarthritis and Cartilage, 11 (Suppl.1), 10-11. Peer Reviewed verified by ORBi |
 | Mathy, M., Devel, P., Piccardi, N., Reginster, J.-Y., & Henrotin, Y. (October 2003). Avocado/soybean unsaponifiables reverse H2O2 decoupling effect on aggrecan, type II collagen and metalloproteases gene expression in human chondrocytes. Osteoarthritis and Cartilage, 11 (Suppl.1), 99. Peer Reviewed verified by ORBi |
 | Burton, S., Mathy, M., Deby-Dupont, G., CRIELAARD, J.-M., Reginster, J.-Y., & Henrotin, Y. (October 2003). P160. Influence of oxygen tension on nitric oxide and prostaglandin E2 production by bovine chondrocytes. Osteoarthritis and Cartilage, 11 (Suppl.1), 58. Peer Reviewed verified by ORBi |
 | Mathy, M., Devel, P., Piccardi, N., Reginster, J.-Y., & Henrotin, Y. (October 2003). Advocado/soybean unsaponifiables decrease the expression of pro-inflammatory genes in human chondrocytes. Osteoarthritis and Cartilage, 11 (Suppl.1), 97-98. Peer Reviewed verified by ORBi |
 | Deberg, M., Labasse, A., Christgau, S., Henriksen, D., Reginster, J.-Y., & Henrotin, Y. (October 2003). Cartilage degradation and oxidative damage in osteoarthritic and rheumatoid arthritic patients. Osteoarthritis and Cartilage, 11 (Suppl.1), 15. Peer Reviewed verified by ORBi |
 | Bruyère, O., Compere, S., Rovati, L. C., Giacovelli, G., DEROISY, R., & Reginster, J.-Y. (September 2003). Five-year follow-up of patients from a previous 3-year randomised, controlled trial of glucosamine sulfate in knee osteoarthritis. Arthritis and Rheumatism, 48 (number 9 (suppl.)), 80. Peer Reviewed verified by ORBi |
 | Richy, F., Gourlay, M., Ross, P. D., Sen, S. S., Radican, L., Ethgen, O., & Reginster, J.-Y. (September 2003). Risk assessment tools for osteoporosis: Scope and limits. Arthritis and Rheumatism, 48 (number 9 (suppl.)), 215. Peer Reviewed verified by ORBi |
 | Bruyère, O., Wuidart, M.-A., Di Palma, E., & Reginster, J.-Y. (September 2003). Controlled whole body vibrations improve health related quality of life in elderly patients. Arthritis and Rheumatism, 48 (9, Suppl. S), 502. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Bruyère, O., Lecart, M.-P., & Henrotin, Y. (September 2003). Naturocetic (glucosamine and chondroitin sulfate) compounds as structure-modifying drugs in the treatment of osteoarthritis. Current Opinion in Rheumatology, 15, 651-655. doi:10.1097/00002281-200309000-00022 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Felsenberg, D., Pavo, I., Stepan, J., Payer, J., Resch, H., Gluer, C. C., Muhlenbacher, D., Quail, D., Schmitt, H., & Nickelsen, T. (September 2003). Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial. Osteoporosis International, 14 (9), 741-749. doi:10.1007/s00198-003-1432-1 Peer Reviewed verified by ORBi |
 | Kung, A. W. C., Ho, A. Y. Y., Ben Sedrine, W., Reginster, J.-Y., & Ross, P. D. (September 2003). Comparison of a simple clinical risk index and quantitative bone ultrasound for identifying women at increased risk of osteoporosis. Osteoporosis International, 14 (9), 716-721. doi:10.1007/s00198-003-1428-x Peer Reviewed verified by ORBi |
 | Gourlay, M., Richy, F., & Reginster, J.-Y. (September 2003). Strategies for the prevention of hip fracture. American Journal of Medicine, 115 (4), 309-317. doi:10.1016/S0002-9343(03)00371-1 Peer Reviewed verified by ORBi |
 | Richy, F. Y., Bruyère, O., Ethgen, O., Cucherat, M., & Reginster, J.-Y. (September 2003). Structural and symptomatic efficacy of glucosamine and chondroitine sulfate in osteoarthritis: a comprehensive meta-analysis. Arthritis and Rheumatism, 48 (number 9 (suppl.)), 214. Peer Reviewed verified by ORBi |
 | Richy, F. Y., & Reginster, J.-Y. (September 2003). Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Arthritis and Rheumatism, 48 (number 9 (suppl.)), 214. Peer Reviewed verified by ORBi |
 | Gourlay, M. L., Richy, F., Garrett, J., Hanson, L., & Reginster, J.-Y. (September 2003). Osteoporosis prevalence estimates for men: variation based on normative data. Arthritis and Rheumatism, 48 (number 9 (suppl.)), 298. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Sanchez, C., Deberg, M., Piccardi, N., Guillou, G. B., Msika, P., & Reginster, J.-Y. (August 2003). Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory mediator production by human osteoarthritic chondrocytes. Journal of Rheumatology, 30 (8), 1825-1834. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Bruyère, O., & Henrotin, Y. (August 2003). New perspectives in the management of osteoarthritis. Structure modification: Facts or fantasy? Journal of Rheumatology. Supplement, 67 (Suppl. 67), 14-20. Peer Reviewed verified by ORBi |
 | Richy, F., Bruyère, O., Ethgen, O., Cucherat, M., Henrotin, Y., & Reginster, J.-Y. (14 July 2003). Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis - A comprehensive meta-analysis. Archives of Internal Medicine, 163 (13), 1514-1522. doi:10.1001/archinte.163.13.1514 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., McClung, M., Coutant, K., Bonvoisin, B., Schimmer, R. C., & Delmas, P. D. (2003). Oral monthly ibandronate: rationale and clinical potential in postmenopausal osteoporosis. Annals of the Rheumatic Diseases. Peer Reviewed verified by ORBi |
 | Ethgen, O., Tellier, V., Sedrine, W. B., De Maeseneer, J., Gosset, C., & Reginster, J.-Y. (June 2003). Health-related quality of life and cost of ambulatory care in osteoporosis: how may such outcome measures be valuable information to health decision makers and payers? BONE, 32 (6), 718-724. doi:10.1016/S8756-3282(03)00089-9 Peer Reviewed verified by ORBi |
 | Bruyère, O., COLLETTE, J., Ethgen, O., Rovati, L. C., Giacovelli, G., Henrotin, Y., Seidel, L., & Reginster, J.-Y. (May 2003). Biochemical markers of bone and cartilage remodeling in prediction of longterm progression of knee osteoarthritis. Journal of Rheumatology, 30 (5), 1043-50. Peer Reviewed verified by ORBi |
 | Collette, J., Viethel, P., Dethor, M., Chevallier, T., Micheletti, M. C., Foidart, J.-M., & Reginster, J.-Y. (May 2003). Comparaison de l'evolution des marqueurs biologiques du remodelage osseux apres six mois de traitement hormonal substitutif par 17 beta-estradiol cutane ou estrogenes sulfoconjugues equins et acetate de nomegestrol. Gynécologie Obstétrique et Fertilité, 31 (5), 434-41. doi:10.1016/S1297-9589(03)00118-8 Peer Reviewed verified by ORBi |
 | Bruyère, O., Dardenne, C.-B., Lejeune, E., Zegels, B., Pahaut, A., Richy, F., Seidel, L., Ethgen, O., Henrotin, Y., & Reginster, J.-Y. (May 2003). Subchondral tibial bone mineral density predicts future joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis. BONE, 32 (5), 541-545. doi:10.1016/S8756-3282(03)00059-0 Peer Reviewed verified by ORBi |
 | Bruyère, O., Collette, J., Delmas, P., Rouillon, A., Roux, C., Seidel, L., Richy, F., & Reginster, J.-Y. (25 April 2003). Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. Maturitas, 44 (4), 259-265. doi:10.1016/S0378-5122(03)00042-2 Peer Reviewed verified by ORBi |
 | Bruyère, O., Henrotin, Y., Honore, A., Rovati, L. C., Seidel, L., Dardenne, C.-B., & Reginster, J.-Y. (April 2003). Impact of the joint space width measurement method on the design of knee osteoarthritis studies. Aging Clinical and Experimental Research, 15 (2), 136-41. doi:10.1007/BF03324491 Peer Reviewed verified by ORBi |
 | Richy, F., Bousquet, J., Ehrlich, G. E., Meunier, P. J., Israel, E., Morii, H., Devogelaer, J.-P., Peel, N., Haim, M., Bruyère, O., & Reginster, J.-Y. (March 2003). Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporosis International, 14 (3), 179-190. doi:10.1007/s00198-003-1398-z Peer Reviewed verified by ORBi |
 | Sen, S., Geling, O., Messina, O., Morales-Torres, J., Riera, G., Angulo-Solimano, J., Neto, J., Frisoli Jr., A., Castro, R., & Reginster, J.-Y. (March 2003). A risk assessment tool (osterorisk) for identifying latin american women with osteoporosis. Revista Metabolismo Oseo y Mineral, 1 (1), 39-40. Peer reviewed |
 | Reginster, J.-Y., Deroisy, R., & Jupsin, I. (February 2003). Strontium ranelate: A new paradigm in the treatment of osteoporosis. Drugs of Today, 39 (2), 89-101. doi:10.1358/dot.2003.39.2.799416 Peer reviewed |
 | Reginster, J.-Y., Kvasz, A., Bruyère, O., & Henrotin, Y. (February 2003). is there any rationale for prescribing hormone replacement therapy (HTR) to prevent or to treat osteoarthritis? Osteoarthritis and Cartilage, 11 (2), 87-91. doi:10.1053/joca.2002.0872 Peer Reviewed verified by ORBi |
 | Sorensen, O. H., Crawford, G. M., Mulder, H., Hosking, D. J., Gennari, C., Mellstrom, D., Pack, S., Wenderoth, D., Cooper, C., & Reginster, J.-Y. (February 2003). Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. BONE, 32 (2), 120-126. doi:10.1016/S8756-3282(02)00946-8 Peer Reviewed verified by ORBi |
 | Boonen, S., Kaufman, J. M., Reginster, J.-Y., & Devogelaer, J. P. (February 2003). Patient assessment using standardized bone mineral density values and a national reference database: implementing uniform thresholds for the reimbursement of osteoporosis treatments in Belgium. Osteoporosis International, 14 (2), 110-115. doi:10.1007/s00198-002-1321-z Peer Reviewed verified by ORBi |
 | Sanchez, C., Mathy-Hartert, M., Deberg, M., Ficheux, H., Reginster, J.-Y., & Henrotin, Y. (01 February 2003). Effects of rhein on human articular chondrocytes in alginate beads. Biochemical Pharmacology, 65 (3), 377-388. doi:10.1016/S0006-2952(02)01485-5 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Tancredi, A., & Rabenda, V. (2003). Glucosamine Sulphate in Osteoarthritis. Business Briefing : Long Term Healthcare Strategies, 57-60. |
 | Mathy-Hartet, M., Devel, P., Piccardi, N., REGINSTER, J.-Y., & Henrotin, Y. (2003). Les insaponifiables d'avocats/soja s'opposent aux effets délétères d'H2O2 sur le métabolisme du cartilage. Revue du Rhumatisme, 70, 1032. Peer reviewed |
 | Park, H. M., Sedrine, W. B., Reginster, J.-Y., & Ross, P. D. (2003). Korean experience with the OSTA risk index for osteoporosis: a validation study. Journal of Clinical Densitometry, 6 (3), 247-50. doi:10.1385/JCD:6:3:247 Peer Reviewed verified by ORBi |
 | Hosking, D., Adami, S., Felsenberg, D., Reginster, J.-Y., Cannata, J., Valimaki, M., Santora, A., Yacik, C., & Zaru, L. (2003). Once weekly alendronate produces a greater increase in bone mineral density than daily risedronate. Calcified Tissue International, 72, 404. Peer Reviewed verified by ORBi |
Ethgen, O., Gosset, C., Richy, F., & Reginster, J.-Y. (2003). Physical function is the most severely impaired health-related quality of life dimension during the aging process [Paper presentation]. Fourth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Nice, France. |
 | Hosking, D., Adami, S., Felsenberg, D., Andia, J. C., Valimaki, M., Benhamou, L., Reginster, J.-Y., Yacik, C., Rybak-Feglin, A., Petruschke, R. A., Zaru, L., & Santora, A. C. (2003). Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Current Medical Research and Opinion, 19 (5), 383-394. doi:10.1185/030079903125002009 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Meunier, P. J. (2003). Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. Osteoporosis International, 14 (Suppl. 3), 56-S65. doi:10.1007/s00198-002-1349-0 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Lecart, M.-P., Sarlet, N., & Halkin, V. (2003). Prevention de la fracture de la hanche chez le sujet age: ou en sommes-nous en 2003? Revue Médicale de Liège, 58 (4), 183-90. Peer reviewed |
 | Mathy, M., Martin, G., Devel, P., Deby, G., Pujol, J. P., Reginster, J.-Y., & Henrotin, Y. (2003). Reactive oxygen species downregulate the expression of pro-inflammatory genes by human chondrocytes. Inflammation Research, 52 (3), 111-8. doi:10.1007/s000110300023 Peer Reviewed verified by ORBi |
 | Rabenda, V., Boniver, J., & Reginster, J.-Y. (2003). Numerus clausus en fin de troisieme candidature en medecine: mort annoncee d'une heresie? Revue Médicale de Liège, 58 (7-8, Jul-Aug), 508-14. Peer reviewed |
 | Deberg, M., Labasse, A., Christgau, S., Henriksen, D., Reginster, J.-Y., & Henrotin, Y. (2003). Dégradation du cartilage et stress oxydatif chez des patients arthrosiques et souffrant d'arthrite rhumatoide. Revue du Rhumatisme, 70, 1034. Peer reviewed |
 | Meunier, P. J., Marquis, P., Lemmel, E. M., Martin, T. J., Sawicki, A., Isaia, G., Benhamou, C., Walravens, M., Beck-Nielsen, H., Diaz-Curiel, M., Seeman, E., & Reginster, J.-Y. (2003). Early effect of strontium ranelate on clinical vertebral fractures in women with postmenopausal osteoporosis. BONE, 32 (S7), 222. Peer Reviewed verified by ORBi |
 | Hosking, D., Adami, S., Felsenberg, D., Reginster, J.-Y., Cannata, J., Välimäki, M., Santora, A., Yacik, C., & Zaru, L. (2003). Once weekly alendronate produces a greater increase in bone mineral density than daily risedronate. BONE, 32 (S7), 207. Peer Reviewed verified by ORBi |
 | Devogelaer, J. P., Dreiser, R. L., Abadie, E., Avouac, B., Bouvenot, G., Abello, J. C., Kaufman, J. M., Koes, B. W., Laslop, A., Lemmel, E., Richy, F., Rozenberg, S., Tavares, V., Valat, J. P., & Reginster, J.-Y. (2003). Guidelines for clinical studies assessing the efficacy of drugs for the management of acute low back pain. Clinical and Experimental Rheumatology, 21 (6, NOV-DEC), 691-694. Peer Reviewed verified by ORBi |
Ethgen, O., Gillain, D., Gillet, P., Gosset, C., Jousten, A., & Reginster, J.-Y. (2003). Etude relative à la mise en œuvre de mécanismes d’aides en faveur des personnes en perte d’autonomie, Rapport final. |
 | Meunier, P. J., & Reginster, J.-Y. (2003). Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis. Osteoporosis International, 14 (Suppl. 3), 66-S76. doi:10.1007/s00198-002-1341-8 Peer Reviewed verified by ORBi |
 | Ethgen, O., Richy, F., Gosset, C., Hanssens, L., & Reginster, J.-Y. (2003). Prevention de la vulnerabilite de la personne agee: un defi demographique. Revue Médicale de Liège, 58 (4), 175-82. Peer reviewed |
 | Bruyère, O., Honore, A., Ethgen, O., Rovati, L. C., Giacovelli, G., Henrotin, Y., Seidel, L., & Reginster, J.-Y. (January 2003). Correlation between radiographic severity of knee osteoarthritis and future disease progression. Results from a 3-year prospective, placebo-controlled study evaluating the effect of glucosamine sulfate. Osteoarthritis and Cartilage, 11 (1), 1-5. doi:10.1053/joca.2002.0848 Peer Reviewed verified by ORBi |
 | Hanssens, L., & Reginster, J.-Y. (2003). Relevance of bone mineral density, bone quality and falls in reduction of vertebral and non-vertebral fractures. Journal of Musculoskeletal and Neuronal Interactions, 3 (3), 189-93. Peer Reviewed verified by ORBi |
 | Bruyère, O., Edwards, J., & Reginster, J.-Y. (2003). Fracture prevention in postmenopausal women. Clinical Evidence, 9, 1186-202. Peer Reviewed verified by ORBi |
 | Burton, S., Mathy-Hartet, M., Dupont, G., Crielaard, J.-M., Reginster, J.-Y., & Henrotin, Y. (2003). Effet de la pression partielle en oxygène sur le métabolisme des chondrocytes bovins en culture. Revue du Rhumatisme, 70, 1035. Peer reviewed |
 | Reginster, J.-Y., Hoszowski, K., Roces Varela, A., Balogh, A., Clements, M., Fiore, C., Cormier, C., Schmidt, W. E., Jensen, J. B., Prince, R., Raeman, F., Rizzoli, R., & Meunier, P. J. (2003). Strontium ranelate : a new effective antiosteoporotic treatment reducing the incidence of vertebral and non vertebral fractures in postmenopausal women with osteoporosis. BONE, 32 (S7), 94. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Deroisy, R., Dougados, M., Jupsin, I., Collette, J., & Roux, C. (December 2002). Prevention of early postmenopausal bone loss by strontium ranelate: The randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporosis International, 13 (12), 925-931. doi:10.1007/s001980200129 Peer Reviewed verified by ORBi |
 | Bruyère, O., Lambert, V., Dardenne, C., Lejeune, E., Zegels, B., Pahaut, A., Richy, F., Seidel, L., Henrotin, Y., & Reginster, J.-Y. (November 2002). Subchondral tibial bone mineral density predicts joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis. Osteoporosis International, 13 (Suppl.3), 51-52. Peer Reviewed verified by ORBi |
 | Meunier, P. J., Lorenc, R. S., Smith, I. G., Roces-Varela, A., Passariello, R., Bonidan, O., Kruse, H. P., Raeman, F., Prince, R., De Chatel, R., Charles, P., Fechtenbaum, J., Roux, C., & Reginster, J.-Y. (November 2002). Strontium ranelate: new efficient anti-osteoporotic agent for treatment of vertebral osteoporosis in postmenopausal women. Osteoporosis International, 13 (Suppl.3), 34. Peer Reviewed verified by ORBi |
 | Sen, S. S., Geling, O., Messina, O. D., Morales-Torres, J., Riera, G., Angulo-Solimano, J. M., Neto, J. F. M., Frisoli Jr, A., Castro, R. S., & Reginster, J.-Y. (November 2002). Identification of key predictors for osteoporosis through use of different analytical techniques. Osteoporosis International, 13 (Suppl.3), 27. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Sanchez, C., Mathy-Hartert, M., Deberg, M., & Reginster, J.-Y. (November 2002). Characterization of the metabolism of osteoarthritic chondrocytes cultured in alginate beads. Osteoporosis International, 13 (Suppl. 3), 52. Peer Reviewed verified by ORBi |
 | Mathy-Hartert, M., Devel, P., Hoormaert, S., Burton, S., Reginster, J.-Y., & Henrotin, Y. (November 2002). Hydrogen peroxide increases transforming factor-β3 gene expression in human chondrocytes and reverses interleukin-1β inhibitory effect. Osteoporosis International, 13 (Suppl.3), 52. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Meunier, P. J. (November 2002). Incidence of osteoporotic non vertebral fractures coming in the strontium ranelate run-in study could validate sample size calculation. Osteoporosis International, 13 (Suppl.3), 36. Peer Reviewed verified by ORBi |
 | Sen, S. S., Geling, O., Messina, O. D., Morales-Torres, J., Riera, G., Angulo-Solimano, J. M., Neto, J. F. M., Frisoli Jr, A., Castro, R. S., & Reginster, J.-Y. (November 2002). A risk assessment tool (OSTEORISK) for identifying latin american women with osteoporosis. Osteoporosis International, 13 (Suppl.3), 26-27. Peer Reviewed verified by ORBi |
 | Adami, S., Felsenberg, D., Hosking, D., Reginster, J.-Y., Cannata, J., Valimaki, M., Santora, A., & Suryawanshi, S. (November 2002). Once-weekly alendronate produces a greater decrease in bone resorption than daily risedronate. Osteoporosis International, 13 (Suppl.3), 14-15. Peer Reviewed verified by ORBi |
 | Bruyère, O., Collette, J., Lejeune, E., Ethgen, O., Richy, F., Seidel, L., Henrotin, Y., & Reginster, J.-Y. (November 2002). Correlation between biochemical markers of bone and cartilage metabolism and structural progression of hand osteoarthritis. A three-year prospective study. Osteoporosis International, 13 (Suppl.3), 51. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Sawicki, A., Devogelaer, J.-P., Padrino, J. M., Kaufman, J.-M., Doyle, D. V., Fardellone, P., Graham, J., Felsenberg, D., Tulassay, Z., Soren-Sen, O. H., Luisetto, G., Rizzoli, R., Blotman, F., Phenekos, C., & Meunier, P. J. (November 2002). Strontium ranelate reduces the risk of hip fracture in women with postmenopausal osteoporosis. Osteoporosis International, 13 (Suppl.3), 14. Peer Reviewed verified by ORBi |
 | Richy, F., Bruyère, O., Ethgen, O., Cucherat, M., Henrotin, Y., & Reginster, J.-Y. (November 2002). Structural and symptomatic efficacy of glucosamine and chondroitine sulfate in osteoarthrits: a comprehensive meta-analysis. Osteoporosis International, 13 (Suppl.3), 55-56. Peer Reviewed verified by ORBi |
 | Marquis, P., De la Loge, C., Roux, C., Meunier, P. J., & Reginster, J.-Y. (November 2002). Strontium ranelate treatment prevents health related quality of life impairement in results from the SOTI study. Osteoporosis International, 13 (Suppl.3), 11. Peer Reviewed verified by ORBi |
 | Pavelka, K., Rovati, L. C., Gatterova, J., Bruyère, O., Deroisy, R., Machacek, S., Giacovelli, G., & Reginster, J.-Y. (November 2002). Pain relief is not a confounder in joint space narrowing assessment of full extension knee radiographs in osteoarthritis structure-modifying drug trials. Osteoporosis International, 13 (Suppl.3), 19-20. Peer Reviewed verified by ORBi |
 | Ethgen, O., Richy, F., De Ceulaer, F., Bruyère, O., & Reginster, J.-Y. (November 2002). Musculoskeletal disorders in a time demographic changes: a real challenge for the future in Europe and Northern America. Osteoporosis International, 13 (Suppl.3), 48-49. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Rovati, L. C., Deroisy, R., Henrotin, Y., Gatterova, J., Machacek, S., Giacovelli, G., & Pavelka, K. (November 2002). Glucosamine sulfate slows-down osteoarthritis progression in postmenopausal women: pooled analysis of two large, independent, randomised, placebo-controlled, double-blind, prospective 3-year trials. Osteoporosis International, 13 (Suppl.3), 60. Peer Reviewed verified by ORBi |
 | Deberg, M., Christgau, S., Henriksen, D. B., Seidel, L., & Reginster, J.-Y. (November 2002). High levels of the type II collagen peptide (COLL 2-1) in serum is predictive of the radiological progressin of knee osteoarthritis. Osteoporosis International, 13 (Suppl.3), 53-54. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Mathy-Hartert, M., Martin, G., Boumediene, K., Pujol, J. P., & Reginster, J.-Y. (November 2002). Reactive oxygen species downregulate the expression of pro-inflammatry genes by humachondrocytes. Osteoporosis International, 13 (Suppl. 3), 53. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Viethel, P., Micheletti, M. C., Chevallier, T., & Andran, M. (November 2002). Prospective validation in 798 postmenopausal women of a new screening tool for osteoporosis risk assessment: OSIRIS® (osteoporosis index of risk). Osteoporosis International, 13 (Suppl.3), 37-38. Peer Reviewed verified by ORBi |
 | Richy, F., Uhoda, E., & Reginster, J.-Y. (November 2002). Development of the Osteoporosis Risk Assessment by Composite Linear Essay (ORACLE). Osteoporosis International, 13 (Suppl.3), 11. Peer Reviewed verified by ORBi |
 | Ethgen, O., Bruyère, O., Richy, F., Paul, I., Gosset, C., & Reginster, J.-Y. (November 2002). Burden of chronic osteoarticular disorders compared to others commonly reported chronic conditions. Results from a large health interview survey of Belgian individuals aged over 45 years. Osteoporosis International, 13 (Suppl.3), 49-50. Peer Reviewed verified by ORBi |
 | Richy, F., Bousquet, J., Devogelaer, J.-P., Ehrlich, G., Meunier, P. J., Peel, N., Morii, H., Ethgen, O., Bruyère, O., & Reginster, J.-Y. (November 2002). Inhaled corticosteroids effects on bone in asthmatic and COPD patients: what is the evidence? Osteoporosis International, 13 (Suppl.3), 22. Peer Reviewed verified by ORBi |
 | Kvasz, A., Bruyère, O., Neuprez, A., & Reginster, J.-Y. (November 2002). Is there any rationale for prescribing hormone replacement therapy (HRT) to prevent or to treat osteoarthritis? Osteoporosis International, 13 (Suppl.3), 59. Peer Reviewed verified by ORBi |
 | Goemare, S., Zmierczak, H., Lauwerier, D., Hoet, H., Roman, E., De Boever, E., & Reginster, J.-Y. (November 2002). Comparison of quantitative ultrasound at the heel with a clinical risk factor score for the assessment of postmenopausal osteoporosis. Osteoporosis International, 13 (Suppl.3), 36. Peer Reviewed verified by ORBi |
 | Goemare, S., Kaufman, J.-M., De Bacquer, D., Boonen, S., Devogelaer, J.-P., & Reginster, J.-Y. (November 2002). Evaluation of a screening program for postmenopausal osteoporosis in primary care setting in Belgium. Osteoporosis International, 13 (Suppl.3), 39. Peer Reviewed verified by ORBi |
 | Sen, S. S., Geling, O., Messina, O. D., Morales-Torres, J., Riera, G., Angulo-Solimano, J. M., Neto, J. F. M., Frisoli Jr, A., Castro, R. S., & Reginster, J.-Y. (November 2002). Comparison of the osteorisk, an osteoporosis risk assessment tool in latin america, with the osteoporosis self-assessment tool (OST). Osteoporosis International, 13 (Suppl.3), 27-28. Peer Reviewed verified by ORBi |
 | Sen, S. S., Geling, O., Messina, O. D., Morales-Torres, J., Riera, G., Angulo-Solimano, J. M., Neto, J. F. M., Frisoli Jr, A., Castro, R. S., & Reginster, J.-Y. (November 2002). Comparison of body weight and body mass index as predictors for osteoporosis among postmenopausal latin american women. Osteoporosis International, 13 (Suppl.3), 27. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Kvasz, A. (November 2002). Structure modifying drugs in osteoarthritis [Paper presentation]. 3rd International Symposium on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Barcelone, Spain. |
 | Ethgen, O., & Reginster, J.-Y. (November 2002). L'evaluation de la qualite de vie dans les essais therapeutiques: un pas vers une approche holistique de la sante. Revue Médicale de Liège, 57 (11), 695-700. Peer reviewed |
 | Deberg, M., Christgau, S., Cloos, P., Henriksen, D. B., Sanchez, C., Labasse, A., Reginster, J.-Y., & Henrotin, Y. (November 2002). Development of new immunoassays for the quantification of inflammatory related cartilage degradation. Osteoporosis International, 13 (Suppl. 3), 54. Peer Reviewed verified by ORBi |
 | Deberg, M., Christgau, S., Henriksen, D. B., Seidel, L., Reginster, J.-Y., & Henrotin, Y. (November 2002). The urinary levels of type II collagen peptide COLL 2-1 and its nitrated form (COLL 2-1 NO2) are correlated with the clinical severity of knee osteoarthritis. Osteoporosis International, 13 (Suppl.3), 54. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Sanchez, C., Deberg, M., Piccardi, N., Miska, P., & Reginster, J.-Y. (November 2002). Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and pro-inflammatory mediators production by human osteoarthritic chondrocytes. Osteoporosis International, 13 (Suppl.3), 53. Peer Reviewed verified by ORBi |
 | Ethgen, O., Tancredi, A., Lejeune, E., Zegels, B., Kvasz, A., & Reginster, J.-Y. (November 2002). A comparative analysis between the time trade-off and the willingness to pay approaches in hip and knee osteoarthritis. Osteoporosis International, 13 (Suppl. 3), 47. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (November 2002). Structure-modifying drugs in osteoarthritis. Osteoporosis International, 13 (Suppl.3), 9. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Diez-Perez, A., Ortolani, S., Pors-Nielsen, S., & Meunier, P. J. (November 2002). Supplementation of calcium-vitamin D should be adapted according to the patients status in international phase 3 program on osteoporosis. Osteoporosis International, 13 (Suppl.3), 35. Peer Reviewed verified by ORBi |
 | Kung, A. W. C., Ho, A. Y. Y., Ben Sedrine, W., & Reginster, J.-Y. (November 2002). Comparison of a simple clinical risk index and quantitative bone ultrasound for identifying women at increased risk of osteoporosis. Osteoporosis International, 13 (Suppl.3), 30-31. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Kung, A., Koh, L., Radican, L., & Ross, P. D. (November 2002). A simple chart for evaluating risk of osteoporosis in Asian women based on the osteoporosis self-assement tool for Asians (OSTA). Osteoporosis International, 13 (Suppl.3), 30. Peer Reviewed verified by ORBi |
 | Richy, F., & Reginster, J.-Y. (November 2002). Efficacy of D-Hormones in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporosis International, 13 (Suppl.3), 21. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Spector, T., Badurski, J., Ortolani, S., Martin, T. J., Diez-Perez, A., Lemmel, E., Balogh, A., Pors-Nielsen, S., Phenokos, C., & Meunier, P. J. (November 2002). Optimizing patient adherence and persistence in strontium ranelate phase 3 program using a short term run-in study. Osteoporosis International, 13 (Suppl.3), 35-36. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Deberg, M., Christgau, S., Henriksen, D. B., Seidel, L., & Reginster, J.-Y. (November 2002). Type II collagen derived fragment (COLL2-1) is new marker predictive of osteoarthritis progression. Osteoporosis International, 13 (Suppl.3), 17. Peer Reviewed verified by ORBi |
 | Bruyère, O., Collette, J., Lejeune, E., Ethgen, O., Richy, F., Seidel, L., Henrotin, Y., & Reginster, J.-Y. (November 2002). Baseline measurement of urine pyridinoline and deoxypyridinoline is correlated with 3-year hip osteoarthritis progression. Osteoporosis International, 13 (Suppl.3), 51. Peer Reviewed verified by ORBi |
 | Bruyère, O., Ethgen, O., Lejeune, E., Giacovelli, G., Richy, F., Seidel, L., Henrotin, Y., Rovati, L. C., & Reginster, J.-Y. (November 2002). Clinical severity of knee osteoarthritis poorly predicts long-term radiographic outcomes. Osteoporosis International, 13 (Suppl.3), 51. Peer Reviewed verified by ORBi |
 | Ethgen, O., Bruyère, O., Tancredi, A., Richy, F., De Ceulaer, F., & Reginster, J.-Y. (November 2002). Patient health profiles in osteoarthritis: is there a difference according to follow-up pattern? Results from the Belgian National Health Interview Survey. Osteoporosis International, 13 (Suppl.3), 49. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (October 2002). Traitement hormonal de la menopause: traitement hormonal substitutif classique ou tibolone? Journal de Gynécologie, Obstétrique et Biologie de la Reproduction, 31 (6), 541-9. Peer Reviewed verified by ORBi |
 | Tannenbaum, H., Berenbaum, F., Reginster, J.-Y., Zacher, J., Robinson, J., Poor, G., Bliddal, H., Uebelhart, D., Adami, S., Navarro, F., Lee, A., Moore, A., & Gimona, A. (September 2002). Lumiracoxib (Prexige) is effective in the treatment of osteoarthritis of the knee: a 13-week, placebo-controlled, active-comparator, double-blind study. Arthritis and Rheumatism, 46 (number 9 (suppl.)), 212. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Sawicki, A., Devogelaer, J.-P., Padrino, J. M., Brandi, M. L., Fardellone, P., Stucki, G., De Chatel, Sorensen, O., Smith, I., Graham, J., Fechtenbaum, J., & Meunier, P. J. (September 2002). Rapid and sustained anti-fracture efficacy of strontium ranelate in postmenopausal osteoporosis. Arthritis and Rheumatism, 46 (number 9 (suppl.)), 584-5. Peer Reviewed verified by ORBi |
 | Hosking, D., Adami, S., Felsenberg, D., Reginster, J.-Y., Cannata, J., Valimaki, M., Santora, A., & Suryawanshi, S. (September 2002). Once weekly alendronate produces a greater decrease in bone resorption than does daily risedronate. Journal of Bone and Mineral Research, 17 (S1), 370. Peer Reviewed verified by ORBi |
 | Deberg, M., Christgau, S., Henriksen, D., Cloos, P., COLLETTE, J., Reginster, J.-Y., & Henrotin, Y. (September 2002). Development of new immunoassays for the quantification of inflammatory related cartilage degradation. Arthritis and Rheumatism, 46 (number 9 (suppl.)), 496. Peer Reviewed verified by ORBi |
 | Bruyère, O., COLLETTE, J., Lejeune, E., Ethgen, O., Richy, F., Seidel, L., Henrotin, Y., & Reginster, J.-Y. (September 2002). Correlation between biochemical markers of bone and cartilage metabolism and structural progression of hand osteoarthritis. A three year prospective study. Arthritis and Rheumatism, 46 (number 9 (suppl.)), 152-3. Peer Reviewed verified by ORBi |
 | Bruyère, O., COLLETTE, J., Lejeune, E., Richy, F., Ethgen, O., Seidel, L., Henrotin, Y., & Reginster, J.-Y. (September 2002). Baseline measurement of urine pyridinoline and deoxypyridinoline is correlated with 3-year hip osteoarthritis progression. Arthritis and Rheumatism, 46 (number 9 (suppl.)), 149. Peer Reviewed verified by ORBi |
 | Bruyère, O., Ethgen, O., Lejeune, E., Giacovelli, G., Richy, F., Seidel, L., Henrotin, Y., Rovati, L., & Reginster, J.-Y. (September 2002). Clinical severity of knee osteoarthritis poorly predicts long-term radiographic outcomes. Arthritis and Rheumatism, 46 (number 9 (suppl.)), 153. Peer Reviewed verified by ORBi |
 | Ethgen, O., Bruyère, O., Richy, F., Paul, I., Gosset, C., & Reginster, J.-Y. (September 2002). Health and economic burden of chronic osteoarticular disorders in the population aged over 45 years: a comparative analysis with other commonly reported chronic health dysfunctions. Arthritis and Rheumatism, 46 (number 9 (suppl.)), 469. Peer Reviewed verified by ORBi |
 | Richy, F., Bousquet, J., Devogelaer, J.-P., Ehrlich, G., Meunier, P., Peel, N., Morii, H., Ethgen, O., Bruyère, O., & Reginster, J.-Y. (September 2002). Meta-analysis of the effects of inhaled corticosteroids on bone in asthmatic and COPD patients. Arthritis and Rheumatism, 46 (number 9 (suppl.)), 464. Peer Reviewed verified by ORBi |
 | Bruyère, O., LAMBERT, V., Dardenne, C., Lejeune, E., Zegels, B., Richy, F., Seidel, L., Henrotin, Y., & Reginster, J.-Y. (September 2002). Subchondral tibial bone mineral density predicts joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis. Arthritis and Rheumatism, 16 (number 9 (suppl.)), 154. Peer Reviewed verified by ORBi |
 | Ethgen, O., Tancredi, A., Lejeune, E., Zegels, B., Kvazs, A., & Reginster, J.-Y. (September 2002). Do willingness to pay and time trade-off approaches suitably reflect health outcomes in hip and knee osteoarthritis? Arthritis and Rheumatism, 46 (number 9 (suppl.)), 73. Peer Reviewed verified by ORBi |
 | Delmas, P. D., Ensrud, K. E., Adachi, J. D., Harper, K. D., Sarkar, S., Gennari, C., Reginster, J.-Y., Pols, H. A. P., Recker, R. R., Harris, S. T., Wu, W. T., Genant, H. K., Black, D. M., & Eastell, R. (August 2002). Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial. Journal of Clinical Endocrinology and Metabolism, 87 (8), 3609-3617. doi:10.1210/jcem.87.8.8750 Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., & Reginster, J.-Y. (July 2002). Risk indices and osteoporosis screening: Scope and limits. Mayo Clinic Proceedings, 77 (7), 622-623. doi:10.4065/77.7.622 Peer Reviewed verified by ORBi |
 | Sedrine, W. B., Chevallier, T., Zegels, B., Kvasz, A., Micheletti, M. C., Gelas, B., & Reginster, J.-Y. (June 2002). Development and assessment of the Osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry. Gynecological Endocrinology, 16 (3), 245-250. doi:10.1080/gye.16.3.245.250 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Rovati, L., Deroisy, R., Henrotin, Y., Gatterova, J., Machacek, S., Gonzalez, C., Giacovelli, G., & Pavelka, K. (June 2002). Glucosamine sulfate slows-down osteoarthritis progression in postmenopausal women: pooled analysis of two large, independent, randomised, placebo-controlled, double-blind, prospective 3-year trials. Annals of the Rheumatic Diseases, 61 (Suppl.1). Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Henrotin, Y., Bruyère, O., Gonzalez, C., Giacovelli, G., & Rovati, L. C. (June 2002). Radiographic severity of knee osteoarthritis is highly correlated with future progression of the disease. Annals of the Rheumatic Diseases, 61 (Suppl.1), 124. Peer Reviewed verified by ORBi |
 | Hosking, D., Adami, S., Felsenberg, D., Reginster, J.-Y., Cannata, J., Valimaki, M., Santora, A., & Suryawanshi, S. (June 2002). Once weekly alendronate produces a greater decrease in bone resorption than daily risedronate. Annals of the Rheumatic Diseases, 61 (Suppl.1). Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Henrotin, Y., Bruyère, O., Gonzalez, C., Giacovelli, G., & Rovati, L. C. (June 2002). Joint space narrowing is poorly correlated with symptoms worsening in knee-osteoarthritis: results from the prospective follow-up of 106, placebo-treated patients for three years. Annals of the Rheumatic Diseases, 61 (Suppl.1), 121. Peer Reviewed verified by ORBi |
 | Pavelka, K., Rovati, L. C., Gatterova, J., Bruyère, O., Deroisy, R., Machacek, S., Giacovelli, G., Gonzalez, C., & Reginster, J.-Y. (June 2002). Pain relief is not a confounder in joint space narrowing assessment of full extension knee radiographs. Annals of the Rheumatic Diseases, 61 (Suppl.1), 118. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Bias, P., & Buchner, A. (June 2002). First clinical results of licofelone (ml3000), an inhibitor of COX-1, COX-2 and 5-LOX, for the treatment of osteoarthritis. Annals of the Rheumatic Diseases, 61 (Suppl.1). Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Henrotin, Y., Deroisy, R., Giacovelli, G., Gonzalez, C., & Rovati, L. (June 2002). Correlation between mean and minimum joint space measurements in a long-term trial with glucosamine sulfate, an osteoarthritis modifying agent. Annals of the Rheumatic Diseases, 61 (Suppl.1). Peer Reviewed verified by ORBi |
 | Durez, P., Felsenberg, D., Stepan, J., Payer, J., Resch, H., Quail, D., Pavo, L., & Reginster, J.-Y. (June 2002). Reduction in vertebral fracture rates by a combination of monofluorophosphate and raloxifene in postmenopausal osteoporosis. Annals of the Rheumatic Diseases, 61 (Suppl.1). Peer Reviewed verified by ORBi |
 | Meunier, P. J., Slosman, D. O., Delmas, P. D., Sebert, J. L., Brandi, M. L., Albanese, C., Lorenc, R., Pors-Nielsen, S., de Vernejoul, M. C., Roces, A., & Reginster, J.-Y. (May 2002). Strontium ranelate: Dose-dependent effects in established postmenopausal vertebral osteoporosis - A 2-year randomized placebo controlled trial. Journal of Clinical Endocrinology and Metabolism, 87 (5), 2060-2066. doi:10.1210/jc.87.5.2060 Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Broers, P., Devogelaer, J. P., Depresseux, G., Kaufman, J. M., Goemaere, S., & Reginster, J.-Y. (May 2002). Interest of a prescreening questionnaire to reduce the cost of bone densitometry. Osteoporosis International, 13 (5), 434-442. doi:10.1007/s001980200051 Peer Reviewed verified by ORBi |
| Sanchez, C., Mateus, M., Defresne, M.-P., Crielaard, J.-M., Reginster, J.-Y., & Henrotin, Y. (April 2002). Metabolism of human articular chondrocytes cultured in alginate beads. Longterm effects of interleukin 1 beta and nonsteroidal antiinflammatory drugs. Journal of Rheumatology, 29 (4), 772-782. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (April 2002). The prevalence and burden of arthritis. Rheumatology, 41 (Suppl. 1), 3-7. doi:10.1093/rheumatology/41.s1.3 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Khaltaev, N. G. (April 2002). Introduction and WHO perspective on the global burden of musculoskeletal conditions. Rheumatology, 41 (Suppl. 1), 1-2. doi:10.1093/rheumatology/41.s1.1 Peer Reviewed verified by ORBi |
 | Johnell, O., Scheele, W. H., Lu, Y. L., Reginster, J.-Y., Need, A. G., & Seeman, E. (March 2002). Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. Journal of Clinical Endocrinology and Metabolism, 87 (3), 985-992. doi:10.1210/jcem.87.3.8325 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Zegels, B., Lejeune, E., Micheletti, M. C., Kvsaz, A., Seidel, L., & Sarlet, N. (February 2002). Influence of daily regimen calcium and vitamin D supplementation on parathyroid hormone secretion. Calcified Tissue International, 70 (2), 78-82. doi:10.1007/s00223-001-0034-1 Peer Reviewed verified by ORBi |
 | Deroisy, R., Collette, J., Albert, A., Jupsin, I., & Reginster, J.-Y. (February 2002). Administration of a supplement containing both calcium and vitamin D is more effective than calcium alone to reduce secondary hyperparathyroidism in postmenopausal women with low 25(OH)vitamin D circulating levels. Aging Clinical and Experimental Research, 14 (1), 13-17. doi:10.1007/BF03324412 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Kvasz, A., Bruyère, O., & Henrotin, Y. (2002). Glucosamine and chondroitine sulfate. In Anti Aging Medizin 2001 : Konferenz der German Society of Anti-Aging Medicine (pp. 97-104). Berlin, Germany: Congres Compact Publ. |
 | Goemaere, S., Zmierczak, H., Van Pottelbergh, I., Toye, K., Daems, M., Zegels, B., Reginster, J.-Y., & Kaufman, J. M. (2002). Prediction of bone mineral density by estrogens precursors, estradiol, SHBG and BMI in elderly women at risk for osteoporotic fractures. Osteoporosis International, 13 (S1), 102. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Meunier, P. J. (2002). Assessment of new non-vertebral osteoporotic fractures during a short-term run-in phase contributes to the internal validation of patient sample size calculations. Osteoporosis International, 13 (S1), 28. Peer Reviewed verified by ORBi |
 | Hosking, D., Adami, S., Felsenberg, D., Reginster, J.-Y., Cannata, J., Valimaki, M., Santora, A., & Suryawanshi, S. (2002). Once weekly alendronate produces a greater decrease in bone resorption than daily risedronate. Osteoporosis International, 13 (S1), 18. Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., & Reginster, J.-Y. (2002). Using the OST index to identify women at risk of osteoporosis : a validation study in Belgium. Osteoporosis International, 13 (S1), 109-110. Peer Reviewed verified by ORBi |
 | Sanchez, C., Deberg, M., Piccardi, N., Msika, P., Reginster, J.-Y., & Henrotin, Y. (2002). Avocado/soybean Unsaponifiables Increase Aggrecan Synthesis and Reduce Catabolic and Pro-inflammatory Mediators Production by Human Osteoarthritic Chondrocytes. Arthritis and Rheumatism, 47, 50-58. Peer Reviewed verified by ORBi |
 | Sanchez, C., Mathy, M., Deberg, M., Reginster, J.-Y., & Henrotin, Y. (2002). Characterization of the Metabolism of Osteoarthritic Chondrocytes Cultured in Alginate Beads. Osteoarthritis and Cartilage, 10 (SA), 34. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Meunier, P. J. (2002). Strontium ranelate antifracture study program : current data. Osteoporosis International, 13 (S1), 153-154. Peer Reviewed verified by ORBi |
 | Holgate, S., Bousquet, J., Chung, K., Bisgaard, H., Pauwels, R., Fabbri, L., Rabe, K., Doherty, M., Snell, N., Cuss, F., D'Amato, M., & Reginster, J.-Y. (2002). Recommendations for the design of clinical trials and the registration of drugs used in the treatment of asthma. International Journal of Pharmaceutical Medicine, 16, 115-127. doi:10.1097/00124363-200206000-00003 Peer Reviewed verified by ORBi |
 | Sanchez, C., Deberg, M., Piccardi, N., Msika, P., Reginster, J.-Y., & Henrotin, Y. (2002). Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and pro-inflammatory mediators production by human osteoarthritic chondrocytes. Osteoarthritis and Cartilage, 10 (Suppl A), 34. Peer Reviewed verified by ORBi |
 | Delmas, P. D., Calvo, G., Boers, M., Abadie, E., Avouac, B., Kahan, A., Kaufman, J. M., Laslop, A., Lekkerkerker, J. F., Nilsson, P., Van Zwieten-Boot, B., Kreutz, G., & Reginster, J.-Y. (2002). The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis. Osteoporosis International, 13 (1), 1-5. doi:10.1007/s198-002-8331-3 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Spector, T., Badurski, J., Ortolani, S., Martin, T. J., Diez-Perez, A., Lemmel, E., Balogh, A., Pors-Nielsen, S., Phenekos, C., & Meunier, P. J. (2002). A short-term run-in study can significantly contribute to increasing the quality of long-term osteoporosis trials. The strontium-ranelate phase 3 program. Osteoporosis International, 13 (S1), 30. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Felsenberg, D., Gluer, C. C., Stepan, J., Schmitt, H., Quail, D., Pavo, I., & Nickelsen, T. (2002). BMD and fracture effects of monofluorophosphate (MFP) combined with raloxifene (RLX) as compared to MFP alone in postmenopausal women with low bone mass. Osteoporosis International, 13 (S1), 18-19. Peer Reviewed verified by ORBi |
 | Meunier, P. J., Roux, C., Fardellone, P., Bonidan, O., Benhamou, C. L., Bourgeois, P., De Vernejoul, M. C., Kuntz, J. L., Dehais, J., Maugars, Y., Weryha, G., Aquino, J. P., Cormier, C., Marcelli, C., Fechtenbaum, J., & Reginster, J.-Y. (2002). Strontium ranelate réduit le risque de fracture vertébrale chez des patientes traitées 3 ans pour ostéoporose postménopausique. Revue du Rhumatisme, 69, 1015. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2002). New perspectives n the medical management of osteoarthritis. Osteoarthritis and Cartilage, 10 (SA), 18-19. Peer Reviewed verified by ORBi |
 | Bruyère, O., Honore, A., Rovati, L. C., Giacovelli, G., Henrotin, Y., Seidel, L., & Reginster, J.-Y. (2002). Radiologic features poorly predict clinical outcomes in knee osteoarthritis. Scandinavian Journal of Rheumatology, 31 (1), 13-6. doi:10.1080/030097402317255309 Peer Reviewed verified by ORBi |
 | Mathy, M., Deby, G., Reginster, J.-Y., Ayache, N., Pujol, J.-P., & Henrotin, Y. (2002). Regulation by reactive oxygen species of interleukin-1beta, nitric oxide and prostaglandin E(2) production by human chondrocytes. Osteoarthritis and Cartilage, 10 (7), 547-55. doi:10.1053/joca.2002.0789 Peer Reviewed verified by ORBi |
Counet, L., de Froidmont, C., Filée, D., Gosset, C., Reginster, J.-Y., Christiaens, W., De Maeseneer, J., Martens, S., Vincke, B., & Willems, S. (2002). Collaboration entre la première et la deuxième ligne : une analyse. Volet complémentaire du projet de recherche : « Accompagnement ambulatoire des patients à haut risque de réhospitalisation et/ou institutionnalisation ». Synthèse. |
 | Henrotin, Y., Mathy, M., Sanchez, C., Martin, G., Boumediene, K., Pujol, J.-P., & Reginster, J.-Y. (2002). Regulation by reactive oxygen species of pro-inflammatory genes in chondrocytes. Osteoarthritis and Cartilage, 10 (Suppl A), 34. Peer Reviewed verified by ORBi |
Filée, D., Gosset, C., Dor, B., Orban, T., & Reginster, J.-Y. (2002). L'audit en médecine générale : outils de dépistage et d'intervention [Paper presentation]. From Mondial "Drogues et dépendances. Enjeux pour la société", Montréal, Canada. |
| Ayache, N., Boumediene, K., Mathy, M., Reginster, J.-Y., Henrotin, Y., & Pujol, J.-P. (2002). Expression of TGF-betas and their receptors is differentially modulated by reactive oxygen species and nitric oxide in human articular chondrocytes. Osteoarthritis and Cartilage, 10 (5), 344-52. doi:10.1053/joca.2001.0499 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Kvasz, A. (2002). Structure-modifying drugs in osteoarthritis. Osteoporosis International, 13 (Suppl. 1), 49-SI50. Peer Reviewed verified by ORBi |
 | Halkin, V., Bruyère, O., & Reginster, J.-Y. (2002). Osteoporosis in the very elderly. Medicographia, 24 (4), 316-321. Peer reviewed |
 | Stepan, J., Payer, J., Resch, H., Reginster, J.-Y., Muehlenbacher, D., Quail, D., Nickelsen, T., & Pavo, I. (2002). The effect on bone turnover of monofluorophosphate (MFP) combined with raloxifene (RLX) as compared to MFP alone in postmenopausal women with low bone mass. Osteoporosis International, 13 (S1), 54. Peer Reviewed verified by ORBi |
 | Goemaere, S., Zmierczak, H., Lauwerier, D., Hoet, H., Roman, E., De Boever, E., Reginster, J.-Y., & Kaufman, J. M. (2002). Comparison of quantitative ultrasound at the heel with a clinical risk factor score for the assessment of postmenopausal osteoporosis. Osteoporosis International, 13 (S1), 73-74. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Diez-Perez, A., Ortolani, S., Pors-Nielsen, S., & Meunier, P. J. (2002). Calcium-vitamin D supplementation in clinical trials of osteoporosis should be titrated on the basis of pre-study assessments. Osteoporosis International, 13 (S1), 24. Peer Reviewed verified by ORBi |
 | Zethraeus, N., Ben Sedrine, W., Caulin, F., Corcaud, S., Gathon, H.-J., Haim, M., Johnell, O., Jonsson, B., Kanis, J. A., Tsouderos, Y., & Reginster, J.-Y. (2002). Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporosis International, 13 (11), 841-857. doi:10.1007/s001980200117 Peer Reviewed verified by ORBi |
 | Bruyère, O., Edwards, J., & Reginster, J.-Y. (2002). Fracture prevention in postmenopausal women. Clinical Evidence, 8, 1089-102. Peer Reviewed verified by ORBi |
Counet, L., de Froidmont, C., Filée, D., Gosset, C., Reginster, J.-Y., Christiaens, W., De Maeseneer, J., Martens, S., Vinke, B., & Willems, S. (2002). Accompagnement ambulatoire des patients à haut risque de réhospitalisation et/ou institutionnalisation. Synthèse. |
Counet, L., de Froidmont, C., Dejace, A., Englebert, L., Gosset, C., Reginster, J.-Y., & Rondal, P. (2002). Intervisions organisées dans le cadre du projet « Fonction de référent hospitalier pour la continuité des soins dans les hôpitaux psychiatriques et généraux » - Exercice 2001. |
 | Bruyère, O., Stephaniak, N., & Reginster, J.-Y. (2002). Biochemical markers in glucocorticoid-induced osteoporosis. In A. Giustina, A. Angeli, E. Canalis, ... F. Manelli (Eds.), Glucocorticoid-induced osteoporosis (pp. 30) 49-59). Basel, Switzerland: Karger. doi:10.1159/000061072 |
Counet, L., de Froidmont, C., Filée, D., Gosset, C., Reginster, J.-Y., Christiaens, W., De Maeseneer, J., Martens, S., Vincke, B., & Willems, S. (2002). Collaboration entre la première et la deuxième ligne : une analyse. Volet complémentaire du projet de recherche : « Accompagnement ambulatoire des patients à haut risque de réhospitalisation et/ou institutionnalisation ». |
Counet, L., de Froidmont, C., Filée, D., Gosset, C., Reginster, J.-Y., Christiaens, W., De Maeseneer, J., Martens, S., Vincke, B., & Willems, S. (2002). Accompagnement ambulatoire des patients à haut risque de réhospitalisation et/ou institutionnalisation. |
 | Henrotin, Y., Sanchez, C., & Reginster, J.-Y. (January 2002). The inhibition of metalloproteinases to treat osteoarthritis: reality and new perspectives. Expert Opinion on Therapeutic Patents, 12 (1), 29-43. doi:10.1517/13543776.12.1.29 Peer Reviewed verified by ORBi |
 | Ethgen, O., Kahler, K. H., Kong, S. X., REGINSTER, J.-Y., & Wolfe, F. (2002). The effect of health related quality of life on reported use of health care resources in patients with osteoarthritis and rheumatoid arthritis: a longitudinal analysis. Journal of Rheumatology, 29 (6), 1147-55. Peer Reviewed verified by ORBi |
 | Pavelka, K., Rovati, L. C., Gatterova, J., Bruyère, O., DEROISY, R., Machacek, S., Giacovelli, G., Gonzalez, C., & Reginster, J.-Y. (2002). Pain relief is not a confounder in joint space narrowing assessment of full extension knee radiographs. Osteoarthritis and Cartilage, 10 (SA), 16-17. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2002). Strontium ranelate in osteoporosis. Current Pharmaceutical Design, 8, 1907-1916. doi:10.2174/1381612023393639 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2002). Relevance of bone mineral density, bone quality and falls in reduction of vertebral and non-vertebral fractures. Osteoporosis International, 13 (S1), 157. Peer Reviewed verified by ORBi |
 | Meunier, P. J., & Reginster, J.-Y. (2002). Dose-related bone effects of strontium ranelate in postmenopausal women. Osteoporosis International, 13 (S1), 153. Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Devogelaer, J. P., Kaufman, J. M., Goemaere, S., Depresseux, G., Zegels, B., Deroisy, R., & Reginster, J.-Y. (October 2001). Evaluation of the Simple Calculated Osteoporosis Risk Estimation (Score) in a Sample of White Women from Belgium. BONE, 29 (4), 374-80. doi:10.1016/S8756-3282(01)00583-X Peer Reviewed verified by ORBi |
 | Paul, I., Bilge, A., Bolly, F., Boland, J., & Reginster, J.-Y. (October 2001). Etude pilote pour le developpement d'un registre de l'infarctus du myocarde en region liegeoise (Belgique). Revue d'Épidémiologie et de Santé Publique, 49 (5), 423-9. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Paul, I., & Henrotin, Y. (July 2001). Comment positionner l'acéclofénac au sein de l'arsenal thérapeutique des pathologies ostéo-articulaires chroniques ? Revue Médicale de Liège, 56 (7), 484-8. Peer reviewed |
 | Henrotin, Y., Deby-Dupont, G., & Reginster, J.-Y. (June 2001). Les mediateurs biochimiques de l'inflammation. Revue Médicale de Liège, 56 (6), 433-42. Peer reviewed |
 | Reginster, J.-Y., & Henrotin, Y. (March 2001). Pharma clinics. Comment je traite.... L'arthrose. 2eme partie: Nouvelles perspectives therapeutiques. Revue Médicale de Liège, 56 (3), 135-9. Peer reviewed |
 | Reginster, J.-Y., Zegels, B., Lejeune, E., Micheletti, M. C., Taquet, A. N., & Albert, A. (February 2001). Influence of Daily Calcium and Vitamin D Supplementation on Parathyroid Hormone Secretion. Gynecological Endocrinology, 15 (1), 56-62. doi:10.1080/gye.15.1.56.62 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Henrotin, Y. (February 2001). Pharma clinics. Comment je traite.... L'arthrose. 1ère partie: Rappel physiopathologique et traitement symptomatique. Revue Médicale de Liège, 56 (2), 63-7. Peer reviewed |
 | McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., Meunier, P., Wasnich, R., Greenwald, M., Kaufman, J.-M., Chesnut, C., & REGINSTER, J.-Y. (2001). Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. New England Journal of Medicine, 344 (5), 333-40. doi:10.1056/NEJM200102013440503 Peer Reviewed verified by ORBi |
 | Henrotin, Y., Labasse, A., Zheng, S. X., Galais, P., Tsouderos, Y., Crielaard, J.-M., & Reginster, J.-Y. (2001). Strontium ranelate increases cartilage matrix formation. Journal of Bone and Mineral Research, 16 (2), 299-308. doi:10.1359/jbmr.2001.16.2.299 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Deroisy, R., Rovati, L. C., Lee, R. L., Lejeune, E., Bruyère, O., Giacovelli, G., Henrotin, Y., Dacre, J. E., & Gosset, C. (January 2001). Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. The Lancet, 357, 251-256. doi:10.1016/S0140-6736(00)03610-2 Peer Reviewed verified by ORBi |
 | Emery, P., Reginster, J.-Y., Appelboom, T., Breedveld, F. C., Edelmann, E., Kekow, J., Malaise, M., Mola, E. M., Montecucco, C., Sanda, M., Sany, J., Scott, D. L., Serni, U., & Seydoux, G. (2001). WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology, 40 (6), 699-702. doi:10.1093/rheumatology/40.6.699 Peer Reviewed verified by ORBi |
Bruyère, O., Lejeune, E., Dardenne, C.-B., Henrotin, Y., & Reginster, J.-Y. (2001). Relationship between subchondral tibial bone mineral density and joint space width at the medial femoro-tibial compartment in patients with knee osteoarthritis. Osteoarthritis and Cartilage, 9 (Suppl.B), 23. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Taquet, A. N., Christiansen, C., Gamwell-Henriksen, E., Christgau, S., Bruyère, O., & COLLETTE, J. (2001). Respective value of four biochemical markers of bone resorption for the diagnosis of postmenopausal osteoporosis and the monitoring of anti-resorptive therapies. Clinical Rheumatology, 5 (Suppl.1), 421. Peer Reviewed verified by ORBi |
Bruyère, O., COLLETTE, J., Delmas, P., Rouillon, A., Roux, C., Seidel, L., & Reginster, J.-Y. (2001). Early (3-month) changes in serum osteocalcin and urinary C-telopeptide of type I collagen could be of interest to identify postmenopausal osteoporotic women with the highest risk to present new vertebral deformities. Arthritis and Rheumatism, 44 (Suppl.1), 257. Peer Reviewed verified by ORBi |
Bruyère, O., Henrotin, Y., Honoré, A., Rovati, L. C., Seidel, L., & Reginster, J.-Y. (2001). Tibial subchondral sclerosis is significantly correlated with long-term (3-year) radiological progression of knee osteoarthritis. Arthritis and Rheumatism, 44 (Suppl.1), 139. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Bruyère, O., Rovati, L. C., Honoré, A., Seidel, L., & Henrotin, Y. (2001). Radiologic features poorly predict clinical outcomes in knee osteoarthritis. Clinical Rheumatology, 5 (Suppl.1), 412. Peer Reviewed verified by ORBi |
Ethgen, O., Van Parijs, P., Delhalle, S., Rosant, S., Bruyère, O., & Reginster, J.-Y. (2001). Importance of social companionship in the determination of health-related quality of life in hip and knee osteoarthrits. Clinical Rheumatology, 5 (Suppl.1), 413. Peer Reviewed verified by ORBi |
Bruyère, O., Zegels, B., Dardenne, C.-B., Lejeune, E., Henrotin, Y., & Reginster, J.-Y. (2001). Measurement of the tibial subchondral bone mineral density: a potential tool for diagnosis and monitoring of knee osteoarthrits. Clinical Rheumatology, 5 (Suppl.1), 411. Peer Reviewed verified by ORBi |
 | Sanchez, C., Deberg, M., Reginster, J.-Y., & Henrotin, Y. (2001). Long-term Effects of Nonsteroidal Antiinflammatory Drugs on Human Chondrocytes in Alginate Beads. Annals of the Rheumatic Diseases, 60 (suppl1), 284. Peer Reviewed verified by ORBi |
 | Sanchez, C., Deberg, M., Reginster, J.-Y., & Henrotin, Y. (2001). Long-term Effects of Nonsteroidal Antiinflammatory Drugs on Human Chondrocytes in Alginate Beads. Osteoarthritis and Cartilage, 9 (supplB), 32. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Mathy, M., Dupont, G., Ayache, N., Pujol, J., & Reginster, J.-Y. (2001). The expression of IL-1β, iNOS and COX-2 genes by human chondrocytes is differentially regulated by reactive oxygen species. Tissue Engineering, 7, 649. Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Radican, L., & Reginster, J.-Y. (2001). On Conducting Burden-of-Osteoporosis Studies: A Review of the Core Concepts and Practical Issues. A Study Carried out under the Auspices of a Who Collaborating Center. Rheumatology, 40 (1), 7-14. Peer Reviewed verified by ORBi |
 | Eastell, R., McClung, M., Reginster, J.-Y., Bensen, W., Seeman, E., Cline, G., Law, L., & Chines, A. (2001). Efficacy of risedronate in decreasing the incidence of femoral neck and intertrochanteric fractures in older women with osteoporosis. Journal of Bone and Mineral Research, 16 (S1), 219. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Durez, P., Kaufman, J., Peretz, A., Dequeker, J., Geusens, P., & Devogelaer, J. (2001). Cumulative and sustained efficacy of raloxifene on the risk of new vertebral fractures after 4 years of treatment in postmenopausal women with osteoporosis. Clinical Rheumatology, 20, 425. Peer Reviewed verified by ORBi |
 | Goemaere, S., Laurier, D., Hoet, H., Roman, E., Ben Sedrine, W., Reginster, J.-Y., & Kaufman, J. (2001). Screening for postmenopausal osteoporosis in Belgium in a primary care setting. Clinical Rheumatology, 20, 422-423. Peer Reviewed verified by ORBi |
 | Watts, N., Sorensen, O., Eriksen, E., & Reginster, J.-Y. (2001). Effect of 5-year risedronate therapy on fracture reduction and bone histology and histomorphometry. Arthritis and Rheumatism, 44 (1220), 256. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Sanchez, C., Deberg, M., Piccardi, N., Guillou, B., & Reginster, J.-Y. (2001). Long-term Effects of Avocado/Soybean Unsaponifiable on Human Chondrocytes Metabolism. Tissue Engineering, 7 (5), 648. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Rovati, L., & Setnikar, I. (2001). Correct regimen of fluoride and calcium reduces the risk of vertebral fractures in postmenopausal osteoporosis [letter to the editor]. Osteoporosis International, 12, 800. doi:10.1007/s001980170058 Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Chevallier, T., Micheletti, M., Gelas, B., & Reginster, J.-Y. (2001). Development of a predictive model and a risk assessment instrument to facilitate diagnostis of low bone mass in postmenopausal women. BONE, S28, 240. Peer Reviewed verified by ORBi |
 | Fujiwara, S., Masunari, N., Suzuki, G., Ben Sedrine, W., & Reginster, J.-Y. (2001). Applying a simple clinical tool to identify osteoporosis among Japanese women. BONE, S28, 172. Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Fujiwara, S., Masunari, N., Suzuki, G., & Reginster, J.-Y. (2001). Validation of the OSTA risk index in Japanese women. Arthritis and Rheumatism, 44 (1231), 258. Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Park, H., & Reginster, J.-Y. (2001). Korean experience with OSTA risk index for osteoporosis : a validation study. Arthritis and Rheumatism, 44 (1246), 260. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Mathy, M., Ayache, N., Pujol, J., & Reginster, J.-Y. (2001). Regulation by reactive oxygen species (ROS) o finterleukine-1 bêta, nitric oxide and prostaglandine E2 production by human chondrocytes. Tissue Engineering, 7, 647. Peer Reviewed verified by ORBi |
Sanchez, C., Reginster, J.-Y., & Henrotin, Y. (2001). Long-term Effects of Nonsteroidal Antiinflammatory Drugs on Human Chondrocytes in Alginate Beads [Poster presentation]. Annual European Congress of Rheumatology (EULAR), Prague, Czechia. |
Henrotin, Y., Mathy-Hartet, M., & Reginster, J.-Y. (2001). Influence of nutraceuticals on cartilage health and integrity. In Proceeding of the Large Breed Health Care Symposium (pp. 34-39). Ed. Peer reviewed |
 | Zegels, B., Eastell, R., Russell, R. G., Ethgen, D., Roumagnac, I., Collette, J., & Reginster, J.-Y. (January 2001). Effect of High Doses of Oral Risedronate (20 Mg/Day) on Serum Parathyroid Hormone Levels and Urinary Collagen Cross-Link Excretion in Postmenopausal Women with Spinal Osteoporosis. BONE, 28 (1), 108-12. doi:10.1016/S8756-3282(00)00410-5 Peer Reviewed verified by ORBi |
 | Koh, L. K., Sedrine, W. B., Torralba, T. P., Kung, A., Fujiwara, S., Chan, S. P., Huang, Q. R., Rajatanavin, R., Tsai, K. S., Park, H. M., & REGINSTER, J.-Y. (2001). A simple tool to identify asian women at increased risk of osteoporosis. Osteoporosis International, 12 (8), 699-705. doi:10.1007/s001980170070 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Zegels, B., Lejeune, E., Taquet, A., Micheletti, M., & Albert, A. (2001). Effect of daily regimen administration of calcium-vitamin D supplements on decrease of parathyroid hormone levels. BONE, S28, 244. Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Chevalier, T., Micheletti, M., Gelas, B., & Reginster, J.-Y. (2001). Development of a predictive model and a risk assessment instrument to facilitate diagnosis of low bone mass in postmenopausal women. Arthritis and Rheumatism, 44 (1570), 314. Peer Reviewed verified by ORBi |
 | De Leval, X., Dogne, J., Delange, J., Reginster, J.-Y., & Henrotin, Y. (2001). Evaluation of classical NSAIDS and COX-2 selective inhibitors on purified ovine enzymes and human whole blood. Annals of the Rheumatic Diseases, 60 (S1), 343. Peer Reviewed verified by ORBi |
Bruyère, O., Ethgen, O., Rovati, L. C., Giacovelli, G., Seidel, L., Henrotin, Y., & Reginster, J.-Y. (2001). Radiographic severity of knee osteoarthrits is highly correlated with future progression of the disease. Osteoarthritis and Cartilage, 9 (Suppl.B), 44-45. Peer Reviewed verified by ORBi |
 | DEROISY, R., Collette, J., Albert, A., JUPSIN, I., & Reginster, J.-Y. (2001). Supplementation with a calcium-vitamin D association is more efficient than calcium alone to reduce secondary hyperparathyroidism in postmenopausal women with low 25(OH) vitamin D circulating levels. Clinical Rheumatology, 20, 424. Peer Reviewed verified by ORBi |
 | Ethgen, O., Tellier, V., Ben Sedrine, W., De Maeseneer, J., Gosset, C., & Reginster, J.-Y. (2001). Health-related quality of life and cost of ambulatory care in osteoporosis. How may such outcome measures be valuable information to health decision markers and payers ? Clinical Rheumatology, 20, 427. Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Ethgen, O., Devogelaer, J., Depresseux, G., Kaufman, J., Goemaere, S., & Reginster, J.-Y. (2001). Evaluation of the proposals of the Belgian social security institute for the reimbursement of bone densitometry, toward a cost effective strategy for osteoporosis screening. Clinical Rheumatology, 20, 421. Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Devogelaer, J., Kaufman, J., Goemaere, S., Depresseux, G., Zegels, B., DEROISY, R., & Reginster, J.-Y. (2001). Evaluation of the simple calculated osteoporosis risk estimation in a sample of Caucasian women from Belgium. Clinical Rheumatology, 20, 420. Peer Reviewed verified by ORBi |
 | Zmierczak, H., Goemaere, S., Daems, M., Toye, K., Zegels, B., Reginster, J.-Y., & Kaufman, J. (2001). Relationship between estrogen precursors, estradiol, body mass index and bone mineral dentiy in elderly women at risk of osteoporotic fractures. Clinical Rheumatology, 20, 422. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Labasse, A., Galais, P., Tsouderos, Y., Crielaard, J.-M., & Reginster, J.-Y. (2001). Strontium ranelate increases cartilage matrix formation. Clinical Rheumatology, 20, 416. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Johnell, O., Scheele, W., Lu, Y., Need, A., & Seeman, E. (2001). The additive effects of alendronate and raloxifene on bone density and biochemical markers of bone remodelling in postmenopausal women with osteoporosis. Clinical Rheumatology, 20, 426. Peer Reviewed verified by ORBi |
 | Allouch, A., Bruwier, M., Comte-Tassin, M., ANDRIANNE, R., Colin, A., Kjiri, K., Reginster, J.-Y., de Leval, L., Ansseau, M., & Legros, J.-J. (2001). Incidence des perturbations psychoendocriniennes au centre interdisciplinaire de l’andropause (CIA) du CHU de Liège : bilan des 7 premiers mois d’activité. Annales d'Endocrinologie, 62 (4), 178. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Sanchez, C., Deberg, M., & Reginster, J.-Y. (2001). Diacerein by its Metabolite Rhein, Down-Regulates Stromelysins and Nitric Oxide Productions and Up-Regulates Aggrecan Production by Human Chondrocytes in Alginate Beads. Clinical Rheumatology, 20 (5), 414. Peer Reviewed verified by ORBi |
 | Alexandersen, P., Toussaint, A., Christiansen, C., Devogelaer, J. P., Roux, C., Fechtenbaum, J., Gennari, C., & REGINSTER, J.-Y. (2001). Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA: Journal of the American Medical Association, 285 (11), 1482-8. doi:10.1001/jama.285.11.1482 Peer Reviewed verified by ORBi |
 | Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., REGINSTER, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., Wang, O., & Mitlak, B. H. (2001). Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal of Medicine, 344 (19), 1434-41. doi:10.1056/NEJM200105103441904 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Slosman, D., Delmas, P., Sebert, J., Brandi, M., Lorenc, R., Pors-Nielsen, S., de Vernejoul, M., Roces, A., & Meunier, P. (2001). Strontium ranelate : dose-dependent effects in postmenopausal osteoporosis : the STRATOS 2-year randomised trial. Clinical Rheumatology, 20, 427-428. Peer Reviewed verified by ORBi |
de Froidmont, C., De Geest, S., Denhaerynck, K., Ghyselen, K., Gosset, C., Hillewaere, L., Moons, P., Reginster, J.-Y., & Tellier, V. (2001). Ontslagmanagement in Belgische psychiatrische ziekenhuizen : Pilootstudie Twede fase. [Discharge mangement in Belgian psychiatric hospitals : Pilot study Second phase]. Summarizing report, 2001. SFP. |
de Froidmont, C., De Geest, S., Denhaerynck, K., Ghyselen, K., Gosset, C., Hillewaere, L., Moons, P., Reginster, J.-Y., & Tellier, V. (2001). Ontslagmanagement in Belgische psychiatrische ziekenhuizen : Pilootstudie Twede fase. [Discharge mangement in Belgian psychiatric hospitals : Pilot study Second phase]. Final report, 2001. SFP. |
 | Reginster, J.-Y., Taquet, A., Christiansen, C., Gamwell-Henriksen, E., Bruyère, O., Collette, J., & Christgau, S. (2001). Bone resorption in postmenopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I. BONE, S28, 177. Peer Reviewed verified by ORBi |
 | de Leval, X., Dogne, J., Delarge, J., Reginster, J.-Y., & Henrotin, Y. (2001). Evaluation of classical NSAIDS and COX-2 selective inhibitors on purified ovine enzymes and human whole blood. Clinical Rheumatology, 20, 416. Peer Reviewed verified by ORBi |
Reginster, J.-Y., & Bruyère, O. (2001). HRT in the prevention and treatment of osteoporosis. In Jaarbook 2000 (pp. 157-166). Vlaamse Vereniging voor Obstetrie en Gynaecologie Publ. |
Bruyère, O., & Reginster, J.-Y. (2001). Fracture prevention. Clinical Evidence, 5, 738-741. Peer Reviewed verified by ORBi |
 | Tellier, V., De Maeseneer, J., De Prins, L., Sedrine, W. B., Gosset, C., & Reginster, J.-Y. (2001). Intensive and Prolonged Health Promotion Strategy May Increase Awareness of Osteoporosis among Postmenopausal Women. Osteoporosis International, 12 (2), 131-5. doi:10.1007/s001980170145 Peer Reviewed verified by ORBi |
 | Henrotin, Y., de Leval, X., Mathy, M., Mouithys-Mickalad, A., Deby, G., Dogné, J.-M., Delarge, J., & Reginster, J.-Y. (2001). In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflammation Research, 50 (8), 391-9. doi:10.1007/PL00000261 Peer Reviewed verified by ORBi |
 | Henrotin, Y., Sanchez, C., Deberg, M., & Reginster, J.-Y. (2001). Long-term Effects of Avocado/Soybean Unsaponifiable on Human Chondrocytes Metabolism. Clinical Rheumatology, 20 (5), 45. Peer Reviewed verified by ORBi |
 | Sanchez, C., Reginster, J.-Y., & Henrotin, Y. (2001). Long-term Effects of Nonsteroidal Antiinflammatory Drugs on Human Chondrocytes in Alginate Beads. Clinical Rheumatology, 20 (5), 416. Peer Reviewed verified by ORBi |
 | Valat, J. P., Accardo, S., REGINSTER, J.-Y., Wouters, M., Hettich, M., & Lieu, P. L. (2001). A comparison of the efficacy and tolerability of meloxicam and diclofenac in the treatment of patients with osteoarthritis of the lumbar spine. Inflammation Research, 50 (Suppl 1), 30-4. Peer Reviewed verified by ORBi |
 | Brandi, M. L., Gennari, L., Cerinic, M. M., Becherini, L., Falchetti, A., Masi, L., Gennari, C., & REGINSTER, J.-Y. (2001). Genetic markers of osteoarticular disorders: facts and hopes. Arthritis Research, 3 (5), 270-80. doi:10.1186/ar316 Peer Reviewed verified by ORBi |
 | Massart, F., REGINSTER, J.-Y., & Brandi, M. L. (2001). Genetics of menopause-associated diseases. Maturitas, 40 (2), 103-16. doi:10.1016/S0378-5122(01)00283-3 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Christiansen, C., Roux, C., Fechtenbaum, J., Rouillon, A., & Tou, K. P. (2001). Intermittent Cyclic Tiludronate in the Treatment of Osteoporosis. Osteoporosis International, 12 (3), 169-77. doi:10.1007/s001980170126 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Henrotin, Y., Christiansen, C., Gamwell-Henriksen, E., Bruyère, O., Collette, J., & Christgau, S. (2001). Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I. Calcified Tissue International, 69 (3), 130-137. doi:10.1007/s002230020042 Peer Reviewed verified by ORBi |
Bruyère, O., Lejeune, E., Dardenne, C.-B., Henrotin, Y., & Reginster, J.-Y. (2001). Relationship between subchondral tibial bone mineral density and joint space width at the medial femoro-tibial compartment in patients with knee osteoarthritis. Clinical Rheumatology, 5 (Suppl.1), 411. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Bruyère, O., Rovati, L. C., Honoré, A., Giacovelli, G., Seidel, L., & Henrotin, Y. (2001). Radiologic features poorly predict clinical outcomes in knee osteoarthritis. Osteoarthritis and Cartilage, 9 (Suppl.B), 49. Peer Reviewed verified by ORBi |
Reginster, J.-Y., COLLETTE, J., Bruyère, O., Rovati, L. C., Giacovelli, G., DEROISY, R., Seidel, L., & Henrotin, Y. (2001). Short term (1-year) changes in keratan sulfate levels predict long-term (3-year) radiological evolution of knee osteoarthritis in patients treated with glucosamine sulfate. Osteoarthritis and Cartilage, 9 (Suppl.B), 35. Peer Reviewed verified by ORBi |
Bruyère, O., Henrotin, Y., Honoré, A., Rovati, L. C., Giacovelli, G., Seidel, L., & Reginster, J.-Y. (2001). Tibial subchondral sclerosis and femoral osteophytes are linked to symptomatic and structural severity of knee osteoarthritis. Osteoarthritis and Cartilage, 9 (Suppl.B), 22. Peer Reviewed verified by ORBi |
Bruyère, O., Zegels, B., Dardenne, C.-B., Lejeune, E., Henrotin, Y., & Reginster, J.-Y. (2001). Measurement of the tibial subchondral bone mineral density: a potential tool for diagnosis and monitoring of knee osteoarthrits. Osteoarthritis and Cartilage, 9 (Suppl.B), 61. Peer Reviewed verified by ORBi |
Ethgen, O., Van Parijs, P., Delhalle, S., Rosant, S., Bruyère, O., & Reginster, J.-Y. (2001). Importance of social companionship in the determination of health-related quality of life in hip and knee osteoarthrits. Osteoarthritis and Cartilage, 9 (Suppl.B), 19-20. Peer Reviewed verified by ORBi |
Henrotin, Y., Sanchez, C., Deberg, M., & Reginster, J.-Y. (2001). Diacerein by its Metabolite Rhein, Down-Regulates Stromelysins and Nitric Oxide Productions and Up-Regulates Aggrecan Production by Human Chondrocytes in Alginate Beads [Poster presentation]. First Biennal Meeting of the European Tissue Engineering Society International (ETES), Freiburg, Germany. |
 | DEROISY, R., Collette, J., Taquet, A., Thines, F., & Reginster, J.-Y. (2001). Comparison of the effect of combined calcium-vitamin D or calcium alone administration on circulating levels of parathyroid hormone (PTH) and 25-OH vitamin D (25-OHD) in ambulatory vitamin D-depleted post-menopausal women. BONE, S28, 231. Peer Reviewed verified by ORBi |
de Froidmont, C., Gosset, C., Reginster, J.-Y., & Tellier, V. (2001). Référent hospitalier pour la continuité des soins dans les hôpitaux psychiatriques belges. Projet pilote : deuxième phase. |
 | Henrotin, Y., Labasse, A., Galais, P., Tsouderos, Y., CRIELAARD, J.-M., & Reginster, J.-Y. (2001). Strontium ranelate increases cartilage matrix formation. BONE, S28, 104. Peer Reviewed verified by ORBi |
 | Rajatanavin, R., Tsai, K., Chan, S., Kung, A., Huang, Q., Kang, M., Chionh, S., Ben Sedrine, W., & Reginster, J.-Y. (2001). Validation of a simple clinical tool to identify Asian women with osteoporosis. BONE, S28, 172. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Zegels, B., DEROISY, R., Lejeune, E., & Taquet, A. (2001). The timing, dose and choice of calcium and vitamin D. BONE, S28, 253. Peer Reviewed verified by ORBi |
 | Hosking, D., Sorensen, O., Mulder, H., Adami, S., Pack, S., Wenderoth, D., & Reginster, J.-Y. (2001). Sustained fracture benefit with five years of risedronate in postmenopausal women. BONE, S28, 229. Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Huang, Q., & Reginster, J.-Y. (2001). Using the OSTA index to identify women at risk of osteoporosis : a validation study in China. Arthritis and Rheumatism, 44 (1233), 258. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Croisier, J.-L., Dubuc, J., Reginster, J.-Y., & Crielaard, J.-M. (2001). Isokinetic evaluation of knee extensors and flexors in patients with unilateral symptomatic gonarthrotis. Clinical Rheumatology, 20, 414. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Zegels, B., Lejeune, E., Taquet, A., Micheletti, M., & Albert, A. (2001). Effect of a daily regimen administration of calcium-vitamin D supplements on decrease of parathyroid hormone levels. Clinical Rheumatology, 20, 424. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Ben Sedrine, W., Chevallier, T., Micheletti, M., & Gelas, B. (2001). Development of a predictive model and a risk assessment instrument to facilitate diagnosis of low bone mass in postmenopausal women. Clinical Rheumatology, 20, 425. Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Broers, P., Devogelaer, J., Depresseux, G., Kaufman, J., Goemaere, S., & Reginster, J.-Y. (2001). Interest of a prescreening questionnaire to reduce the cost of bone densitometry. Clinical Rheumatology, 20, 420-421. Peer Reviewed verified by ORBi |
 | Ayache, N., Boumediene, K., Mathy-Hartert, M., Reginster, J.-Y., Henrotin, Y., & Pujol, J. (2001). Expression of transforming growth factors and their receptors is differentially modulated by reactive oxygen species and nitric oxide in human articular chondocytes. Osteoarthritis and Cartilage, 9SB, 42-S43. Peer Reviewed verified by ORBi |
 | Andriamanalijaona, R., Ayache, N., Mathy-Hartert, M., Reginster, J.-Y., Henrotin, Y., Pujol, J., & Boumediene, K. (2001). Interleukine-1 β regulation of transforming growth factor-β1 expression in articular chondrocytes : influence of aceclofenac. Osteoarthritis and Cartilage, 9SB, 56. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2001). Risedronate Increases Bone Mineral Density and Reduces the Vertebral Fracture Incidence in Postmenopausal Women. Clinical and Experimental Rheumatology, 19 (1), 121-2. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (2001). Stand der osteoporose-Therapie. Ein Medizinischer Skandal. MMW Fortschritte der Medizin, 143 (14), 43. Peer Reviewed verified by ORBi |
 | Mathy-Hartert, M., Dupont, G., Ayache, N., Pujol, J., Reginster, J.-Y., & Henrotin, Y. (2001). The expression of IL-1 β, iNOS and COX-2 genes by human chondrocytes is differentially regulated by reactive oxygen species. Osteoarthritis and Cartilage, 9SB, 56-S57. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Mathy-Hartert, M., Dupont, G., Ayache, N., Pujol, J., & Reginster, J.-Y. (2001). The expression of IL-1bêta, iNOS and COX-2 genes by human chondrocytes in differentially regulated by reactive oxygen species. Clinical Rheumatology, 20, 415. Peer Reviewed verified by ORBi |
Bruyère, O., COLLETTE, J., Delmas, P., Rouillon, A., Roux, C., Seidel, L., & Reginster, J.-Y. (2001). Early (3-month) changes in serum osteocalcin and urinary C-telopeptide of type I collagen could be of interest to identify postmenopausal osteoporotic women with the highest risk to present new vertevral deformities. Clinical Rheumatology, 5 (Suppl.1), 426. Peer Reviewed verified by ORBi |
Bruyère, O., COLLETTE, J., Delmas, P., Rouillon, A., Seidel, L., & Reginster, J.-Y. (2001). Interest of four biochemical markers of bone turnover in prediction of baseline and long-term (changes) of bone mineral density in postmenopausal osteoporotic women. Clinical Rheumatology, 5 (Suppl.1), 426. Peer Reviewed verified by ORBi |
Reginster, J.-Y., COLLETTE, J., Bruyère, O., Rovati, L. C., Giacovelli, G., DEROISY, R., Seidel, L., & Henrotin, Y. (2001). Short term (1-year) changes in keratan sulfate levels predict long-term (3-year) radiological evolution of knee osteoarthritis in patients treated with glucosamine sulfate. Arthritis and Rheumatism, 44 (Suppl.1), 139. Peer Reviewed verified by ORBi |
Bruyère, O., & Reginster, J.-Y. (2001). Fracture prevention in postmenopausal women. Clinical Evidence, 6, 831-843. Peer Reviewed verified by ORBi |
Bruyère, O., Henrotin, Y., Honoré, A., Rovati, L. C., Seidel, L., Dardenne, C.-B., & Reginster, J.-Y. (2001). Impact of joint space width measurement method on sample size calculation in knee osteoarthritis studies. Clinical Rheumatology, 5 (Suppl.1), 413. Peer Reviewed verified by ORBi |
Bruyère, O., Ethgen, O., Rovati, L. C., Seidel, L., Henrotin, Y., & Reginster, J.-Y. (2001). Radiographic severity of knee osteoarthrits is highly correlated with future progression of the disease. Clinical Rheumatology, 5 (Suppl.1), 412. Peer Reviewed verified by ORBi |
Bruyère, O., Lejeune, E., Dardenne, C.-B., Henrotin, Y., & Reginster, J.-Y. (2001). Relationship between subchondral tibial bone mineral density and joint space width at the medial femoro-tibial compartment in patients with knee osteoarthritis. Arthritis and Rheumatism, 44 (Suppl.1), 138. Peer Reviewed verified by ORBi |
Ethgen, O., Van Parijs, P., Delhalle, S., Rosant, S., Bruyère, O., & Reginster, J.-Y. (2001). Importance of social companionship in the determination of health-related quality of life in hip and knee osteoarthrits. Arthritis and Rheumatism, 44 (Suppl.1), 183. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Sanchez, C., Deberg, M., & Reginster, J.-Y. (2001). Diacerein by its Metabolite Rhein, Down-Regulates Stromelysins and Nitric Oxide Productions and Up-Regulates Aggrecan Production by Human Chondrocytes in Alginate Beads. Tissue Engineering, 7 (5), 648. Peer Reviewed verified by ORBi |
 | Lou, S., Koh, L., Yang, B., Kung, A., Park, H., Radican, L., Ross, P., Reginster, J.-Y., & Ben Sedrine, W. (2001). A simple clinical tool to identify Asian women with osteoporosis. Journal of Rheumatology, 28 (S63), 26. Peer Reviewed verified by ORBi |
 | Bensen, W., Eastell, R., Reginster, J.-Y., & McClung, M. (2001). The effect of risedronate on hip fracture risk in elderly women with osteoporosis. Journal of Rheumatology, 28 (S63), 24. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Sanchez, C., Deberg, M., Piccardi, N., Guillou, B., & Reginster, J.-Y. (2001). Long-term Effects of Avocado/Soybean Unsaponifiable on Human Chondrocytes Metabolism. Osteoarthritis and Cartilage, 9 (supplB), 25. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Gillet, P., & Gosset, C. (2001). Secular increase in the incidence of hip fractures in Belgium between 1984 and 1996: need for a concerted public health strategy. Bulletin of the World Health Organization, 79 (10), 942-6. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., DEROISY, R., Tsouderos, Y., JUPSIN, I., & Roux, C. (2001). Prevention of early postmenopausal bone loss by strontium ranelate : a randomised, two-year, double-blind, placebo-controlled trial. Journal of Bone and Mineral Research, 16 (S1), 219. Peer Reviewed verified by ORBi |
 | McClung, M., Geusens, P., Miller, P., Zippel, H., Bensen, W., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., Meunier, P., Wasnich, R., Greenwald, M., Kaufman, J., Chestnut III, & Reginster, J.-Y. (2001). Effect of risedronate on the risk of hip fracture in elderly women. Clinical Rheumatology, 20, 432. Peer Reviewed verified by ORBi |
 | Watts, N., Brown, J., Hosking, D., Adami, S., Mulder, H., Reginster, J.-Y., Kasibhatla, C., & Chines, A. (2001). Sustained fracture risk reduction over 5 years with risedronate therapy. Journal of Bone and Mineral Research, 16 (S1), 217. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Sakar, S., COLLETTE, J., Zegels, B., Henrotin, Y., Bruyère, O., Wrong, M., Harper, K., & Agnusdei, D. (2001). Relationship between 1-year change in bone turnover marker PINP and 3-year vertebral fracture risk reduction with raloxifene therapy in postmenopausal women with osteoporosis: result from the MORE trial. BONE, 28 (Suppl.1), 239. Peer Reviewed verified by ORBi |
Reginster, J.-Y., COLLETTE, J., Zegels, B., Henrotin, Y., Bruyère, O., & Durez, P. (2001). Relationship between 1-year change in bone turnover marker PINP and 3-year vertebral fracture risk reduction with raloxifene therapy in postmenopausal women with osteoporosis: result from the MORE trial. Clinical Rheumatology, 5 (Suppl.1), 425. Peer Reviewed verified by ORBi |
Bruyère, O., Henrotin, Y., Honoré, A., Rovati, L. C., Giacovelli, G., Seidel, L., & Reginster, J.-Y. (2001). Tibial subchondral sclerosis is significantly correlated with long-term (3-year) radiological progression of knee osteoarthritis. Osteoarthritis and Cartilage, 9 (Suppl.B), 23. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Taquet, A. N., Christiansen, C., Gamwell-Henriksen, E., Bruyère, O., COLLETTE, J., & Christgau, S. (2001). Bone resorption in postmenopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I. Clinical Rheumatology, 5 (Suppl.1), 427. Peer Reviewed verified by ORBi |
Bruyère, O., Henrotin, Y., Honoré, A., Rovati, L. C., Seidel, L., & Reginster, J.-Y. (2001). Tibial subchondral sclerosis is significantly correlated with long-term (3-year) radiological progression of knee osteoarthritis. Clinical Rheumatology, 5 (Suppl.1), 412. Peer Reviewed verified by ORBi |
Bruyère, O., Henrotin, Y., Honoré, A., Rovati, L. C., Seidel, L., & Reginster, J.-Y. (2001). Tibial subchondral sclerosis and femoral osteophytes are linked to symptomatic and structural severity of knee osteoarthritis. Clinical Rheumatology, 5 (Suppl.1), 411. Peer Reviewed verified by ORBi |
 | Appelboom, T., Schuermans, J., Verbruggen, G., Henrotin, Y., & REGINSTER, J.-Y. (2001). Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. Scandinavian Journal of Rheumatology, 30 (4), 242-7. doi:10.1080/030097401316909602 Peer Reviewed verified by ORBi |
 | Henrotin, Y., Sanchez, C., Deberg, M., & Reginster, J.-Y. (2001). Long-term effects of nonsteroidal antiinflammatory drugs on human chrondrocytes in alginate beads. Tissue Engineering, 7 (5), 648. Peer Reviewed verified by ORBi |
 | Vignon, E., Gamero, P., Delmas, P., Avouac, B., Bettica, P., Boers, M., Ehrich, E., MacKillop, N., Rovati, L., Serni, U., Spector, T., & Reginster, J.-Y. (2001). Recommandations for the registration of drugs used in the treatment of osteoarthritis : an update on biochemical markers. Osteoarthritis and Cartilage, 9, 289-293. Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Ethgen, O., Devogelaer, J., Kaufman, J., Goemaere, S., Depresseux, G., & Reginster, J.-Y. (2001). Toward an efficient strategy for osteoporosis screening : diagnostic accuracy and cost effectiveness of the proposals of the Belgian social security institute. Arthritis and Rheumatism, 44 (1598), 319. Peer Reviewed verified by ORBi |
 | Pols, H., Eastell, R., Delmas, P., Adachi, J., Ensrud, K., Harper, K., Sarkar, S., Gennari, C., Reginster, J.-Y., Recker, R., Harris, S., Wu, W., Black, D., & Genant, H. (2001). Early onset and sustained efficacy of raloxifene on incident vertebral fractures in postmenopausal women with ostoporosis : 4-year results from the MORE trial. BONE, S28, 85. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Mathy-Hartert, M., Ayache, N., Pujol, J., & Reginster, J.-Y. (2001). Regulation by reactive oxygen species (ROS) of interleukin-1 bêta, nitric oxide and prostaglandin E2 production by human chondrocytes. Clinical Rheumatology, 20, 415. Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Lin Liu, G., & Reginster, J.-Y. (2001). A simple table based on age and weight identifies Asian women at risk of osteoporosis. Arthritis and Rheumatism, 44 (1232), 258. Peer Reviewed verified by ORBi |
 | Cooper, C., Reginster, J.-Y., McClung, M., Zorich, N., & Li, Z. (2001). Rapid and sustained hip fracture risk reduction with risedronate in elderly women with osteoporosis. BONE, S28, 223. Peer Reviewed verified by ORBi |
 | Zheng, S. X., Mouithys-Mickalad, A., Dupont, G., Deby, C., Maroulis, A. P., Labasse, A. H., Lamy, M., Crielaard, J.-M., Reginster, J.-Y., & Henrotin, Y. (November 2000). In Vitro Study of the Antioxidant Properties of Nimesulide and 4-Oh Nimesulide: Effects on Hrp- and Luminol-Dependent Chemiluminescence Produced by Human Chondrocytes. Osteoarthritis and Cartilage, 8 (6), 419-25. doi:10.1053/joca.1999.0317 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Donazzolo, Y., Brion, N., & Lins, R. (September 2000). Estradiol Pharmacokinetics after Transdermal Application of Patches to Postmenopausal Women: Matrix Versus Reservoir Patches. Climacteric: the Journal of the International Menopause Society, 3 (3), 168-75. doi:10.1080/13697130008500093 Peer Reviewed verified by ORBi |
 | Manzambi Kuwekita, J., Tellier, V., Bertrand, F., Albert, A., Reginster, J.-Y., & Van Balen, E. H. (August 2000). Les determinants du comportement de recours au centre de sante en milieu urbain africain: resultats d'une enquete de menage menee a Kinshasa, Congo. Tropical Medicine and International Health, 5 (8), 563-70. doi:10.1046/j.1365-3156.2000.00588.x Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Devogelaer, J., Kaufman, J., Goemaere, S., Depresseux, G., Bruyère, O., & Reginster, J.-Y. (March 2000). Interest of the simple calculated osteoporosis risk estimation (SCORE) tool for a more rational use of bone densitometry. Value in Health, 3, 94. Peer Reviewed verified by ORBi |
Henrotin, Y., Croisier, J.-L., Dumont, R., Debry, O., Huskin, J.-P., Dubuc, J. E., Leflot, J. P., Reginster, J.-Y., & Crielaard, J.-M. (March 2000). Isokinetic evaluation of knee extensors and flexors in patients with unilateral symptomatic gonarthrosis. Isokinetics and Exercise Science, 8, 41. Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Devogelaer, J.-P., Kaufman, J.-M., Goemaere, S., Depresseux, G., Bruyère, O., & Reginster, J.-Y. (March 2000). The simple calculated osteoporosis risk estimation (SCORE) does not allow identification of Belgian women with a high risk of osteoporosis. Value in Health, 3, 94-95. Peer Reviewed verified by ORBi |
 | Wuster, C., Albanese, C., De Aloysio, D., Duboeuf, F., Gambacciani, M., Gonnelli, S., Gluer, C. C., HANS, D., Joly, J., REGINSTER, J.-Y., De Terlizzi, F., & Cadossi, R. (2000). Phalangeal osteosonogrammetry study: age-related changes, diagnostic sensitivity, and discrimination power. The Phalangeal Osteosonogrammetry Study Group. Journal of Bone and Mineral Research, 15 (8), 1603-14. doi:10.1359/jbmr.2000.15.8.1603 Peer Reviewed verified by ORBi |
 | De Leval, X., Henrotin, Y., Labasse, A., Reginster, J.-Y., Neven, P., Delarge, J., Somers, F., Masereel, B., Pirotte, B., & Dogne, J.-M. (2000). Comparison of the effects of nimesulide and nimesulide-L-lysine on PGE2 production by COX-1 and COX-2 and on chondrocyte metabolism in vitro. Pharmacy and Pharmacology Communications, 6, 83-87. doi:10.1211/146080800128735683 Peer reviewed |
De Leval, X., Dogne, J.-M., Masereel, B., Pirotte, B., Reginster, J.-Y., Neven, P., Labasse, A., Delarge, J., & Henrotin, Y. (2000). Profile of nimesulide and nimesulide-L-lysine-β-cyclodextrin on chondrocyte metabolism. Fundamental and Clinical Pharmacology, 14, 167. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Croisier, J.-L., Reginster, J.-Y., & CRIELAARD, J.-M. (2000). Bases scientifiques du traitement physique de la gonarthrose. Kiné 2000 : Revue Européenne de la Kinésitherapie, 11 (4), 86-94. Peer reviewed |
 | Mouithys-Mickalad, A., Zheng, S. X., Dupont, G., Deby, C., Lamy, M., Reginster, J.-Y., & Henrotin, Y. (2000). In vitro study of the antioxidant properties of non steroidal anti-inflammatory drugs by chemiluminescence and electron spin resonance (ESR). Free Radical Research, 33 (5), 607-21. doi:10.1080/10715760000301131 Peer Reviewed verified by ORBi |
De Leval, X., Dogné, J.-M., Delarge, J., Pirotte, B., Dupont, G., Mathy-Hartert, M., Chahboune, J., Labasse, A., Neven, P., Reginster, J.-Y., & Henrotin, Y. (2000). Comparative effects of nimesulide, nimesulide L-lysine and nimesulide L-lysine L-arginine on human articular chondrocytes in vitro. Mediators of Inflammation, 9, 51. Peer Reviewed verified by ORBi |
Dogne, J.-M., De Leval, X., Delarge, J., Dupont, G., Mathy-Hartert, M., Chahboune, J., Labasse, A., Neven, P., Somers, F., Pirotte, B., Reginster, J.-Y., & Henrotin, Y. (2000). Synthesis and evaluation of non-carboxylic pyridinic derivatives as cyclooxygenase inhibitors. Mediators of Inflammation, 9, 52. Peer Reviewed verified by ORBi |
 | Kaufman, J. M., Body, J. J., Boonen, S., Devogelaer, J. P., Raeman, F., Rozenberg, S., & REGINSTER, J.-Y. (2000). L'osteoporose involutive de la femme: strategie therapeutique. Un point de vue actualise du Belgian Bone Club. Revue Médicale de Liège, 55 (5), 443-8. Peer reviewed |
 | Reginster, J.-Y., COLLETTE, J., Rovati, L. C., DEROISY, R., Honore, A., Bruyère, O., Seidel, L., & Henrotin, Y. (2000). Biochemical markers of bone and cartilage remodeling are poorly correlated with clinical and radiological severity of knee osteoarthritis. Arthritis and Rheumatism, 43 (Suppl.1), 339. Peer Reviewed verified by ORBi |
 | Delmas, P., Ensrud, K., Harper, K., Wu, W., Adachi, J., Eastell, R., Gennari, C., Reginster, J.-Y., Pols, H., Recker, R., Bjarnason, N., Sarkar, S., Black, D., & Genant, H. (2000). Effects of raloxifene on bone mineral density and biochemical markers of bone turnover in postmenopausal women with osteoporosis : 4-year results from the MORE trial. Journal of Bone and Mineral Research, 15 (S1), 556. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., DEROISY, R., Paul, I., Lee, R., Giacovelli, G., Dacre, J., Rovati, L., & Gosset, C. (2000). Glucosamine sulfate significantly reduces progression of knee osteoarthritis over 3 years : a large randomized, placebo-controlled, double-blind, prospective trial. Osteoarthritis and Cartilage, 8, 151. Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Devogelaer, J., Kaufman, J., Goemaere, S., Depresseux, G., Bruyère, O., & Reginster, J.-Y. (2000). The simple calculated ostoporosis risk estimation (SCORE) does not allow to identify Belgian women with a high risk of osteoporosis. Osteoporosis International, 11 (S2), 3. Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Broers, P., Brands, G., Devogelaer, J., Depresseux, G., Kaufman, J., Goemaere, S., de Froidmont, C., & Reginster, J.-Y. (2000). Interest of a simple pre-screening test for optimizing the cost/benefit value of bone densitometry. Osteoporosis International, SS (S5), 13. Peer Reviewed verified by ORBi |
 | Halkin, V., & Reginster, J.-Y. (2000). Psychiatrie en osteoporose. Agenda Psychiatrie, 14, 14. Peer reviewed |
 | Halkin, V., & Reginster, J.-Y. (2000). Het botkapitaal : een spaarboekje dat in de wieg begint. De Agenda Pediatrie, 22, 14. Peer reviewed |
 | Reginster, J.-Y., & Halkin, V. (2000). Preventie van postmenopauzale osteoporose. De agenda Gynaecologie, 19, 17-19. Peer reviewed |
 | Reginster, J.-Y., Ethgen, O., & Dang Vu, T. (2000). La chondroprotection aujourd’hui. Rhumatologie, 52 (8), 13-16. Peer Reviewed verified by ORBi |
Abraham, I., Bollen, S., de Froidmont, C., De Geest, S., Dejace, A., Englebert, L., Gosset, C., Hogge, Y., Indenkleef, S., Milisen, K., Moons, P., Reginster, J.-Y., Rondal, P., Steeman, E., Tellier, V., & Wouters, B. (2000). Pilootproject : ontslagmanagement in Belgische ziekenhuizen. [Pilot study : discharge management in Belgian hospitals]. Summarizing report, 2000. SFP. |
Abraham, I., Bollen, S., de Froidmont, C., De Geest, S., Dejace, A., Englebert, L., Gosset, C., Hogge, Y., Indenkleef, S., Milisen, K., Moons, P., Reginster, J.-Y., Rondal, P., Steeman, E., Tellier, V., & Wouters, B. (2000). Pilootproject : ontslagmanagement in Belgische ziekenhuizen. [Pilot study : discharge management in Belgian hospitals]. Final report, 2000. SFP. |
 | Reginster, J.-Y., Bruyère, O., Audan, M., Avouac, B., Body, J.-J., Bouvenot, G., Brandi, M.-L., Gennari, C., Kaufman, J.-M., Lemmel, E.-M., Vanhaelst, L., Weryha, G., & Devogelaer, J.-P. (2000). Do estrogens effectively prevent osteoporosis-related fractures? Calcified Tissue International, 67, 191-194. doi:10.1007/s002230001135 Peer Reviewed verified by ORBi |
 | Henrotin, Y., Zheng, S., Mouithys-Mickalad, A., Deby-Dupont, G., Deby, C., Lamy, M., CRIELAARD, J.-M., & Reginster, J.-Y. (2000). In vitro study of the antioxydant properties of the nimesulide and 4OH nimesulide : effect on HRP- and luminol-dependent chemiluminescence produced by human chondrocytes. Annals of the Rheumatic Diseases, 59 (S1), 265. Peer Reviewed verified by ORBi |
 | Ethgen, O., Kahler, K., Kong, S., Reginster, J.-Y., & Wolfe, F. (2000). Health-related quality of life scores and future use of health care resources in patients with rheumatoid arthritis and osteoarthritis : implication for health services research in arthritis. Annals of the Rheumatic Diseases, 59 (S1), 277. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., COLLETTE, J., Rovati, L. C., DEROISY, R., Bruyère, O., & Henrotin, Y. (2000). Changes in serum osteocalcin but not other serum and urinary markers of bone and cartilage metabolism, measured after 12 months, are significantly correlated to long-term (36 monts) structural changes in knee osteoarthritis. Arthritis and Rheumatism, 43 (Suppl.1), 398. Peer Reviewed verified by ORBi |
 | Eastell, R., Adachi, J., Harper, K., Sarkar, S., Delmas, P., Ensrud, K., Gennari, C., Reginster, J.-Y., Pols, H., Recker, R., Harris, S., Wu, W., Genant, H., & Black, D. (2000). The effects of raloxifene on incident vertebral fractures in postmenopausal women with osteoporosis : 4-year results from the MORE trial. Journal of Bone and Mineral Research, 15 (S1), 229. Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Goemaere, S., Depresseux, G., Ethgen, O., Devogelaer, J., Kaufman, J., & Reginster, J.-Y. (2000). The simple calculates osteoporosis risk estimation (score) tool is more useful to reduce densitometry costs than for selecting patient with high risk of osteoporosis. Arthritis and Rheumatism, 43 (S1), 809. Peer Reviewed verified by ORBi |
 | Bensen, W., Piette, F., Ettinger, M., Horlait, S., DiMunno, O., Silverman, S., Bos, K., & Reginster, J.-Y. (2000). Risedronate significantly reduces hip fracture risk in elderly women with osteoporosis. Journal of Bone and Mineral Research, 15 (S1), 226. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Alexandersen, P., Devogelaer, J., Roux, C., Gennari, C., Fechtenbaum, J., Toussaint, A., & Christiansen, C. (2000). Failure of ipriflavone to significantly reduce vertebral fracture rates and to increase bone mineral density in postmenopausal osteoporosis : the IMEFS study. Arthritis and Rheumatism, 43 (S1), 1898. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., DEROISY, R., Lee, R., Rovati, L., Lejeune, E., Giacovelli, G., Henrotin, Y., Dacre, J., & Gosset, C. (2000). Long-term disease modifying effect by glucosamine sulfate in knee osteoarthritis : relationship between structure and symptom changes. Annals of the Rheumatic Diseases, 59 (S1), 55. Peer Reviewed verified by ORBi |
 | Ethgen, O., Tellier, V., Ben Sedrine, W., De Maeseneer, J., Gosset, C., & Reginster, J.-Y. (2000). Health-related quality of life and cost of ambulatory care in osteopororis . May such outcome measures be valuable information to health decision makers and payers ? Osteoporosis International, 11 (S5), 5-S6. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Halkin, V. (2000). Les propriétés de la glucosamine. Journal de Pharmacie de Belgique, 55 (5), 118-121. Peer Reviewed verified by ORBi |
 | McClung, M., Eastell, R., Bensen, W., Benhamou, C., Chesnut, C., Adami, S., DiGennaro, J., Axelrod, D., & Reginster, J.-Y. (2000). Risedronate reduces hip fracture risk in elderly women with osteoporosis. Osteoporosis International, 11 (S2), 207. Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Goemaere, S., Depresseux, G., Ethgen, O., Devogelaer, J., Kaufman, J., & Reginster, J.-Y. (2000). Validation of the critera proposed by the Belgian social security institute for reimbursement of bone mineral density : a study in a sample of 4727 ambulatory subjects. Arthritis and Rheumatism, 43 (S1), 453. Peer Reviewed verified by ORBi |
 | Ethgen, O., Khaler, K., Kong, S., Reginster, J.-Y., & Wolfe, F. (2000). Are health-related quality of life scores useful in predicting the use of the health care services ? Exploration in patients with osteoarthritis. Arthritis and Rheumatism, 43 (S1), 582. Peer Reviewed verified by ORBi |
Abraham, I., Bollen, S., de Froidmont, C., De Geest, S., Dejace, A., Englebert, L., Ghyselen, K., Gosset, C., Hillewaere, L., Hogge, Y., Milisen, K., Moons, P., Reginster, J.-Y., Rondal, P., Sente, C., Steeman, E., Telliler, V., & Vanham, P. (2000). Pilootproject : Ontslagmanagement in Belgische Psyciatrische Ziekenhuizen. [Pilot study : discharge management in Belgian psychiatric hospitals]. Summarizing report, 2000. SFP. |
Abraham, I., Bollen, S., de Froidmont, C., De Geest, S., Dejace, A., Englebert, L., Ghyselen, K., Gosset, C., Hillewaere, L., Hogge, Y., Milisen, K., Moons, P., Reginster, J.-Y., Rondal, P., Sente, C., Steeman, E., Tellier, V., & Vanham, P. (2000). Pilootproject : Ontslagmanagement in Belgische Psyciatrische Ziekenhuizen. [Pilot study : discharge management in Belgian psychiatric hospitals]. Final report, 2000. SFP. |
 | Henrotin, Y., Mouithys-Mickalad, A., Mathy-Hartert, M., Zheng, S., Dupont, G., & Reginster, J.-Y. (2000). The antioxidant properties of non stroidal anti-inflammatory drugs. Osteoarthritis and Cartilage, 8, 36. Peer Reviewed verified by ORBi |
de froidmont, C., Dejace, A., Englebert, L., Gosset, C., Goethals, M., Hogge, Y., Reginster, J.-Y., Rondal, P., Sente, C., Tellier, V., & Vanham, P. (2000). Référent hospitalier pour la continuité des soins. Projet pilote : Référent hospitalier pour la continuité des soins dans les hôpitaux psychiatriques belges de 1998 – 1999. |
de Froidmont, C., Gosset, C., Dejace, A., Englebert, L., Tellier, V., Reginster, J.-Y., & Rondal, P. (2000). Référent hospitalier pour la continuité des soins. Etude pilote : Référent hospitalier pour la continuité des soins dans les hôpitaux généraux belges de 1998 – 1999. |
 | Ethgen, O., Tellier, C., Ben Sedrine, W., De Maeseneer, J., Gosset, C., & Reginster, J.-Y. (2000). Health-related quality of life and cost of ambulatory care in osteoporosis. May such outcome measures be valuable information to health decision makers and payers ? [Paper presentation]. Second International Meeting on Social and Economic Aspects of Osteroporosis and Bone Diseases, Liège, Belgium. |
 | Bruyère, O., COLLETTE, J., Zegels, B., Rovati, L. C., Seidel, L., Henrotin, Y., & Reginster, J.-Y. (2000). Baseline values and early (6-month) changes in total and bone specific alkaline phosphatase do not predict long-term (4-year) bone mineral density changes in postmenopausal osteoporotic women treated with fluoride. Arthritis and Rheumatism, 43 (S1), 199. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Henrotin, Y. (2000). Conception actuelle du traitement de l’arthrose. Revue de la Médecine Générale, 177, 382-389. Peer reviewed |
Reginster, J.-Y., Taquet, A.-N., & Bruyère, O. (2000). Skeletal effect of selective oestrogen receptor modulators (SERMs). In SERMs, a novel option to maintain health in the menopause (pp. 49-61). London, United Kingdom: Martin Dunitz Publ. |
Reginster, J.-Y., Paul, I., Fraikin, G., & Bruyère, O. (2000). Bisphosphonates. In The management of the menopause : the Millenium Review (pp. 297-304). London, United Kingdom: Parthenon Publ. |
Ben Sedrine, W., Devogelaer, J.-P., Kaufman, J.-M., Goemaere, S., Depresseux, G., Bruyère, O., & Reginster, J.-Y. (2000). The simple calculated osteoporosis risk estimation (SCORE) does not allow identification of Belgian women with a high risk of osteoporosis. Annals of the Rheumatic Diseases, 59 (Suppl.1), 80. Peer Reviewed verified by ORBi |
 | REGINSTER, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., & Eastell, R. (2000). Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporosis International, 11 (1), 83-91. doi:10.1007/s001980050010 Peer Reviewed verified by ORBi |
| Henrotin, Y., Mouithys-Mickalad, A., Zheng, S., Deby-Dupont, G., Deby, C., LAMY, M., & Reginster, J.-Y. (2000). In vitro study of the antioxydant properties of nonsteroidal anti-inflammatory drugs by chemiluminescence and electron spin resonance (ESR). Annals of the Rheumatic Diseases, 59 (S1), 187. Peer Reviewed verified by ORBi |
 | Fogelman, I., Ribot, C., Smith, R., Ethgen, D., Sod, E., & REGINSTER, J.-Y. (2000). Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. Journal of Clinical Endocrinology and Metabolism, 85 (5), 1895-900. doi:10.1210/jc.85.5.1895 Peer Reviewed verified by ORBi |
 | Alexandersen, P., Toussaint, A., Reginster, J.-Y., Christiansen, C., Devogelaer, J., Gennari, C., Roux, C., & Fechtenbaum, J. (2000). Ipriflavone has no effect on bone metabolism and causes lymphopenia in osteopenic women. Journal of Bone and Mineral Research, 15 (S1), 198. Peer Reviewed verified by ORBi |
 | Johnell, O., Lu, Y., Seeman, E., Reginster, J.-Y., & Scheele, W. (2000). Effect of raloxifene and alendronate on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis. Osteoporosis International, 11 (S2), 184. Peer Reviewed verified by ORBi |
Croisier, J.-L., Henrotin, Y., Dumont, R., Debry, O., Reginster, J.-Y., & Crielaard, J.-M. (2000). Evaluation isocinétique des muscles du genou au cours de la gonarthrose. In Isocinétisme et personnes âgées (pp. 19-21). ERRF Montpellier Editeur. |
 | Henrotin, Y., Zheng, S. X., Labasse, A. H., Dupont, G., Crielaard, J.-M., & REGINSTER, J.-Y. (2000). Modulation of human chondrocyte metabolism by recombinant human interferon. Osteoarthritis and Cartilage, 8 (6), 474-82. doi:10.1053/joca.1999.0323 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Gillot, V., Bruyère, O., & Henrotin, Y. (2000). Evidence of nutriceutical effectiveness in the treatment of osteoarthritis. Current Rheumatology Reports, 2 (6), 472-477. doi:10.1007/s11926-000-0023-9 Peer Reviewed verified by ORBi |
 | Christgau, S., Henrotin, Y., Enriksen, D., Rovati, L., Collette, J., DEROISY, R., Christiansen, C., & Reginster, J.-Y. (2000). Cartilage degradation in knee osteoarthritis patients with elevated levels of urinary collagen type II C-telopeptide fragments. Arthritis and Rheumatism, 43 (S1), 1243. Peer Reviewed verified by ORBi |
 | Seeman, E., McClung, M., Zippel, H., Bensen, W., Cooper, C., Benhamou, C., DiGennaro, J., Zorich, N., & Reginster, J.-Y. (2000). Rapid and sustained effects of risedronate in reducting hip fracture risk in elderly women with osteoporis. Journal of Bone and Mineral Research, 15 (S1), 149. Peer Reviewed verified by ORBi |
 | Greenwald, M., Fischer, M., Poiley, J., Bos, K., & Reginster, J.-Y. (2000). Rapid and consistent effect of risedronate on vertebral fracture risk reduction in elderly postmenopausal women. Journal of Bone and Mineral Research, 15 (S1), 226. Peer Reviewed verified by ORBi |
 | Silverman, S., Geusens, P., Bensen, W., Benhamou, L., Fogelman, I., Zorich, N., & Reginster, J.-Y. (2000). Risedronate reduces hip fracture risk in elderly women with osteoporosis with a rapid and sustained effect. Arthritis and Rheumatism, 43 (S1), 781. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Croisier, J.-L., Dumont, R., Debry, O., HUSKIN, J.-P., Dubuc, J., Leflot, J., Reginster, J.-Y., & CRIELAARD, J.-M. (2000). Isokinetic evaluation of knee extensors and flexors in patients with unilateral symptomatic gonarthrosis. Annals of the Rheumatic Diseases, 59 (S1), 275. Peer Reviewed verified by ORBi |
 | Tellier, V., De Maeseneer, J., Cartier, P., De Prins, L., Ben Sedrine, W., Gosset, C., & Reginster, J.-Y. (2000). Intensive and prolonged health promotion strategy may increase self-reported osteoporosis prevalence among postmenopausal women. Annals of the Rheumatic Diseases, 59 (S1), 58. Peer Reviewed verified by ORBi |
Tellier, V., de Froidmont, C., Paul, I., Gosset, C., & Reginster, J.-Y. (2000). Nutritional aspects in suveys : why making it complicated when it can be simple. Examples from the first belgian national health interview survey (1997) [Paper presentation]. 6ème Symposium de la Santé Publique, Bruxelles, Belgium. |
 | Reginster, J.-Y., Taquet, A., & Fraikin, G. (2000). Osteoporose bij de bejaarde. Medi-Sfeer, 103, 15-19. Peer reviewed |
 | Reginster, J.-Y., & Halkin, V. (2000). Eigenschappen van glucosamine. Medi-Sfeer, 116, 10-14. Peer reviewed |
 | REGINSTER, J.-Y., & BETZ, R. (2000). Evidence-based medicine. Apport des etudes epidemiologiques. Revue Médicale de Liège, 55 (4), 211-5. Peer reviewed |
Ben Sedrine, W., Devogelaer, J.-P., Kaufman, J.-M., Goemaere, S., Depresseux, G., Bruyère, O., & Reginster, J.-Y. (2000). Interest of the simple calculated osteoporosis risk estimation (SCORE) tool for a more rational use of bone densitometry. Annals of the Rheumatic Diseases, 59 (Suppl.1), 80-81. Peer Reviewed verified by ORBi |
 | Mathy-Hartert, M., Ayache, N., Boumediene, K., Pujol, J., Reginster, J.-Y., & Henrotin, Y. (2000). Effects of antioxidants on interleukin-1β, nitric oxide and prostaglandin E2 production by human chondrocytes. Osteoarthritis and Cartilage, 8, 1. Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Koh, L., Radican, L., Ross, P., Torralba, T., & Reginster, J.-Y. (2000). A simple clinical tool to identify Asian women with osteoporosis. Osteoporosis International, 11 (S5), 9. Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Devogelaer, J., Kaufman, J., Goemaere, S., Depresseux, G., Bruyère, O., & Reginster, J.-Y. (2000). Interest of the simple calculated osteoporosis risk estimation (SCORE) tool for a more rational use of bone densitometry. Osteoporosis International, SS (S5), 13. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Bruyère, O. (January 2000). Alternatives à l'hormonothérapie substitutive comme prévention de l'ostéoporose postménopausique. Lettre du Gynécologue, 248, 15-17. |
 | Halkin, V., & Reginster, J.-Y. (2000). Le capital osseux : une épargne qui débute au berceau. L'agenda Pédiatrie, 22, 14. Peer reviewed |
 | Kaufman, J. M., Johnell, O., Abadie, E., Adami, S., Audran, M., Avouac, B., Ben Sedrine, W., CALVO, G., Devogelaer, J. P., Fuchs, V., Kreutz, G., Nilsson, P., Pols, H., Ringe, J., Van Haelst, L., & REGINSTER, J.-Y. (2000). Background for studies on the treatment of male osteoporosis: state of the art. Annals of the Rheumatic Diseases, 59 (10), 765-72. doi:10.1136/ard.59.10.765 Peer Reviewed verified by ORBi |
 | Bruyère, O., & Reginster, J.-Y. (2000). Fracture prevention. New topic. Clinical Evidence, 4, 587-590. Peer Reviewed verified by ORBi |
De Leval, X., Dogne, J. M., Masereel, B., Pirotte, B., Reginster, J.-Y., Neven, P., Labasse, A., Delarge, J., & Henrotin, Y. (20 November 1999). Profile of nimesulide and nimesulide-L-lysine-β-cyclodextrin on chondrocyte metabolism [Poster presentation]. Réunion de la Société Belge de Physiologie et de Pharmacologie Fondamentales et Cliniques, Bruxelles, Belgium. |
 | Reginster, J.-Y., de Froidmont, C., Lecart, M. P., Sarlet, N., & Defraigne, J.-O. (October 1999). Alphacalcidol in Prevention of Glucocorticoid-Induced Osteoporosis. Calcified Tissue International, 65 (4), 328-31. doi:10.1007/s002239900706 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Agnusdei, D., Gennari, C., & Kicovic, P. M. (October 1999). Association of Tibolone and Fluoride Displays a Pronounced Effect on Bone Mineral Density in Postmenopausal Osteoporotic Women. Gynecological Endocrinology, 13 (5), 361-8. doi:10.3109/09513599909167580 Peer Reviewed verified by ORBi |
De Leval, X., Dogne, J. M., Delarge, J., Pirotte, B., Dupont, G., Mathy-Hartert, M., Chahboune, J., Labasse, A., Neven, P., Reginster, J.-Y., & Henrotin, Y. (17 September 1999). Comparative effects of nimesulide, nimesulide L-lysine and nimesulide L-lysine L-arginine on human articular chondrocytes in vitro [Poster presentation]. Groupe de Contact FNRS/FRSM “Mécanismes Cellulaires de l’Inflammation", Bruxelles, Belgium. |
Dogne, J. M., De Leval, X., Delarge, J., Dupont, G., Mathy-Hartert, M., Chahboune, J., Labasse, A., Neven, P., Somers, F., Pirotte, B., Reginster, J.-Y., & Henrotin, Y. (17 September 1999). Synthesis and evaluation of non-carboxylic pyridinic derivatives as cyclooxygenase inhibitors [Poster presentation]. Groupe de Contact FNRS/FRSM “Mécanismes Cellulaires de l’Inflammation", Bruxelles, Belgium. |
De Leval, X., Dogne, J. M., Neven, P., Labasse, A., Masreel, B., Somers, F., Pirotte, B., De Tullio, P., Delarge, J., Reginster, J.-Y., & Henrotin, Y. (May 1999). Evaluation de la sélectivité COX-1 vs COX-2 de drogues à potentialités anti-inflammatoires [Poster presentation]. Treizièmes Journées Franco-Belges de Pharmacochimie, Liège, Belgium. |
 | Henrotin, Y., & Reginster, J.-Y. (May 1999). In-Vitro Differences among Nonsteroidal Antiinflammatory Drugs in Their Activities Related to Osteoarthritis Pathophysiology. Osteoarthritis and Cartilage, 7 (3), 355-7. doi:10.1053/joca.1998.0197 Peer Reviewed verified by ORBi |
 | Henrotin, Y., & Reginster, J.-Y. (May 1999). Anabolic Events in Osteoarthritis. Osteoarthritis and Cartilage, 7 (3), 310-2. doi:10.1053/joca.1998.0175 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Devogelaer, J. P., Kaufman, J. M., Appelboom, T., & Vanhaelst, L. (April 1999). L'ostéoporose d'involution chez la femme. Revue Médicale de Liège, 54 (4), 335-40. Peer reviewed |
 | Reginster, J.-Y., Devogelaer, J. P., Kaufman, J. M., Appelboom, T., & Vanhaelst, L. (March 1999). Comment j'explore ... l'ostéoporose: mesure de la masse osseuse et analyses biologiques. Revue Médicale de Liège, 54 (3), 184-8. Peer reviewed |
Reginster, J.-Y., Henrotin, Y., & Gosset, C. (March 1999). Promising New Agents in Osteoporosis. Drugs in R&D, 1 (3), 195-201. doi:10.2165/00126839-199901030-00001 Peer Reviewed verified by ORBi |
de Froidmont, C., Dejace, A., Englebert, L., Gosset, C., Hooge, Y., Reginster, J.-Y., Rondal, P., Abraham, I., Borgermans, L., Indenkleef, S., Moons, P., Milisen, K., Steeman, E., & Wouters, B. (1999). Etude pilote : Case management intégré dans les hôpitaux belges. |
Reginster, J.-Y., Halkin, V., Fraikin, G., Taquet, A. N., Paul, I., Brends, G., & Gosset, C. (1999). Established postmenopausal osteoporosis – Assessment of treatment options. Menopause Review, 1 (IV), 39-55. |
 | Henrotin, Y., Zheng, S., Labasse, A., Dupont, G., Crielaard, J.-M., & Reginster, J.-Y. (1999). In vitro effect of recombinant human interferon on basal and IL- stimulated stromelysin, proteoglycans, cytokines (IL-6, IL-8, IL-10), nitric oxide and IL-1ra. Arthritis and Rheumatism, 42 (S1), 254. Peer Reviewed verified by ORBi |
 | Kaufman, J., Compston, J., Audran, M., Avouac, B., Devogelaer, J., Lemmel, E., Vanhaelst, L., & Reginster, J.-Y. (1999). Recommendations for the registration of drugs intended for use in the treatment of male osteoporosis. Calcified Tissue International, 65, 4-7. doi:10.1007/s002239900649 Peer Reviewed verified by ORBi |
 | Brown, J., Hosking, D., Ste-Marie, L., Johnston, C., Reginster, J.-Y., Ryan, W., Johnson, T., & Bekker, P. (1999). Risedronate, a highly effective, short-term oral treatment for Paget’s disease: a dose-response study. Calcified Tissue International, 64, 93-99. doi:10.1007/s002239900584 Peer Reviewed verified by ORBi |
Henrotin, Y., & Reginster, J.-Y. (1999). In vitro models for the study of cartilage damage and repair. In J.-Y. Reginster, J.-P. Pelletier, J. Martel-Pelletier, ... Y. Henrotin (Eds.), Osteoarthritis: Clinical and experimental aspects (pp. 53-58). Springer. |
 | Pelletier, J., & Reginster, J.-Y. (1999). The influence of tissular cross-talking on osteoarthritis progression: role of non steroidal antiinflammatory drugs. Osteoarthritis and Cartilage, 7, 306-307. Peer Reviewed verified by ORBi |
Henrotin, Y., Labasse, A., Crielaard, J.-M., & Reginster, J.-Y. (1999). In vitro induced imbalance between stromelysin and TIMP-1 production by human chondrocytes. Osteoarthritis and Cartilage, 7 (SA), 33. Peer Reviewed verified by ORBi |
McClung, M., Eastell, R., Watts, N., Fogelman, I., Hooper, M., Ernst, T., Bettica, P., & Reginster, J.-Y. (1999). Risedronate is well-tolerated in women with osteoporosis. Journal of Bone and Mineral Research, 14 (S1), 538. Peer Reviewed verified by ORBi |
Appelboom, T., Reginster, J.-Y., Schuermans, J., & Verbruggen, G. (1999). Efficacy and safety of avocado soybean unsaponifiable (ASU)at two different daily doses in treatment of symptomatic osteoarthritis of the knee (KOA). Osteoarthritis and Cartilage, 7 (SA), 117. Peer Reviewed verified by ORBi |
Reginster, J.-Y. (1999). Review of bone formation stimulants. Osterologia-Osteology, 2, 31-33. Peer reviewed |
Halkin, V., & Reginster, J.-Y. (1999). Calcitonine dans la prévention secondaire et tertiaire de l’ostéoporose. Medi-Sphere, 3, 39-41. Peer reviewed |
Reginster, J.-Y. (1999). Bisphosphonates : an update. Osteologia-Osteology, 2, 44-45. Peer reviewed |
 | Reginster, J.-Y., Gillet, P., Ben Sedrine, W., Brands, G., Ethgen, O., de Froidmont, C., & Gosset, C. (1999). Direct costs of hip fractures in patients over 60 years of age in Belgium. PharmacoEconomics, 15 (5), 507-514. doi:10.2165/00019053-199915050-00008 Peer Reviewed verified by ORBi |
Eastell, R., Minne, H., Sorensen, O., Hooper, M., Ritter-Hencrick, C., Pack, S., Roumagnac, I., Ethgen, D., & Reginster, J.-Y. (1999). Risedronate reduces fracture risk in women with established postmenopausal osteoporosis. Calcified Tissue International, 64 (S1), 43. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1999). Treatment of osteoporosis : where are we and where are we going to. Morphologie, 83 (261), 41-5. Peer Reviewed verified by ORBi |
Tellier, V., De Maeseneer, J., Cartier, P., De Prins, L., Ben Sedrine, W., Gosset, C., & Reginster, J.-Y. (1999). Communication strategy increases osteoporosis awareness in postmenopausal women. Journal of Bone and Mineral Research, 14 (S1), 385. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Roux, C., Jupsin, I., Tupinon-Mathieu, I., & Tsouderos, Y. (1999). Safety of strontium ranelate in prevention of postmenopausal bone loss - a double-blind, prospective, placebo-controlled study. Journal of Bone and Mineral Research, 14 (S1), 412. Peer Reviewed verified by ORBi |
Ribot, C., Smith, R., Fogelman, I., Bettica, P., Pack, S., Ethgen, D., & Reginster, J.-Y. (1999). Risedronate increases bone mineral density and is well-tolerated in postmenopausal women with low bone mineral density. Journal of Bone and Mineral Research, 14 (S1), 136. Peer Reviewed verified by ORBi |
Roux, C., Keller, M., Eastell, R., McKeever, C., Pack, S., Ethgen, D., Reginster, J.-Y., & Chesnut, C. (1999). Risedronate significantly reduces vertebral and non-vertebral fractures in osteoporotic women. Journal of Bone and Mineral Research, 14 (S1), 538. Peer Reviewed verified by ORBi |
 | Roux, C., Dougados, M., Reginster, J.-Y., Jupsin, I., Provvedini, D., & Tsouderos, Y. (1999). Prévention de la perte osseuse postménopausique par strontium ranelate. Revue du Rhumatisme, 1bis, 103. Peer Reviewed verified by ORBi |
de Froidmont, C., Gosset, C., Reginster, J.-Y., Tellier, V., Dejace, A., & Englebert, L. (1999). Assessing and improving quality of life of caregivers significantly reduces the risk of new hospitalisation in elderly subjects [Paper presentation]. 6th Annuel Conference of the International Society for Quality of Life Research, Barcelone, Spain. |
 | de Leval, X., Dogné, J.-M., Neven, P., Labasse, A., Delarge, J., Reginster, J.-Y., & Henrotin, Y. (1999). Effects of Nimesulide and Indometacin on Cox-1 and Cox-2: A Comparative Study. Journal de Pharmacie de Belgique, 54 (3), 89-90. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (Ed.), Gathon, H.-J. (Other coll.), Marciniak, A. (Other coll.), Ben Sedrine, W. (Other coll.), Best, J. (Other coll.), Caulin, F. (Other coll.), Corcaud, S. (Other coll.), Dawson, A. (Other coll.), Ethgen, D. (Other coll.), Paschen, B. (Other coll.), & Sprafka, J. M. (Other coll.). (1999). Recommandations for Health Economics Evaluations of interventions in Osteoporosis (Haim Nemerson, M., Trans.). World Health Organization. |
 | Tellier, V., Gosset, C., De Prins, L., De Maseneer, J., & Reginster, J.-Y. (1999). Role of the socio-economic determinants, life style and health locus of control in the perceived health functional status in chronically ill elderly. Quality of Life Research, 8, 635. Peer Reviewed verified by ORBi |
 | Miller, P., Roux, C., McClung, M., Adami, S., Eastell, R., Pack, S., Ethgen, D., & Reginster, J.-Y. (1999). Risedronate reduces hip fractures in patients with low femoral neck bone mineral density. Arthritis and Rheumatism, 42 (S1), 287. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Deroisy, R., Paul, I., Hansenne, M., & Ansseau, M. (1999). Depressive vulnerability is not an independent risk factor for osteoporosis in postmenopausal women. Maturitas, 33 (2), 133-7. doi:10.1016/S0378-5122(99)00057-2 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Taquet, A., & Fraikin, G. (1999). L’ostéoporose chez la personne âgée. Medi-Sphere, 103, 15-19. Peer reviewed |
Henrotin, Y., Croisier, J.-L., Dumont, R., Debry, O., HUSKIN, J.-P., Dubuc, J., Leflot, J., Reginster, J.-Y., & Crielaard, J.-M. (1999). Isokinetic evaluation of knee extensors and flexors in patients with unilateral symptomatic gonarthrosis. Osteoarthritis and Cartilage, 7 (SA), 94. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., DEROISY, R., Paul, I., Lee, R., Henrotin, Y., Giacovelli, G., Dacre, J., Rovati, L., & Gosset, C. (1999). Glucosamine sulfate significantly reduces progression of the knee osteoarthritis over 3 years : a large randomised, placebo-controlled, double-blind, prospective trial. Arthritis and Rheumatism, 42 (S1), 400. Peer Reviewed verified by ORBi |
 | Ben Sedrine, W., Broers, P., Brands, G., Devogelaer, J., Depresseux, G., Kaufman, J., Goemaere, S., de Froidmont, C., & Reginster, J.-Y. (1999). Interest of a simple pre-screening test for optimazing the cost/benefit value of bone densitometry. Arthritis and Rheumatism, 42 (S1), 289. Peer Reviewed verified by ORBi |
 | Tellier, V., Ben Sedrine, W., Gosset, C., Cartier, P., de Maeseneer, J., de Prins, L., & Reginster, J.-Y. (1999). Effects of an intensive communications strategies on postmenopausal osteoporosis awareness in women. Arthritis and Rheumatism, 42 (S1), 356. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Taquet, A., Christiansen, C., Gamwell-Henriksen, F., & Collette, J. (1999). Comparison of four markers of bone resorption as diagnostic or monitoring tools in postmenopausal osteoporosis. Arthritis and Rheumatism, 42 (S1), 291. Peer Reviewed verified by ORBi |
Henrotin, Y., Labasse, A., Guillou, B., Crielaard, J.-M., & Reginster, J.-Y. (1999). Advocado/soybean unsaponifiable mixture increased high molecular weight proteoglycans synthesis by human articular chondrocytes. Annals of Rheumatoid Arthritis, 230, 963. Peer reviewed |
 | Gabriel, A., Detilleux, J., Jolly, S., Reginster, J.-Y., Collin, B., & Dessy, C. (January 1999). Morphometrical study of the equine navicular bone: age-related changes and influence of exercise. Veterinary Research Communications, 23 (1), 15-40. doi:10.1023/A:1006102921304 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1999). Fluoride for the treatment of osteoporosis. Annals of Internal Medicine, 130, 240-241. doi:10.7326/0003-4819-130-3-199902020-00011 Peer Reviewed verified by ORBi |
Reginster, J.-Y., & Henrotin, Y. (1999). New Therapeutic options. Bone Depeche, 5, 95-101. Peer reviewed |
 | Reginster, J.-Y., Kuntz, D., Verdickt, W., Franssen, M., Guillevin, L., Menkes, C. J., & Nielsen, K. (1999). Prophylactic Use of Alfacalcidol in Corticosteroid-Induced Osteoporosis. Osteoporosis International, 9 (1), 75-81. doi:10.1007/s001980050118 Peer Reviewed verified by ORBi |
 | Henrotin, Y., Labasse, A. H., Simonis, P. E., Zheng, S. X., Dupont, G., Famaey, J. P., Crielaard, J.-M., & Reginster, J.-Y. (1999). Effects of Nimesulide and Sodium Diclofenac on Interleukin-6, Interleukin-8, Proteoglycans and Prostaglandin E2 Production by Human Articular Chondrocytes in Vitro. Clinical and Experimental Rheumatology, 17 (2), 151-60. Peer Reviewed verified by ORBi |
Henrotin, Y., Zheng, S., Labasse, A., Dupont, G., Crielaard, J.-M., & Reginster, J.-Y. (1999). In vitro effects of recombinant human interferon on basal and IL-1bêta stimulated stomelysin, proteoglycans, cytokines (IL-6, IL-8, IL-10), nitric oxide and IL-1ra. Osteoarthritis and Cartilage, 7 (SA), 31. Peer Reviewed verified by ORBi |
Reginster, J.-Y. (1999). L’utilisation du fluor dans la thérapeutique de l’ostéoporose. Synoviale, 81, 7-8. Peer reviewed |
 | Reginster, J.-Y., Halkin, V., Henrotin, Y., & Gosset, C. (1999). Treatment of Osteoporosis: Role of Bone-Forming Agents. Osteoporosis International, 9 Suppl 2, 91-6. doi:10.1007/PL00004167 Peer Reviewed verified by ORBi |
Slosman, D., Provedini, D., Meunier, P., Delmas, P., Sebert, J., Vernejoul, M., Tsouderos, Y., & Reginster, J.-Y. (1999). The use of different dual X-ray absorptiometry brands in a multicenter clinical trial. Journal of Clinical Densitometry, 2, 37-44. doi:10.1385/JCD:2:1:37 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Deroisy, R., Pirenne, H., Frederick, I., Dewé, W., Albert, A., Collette, J., Zheng, S. X., & Gosset, C. (1999). High Prevalence of Low Femoral Bone Mineral Density in Elderly Women Living in Nursing Homes or Community-Dwelling: A Plausible Role of Increased Parathyroid Hormone Secretion. Osteoporosis International, 9 (2), 121-8. doi:10.1007/s001980050124 Peer Reviewed verified by ORBi |
Fogelman, I., Ribot, C., Smith, R., Bettica, P., Pack, S., Ethgen, D., & Reginster, J.-Y. (1999). Risedronate produces dose-dependent increases in bone mineral density in postmenopausal women with low bone mass. Calcified Tissue International, 64 (S1), 69. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1999). Bisphosphonates in the prevention and treatment of osteoporosis : state of the art. Climacteric: the Journal of the International Menopause Society, 2 (S12-5), 43. Peer Reviewed verified by ORBi |
 | Goemaere, S., Zegels, B., Toye, K., CREMERS, S., Demuynck, R., Daems, M., Dobbelaere, K., Ben Sedrine, W., Albert, A., Dewé, W., Kaufman, J., & Reginster, J.-Y. (1999). Limited clinical utility of a self-evaluating risk assessment scale for postmenopausal osteoporosis: lack of predictive value of lifestyle-related factors. Calcified Tissue International, 65 (5), 354-358. doi:10.1007/s002239900712 Peer Reviewed verified by ORBi |
De Leval, X., Dogne, J., Neven, P., Labasse, A., Delarge, J., Reginster, J.-Y., & Henrotin, Y. (1999). Effects of nimesulide and indomethacin on cyclooxygenaxse-1 and 2 : a comparative study. Osteoarthritis and Cartilage, 7 (SA), 32. Peer Reviewed verified by ORBi |
Delmas, P., Ensrud, K., Harris, S., Pols, H., Recker, R., Reginster, J.-Y., Adachi, J., Eastell, R., Gennari, C., Bjarnason, N., Mitlak, B., Knickerbocker, R., Black, D., & Genant, H. (1999). Raloxifene therapy for 3 years reduces the risk of incident vertebral fractures in postmenopausal women. Calcified Tissue International, 64 (S1), 43. Peer Reviewed verified by ORBi |
 | Lips, P., Cooper, C., Agnusdei, D., Caulin, F., Egger, P., Johnell, O., Kanis, J., Kellingray, S., Leplege, A., Liberman, U., McCloskey, E., Minne, H., Reeve, J., Reginster, J.-Y., Scholz, M., Todd, C., de Vernejoul, M., & Wiklung, I. (1999). Quality of life in patients with vertebral fractures : validation of the quality of life questionnaire of the European Foundation for Osteoporosis. (QUALEFFO). Osteoporosis International, 10, 150-160. doi:10.1007/s001980050210 Peer Reviewed verified by ORBi |
 | Gillet, P., & Reginster, J.-Y. (1999). Increased number of hip fractures. The Lancet, 353 (9170), 2160-1. doi:10.1016/S0140-6736(05)75601-4 Peer Reviewed verified by ORBi |
Croisier, J.-L., Henrotin, Y., Dumont, R., Huskin, J.-P., Dubuc, J. E., Leflot, J. P., Reginster, J.-Y., & Crielaard, J.-M. (December 1998). Gonarthrose: intérêt de l'évaluation isocinétique. Kiné 2000 : Revue Européenne de la Kinésitherapie, 9 (98/5), 90. |
Gabriel, A., Jolly, S., Detilleux, J., Dessy, C., Collin, B., & Reginster, J.-Y. (November 1998). Morphometric Study of the Equine Navicular Bone: Variations with Breeds and Types of Horse and Influence of Exercise. Journal of Anatomy, 193 ((Pt 4)), 535-49. doi:10.1017/S0021878298004117 Peer Reviewed verified by ORBi |
 | Halkin, V., & Reginster, J.-Y. (October 1998). Efficacy and Tolerability of Calcitonin in the Prevention and Treatment of Osteoporosis. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, 10 (4), 295-300. doi:10.2165/00063030-199810040-00004 Peer Reviewed verified by ORBi |
 | Henrotin, Y., Zheng, S. X., Dupont, G., Labasse, A. H., Crielaard, J.-M., & Reginster, J.-Y. (August 1998). Nitric Oxide Downregulates Interleukin 1β (IL-1β) Stimulated IL-6, IL-8, and Prostaglandin E2 Production by Human Chondrocytes. Journal of Rheumatology, 25 (8), 1595-601. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Meurmans, L., Zegels, B., Rovati, L. C., Minne, H. W., Giacovelli, G., Taquet, A. N., Setnikar, I., Collette, J., & Gosset, C. (01 July 1998). The Effect of Sodium Monofluorophosphate Plus Calcium on Vertebral Fracture Rate in Postmenopausal Women with Moderate Osteoporosis. A Randomized, Controlled Trial. Annals of Internal Medicine, 129 (1), 1-8. doi:10.7326/0003-4819-129-1-199807010-00001 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Taquet, A. N., & Gosset, C. (June 1998). Therapy for Osteoporosis. Miscellaneous and Experimental Agents. Endocrinology and Metabolism Clinics of North America, 27 (2), 453-63. doi:10.1016/S0889-8529(05)70016-5 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Paul, I., & Gosset, C. (1998). Current Status of fluoride salts to treat postmenopausal osteoporosis. Current Opinion in Orthopaedics, 9 (V), 7-10. doi:10.1097/00001433-199810000-00002 Peer Reviewed verified by ORBi |
Henrotin, Y., Zheng, S., Dupont, G., Labasse, A., Simonis, P., Crielaard, J.-M., & Reginster, J.-Y. (1998). L’INF gamma est un inhibiteur puissant de la synthèse d’IL-8 par les chondrocytes humains. Revue du Rhumatisme, 11, 744. Peer Reviewed verified by ORBi |
Henrotin, Y., Zheng, S., Dupont, G., Labasse, A., Simonis, P., Crielaard, J.-M., & Reginster, J.-Y. (1998). IFN gamma inhibits IL-8 production by IL-1bêta and TNFalpha stimulated human chondrocytes. Revue du Rhumatisme, 11, 668. Peer Reviewed verified by ORBi |
Henrotin, Y., Zheng, S., Dupont, G., Labasse, A., Simonis, P., Crielaard, J.-M., & Reginster, J.-Y. (1998). Effets du monoxyde d’azote (NO) sur le métabolisme des chondrocytes. Revue du Rhumatisme, 11, 742. Peer Reviewed verified by ORBi |
Henrotin, Y., Labasse, A., Zheng, S., & Reginster, J.-Y. (1998). In vitro models for the study of cartilage damage and repair. Rheumatology in Europe, 27 (S2), 7. Peer reviewed |
Reginster, J.-Y. (1998). Which test for which patient ? Osteoporosis International, 8 (S3), 152. Peer Reviewed verified by ORBi |
 | DEROISY, R., Collette, J., Chevalier, T., Breuil, V., & Reginster, J.-Y. (1998). Effects of two 1-year calcium and vitamin D3 treatments on bone remodeling markers and femoral bone density in elderly women. Current Therapeutic Research, 59 (12), 850-862. doi:10.1016/S0011-393X(98)85050-9 Peer Reviewed verified by ORBi |
Henrotin, Y., Labasse, A., Deloffre, P., Tsouderos, Y., & Reginster, J.-Y. (1998). Regulation of the chondrocyte metabolism by a new divalent strontium salt (S12911). BONE, 23 (S5), 344. Peer Reviewed verified by ORBi |
Reginster, J.-Y. (1998). What is the role of bone forming agents ? Osteoporosis International, 8 (S3), 4. Peer Reviewed verified by ORBi |
 | Gennari, C., & Reginster, J.-Y. (1998). Bisphosphonates and osteoporosis treatment in Italy. Aging Clinical and Experimental Research, 10, 284-294. doi:10.1007/bf03339790 Peer Reviewed verified by ORBi |
 | Henrotin, Y., & Reginster, J.-Y. (1998). Le cartilage articulaire peut-il se régénérer ? (2ème partie). Le Généraliste, 415, 11. Peer reviewed |
 | Henrotin, Y., & Reginster, J.-Y. (1998). Le cartilage articulaire peut-il se régénérer ? (1ère partie). Le Généraliste, 414, 31. Peer reviewed |
 | Reginster, J.-Y., Dethor, M., Pirenne, H., Dewé, W., & Albert, A. (1998). Reproducibility and diagnostic sensitivity of ultrasonometry of the phalanges to assess osteoporosis. International Journal of Gynecology and Obstetrics, 63 (1), 21-8. doi:10.1016/S0020-7292(98)00113-1 Peer Reviewed verified by ORBi |
DEROISY, R., Taquet, A., Dewe, W., Albert, A., Collette, J., Gosset, C., & Reginster, J.-Y. (1998). Parathyroid hormone plasma concentration in response to low 25-OH vitamin D circulating levels increase with age in elderly women. Osteoporosis International, 8 (S3), 40. Peer Reviewed verified by ORBi |
Ensrud, K., Black, D., Recker, R., Harris, S., Delmas, P., Pols, H., Reginster, J.-Y., Bjarnason, N., Gennari, C., Gennant, H., Knickerbocker, R., Eastell, R., Adachi, J., & Mitlak, B. (1998). The effect of 2 and 3 years of Raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis. BONE, 23 (S5), 174. Peer Reviewed verified by ORBi |
Slosman, D., Milsztain, N., Perron, C., Meunier, P., Reginster, J.-Y., & Tupinon, I. (1998). DXA parameters related to internal reference system as predictors of an in vivo variability of BMD measurement from a study on 3808 patients involving 75 centres. Osteoporosis International, 8 (S3), 64. Peer Reviewed verified by ORBi |
Ben Sedrine, W., Reginster, J.-Y., Radican, L., & de Froidmont, C. (1998). Assessment of osteoporosis disease burden in countries currently lacking such studies. BONE, 23 (S5), 306. Peer Reviewed verified by ORBi |
Slosman, D., Alekxandrova, I., Billet, J., Allaoua, S., Lemmon, J., Meunier, P., Reginster, J.-Y., & Provvedini, D. (1998). The Bland and Altman method adapted to quality control of dual-energy X-ray absorptiometry. Osteoporosis International, 8 (S3), 64. Peer Reviewed verified by ORBi |
Reginster, J.-Y. (1998). New evidence for the fracture-reducing effectiveness of monofluorophosphate: practical implications. Osteoporosis International, 8 (S3), 148. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Roux, C., Jupsin, I., Provvedini, D., Birman, P., & Tsouderos, Y. (1998). Strontium Ranelate for the prevention of bone loss of early postmenopause. Clinical Rheumatology, 17 (10), 431. Peer Reviewed verified by ORBi |
 | Russell, A., Recart, S., Reginster, J.-Y., & Arinoviche, R. (1998). Minimum standards in diagnosis and treatment of osteoporosis. Journal of Rheumatology, 25 (8), 1634-1637. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Labasse, A. H., Jaspar, J. M., De Groote, D. D., Zheng, S. X., Guillou, G. B., & Reginster, J.-Y. (1998). Effects of three avocado/soybean unsaponifiable mixtures on metalloproteinases, cytokines and prostaglandin E2 production by human articular chondrocytes. Clinical Rheumatology, 17 (1), 31-9. doi:10.1007/BF01450955 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Ben Sedrine, W., & Gosset, C. (1998). Les thérapeutiques à visée spécifiquement osseuse dans le traitement de l'ostéoporose postménopausique. Aspects pharmaco-économiques. Revue Médicale de Liège, 53 (5), 290-293. Peer reviewed |
 | Lemmel, E., Reid, D., Nuki, G., Avouac, B., Bardin, T., Bouvenot, G., Van Cauwenberge, H., Cluzel, M., Devogelaer, J., Duff, G., Emery, P., Ethgen, D., Kreutz, G., Menkes, C., Reidel, H., Serni, U., Van der Auwera, P., White-Guay, B., & Reginster, J.-Y. (1998). Recommendations for the registration of drugs used in the treatment of rheumatoid arthritis. British Journal of Rheumatology, 37, 211-215. Peer Reviewed verified by ORBi |
Henrotin, Y., Zheng, S., Dupont, G., Labasse, A., Crielaard, J.-M., & Reginster, J.-Y. (1998). Regulatory role of nitric acid (NO) in chondrocyte responses to cytokines. BONE, 23 (S5), 344. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Avouac, B., & Gosset, C. (1998). Regulatory requirements : clinical evaluation of drug therapy. In J.-Y. Reginster, J. P. Pelletier, J. Martel-Pelletier, ... Y. Henrotin, Experimental and Clinical Aspects of Osteoarthritis (pp. 421-430). New-York, United States: Springer Publ. |
Slosman, D., Milsztajn, N., Billet, J., Reginster, J.-Y., Provvedini, D., Tupinon, I., & Meunier, P. (1998). Centralized quality management of bone densitometry for clinical trial and private practice: The use of ISO standard by GECAP (Geneva Quality Assessment Program). BONE, 23 (S5), 409. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Roux, C., Jupsin, I., Provvedini, D., Birman, P., & Tsouderos, Y. (1998). Strontium Ranelate for the prevention of bone loss of early postmenopause. Osteoporosis International, 8 (S3), 12. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Roux, C., Christiansen, C., Rouillon, A., & Tiou, C. (1998). Intermittent cyclical low dose tiludronate in treatment of postmenopausal osteoporosis. Report of two phase III European studies (2305 patients). BONE, 23 (S5), 594. Peer Reviewed verified by ORBi |
Caudron, I., Henrotin, Y., Reginster, J.-Y., & Serteyn, D. (1998). Computerised method to measure asymetrical articular compression on digitised X-rays. In Rivista SIDI Proceedings 5th WEVA Congress (1st part) (pp. 47-52). Ed. Peer reviewed |
Abraham, I., Borgermans, L., de Froidmont, C., Dejace, A., Englebert, L., Gosset, C., Hogge, Y., Indenkleef, S., Milisen, K., Moons, P., Reginster, J.-Y., Rondal, P., Steeman, E., & Wouters, B. (1998). Case management : pilootproject case management in Belgische ziekenhuizen. [Case management : pilot study on case management in Belgian hospitals]. Summarizing report, 1998. SFP. |
Abraham, I., Borgermans, L., de Froidmont, C., Dejace, A., Englebert, L., Gosset, C., Hogge, Y., Indenkleef, S., Milisen, K., Moons, P., Reginster, J.-Y., Rondal, P., Steeman, E., & Wouters, B. (1998). Case management : pilootproject case management in Belgische ziekenhuizen. [Case management : pilot study on case management in Belgian hospitals] . Final report, 1998. SFP. |
Deroisy, R., Collette, J., Dewe, W., Albert, A., Gosset, C., & Reginster, J.-Y. (1998). Increased parathyroïd hormone secretions as a risk factor for femoral osteoporosis in elderly women. Osteoporosis International, 8 (S3), 40. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Gosset, C., & Fraikin, G. (1998). Biophosphonates for the treatment of osteoporosis. In Osteoporosis : Diagnosis and management (pp. 13-130). London, United Kingdom: Meunier P.J. Ed., Dunitz M. Publ. |
 | Reginster, J.-Y., Frederick, I., Deroisy, R., Dewe, W., Taquet, A. N., Albert, A., Collette, J., Pirenne, H., Zheng, S. X., & Gosset, C. (1998). Parathyroid hormone plasma concentrations in response to low 25-OH vitamin D circulating levels increases with age in elderly women. Osteoporosis International, 8 (4), 390-2. doi:10.1007/s001980050080 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Roux, C., Tsouderos, Y., & Jupsin, I. (1998). Role of the Strontium Ranelate in the prevention of early postmenopausal bone loss : a double-blind, prospective, randomized, placebo-controlled study. Arthritis and Rheumatism, 41, 129. Peer Reviewed verified by ORBi |
 | Stevenson, J., GASPARD, U., Avouac, B., Bricaire, C., Cardozo, L., Collins, P., Devogelaer, J., Dören, M., Gennari, C., Kaufman, J., Kuttenn, F., Ringe, J., Scarafiotti, C., Vanhaelst, L., Zichella, L., Ziegler, R., & Reginster, J.-Y. (1998). Points to consider for the development of new indications for hormone replacement therapies and estrogen-like molecules. Climacteric: the Journal of the International Menopause Society, 1, 12-17. doi:10.3109/13697139809080676 Peer Reviewed verified by ORBi |
 | DEROISY, R., Collette, J., Albert, A., Leber, C., Micheletti, M., Zartarian, M., & Reginster, J.-Y. (1998). Comparison of the short-term effects of three oral calcium vitamin D formulations and placebo on calcium metabolism. Current Therapeutic Research, 59 (6), 370-378. doi:10.1016/S0011-393X(98)85039-X Peer Reviewed verified by ORBi |
 | Meunier, P., Sebert, J., Reginster, J.-Y., Briancon, D., Appelboom, T., Netter, P., Loeb, G., Rouillon, A., Barry, S., Evreux, J., Avouac, B., & Marchandise, X. (1998). Fluoride salts are no better prevention at preventing new vertebral fractures than calcium-vitamine D in postmenopausal osteoporosis : the FAVOStudy. Osteoporosis International, 8, 4-12. Peer Reviewed verified by ORBi |
 | Dere, W., Avouac, B., Boers, M., Buxton, M., Christiansen, C., Dawson, A., Gennari, C., Guillemin, F., Lawets, H., Ornskov, F., Roumagnac, I., & Reginster, J.-Y. (1998). Recommendations for the health economic analysis to be performed with a drug to be registered in prevention or treatment of osteoporosis. Calcified Tissue International, 63, 93-97. Peer Reviewed verified by ORBi |
Henrotin, Y., & Reginster, J.-Y. (1998). Le cartilage articulaire peut-il se régénérer ? Journal du Médecin (Le), 1129, 33. Peer reviewed |
Henrotin, Y., Zheng, S., Dupont, G., Labasse, A., Simonis, P., Crielaard, J.-M., & Reginster, J.-Y. (1998). Nitric oxid (NO) down-regulates cytokines and PGE2 production by human chondrocytes. Revue du Rhumatisme, 11, 667. Peer Reviewed verified by ORBi |
Henrotin, Y., Croisier, J.-L., Dumont, R., Huskin, J.-P., Dubuc, J. E., Leflot, J. P., Reginster, J.-Y., & Crielaard, J.-M. (November 1997). Isokinetic testing of knee musculature in patient with unilateral gonarthrosis. Revue du Rhumatisme, 11, 740. Peer Reviewed verified by ORBi |
Henrotin, Y., Croisier, J.-L., Dumont, R., Huskin, J.-P., Dubuc, J. E., Leflot, J. P., Reginster, J.-Y., & Crielaard, J.-M. (November 1997). Evaluation isocinétique concentrique du genou chez le patient gonarthrosique. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 11, 850. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Albert, A., Deroisy, R., Collette, J., Vrijens, B., Blacker, C., Brion, N., Caulin, F., Mayolle, C., Regnard, A., Scholler, R., & Franchimont, P. (June 1997). Plasma Estradiol Concentrations and Pharmacokinetics Following Transdermal Application of Menorest 50 or Systen (Evorel) 50. Maturitas, 27 (2), 179-86. doi:10.1016/S0378-5122(97)00027-3 Peer Reviewed verified by ORBi |
 | Deroisy, R., Zartarian, M., Meurmans, L., Nelissenne, N., Micheletti, M. C., Albert, A., & Reginster, J.-Y. (May 1997). Acute Changes in Serum Calcium and Parathyroid Hormone Circulating Levels Induced by the Oral Intake of Five Currently Available Calcium Salts in Healthy Male Volunteers. Clinical Rheumatology, 16 (3), 249-53. doi:10.1007/BF02238959 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (April 1997). Comment je traite ... L'ostéoporose sénile. Revue Médicale de Liège, 52 (4), 267-9. Peer reviewed |
 | Reginster, J.-Y., Deroisy, R., Collette, J., Albert, A., & Zegels, B. (March 1997). Prediction of Bone Loss Rate in Healthy Postmenopausal Women. Calcified Tissue International, 60 (3), 261-4. doi:10.1007/s002239900226 Peer Reviewed verified by ORBi |
 | Halkin, V., Francotte-Lempereur, N., Debrun, A., & Reginster, J.-Y. (March 1997). Le cas clinique du mois. Ostéoporose et beta-thalassémie. Revue Médicale de Liège, 52 (3), 138-41. Peer reviewed |
Gosset, C., De Prins, L., Tellier, V., Cartier, P., Heyerick, P., Devos, M., Dhooghe, E., De Maeseneer, J., & Reginster, J.-Y. (1997). Fidélité du patient au médecin généraliste et consommation des soins de santé : une approche multivariée. Dans le cadre du projet “ Dossier médical ” de l’I.N.A.M.I., Rapport final de synthèse. |
 | Henrotin, Y., Zheng, X., Dupont, G., Labasse, A., Crielaard, J.-M., & Reginster, J.-Y. (1997). Régulation de la synthèse de cytokines pro-inflammatoires par l’oxyde nitrique (NO). Revue du Rhumatisme, 64 (11), 763. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Deroisy, R., Zegels, B., Denis, D., Reginster-Haneuse, G., Wilkin, P., Taziaux, P., Albert, A., & Boelen, C. (1997). Prévention de l'ostéoporose à Liège. Evaluation d'un essai de partenariat entre médecins généralistes et spécialistes universitaires (1). Revue Médicale de Liège, 52 (1), 31-36. Peer reviewed |
Henrotin, Y., Labasse, A., Zheng, S., De Groote, D., Jaspar, J., Guillou, B., & Reginster, J.-Y. (1997). The effect of avocado and soybean unsaponifiables on freshly isolated human articular chondrocytes. Rheumatology in Europe, 26 (S2), 280. Peer reviewed |
 | Meunier, P., Slosman, D., Delmas, P., Sebert, J., Albanese, C., Brandi, M., Lorenc, R., Beck-Jensen, J., de Vernejoul, M., Provvedini, D., Tsouderos, Y., & Reginster, J.-Y. (1997). Strontium ranelate as a treatment of vertebral osteoporosis. Journal of Bone and Mineral Research, 12 (S1), 129. Peer Reviewed verified by ORBi |
 | Glüer, C., & Reginster, J.-Y. (1997). Quantitative ultrasound techniques for the assessment of osteoporosis : Expert agreement on current status. Journal of Bone and Mineral Research, 12 (8), 1280-1288. doi:10.1359/jbmr.1997.12.8.1280 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Kuntz, D., Verdickt, W., Wouters, M., Guillevin, L., Menkes, C., & Rawlinson, D. (1997). Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. BONE, 20, 9. Peer Reviewed verified by ORBi |
 | Kaufman, J., Devogelaer, J., Raeman, F., Rozenberg, S., Body, J., Westhovens, R., & Reginster, J.-Y. (1997). Prevention and treatment of postmenopausal osteoporosis. National consensus of the Belgian Bone Club". Clinical Rheumatology, 16 (4), 343-345. doi:10.1007/BF02242449 Peer Reviewed verified by ORBi |
 | Ethgen, O., Ethgen, D., Guillemin, F., & Reginster, J.-Y. (1997). Comparative analysis of healthcare use in patients with rheumatoid arthritis and control subjects without chronic disease. Calcified Tissue International, 61, 510. Peer Reviewed verified by ORBi |
 | Gillet, P., Gosset, C., & Reginster, J.-Y. (1997). Osteoporosis : The interest of a prospective vision. Calcified Tissue International, 61, 499. Peer Reviewed verified by ORBi |
 | Lequesne, M., Fannius, J., Reginster, J.-Y., Verdickt, W., & Vincent du Laurier, M. (1997). Essai comparatif de deux antalgiques, la floctafénine et le paracétamol, au cours de l’arthrose des membres inférieurs. Revue du Rhumatisme, 64 (5), 349-355. Peer Reviewed verified by ORBi |
 | Zheng, S. X., Vrindts-Gevaert, Y., Lopez, M.-J., De Groote, D., Zangerlé, P.-F., Collette, J., Franchimont, N., Geenen, V., Albert, A., & Reginster, J.-Y. (January 1997). Increase in Cytokine Production (Il-1 Beta, Il-6, Tnf-Alpha but Not Ifn-Gamma, Gm-Csf or Lif) by Stimulated Whole Blood Cells in Postmenopausal Osteoporosis. Maturitas, 26 (1), 63-71. doi:10.1016/S0378-5122(96)01080-8 Peer Reviewed verified by ORBi |
 | Henrotin, Y., Zheng, X., Dupont, G., Labasse, A., Crielaard, J.-M., & Reginster, J.-Y. (1997). Modulation of chondrocyte cytokines synthesis by endogeneously produced nitric oxide. Revue du Rhumatisme, 11, 668. Peer Reviewed verified by ORBi |
Henrotin, Y., Zheng, X., Dupont, G., Labasse, A., Degroote, D., Jaspar, J., Crielaard, J.-M., & Reginster, J.-Y. (1997). Modulation of chondrocyte cytokines synthesis by endogeneously produced nitric oxide. Rheumatology in Europe, 26 (S2), 83. Peer reviewed |
| Fledelius, C., Kolding, I., Qvist, P., Bonde, M., Hassager, C., Reginster, J.-Y., Hejgaard, J., Frokiaer, H., & Christiansen, C. (1997). Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide 1 chain of type I collagen. Application in an enzyme immunoassay and comparison to Crosslaps TM Elisa. Scandinavian Journal of Clinical and Laboratory Investigation, 57, 73-83. doi:10.1080/00365519709057821 Peer Reviewed verified by ORBi |
 | Henrotin, Y., Labasse, A., Zheng, S., Guillou, B., & Reginster, J.-Y. (1997). Etude in vitro des effets des résidus insaponifiables d’avocat et de soja (IAS) sur le métabolisme des chondrocytes humains. Revue du Rhumatisme, 64 (11), 822. Peer Reviewed verified by ORBi |
Lequesne, M., Fannius, J., Reginster, J.-Y., Verdickt, W., & Vincent du Laurier, M. (1997). Floctafenin versus acetaminophen for pain control in patients with osteoarthritis in the lower limbs. Revue du Rhumatisme, 64 (5), 327-333. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Gennari, C., Hosking, D., Ringe, J., & Meunier, P. (1997). Pour l’optimisation de la stratégie thérapeutique dans la maladie osseuse de Paget. Revue du Rhumatisme, 64 (4), 221-223. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Gennari, C., Hosking, D., Ringe, J., & Meunier, P. (1997). Optimizing the treatment of Paget’s disease of bone. Revue du Rhumatisme, 64 (4), 207-209. Peer Reviewed verified by ORBi |
Reginster, J.-Y. (1997). Prévention de l’ostéoporose. Medi-Sphere, 6, 7-11. |
Devogelaer, J., Reginster, J.-Y., Raeman, F., Westhovens, R., Rozenberg, S., Body, J., & Kaufman, J. (1997). Diagnostic de l'ostéoporose. Medipractice, 21, 13-48. Peer reviewed |
 | Henrotin, Y., Labasse, A., Zheng, S., Guillou, B., & Reginster, J.-Y. (1997). The effect of avocado and soybean unsaponifiables on freshly isolated human articular chondrocytes. Revue du Rhumatisme, 11, 718. Peer Reviewed verified by ORBi |
Henrotin, Y., Famaey, J., Labasse, A., Zheng, X., Simonis, P., Crielaard, J.-M., & Reginster, J.-Y. (1997). Nimesulide, a novel NSAID of the sulfonanilide class, inhibits PGE2 production by human chondrocytes without affecting proteoglycans synthesis. Rheumatology in Europe, 26 (S2), 170. Peer reviewed |
 | Devogelaer, J., Reginster, J.-Y., Raeman, F., Westhovens, R., Rozenberg, S., Body, J., & Kaufman, J. (1997). Gezonheidszorg : actuele standpunten. Diagnostiek van osteoporose. Tijdschrift voor Geneeskunde, 53 (10), 639-645. Peer Reviewed verified by ORBi |
 | Goemaere, S., Zegels, B., Toye, K., Cremer, S., Demuynck, R., Vanheusden, E., Albert, A., Dewe, W., Kaufman, J., & Reginster, J.-Y. (1997). Diagnostic efficiency of a self-evaluating risk assessment for postmenopausal osteoporosis. Calcified Tissue International, 61, 502. Peer Reviewed verified by ORBi |
 | Lips, P., Cooper, C., Agnusdei, D., Caulin, F., Egger, P., Johnell, O., Kanis, J., Liberman, U., Minne, H., Reeve, J., Reginster, J.-Y., de Vernejoul, M., & Wiklund, I. (1997). Quality of life as outcome in the treatment of osteoporosis : The development of a questionnaire for quality of life by the European Foundation for Osteoporosis. Osteoporosis International, 7, 36-38. doi:10.1007/BF01623457 Peer Reviewed verified by ORBi |
 | Gillet, P., Gosset, C., & Reginster, J.-Y. (1997). Direct social costs of Osteoporotice hip fractures in Belgium. Calcified Tissue International, 61, 499. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Taquet, A. N., Fraikin, G., Gosset, C., & Zegels, B. (1997). Parathyroid hormone in the treatment of involutional osteoporosis : back to the future. Osteoporosis International, 7 (Suppl 3), 163-8. doi:10.1007/BF03194365 Peer Reviewed verified by ORBi |
Gosset, C., De Prins, L., Tellier, V., Heyerick, P., De Maeseneer, J., & Reginster, J.-Y. (1997). Fidélité du patient au médecin généraliste et consommation des soins de santé : une approche multivariée. Dans le cadre du projet “ Dossier médical ” de l’I.N.A.M.I., Rapport technique. |
De Spiegelaere, M., Gosset, C., Vandenbusshe, P., Tonglet, R., Hennart, P., & Reginster, J.-Y. (1997). Etude de l’applicabilité de la démarche de Santé communautaire aux structures de prévention de l’O.N.E. |
Reginster, J.-Y., Halkin, V., Gosset, C., & Deroisy, R. (1997). The role of bisphosphonates in the treatment of osteoporosis. Drugs of Today, 33, 563-570. Peer reviewed |
 | Reginster, J.-Y., Bufalino, L., Christiansen, C., Devogelaer, J. P., Gennari, C., Riis, B. J., & Roux, C. (1997). Design for an Ipriflavone Multicenter European Fracture Study. Calcified Tissue International, 61 (Suppl 1), 28-32. doi:10.1007/s002239900382 Peer Reviewed verified by ORBi |
 | Clemmesen, B., Ravn, P., Zegels, B., Taquet, A., Christiansen, C., & Reginster, J.-Y. (1997). A 2-year phase II study with 1-year of follow-up of risedronate (NE58095) in postmenopausal osteoporosis. Osteoporosis International, 7, 488-495. doi:10.1007/PL00004152 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1997). Lecture critique d’un essai thérapeutique. Revue du Rhumatisme, 64 (3), 84-86. Peer Reviewed verified by ORBi |
Gosset, C., Tellier, V., De Prins, L., Cartier, P., De Maeseneer, J., & Reginster, J.-Y. (1997). Drug consumption in a Belgian subpopulation of peaple older than 45 years [Paper presentation]. 5ème Symposium de la Santé Publique, Bruxelles, Belgium. |
 | Reginster, J.-Y. (January 1997). Calcitonine et vieillissement osseux. Pathologie Biologie, 45 (1), 52-6. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Meurmans, L., Zegels, B., Rovati, L., Minne, H., Giacovelli, G., Taquet, A., Setnikar, I., & Collette, J. (1997). Sodium monofluorophosphate reduces vertebral fractures in moderate postmenopausal osteoporosis. Journal of Bone and Mineral Research, 12 (S1), 104. Peer Reviewed verified by ORBi |
 | Goemaere, S., Zegels, B., Toye, K., Cremer, S., Demuynck, R., Vanheusden, E., Albert, A., Dewe, W., Kaufman, J., & Reginster, J.-Y. (1997). Diagnosis efficiency of a self-evaluating risk assessment for postmenopausal osteoporosis. Journal of Bone and Mineral Research, 12 (S1), 495. Peer Reviewed verified by ORBi |
Henrotin, Y., Labasse, A., Zheng, S., Guillou, B., & Reginster, J.-Y. (1997). The effect of avocado and soybean unsaponifiables on freshly isolated human articular chondrocytes. Arthritis and Rheumatism, 40 (S9), 89. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Dethor, M., Pirenne, H., Dewe, W., & Albert, A. (1997). Analytical performance and diagnostic efficiency of quantitative ultrasonography of the phalanxes. Journal of Bone and Mineral Research, 12 (S1), 384. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (January 1997). Miscellaneous and Experimental Agents. American Journal of the Medical Sciences, 313 (1), 33-40. doi:10.1097/00000441-199701000-00006 Peer Reviewed verified by ORBi |
 | Henrotin, Y., Labasse, A., Degroote, D., Zheng, X., Simonis, P., Roma, J., Crasborn, L., Crielaard, J.-M., & Reginster, J.-Y. (1997). In vitro study on the effects of aceclofenac on proteoglycan and type II collagen production by human chondrocytes. Osteoarthritis and Cartilage, 5, 61. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Labasse, A., Degroote, D., Zheng, X., Simonis, P., Roma, J., Crasborn, L., Crielaard, J.-M., & Reginster, J.-Y. (1997). In vitro effects of aceclofenac on cytokines (IL-6, IL-8, LIF) and PGE2 production by human chondrocytes. Osteoarthritis and Cartilage, 5, 30. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Labasse, A., Zheng, X., Simonis, P., Deloffre, P., Tsouderos, Y., Crielaard, J.-M., & Reginster, J.-Y. (1997). IGF-1 but not IL-1bêta effects on the proteoglycan production by chondrocytes are regulated by strontium salts. Osteoarthritis and Cartilage, 5, 30. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Labasse, A., Zheng, X., Simonis, P., Deloffre, P., Tsouderos, Y., Crielaard, J.-M., & Reginster, J.-Y. (1997). S12911, a new divalent strontium salt increases cartilage matrix formation. Osteoarthritis and Cartilage, 5, 61. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Compston, J. (1997). GREES recommendations for the Registration of new drugs in the prevention and treatment of osteoporosis. Calcified Tissue International, 60, 488. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Zartarian, M., & Colau, J. C. (November 1996). Influence de l'association du nomegestrol acetate sur l'amélioration de la qualité de vie induite par une estrogenotherapie chez la femme ménopausée. Contraception, Fertilite, Sexualité, 24 (11), 847-51. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (October 1996). Prévention de l'ostéoporose postménopausique: œstrogènes et thérapeutiques non hormonales. Revue Médicale de Liège, 51 (10), 649-53. Peer reviewed |
 | Bassleer, C., Franchimont, P., Henrotin, Y., Franchimont, N., Geenen, V., & Reginster, J.-Y. (March 1996). Effects of Ipriflavone and Its Metabolites on Human Articular Chondrocytes Cultivated in Clusters. Osteoarthritis and Cartilage, 4, 1-8. doi:10.1016/S1063-4584(96)80002-1 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1996). Calcitonin. Current Opinion in Orthopaedics, 7, 31-34. doi:10.1097/00001433-199610000-00007 Peer Reviewed verified by ORBi |
 | Deroisy, R., Pirenne, H., FREDERICK, I., Zegels, B., Taquet, A., Noel, V., Albert, A., & Reginster, J.-Y. (1996). Densité osseuse fémorale et carence vitaminique D dans une population de femmes âgées. Archives of Public Health, 53 (S1), 37. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (January 1996). Les bisphosphonates. Revue Médicale de Liège, 51 (1), 120-2. Peer reviewed |
 | DEROISY, R., Zheng, X., Pirenne, H., Frederick, I., COLLETTE, J., & Reginster, J.-Y. (1996). 25-OH vitamin D deficiencies and secondary hyperparathyroidism in elderly women living at home or in nursing/retirement homes. Osteoporosis International, 6 (S1), 119. Peer Reviewed verified by ORBi |
 | Zheng, S., Geenen, V., Vrindts, Y., Lopez, M., De Groote, D., Zangerlé, P.-F., COLLETTE, J., & Reginster, J.-Y. (1996). Increase in IL-1bêta, IL-6, and TNF-alpha production in postmenopausal osteoporosis. Osteoporosis International, 6 (S1), 101. Peer Reviewed verified by ORBi |
 | Meunier, P., Sebert, J., Reginster, J.-Y., Avouac, B., Briancon, D., Fauquert, P., Appelboom, T., Netter, P., Loeb, G., Rouillon, A., & Barry, S. (1996). Fluoride salts compared to calcium-vitamin D in the treatment of established osteoporosis: The FAVOS study. Osteoporosis International, 6 (S1), 251. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Labasse, A., Zheng, S., De Groote, D., Jaspar, J., Guillou, B., & Reginster, J.-Y. (1996). Effects of three avocado/soybean unsaponifiable mixtures on human chondrocytes metabolism. Arthritis and Rheumatism, 39, 226. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1996). Treatment of bone in elderly subjects: calcium, vitamine D, fluor, bisphosphonates, calcitonin. Hormone Research, 45, 301. Peer Reviewed verified by ORBi |
 | Roux, C., DEROISY, R., Basse-Cathalinat, B., Combe, B., Geusens, P., Meunier, P., Ribot, C., Rossi, M., Sebert, J., Bonvoisin, B., Listrat, V., & Reginster, J.-Y. (1996). Prevention of early postmenopausal bone loss with oral tiludronate. Osteoporosis International, 6 (S1), 249. Peer Reviewed verified by ORBi |
 | Taquet, A., Clemmensen, B., Zegels, B., Ravin, P., Christiansen, C., Roumagnac, I., & Reginster, J.-Y. (1996). A three-year double-blind placebo-controlled study of risedronate in postmenopausal osteoporosis. Osteoporosis International, 6 (S1), 262. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Semler, J., Alexandre, C., Body, J., & Appelboom, T. (1996). Analgesic effect of elcatonin in postmenopausal osteoporosis. Osteoporosis International, 6 (S1), 249. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1996). New bisphosphonates for the treatment of osteoporosis : concerns and hopes. Revue du Rhumatisme, 63 (7-8), 461-464. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1996). L’ostéomalacie : étiologie, clinique, physiopathologie et thérapeutique. Le Monde Médical de la Femme, 330 (23), 18-21. Peer reviewed |
 | Henrotin, Y., Labasse, A., Zheng, S., De Groote, D., Jaspar, J., Guillou, B., & Reginster, J.-Y. (1996). Effects of three avocado/soybean unsaponifiable mixtures on metalloproteinases, prostaglandin E2, proteoglycans and cytokines production by human articular chondrocytes. Revue du Rhumatisme, 63, 751. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Labasse, A., Zheng, S., Deloffre, P., Tsouderos, Y., & Reginster, J.-Y. (1996). Effets d’un sel de strontium (S12911) sur le métabolisme des chondrocytes articulaires humains in vitro. Revue du Rhumatisme, 63, 879. Peer Reviewed verified by ORBi |
 | Meurmans, L., Zegels, B., Rovati, L., Taquet, A., & Reginster, J.-Y. (1996). Réduction de l’incidence fracturaire vertébrale chez des femmes ostéoporotiques traitées par monofluorophosphate de sodium : une étude randomisée, placebo-controllée et double aveugle. Revue du Rhumatisme, 63, 788. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Labasse, A., Jaspar, J., De Groote, D., Zheng, S., & Reginster, J.-Y. (1996). Is IL-6 capable to modify chondrocyte metabolism ? Clinical Rheumatology, 15, 539. Peer Reviewed verified by ORBi |
 | Hosking, D., Meunier, P., Ringe, J., Reginster, J.-Y., & Gennari, C. (1996). Paget’s disease of bone : diagnosis and management. BMJ: British Medical Journal, 312, 491-494. doi:10.1136/bmj.312.7029.491 Peer reviewed |
 | Dougados, M., Devogelaer, J., Annefeldt, M., Avouac, B., Bouvenot, G., Cooper, C., Dieppe, P., Ethgen, D., Garattini, S., Jones, E., Kaufman, J., Lemming, M., Lemmel, E., Lohmander, S., Menkes, C., Nuki, G., Paolozzi, L., Pujol, J., Rovati, L., ... Reginster, J.-Y. (1996). Recommendations for registration of drugs used in the treatment of osteoarthritis. Annals of the Rheumatic Diseases, 55, 552-557. doi:10.1136/ard.55.8.552 Peer Reviewed verified by ORBi |
 | Slosman, D., Meunier, P., Delmas, P., Sebert, J., De Vernejoul, M., Provvedini, D., Tsouderos, Y., & Reginster, J.-Y. (1996). The pivotal role of cross-calibration and quality control in an international clinical trial of the strontium salt S-12911 involving multiple DXA brands. Osteoporosis International, 6 (S1), 168. Peer Reviewed verified by ORBi |
 | Compston, J., Audran, M., Avouac, B., Bouvenot, G., Devogelaer, J., Eastell, R., Fabris, F., Gennari, C., Jones, E., Kaufman, J., Lemmel, E., Mazzuoli, G., Reid, D., Ringe, J., Vanhaelst, L., Ziegler, R., & Reginster, J.-Y. (1996). Recommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis. Calcified Tissue International, 59, 323-327. doi:10.1007/s002239900134 Peer Reviewed verified by ORBi |
 | Henrotin, Y., Labasse, A., Zheng, S., De Groote, D., Jaspar, J., Guillou, B., & Reginster, J.-Y. (1996). Comparaison des effets de trois mélanges d’insaponifiables d’avocat et de soja sur le métabolisme des chondrocytes articulaires humains in vitro. Revue du Rhumatisme, 63, 879. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Labasse, A., Zheng, S., Deloffre, P., Tsouderos, Y., & Reginster, J.-Y. (1996). S12911, a new divalent strontium salt stimulates cartilage matrix formation. Revue du Rhumatisme, 63, 751. Peer Reviewed verified by ORBi |
 | Henrotin, Y., De Groote, D. D., Labasse, A. H., Gaspar, S. E., Zheng, S. X., Geenen, V., & Reginster, J.-Y. (1996). Effects of exogenous IL-1 beta, TNF alpha, IL-6, IL-8 and LIF on cytokine production by human articular chondrocytes. Osteoarthritis and Cartilage, 4 (3), 163-73. doi:10.1016/S1063-4584(96)80012-4 Peer Reviewed verified by ORBi |
 | Gillet, P., Reginster-Haneuse, G., & Reginster, J.-Y. (1996). Direct social costs of osteoporotic hip fractures in Belgium. Osteoporosis International, 6 (S1), 119. Peer Reviewed verified by ORBi |
Reginster, J.-Y. (1996). La place des bisphosphonates dans le traitement de l’ostéoporose. Lettre du Rhumatologue, 222, 3-7. Peer reviewed |
Reginster, J.-Y. (1996). Ipriflavone in prevention and treatment of postmenopausal and senile osteoporosis. Osteoporosis News, 4, 1-7. Peer reviewed |
 | Biquet, I., COLLETTE, J., Dauphin, J., Albert, A., Thunus, L., Deby-Dupont, G., & Reginster, J.-Y. (1996). Prevention of postmenopausal bone loss by administration of boron. Osteoporosis International, 6 (S1), 249. Peer Reviewed verified by ORBi |
 | Meunier, P., Slosman, D., Delmas, P., Sebert, J., Albanese, C., Brandi, M., Lorenc, R., Sorensen, O., DeVernejoul, M., Provvedini, D., Tsouderos, Y., & Reginster, J.-Y. (1996). The strontium salt S-12911 : a new candidate for the treatment of osteoporosis. Osteoporosis International, 6 (S1), 241. Peer Reviewed verified by ORBi |
 | Lips, P., Agnusdei, D., Caulin, F., Cooper, C., Johnell, O., Kanis, J., Liberman, U., Minne, H., Reeve, J., Reginster, J.-Y., de Vernejoul, M., & Wiklund, I. (1996). The validation of the EFFO questionnaire for quality of life in patients with vertebral osteoporosis (QUALEFFO). Osteoporosis International, 6 (S1), 227. Peer Reviewed verified by ORBi |
 | DEROISY, R., Zheng, X., Pirenne, H., Frederick, I., & Reginster, J.-Y. (1996). Femoral osteoporosis in community-dwelling elderly females and controls living in retirement or nursing homes. Osteoporosis International, 6 (S1), 118. Peer Reviewed verified by ORBi |
 | Meurmans, L., Zegels, B., Rovati, L., Taquet, A., & Reginster, J.-Y. (1996). Sodium monofluorophosphate reduces fracture incidence in women with postmenopausal osteoporosis : a randomized, placebo-controlled, double-blind study. Revue du Rhumatisme, 63, 672. Peer Reviewed verified by ORBi |
 | Ringe, J., Reginster, J.-Y., Gennari, C., Hosking, D., & Meunier, P. (1996). Richtlinien für eine verbesserte Therapiesstrategie bei Patienten mit Ostitis deformans Paget. Zeitschrift für Rheumatologie, 55, 256-259. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1996). L’ostéoporose en questions : plus dure sera la chute. Stethoscopie Magazine, 63, 19-20. Peer reviewed |
 | Reginster, J.-Y. (1996). Les bisphosphonates constituent-ils un réel progrès thérapeutique dans l’ostéoporose ? Médecine et Hygiène, 54, 1497-1501. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1996). Cost effectiveness of treatment in osteoporosis. Journal of Rheumatology, 23 (7), 1312-1313. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1996). Exercice physique et ostéoporose. Le Monde Médical de la Femme, 309 (15), 25-27. Peer reviewed |
 | Reginster, J.-Y. (1996). Harmonization of clinical practice guidelines for the prevention and treatment of osteoporosis and osteopenia in Europe : a difficult challenge. Calcified Tissue International, 59 (S1), 24-S29. doi:10.1007/s002239900172 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Roux, C., & Riis, B. (1996). Design of IMEPS (Ipriflavone Multicentric European Fracture Study). Osteoporosis International, 6 (S1), 318. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Agnusdei, D., Gennari, C., & Kicovic, P. (1996). Association of tibolone and fluoride displays a pronounced effect of bone mineral density in postmenopausal women. Osteoporosis International, 6 (S1), 210. Peer Reviewed verified by ORBi |
Gillet, P., Reginster-Haneuse, G., & Reginster, J.-Y. (1996). Incidence et coûts sociaux directs de la fracture du fémur. Les Nouvelles de Rhumatologie, 1, 8. Peer reviewed |
Reginster, J.-Y. (1996). Calcium et squelette, base physiologique d’une prévention. Les Nouvelles de Rhumatologie, 1, 3-7. Peer reviewed |
 | Reginster, J.-Y., Albert, A., Deroisy, R., Collette, J., Vrijens, B., Blacker, C., Brion, N., Caulin, F., Mayolle, C., Regnard, A., Sholler, R., & Franchimont, P. (1996). Plasma Concentration of Estradiol Following Transdermal Administration of Systen 50 or Menorest 50. Scandinavian Journal of Rheumatology. Supplement, 103, 94-8, discussion 99-100. doi:10.3109/03009749609103761 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1996). Evaluation du rôle préventif des oestroprogestatifs et des thérapeutiques non hormonales dans le cadre de l'ostéoporose postménopausique. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction, 25 (7), 677-83. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Gosset, C., & Reginster-Haneuse, G. (1996). Falls among the elderly: a community problem. Archives of Public Health, 54, 363-372. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (January 1996). La calcitonine. Revue Médicale de Liège, 51 (1), 116-9. Peer reviewed |
 | Bassleer, C., Jaspar, J.-M., Reginster, J.-Y., & Geenen, V. (1996). Effets de l'interleukine 1 sur les chondrocytes humains cultivés en agrégats. Revue du Praticien, 46 (6 Spec No), 31-S34. Peer reviewed |
 | Zegels, B., Taquet, A., Eastell, R., Russell, R., Pack, S., & Reginster, J.-Y. (1996). Biochemical evidence of antiresorptive effect of risedronate in established osteoporosis. Osteoporosis International, 6 (S1), 249. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1996). Role of ipriflavone in prevention and treatment of osteoporosis. Osteoporosis International, 6 (S1), 236. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., DEROISY, R., LECART, M.-P., Zegels, B., Denis, D., SARLET, N., Reginster-Haneuse, G., Albert, A., & Boelen, C. (1996). Prévention de l’ostéoporose à Liège. Histoire d’un PIGEPS : dix ans plus tard. Santé Publique: Revue Multidisciplinaire pour la Recherche et l'Action, 2, 139-150. Peer Reviewed verified by ORBi |
 | Morales-Torres, J., Reginster, J.-Y., & Hochberg, M. (1996). Rheumatic and musculoskeletal diseases and impaired quality of life. A challenge for rheumatologists. Journal of Rheumatology, 23, 1-3. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1996). Nouveaux bisphosphonates dans l’ostéoporose : craintes et espoirs. Revue du Rhumatisme, 63 (7-8), 545-548. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Zheng, S. (1996). Interleukine 1 et métabolisme osseux. Revue du Praticien, 46, 672-674. Peer reviewed |
 | Gillet, P., & Reginster, J.-Y. (1996). Incidence et coûts sociaux directs de la fracture du fémur. Archives of Public Health, 53 (S1), 61. Peer Reviewed verified by ORBi |
Reginster, J.-Y. (1996). Treatment of osteoporosis: where are we and where are we going to. Revista de Reumatologia, 4, 105-109. Peer reviewed |
Reginster, J.-Y. (1996). Treatment of osteoporosis. Medycina Po Dyplomie, 28-33. Peer reviewed |
 | REGINSTER, J.-Y., Distel, M., & Bluhmki, E. (1996). A double-blind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis. British Journal of Rheumatology, 35 (Suppl 1), 17-21. doi:10.1093/rheumatology/35.suppl_1.17 Peer Reviewed verified by ORBi |
 | Gillet, P., Reginster-Haneuse, G., & Reginster, J.-Y. (1996). Osteoporosis : the interest of a prospective vision. Osteoporosis International, 6 (S1), 119. Peer Reviewed verified by ORBi |
 | Combe, B., Audran, M., Sebert, J., Mazières, B., Michaut, S., Devogelaer, J., Dricot, J., & Reginster, J.-Y. (1996). Efficacy of long-term treatment of Paget’s disease with tiludronate 400 mg/day. Journal of Bone and Mineral Research, 11 (S1), 372. Peer Reviewed verified by ORBi |
 | Audran, M., Combe, B., Michaut, S., Devogelaer, J., Dricot, J., & Reginster, J.-Y. (1996). Low risk in fractures in long-term treatment of Paget’s disease with tiludronate. Journal of Bone and Mineral Research, 11 (S1), 372. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Zegels, B., Meurmans, L., Rovati, L., Taquet, A., Setnikar, I., & COLLETTE, J. (1996). Monofluorophosphate decreases vertebral fracture rate in postmenopausal osteoporosis: a randomised, placebo-controlled, double blind study. Osteoporosis International, 6 (S1), 239. Peer Reviewed verified by ORBi |
 | DEROISY, R., Albert, A., Zheng, S., COLLETTE, J., & Reginster, J.-Y. (1996). 25-OH vitamin D levels in healthy ambulatory postmenopausal women. Osteoporosis International, 6 (S1), 119. Peer Reviewed verified by ORBi |
 | Lips, P., Agnusdei, D., Caulin, F., Cooper, C., Johnell, O., Kanis, J., Liberman, U., Minne, H., Reeve, J., Reginster, J.-Y., de Vernejoul, M., & Wiklund, I. (1996). The development of a European questionnaire for quality of life in patients with vertebral osteoporosis. Scandinavian Journal of Rheumatology, 25 (103), 84-85. doi:10.3109/03009749609103757 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Lecart, M. P. (November 1995). Efficacy and Safety of Drugs for Paget's Disease of Bone. BONE, 17 (5 Suppl), 485S-488. doi:10.1016/8756-3282(95)00276-6 Peer Reviewed verified by ORBi |
Gillet, P., & Reginster, J.-Y. (1995). Incidence and direct social costs of hip fractures from 1984 to 1993 in Belgium. Journal of Bone and Mineral Research. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Jupsin, I., Deroisy, R., Biquet, I., Franchimont, N., & Franchimont, P. (June 1995). Prevention of Postmenopausal Bone Loss by Rectal Calcitonin. Calcified Tissue International, 56, 539-42. doi:10.1007/BF00298586 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (June 1995). Calcium et squelette: base physiologique d'une prévention. Revue Médicale de Liège, 50 (6), 244-8. Peer reviewed |
 | Reginster, J.-Y., Deroisy, R., Lecart, M. P., Sarlet, N., Zegels, B., Jupsin, I., de Longueville, M., & Franchimont, P. (May 1995). A Double-Blind, Placebo-Controlled, Dose-Finding Trial of Intermittent Nasal Salmon Calcitonin for Prevention of Postmenopausal Lumbar Spine Bone Loss. American Journal of Medicine, 98 (5), 452-8. doi:10.1016/S0002-9343(99)80344-1 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Deroisy, R., Zegels, B., Jupsin, I., Albert, A., & Franchimont, P. (March 1995). Long-Term Performance in Vitro and in Vivo of Dual-Energy X-Ray Absorptiometry. Clinical Rheumatology, 14 (2), 180-6. doi:10.1007/BF02214940 Peer Reviewed verified by ORBi |
Henrotin, Y., Franchimont, P., & Reginster, J.-Y. (1995). Interactions between IL-1bêta, IL-6, IL-8 and LIF produced by human chondrocytes. The Official EULAR Journal for Education and Information, 24, 134. Peer reviewed |
Franchimont, N., Weekers, L., Gaspar, S., & Reginster, J.-Y. (1995). Effect of activine on bone formation and on interleukine-6 production by human osteoblast-like cells in vitro [Poster presentation]. XIIth International Conference on Calcium Regulatory Hormones, Melbourne, Australia. |
 | Thiry-Blaise, L. M., Taquet, A. N., Reginster, J.-Y., Nusgens, B., Franchimont, P., & Lapiere, C. M. (January 1995). Investigation of the Relationship between Osteoporosis and the Collagenase Gene by Means of Polymorphism of the 5'upstream Region of This Gene. Calcified Tissue International, 56, 88-91. doi:10.1007/BF00298750 Peer Reviewed verified by ORBi |
 | Roux, C., Gennari, C., Farrerons, J., Devogelaer, J. P., Mulder, H., Kruse, H. P., Picot, C., Titeux, L., REGINSTER, J.-Y., & Dougados, M. (1995). Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis and Rheumatism, 38 (6), 851-8. doi:10.1002/art.1780380620 Peer Reviewed verified by ORBi |
 | Roux, C., Gennari, C., Farrerons, J., Devogelaer, J., Mulder, H., Kruse, H., Picot, C., Titeux, L., Reginster, J.-Y., & Dougados, M. (1995). Comparative double-blind multicenter study of the efficacy of tiludronate and etidronate in Paget's disease of bone. BONE, 16 (S1), 503. Peer Reviewed verified by ORBi |
 | Henrotin, Y., De Groote, D., Labasse, A., Deby, C., Geenen, V., & Reginster, J.-Y. (1995). Cytokines and cartilage degradation. Mediators of Inflammation, 4, 229-230. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., & Franchimont, P. (1995). De réels progrès ont-ils été faits dans le traitement de l'ostéoporose ? Medi-Sphere, 39, 7-14. Peer reviewed |
 | Reginster, J.-Y. (1995). Fracture de la hanche. Données épidémiologiques et approche thérapeutique. Le Monde Médical de la Femme, 8, 23-25. Peer reviewed |
 | GILLET, P., Reginster-Haneuse, G., & Reginster, J.-Y. (1995). Incidence et coûts sociaux directs de la fracture du col du fémur, en Belgique, de 1984 à 1993. Revue du Rhumatisme, 10, 698. Peer Reviewed verified by ORBi |
 | Chesnut, C., & Reginster, J.-Y. (1995). Tiludronate for bone diseases. BONE, 17 (S5), 471. doi:10.1016/8756-3282(95)00257-2 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Compston, J., Jones, E., Kaufman, J., Audran, M., Bouvenot, G., Frati, L., Mazzuoli, G., Gennari, C., Lemmel, E., Ringe, J., Sebert, J., Vanhaelst, L., & Avouac, B. (1995). Recommendations for the registration of new chemical entities used in the prevention and treatment of osteoporosis. Calcified Tissue International, 57, 247-250. doi:10.1007/BF00298877 Peer Reviewed verified by ORBi |
Zegels, B., Balena, R., Eastell, R., Russell, R., Pack, S., & Reginster, J.-Y. (1995). Effect of risedronate on collagen cross-links in postmenopausal osteoporosis. Journal of Bone and Mineral Research, 10 (s1), 455. Peer Reviewed verified by ORBi |
Franchimont, N., Franchimont, P., Weekers, L., Gaspar, S., & Reginster, J.-Y. (1995). Organic silicon decreases interleukine-6 but not leukemia inhibitory factor in human osteoblast-like cells in vitro [Poster presentation]. XII th International Conference on Calcium Regulatory Hormones, Melbourne, Australia. |
 | GILLET, P., Reginster-Haneuse, G., & Reginster, J.-Y. (1995). Incidence and direct social costs of hip fracture from 1984 to 1993 in Belgium. Journal of Bone and Mineral Research, 10 (S1), 463. Peer Reviewed verified by ORBi |
Reginster, J.-Y. (1995). Notre squelette a-t-il vraiment besoin de calcium ? Pourquoi quand et comment supplémenter ? Synoviale, 44, 35-40. Peer reviewed |
 | Reginster, J.-Y. (1995). Treatment of Bone in Elderly Subjects: Calcium, Vitamin D, Fluor, Bisphosphonates, Calcitonin. Hormone Research, 43 (1-3), 83-8. doi:10.1159/000184243 Peer Reviewed verified by ORBi |
 | Deroisy, R., Pirenne, H., Frederick, I., Zegels, B., Taquet, A., Noel, V., Zheng, Z., & Reginster, J.-Y. (1995). Densité osseuse fémorale et carence vitaminique D dans une population de femmes âgées. Revue du Rhumatisme, 10, 763. Peer Reviewed verified by ORBi |
 | Deroisy, R., Pirenne, H., Frederick, I., Zegels, B., Taquet, A., Noel, V., Zheng, Z., & Reginster, J.-Y. (1995). Femoral bone density and vitamin D deficiency in elderly women. Archives of Public Health, 52 (S1), 81. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Janssen, C., DEROISY, R., Zegels, B., Albert, A., & FRANCHIMONT, P. (1995). Bone mineral density of the spine and the hip measured with dual energy X-ray absorptiometry: normal range and fracture threshold for western European (Belgian) postmenopausal females. Clinical Rheumatology, 14 (1), 68-75. doi:10.1007/BF02208087 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1995). The role of bisphosphonates in the prevention and treatment of osteoporosis. Clinical Rheumatology, 14 (3), 22-25. doi:10.1007/BF02210684 Peer Reviewed verified by ORBi |
 | DEROISY, R., Zartarian, M., Meurmans, L., Albert, A., Franchimont, P., & Reginster, J.-Y. (1995). Comparison of calcium absorption measured by changes in serum calcium and parathormone, after oral acute administration of 500 mg calcium from five different calcium salts compared with a placebo. BONE, 16 (S1), 98. Peer Reviewed verified by ORBi |
 | PTAK, J., Legrand, R., Albert, A., Franchimont, P., & Reginster, J.-Y. (1995). Influence de la densité osseuse généralisée en implantologie orale. Actualités Odonto-Stomatologiques, 189, 41-49. Peer Reviewed verified by ORBi |
Reginster, J.-Y. (1995). Management of high turnover osteoporosis with calcitonin. Osteoporosis Digest, 3, 13-15. Peer reviewed |
 | Deroisy, R., Pirenne, H., Frederick, I., Zegels, B., Taquet, A., Noel, V., Zheng, Z., & Reginster, J.-Y. (1995). Femoral bone density and vitamin D deficiency in elderly women. Journal of Bone and Mineral Research, 10 (S1), 463. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Deroisy, R., & Franchimont, P. (15 December 1994). Traitement de l'ostéoporose: données actuelles et perspectives. Revue du Rhumatisme, 61 (10, Pt 2), 155S-164. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Meurmans, L., Deroisy, R., Jupsin, I., Biquet, I., Albert, A., & Franchimont, P. (August 1994). A 5-Year Controlled Randomized Study of Prevention of Postmenopausal Trabecular Bone Loss with Nasal Salmon Calcitonin and Calcium. European Journal of Clinical Investigation, 24 (8), 565-9. doi:10.1111/j.1365-2362.1994.tb01108.x Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Treves, R., Renier, J. C., Amor, B., Sany, J., Ethgen, D., Picot, C., & Franchimont, P. (May 1994). Efficacy and Tolerability of a New Formulation of Oral Tiludronate (Tablet) in the Treatment of Paget's Disease of Bone. Journal of Bone and Mineral Research, 9 (5), 615-9. doi:10.1002/jbmr.5650090505 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (01 May 1994). Calcitonine en prévention et traitement de l'ostéoporose. Revue Médicale de Liège, 49 (5), 253-9. Peer reviewed |
 | Reginster, J.-Y. (April 1994). La prévention de l'ostéoporose postménopausique en cas de contre-indications des œstrogènes. Revue Médicale de Liège, 49 (4), 194-8. Peer reviewed |
 | Reginster, J.-Y., Denis, D., Deroisy, R., Lecart, M. P., De Longueville, M., Zegels, B., Sarlet, N., Noirfalisse, P., & Franchimont, P. (January 1994). Long-Term (3 Years) Prevention of Trabecular Postmenopausal Bone Loss with Low-Dose Intermittent Nasal Salmon Calcitonin. Journal of Bone and Mineral Research, 9 (1), 69-73. doi:10.1002/jbmr.5650090110 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., DEROISY, R., & Franchimont, P. (1994). De réels progrès ont-ils été faits dans le traitement de l'ostéoporose ? Medisearch, 81, 39-45. Peer reviewed |
Reginster, J.-Y., Denis, D., Bartsch, V., DEROISY, R., Zegels, B., & Franchimont, P. (1994). Acute biochemical variations induced by four different calcium salts in healthy male volunteers. Equilibre, 19, 5. Peer reviewed |
 | Zheng, X., Vrindts, Y., de Groote, D., Franchimont, N., Reginster, J.-Y., & Franchimont, P. (1994). Direct stimulations of cytokines (IL1-Beta, IL2, IL6, TNF-Alpha, IFN-Gamma, GM-CSF, LIF) in whole blood. Differences between normal and osteoporotic postmenopausal women. Journal of Bone and Mineral Research, 9 (S1), 322. Peer Reviewed verified by ORBi |
 | Roux, C., Gennari, C., Farrenons, J., Devogelaer, J., Mulder, H., Kruse, H., Picot, C., Titeux, L., Reginster, J.-Y., & Dougados, M. (1994). Tiludronate and etidronate in Paget's disease of bone: a comparative prospective double-blind multicenter study. Journal of Bone and Mineral Research, 9 (S1), 296. Peer Reviewed verified by ORBi |
 | Franchimont, P., Bassleer, C., Henrotin, Y., & Reginster, J.-Y. (1994). Effet de l'ipriflavone et de ses métabolites sur la synthèse de métalloprotéases, induite par l'interleukine I, dans un modèle de chondrocytes humains. Revue du Rhumatisme, 10, 694. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Reginster, J.-Y., & Franchimont, P. (1994). Interactions between IL-Ibêta, IL-6, IL-8, and LIF produced by human articular chondrocytes. Osteoarthritis and Cartilage, 2 (S1), 52. Peer Reviewed verified by ORBi |
 | Franchimont, P., Bassleer, C., Henrotin, Y., & Reginster, J.-Y. (1994). Effects of ipriflavone and its metabolites on human articular chondrocytes cultivated in clusters. Osteoarthritis and Cartilage, 2 (S1), 51. Peer Reviewed verified by ORBi |
 | Roux, C., Gennari, C., Farrerons, I., Devogelaer, J., Mulder, H., Kruse, H., Michaut, S., Reginster, J.-Y., & Dougados, M. (1994). Tiludronate et étidronate au cours de la maladie de Paget: étude comparative prospective, multicentrique en double aveugle. Revue du Rhumatisme, 10, 672. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., & Franchimont, P. (1994). De réels progrès ont-ils été faits dans le traitement de l'ostéoporose ? Les Nouvelles de Rhumatologie, 4, 3-8. Peer reviewed |
Reginster, J.-Y. (1994). La Chronique du Belgian Bone Club: l'Epidémiologie et le coût social de l'ostéoporose. Le Monde Médical, 1, 29-30. Peer reviewed |
Reginster, J.-Y. (1994). Evaluation of agents used in osteoporosis: What are the needs ? Osteoporosis Japan, 2, 33-40. Peer reviewed |
 | DEROISY, R., Zartarian, M., Meurmans, L., Albert, A., & Reginster, J.-Y. (1994). Comparaison de l'absorption de calcium, appréciée par la mesure des variations de la calcémie et de la parathormone sérique, après l'administration orale aiguë de 500 mg de calcium élément sous 5 formulations différentes de sels calciques, comparé à un placebo. Revue du Rhumatisme, 10, 669. Peer Reviewed verified by ORBi |
 | Franchimont, P., Bassleer, C., Henrotin, Y., & Reginster, J.-Y. (1994). Effet de l'ipriflavone et de ses métabolites sur la synthèse de protéoglycans et de collagène par les chondrocytes humains cultivés en 3 dimensions. Revue du Rhumatisme, 10, 694. Peer Reviewed verified by ORBi |
 | Franchimont, P., Bassleer, C., Henrotin, Y., & Reginster, J.-Y. (1994). Ipriflavone inhibits interleukin-I stimulated neutral metalloprotease synthesis in human chondrocytes cultivated in clusters. Osteoarthritis and Cartilage, 2 (S1), 52. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Ohnishj, H., Murakami, H., Suda, T., Nakamura, T., Bonvoisin, B., Barbier, A., & Geusens, P. (1994). Tiludronate and osteoporosis: further evidence of safety and efficacy. Journal of Bone and Mineral Research, 9 (S1), 199. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Roux, C., Picot, C., Franchimont, P., & Dougados, M. (1994). Evidence that oral tiludronate is a highly effective therapy of Paget's disease of bone. Journal of Bone and Mineral Research, 25, 83. Peer Reviewed verified by ORBi |
Reginster, J.-Y. (1994). Les oestrogènes dans la prévention de l'ostéoporose postménopausique. Synoviale, 30, 1-7. Peer reviewed |
WANG, F.-C., Collignon, L., REGINSTER, J.-Y., & Franchimont, P. (1994). Effet de la prise de Condrosulf® 400 dans l'arthrose d'Heberden et de Bouchard [Paper presentation]. Symposium Européen sur le Condrosulf® 400. |
 | Reginster, J.-Y. (December 1993). Ipriflavone: Pharmacological Properties and Usefulness in Postmenopausal Osteoporosis. Bone and Mineral, 23 (3), 223-32. doi:10.1016/S0169-6009(08)80099-2 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (30 November 1993). Calcitonin for Prevention and Treatment of Osteoporosis. American Journal of Medicine, 95 (5A), 44S-47. doi:10.1016/0002-9343(93)90382-Y Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Denis, D., Bartsch, V., Deroisy, R., Zegels, B., & Franchimont, P. (September 1993). Acute Biochemical Variations Induced by Four Different Calcium Salts in Healthy Male Volunteers. Osteoporosis International, 3, 271-5. doi:10.1007/BF01623832 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Gaspar, S., Deroisy, R., Zegels, B., & Franchimont, P. (September 1993). Prevention of Osteoporosis with Nasal Salmon Calcitonin: Effect of Anti-Salmon Calcitonin Antibody Formation. Osteoporosis International, 3, 261-4. doi:10.1007/BF01623830 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Christiansen, C., Dequinze, B., Deroisy, R., Gaspard, U., Taquet, A. N., & Franchimont, P. (July 1993). Effect of Transdermal 17 Beta-Estradiol and Oral Conjugated Equine Estrogens on Biochemical Parameters of Bone Resorption in Natural Menopause. Calcified Tissue International, 53, 13-6. doi:10.1007/BF01352008 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Treves, R., Renier, J., Amor, B., Sany, J., Ethgen, D., & Franchimont, P. (1993). Efficacy and tolerance of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone. Calcified Tissue International, 52 (S2), 82. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Treves, R., Renier, J., Amor, B., Sany, J., Ethgen, D., & Franchimont, P. (1993). Efficacy and tolerance of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone. Calcified Tissue International, 52 (S1), 66. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1993). Comment assurer efficacement le dépistage de l'ostéoporose ? Lettre du Rhumatologue, 196, 3-4. Peer reviewed |
 | Henrotin, Y., Labasse, A., Reginster, J.-Y., & Franchimont, P. (1993). Effet de l'IL1béta sur la production de cytokines (LIF, IL6, GMCSF) par les chondrocytes articulaires humains in vitro. Revue du Rhumatisme, 60, 684. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Meurmans, L., Zegels, B., Darte, C., COLLETTE, J., DEROISY, R., & Franchimont, P. (1993). New radioimmunoassay for determination of bone specific iso-enzymes of serum alkaline phosphatases activity (Ostase°): validation and clinical perspective. Journal of Bone and Mineral Research, 8 (S1), 261. Peer Reviewed verified by ORBi |
 | Slosman, D., Delmas, P., Sebert, J., Reginster, J.-Y., Duboeuf, F., Birman, P., Tsouderos, Y., & Meunier, P. (1993). Value and limitations of cross-calibration in a multicenter study involving different DXA brands. Journal of Bone and Mineral Research, 8 (S1), 348. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Ethgen, D., Barbier, A., Geusens, P., Lecart, M., Chappard, D., de Vernejoul, M., Zegels, B., & Franchimont, P. (1993). Evidence that tiludronate is an interesting perspective for prevention and treatment of postmenopausal osteoporosis. Journal of Bone and Mineral Research, 8 (S1), 326. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Zegels, B., Meurmans, L., Bekkering, M., Rovati, L., Setnikar, I., & Franchimont, P. (1993). Efficacy and safety of monofluorophosphate and calcium in postmenopausal osteoporosis. Revista Espanola de Reumatologia: Organo Oficial de la Sociedad Espanola de Reumatologia, 20 (S1), 186. Peer reviewed |
 | Bassleer, C., Reginster, J.-Y., & Franchimont, P. (1993). Effects of glucosamine on differentiated human chondrocytes cultivated in clusters. Revista Espanola de Reumatologia: Organo Oficial de la Sociedad Espanola de Reumatologia, 20 (S1), 95. Peer reviewed |
Reginster, J.-Y., Colson, F., Morlock, G., Combe, B., Ethgen, D., & Geusens, P. (1993). Evaluation of efficacy and safety of oral tiludronate in Paget's disease of bone: a double-blind, dose-ranging, placebo-controlled study. Arthritis and Rheumatism, 36, 134. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1993). Bisphosphonates in prevention and treatment of postmenopausal osteoporosis. Revista Espanola de Reumatologia: Organo Oficial de la Sociedad Espanola de Reumatologia, 20 (S1), 84. Peer reviewed |
 | Reginster, J.-Y., & Franchimont, P. (1993). Piroxicam-Beta-Cyclodextrin in the Treatment of Acute Pain of Rheumatic Disease. European Journal of Rheumatology and Inflammation, 12 (4), 38-46. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1993). Calcitonins: Newer Routes of Delivery. Osteoporosis International, 3 (Suppl 2), 3-7. doi:10.1007/BF01623220 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., DEROISY, R., LECART, M.-P., Zegels, B., Sarlet, N., de Longueville, M., Albert, A., & Franchimont, P. (1993). Nasal salmon calcitonin for prevention of early postmenopausal bone loss: a dose-ranging placebo controlled study. Journal of Bone and Mineral Research, 8 (S1), 340. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Ethgen, D., Barbier, A., Geusens, P., Lecart, M., & Franchimont, P. (1993). Oral Tiludronate: a new perspective for prevention and treatment of postmenopausal osteoporosis. Calcified Tissue International, 52 (S2), 30. Peer Reviewed verified by ORBi |
Reginster, J.-Y. (1993). Ostéoporose postménopausique: le point sur la thérapeutique. Medisearch, 73, 5-11. Peer reviewed |
 | Reginster, J.-Y., Lecart, M.-P., Deroisy, R., Ethgen, D., Zegels, B., & Franchimont, P. (January 1993). Paget's Disease of Bone Treated with a Five Day Course of Oral Tiludronate. Annals of the Rheumatic Diseases, 52 (1), 54-7. doi:10.1136/ard.52.1.54 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1993). Calcitonin use in non osteoporotic diseases. Calcified Tissue International, 52 (S1), 101. Peer Reviewed verified by ORBi |
 | Henrotin, Y., Labasse, A., Reginster, J.-Y., & Franchimont, P. (1993). Effet du leukemia inhibiting factor (LIF) sur le métabolisme des chondrocytes articulaires humains in vitro. Revue du Rhumatisme, 60, 682. Peer Reviewed verified by ORBi |
Reginster, J.-Y. (1993). L'ostéoporose. Medipractice Digest, 11-17. Peer reviewed |
 | Franchimont, N., Bassleer, C., Reginster, J.-Y., Bassleer, R., & Franchimont, P. (1993). Human bone cells from abundant matrix in tridimentional culture. Calcified Tissue International, 52 (S1), 10. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Sarlet, N., Deroisy, R., Albert, A., Gaspard, U., & Franchimont, P. (November 1992). Minimal Levels of Serum Estradiol Prevent Postmenopausal Bone Loss. Calcified Tissue International, 51, 340-3. doi:10.1007/BF00316876 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Colson, F., Morlock, G., Combe, B., Ethgen, D., & Geusens, P. (August 1992). Evaluation of the Efficacy and Safety of Oral Tiludronate in Paget's Disease of Bone. A Double-Blind, Multiple-Dosage, Placebo-Controlled Study. Arthritis and Rheumatism, 35 (8), 967-74. doi:10.1002/art.1780350819 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Azria, M., Lismonde, S., Bleicher, M., Franchimont, N., Behhar, M., Albert, A., & Franchimont, P. (June 1992). Endogenous Production of Specific Antibodies Does Not Decrease Hypocalcemic Response to Calcitonin in Young Rabbits. Calcified Tissue International, 50, 518-20. doi:10.1007/BF00582165 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Deroisy, R., Bruwier, M., & Franchimont, P. (May 1992). Calcitonin Metabolism in Senile (Type II) Osteoporosis. Osteoporosis International, 2, 141-5. doi:10.1007/BF01623821 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Deroisy, R., Fontaine, M. A., & Franchimont, P. (March 1992). Influence of Estrogen Replacement Therapy on Endogenous Calcitonin Production Rates. Gynecological Endocrinology, 6 (1), 65-71. doi:10.3109/09513599209081008 Peer Reviewed verified by ORBi |
Reginster, J.-Y. (1992). L'entrée des bisphosphonates dans le traitement de l'ostéoporose : des résultats prometteurs. Revue du Praticien, 6, 541-546. Peer reviewed |
Reginster, J.-Y., Sarlet, N., Albert, A., DEROISY, R., & Franchimont, P. (1992). Estrogen replacement therapy and inhibition of bone resorption. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 528. Peer Reviewed verified by ORBi |
WANG, F.-C., Collignon, L., REGINSTER, J.-Y., & Franchimont, P. (1992). Orales Chondroïtinsulfat bei Arthrose. Litera Rheumatologica. |
Reginster, J.-Y., Denis, D., Bartsch, V., DEROISY, R., & Franchimont, P. (1992). Comparison of acute biochemical variations induced by ingestion of different calcium salts in healthy volunteers. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 526. Peer Reviewed verified by ORBi |
Bekker, P., Valentin-Opran, A., Brown, J., Siris, E., Sainte-Marie, L., Ryan, W., Johnson, C., Reginster, J.-Y., Hosking, D., Axelrod, D., & Singer, F. (1992). Risedronate : dose response in Paget's disease. Bone and Mineral, 17 (S1), 536. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Ethgen, D., DEROISY, R., & Franchimont, P. (1992). Evidence that oral tiludronate is a first line prevention of postmenopausal osteoporosis. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 528. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1992). Management of High Turnover Osteoporosis with Calcitonin. BONE, 13 (Suppl 2), 37-40. doi:10.1016/8756-3282(92)90195-3 Peer Reviewed verified by ORBi |
 | Bassleer, C., Henrotin, Y., Reginster, J.-Y., & Franchimont, P. (1992). Effects of tiaprofenic acid and acethylsalicylic acid on human articular chondrocytes in 3-dimensional culture. Journal of Rheumatology, 19, 1433-1438. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1992). Oral Tiludronate: Pharmacological Properties and Potential Usefulness in Paget's Disease of Bone and Osteoporosis. BONE, 13 (5), 351-4. doi:10.1016/8756-3282(92)90450-B Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Sarlet, N., & Franchimont, P. (1992). Relation between calcium intake during different periods of life and bone mineral content at the menopause. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 527. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1992). Calcitonin and bone diseases. The Lancet, 339, 1064-1065. doi:10.1016/0140-6736(92)90593-R Peer Reviewed verified by ORBi |
Mottard, L., Lecart, M., & Reginster, J.-Y. (1992). Antagonistes calciques et calcithérapie : incompatibilité ? Actualité Médicale Belge, 335, 11. Peer reviewed |
Reginster, J.-Y., DEROISY, R., Zegels, B., Lecart, M., Denis, D., & Franchimont, P. (1992). Intérêts et limites de l'absorptiométrie biphotonique dans le dépistage de l'ostéoporose postménopausique. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 511. Peer Reviewed verified by ORBi |
Lecart, M., Reginster, J.-Y., DEROISY, R., Sarlet, N., Ethgen, D., & Franchimont, P. (1992). Treatment of Paget’s disease of bone with high doses of oral tiludronate given during a five-day course therapy. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 526. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Lecart, M., DEROISY, R., Sarlet, N., Albert, A., & Franchimont, P. (1992). Normal values for lumbar and femoral bone mineral density in Western European postmenopausal females, comparison of dual photon absorptiometry and quantitative digital radiography. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 527. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Sarlet, N., Albert, A., Lecart, M., & Franchimont, P. (1992). Bone mineral content of lumbar spine and hip in a normal european female population: comparison of dual photon absorptiometry and quantitative digital radiology. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 528. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Albert, A., Taquet, A., Jupsin, I., Denis, D., & Franchimont, P. (1992). Long term (3 years) prevention of trabecular postmenopausal bone loss with low dose intermittent nasal salmon calcitonin. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 527. Peer Reviewed verified by ORBi |
Fontaine, M., Reginster, J.-Y., Gaspar, S., & Franchimont, P. (1992). Assessment of monomeric human calcitonin extraction by SEP-PAK C18. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 526. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., JEUGMANS, A.-M., Franssen, M., Sarlet, N., McIntyre, H. D., & Franchimont, P. (January 1992). The Effect of Nasal hCT on Bone Turnover in Paget's Disease of Bone--Implications for the Treatment of Other Metabolic Bone Diseases. British Journal of Rheumatology, 31 (1), 35-9. doi:10.1093/rheumatology/31.1.35 Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Albert, A., Sarlet, N., & Franchimont, P. (1992). Long-term precision of quantitative digital radiology. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 527. Peer Reviewed verified by ORBi |
Reginster, J.-Y., JEUGMANS, A.-M., Wouters, M., Sarlet, N., Mc Intyre, H., & Franchimont, P. (1992). The effect of nasal hCT on bone turnover in Paget's disease of bone. Implications for the treatment of other metabolic bone diseases. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 528. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (25 November 1991). Effect of Calcitonin on Bone Mass and Fracture Rates. American Journal of Medicine, 91 (5B), 19S-22. doi:10.1016/0002-9343(91)90242-P Peer Reviewed verified by ORBi |
 | Wang, F.-C., de Marneffe, P., Reginster, J.-Y., Crielaard, J.-M., & Franchimont, P. (June 1991). Actualités en médecine de l'appareil locomoteur. Vascularité urticarienne: à propos d'un cas. Revue Médicale de Liège, 46 (6), 336-42. Peer reviewed |
Reginster, J.-Y., DEROISY, R., Sarlet, N., & Franchimont, P. (1991). Nasal salmon calcitonin in prevention of postmenopausal osteoporosis. Revista Clinica Espanola, 188, 46-48. Peer Reviewed verified by ORBi |
Reginster, J.-Y. (1991). Comment utiliser les calcitonines dans l'ostéoporose ? Dialogue Omni-praticien, 1233, 2-3. Peer reviewed |
Reginster, J.-Y. (1991). Therapeutic approaches of postmenopausal osteoporosis. Gynecological Endocrinology, 5 (S), 21. Peer Reviewed verified by ORBi |
Reginster, J.-Y. (1991). Prévention de l'ostéoporose postménopausique : alternatives aux oestrogènes. Synoviale, 6, 13-17. Peer reviewed |
Reginster, J.-Y., & Franchimont, P. (1991). Antibodies and resistance: fact or fantasy. Hungarian Rhumatology, 32, 251. Peer reviewed |
 | Reginster, J.-Y. (1991). Une évolution inéluctable. Jeune Pratique, 50, 18-20. Peer reviewed |
 | Reginster, J.-Y. (1991). Quelles alternatives aux oestrogènes pour la prévention de l'ostéoporose post-ménopausique ? Lettre du Rhumatologue, 170, 16-18. Peer reviewed |
 | Reginster, J.-Y., DEROISY, R., & Franchimont, P. (1991). Effects of different calcium formulations on calcium absorption in healthy volunteers. Advances in Therapy, 8 (2), 86-91. Peer Reviewed verified by ORBi |
Reginster, J.-Y. (1991). Contribution personnelle à la compréhension de la physiopathologie et à la prévention de l'ostéoporose postménopausique. Acta Physiotherapica et Rheumatologica Belgica, 1, 20-30. Peer reviewed |
Reginster, J.-Y., Ethgen, D., DEROISY, R., & Franchimont, P. (1991). Evidence that oral tiludronate is a first line prevention of post-menopausal osteoporosis. Calcified Tissue International, 48, 153. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Dequinze, B., & Franchimont, P. (1991). Comparison of antiosteoclastic activity of Estraderm TTS50 and Premarin 0.625 in healthy postmenopausal females. Hungarian Rhumatology, 32, 185. Peer reviewed |
Reginster, J.-Y. (1991). Epidemiology of osteoporosis. International Journal of Gynecology and Obstetrics, 2, 200. Peer Reviewed verified by ORBi |
WANG, F.-C., Collignon, L., REGINSTER, J.-Y., & Franchimont, P. (1991). Chondroïtine-sulfate in Heberden's and Bouchard's osteoarthritis [Paper presentation]. EULAR. |
 | Reginster, J.-Y., Denis, D., Deroisy, R., Albert, A., Sarlet, N., Collette, J., & Franchimont, P. (June 1990). Dual Photon Absorptiometry of Lumbar Spine in West European (Belgian) Postmenopausal Females: Normal Range and Fracture Threshold. Clinical Rheumatology, 9 (2), 220-4. doi:10.1007/BF02031972 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., DEROISY, R., Lecart, M., SARLET, N., Fontaine, M., Albert, A., & Franchimont, P. (1990). Calcitonin and Postmenopausal Bone Loss. Experimental Gerontology, 25, 349-56. doi:10.1016/0531-5565(90)90072-A Peer Reviewed verified by ORBi |
Reginster, J.-Y., Lecart, M., DEROISY, R., SARLET, N., Ethgen, D., & Franchimont, P. (1990). Treatment of Paget's disease of bone with high doses of oral tiludronate given during a five-day course therapy. Journal of Bone and Mineral Research, 5 (S2), 170. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Lecart, M., DEROISY, R., SARLET, N., Denis, D., Albert, A., COLLETTE, J., & Franchimont, P. (1990). Prevention of postmenopausal bone loss by tiludronate. Menopause Digest, 4, 28. Peer reviewed |
Reginster, J.-Y., & Lecart, M. (1990). Les lombalgies: diagnostic différentiel. Reuma, 34, 7-8. Peer reviewed |
 | Reginster, J.-Y. (1990). Calcitonine et ostéoporose: Mythe ou réalité. Lettre du Rhumatologue, 140, 1-4. Peer reviewed |
 | Reginster, J.-Y., Gennari, C., Mautalen, C., Deroisy, R., Denis, D., Lecart, M. P., Vandalem, J. L., Collette, J., & Franchimont, P. (1990). Influence of Specific Anti-Salmon Calcitonin Antibodies on Biological Effectiveness of Nasal Salmon Calcitonin in Paget's Disease of Bone. Scandinavian Journal of Rheumatology, 19 (1), 83-6. doi:10.3109/03009749009092626 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Azria, M., Gaspar, S., Attinger, M., Albert, A., Bleicher, M., Almer, S., Behkar, C., & Franchimont, P. (1990). The effect of salmon calcitonin on blood-ionized calcium in the presence of anti-salmon calcitonin antibodies (from pagetic patients) in young rabbits. Current Therapeutic Research, 47 (6), 1063-1072. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Crommen, J., Renson, M., & Franchimont, P. (1990). Percutaneous administration of indomethacin in rheumatoid arthritis, evaluation of two topical preparations. Current Therapeutic Research, 47 (3), 548-553. Peer Reviewed verified by ORBi |
Reginster, J.-Y., & Lecart, M. (1990). Les lombalgies: diagnostic différentiel. Reuma, 35, 3-5. Peer reviewed |
Reginster, J.-Y., DEROISY, R., Lecart, M., Ethgen, D., & Franchimont, P. (1990). Prevention of postmenopausal bone loss by tiludronate. Japanese Journal of Bone and Metabolism, 8, 289. Peer reviewed |
Reginster, J.-Y. (1990). Calcitonine, ménopause et ostéoporose. Cycléos, 5, 15-20. Peer reviewed |
 | Reginster, J.-Y., Almer, S., Gaspar, S., Albert, A., Deroisy, R., & Franchimont, P. (June 1989). Hypocalcémie induite chez le sujet pagétique par la calcitonine salmine nasale. Effets des anticorps anti-calcitonine salmine. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 56 (7), 563-7. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Geusens, P., Nijs, J., Denis, D., Franchimont, P., & Dequeker, J. (May 1989). In Vivo Long-Term Precision of Spinal Bone Mass Measurement by Dual Photon Absorptiometry. Bone and Mineral, 6 (2), 225-9. doi:10.1016/0169-6009(89)90053-6 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Deroisy, R., Albert, A., Denis, D., Lecart, M.-P., Collette, J., & Franchimont, P. (March 1989). Relationship between Whole Plasma Calcitonin Levels, Calcitonin Secretory Capacity, and Plasma Levels of Estrone in Healthy Women and Postmenopausal Osteoporotics. Journal of Clinical Investigation, 83 (3), 1073-7. doi:10.1172/JCI113950 Peer Reviewed verified by ORBi |
 | Henrotin, Y., Bassleer, C., Reginster, J.-Y., & Franchimont, P. (March 1989). Effects of Etodolac on Human Chondrocytes Cultivated in Three Dimensional Culture. Clinical Rheumatology, 8 (Suppl 1), 36-42. doi:10.1007/BF02214108 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Strause, L., Deroisy, R., Lecart, M. P., Saltman, P., & Franchimont, P. (1989). Preliminary Report of Decreased Serum Magnesium in Postmenopausal Osteoporosis. Magnesium, 8 (2), 106-9. Peer Reviewed verified by ORBi |
 | Sarlet, N., Reginster, J.-Y., GASPARD, U., DEROISY, R., Denis, D., Lecart, M., & Franchimont, P. (1989). Determination of minimal serum estradiol for prevention of postmenopausal bone loss. Calcified Tissue International, 44, 69. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., DEROISY, R., Denis, D., Lecart, M., & Franchimont, P. (1989). Salmon calcitonin : state of the art in prevention of postmenopausal bone loss ? Acta Belgica. Medica Physica, 12, 41-46. Peer Reviewed verified by ORBi |
 | FOIDART-DESSALLE, M., Reginster, J.-Y., & Franchimont, P. (1989). Complications neurologiques de la maladie de Paget. Revue Médicale de Liège, 11, 396-401. Peer reviewed |
Reginster, J.-Y., & Lecart, M. (1989). Les lombalgies: diagnostic différentiel. Problèmes Pratiques de Rhumatologie, 24, 1-6. Peer reviewed |
Reginster, J.-Y. (1989). Peut-on influencer les modifications du cartilage dans l'arthrose ? Thérapie Express, 9, 1-2. Peer reviewed |
Reginster, J.-Y., DEROISY, R., Denis, D., Lecart, M., Sarlet, N., & Franchimont, P. (1989). Calcitonin for prevention of postmenopausal bone loss: rational and results. European Journal of Clinical Investigation, 19, 88. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Lecart, M., Fontaine, M., DEROISY, R., & Franchimont, P. (1989). Corticostéroides et tissu osseux. Revue Médicale de Liège, 10, 365-373. Peer reviewed |
 | Reginster, J.-Y., Sarlet, N., DEROISY, R., Lecart, M., GASPARD, U., Albert, A., & Franchimont, P. (1989). Comparison of serum estrone levels, urinary calcium and urinary hydroxyproline in eugonadal and postmenopausal women with or without estrogen replacement therapy. Journal of Bone and Mineral Research, 4 (S1), 291. Peer Reviewed verified by ORBi |
Reginster, J.-Y. (1989). Quelles méthodes utiliser pour mesurer la densité osseuse ? Rhumatologie Pratique, 35, 5-7. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Denis, D., Lecart, M., & Franchimont, P. (1989). Salmon calcitonin: state of the art in prevention of postmenopausal bone loss. Journal Belge de Médecine Physique et de Réhabilitation, 12, 41-46. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Lecart, M., DEROISY, R., Sarlet, N., Denis, D., Albert, A., & Franchimont, P. (1989). Normal values for lumbar and femoral bone mineral density in western european postmenopausal females, comparison of dual photon absorptiometry and quantitative digital radiology. Journal of Bone and Mineral Research, 4 (S1), 290. Peer Reviewed verified by ORBi |
 | Lecart, M., Reginster, J.-Y., DEROISY, R., Denis, D., Sarlet, N., & Franchimont, P. (1989). Short-term therapy of Paget's disease of bone by increasing doses of a new bisphosphonate: chloro-4-thiomethylene bisphosphonate. Calcified Tissue International, 44, 87. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., DEROISY, R., Lecart, M., & Franchimont, P. (1989). (Chloro-4 phenyl) thiomethylene bisphosphonate in Paget’s bone disease. Acta Belgica. Medica Physica, 12, 47-52. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Sarlet, N., DEROISY, R., Denis, D., Lecart, M., & Franchimont, P. (1989). Comparaison de l'effet ostéoprotecteur des oestrogènes conjugués équins administrés par voie orale et du 17 beta-oestradiol percutané. Revue Médicale de Liège, 2, 55-60. Peer reviewed |
 | Denis, D., Lecart, M., DEROISY, R., JEUGMANS, A.-M., Albert, A., Reginster, J.-Y., & Franchimont, P. (1989). Un an de traitement de la maladie osseuse de Paget par spray nasal de calcitonine de saumon. Revue Médicale de Liège, 1, 23-27. Peer reviewed |
Reginster, J.-Y., & SARLET, N. (1989). Prévention et traitement de l'ostéoporose postménopausique. Problèmes Pratiques de Rhumatologie, 19, 1-4. Peer reviewed |
 | Reginster, J.-Y., Lecart, M. P., Deroisy, R., Sarlet, N., Denis, D., Ethgen, D., Collette, J., & Franchimont, P. (1989). Prevention of Postmenopausal Bone Loss by Tiludronate. The Lancet, 2 (8678-8679, Dec 23-30), 1469-71. doi:10.1016/S0140-6736(89)92927-9 Peer Reviewed verified by ORBi |
 | Franchimont, P., Urbain-Choffray, D., Lambelin, P., Fontaine, M. A., Frangin, G., & Reginster, J.-Y. (January 1989). Effects of Repetitive Administration of Growth Hormone-Releasing Hormone on Growth Hormone Secretion, Insulin-Like Growth Factor I, and Bone Metabolism in Postmenopausal Women. Acta Endocrinologica, 120 (1), 121-8. doi:10.1530/acta.0.1200121 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Lecart, M., DEROISY, R., Sarlet, N., Denis, D., Albert, A., COLLETTE, J., & Franchimont, P. (1989). Prevention of postmenopausal bone loss by intermittent oral bisphosphonate: Chloro-4-phenyl thiomethylene bisphosphonate: a one year double-blind study. Journal of Bone and Mineral Research, 4 (S1), 214. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Azria, M., Bleicher, M., Fontaine, M., & Franchimont, P. (1989). Antibodies against salmon calcitonin: absence of blocking properties. Journal of Bone and Mineral Research, 4 (S1), 948. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Lecart, M., & Franchimont, P. (1989). (Chloro-4-phenyl) thiomethylene bisphosphonate in Paget's bone disease. Journal Belge de Médecine Physique et de Réhabilitation, 12, 47-52. Peer Reviewed verified by ORBi |
Lecart, M., & Reginster, J.-Y. (1989). La maladie osseuse de Paget. Problèmes Pratiques de Rhumatologie, 22, 1-4. Peer reviewed |
Reginster, J.-Y. (1989). La prescription d'acide acétylsalycillique dans l'arthrose est-elle encore actuelle ? Dialogue Hospitalo-Praticien, 1173, 1-2. Peer reviewed |
 | Reginster, J.-Y., Deroisy, R., Denis, D., Lecart, M. P., Sarlet, N., & Franchimont, P. (September 1988). Is There Any Place for Salmon Calcitonin in Prevention of Postmenopausal Bone Loss? Gynecological Endocrinology, 2 (3), 195-204. doi:10.3109/09513599809029344 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., JEUGMANS, A.-M., Albert, A., Denis, D., & Franchimont, P. (June 1988). One Year's Treatment of Paget's Disease of Bone by Synthetic Salmon Calcitonin as a Nasal Spray. Journal of Bone and Mineral Research, 3 (3), 249-52. doi:10.1002/jbmr.5650030302 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Denis, D., Albert, A., Lismonde, S., Heynen, G., Deroisy, R., & Franchimont, P. (1988). Influence of the Nature of Calcium Salts on Serum Calcium, Phosphorus, Calcitonin, Growth Hormone, and Somatomedin C. Research in Experimental Medicine, 188, 131-7. doi:10.1007/BF01852269 Peer reviewed |
 | Reginster, J.-Y., DEROISY, R., & Franchimont, P. (1988). An estimation of the endogenous secretion of calcitonin in normal and pre and postmenopausal osteoporotic women. Journal of Bone and Mineral Research, 3 (S1), 159. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Franchimont, P. (1988). Nasal calcitonin in prevention of early postmenopausal bone loss. A 18-month study. Journal of Bone and Mineral Research, 3 (S1), 163. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Strause, L., Saltman, P., & Franchimont, P. (1988). Trace elements and postmenopausal osteoporosis: a preliminary report of decreased serum manganese. Medical Science Research, 16, 337-338. Peer reviewed |
Reginster, J.-Y., & Franchimont, P. (1988). L'ostéoporose. Reumatismo, 31, 1-2. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1988). Le syndrome neuroalgodystrophique. Medisearch, 23, 13-24. Peer reviewed |
 | Lecart, M., Denis, D., DEROISY, R., Reginster, J.-Y., & Franchimont, P. (1988). La maladie de Paget 100 ans après Sir Paget. Revue Médicale de Liège, 23, 765-784. Peer reviewed |
Lecart, M., Denis, D., DEROISY, R., Sarlet, N., Reginster, J.-Y., & Franchimont, P. (1988). L'ostéoporose postménopausique : un combat pour l'avenir. Contraception Fertilité Sexualité, 2, 23-32. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Denis, D., Albert, A., DEROISY, R., Lecart, M., Fontaine, M., & Franchimont, P. (1988). Prevention of early postmenopausal bone loss by intranasal calcitonin - a controlled, randomised study lasting one year in normal women. Gynecological Endocrinology, 2, 21. Peer Reviewed verified by ORBi |
Reginster, J.-Y., DEROISY, R., Denis, D., & Franchimont, P. (1988). An estimation of the endogenous secretion of calcitonin in normal and pre and postmenopausal osteoporotic women. Gynecological Endocrinology, 2, 164. Peer Reviewed verified by ORBi |
 | Wouters, M., Francois, A., Schoutens, A., Orloff, S., & Reginster, J.-Y. (1988). Does rheumatoid arthritis induce bone loss per se ? Medical Science Research, 16, 1215-1216. Peer reviewed |
 | Reginster, J.-Y., Lecart, M., GASPARD, U., & Franchimont, P. (1988). Le point sur l'ostéoporose. Medical Trends, 7, 401-412. |
Reginster, J.-Y., & Franchimont, P. (1988). Osteoporose : van bestrijding tot behandeling. Medical Trends, 7, 391-405. |
 | Reginster, J.-Y., JEUGMANS, A.-M., Albert, A., Denis, D., Deroisy, R., LECART, M.-P., Fontaine, M. A., Collette, J., & Franchimont, P. (1988). Biological and Clinical Assessment of a New Bisphosphonate, (Chloro-4 Phenyl) Thiomethylene Bisphosphonate, in the Treatment of Paget's Disease of Bone. BONE, 9 (6), 349-54. doi:10.1016/8756-3282(88)90115-9 Peer Reviewed verified by ORBi |
Reginster, J.-Y. (1988). Tendinite du genou : quel schéma thérapeutique ? Dialogue Hospitalo-Praticien, 1119, 1-2. Peer reviewed |
 | Lecart, M., JEUGMANS, A.-M., Albert, A., Denis, D., DEROISY, R., Fontaine, M., COLLETTE, J., Reginster, J.-Y., & Franchimont, P. (1988). Effets biologiques et cliniques d'un nouveau bisphosphonate (chloro-4-phényl) thiométhylène bisphosphonate dans la maladie osseuse de Paget. Revue Médicale de Liège, 24, 799-806. Peer reviewed |
Reginster, J.-Y. (1988). La calcitonine a-t-elle un rôle dans la physiopathologie de la perte osseuse postménopausique et une place dans sa prévention ? Rheumatology News Ghent, 12, 43-53. Peer reviewed |
Reginster, J.-Y. (1988). Prévention de l'ostéoporose postménopausique. Actualité Thérapeutique, 67, 9-11. Peer reviewed |
Franchimont, P., Fontaine, M., & Reginster, J.-Y. (1988). Hormonal investigation in osteoporosis. Acta Clinica Belgica, 43 (S1), 12-S13. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Denis, D., Albert, A., Deroisy, R., Lecart, M. P., Fontaine, M. A., Lambelin, P., & Franchimont, P. (26 December 1987). 1-Year Controlled Randomised Trial of Prevention of Early Postmenopausal Bone Loss by Intranasal Calcitonin. The Lancet, 2 (8574), 1481-3. doi:10.1016/S0140-6736(87)92619-5 Peer Reviewed verified by ORBi |
Reginster, J.-Y., Denis, D., Albert, A., & Franchimont, P. (April 1987). Assessment of the Biological Effectiveness of Nasal Synthetic Salmon Calcitonin (Ssct) by Comparison with Intramuscular (I.M.) or Placebo Injection in Normal Subjects. Bone and Mineral, 2 (2), 133-40. Peer Reviewed verified by ORBi |
Reginster, J.-Y., & Franchimont, P. (1987). Lombalgies : quels pièges à éviter ? Dialogue Hospitalo-Praticien, 1070, 1-2. Peer reviewed |
Reginster, J.-Y., Denis, D., JEUGMANS, A.-M., Albert, A., Lambelin, P., Fontaine, M., & Franchimont, P. (1987). Treatment of Paget's disease of bone by a new diphosphonate: SR41319B. Journal of Bone and Mineral Research, 2 (S1), 90. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Albert, A., Deprez, M., Denis, D., Lambelin, P., Hendrick, J., & Franchimont, P. (1987). Relation between weight, body mass index, serum estrone, lumbar BMC and BMD and biochemical parameters reflecting bone turnover in healthy postmenopausal women. Journal of Bone and Mineral Research, 2 (S1), 217. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Albert, A., Denis, D., Lambelin, P., Hendrick, J., & Franchimont, P. (1987). Relation between weight, body mass index, serum estrone, lumbar BMC and BMD and biochemical parameters reflecting bone turnover in healthy postmenopausal women. Clinical and Experimental Rheumatology, 5 (S2), 129. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Denis, D., JEUGMANS, A.-M., Albert, A., Lambelin, P., Fontaine, M., & Franchimont, P. (1987). Treatment of Paget's disease of bone by a new bisphosphonate: SR41319B. Clinical and Experimental Rheumatology, 5 (S2), 75. Peer Reviewed verified by ORBi |
 | Desaive, C., Servais, R., COLLETTE, J., Denis, D., Reginster, J.-Y., & Franchimont, P. (1987). Valeur pronostique des marqueurs tumoraux en cas de cancer colo-rectal : CEA et CA 19-9. Acta Gastro-Enterologica Belgica, 40, 65-78. Peer Reviewed verified by ORBi |
Reginster, J.-Y. (1987). L'algodystrophie. Medical Update, 2, 1-4. |
 | CRIELAARD, J.-M., Reginster, J.-Y., Beaujean, M., Constant, C., Kessel, F., Cordier, E., & Franchimont, P. (1986). Médecine physique et rééducation dans le traitement des syndromes du défilé cervico-scapulo-thoracique. Acta Belgica. Medica Physica, 9, 303-308. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Urbin-Choffray, D. (1986). Quels aliments grèvent le pronostic des affections rhumatismales ? Actualité Médicale Belge, 118, 9. Peer reviewed |
 | Reginster, J.-Y. (1986). L'ostéoporose passée sous microscope. Actualité Médicale Belge, 112, 6-7. Peer reviewed |
Reginster, J.-Y., Albert, A., & Franchimont, P. (1986). Traitement de la maladie osseuse de Paget par la calcitonine synthetique de saumon administree par voie nasale. Revue Médicale de Liège, 41 (1), 13-8. Peer reviewed |
Reginster, J.-Y., & Franchimont, P. (1986). La calcitonine a-t-elle un rôle dans la physiopathologie de la perte osseuse postménopausique et une place dans sa prévention ? Hormone, Reproduction et Métabolisme, 3, 261-264. Peer reviewed |
 | Reginster, J.-Y., FOIDART-DESSALLE, M., Leroy, C., & Franchimont, P. (1986). L'hypochondroplasie: dystrophie héréditaire. Revue Médicale de Liège, 61, 533-537. Peer reviewed |
 | Reginster, J.-Y., GRITTEN, C., & Franchimont, P. (1986). L'algodystrophie. Revue Médicale de Liège, 61, 996-1003. Peer reviewed |
CRIELAARD, J.-M., Bodart, A., Urbin-Choffray, D., Reginster, J.-Y., Pirnay, F., & Franchimont, P. (1986). Influence de l'activité physique sur le contenu minéral osseux des femmes ménopausées. Médecine du Sport, 60, 261-263. Peer reviewed |
Reginster, J.-Y., Urbin-Choffray, D., Denis, D., Gatsinzi, C., Pirnay, F., & Franchimont, P. (1986). Contribution to the problem of the reproducibility of dual photon absorptiometry. Journal of Bone and Mineral Research, 1 (S1), 280. Peer Reviewed verified by ORBi |
Strause, L., Reginster, J.-Y., Franchimont, P., & Saltman, P. (1986). Differences in serum trace elements concentration in osteoporotic and age-matched comparison patients: preliminary results. Journal of Bone and Mineral Research, 1 (S1), 234. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Albert, A., & Franchimont, P. (1986). Treatment of Paget's disease of bone by the nasal spray of calcitonin. Journal of Bone and Mineral Research, 1, 152. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y. (1986). Les mille et une facettes du syndrome de Raynaud. Actualité Médicale Belge, 114, 11. Peer reviewed |
Reginster, J.-Y., Gaspar, S., & Franchimont, P. (1986). Occurrence of the antibodies against synthetic salmon calcitonin during treatment of the Paget's disease of bone by nasal spray. Journal of Bone and Mineral Research, 1 (S1), 348. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., WAGEMANS, M., Delvaux, T., & Franchimont, P. (1986). L'ostéomalacie: étiologie, clinique, physiopathologie et thérapeutiques. Revue Médicale de Liège, 61, 174-178. Peer reviewed |
 | CRIELAARD, J.-M., Reginster, J.-Y., & Franchimont, P. (1985). Spondylolyse et spondylolisthesis: contre-indication à la pratique sportive. Revue Médicale de Liège, 40, 215-219. Peer reviewed |
 | Reginster, J.-Y., Desaive, C., Denis, D., COLLETTE, J., & Franchimont, P. (1985). Dosage pré-opératoire et post-opératoire de l'antigène carcino-embryonnaire : facteur pronostic dans les néoplasies rectocoliques opérées. Revue Médicale de Liège, 40, 85-90. Peer reviewed |
 | Reginster, J.-Y., Simar, L., Membre, H., & Franchimont, P. (1985). La biopsie osseuse transiliaque antérieure et l'histomorphométrie osseuse quantitative, intérêt en pathologie ostéoarticulaire. Revue Médicale de Liège, 40, 533-538. Peer reviewed |
 | Reginster, J.-Y., & Franchimont, P. (1985). Pourquoi et comment prévenir l'ostéoporose postménopausique ? Revue Médicale de Liège, 40, 811-813. Peer reviewed |
Reginster, J.-Y., & Franchimont, P. (1985). Intérêt actuel de la calcitonine en pathologie ostéoarticulaire. Tempo Médical, 53, 67-76. Peer reviewed |
 | Reginster, J.-Y. (1985). Le rôle du magnésium dans la contraction musculaire. Semper, 99, 29-30. Peer reviewed |
 | Bassleer, C., Reginster, J.-Y., Dachy, M., Gysen, P., Bassleer, R., & Franchimont, P. (1985). The effect of IR-helium-neon laser in human chondrocyte cultivated in three dimensions. Calcified Tissue International, 38 (S1), 38. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Franchimont, P. (1985). La calcitonine 25 ans après. Médecine et Hygiène, 43, 3808-3814. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., GRITTEN, C., Diverse, P., Hauwaert, C., Halleux, R., & Franchimont, P. (1985). Evolution de la maladie osseuse de Paget pendant et après traitement par de faibles doses d'étidronate disodique. Revue Médicale de Liège, 40, 417-422. Peer reviewed |
 | Reginster, J.-Y., Urbain-Choffray, U., Maertens de Noordhout, B., Vandervoort, A., & Franchimont, P. (1985). La synovite villo-nodulaire pigmentée du genou, à propos de deux cas. Revue Médicale de Liège, 40, 506-509. Peer reviewed |
 | Reginster, J.-Y., & Franchimont, P. (1985). Side effect of SSCT given by intranasal spray compared with intra-muscular injection. Clinical and Experimental Rheumatology, 3, 155-157. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Maertens de Noordhout, B., Albert, A., Dupont-Onkelinx, A., & Franchimont, P. (1985). Serum and erythrocyte magnesium in osteoporotic and osteoarthritic postmenopausal women. Magnesium, 4, 208. Peer reviewed |
 | Reginster, J.-Y., & Franchimont, P. (1985). Comparaison des effets secondaires entraînés par l'administration de calcitonine synthétique de saumon par voie I.M. et sous forme de spray nasal. Revue Médicale de Liège, 40, 667-669. Peer reviewed |
 | Reginster, J.-Y., & Franchimont, P. (1985). L'ostéosarcome pagétique: prévention, diagnostic, attitude et pronostic. Revue Médicale de Liège, 40, 68-74. Peer reviewed |
 | Reginster, J.-Y., & Franchimont, P. (1985). Intérêt de la calcitonine en 1985 en pathologie ostéoarticulaire. Revue Médicale de Liège, 40, 225-233. Peer reviewed |
Franchimont, P., & Reginster, J.-Y. (1985). Apparition d'une polymyosite dans le décours tardif d'une hépatite B. Patient Care, 8, 43-48. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Gysen, P., Malaise, M., & Franchimont, P. (1985). Modifications des proteoglycans articulaires durant traitement par l'acide tiaprofénique. Revue Médicale de Liège, 40 (17), 596-599. Peer reviewed |
Reginster, J.-Y., Damas, P., & Franchimont, P. (1985). Anaesthetic risks in osteoarticular disorders. Clinical Rheumatology, 4 (1), 30-38. doi:10.1007/BF02032315 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Albert, A., & Franchimont, P. (1985). Salmon-calcitonin nasal spray in Paget's disease of bone: preliminary results in five patients. Calcified Tissue International, 37 (6), 577-80. doi:10.1007/BF02554908 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., GRITTEN, C., Diverse, P., Hauwaert, C., CRIELAARD, J.-M., Halleux, R., & Franchimont, P. (1985). Traitement de la maladie osseuse de Paget par l'étidronate disodique à faible dose. Apparition de leucopénies transitoires réversibles suspectes. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 52, 145-150. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Albert, A., Denis, D., & Franchimont, P. (1985). Influence de la nature d'un sel de calcium administré sur les taux sériques de somatomédine C, calcium et PTH. Tribune Médicale, 149, 50-51. Peer reviewed |
 | Reginster, J.-Y. (1985). Magnésium et système cardio-vasculaire. Semper, 98, 26-27. Peer reviewed |
 | Reginster, J.-Y., CRIELAARD, J.-M., Bassleer, C., Gysen, P., Bastings, M., & Franchimont, P. (1985). Traitement de la chondromalacie rotulienne primitive par l'association de rééducation du quadriceps et l'irradiation laser-infra rouges. Acta Belgica. Medica Physica, 8, 193-194. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., & Franchimont, P. (1984). Effect of nasal administration of synthetic salmon calcitonin on Paget's disease of bone. Calcified Tissue International, 36 (S2), 77. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Desaive, C., COLLETTE, J., Zangerlé, P.-F., Denis, D., & Franchimont, P. (1984). Intérêt du dosage sérique radio-immunologique de l'antigène carcino-embryonnaire dans la surveillance des cancers rectocoliques opérés. Annales de Gastroentérologie et d'Hépatologie, 20, 203-206. Peer reviewed |
 | Reginster, J.-Y., Deprez, F., & Franchimont, P. (1984). Intérêt d'une kinésithérapie intensive dans la prévention de la déperdition de la masse osseuse chez les traumatisés alités. Revue Médicale de Liège, 39, 524-529. Peer reviewed |
 | Reginster, J.-Y., & Franchimont, P. (1984). Apparition d'une polymyosite dans le décours tardif d'une hépatite B. Revue Médicale de Liège, 39, 749-756. Peer reviewed |
 | Reginster, J.-Y., Damas, P., & Franchimont, P. (1984). L'anesthésie en pathologie ostéoarticulaire et ses problèmes spécifiques. Revue Médicale de Liège, 39 (1), 14-24. Peer reviewed |
Franchimont, P., & Reginster, J.-Y. (1984). Quels examens demander face à une polyarthralgie ? Dialogue Hospitalo-Praticien, 854, 4. Peer reviewed |
Reginster, J.-Y., Deprez, F., & Franchimont, P. (1984). Effets de la kinésithérapie intensive sur les perturbations du métabolisme osseux, consécutivement à une immobilisation post-traumatique. Cahiers de Kinésithérapie, 107, 69-77. Peer reviewed |
 | Reginster, J.-Y., Damas, P., & Franchimont, P. (1984). Specific risks of anesthesia in patients with osteoarticular disease. Acta Anaesthesiologica Belgica, 35 (2), 105-121. Peer Reviewed verified by ORBi |
Reginster, J.-Y., Deprez, F., & Franchimont, P. (1984). La prévention de l'ostéoporose d'immobilisation : une indication majeure de la kinésithérapie intensive. Revue de Kinésithérapie et de Réadaptation, 3, 3-9. Peer reviewed |
 | Reginster, J.-Y., Deprez, F., & Franchimont, P. (1983). Intérêt d'une kinésithérapie dans la prévention de la déperdition de masse osseuse chez les traumatisés alités. Acta Belgica. Medica Physica, 6, 147-152. Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Desaive, C., COLLETTE, J., Zangerlé, P.-F., & Franchimont, P. (1983). La surveillance des cancers rectocoliques opérés, une application pratique du CEA. Revue Médicale de Liège, 38, 581-585. Peer reviewed |
Reginster, J.-Y., & Franchimont, P. (1983). Risques de l'anesthésie en pathologie ostéoarticulaire. Ars Medici, 1 (3), 268-288. Peer reviewed |
